


# Visit booth #1816

Find out whether PRISTIQ is appropriate for your patients suffering from MDD



PRISTIQ is indicated for the treatment of major depressive disorder in adults.

# **Important Safety Information for PRISTIQ**

#### WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of PRISTIQ or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. PRISTIQ is not approved for use in pediatric patients.


#### **Contraindications**

- PRISTIQ is contraindicated in patients with a known hypersensitivity to PRISTIQ or venlafaxine.
- PRISTIQ must not be used concomitantly with an MAOI or within 14 days of stopping an MAOI. Allow 7 days after stopping PRISTIQ before starting an MAOI.

#### Warnings and Precautions

 All patients treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of treatment and when changing the dose. Consider changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or includes symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or suicidality that are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Families and caregivers of patients being treated with antidepressants should be alerted about the need to monitor patients.

- Development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome-like reactions have been reported with SNRIs and SSRIs alone, including PRISTIQ treatment, but particularly with concomitant use of serotonergic drugs, including triptans, with drugs that impair the metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. If concomitant use with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Concomitant use of PRISTIQ with serotonin precursors is not recommended.
- Patients receiving PRISTIQ should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies. Pre-existing hypertension should be controlled before starting PRISTIQ. Caution should be exercised in treating patients with pre-existing hypertension or other underlying conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported. For patients who experience a sustained increase in blood pressure, either dose reduction or discontinuation should be considered.



- SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and other anticoagulants may add to this risk.
- Mydriasis has been reported in association with PRISTIQ; therefore, patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma (angle-closure glaucoma) should be monitored.
- PRISTIQ is not approved for use in bipolar depression. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine the risk of bipolar disorder.
- As with all antidepressants, PRISTIQ should be used cautiously in patients with a history or family history of mania or hypomania, or with a history of seizure disorder.
- Caution is advised in administering PRISTIQ to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders. Increases in blood pressure and small increases in heart rate were observed in clinical studies with PRISTIQ. PRISTIQ has not been evaluated systematically in patients with a recent history of myocardial infarction, unstable heart disease, uncontrolled hypertension, or cerebrovascular disease.
- Dose-related elevations in fasting serum total cholesterol, LDL (low density lipoprotein) cholesterol, and triglycerides were observed in clinical studies. Measurement of serum lipids should be considered during PRISTIQ treatment.
- On discontinuation, adverse events, some of which may be serious, have been reported with PRISTIQ and other SSRIs and SNRIs. Abrupt discontinuation of PRISTIQ has been associated with the appearance of new symptoms. Patients should be monitored for symptoms when discontinuing treatment. A gradual reduction in dose rather than abrupt cessation is recommended whenever possible.
- The recommended dose in patients with severe renal impairment or

- end-stage renal disease (ESRD) is 50 mg every other day. The dose should not be escalated in patients with moderate or severe renal impairment or ESRD.
- Products containing desvenlafaxine and products containing venlafaxine should not be used concomitantly with PRISTIQ.
- Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia.
- Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported.

#### **Adverse Reactions**

• The most commonly observed adverse reactions in patients taking PRISTIQ vs placebo for MDD in short-term fixed-dose premarketing studies (incidence ≥5% and at least twice the rate of placebo in the 50-mg dose group) were nausea (22% vs 10%), dizziness (13% vs 5%), hyperhidrosis (10% vs 4%), constipation (9% vs 4%), and decreased appetite (5% vs 2%).

Reference: 1. Pristiq® (desvenlafaxine) Prescribing Information, Wyeth Pharmaceuticals Inc.

# Please see brief summary of Prescribing Information on adjacent pages.

For more information on PRISTIQ, please visit  ${\it www.PristiqHCP.com}$ .

Wyeth is a wholly owned subsidiary of Pfizer Inc. To learn more, please visit www.pfizer.com.





PQP00080C © 2010 Pfizer Inc. All rights reserved. April 2010



#### **Extended-Release Tablets**

BRIEF SUMMARY. See package insert for full Prescribing Information. For further product information and current package insert, please visit www.wyeth.com or call our medical communications department toll-free at 1-800-934-5556

WARNING: Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Pristig or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24 there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicidal Patients of all news who are started on antidepressant therapy should be monitored amorpristably suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Pristiq is not approved for use in pediatric patients [see Warnings and Precautions (5.1), Use in Specific Populations (8.4), and Patient Counseling Information (17.1 in the full prescribing information].

INDICATIONS AND USAGE: Pristiq, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder (MDD).

CONTRAINDICATIONS: Hypersensitivity-Hypersensitivity to desveniafaxine succinate, veniafaxine hydrochloride or to any excipients in the Pristiq formulation. Monoamine Oxidase Inhibitors-Pristiq must not be used concomitantly in patients taking monoamine oxidase inhibitors (MAOIs) or in patients who have taken MAOIs within the preceding 14 days due to the risk of serious, sometimes fatla, drug interactions with SNRI or SSRI treatment or with other serotonergic drugs. Based on the half-life of desveniafaxine, at least 7 days should be allowed after stopping Pristiq before starting an MAOI [see Dosage and Administration (2.6) in the full prescribing information].

WARNINGS AND PRECAUTIONS: Clinical Worsening and Suicide Risk-Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There tertain unterpsychiatic disorders, and triese disorders treinserves are the studiest present of success treited has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. The pooled analyses of placebo-controlled studies in children and adolescents with MDD, obsessive-compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term studies of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled studies in adults with MDD or other psychiatric disorders included a total of 295 short-term studies (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in Table 1 of the full prescribing information. No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was number of cases of suicidality per 1000 patients treated) are provided in Table 1 of the full prescribing information. No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on suicide. It is unknown whether the suicidality risk extends to longer-term use, ie, beyond several months. However, there is substantial evidence from placebocontrolled maintenance studies in adults with depression that the use of antidepressants can delay the recurrence of depression. All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms adult and pennative patients being treated with antioutpressaries for high prefessive distorted as went as for our indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [see Warnings and Precautions (5.9) and Dosage and Administration (2.3) in the full prescribing information for a description of the risks of discontinuation of Pristiq]. Families and caregivers of patients being information for a description of the risks of discontinuation of Pristiq!. Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for Pristig should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. Screening patients for bipolar disorder. A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (flowiph not established in controlled studies) that treating such an episode with an antidirect sand. believed (though at major depressive episode may be the linitial presentation of hipotal district. It is general believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder, such screening should include a detailed psychiatric history including a family history of suicide, bipolar disorder, and depression. It should be noted that Pristig is not approved for use in treating bipolar depression. Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like for use in treating bipolar depression. Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions—The development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including Pristiq reatment, but particularly with concomitant use of serotonergic drugs (including triptans), with drugs that impair metabolism serotonin including MAIsly, or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (eg, hyperreflexia, incoordination) and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea). Serotonin syndrome in its most severe form can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability hossible rapid fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms. The concomitant use of Pristiq with MAIslis with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The concomitant use of Pristiq with serotonin precursors (such as tryptophan) is not recommended. Treatment with Pristiq and any concomitant steronergic or precursors (such as tryptophan) is not recommended. Treatment with Pristiq and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur, and supportive symptomatic treatment should be initiated. **Elevated Blood Pressure**- Patients receiving Pristiq should have regular monitoring of blood pressure since dose-dependent increases were observed in clinical studies. Pre-existing hypertension should be controlled before initiating treatment with Pristiq. Caution should be exercised in treating patients with pre-existing hypertension or other underlying conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported with Pristiq. <u>Sustained hypertension</u>- Sustained blood pressure increases could have adverse consequences. For patients who experience a sustained increase in blood pressure while receiving Pristiq, either dose reduction or discontinuation should be considered [see Adverse Reactions (6.1)]. Treatment with Pristiq in uses reduction or inscontinuation should be considered (see Auterse Reactions (n. /l). Realment with Fristig controlled studies was associated with sustained hypertension, defined as treatment-emergent supine diastolic blood pressure (SDBP) ≥90 mm Hg and ≥10 mm Hg above baseline for 3 consecutive on-therapy visits. In clinical studies, regarding the proportion of patients with sustained hypertension, the following rates were observed: placebo (0.5%), Pristig 200 mg (1.1%), and Pristig 400 mg (2.3%). Analyses of patients in Pristiq controlled studies who met criteria for sustained hypertension revealed a

dose-dependent increase in the proportion of patients who developed sustained hypertension. Abnormal Bleeding-SSRIs and SNRIs can increase the risk of bleeding events. Concomitant use of aspirin, other drugs that affect platelet function, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants can add to this risk Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Pristiq and NSAIDs, aspirin, or other drugs that affect coagulation or bleeding. Narrow-angle Glaucoma-Mydriasis has been reported in association with Pristig; therefore, patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma (angle-closure glaucoma) should be monitored. Activation of Mania/Hypomania-During all MDD and VMS (vasomotor symptoms) phase 2 and phase 3 studies, mania was reported for approximately 0.1% of patients treated with Pristig. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants. As with all antidepressants, Pristig should be used cautiously in patients with a history or family history of mania or hypomania. Cardiovascular/Gerebrovascular Disease-Caution is advised in administering Pristig to patients with a reference and proposition disorders (see Adverse administering Pristiq to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders [see Adverse Reactions (6.1)]. Increases in blood pressure and heart rate were observed in clinical studies with Pristiq. Pristiq has not been evaluated systematically in patients with a recent history of myocardial infarction, unstable heart disease, uncontrolled hypertension, or cerebrovascular disease. Patients with these diagnoses, except for disease, uncontrolled hypertension, or cerebrovascular disease. Patients with these diagnoses, except for cerebrovascular disease, were excluded from clinical studies. Serum Cholesterol and Triglyceribe Elevation. Dose-related elevations in fasting serum total cholesterol, LDL (low-density lipoprotein) cholesterol, and triglycerides were observed in the controlled studies. Measurement of serum lipids should be considered during reatment with Pristiq [see Adverse Reactions (6.1)]. Discontinuation of Treatment with Pristiq-Discontinuation symptoms have been systematically and prospectively evaluated in patients treated with Pristiq during clinical studies in major depressive disorder. Abrupt discontinuation or dose reduction has been associated with the appearance of new expenditure that include distripace, pages handed printing incompile distripace, anytich. saudes in ringio upersavie disconer. Autopir discominatariori no dose redución has beer associated with de appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis. In general, discontinuation events occurred more frequently with longer duration of therapy. During marketing of SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors) and SSRIs (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring soms gelective commitmetration in minutus, meter have been spontaneous reports or actives events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, paresthesia, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored for these symptoms when discontinuing treatment with Pristiq. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose roupon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate [see Dosage and Administration (2.4) and Adverse Reactions (6.1) in full prescribing information). Renal Impairment-In patients with moderate or severe renal impairment or end-stage renal disease (ESRD) the clearance of Pristiq was decreased, thus prolonging the elimination half-life of the drug. As a result, there were potentially clinically significant increases in exposures to Pristiq [see Clinical Pharmacology (12.6) in full prescribing information]. Dosage adjustment (50 mg every other day) is necessary in patients with severe renal impairment or ESRD. The doses should not be escalated in patients with moderate or severe renal impairment or ESRD [see Dosage and Administration (2.2) in full prescribing information]. Suzure-Cases of seizure have been reported in premarketing clinical studies with Pristiq. Pristiq should be prescribed with caution in patients with a seizure disorder. **Hyponatrenia**-Hyponatrenia-Hyponatrenia can occur as a result of treatment with SSRIs and SNRIs, including Pristiq, In many cases, this hyponatremia and papears to be the result of the syndrome of inappropriate antidiuretic hormone secretion Hyponatremia- Hyponatremia can occur as a result of treatment with SSRIs and SNRIs, including Pristiq, In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretical (SIADH). Elderly patients can be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.6) in full prescribing information]. Discontinuation of Pristig should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted. Coadministration of Drugs Containing Desvenlafaxine and Venlafaxine- Desvenlafaxine is the major active metabolite of venlafaxine. Products containing desvenlafaxine and products containing venlafaxine should not be used concomitantly with Pristiq. Interstitial Lung Disease and Eosinophilic Pneumonia- Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of Pristig) therapy have been rarely reported. The possibility of these adverse events should be considered in patients treated with Pristig who present with progressive dyspnea, cough, or chest discomfort. Such patients should undergo a prompt medical evaluation, and discontinuation of Pristig should be considered.

ADVERSE REACTIONS: Clinical Studies Experience: The most commonly observed adverse reactions in Pristig-

ADVERSE REACTIONS: Clinical Studies Experience: The most commonly observed adverse reactions in Pristiq-treated MDD patients in short-term fixed-dose studies (incidence ≥5% and at least twice the rate of placebo in the treated MDD patients in short-term fixed-dose studies (incidence >5% and at least twice the rate of placebo in the 50- or 100-mg dose groups) were nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders. Adverse reactions reported as reasons for discontinuation of treatment-The most common adverse reactions leading to discontinuation in at least 2% of the Pristig-treated patients in the short-term studies, up to 8 weeks, were nausea (4%); dizziness, hadache and vomiting (2% each); in the long-term study, up to 9 months, the most common was vomiting (2%). Common adverse reactions in placebo-controlled MDD studies. Table 3 in full Pl shows the incidence of common adverse reactions that occurred in ≥2% of Pristig-treated MDD patients at any dose in the 8-week, placebo-controlled, fixed-dose, premarketing clinical studies. In general, the adverse reactions were most frequent in the first week freatment. Cardiac disorders: Palpitations, Tachycardia, Blood pressure increased; Gastrointestinal disorders: Nausea, Dry mouth, Diarrhea, Constipation, Vomiting; General disorders and administration site conditions: Fatigue, Chilis, Feeling jittery, Asthenia; Metabolism and nutrition disorders: Decreased appetite, weight decreased; Neurous system disorders: Dizziness, Somnolence, Headache, Tremor, Paraesthesia, Disturbance in attention; Psychiatric Disorders: Insomnia, Anxiety, Nervousness, Irritability, Abnormal dreams; Renal and urinary disorders: Subisiders: Swin and subcutaneous tissue disorders: Disorders: Insomnia, Anxiety, Nervousness, Irritability, Abnormal dreams; Renal and urinary disorders: Storders: Hyperiatory, thoracic, and mediastinal disorders: Yawning; Skin and subcutaneous tissue disorders: Hyperhidrosis, Rash; Special Senses: Vision blurred; Mydriasis, Tinnitus, Dysgeusia; <u>Vascular Disorders: Hot flush. Sexual function adverse reactions: Table 4 shows the incidence of sexual function adverse reactions that occurred in ≥2% of Pristiq-treated MDD patients in any fixed-dose group (8-week, placebo-controlled, fixed and flexible-dose, premarketing clinical studies). Men Only: Anorgasmia, Libido decreased, Orgasm abnormal, Ejaculation delayed, Erectile dysfunction, Ejaculation disorder, Ejaculation failure, Sexual dysfunction; Women Only: Anorgasmia; Other adverse reactions observed in premarketing clinical studies: Other infrequent adverse reactions occurring at an incidence of <2% in MDD patients treated with Pristiq were: Immune system disorders — Neyrous system disorders — Weight increased, liver function test abnormal, blood prolactin increased. Nervous system disorders — Convulsion, syncope, extrapyramidal disorder. Musculoskeletal and connective tissue disorders — Musculoskeletal attiffness. Psychiatric disorders — Depersonalization, hypomanian. Respiratory, thoracic and mediastinal disorders — Epistaxis. Lescular disorders — Orthostatic hypotension. In clinical studies rhere were uncommon reports of ischemic cardiac adverse events, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors. More patients experienced these events during Pristig treatment as compared to placebo [see Warnings and Precautions</u> patients experienced these events during Pristig treatment as compared to placebo [see Warnings and Precautions (5.7)]. <u>Discontinuation events</u>-Adverse events reported in association with abrupt discontinuation, dose reduction or tapering of treatment in MDD clinical studies at a rate of ≥5% include dizziness, nausea, headache, irritability, or tapering of treatment in MDD clinical studies at a rate of ±5% include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, ahnormal dreams, fatigue, and hyperhidrosis. In general, discontinuon events occurred more frequently with longer duration of therapy [see Dosage and Administration (2.4) and Warnings and Precautions (5.9) in full prescribing information]. Laboratory, ECB and vital sign changes observed in MDD clinical studies. The following changes were observed in placebo-controlled, short-term, premarketing MDD studies with Pristig. Lipids-Elevations in fasting serum total cholesterol, LDL (low-density lipoprotein) cholesterol, and triglycerides occurred in the controlled studies. Some of these abnormalities were considered potential clinically significant [see Warnings and Precautions (5.8)]. Proteinuria-Proteinuria, greater than or equal to trace, was observed in the fixed-dose controlled studies (see Table 6 in full prescribing information). This proteinuria was not associated with increases in BUN or creatinine and was generally transient. ECG changes-Electrocardiograms were obtained from 1,492 Pristig-treated patients with major depressive disorder and 984 placebo-treated patients in clinically relievant differences were observed between Pristig-treated and obtained into 11,322 Fristiq-freated patients with mildor depressive distorted and 934 placebo-freated patients with clinical studies lasting up to 8 weeks. No clinically relevant differences were observed between Pristiq-freated and placebo-treated patients for OT, OTc, PR, and QRS intervals. In a thorough OTc study with prospectively determined criteria, desventafaxine did not cause OT prolongation. No difference was observed between placebo and desventafaxine treatments for the QRS interval. Vital sign changes-Table 7 summarizes the changes that were observed in placebo-controlled, short-term, premarketing studies with Pristiq in patients with MDD (doses 50 400 mg). Relative to placebo, Pristiq was associated with mean increase of up to 2.1 mm Hg in systolic blood pressure, 2.3 mm Hg in diastolic blood pressure, and 4.1 bpm with supine pulse. At the final on-therapy essessment in the 6-month duple-billing hazerbo-controlled place of a long-term study in nations who had pressure, 2.3 mm Hg in diastolic blood pressure, and 4.1 bpm with supine pulse. At the final on-therapy assessment in the 6-month, double-blind, placebo-controlled phase of a long-term study in patients who had responded to Pristiq during the initial 12-week, open-label phase, there was no statistical difference in mean weight gain between Pristiq- and placebo-treated patients. Orthostatic hypotension—In the short-term, placebo-controlled clinical studies with doses of 50-400 mg, systolic orthostatic hypotension (decrease ≥30 mm Hg from supine to standing position) occurred more frequently in patients ≥65 years of age receiving Pristiq (8.0%, 7/87) versus placebo (0.7%, 8/1,218). Adverse Reactions Identified During Post-Approval Use—The following adverse reaction has been identified during post-approval use of Pristiq. Because post-approval reactions are reported

voluntarily form a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin and subcutaneous tissue discorders — Angiodenna. Adverse Reactions Reported With Other SMRIs- Although the following are not considered adverse reactions for desevenitations excionate, they are adverse reactions for other SMRIs and may also occur with desevenitations of redevenitations in contributions with desevenitation succinate, they are adverse reactions for other SMRIs and may also occur with desevenitations and them systematically evaluated. Consequently, caution is advised when Pristig is taken in combination with other CNS-active drugs has an other systematically evaluated. Consequently, caution is advised when Pristig is taken in combination with other CNS-active drugs [SMRIs part Activation of Pristig SMRIs or SSRIs, or who have recently had SMRI or SRIs therapy discontinuely drive in Intilation of an Mool (see Contributional Consequence) and pristig CNRIst or SSRIs, or who have recently had SMRI or SRIs therapy discontinuely drive in Intilation of an Mool (see Contributional Consequence). The contribution of the service of

escalation above 10 mg/day is not recommended [see Unical Pharmacology (12.6)].

VERDOSAGE: Human Experience with Overdosage- There is limited clinical experience with desvenlafaxine succinate overdosage in humans. In premarketing clinical studies, no cases of fatal acute overdose of desvenlafaxine were reported. The adverse reactions reported within 5 days of an overdose > 600 mg that were possibly related to Pristiq included headache, vomitting, agitation, dizzness, nausea, constipation, diarrhea, dry mouth, paresthesia, and tachycardia. Desvenlafaxine (Pristiq) is the major active metabolite of venlafaxine. Overdose experience reported with venlafaxine (the parent drug of Pristiq) is presented below; the identical information can be found in the Overdosage section of the venlafaxine package insert. In postmarketing experience, overdose with venlafaxine (the parent drug of Pristiq) has occurred predominantly in combination with alcohol and/or other drugs. The most comprohy reported events in overdoseae include bachycardic happes in alcohol and/or other drugs. The most commonly reported events in overdosage include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and vomiting. Electrocardiogram changes (eg, prolongation of QT interval, bundle branch block, QRS prolongation), sinus and ventricular tachycardia, revel of consciousness (anjung from sommonere to conta), inyoriasis, setzures, and voluming, electrocanoughance changes (eg., prolongation of QT interval, bundle branch block, QRS prolongation), sinus and ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been reported. Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher presisting burden of suicider risk factors than SSRI-treated patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as opposed to some characteristic(s) of venlafaxine-treated patients, is not clear. Prescriptions for Pristiq should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.

Management of Overdosage-Treatment should consist of those general measures employed in the management of overdosage with any SSRI/SNRIB. Insure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs: General supportive and symptomatic measures are also recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal should be administered. Induction of emesis is not recommended. Because of the moderate volume of distribution of this drug, forced diuresis, dialysis, tempogrifusion, and exchange transfusion are unlikely to be of benefit No specific antidotes for desvenlafaxine are known. In managing an overdose, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center are liste

This brief summary is based on Pristiq Prescribing Information W10529C013, revised February 2010.

265881-01 © 2010 Pfizer Inc. All rights reserved. April 2010



# HUMAN RIGHTS **AWARD**

#### → PURPOSE ←

The Human Rights Award was established to recognize an individual and an organization whose efforts exemplify the capacity of human beings to act courageously and effectively to prevent human rights violations, to protect others from human rights violations and their psychiatric consequences, and to help victims recover from human rights abuses.

#### → Nomination Procedures ←

APA members are asked to submit nominations by July 1, 2010 to:

Council on Psychiatry and Law American Psychiatric Association c/o Yoshie Davison, Staff Liaison 1000 Wilson Blvd., Suite 1825 Arlington, VA 22209 E-mail: advocacy@psych.org

The nomination letter should succinctly describe the contributions that are the basis for the nomination and be accompanied by a curriculum vitae of the nominee. The Council on Psychiatry and Law will serve as the award review panel in determining the recipients of this award. The recipients will receive a plaque which will be awarded during the Convocation at the APA's Annual Meeting in May 2011.

# saac Rav Awa

The American Psychiatric Association and the American Academy of Psychiatry and the Law invites nominations for the Isaac Ray Award for 2011. This Award honors Dr. Isaac Ray, one of the original founders and the fourth President of the American Psychiatric Association, and is presented to a person who has made outstanding contributions to forensic psychiatry or to the psychiatric aspects of jurisprudence. The Award, which will be presented at the Convocation of Fellows at the Annual Meeting of the American Psychiatric Association in Honolulu, HI, in May 2011, includes an honorarium of \$1,500. The recipient obligates him or herself to deliver a lecture or series of lectures on these subjects and to present the manuscript for publication.


Nominations are requested as follows:

- 1. Primary nominating letter (sent with the consent of the candidate), which includes a curriculum vitae and specific details regarding the candidate's qualifications for the Award.
- Supplemental letter from a second nominator in support of the candidate. Additional letters related to any particular candidate will not be accepted or reviewed by the Award Committee. Nominators should not submit letters on behalf of more than one candidate.

The deadline for receipt of nominations is July 1, 2010. Nominations will be kept in the pool of applicants for two years.

Nominations, as outlined above, should be submitted to:

Renee L. Binder, M.D., Chairperson c/o Yoshie Davison, Staff Liaison Isaac Ray Award Committee **American Psychiatric Association** 1000 Wilson Boulevard, Suite 1825 Arlington, VA 22209 E-mail: advocacy@psych.org



- DVD-ROM with online access available for purchase
- Exclusive on-site attendee pricing\* save up to \$500
- Earn AMA PRA Category 1 Credit™

For more information or to purchase, visit the booths located in Lobby B1 or near the Registration Area in Hall B2.

# The 2010 APA ANNUAL MEETING ONLINE

www.psych.org/amlibrary

The American Psychiatric Association is accredited by the ACCME to provide continuing medical education for physicians. The APA designates (each of the presentations) in this educational activity for a maximum of 1-3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.



<sup>\*</sup> On-site pricing expires May 26, 2010. Residents/Students save \$500, other attendees save \$400



#### PROGRAM BOOK, NEW RESEARCH PROGRAM BOOK, EXHIBITS GUIDE

his book contains the Program Book, New Research Program Book and Exhibits Guide. Listed below you will find the Table of Contents for ease in locating information about this meeting and the City of New Orleans. Located within the Program Book you will find a topic index in addition to subspecialty, topic and other program tracks that will assist you in finding scientific sessions of interest. The individual program for each day of the meeting is separated by pull-out tabs so that you can easily find the day(s) of the meeting that interests you. The program is listed by start time with the formats listed alphabetically under those times. To make it even easier to plan your day a separate Days-at-a-Glance has

been included with your registration materials. The New Research Program Book contains all of the posters that will be presented at this meeting, along with a topic index that contains only the posters that are on the New Research Program. The Exhibits Guide contains a list of the exhibitors and a floor plan of the exhibit hall, along with information about the Product Theaters.

If you have any questions about this book or the scientific program, please feel free to stop by the Scientific Programs Office, Room 204, Second Level, Morial Convention Center and an APA staff person will be happy to assist you. All central office APA staff will be wearing green badges. Please feel free to direct your questions to any APA staff.









GUIDE TO THIS BOOK5	Tuesday's Program103
Table of Contents5	Wednesday's Program117
SCIENTIFIC PROGRAM COMMITTEE PHOTO6	TOPIC INDEX126
WELCOME LETTER FROM APA PRESIDENT, ALAN F. SCHATZBERG, M.D	New Research Program Book137
	Monday's Program138
WELCOME LETTER FROM SCIENTIFIC PROGRAM CO-CHAIRS: JULIO LICINIO, M.D. AND DONALD M. HILTY, M.D	TUESDAY'S PROGRAM150
	Wednesday's Program159
GENERAL INFORMATION AND KEY LOCATIONS8	TOPIC INDEX165
SHUTTLE BUS SCHEDULE	Exhibits Guide169
HOTEL LOCATIONS AND CITY MAP15	GENERAL INFORMATION
FLOOR PLANS	·
Presidents of U.S. Allied Organizations22	PRODUCT THEATERS
Presidents of International Allied	•
ORGANIZATIONS24	EXHIBITORS WITH PRODUCT/ SERVICE DESCRIPTIONS189
SPECIAL ACKNOWLEDGEMENTS	EXHIBITORS BY PRODUCT/
DISCLOSURE INDEX	Service Listing210
PROGRAM BOOK	CAREER FAIR AND PUBLISHING
FORMAT DESCRIPTIONS58	BOOK FAIR EXHIBITORS214
Daily Attendance Log 60	NUMERICAL LIST OF EXHIBITORS BY BOOTH NUMBER218
SATURDAY'S PROGRAM61	EXHIBIT HALL FLOOR PLAN219
SUNDAY'S PROGRAM75	List of Advertisers225
Mondays' Program85	AUTHOR/PRESENTER INDEX226



Front Row - Seated Left to Right: Geetha Jayaram, M.D., Joel J. Silverman, M.D., Donald M. Hilty, M.D. (Co-Chairperson), Julio Licinio, M.D., (Chairperson), Alan F. Schatzberg, M.D. (APA President), Renato D. Alarcon, M.D., Annette M. Matthews, M.D. Second Row - Standing Left to Right: Stephen M. Goldfinger, M.D., Mark S. George, M.D., Iqbal Ahmed, M.D., Maria I. Lapid, M.D., Sidney H. Weissman, M.D., Catherine C. Crone, M.D., Carlos N. Pato, M.D., Michele T. Pato, M.D., Tana A. Grady-Weliky, M.D. Third Row - Standing Left to Right: Carl B. Feinstein, M.D., Michael F. Myers, M.D., Radu V. Saveanu, M.D., Kenneth R. Silk, M.D., Madhukar H. Trivedi, M.D., Jesse H. Wright, M.D., Barton J. Blinder, M.D., Josepha A. Cheong, M.D. Not Pictured: David A. Baron, D.O., M.Ed., Maurizio Fava, M.D., Terrence A. Ketter, M.D., Surinder S. Nand, M.D.

# Dear Colleagues and Guests:

elcome to the 163rd Annual Meeting of the American Psychiatric Association in New Orleans, a unique American city and world-class conference location noted for its rich cultural diversity, arts and entertainment, and outstanding restaurants. I think you'll find the program stronger than ever this year, reflecting a combination of new science and clinical advances.

"Pride and Promise: Toward a New Psychiatry" is my theme for the meeting. To implement this theme, we called on our academic leaders to develop a comprehensive and balanced program, inviting the best psychiatristscientists from around the world to present their work in special lectures, scientific symposia, workshops and other interactive sessions. Senior scholars such as Daniel Weinberger, M.D., Florian Holsboer, M.D., Ph.D., Eve Johnstone, M.D., Mario Maj, M.D., Ph.D., Raquel Gur, M.D., Ph.D., and Francene Benes, MD, PhD, will address us on their exciting work in depression and schizophrenia. We will also have some of the top young M.D./Ph.D.s from around the country—such as Karl Deisseroth, Kerry Ressler, Vikaas Sohol, Amit Etkin, and others—show us where the field is heading.

We are delighted to be partnering once again with the National Institute on Drug Abuse (NIDA) to show how cutting-edge science on substance use disorders is informing clinical practice. Lectures by its director, Nora Volkow, M.D., and A. Thomas McLellan, Ph.D., deputy

director of the White House Office of National Drug Control Policy, are headlining the NIDA track.

FocusLive, the Advances In series (in partnership with the American Psychiatric Publishing Inc.), Advances in Medicine, and Advances in Research (the latter chaired by former NIMH director and APA president Herbert Pardes, M.D.), all return by popular demand. Attendees also have the opportunity to be in the vanguard regarding DSM-5. A special track of DSM-5 sessions will provide insight into the evolving manual and will solicit attendees' opinions on a number of key issues.

Look for symbols throughout the Program Book to help you find sessions in a variety of topical tracks that may relate to your research interests and clinical practice as well as subspecialty tracks published in the Days-At-a-Glance brochure. We hope these tools will make it easier for you to navigate the meeting and we would appreciate your feedback on this innovation.

My thanks go to co-chairs, Julio Licinio, M.D., and Donald Hilty, M.D., and members of the Scientific Program Committee, and to the APA staff members who have all worked so diligently to ensure the breadth and quality of the 2010 Annual Meeting program.

Sincerely,

Ale o. lehgher 100

Alan F. Schatzberg, M.D.

### Dear APA Members and Guests:

elcome to New Orleans for the 163rd Annual Meeting of the American Psychiatric Association. We are proud to contribute to the resurgence of this unique American city. As always, APA members will not want to miss two activities on Sunday: the Business Meeting (12:30 p.m.-1:30 p.m.) and the Opening Session (4:30 p.m.-5:45 p.m.). Please also make sure to attend the Convocation of Distinguished Fellows on Monday beginning at 5:30 p.m., which recognizes newly inducted fellows and distinguished fellows and honors this year's award recipients. We are excited to have acclaimed actor and author, Carrie Fisher, present the William C. Menninger Memorial Lecture following the Convocation.

This year the Scientific Program Committee (SPC) collaborated with APA President, Dr. Alan F. Schatzberg, to plan an exciting and eventful program reflecting his theme, Pride and Promise: Toward a New Psychiatry. We've taken "Toward a New Psychiatry" to heart in crafting some major innovations in the meeting. Two changes are most notable: 1) the core Scientific Program now starts on Saturday, thus enabling clinicians to take less time away from their offices; and 2) a new publication, the Annual Meeting Guide, combining the Program Book, the New Research Poster Program and the Exhibits Guide in one handy volume.

The Scientific Program Committee selected sessions in a broad spectrum of approaches to teaching and learning: symposia, workshops and other small interactive sessions, lectures, case conferences, and forums. This year we are

the introducing the seminar format, an extended-learning session, and we are experimenting with evening (7 p.m.-10 p.m.) media workshops. All are part of the CME Scientific Program open to all registrants.

We would like to encourage you particularly to attend the five Presidential Symposia on the neurobiology of antidepressant treatment response (with the Society of Biological Psychiatry), comparative effects of psychotropic drugs, basic and translational neuroscience to improve treatment, psychiatric genetics and health care reform.

We encourage all attendees to either fill out an evaluation here or to do so online following the meeting as you reflect on your experiences. Your feedback on the relevance and quality of this year's program to your practice needs as well as your insights into gaps in knowledge and clinical practice that we can address in future meetings is highly valued. Once again, welcome to New Orleans, a city, which like our meeting, can also be defined by "Pride and Promise." We are delighted to have the privilege of sharing with you the best that our field has to offer.

Sincerely,

Julio Licinio, M.D. Co-Chairperson Scientific Program Committee Danald M. Hilton

Don Hilty, M.D. Co-Chairperson Scientific Program Committee





#### KEY LOCATIONS IN THE MORIAL CONVENTION CENTER

APA ALLIANCE Halls A/B Lobby, First Level
APA ART ASSOCIATION Hall A Lobby, First Level
APA JOB BANK AND PLACEMENT CENTER Exhibit Halls B-D, First Level
APA MEMBER CENTER Exhibit Halls B-D, First Level
APA News Room Rooms 211-213, Second Level
APA PERIODICALS Exhibit Halls B-D, First Level
AUDIOVISUAL PREVIEW ROOM Room 207, Second Level
CME CERTIFICATE OF Exhibit Halls B/C, First Level
Attendance and Evaluation Course Enrollment Exhibit Halls B/C, First Level
DAILY BULLETIN Room 216, Second Level
DVD, MP3, AND APA ONLINE LIBRARY SALES Halls A/B Lobby, First Level
<b>Exhibitor Registration</b> Hall B Lobby, First Level
Exhibits/
Publishers' Book Fair Exhibit Halls B-D, First Level
PUBLISHERS' BOOK FAIR Exhibit Halls B-D, First Level  FIRST AID Medical Services 1,  (outside of Exhibit Hall B, First Level)
FIRST AID Medical Services 1,
FIRST AID Medical Services 1, (outside of Exhibit Hall B, First Level)
FIRST AID
FIRST AID
FIRST AID
FIRST AID

#### APA ALLIANCE

Located in Halls A/B Lobby, First Level, Morial Convention Center. The days and hours of operation are as follows: Saturday-Tuesday, 9:00 a.m.-4:00 p.m. Stop by to obtain information on the Alliance's program schedule and information on membership.

#### APA ART ASSOCIATION

Located in Hall A Lobby, First Level, Morial Convention Center. The days and hours of operation are as follows: Sunday, 10:00 a.m.-4:30 p.m.; Monday-Tuesday, 10:00 a.m.-5:00 p.m.; and Wednesday, 10:00 a.m.-3:00 p.m. This exhibit includes paintings, photography, ceramics, and crafts created by APA members and/or their significant others. Stop by for information on joining the APA Art Association.

#### APA JOB BANK AND PLACEMENT CENTER

Visit the APA Job Bank, located in Exhibit Halls B-D, First Level, Morial Convention Center, to search the most comprehensive online listing of psychiatric positions! The days and hours of operation are as follows: Saturday-Tuesday, 7:30 a.m.-4:00 p.m. Candidates: Register to post your resume, receive instant job alerts, use the career tools and more. Employers: Post your job opening during the meeting to get results as soon as possible. For more information on the Job Bank, visit www.psych.org/jobbank. A representative will be available on-site to provide assistance.

#### APA MEMBER CENTER

Located in Exhibit Halls B-D, First Level, Morial Convention Center. The days and hours of operation are as follows: Saturday-Tuesday, 10:00 a.m.-4:00 p.m. The Member Center closes at 4:00 p.m. on Tuesday. A few of the many APA activities exhibited include: Membership; APA's Internet-Based Programs; Continuing Medical Education; Quality Improvement; Psychiatric Services; Clinical Resources; Advocacy Tools; Career Development; Practice Management; and APA Periodicals.

#### APA NEWS ROOM AND COMMUNICATIONS OFFICE

Located in Rooms 211-213, Second Level, Morial Convention Center. The days and hours of operation are as follows: Saturday, 11:00 a.m.-5:00 p.m.; Sunday-Tuesday, 8:00 a.m.-6:00 p.m.; and Wednesday, 8:00 a.m.-1:00 p.m. These rooms are for the use of registered press and credentialed public relations representatives only.

#### APA PERIODICALS

Editorial staff from the American Journal of Psychiatry, Psychiatric Services, Academic Psychiatry, Journal of *Neuropsychiatry and Clinical Neurosciences, Psychosomatics,* and APA's CME journal, Focus, will be on hand to demonstrate online access for subscribers, and answer questions regarding submissions. Visitors can also purchase or renew subscriptions to all APA/APPI journals at the APPI booth, located in the Exhibit Hall. Complimentary copies of *Psychiatric News* will be available at stands located throughout the Morial Convention Center. Persons who wish to contact editors or reporters of Psychiatric News are asked to leave a message on the message board in the Meetings and Conventions Office, located in Room 214, Second Level, Morial Convention Center. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit in the APA Member Center, located in Exhibit Halls B-D, First Level, Morial Convention Center.

#### AUDIOVISUAL PREVIEW ROOM

Located in Room 207, Second Level, Morial Convention Center. The days and hours of operation are as follows: Saturday-Tuesday, 7:30 a.m.-4:30 p.m.; and Wednesday, 7:30 a.m.-2:00 p.m. The Scientific Program Committee expects all presenters to preview their audiovisual materials prior to their sessions to familiarize themselves with the equipment. For your convenience, an audiovisual technician will be available to assist you and answer your questions.

#### CME CERTIFICATE OF ATTENDANCE AND EVALUTAION

The Scientific Program Committee needs your recommendations and evaluations to assess the effectiveness of the program and plan next year's Annual Meeting. The general evaluation is available online at the CME Certificate of Attendance booth, located in Exhibit Halls B/C, First Level, Morial Convention Center. The days and hours of operation are as follows: Saturday-Tuesday, 7:30 a.m.-4:00 p.m.; and Wednesday, 7:30 a.m.-5:30 p.m. After you complete the general evaluation you will receive a personalized Certificate of Attendance. This certificate can either be obtained on-site by visiting the CME Certificate of Attendance booth OR you may access the web-based evaluation from your own computer either during or after the meeting by visiting www.psych. org/annualmeetingcme. You will need your badge number to obtain the CME Certificate of Attendance and access the evaluation form using the web. Please Note: APA no longer offers a paper version of the general evaluation form.

#### CONTINUING MEDICAL EDUCATION

#### **EDUCATIONAL OBJECTIVES**

At the conclusion of this meeting the participant will be able to:

- 1. Review new research findings in the fields of psychiatry and neuroscience and address gaps in knowledge;
- 2. Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
- **3.** Identify and remove barriers to the transfer of new knowledge for your practice, including provision of culturally competent care for diverse populations;
- 4. Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and

5. Recognize mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 50 AMA PRA Category 1 Credits T. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Please note: Formats on the scientific program, as outlined below, have been approved for CME credit.

The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for AMA PRA Category 1 Credit<sup>™</sup>. Sessions in the following program formats are designated as category 1: Advances in ... Series; Case Conferences; CME Courses; Focus Live; Forums; Industry-Supported Symposia; Lectures; Master Courses; Presidential Symposia; Scientific and Clinical Reports; Seminars; Small Interactive Sessions; Symposia; and Workshops.

New Research Poster Sessions are not designated for AMA PRA Category 1 Credit ....

Scientific sessions are open to all Annual Meeting registrants with the exception of Case Conferences, which are open to APA members only. CME Courses and Master Courses require an additional fee.

To document CME credit earned at the Annual Meeting, participants should maintain a list of sessions they attended. Credit is earned on an hour-for-hour basis. A daily attendance log is provided in this book for listing your sessions and

#### COURSE ENROLLMENT

#### Ticket Purchase Is Required For All Courses.

Located in Exhibit Halls B/C, First Level, Morial Convention Center. The days and hours of operation are the same as registration. Course tickets not sold in advance will be available on-site at the Course Enrollment Area beginning at 12 noon on Friday. You must be registered for the meeting before you can enroll in courses.

#### DAILY BULLETIN

Located in Room 216, Second Level, Morial Convention Center, the Daily Bulletin accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday and Wednesday issues can be dropped off in Room 216 by 12 noon the day before the publication date.

#### DVD, MP3, AND APA ONLINE LIBRARY SALES

Located in Halls A/B Lobby, First Level, Morial Convention Center. The days and hours of operation are as follows: Saturday-Wednesday, 9:00 a.m.-5:00 p.m. Over 100 hours of CME programs will be available for purchase on DVD, MP3, and the APA Online Library.

#### EXHIBITOR REGISTRATION

Located in Hall B Lobby, First Level, Morial Convention Center. The days and hours of operation are as follows: Wednesday-Friday, 8:00 a.m.-5:00 p.m.; Saturday, 8:00 a.m.-6:00 p.m.; Sunday, 7:30 a.m.-4:00 p.m.; and Monday-Tuesday, 8:00 a.m.-4:00 p.m. Registered exhibitors will receive red badges that will permit access only to his/her exhibit booth in the Exhibit Hall and to ride the APA shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

#### EXHIBITS/PUBLISHERS' BOOK FAIR

Commercial and educational exhibits will be located in Exhibit Halls B-D, First Level, Morial Convention Center, along with the Publishers' Book Fair. For your convenience, the Publishers' Book Fair will be open on Saturday, from 10:00 a.m.-4:00 p.m. Educational and commercial exhibit hours are as follows: Sunday-Tuesday, 10:00 a.m.-4:00 p.m. The exhibits and Publishers' Book Fair close at 4:00 p.m. on Tuesday.

#### FIRST AID

Located in Medical Services 1, (outside of Exhibit Hall B), First Level, Morial Convention Center, the hours of operation are as follows: Monday, May 17-Wednesday, May 26. First aid opens 30 minutes prior to the show opening and closes 30 minutes after the last event of the evening.

#### LOST AND FOUND

Located in Room 214, Second Level, Morial Convention Center. The days and hours of operation are listed under Meetings and Conventions Office.

#### MEETINGS AND CONVENTIONS OFFICE

Located in Room 214, Second Level, Morial Convention Center. The days and hours of operation are as follows: Friday, 8:00 a.m.-5:00 p.m.; Saturday, 6:30 a.m.-4:30 p.m.; Sunday, 7:00 a.m.-5:30 p.m.; Monday, 7:00 a.m.-6:30 p.m.; and Tuesday-Wednesday, 7:00 a.m.-5:30 p.m. The staff located in the Meetings and Conventions Office is in charge of the logistics for the meeting. Lost and found is also located in this office.

#### MESSAGE CENTERS

Located in Halls A/B Lobby, First Level; Exhibit Halls B/C, First Level; and North Skylight, Second Level, Morial Convention Center. The days and hours of operation are as follows: Friday, 12 noon-4:00 p.m.; Saturday-Tuesday, 7:30 a.m.-4:00 p.m.; and Wednesday, 7:30 a.m.-4:00 p.m. Messages can be left and retrieved at any of the Message Centers. Registrants whose names appear on these monitors should pick up their message at one of the three Message Centers.

#### REGISTRATION

Admission To All Sessions Is By Registration Badge Only.

Located in Exhibit Halls B/C, First Level, Morial Convention Center. The days and hours of operation are as follows: Friday, 12 noon-5:00 p.m.; Saturday,-Tuesday, 7:30 a.m.-4:00 p.m.; and Wednesday, 7:30 a.m.-2:00 p.m. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book/New Research Program Book/Exhibits Guide, APA Member Center Guide, New Research Program Abstracts, and for most categories, the Syllabus. Registration badges are required for all sessions and the Exhibit Hall. Only an APA member badge will admit you to the Business Meeting.

#### **Badge Color Codes:**

Blue=Members; Yellow=Nonmembers; Silver=Press: Red=Exhibitors: Green=APA Staff; and Clear=Temporary Personnel.

#### SCIENTIFIC PROGRAMS OFFICE

Located in Room 204, Second Level, Morial Convention Center. The days and hours of operation are as follows: Friday, 12 noon-4:00 p.m.; and Saturday-Wednesday, 7:30 a.m.-5:00 p.m. Come to this office if you have questions about:

- 1. Scientific sessions listed in the Program Book or Syllabus;
- 2. Adding audiovisual equipment to scientific sessions;
- 3. Scientific program changes;
- 4. Submitting a scientific session for the 2011 Annual Meeting; and
- **5.** The 2010 Institute on Psychiatric Services.

#### SCIENTIFIC SESSION CAPACITY GUIDELINES

If overcrowding occurs in a scientific session we ask your assistance so that all in attendance can benefit. Please abide by the following guidelines if you are in a crowded room.

- 1. Take a seat as close to the front of the room as possible;
- 2. Move to the center of the row and fill all seats, so that chairs are available on the aisles for additional attendees:
- **3.** Don't stand or sit in the aisles or lean against walls. Overcrowding of meeting rooms may subject the session to shut down by the Fire Marshall; therefore, please either find a seat or attend another session; and
- **4.** If there are no seats available, a DVD of the session might be available. Please check the DVD order form that is included with your registration materials.

# 🥵 GENERAL INFORMATION

#### SHUTTLE BUS SERVICE

You must be a registered attendee or a registered exhibitor to ride on the courtesy shuttle bus. Shuttle bus service will begin on Saturday, at approximately 7:00 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule and will conclude on Wednesday, at 5:00 p.m. The Morial Convention Center will serve as the "hub" for all shuttle bus routes. The Shuttle Bus Desk is located in Halls A/B Lobby, First Level, Morial Convention Center. A detailed shuttle bus schedule will be available upon receipt of your registration materials and will be posted in the lobbies of participating hotels.

#### **SMOKING POLICY**

There will be **NO SMOKING** in scientific sessions or in the Exhibit Hall. Smoking will only be permitted in designated areas.

#### TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Attendees are welcome to use their own small, portable audiotape recorders to record any session except Case Conferences, unless prohibited by the presenters. Larger, professional tape recorders are not permitted except for use by registered members of the working press in accordance with APA Press Policies. APA has authorized

a professional firm to tape sessions. Badges of personnel representing this firm will clearly identify them. Attendees are not permitted to photograph (including with cell phone cameras) or videotape any session because the intrusive nature of the recording may disrupt the session.

#### FUTURE APA MEETINGS APA ANNUAL MEETINGS

May 14-18, 2011 Honolulu, HI

May 5-9, 2012 Philadelphia, PA

May 18-22, 2013 San Francisco, CA

#### INSTITUTES ON PSYCHIATRIC SERVICES

October 14-17, 2010 Boston, MA

San Francisco, CA October 27-30, 2011

October 4-7, 2012 New York, NY

The Preliminary Program for the 2010 Institute on Psychiatric Services, which includes registration, housing, air travel, and program information is available on the web at <www.psych. org/IPS>.





# The APA Store – Pride in Your Profession

Show pride in your profession by displaying your APA logo merchandise! Stop by the APA Store during the Annual Meeting in New Orleans to choose from office products, menswear, ladies fit t-shirts, children's wear, accessories and more.



#### **LOCATION:**

**Ernest N. Morial Convention Center, Main Registration Hall** (next to the APA Membership Desk.)

#### **APA STORE HOURS:**

Saturday, May 22 through Tuesday, May 25: 8:00am - 4:00pm

Wednesday, May 26: 8:00am - 2:00pm





#### TO THE ERNEST N. MORIAL CONVENTION CENTER

omplimentary shuttle service is provided between the Ernest N. Morial Convention Center (ENMCC) and the official APA hotels listed below. The ENMCC will operate as the

"hub" of the APA shuttle bus system. All routes will begin and end there. Shuttle information signs will be posted in the lobby of each shuttle hotel. Check the sign in your hotel lobby for additional information and changes.

SHUTTLE SCHEDULE					
SATURDAY, May 22, 2010	7:00 am-5:30 pm *	Every 20 minutes			
	7:30 am-10:00 am	Every 10-15 minutes			
SUNDAY, May 23, 2010	10:00 am-3:30 pm	Every 20 minutes			
	3:30 pm-6:30 pm	Every 10-15 minutes			
	6:30 pm-7:30 pm *	Every 20 minutes			
	7:30 am-10:00 am	Every 10-15 minutes			
MONDAY, May 24, 2010	10:00 am-3:30 pm	Every 20 minutes			
	3:30 pm-7:30 pm *	Every 10-15 minutes			
	7:30 am-10:00 am	Every 10-15 minutes			
TUESDAY, May 25, 2010	10:00 am-3:30 pm	Every 20 minutes			
	3:30 pm-6:30 pm *	Every 10-15 minutes			
	7:30 am-11:00 am	Every 10-15 minutes			
WEDNESDAY, May 26, 2010	11:00 am-3:30 pm	Every 20 minutes			
	3:30 pm-5:30 pm *	Every 10-15 minutes			

<sup>\*</sup> This is the time that the last shuttle departs from ENMCC returning to hotels. Last shuttle from hotels to ENMCC departs 1 hour prior to this time.

### HOTELS WITHIN WALKING DISTANCE TO THE ENMCC

Courtyard Convention Center

**Embassy Suites** 

Hampton Inn & Suites Convention Center

Hilton Garden Inn Convention Center

Hilton New Orleans Riverside

Hotel New Orleans

New Orleans Marriott Convention Center

Renaissance Arts Hotel

Residence Inn Convention Center

Springhill Suites Convention Center

Wyndham Riverfront New Orleans

HOTELS LISTED IN ORDER OF PICK UP				
	HOTEL	BOARDING LOCATION		
	Westin New Orleans Canal Place	Curbside on Iberville		
ROUTE #1 RED	Doubletree New Orleans	Curbside on Tchoupitoulas, across the street		
	W New Orleans	At Doubletree New Orleans		
	Windsor Court Hotel	At Doubletree New Orleans		
	Loews New Orleans	Curbside on Poydras		
	Staybridge Suite New Orleans	At Loews		
Route #2 YELLOW	New Orleans Marriott	Curbside on Canal		
Noule #2 TELLOW	Holiday Inn French Quarter	At New Orleans Marriott		
	Omni Royal Crescent Hotel	Corner of Camp and Gravier		
	Sheraton	Curbside on Canal		
Route #3 BLUE	St. James Hotel	Curbside on Magazine		
	Country Inn & Suites	At St. James Hotel		
	Pelham Hotel	At St. James Hotel		
	Astor Crowne Plaza	Curbside on Canal		
Route #4 ORANGE	Ritz Carlton	Curbside on Canal		
	Chateau Bourbon	At Ritz Carlton		
	InterContinental New Orleans	Curbside on Poydras, at St. Charles		
	Hilton Saint Charles Avenue	At InterContinental		
	Hampton Inn Downtown French Quarter	Curbside on Carondelet		
Route #5 GREEN	Hilton Garden Inn French Quarter	At Hampton Inn		
	Holiday Inn Express French Quarter	At Hampton Inn		
	Renaissance Pere Marquette	At Hampton Inn		
	JW Marriott	Curbside on Canal		
	Courtyard Downtown St. Charles	At JW Marriott		
	The Roosevelt, Waldorf Astoria	Curbside on Baronne		
Route #6 PINK	Le Pavillon	Curbside on Baronne		
RUULE #O PINN	Drury Inn & Suites	Curbside on Poydras		
	Whitney	Curbside on Poydras		
	Hotel Monteleone	On Bienville at Royal		
	St. Ann Marie Antoinette Hotel	On Bienville at Royal		
Route #7 PURPLE	Royal Sonesta	On Bienville at Bourbon		
	Saint Louis Hotel	On Bienville at Bourbon		
	Chateau LeMoyne French Quarter	On Bienville at Dauphine		
	Maison Dupuy Hotel	On Toulouse at Burgundy		
Route #8 BLACK	Inn on Bourbon Ramada Plaza	On Toulouse at Bourbon		
	Omni Royal Orleans	On Toulouse at Chartres		

# 163rd Annual Meeting of the American Psychiatric Association

**Rethinking Schizophrenia Management:** 

#### Monday, May 24, 2010

**Ernest N. Morial Convention Center** New Orleans, Louisiana Room 231/232

9:30 AM - 10:00 AM


#### **Speaker**

Henry A. Nasrallah, MD

Professor of Psychiatry and Neuroscience University of Cincinnati College of Medicine Cincinnati, Ohio

Paid for and content controlled by:





- This promotional educational activity is not accredited
- The program content is developed by Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
- Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines
- · Invitations to participants may not be extended to include spouses or other guests

The Industry Product Theater's content and the views expressed therein are those of the sponsor and not of APA or APF.

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2010 May 2010 01PM10020E

Please join us for a Product Theater Presentation at the 163rd Annual Meeting of the American Psychiatric Association

Coffee and Refreshments will be served

**Acute Treatment of Schizoaffective Disorder:** 

Addressing the Clinical Challenges

### ■ Tuesday, May 25, 2010

**Ernest N. Morial Convention Center** 

New Orleans, Louisiana Room 231/232

9:30 AM - 10:00 AM

#### **■ SPEAKER**

Jelena L. Kunovac, MD, MS

Founder and Medical Director **Excell Research** Oceanside, California

If you are licensed in any state or other jurisdiction or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements. Your name, the value, and purpose of any educational item, meal or other items of value you received may be reported as required by state or federal law. Once reported, this information may be publicly accessible. Thank you for your cooperation.

- This promotional educational activity is not accredited
- The program content is developed by Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
- Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines
- Invitations to participants may not be extended to include spouses or other guests

The Industry Product Theater's content and the views expressed therein are those of the sponsor and not of APA or APE.



Paid for and content controlled by:











# Join APA at the Annual Meeting and Qualify for a Rebate!



# **How Do I Qualify?**

You may qualify if you:

- 1. Are a psychiatrist residing in the U.S. or Canada and,
- 2. Have paid the full-time non-member registration fee for the Annual Meeting (\$905.00 advance, \$950.00 on-site).

# **How Do I Apply?**

- 1. Stop by one of the APA Membership Booths either in the Registration area (near the Registrar) or in the APA Member Center (Exhibit Halls B–D) to fill out an APA Membership Application. The application must be submitted on-site during the meeting at one of these locations.
- 2. Additional documentation—proof of ACGME-AOA or RCPS(C)—approved psychiatry residency training and a current, valid medical license must be received by APA no later than June 30, 2010.


#### **How Does the Rebate Work?**


- 1. Your local psychiatric district branch must approve the application no later than September 30, 2010.
- 2. The difference between the member and non-member Annual Meeting registration fee will be applied towards your pro-rated 2010 national and local dues. The remaining balance of the rebate amount will be applied toward future years' dues.\*

# Why Should I Join?

When you join the APA, you become part of a 38,000 member organization of physicians who specialize in the diagnosis, treatment, and prevention of mental illnesses. The APA unites psychiatrists from around the world and brings together practice, education, and research at all levels. As the largest psychiatric membership organization in the world, we are dedicated to promoting the highest quality care for patients, providing continuing education and research into mental illnesses, and advocating for psychiatrists and their profession.

Please visit www.psych.org/membership for additional information or stop by one of the APA Membership Booths at the Annual Meeting to learn more about the benefits of membership.





- 1 ASTOR CROWNE PLAZA
- 2 CHATEAU BOURBON
- 3 CHATEAU LEMOYNE FRENCH QUARTER
- 4 COUNTRY INN & SUITES
- 5 COURTYARD CONVENTION CENTER
- 6 COURTYARD DOWNTOWN ST. CHARLES
- 7 DOUBLETREE NEW ORLEANS
- 8 DRURY INN & SUITES
- 9 EMBASSY SUITES NEW ORLEANS
- 10 HAMPTON INN & SUITES CONV CTR
- 11 HAMPTON INN DOWNTOWN FQ
- 12 HILTON GARDEN INN CONV CTR

- 13 HILTON GARDEN INN FQ
- 14 HILTON NEW ORLEANS RIVERSIDE
- 15 HILTON ST. CHARLES AVENUE
- 16 HOLIDAY INN EXPRESS FQ
- 17 HOLIDAY INN FRENCH QUARTER
- 18 HOTEL MONTELEONE
- 19 HOTEL NEW ORLEANS
- **20** IBERVILLE SUITES
- 21 INN ON BOURBON, RAMADA PLAZA
- 22 INTERCONTINENTAL NEW ORLEANS
- 23 JW MARRIOTT
- 24 LE PAVILLON


- 25 LOEWS NEW ORLEANS
- **26 MAISON DUPUY HOTEL**
- 27 NEW ORLEANS MARRIOTT
- 28 NEW ORLEANS MARRIOTT CONV CTR
- 29 OMNI ROYAL CRESCENT HOTEL
- 30 OMNI ROYAL ORLEANS
- 31 PELHAM HOTEL
- 32 RENAISSANCE ARTS HOTEL
- 33 RENAISSANCE PERE MARQUETTE
- 34 RESIDENCE INN CONV CTR
- 35 RITZ CARLTON NEW ORLEANS
- 34 KESIDENGE INN GONV CIK

**36 ROYAL SONESTA HOTEL** 


- 37 ST. LOUIS HOTEL
- **38 SHERATON NEW ORLEANS**
- 39 SPRINGHILL SUITES CONV CTR
- 40 ST. ANN-MARIE ANTIONETTE HOTEL
- 41 ST. JAMES HOTEL
- 42 STAYBRIDGE SUITES NEW ORLEANS
- 43 THE ROOSEVELT, WALDORF ASTORIA
- 44 THE WHITNEY, WYNDHAM HISTORIC HOTEL
- 45 W NEW ORLEANS
- 46 WESTIN NEW ORLEANS CANAL PLACE
- 47 WINDSOR COURT HOTEL
- **48** WYNDHAM RIVERFRONT




#### FIRST LEVEL



#### SECOND LEVEL



CITYSIDE MEETING ROOMS










#### THIRD FLOOR



FOURTH FLOOR











# 🥵 FLOOR PLANS/HILTON NEW ORLEANS RIVERSIDE

#### STREET LEVEL











- · One of the five largest free-standing behavioral health providers in the U.S.
- · Access to diverse career experiences in a behavioral health environment
- Adjunct assistant professor appointment with Michigan State University's College of **Human Medicine**
- · Full continuum of services for children, adolescents and adults
- Christian integrity and compassion



www.pinerest.org

Remember to visit us at the APA Annual Meeting! (Booth 2013)



# Turn to NeuroStar®

NeuroStar Transcranial Magnetic Stimulation Therapy® is the only FDA-cleared, non-drug, non-invasive treatment for depression.

NeuroStarTMS Therapy® is indicated for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement



from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.

Meet the TMS Experts at the APA Booth # 224. For schedule and topics visit www.neurostartms.com/meettheexperts



A new direction in the treatment of depression.

For a free information pack on how NeuroStar® TMS may work for you and your patients contact us at 877-600-7555 or visit us on the web at www.neurostartms.com

# PRESIDENTS OF U.S. ALLIED ORGANIZATIONS

Academy of Cognitive Therapy

Robert Leahy, M.D.

Academy of Organizational and Occupational Psychiatry

Steven E. Pflanz, M.D.

American Academy of Addiction Psychiatry

Joseph G. Liberto, M.D.

American Academy of Child and Adolescent **Psychiatry** 

Laurence L. Greenhill, M.D.

American Academy of Family Physicians

Lori J. Heim, M.D., FAAFP

American Academy of Neurology

Robert C. Griggs, M.D., FAAN

American Academy of Psychiatry and the Law

Stephen G. Billick, M.D.

American Academy of Psychoanalysis and Dynamic Psychiatry

Cesar A. Alfonso, M.D.

American Association for Emergency Psychiatry

Scott L. Zeller, M.D.

American Association for Social Psychiatry

Charles W. Huffine, Jr., M.D.

American Association for the Advancement of Science

Alice X. Huang, M.D.

American Association of Chairs of Departments of Psychiatry

Laura W. Roberts, M.D.

American Association of Community Psychiatrists

Hunter L. McQuistion, M.D.

American Association of Directors of Psychiatric Residency Training

Sheldon Benjamin, M.D.

American Association of Psychiatric Administrators Douglas M. Brandt, M.D.

American Association on Mental Retardation

Joanna Pierson, Ph.D.

American Association of Practicing Psychiatrists

Ianis G. Chester, M.D.

American Board of Psychiatry and Neurology, Inc.

Larry R. Faulkner, M.D.

American College of Emergency Physicians

Angela Gardner, M.D., FACEP

American College of Obstetricians and Gynecologists

Richard N. Waldman, M.D.

American College of Physicians-American Society of Internal Medicine

J. Fredo Ralston, Jr., M.D., FACD

American College of Psychiatrists

John M. Oldham, M.D.

American College of Psychoanalysts

Varmik D. Volkan, M.D.

American College of Suraeons

LaMar S. McGinnis, Jr., M.D., **FACS** 

American Group Psychotherapy Association

Jeffrey Kleinberg, Ph.D., CGP,

American Medical Association

Ardis Dee Hoven, M.D.

American Medical Women's Association

Eliza L. Chin, M.D.

American Neurological Association

Robert L. Macdonald, M.D., Ph.D.

American Neuro-psychiatric Association

Paula T. Trzepacz, M.D.

American Nurses Association Rebecca M. Patton, M.S.N., R.N., CNOR

American Orthopsychiatric Association

Andres J. Pumariega, M.D.

American Psychiatric Association Alliance

Kay Brada

American Psychoanalytic Association

Prudy Gourguechan, M.D.

American Psychological Association

Carol D. Goodheart, Ed.D.

American Society for Adolescent Psychiatry

Ioe Kenan, M.D.

American Society of Addiction Medicine

Louis E. Baxter, M.D.

American Society of Clinical Psycho-pharmacology, Inc.

John M. Kane, M.D.

Association for Academic Psychiatry

Michele T. Pato, M.D.

Association for Behavioral and Cognitive Therapies

Frank Andrasik, Ph.D.

Association of American Medical Colleges

Darrell G. Kirch, M.D.

ACMNA, The College for Behavioral Health Leadership

Pamela Greenberg, M.P.P.

Association of Chinese American Psychiatrists

Edmond H. Pi, M.D.

Association of Gay and Lesbian Psychiatrists

Ubaldo Leli, M.D.

Association of Women **Psychiatrists** 

Eva M. Szigethy, M.D.

Black Psychiatrists of

Napoleon B. Higgins, Jr., M.D.

Council of Medical Specialty Societies

James H. Scully, Jr, M.D.

Depression and Bipolar Support Alliance

Peter C. Ashenden, M.D.

Group for the Advancement of Psychiatry

Dave A. Baron, D.O.

Indo-American Psychiatric Association

Shivkumar S. Hatti, M.D., M.B.A.

Latin American Psychiatry Association

Edgardo Belfort, M.D.

National Alliance for Research on Schizophrenia and Depression

Benita Strobe, M.D.

National Alliance on Mental Illness (NAMI)

Stephen H. Feinstein, Ph.D.

National Association of Psychiatric Health Systems

Kevin Sheehan, M.D.

National Association of Social Workers, Inc.

James J. Kelly, Ph.D., A.C.S.W.

National Council for Community Behavioral Healthcare

Linda Rosenberg, M.D.

National Institute on Alcohol Abuse and Alcoholism

Kenneth Warren, Ph.D.

National Institute of Mental Health

Thomas R. Insel, M.D.

National Institute on Drug Abuse, NIH Nora D. Volkow, M.D.

National Mental Health Association

David Shern, M.D.

Philippine Psychiatrists in America

Pia N. Reyes, M.D.

Turkish American Neuropsychiatric Association

Erol Ucer, M.D.



## PRESIDENTS OF INTERNATIONAL ALLIED ORGANIZATIONS

Albanian Psychiatric Association

Professor Afrim Dangëllia

Psychiatric Association Professor Farid Kacha

Argentinean Association of Psychiatrists

Dr. Nestor F. Marchant

Argentinean Psychiatrists Association (APSA)

Professor Juan Carlos Stagnaro

Foundation for Interdisciplinary Investigation of Communication (Argentina)

Professor Miguel Angel Materazzi

Armenian Association of Psychiatrists and Narcologists

Dr. Armen Soghoyan

The Royal Australian and New Zealand College of Psychistrists

Dr. Richard Prytula

Austrian Association of Psychiatry and Psychotherapy Professor Michael Musalek

Azerbaijan Psychiatric Association

Professor Nadir Ismayilov Arab Gulf Psychiatric Association

Professor Mohamed Al-Haddad

Bangladesh Association of **Psychiatrists** 

Professor Abdus Sobhan

Barbados Association of **Psychiatrists** 

Dr. Sharon Harvey

Byelorussian Psychiatric Association Professor Roman A. Evsegneev

Royal Society of Mental Medicine of Belgium Professor Jean Bertrand

Society of Flemish Neurologists and Psychiatrists (Belgium)

Professor Bernard Sabbe

Bolivian Society of Psychiatry Dr. Nils Noya Tapia

Psychiatric Association of Bosnia and Herzegovina

Professor Marija Burgic-Raďmanovic

Brazilian Association of Psychiatry Dr. João Alberto Carvalho

Psychiatric Association of Rio de Janeiro State (Brazil)

Dr. Fatima Vasconcellos

Society of Psychiatry of Rio Grande do Sul (Brazil)

Dr. Fernando Lejderman

Bulgarian Psychiatric Association

Dr. Temenuzka Mateva

Canadian Psychiatric Association

Dr. Stanley Yaren

Society of Neurology, Psychiatry and Neurosurgery (Chile)

Dr. Juan Maass

Chinese Society of Psychiatry Dr. Jingping Zhao

Hong Kong College of Psychiatrists

Dr. Hung Se Fong

Colombian Psychiatric Association

Dr. Louis Alfredo Montenegro Chamorro

Costa Rican Psychiatric Association Dr. Sisy Castillo-Ramirez

Croatian Psychiatric Association Professor Ljubomir Hotujac

Society of Psychiatry Dr. Miguel Valdes Mier Cyprus Psychiatric Association

Dr. Neophytos Papaneophytou

Czech Psychiatric Association Professor Jiri Raboch

Psychiatric Association Dr. Anders Fink-Jensen

Dominican Society of Psychiatry

Dr. Fior Solis de Mendez

Ecuadorian Association of Psychiatry

Dr. José Cruz Dueñas

Egyptian Psychiatric Association

Professor Ahmed Okasha

Salvadorean Association of Psychiatry

Dr. Claudia Beatriz Barahona Navarrete

Estonian Psychiatric Association

Dr. Andres Lehtmets

Ethiopian Psychiatric Association

Dr. Mesfin Araya

Psychiatric Association

Professor Jyrki Korkeila

French Association of Psychiatrists in Private Practice

Dr. Olivier Schmitt

Association of Psychiatry Professor Bernard Gibello

French Psychiatric Information Society

Dr. Nicole Garret-Gloanec

International Society of Psychopathology of Expression

Dr. Laurent Schmitt

Medical Psychologic Society (France)

Dr. Mirabel Sarron

The Psychiatric Evolution (France)

Dr. Yves Thoret

Society of Georgian Psychiatrists

Professor George Naneishvili

German Association for Psychiatry and Psychotherapy (formerly: German Society of Psychiatry, Psychotherapy and Nervous Disorders DGPPN)

Dr. Frank Schneider

Ghana Psychiatric Association

Dr. Sammy Ohene

Hellenic Psychiatric Association (Greece)

Professor Nikolaos Tzavaras

Hellenic Society of Neurology and Psychiatry (Greece)

Professor Costas Stefanis

Guatemalan Psychiatric Association Dr. See King Emilio Quinto

Honduran Society of Psychiatry Dr. Mario Mendoza

Hungarian Psychiatric Association Professor Janos Harmatta

Icelandic Psychiatric Association Dr. Kristófer Thorleifsson

Indian Psychiatric Society Dr. E. Mohandas

Indonesian Psychiatric Association Dr. Tun Kurniasih Bastaman

Iranian

Psychiatric Association

Dr. S. Ahmad Jalili

Iraqi Society of **Psychiatrists** 

Dr. Qassim Hadi Al-Awadi



#### PRESIDENTS OF INTERNATIONAL ALLIED ORGANIZATIONS

College of Psychiatry of Ireland (formerly, Irish College of Psychiatrists)

Dr. Justin Brophy

Psychiatric Association

Dr. Zeev Kaplan

Italian Association for Research in Schizophrenia

Professor Carlo Lorenzo Cazzullo

Psychiatric Association

Dr. Alberto Siracusano

Jamaica Psychiatric Association

Dr. Yvonnie Bailey-Davidson

Japanese Society of Psychiatry and Neurology

Professor Haruo Kashima

Jordan Association of Psychiatrists

Dr. Tawfik Daradkeh

Kazakh Association of Psychiatrists and Narcologists

Professor Saltanat Nurmagambetova

Psychiatric Association Dr. Marx M. Okonji

Korean Neuropsychiatric Association

Dr. Byoung Hoon Oh

Kuwait Psychiatric Association

Professor Essam A. Al-Ansari

Psychiatric Association Dr. Abjalal Begmatov

Latvian Psychiatric Association Dr. Elmars Terauds

Lebanese Psychiatric Society Dr. Nabil Mikati

Libyan Association of Psychiatry, Neurology and Neurosurgery

Dr. Ali Elroey

Lithuanian Psychiatric Association

Professor Algirdas Dembinskas

Luxembourguese Society of Psychiatry, Neurology and Psychotherapy

Dr. Chretien Jacoby

Psychiatric Association of Macedonia (Republic of Macedonia, FYROM)

Dr. Antoni Novotni

Malaysian Psychiatric Association

Dr. Yen Teck Hoe

Mauritius Psychiatric Association

Dr. Parmanun Jagaunath

Mexican **Psychiatric** Association

Professor Martha Patricia Ontiveros Uribe

Mexican Society of Neurology and Psychiatry

Dr. Juan Ignacio Rosales

League for Mental Health from Republic of Moldova

Dr. Mihail Hotineanu

Mongolian Mental Health Association

Dr. Ayushjav Bayanhuu

Montenegrin Psychiatric Association Dr. Lidija Injac-Stevovic

Society of Psychiatry

Dr. Tazi Imane

Mvanmar Medico-Psychological Society

Professor Sao Sai Lon

Psychiatrists' Association of Nepal

Dr. Surendra Sherchan

Netherlands Psychiatric Association

Professor Rutger Jan van der Gaag

Nicaraguan Psychiatric Association

Dr. José Santiago Sequeira

Association of Psychiatrists in Nigeria

Dr. Owoidoho Udofia

Norwegian Psychiatric Association

Dr. Jan Olav Johannessen

Pakistan Psychiatric Society

Dr. Haroon Chaudhry

Palestinian Psychiatric Association

Dr. Bassam Ashhab

Panamanian Society of Psychiatry

Dr. Miguel Angel Cedeño Tello

Papua New Guinea Psychiatric Association

Dr. Umadevi Ambihaipahar

Paraguayan Society of Psychiatry

Dr. José Britez Cantero

Psychiatric Association

Dr. Hugo Esteban Chávez Ortiz

Philippine Psychiatric Association

Dr. Imelda Batar

Polish Psychiatric Association Professor Aleksander

Araszkiewicz Portuguese

Association of Psychiatry Professor Jose C. Dias Cordeiro

Portuguese Society of Psychiatry and Mental Health

Professor Adriano S. Vaz-Serra

Association of Free Psychiatrists of Romania Professor Aurel Romila Romanian Psychiatric Association

Professor Dan Prelipceanu

Independent Psychiatric Association of Russia

Professor Yury Savenko

Russian Society of Psychiatrists Professor Valery N. Krasnov

Saudi Psychiatric Association Dr. Mahdi S. Abumadini

Society of Psychopathology and Mental Hygiene of Dakar (Senegal)

Dr. Daouda Sow

Association of Psychiatric Institutions of Serbia - UPUS

Dr. Tatjana Voskresenski

Serbian Psychiatric Association

Professor Miroslava Jasovic-Gasic

Singapore Psychiatric Association Dr. Alex Hsin Chuan Su

Slovak Psychiatric Association Professor Livia Vavrusova

Psychiatric Association of Slovenia

Dr. Peter Pregelj

South African Society of Psychiatrists (SASOP)

Dr. Jan Chabalala

Spanish Association of Neuropsychiatry

Dr. Maria Fé Bravo Ortiz

Society of Psychiatry Professor Jerónimo Saiz

Sri Lanka College of Psychiatrists

Dr. Balapuwadige Jayan Mendis

Sudanese Association of Psychiatrists Dr. Abdullah Abdelrahman



### PRESIDENTS OF INTERNATIONAL ALLIED ORGANIZATIONS

Swedish

Psychiatric Association

Dr. Lise-Lotte Risö Bergerlind

Swiss

Society of Psychiatry

Dr. Hans Kurt

Syrian Arab

Association of Psychiatrists

Professor Pierre Chiniara

Taiwanese

Society of Psychiatry

Professor Cheng-Chung Chen

Psychiatric Association of Thailand

Professor Udomratn Pichet

Tunisian Society of Psychiatry

Dr. Essedik Jeddi

Psychiatric Association of

Turkey

Turkish

Neuro-Psychiatric Association

Professor Seref Özer

Professor

Peykan G. Gökalp

Uganda Psychiatric Association

Dr. Fred Nsobya Kigozi

Ukraine Scientific Society of Neurologists,

Psychiatrists and Narcologists

Professor Petro V. Voloshyn

Ukrainian

Psychiatric Association

Professor

Viktor Shumlyanski

The Royal College of Psychiatrists

Professor Dinesh Bhugra

Society of Psychiatry of Uruquav

Dr. Vicente Pardo

Association of Psychiatrists of Uzbekistan

Professor Ulugbek Alimov

Venezuelan Society of Psychiatry

Dr. Néstor Macías

Yemen

Psychiatrists and Neurologists Association

Professor

Abdelmagid S. Al-Khulaidi

# International psychiatrists –

Join APA at the Annual Meeting and receive immediate member savings!

Are you planning to visit the American Psychiatric Publishing, Inc. (APPI) bookstore while in New Orleans to purchase your psychiatry, mental health and behavioral science books and journals? Join the APA before you buy to take advantage of member savings immediately. APA Members receive a special 15% discount for purchases made at the APPI Bookstore at the 2010 Annual Meeting. APA Members receive a 10% discount throughout the year.

# How do I join?

Defined by the World Bank

As of July 2009

Complete an International membership application onsite (available at one of the membership desks in the Member Center or in the main registration hall) and submit it along with a copy of your medical license, psychiatry residency training certificate and your membership dues to the membership desk located in the main registration hall, next to the APA Store. APA staff will process your membership and issue your APA membership card. Show your card when making APPI purchases to receive your member discount!

# How much are International membership dues?

APA's International membership dues are based on your country of residence income group category defined by the World Bank. There are four categories:

Income Category	Group Category	APA Dues
High Income	HI	\$205 USD
Upper Middle Income	UMI	\$175 USD
Lower Middle Income	LMI	\$125 USD
Low Income	LI	\$50 USD





# INTERNATIONAL **DISCUSSION GROUPS**



# **APA 163rd Annual Meeting**

#### Hilton New Orleans Riverside

Join us at the APA international discussion groups. These discussions afford psychiatrists the opportunity to meet and discuss relevant medical and mental health issues pertinent to the world. These groups are open to all Annual Meeting attendees and chaired by APA members.

# **Sunday, May 23, 2010**

10:00am - noon

**Middle East Discussion Group** 

Ascot Room, Third Floor

1:00 - 3:00pm

International Lesbian, Gay, Bisexual, and Transgender Discussion Group

Norwich Room, Third Floor

3:00 - 5:00pm

**Africa Discussion Group** 

Elmwood Room, Third Floor

# Monday, May 24, 2010

1:00 - 3:00pm

**Pacific Rim Discussion Group** 

Grand Salon C, Section 15, First Level

2:00-4:00pm

**South Asia Discussion Group** 

Grand Salon C, Section 16, First Level

# **Tuesday, May 25, 2010**

12:30-2:30pm

**Europe Discussion Group** 

Prince of Wales Room, Second Floor

# Those interested in mental health issues in Latin

America may wish to attend the Latin American Psychiatric Association (APAL) allied organization meeting Sunday, May 23 from 8:30 AM to 1:00 PM. Further information is available in the Directory of Activities.





# Pioneering science for exceptional care

care for patients with psychiatric and substance abuse disorders.

Yale-New Haven is also a place where pioneering science leads clinical care in important new directions. Our researchers are developing experimental treatments for psychiatric and substance abuse disorders that may help patients who fail to respond to standard therapies. For example, we have developed an experimental technique that uses magnetic brain stimulation to suppress auditory hallucinations that failed to respond to any available medications.

Yale-New Haven Psychiatric Hospital is a place where the exciting advances in science are working for our patients.



Yale-New Haven Hospital is the primary teaching hospital of Yale School of Medicine and is ranked among the nation's best hospitals by U.S.News & World Report.



www.ynhh.org

# SPECIAL ACKNOWLEDGEMENTS

American Academy of Psychiatry and the Law: co-support of the Manfred S. Guttmacher Award Lecture.

American Association of Chairs of Departments of Psychiatry: support of the APA/AACDP Research Mentorship Award.

American Association of Psychiatric Administrators: co-support of the Administrative Psychiatry Award Lecture

American Psychiatric Association/Hurricane Disaster Relief Fund: Support of the Disaster Psychiatry

American Psychiatric Foundation: support of the APIRE Practice Research Network.; Award for Research in **Psychiatry** 

Association of Professional Chaplains: partial support of the Oskar Pfister Award Lecture

Association of Women Psychiatrists: support of the joint AWP/APA Women's Caucus reception and meeting, and co-support of the Alexandra Symonds Award Lecture

AstraZeneca Pharmaceuticals, LP: support of the APA/AstraZeneca Minority Fellowship, minority fellows poster session and receptions, the American Psychiatric Foundation "Conversations" event, and the APIRE/ AstraZeneca Young Minds in Psychiatry Award; Mind Games resident competition.

Bristol-Myers Squibb Company: support of the President's Dessert and Reception; and the Solomon Carter Fuller Award and partial support of the American Psychiatric Foundation Annual Benefit,; APA Fellowship on Public Psychiatry.

Bristol-Myers Squibb, Sweden: Support of the Global Psychiatry: A session for US and International Residents

Center for Mental Health Services: support of the APIRE Practice Research Network (PRN); and the APA's HIV-related education programs and materials.

Center for Substance Abuse Treatment: support of the APIRE Practice Research Network (PRN); and an audience response system for the course, "Office-Based Buprenorphine Treatment of Opioid-Dependent Patients.

#### Dainippon Sumitomo Pharma America:

support of the Symposium "New Developments in Schizophrenia Research and Practice: From the Pipeline to the Clinic."

Estate of Agnes Purcell McGavin: support of the Agnes Purcell McGavin Awards for Distinguished Career Achievement in Child and Adolescent psychiatry, and for Prevention.

Estate of Dorothy C. Kempf: support of APIRE/ Kempf Fund Award for Research Development in Psychobiological Psychiatry Awards.

Estate of Judd Marmor, M.D.: support of the Judd Marmor Award Lecture

Forest Laboratories, Inc.: partial support of the American Psychiatric Foundation's Annual Benefit

Harding Foundation: partial support of the Oskar Pfister Award Lecture.

Ittleson Foundation: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Lilly USA LLC: support of the Adolf Meyer Award Lecture; the APA/Lilly Psychiatric Research Fellowship; and the APA/Lilly Resident Research Awards., Chief Resident Leadership Program, International Dinner Symposium, and partial support of the American Psychiatric Foundation's Annual Benefit; and support of the Symposium, "Novel Approaches to Assessing and Treating Depression in the Medically-Ill."

Merck & Co., Inc.: support of the Internet Café, Bottled Water.

#### National Institute of Mental Health (NMIH):

co-support of the APA/NIMH Vestermark Psychiatry Educator Award Lecture, and the Research Colloquium for Junior Investigators; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees

Ortho-McNeil-Janssen Pharma Inc: partial support of the American Psychiatric Foundation Annual Benefit; the support of the Committee of Asian-American Psychiatrists recruitment reception; and the American Psychiatric Institute for Research and Education/Janssen Resident Psychiatric Research Scholars.

Pfizer, Inc: support of the APIRE/Wyeth Pharmaceuticals M.D., Ph.D., Research Fellowship; the Jeanne Spurlock, M.D. Congressional Fellowship, co-support of the Alexandra Symonds Award Lecture and partial support of the American Psychiatric Foundation's Annual Benefit.

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture and the Resident & Early Career Psychiatrist Town-Hall

Sepracor, Inc., support of the Daily Bulletin.

Meeting with Dr. Carol Bernstein.

Shire US, Inc.: support of the APA Child and Adolescent Psychiatry Fellowship.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program.

University of Nebraska: support of the Frank J. Menolascino Award for Psychiatric Services for persons with Mental Retardation/Developmental Disabilities.

### Please Join Us for a Product Theater Presentation at the 163<sup>rd</sup> Annual Meeting of the American Psychiatric Association

Ernest N. Morial Convention Center • New Orleans, Louisiana



Sunday, May 23, 2010 4:00 pm - 4:30 pm Room 231/232

#### Roger S. McIntyre, MD, FRCPC

Associate Professor of Psychiatry and Pharmacology University of Toronto Head, Mood Disorders Psychopharmacology Unit

#### www.mdpu.ca

University Health Network Toronto, Ontario Canada

In adherence with PhRMA quidelines, spouses or other guests are not permitted to attend company-sponsored programs. Thank you for your cooperation.

This is a promotional event. CME credit will not be available for this session. Speakers are presenting on behalf of Merck.

The Industry Product Theater's content and the views expressed therein are those of the sponsor and not of APA or APF.

Sponsored by



Copyright © 2010 N.V. Organon, a subsidiary of Merck & Co., Inc. All rights reserved.

### Please Join Us for a Product Theater Presentation at the 163<sup>rd</sup> Annual Meeting of the American Psychiatric Association

Ernest N. Morial Convention Center • New Orleans, Louisiana

# **Important Clinical Information** About Schizophrenia

Monday, May 24, 2010 4:00 pm - 4:30 pm

Room 231/232

#### Steven G. Potkin, MD

Professor of Psychiatry and Human Behavior Director of Research Robert R. Sprague Endowed Chair in Brain Imaging Director of UCI Brain **Imaging Center** University of California Irvine, California **USA** 

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs. Thank you for your cooperation.

This is a promotional event. CME credit will not be available for this session. Speakers are presenting on behalf of Merck.

The Industry Product Theater's content and the views expressed therein are those of the sponsor and not of APA or APF.



Sponsored by



Copyright © 2010 N.V. Organon, a subsidiary of Merck & Co., Inc. All rights reserved.

# **Certificate of Attendance** How do you obtain it?

163as ANNUAL MEETING AMERICAN PSYCHIATRIC ASSOCIATION

**Get your certificate in person or online.** 

### To receive your certificate in person:

complete the general evaluation form at the CME Certificate of Attendance Booth located in Hall B/C in the Convention Center

#### **Types of Certificate**

- Certificate of Credit for physicians
- Certificate of Attendance for non-physicians

### **CME Certificate of Attendance Booth Located in Hall B/C**

Hours of Operation:

Saturday	May 22	7:30am-4:00pm
Sunday	May 23	7:30am-4:00pm
Monday	May 24	7:30am-4:00pm
Tuesday	May 25	7:30am-4:00pm
Wednesday	May 26	7:30am-5:00pm

# **Certificate is Available During or After the Meeting**

### **To receive your Certificate Online:**

complete the online evaluation at:

# psych.org/annualmeetingCME

The website will remain active until August 15 2010.

#### Follow these simple steps:

- 1. Use your 6-digit badge number to access the General Evaluation form
- 2. Complete the Evaluation
- 3. Confirm your personal details
- 4. Enter the number of credits earned
- 5. Email the certificate to yourself
- 6. Print certificate for your records

#### **Accreditation & Designation**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Psychiatric Association designates this educational activity for a maximum of 50 AMA PRA Category 1 Credits<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The scientific program offers a variety of sessions that meet the criteria for AMA PRA Category 1 Credit™.

> For questions, contact the American Psychiatric Association Department of CME

E-mail: educme@psych.org

# ake the Mystery Out of "Insurance Speak"

Bring your medical professional liability insurance and risk management questions to The Psychiatrists' Program's **Booth** #916. Litigation specialists, risk managers and insurance underwriting specialists from Professional Risk Management Services, Inc. will provide you with insurance information and individualized risk management advice to help you protect your practice.

Stop by Booth #916 to learn more about The Program's features\* including:

- · Top-notch legal counsel with a proven track record
- · Risk Management Consultation Service (RMCS) helpline
- Administrative and Governmental Billing Defense Costs Endorsement
- · Coverage for forensic psychiatric services included in the policy
- Discounts such as early career, child and adolescent, moonlighting residents, part-time and risk management education

If you are a participant in The Psychiatrists' Program, be sure to stop by and ask for your complimentary "For Participants Only" customer service resource.

# The Psychiatrists' Program

Professional Liability Insurance Designed for Psychiatrists

For more information:

Call: (800) 245-3333, ext. 389 • E-mail: TheProgram@prms.com Visit: www.psychprogram.com

Managed by Professional Risk Management Services, Inc.
(In California, d/b/a Transatlantic Professional
Risk Management and Insurance Services)



#### AMERICAN PSYCHIATRIC ASSOCIATION CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

he American Psychiatric Association requires disclosure by all program planners and presenters at CME activities of any financial or other affiliation with commercial organization(s) that may have a direct or indirect interest in the subject matter of the educational activity. A "financial interest" may include, but is not limited to: being an employee and/or being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include holding a position on an advisory committee, speakers' bureau or some other role or benefit to a supporting organization.

In compliance with the ACCME's Standards for Commercial Support, the APA has a management of conflict (MCI) process for all CME activities. This process ensures that all conflicts of interest are identified, managed and resolved prior to the educational activity. Additionally, the prospective audience must be informed of the presenters' or program planners' affiliations with every commercial interest by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual

equipment is used for the presentation). Disclosing to learners the relevant financial relationships that were present and resolved assists learners in assessing the potential for bias in the information that is presented. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The presenters on the following pages have indicated that either they or an immediate family member have a financial interest or other affiliation with a commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients; the company name and affiliation is also listed. Providers of clinical service directly to patients are not considered to be commercial interests.

The second group of presenters has indicated neither they nor an immediate family member has any significant relationship to disclose. All presenters and planners must complete a disclosure in order to participate in an APA CME activity.

This disclosure listing includes the presenters of the Scientific Program and New Research Poster Sessions.



New Orleans Convention and Visitors Bureau

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Aaronson, Scott T		Neuronetics				
Abouzaid, Safiya				Ortho McNeil		
Agid, Ofer		Pfizer, Eli Lilly				
Apiquian, Rogelio		Janssen Cilag			Janssen Cilag, AZ	
Appelbaum, Paul	COVR				-	
Arnold, Lesley M		Eli Lilly, Cypress Bioscience, Wyeth-Ayerst, Boehringer Ingelheim, Forest, Allergan, Takeda, UCB Pharma, Pfizer	Eli Lilly, Pfizer, Cypress Bioscience, Wyeth-Ayerst, Boehringer Ingelheim, Allergan, Forest		Eli Lilly, Pfizer, Forest	
Ascher-Svanum, Haya	Eli Lilly			Eli Lilly		
Ash, Peter		Boehringer Ingelheim, BMS, Eli Lilly, Pfizer, Sanofi Aventis, Labopharm, PGxHealth, Takeda, Wyeth-Ayerst	Boehringer Ingelheim, BMS, Eli Lilly, Pfizer, Sanofi Aventis		Eli Lilly	Royalties: Guilford Pub. and Healthcare Technology Systems.
Baldwin, David		Pfizer	Pfizer			
Balfour, Margaret						BMS sponsored APA Fellowship
Bandelow, Borwin		AZ, Cephalon, Lilly Research Laboratories, Lundbeck, Pfizer, Roche Biosciences, Wyeth-Ayerst			AZ, BMS, Dainippon Sumitomo, Janssen Cilag, Lilly Research Laboratories, Lundbeck, Pfizer, Solvay, Wyeth- Ayerst	
Barber, Jacques			NIMH, Pfizer			Guilford Publ. Author
Barkley, Russell A		Shire, Eli Lilly			Janssen Cilag, Janssen- Ortho, Novartis	
Barlow, Carrolee				Brain Cells Inc		
Batki, Steven			Alkermes			
Bauer, Michael		Servier, Janssen-Cilag, Lundbeck, BMS, Otsuka	Stanley Medical Research Institute, NARSAD, AZ, Eli Lilly		GSK, Pfizer	
Beezhold, Julian					AZ, Eli Lilly, Janssen Cilag	
Benjamin, Sheldon			Advanced Neuromodulation Systems			Brain Educators, LLC Publisher of the Brain Card
Bennett, Robert M		Jazz, Eli Lilly, Pfizer	Jazz, Pfizer, Merck			
Berk, Michael		AZ, BMS, Eli Lilly, GSK, Janssen Cilag, Lundbeck, Servier	MBF Biosciences, BMS, Stanley Medical Research Institute, Eli Lilly, GSK, Organon, Novartis, Mayne Pharma, Servier		AZ, BMS, Eli Lilly, GSK, Janssen Cilag, Lundbeck, Pfizer, Sanofi-Synthelabo, Servier, Solvay, Wyeth- Ayerst	
Bisaga, Adam			Alkermes			
Black, Donald W.			AZ, Forest			
Blanco, Roberto						BMS sponsored APA Fellowship
Brams, Mathew		Eli Lilly, Novartis, McNeil, Shire US	AZ, BMS, Forest, GSK R&D, McNeil, Shire US, Novartis, Sanofi Aventis, Eli Lilly		Eli Lilly, Shire US, Novartis, Pfizer, McNeil, AZ, Cephalon	
Brooks, John					AZ, Eli Lilly, Pfizer, Schering	
Brottman, Glenn		Neuronetics				
Brown, Thomas E.		Novartis, Abbott, Eli Lilly	Eli Lilly			

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Bryan, Dirks	Shire, Johnson & Johnson			Shire		
Buckley, Peter		Janssen	Janssen, Pfizer			
Busner, Joan				United BioSource		
Calabrese, Joseph			Abbott, AZ, BMS, Cephalon, Eli Lilly, GSK, Janssen, Repligen, Stanley Medical Research Institute, Takeda, Wyeth-Ayerst			Advisory boards: Abbott, AZ, BMS, Dainippon Sumitomo, EPI-Q, Forest, France Foundation, GSK, Janssen, Johnson & Johnson, Lundbeck, Neurosearch, Ortho McNeil, Otsuka, Repligen, Pfizer, Schering, Servier, Solvay, Supernus, Synosia, and Wyeth-Ayerst. CME activities: Solvay, Wyeth-Ayerst, AZ, BMS, France Foundation, GSK, Janssen, Johnson & Johnson, Sanofi Aventis, Schering, and Pfizer.
Cameron, Carter		Merck, Eli Lilly, Eli Lilly, Pfizer, Servier				
Carpenter, Linda		Neuronetics, Wyeth-Ayerst	Dept. of Defense, NIMH, Medtronic, Cyberonics, Neuronetics, Nat'l Alliance for Research in Schizophrenia and Affective Disorders, Sepracor, UCB Pharma		Neuronetics	
Carpenter, William		Eli Lilly, Schering-Plough, France				
Case, Michael G				Eli Lilly		
Casey, David					Pfizer, Eisai	
Castilla-Puentes, Ruby	GSK			Johnson & Johnson		
Cazorla, Pilar				Schering		
Chalk, Mady			Alkermes			
Chang, Kiki		Eli Lilly, Abbott, GSK, Otsuka	AZ, Otsuka, Eli Lilly		Eli Lilly, AZ, Abbott	
Childress, Ann		Shire, Novartis	Eli Lilly, Shire, Novartis, BMS, Somerset, Abbott, Ortho-McNeil Janssen, Johnson & Johnson		Shire, Novartis, BMS	
Chilton, Julie						Shire US Fellowship, Eli Lilly Travel Grant
Cía, Alfredo		Roche Labs.	Wyeth-Ayerst Research			
Clark, Michael		Eli Lilly, Pfizer			Eli Lilly, Pfizer	
Classi, Peter				Eli Lilly		
Clayton, Anita		Concert, New England Research Institute, TransTech Pharma, Boehringer Ingelheim, BMS, Eli Lilly, Sanofi Aventis, Takeda	Biosante, Boehringer Ingelheim, BMS			Ballantine Books Royalty, Eli Lilly Honorarium
Coffey, Barbara			Tourette Syndrome Assoc., Boehringer Ingelheim, BMS, NIMH, Novartis		Tourette Syndrome Assoc.	
Conant-Norville, David					McNeil, Novartis	
Connor, Daniel F			Shire		Shire, Abbott	
Coppola, Danielle				Johnson & Johnson		
Cucchiaro, Josephine				Dainippon Sumitomo		

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Cutler, Andrew		Abbott, Forest Research Inst., AZ, BMS, GSK, Janssen, Lilly Research Labs., Ortho McNeil, Otsuka, Pfizer, Sepracor, Shire, Supernus	Abbott, AZ, BMS, Forest Research Inst., GSK, Janssen, Jazz, Johnson & Johnson, Lilly Research Labs., McNeil, Memory Pharamceuticals, Merck, Novartis, Ortho McNeil, Otsuka, Pfizer, Sanofi Aventis, Sepracor, Shire, Solvay, Supernus, Wyeth-Ayerst		Abbott, AZ, BMS, GSK, Lilly Research Labs., Ortho McNeil, Otsuka, Pfizer, Sepracor, Shire	
Daniel, David				United BioSource		
Darwish, Mona	Cephalon			Cephalon		
Datto, Catherine				AZ		
DeBattista, Charles	Corcept Therapeutics		CNS Response, Brain Resource Ltd., Neuropace, GSK, Wyeth-Ayerst, Lilly Research Labs., Cephalon, Cyberonics, Neuronetics, Novartis, AZ, Forest, Medtronics, Boehringer Ingelheim, Advanced Neuromodulation Systems, Pfizer		Lilly Research Labs., GSK, Pfizer, Cephalon, Wyeth-Ayerst, BMS, AZ, Cyberonics, Corcept Therapeutics, Forest	
Demitrack, Mark	Lilly Research Labs., Wyeth- Ayerst			Neuronetics		
Derstine, Timothy					AZ, BMS, Eli Lilly, Forest, Wyeth-Ayerst, Neuronetics	
Desai, Abhilash		Forest			Forest, Novartis	
Dimsdale, Joel			Sepracor			
D'Mello, Dale					Pfizer, AZ, Schering	
Doghramji, Karl	Merck	Assure RX, Sanofi-Synthelabo, Sepracor, Sanofi Aventis			GSK, Boehringer Ingelheim, Sepracor, Sanofi Aventis, Jazz, Takeda, Forest	
Donevan, Sean				Pfizer		
Dougherty, Darin		Medtronic, Inc.	Forest, Eli Lilly, Cyberonics, Medtronics			
Dubovsky, Steven			Pfizer, Otsuka, Sumitomo, Biogen			
Dulcan, Mina		Care Management Technologies, Eli Lilly				American Psychiatric Pub. Book Royalties, Eli Lilly ADHD Advisory Board
Durkin, Michael				Ortho-McNeil Janssen		
Earley, Willie W				AZ		
Edinger, Jack		Philips	Philips			
Ellison, James			Elan		Eli Lilly, Forest	
Epperson, C. Neill	Pfizer	Wyeth-Ayerst	Eli Lilly			
Ercan, Eyup					Janssen-Cilag	
Eriksson, Hans				AZ		
Etkin, Amit		NeoStim				
Fahim, Raafat				NABI Biopharma- ceuticals		
Fatemi, S. Hossein			NIH			

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Fava, Maurizio	Compellis	Aspect Medical Systems, Auspex Pharm, CNS Response, Compellis, Fabre-Kramer Phar, Grunenthal GmBH, Janssen, Knoll, Labopharm, Lorex, Lundbeck, Neuronetics, Nutrition 21, Pam Lab LLC, Pharmastar, Pharmavite, Precision Human Biolaboratory, Somaxon, Somerset, Synthelabo, Tetragenex, Sepracor, Schering-Plough, France, Takeda, Vanda, Boehringer Ingelheim, Abbott, Alkermes, AZ, BrainCells, Inc, BMS, Cephalon, Eli Lilly, Forest, GSK, Johnson & Johnson, Novartis, NIMH, Organon, Pfizer, Roche Labs., Sanofi Aventis, Shire US, Solvay, Wyeth-Ayerst Research, Amarin, Bayer AG Pharma Div., Biovail Labs., Cypress Bioscience, EPIX, Jazz, MedAvante, Merck, Neuronetics, Trascept Pharm	Abbott, Alkermes, Aspect Medical Systems, AZ, Eli Lilly, Ganeden, Lichtwer Pharma GmbH, Lorex, National Alliance for Research in Schizophrenia and Affective Disorders, National Center for Complementary and Alternative Medicine, NIDA, NIMH, Novartis, Pam Lab, Pharmavite, Synthelabo, BMS, BrainCells, Inc, GSK, Johnson & Johnson, Organon, Pfizer, Sanofi Aventis, Shire US, Solvay, Wyeth-Ayerst, Cephalon		AZ, Belvoir Publishing, Boehringer Ingelheim, BMS, Cephalon, Eli Lilly, GSK, Novartis, Organon, Pfizer, Pharmastar, Wyeth-Ayerst, United BioSource	
Feltner, Douglas				Pfizer		
Ferrando, Stephen					AZ, Pfizer	
Finigan, Michael W			Alkermes			
First, Michael B.		MedAvante, Novartis, Cephalon, Memory Pharma. GSK				
Fishman, Robert S				Alexza		
Forester, Brent					Eli Lilly, AZ, Novartis, Pfizer	
Frank, Ellen		Servier				Guilford Publ. royalties
Frasch, Karel J						Travel expenses: AZ, Janssen Cilag, Eli Lilly. Speaker honoraria: Janssen Cilag
Freeman, Ellen			Forest Research Inst., Xanodyne			
Freudenreich, Oliver		Beacon Health Strategies	Cephalon, Pfizer		Reed Medical Education	Lippincott royalties
Frey,, Benicio		Wyeth-Ayerst	Wyeth-Ayerst, Bristol-Myers, Eli Lilly		AZ, Wyeth-Ayerst	
Friedman, Joseph		Acadia, Teva, EMD Serono	Acadia, Teva, GSK, Pfizer, Novartis, Ingelheim-Boehringer, Epivax		AZ, Teva, GSK, Ingelheim-Boehringer	
Frye, Mark		Dainippon Sumitomo, Cephalon, Medtronic, Inc., Ortho-McNeil Janssen, Schering-Plough, France, Pfizer				AZ CME supported activity, BMS CME supported activity, Eli Lilly CME supported activity, GSK CME supported activity, Otsuka CME supported activity, Pfizer CME supported activity, Schering-Plough, France CME supported activity
Fu, Dong-Jing				Ortho-McNeil Janssen		
Gaebel, Wolfgang		Janssen Cilag, Lundbeck			Lilly Research Labs.	
Gastfriend, David R.				Alkermes		
Gau, Susan Shur-Fen					Janssen-Cilag, Lilly Research Labs.	
Gaviria, Silvia		Wyeth-Ayerst			Wyeth-Ayerst	
Gelenberg, Alan		Cyberonics, Eli Lilly, Forest, GSK, NIH, Pfizer, Takeda, Wyeth-Ayerst, AZ	Eli Lilly	Healthcare Technology Systems		

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME Employee	SPEAKER Bureau	OTHER FINANCIAL Interest
Genovese, Michael					Wyeth-Ayerst, Reckitt Benckiser, AZ Canada, Forest, Sanofi Aventis	
George, Mark S.		BrainSonix, Cephos, NeoStim, NeoSync, PureTech Ventures, MECTA Corp, BrainSonix, Cephos, NeoStim, NeoSync, PureTech Ventures, GSK, Jazz, Cyberonics, Neuropace, Brainsway Inc, Neuronetics	Force Protection, MECTA Corp, Brainsway Inc, Dept. of Defense, NARSAD, NIDA, NIMH			American Psychiatric Pub., Lippincott and Wiley One, royalties. Elsevier Press, journal editor. Neuronetics Co. donated equipment for OPT-TMS trial/VA suicide study.
Ghaemi, S. Nassir			Pfizer			
Ginsberg, Lawrence D.			Abbott, Alkermes, AZ, BMS, Cephalon, Cyberonics, Forest, GSK, Janssen, Jazz, Eli Lilly, McNeil, Neurocrine Biosciences, Novartis, Noven, Organon USA, Ortho McNeil, Otsuka, Pam Lab LLC, Pfizer, Sanofi Aventis, Shire, Takeda, UCB Pharma, Wyeth-Ayerst			
Glick, Ira	Janssen	Janssen, Medivation, Lundbeck	Otsuka, Boots, Pfizer, Lundbeck		AZ, Pfizer	
Goff, Donald		GSK, Merck, Eli Lilly, Wyeth-Ayerst, Organon, Novartis, Pfizer, Cephalon, Solvay, Xenoport, Dainippon Sumitomo, Vanda, BMS, AZ, Xytis, Proteus, Forest, Lippincott, Indevus, Lundbeck, Otsuka, Schering, Ortho-McNeil Janssen,	Cephalon, Novartis, Pfizer			
Gogineni, R. Rao					BMS, Novartis, Novartis	
Goldberg, Joseph		Cephalon, Eli Lilly			AZ, Eli Lilly, GSK, Pfizer, Janssen-Cilag	
Goldfinger, Stephen M.	Johnson & Johnson, Eli Lilly, Teva	Teva	Janssen			Merck, attened speaker training group. Pfizer and Janssen, members of my department receive grant support.
Goldman, Morris			GSK Beechum			
Gommoll, Carl				Forest Research Inst.		
Goodkin, Karl		Amgen	Ortho-McNeil Janssen		Merck	
Goodman, David W.		GSK, Forest, Lilly Research Labs., Shire US, McNeil, Novartis	Forest, Shire US, McNeil, Cephalon		GSK, Forest, Lilly Research Labs., Shire US, McNeil, Wyeth-Ayerst, Novartis	Honoraria: McNeil, Wyeth-Ayerst, Novartis, GSK, Forest, Lilly Research Labs., Shire US
Gould, Todd		Astellas Pharma US				
Graham, Stephen M				Forest Research Inst.		
Greco IV, Nicholas				Abbott		
Green, Alan I.	Pfizer		Lilly Research Labs., Janssen			
Greenberg, William				Forest Research Inst.		
Greist, John			Pfizer			Pfizer Advisory Board Consultant
Grossberg, George		Forest, Novartis, Pfizer	Elan, Forest Research Inst., BMS, Novartis, NIH, NIMH			Safety Monitoring Boards: Abbott, Schering-Plough, France
Guico-Pabia, Christine J				Pfizer		
Hamarman, Stephanie					McNeil, BMS, Novartis, Pam Lab LLC, Shire US	

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Hammerness, Paul G			Shire US, Ortho-McNeil Janssen			CME/professional writing: Abbott, Eli Lilly, Forest
Harbin, Henry		CNS Response				
Harris, Herbert W		Valeant				
Harvey, Philip D.		Eli Lilly, Janssen Research Foundation, Merck, Shire, Solvay, Dainippon Sumitomo				
Hasler, Gregor		AZ				
Hendren, Robert			NIMH			
Hirshkowitz, Max			Cephalon, Merck		Sanofi Aventis, Cephalon, Takeda	
Hollander, Eric		Lundbeck				
Holsboer, Florian	Affectis, Ceuticals					
Holtzheimer, Paul		Advanced Neuromodulation Systems	NARSAD, NIMH, Dana Foundation, Stanley Foundation			
Hoschl, Cyril		Servier			Eli Lilly	Lundbeck LINF faculty member
losifescu, Dan			Aspect Medical Systems, Forest, Janssen, NARSAD, NIH		Eli Lilly, Forest, Pfizer	Reed Medical Education Honoraria
Ishiyama, Takeo				Dainippon Sumitomo		
Jain, Rakesh		Shire US, Lilly Research Labs.	Shire US		Shire US, Lilly Research Labs., Lilly Research Labs., Forest, Pfizer	
Janicak, Philip G		BMS, Otsuka, Neuronetics	Otsuka, Neuronetics		Pfizer, AZ, BMS, Otsuka, Janssen, Neuronetics	
Jeste, Dilip						Donate medication for a NIMH-funded research grant: AZ, BM, Eli Lilly, Janssen
Jibson, Michael					AZ	
Joep, Schoemaker				Schering		
Kalali, Amir H	Cypress Bioscience	AZ, Ortho-McNeil Janssen, Vanda		Quintiles	AZ, GSK	
Kane, Cecelia				Pfizer		
Kane, John M.	MedAvante	BMS, Cephalon, Johnson & Johnson, Lundbeck, Otsuka, Pfizer, AZ, Eli Lilly, Janssen, Vanda, Wyeth-Ayerst			AZ, BMS, Eli Lilly, Janssen	
Kapczinski,, Flavio		Eli Lilly, GSK	AZ			
Karayal, Onur N				Pfizer		
Karlsson, Hasse					Janssen Cilag, Lundbeck, BMS	
Katon, Wayne	Eli Lilly, Pfizer, Forest, Wyeth- Ayerst					Eli Lilly Advisory Board
Keitner, Gabor						American Psychiatric Publishing, Inc. Book Contract
Kellner, Charles			NIMH			
Kennedy, Sidney H.		St. Jude Medical, Biovail Labs., Boehringer Ingelheim, Eli Lilly, GSK, Janssen-Ortho, Lundbeck, Pfizer, Servier, Wyeth-Ayerst	St. Jude Medical, AZ, BrainCells, Inc, Eli Lilly, GSK, Janssen-Ortho, Lundbeck		Biovail Laboratories, Inc., GSK, Janssen-Ortho, Lundbeck, Servier, Wyeth-Ayerst, AZ	

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Kern Sliwa, Jennifer				Ortho-McNeil Janssen		
Kessler, Ronald		Merck, Shire US, GSK, Trascept Pharm, Takeda, Ortho McNeil, Pfizer	EPI-Q, Sanofi Aventis, Janssen- Ortho, NIH, Shire US, Pfizer			
Ketter, Terence A		Valeant, Abbott, AZ, BMS, Dainippon Sumitomo, Eli Lilly, GSK, Janssen, Jazz, Novartis, Organon, Solvay, Vanda, Wyeth-Ayerst, Xenoport	Valeant, Abbott, AZ, BMS, Cephalon, Eli Lilly, GSK R&D, Pfizer, Repligen, Wyeth-Ayerst			Lecture Honoraria: Valeant, Abbott, AZ, BMS, Eli Lilly, GSK, Noven, Otsuka, Pfizer. Spouse/employee: Johnson & Johnson.
Kirby, Mary				Cephalon		
Kleber, Herbert		Johnson & Johnson, Neuromed, US World Med, Perdue Pharma., Grunenthal GmBH, Reckitt Benckiser, Abbott, Alkermes			Johnson & Johnson, Abbott	Grunenthal GmBH SAB
Kogan, Jane N			Ortho-McNeil Janssen			
Kohn, Robert			NIH		Forest, Pfizer, Novartis	
Koslow, Stephen	Brain Resource Ltd.	Brain Resource Ltd.				
Kosten, Thomas	Pfizer, Johnson & Johnson	Alkermes, Synosia			Reckitt Benckiser	
Kozma, Chris		Ortho-McNeil Janssen				
Krupitsky, Evgeny M			Alkermes			
Krystal, Andrew D		AZ, Johnson & Johnson, Sepracor, Abbott, Arena, GSK	Sanofi Aventis, Cephalon, GSK, Merck, Neurocrine, Pfizer, Sepracor, Somaxon, Takeda, Trascept Pharm, Astellas Pharma US, Inc., Respironics, Evotec, Axiom			Inventor on a Duke University Patent licensed to MECTA Corp. Advisory boards: BMS, Neurogen, Organon, Respironics, Kingsdown, CHDI, Actellion, Arena, Astellas Pharma US, Cephalon, Eli Lilly, GSK, Johnson & Johnson, Neurocrine, Roche Biosciences, Sanofi Aventis, Sepracor, Somaxon, Takeda, Trascept Pharm, Jazz, Merck, Novartis, Organon, Ortho-McNeil Janssen, Pfizer. Lecture fees: Sanofi Aventis, Cephalon, Sepracor, Takeda.
Kyomen, Helen H.		AZ, Bayer Corp. Pharma Div., BMS, Merck, Eli Lilly, Roche Labs., GSK, Novartis, UCB Pharma, Wyeth- Ayerst, Pfizer	Bayer Corp. Pharma Div., BMS, Eli Lilly, Roche Labs., UCB Pharma, Wyeth-Ayerst, Pfizer, NIH			
Lam, Raymond		Litebook Company, Inc., GSK, Wyeth-Ayerst Canada, Lundbeck, Takeda, AZ, Eli Lilly	Advanced Neuromodulation Systems, BrainCells, Inc, AZ Canada, Litebook Company, Inc., Lundbeck		Servier, Janssen-Ortho, Biovail Labs.	
Lambert, Timothy		Ortho-McNeil Janssen, Eli Lilly, Pfizer	Ortho-McNeil Janssen		Ortho-McNeil Janssen, Eli Lilly, Pfizer, AZ	
Lavretsky, Helen			Forest Research Inst.			
Lawrie, Stephen			Wyeth-Ayerst		Eli Lilly	
Lazarus, Arthur	AZ			AZ		
Le, Trong K				Eli Lilly		
Levenson, James		Eli Lilly				
Levkovitz, Yechiel		Brainsway Inc				
Levounis, Petros					AZ, Pfizer	
Lewis-Fernández, Roberto			Eli Lilly			
Lewy, Alfred		Servier, Takeda				
Licinio, Julio	DeCode Genetics	Nature Publishing Group	NIH			

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Lieberman, Jeffrey			Allon Therapeutics, Forest, Merck, Pfizer			Eli Lilly Advisory Board, Repligen Patent, Bioline Advisory
Links, Paul			Eli Lilly Canada			
Lisanby, Sarah	Eli Lilly		Brainsway Inc, St. Jude Medical, Advanced Neuromodulation Systems, Cyberonics, NARSAD, Neuronetics, NIH, Stanley Medical Research Institute			Equipment support: Magstim and Magventure.
Litman, Robert E			AZ			
Liu, Xianchen	Eli Lilly			Eli Lilly		
Locklear, Julie				AZ		
Lusskin, Shari					Wyeth-Ayerst, AZ	
Mandel, Francine				Pfizer		
Mangurian, Christina						Honoraria from APIRE/Janssen to mentor a resident who won a research scholarship.
Manohar, Velandy					Eli Lilly, Pfizer, AZ	
Mao, Alice		Eli Lilly, Novartis			Eli Lilly, BMS, McNeil, Shire US, Novartis	
Marder, Stephen		BMS, Lundbeck, Otsuka, Wyeth- Ayerst, Pfizer, Schering, Roche Biosciences, BMS				
Markowitz, John			NIMH			
Marsh, Laura			Forest Research Inst.			
Martin, Peter						BMS APA/BMS Public Psychiatry Fellowship
Masand, Prakash	Orexigen, Titan Pharmaceuticals Inc.	Dainippon Sumitomo, Eli Lilly, Pam Lab LLC, Pfizer, Sanofi Aventis, Schering, UCB Pharma			Eli Lilly, Forest, GSK, Janssen Cilag, Pfizer, Schering, UCB Pharma	
McCarthy, Kevin			NIMH, Pfizer			
McDonald, William M.			Neuronetics, GSK, Wyeth-Ayerst			
McDougle, Christopher		BMS, Forest Research Inst.	BMS		BMS	
McGorry, Patrick			Janssen Cilag, AZ		Janssen Cilag	
McInnis, Melvin G.		Wyeth-Ayerst	NIMH		Janssen, BMS	
McIntyre, Roger			Eli Lilly, Janssen-Ortho, Shire US, Stanley Medical Research Institute, NARSAD		Janssen-Ortho, AZ, Eli Lilly, Lundbeck, Lundbeck, Biovail Laboratories, Inc., Wyeth- Ayerst	Advisory Boards: AZ, BMS, France Foundation, GSK, Janssen-Ortho, Solvay, Eli Lilly, Organon, Lundbeck, Biovail Labs., Pfizer, Shire, Schering- Plough, France. CME Activities: AZ, BMS, France Foundation, CME Outfitters, Solvay, Postgraduate Press.
McQuistion, Hunter		Janssen				
Meltzer, Herbert Y		Janssen, Pfizer, Roche Biosciences, Otsuka, Dainippon Sumitomo, Bioline, Wyeth-Ayerst, Abbott, Cephalon, Eli Lilly, Suregene, Azur, Minster, Schering-Plough, France, Acadia, Novartis, Biovail Labs., Lundbeck	Bioline, Minster, Abbott, Cephalon, Eli Lilly, Pfizer, Otsuka, Janssen, Dainippon Sumitomo, Wyeth-Ayerst			

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Menza, Matthew		BMS, Labopharm, Ono	AZ, Boehringer Ingelheim, BMS, Forest, GSK, Lilly Research Labs., Merck, Pfizer, Sanofi Aventis, Sepracor, Takeda, Wyeth-Ayerst			
Meyer, Jonathan M		AZ, BMS, Wyeth-Ayerst, Dainippon Sumitomo, Janssen, Vanda, Organon, Pfizer,	NIMH, BMS, Pfizer			
Meyer- Lindenberg, Andreas		Lundbeck, GSK, Hoffman-LaRoche			Eli Lilly, Janssen Cilag, AZ, Pfizer, Servier	
Milev, Roumen					AZ, Eli Lilly Canada, JanssenCanada, Pfizer Canada, Servier Canada, Wyeth-Ayerst Canada	
Mischoulon, David		BMS	Pam Lab LLC, Amarin, Nordic Naturals, Ganeden		Reed Medical Education, Nordic Naturals	Back Bay Scientific Royalties
Misri, Shaila			AZ Canada, Forest Research Inst.		AZ Canada, Wyeth-Ayerst	
Mitchell, James			Eli Lilly, GSK			
Montaner, Julio		Panacos	Argos Therapeutics, Bioject Inc, Merck Frosst, Abbott, Boehringer Ingelheim, BMS, Gilead Sciences, GSK, Hoffman-LaRoche, Janssen- Ortho, Pfizer, Schering, Serono, Tibotec-Virco, Theratechnologies, Trimeris		Merck Frosst, Abbott, Boehringer Ingelheim, Gilead Sciences, GSK, Pfizer, Tibotec-Virco	
Montgomery, Stuart A		Lundbeck, Merck, Merz, Roche Biosciences, Sanofi Aventis, Shire, Takeda, Takeda, Lilly Research Labs., Pfizer, PharmaNeuroBoost, Sepracor, Servier, UCB Pharma, Wyeth-Ayerst			BMS, Johnson & Johnson, AZ, GSK	
Mrazek, David						Assure RX Assure Rx has licensed intellectual property and I have an interest in this
Mukherjee, Dahlia			NIMH, Pfizer			
Muniz, Rafael	Novartis			Novartis		
Musgnung, Jeff				Pfizer		
Muskin, Philip					AZ, BMS, Forest, Jazz, Lilly Research Labs., Wyeth-Ayerst	
Mustafa, Husain			NIMH, NIMH, Advanced Neuromodulation Systems, Neuronetics, Stanley Medical Research Institute, Stanley Foundation, Cyberonics			
Nahas, Ziad H.		Neuronetics	Cyberonics, Medtronic, Inc., Brainsway Inc, NIMH, National Alliance for Research in Schizophrenia and Affective Disorders, Neuronetics		Neuronetics	
Narasimhan, Meera			Forest, AZ, BMS, Otsuka, Janssen		AZ, BMS, Schering- Plough, France	
Neal, Denita				PRMS		
Nelson, Randy		Oxford Press				
Newcomer, John W		AZ, Lundbeck, Janssen, Otsuka, Pfizer, Solvay, Vanda, Wyeth-Ayerst, BMS	NIMH, NARSAD, Janssen, Pfizer, Wyeth-Ayerst			Data Safety Monitoring Committee: Schering, Dainippon Sumitomo, Organon

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Nielsen, Jimmi					BMS	
Ninan, Philip	Wyeth-Ayerst			Wyeth-Ayerst		
Nyberg, Svante				AZ		
O'Brien, Charles		Abbott, Reckitt Benckiser, Pfizer, Embera Neuro-Therapeutics				
O'Gorman, Cedric				Pfizer		
Olin, Jason T	Novartis			Novartis		
Oquendo, Maria	BMS		AZ, Janssen Cilag, BMS, Pfizer, Eli Lilly, Shire			
O'Reardon,, John			Medtronic, Cyberonics		Eli Lilly	
Ostacher, Michael J		Pfizer	Pfizer		AZ, BMS, Eli Lilly, Forest, GSK, Janssen, Pfizer	
Ozerdem, Aysegul		AZ, BMS, Eli Lilly, GSK, Janssen Cilag, Schering-Plough, France, Egis			AZ, BMS, Eli Lilly, GSK, Egis, Janssen Cilag	Sanofi Aventis Travel grant for conference attendance
Pappadopulos, Elizabeth				Pfizer		
Parikh, Sagar			Apotex, AZ, Biovail Laboratories, Inc., BMS, GSK, Janssen, Lilly Research Labs., Lundbeck, Novartis, Pfizer, Wyeth-Ayerst Research			
Patel, Amita					AZ, BMS, Eli Lilly, Forest, Wyeth-Ayerst	
Patel, Jayendra			Johnson & Johnson, BMS, Forest, Wyeth-Ayerst			
Patkar, Ashwin A.		BMS, Reckitt Benckiser, Forest	Alkermes, BMS, Cephalon, GSK, Merck, Lundbeck, Jazz, Titan, Shire, Pfizer, Forest		BMS, Pfizer, Reckitt Benckiser, Alkermes, Merck	
Perahia, David G.S.				Eli Lilly		
Perlis, Roy H.					AZ, Eli Lilly	
Petitjean, Francois					BMS, Servier	
Petry, Nancy M.			NIDA, NIMH, NIH, NIAAA			
Phillips, Katharine A			AFSP, NIMH			Guilford Pub., future royalties, Forest Medication only for a study sponsored and funded by the NIMH
Pollack, Mark		Brain Cells Inc, Eli Lilly, Pfizer, MedAvante	BMS, Forest, Forest, GSK, Eli Lilly, Sepracor			CME Activities: AZ, Sepracor, Pfizer, MedAvante Equity
Pope, Harrison			Solvay, Ortho McNeil			
Pope, Laura	Avanir					
Preskorn, Sheldon H.		Abbott, Aventis, Bayer Corp. Pharma. Div, Biovail Labs., Boehringer Ingelheim, BMS, Eli Lilly, Innapharma, Jazz, Merck, Novartis, Organon, Otsuka, Allergan, Eisai, Fabre-Kramer Phar, Forest, Glaxo, Johnson & Johnson, KV, Lilly Research Labs., Lundbeck, Mallinckrodt, Memory Pharma., NIH, Pfizer, Roche Labs., Sanofi, Schering-Plough, France, Sepracor, Trascept Pharm, Somerset, AZ, Cyberonics, Dainippon Sumitomo, Neurosearch, Shire US, Solvay, Wyeth-Ayerst				

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Prince, Jefferson		AZ, Eli Lilly, Shire US			McNeil	
Qiao, Meihua				Eli Lilly		
Rapaport, Mark		Astellas Pharma US, BCI, Wyeth- Ayerst, NIMH, Dainippon Sumitomo, BrainCells, Inc, Quintiles, Pfizer, Takeda	National Center for Complementary and Alternative Medicine, CME Outfitters, CME Institute, NIMH			
Rasenick, Mark		Lundbeck, Eli Lilly, Stroke-Med	NIH, Dept. of Defense, Lundbeck, Eli Lilly			Pax Neuroscience Significant Financial Interest
Rasgon, Natalie		Forest, Wyeth-Ayerst	Forest, Wyeth-Ayerst			
Reed, Robin			BMS			
Renner, John	Johnson & Johnson					
Ressler, Kerry						Patent/Co-founder: Extinction Pharma. and Therapads, Inc.
Reynolds, Charles			Lilly Research Labs.			
Ries, Richard					Reckitt Benckiser, Eli Lilly, AZ, Janssen Cilag, Pfizer	
Robbins, Trevor		Pfizer, Eli Lilly, Roche Labs., GSK, Cambridge, UK Cognition, Allon Therapeutics	Pfizer, Eli Lilly, GSK, Cambridge, UK Cognition			
Romeo, Sarah A			AZ, Boehringer Ingelheim, BMS, Eli Lilly, Forest, Janssen, Pfizer, Shire, Sanofi Aventis, Takeda, GSK, Cephalon			
Rosenbaum, Jerrold	MedAvante	Auspex Pharm, MedAvante, Neuronetics, Supernus, Compellis				
Roses, Allen						Sole Owner: Cabernet Pharma., Shiraz Pharma., Zinfandel Pharma.
Rostain, Anthony		Ortho-McNeil Janssen, Ortho McNeil, Shire US			Eli Lilly, Shire US, Ortho McNeil	
Rothschild, Anthony		Pfizer, GSK, Forest, Eli Lilly	Cyberonics, Wyeth-Ayerst			
Ruano, Gualberto				Genomas Inc		
Rubin, Jonathan				Shire		
Russo, Leo				Shire		
Sagman, Doron	Eli Lilly Canada			Eli Lilly Canada		
Sahakian, Barbara		Cambridge, UK Cognition, Novartis, Shire, GSK, Lilly Research Labs., Boehringer Ingelheim				
Sajatovic, Martha		AZ, GSK, The Cognition Group, United BioSource, ePharma Solutions	NIMH, AZ, GSK			
Schiffer, Randolph	Johnson & Johnson					
Schlaepfer, Thomas	PNB Inc., Belgium	PNB Inc., Belgium, Eli Lilly, BMS, AZ			Eli Lilly, AZ	
Schoedel, Kerri		Avanir Corporation				
Schulz, S. Charles		Eli Lilly	AZ			
Sharma, Verinder		AZ, BMS, Eli Lilly, Janssen, Pfizer	AZ, BMS, Eli Lilly, Lundbeck, Servier, Stanley Foundation		Pfizer, AZ, Eli Lilly, Janssen	
Shea, Shawn		Merck				

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Sheehan, David V		Solvay, Jazz, GSK, AZ, Wyeth- Ayerst, BMS, Pfizer, Lilly Research Labs., Takeda, Labopharm, Sanofi Aventis	AZ, BMS, GSK, Jazz, Pfizer, Sanofi Aventis, Wyeth-Ayerst			
Sheline, Yvette		Eli Lilly			Eli Lilly	
Shrivastava, Amresh			Roche Labs., Eli Lilly		AZ Canada, Janssen- Ortho, Janssen Cilag	
Sikirica, Mirko				Johnson & Johnson		
Singh, Jaskaran				Johnson & Johnson		
Sivrioglu, Yusuf			Novartis			
Sledge, William	Pfizer		Eli Lilly			
Smith, David					AZ, Eli Lilly, Forest, Pfizer	
Smith, Eric			Forest Research Inst.			
Soares, Claudio		AZ, Wyeth-Ayerst, Eli Lilly, Bayer Corp. Pharma. Div.	Hamilton Community Foundation, Alergen NCE, AZ, Wyeth-Ayerst, Eli Lilly, Allergan		AZ, Wyeth-Ayerst, Eli Lilly	
Sohal, Vikaas		Neuropace				
Spera, Allan				Forest Research Inst.		
Stahl, Stephen		AZ, Arena, Avera Pharm, Boehringer Ingelheim, BMS, Cypress Bioscience, Dainippon Sumitomo, Eli Lilly, Forest, GSK, Jazz, Labopharm, Janssen, Lundbeck, Neuronetics, Marinus, Novartis, Noven, Pam Lab LLC, Pfizer, Sanofi Pharmaceuticals, Inc., Shire, Wyeth-Ayerst, Wyeth- Ayerst, Vanda, Solvay	Alkermes, AZ, Boehringer Ingelheim, Cephalon, Dainippon Sumitomo, Forest, Johnson & Johnson, Novartis, Organon, Pam Lab LLC, Pfizer Canada, Pfizer, Schering, Sepracor, Shire US, Takeda, Vanda, Wyeth-Ayerst		Pfizer Canada, Pfizer, Wyeth-Ayerst, AZ	
Starr, Harriette L.				Ortho-McNeil Janssen		
Stein, Bradley D			Ortho-McNeil Janssen			
Stein, Murray		AZ, Brain Cells Inc, BMS, Comprehensive Neuroscience, Eli Lilly, Forest, Jazz, Johnson & Johnson, Mindsite, Pfizer, Sepracor, Trascept Pharm	Eli Lilly, GSK, Hoffman- LaRoche			
Stewart, Donna		Eli Lilly, Wyeth-Ayerst, Boehringer Ingelheim				
Stigler, Kimberly A.			BMS, Janssen, NIMH			
Strakowski, Stephen		Pfizer	Eli Lilly, Janssen, Pfizer, Forest, AZ, BMS, Martek Biosciences, Nutrition 21, Repligen, Johnson & Johnson, Shire, Somerset, NIDA, NIAAA, NARSAD, Thrasher Foundation		France Foundation	
Stroups, T. Scott		Janssen				
Sukhera, Javeed						AZ Recipient of funded APA travel fellowship.
Sullivan, Patrick		SAB	Eli Lilly			
Suppes, Trisha		Orexigen	AZ, NIMH			

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Surman, Craig		Shire US, Takeda, McNeil	McNeil, Shire US, NIH, Takeda		McNeil, Novartis, Shire US	JanssenCanada Sponsored talks, Shire US Educcational and Survey Funding
Swanson, James M.		Alza/McNeil, Trascept Pharm, UCB Pharma				
Swartz, Holly		Pfizer, Servier	BMS		AZ, Eli Lilly, WebMD	BMS Honoraria for Book Chapter, Servier Honoraria for Book Chapter, Eli Lilly CME speaking honorarium, AZ CME speaking honorarium
Szpindel, Isaac					Eli Lilly Canada, JanssenCanada, Shire US, Purdue Pharma	
Tafesse, Eskinder	AZ			AZ		
Targum, Steven	BrainCells, Inc, United BioSource	BrainCells, Inc., GSK R&D, Johnson & Johnson, Memory Pharamceuticals, Dainippon Sumitomo				
Thase, Michael	MedAvante	GSK, MedAvante, Neuronetics, Novartis, Organon USA, Shire US, AZ, BMS, Supernus, Takeda, Trascept Pharm, Wyeth-Ayerst, Eli Lilly	NIMH, Eli Lilly, GSK, Sepracor		BMS, Eli Lilly, Wyeth- Ayerst, AZ	
Thase, Michael E	MedAvante	Neuronetics, Novartis, Organon USA, Shire US, Trascept Pharm, Wyeth-Ayerst, AZ, BMS, Eli Lilly, GSK, MedAvante, Supernus, Takeda	Eli Lilly, GSK, NIMH, Sepracor		AZ, Eli Lilly, Wyeth- Ayerst	
Tohen,, Mauricio		AZ, BMS, Eli Lilly, GSK, Johnson & Johnson, Sepracor, Wyeth		Eli Lilly		Spouse current employee and minor stockholder of Eli Lilly
Townsend, Mark		Jazz	Otsuka, BMS			
Trimble, Michael		Pfizer, Sanofi Aventis, Janssen Cilag				
Trzepacz, Paula				Eli Lilly		
Tsuang, John					Lilly Research Labs., Janssen	
Turkington, Douglas					Janssen Cilag, BMS	
Turner, Norris				Ortho-McNeil Janssen		
Van Ameringen, Michael		Biovail Laboratories, Inc., Shire, JanssenCanada, Lundbeck Canada, Pfizer, Servier Canada, Wyeth- Ayerst Canada	Sanofi Aventis, Eli Lilly Canada, Pfizer, JanssenCanada, NIMH, Servier Canada, Wyeth-Ayerst Canada		Wyeth-Ayerst Canada, Biovail Laboratories, Inc., JanssenCanada, Pfizer	
Varughese, Sajan				Shire		
Vaswani, Sanjay					Wyeth-Ayerst, GSK	
Viguera, Adele			AZ, Berlex Laboratories, Inc., BMS, Forest, Eli Lilly, GSK Beechum Pharmaceuticals, Janssen, Pfizer, Sepracor, Wyeth-Ayerst, Epilepsy Foundation, NIMH, National Alliance for Research in Schizophrenia and Affective Disorders, Stanley Medical Research Institute			
Vince, Bradley			BMS, Johnson & Johnson, Novartis, Otsuka, Pfizer, Sepracor, Shire US, Takeda, Abbott			

NAME	STOCK	CONSULTANT	GRANT-RESEARCH Support	FULL-TIME EMPLOYEE	SPEAKER Bureau	OTHER FINANCIAL Interest
Vogel-Scibilia, Suzanne E.					Pfizer, BMS	
Wahlstrom, Carl		Neuronetics				
Walkup, John						Royalties: Oxford Press, Guilford Pub. Free drug and placebo for completed NIMH study: Pfizer, Eli Lilly, Abbott.
Walsh, B. Timothy			AZ			
Wang, Po			Eli Lilly, Forest, Dainippon Sumitomo		GSK, Pfizer, BMS, AZ	
Weiden, Peter		AZ, BMS, Otsuka, Ortho-McNeil Janssen, Organon, Pfizer, Shire, Vanda, Wyeth-Ayerst	AZ, BMS, Otsuka, Ortho-McNeil Janssen			
Weisler, Richard	Pharmacia & Upjohn, Burroughs- Wellcome, Dainippon Sumitomo, NIMH	Otsuka, Pfizer, Pharmacia & Upjohn, Repligen, Sanofi- Synthelabo, Schwabe, Solvay, Synaptic, Vela, Wyeth-Ayerst, Wyeth-Ayerst, Abbott, AZ, Biovail Labs., BMS, Burroughs-Wellcome, Ciba Geigy Pharma. Div., Cortex, Forest Research Inst., GSK, Janssen Cilag, Lundbeck	Organon, Otsuka, Pharmacia & Upjohn, Repligen, Sandoz, Sanofi Aventis, Sanofi-Synthelabo, Schwabe, Sepracor, Shire US, Solvay, Takeda, TAP Pharma, UCB Pharma, Abbott, AZ, Biovail Labs., BMS, Burroughs-Wellcome, Cephalon, Ciba Geigy Pharma. Div., Corcept Therapeutics, Eisai, Eli Lilly, Forest Research Inst., GSK, Janssen Cilag, Johnson & Johnson, Lundbeck, Merck, McNeil, NIMH, Neurochem, Novartis		Otsuka, Pharmacia & Upjohn, Sanofi- Synthelabo, Schwabe, Solvay, Synaptic, Vela, Wyeth-Ayerst, Organon, Abbott, AZ, Biovail Labs., BMS, Burroughs- Wellcome, Ciba Geigy Pharma. Div., Forest Research Inst., GSK, Janssen Cilag, Johnson & Johnson, Lundbeck	
Weiss, Roger			Eli Lilly			
Weissman, Myrna			NIMH, NIDA, NARSAD			MultiHealth Systems Inc. Receive royalties
West, Joyce			AZ, BMS, Eli Lilly, Forest, Pfizer, Janssen-Ortho, Wyeth-Ayerst			
Wigal, Sharon					Ortho-McNeil Janssen	
Wilens, Timothy E		Abbott, AZ, McNeil, Eli Lilly, NIDA, Novartis, Merck, Shire	Abbott, McNeil, Eli Lilly, NIDA, Merck, Shire		Eli Lilly, McNeil, Novartis, Shire	Guilford Publications Published book
Wise, Michael		Eli Lilly			BMS, Eli Lilly, Lundbeck	
Wise, Thomas		Eli Lilly, Pfizer			Eli Lilly, Pfizer	
Wisner, Katherine		Eli Lilly				Novartis donation of active and placebo estradiol patches for an NIMH funded randomized controlled trial
Woodbury-Farina, Michael			BMS		BMS, Novartis	
Woods, Scott		Schering-Plough, France	Pfizer			
Wright, Jesse	Mindstreet				Wyeth-Ayerst	
Yatham, Lakshmi		Pfizer, Janssen, BMS, Servier, AZ, Schering Plough, Cephalon, Sanofi Aventis	BMS, Servier		AZ, Janssen, Pfizer, BMS	
Yehuda, Rachel			Eli Lilly			
Yohanan, Monique	Johnson & Johnson					
Youcha, Sharon				Shire		
Zeanah, Charles						Guilford Publications Book royalties
Ziegler, Penelope					Medicom Worldwide Inc.	
Zun, Leslie		Alexza Molecular Delivery			Sanofi Aventis	



#### THE FOLLOWING PRESENTERS INDICATED NEITHER THEY NOR AN IMMEDIATE MEMBER OF THEIR FAMILY HAVE ANY SIGNIFICANT RELATIONSHIP TO DISCLOSE

Abbas, Muhammad A Abbey, Susan Abdallah, Chadi Abela, John Abrams, Alan Abramson, Ronald Abreu, Lena Acosta-Uribe, Juliana

Adams, Jr., Curtis Adams, Julie Addington, Jean Adelson, Stewart Adler. Lawrence Afifi, Samah Aggarwal, Neil Ahmed. Serae Aizenstein, Howard

Akkisi Kumsar, Neslihan Aklin Will Alam, Faouzi Alao, Adekola Alaräisänen, Antti Alarcon, Renato Alcorn, Harry Ali, Asghar-Ali Ali, Mohamed Almeida, Karla Al-Saadi, Sam Amini, Mona Amir, Asad

An, Hoyoung Anson, Andrew Anzia, Joan

Apter, Gisèle Arean, Patricia Arlinghaus, Kimberly Aslam, Sunny P Asmal, Laila Atdjian, Sylvia Atkins, Robert Atri. Ashutosh Axelson, Alan aydin, cahide Ayuso, Jose Luis

Azeem, Muhammad Waqar Baez-Sierra, Deyadira Baig, Muhammad R

Bailey, Rahn Baker, Allison Baler, Ruben Balis. Theodora Ball, Valdesha

Balon, Richard

Bailey, John

Bandstra, Belinda Baptista, Trino J Barak, Yoram Barber, Marv Barr, Ellen Barreira, Paul

Bateman, Anthony

Bates Lisa

Bauer, Amy Baum, Antonia Becker Daniel Beighley, Paul Belfort, Edgard Belnap, Barri Bender, Donna Benedek, Elissa Benes, Francine Benitez, Joachim Benyamina, Amine Beresin, Eugene Berkson, Sarah Berlin, Jon

Bernstein, Carol Berthoud, Hans-Rudolf Bestha, Durga Bhugra, Dinesh Bishnoi, Ram Jeevan Bishop-Baier, Margaret

Biskin, Robert Bjork, James Bjornsson, Andri S Blake, Martin

Blasco-Fontecilla, Hilario

Block, Jerald Boettaer. Soenke Bokarius, Vladimir Boland, Robert J. Bolton, James Bonnie, Richard Book, Howard Booty, Andrew Boutros, Nash Boyce, Cheryl Anne Boyer, Jenny Bradley, John Brady, Kathleen Brendel, David H.

Brendel, Rebecca Brietzke, Elisa Briones, David Briscoe, Brian

Brod, Thomas M. Bromander, Sara Brooks, Beth Ann Broudy, Carolyn Brown, Richard

Brum Moraes, Juliana Budney, Alan Buie, Stephen

Buist, Anne Bullock, Karen Buoli, Massimiliano Burd, Ronald Burke, Jack

Burton, M. Caroline Byatt, Nancy Cabaniss, Deborah Cain, Tonier

Burpee, Stacey

Calderon-Abbo, Jose Caligor, Eve Calzada, Esther Camarena, Enrique Campayo, Antonio Campbell, Frank Campbell, Herbert Campbell, William

Candilis, Philip Canuso, Amy Cao, Xiaohua Caplan, Jason Carballo, Juan J Caring, Joanne Carney, Colleen Carroll, lan Carroll, Kathleen Carter, Anne

Casey, B.J. Castellano, F. Xavier Castellanos, Daniel

Carter, Diana

Castilla-Puentes, Wilma Castro-Loli, Piero I Caudill, Marissa Cavender, Jennifer Cebolla, Susana S Ceranoglu, Tolga Cernovsky, Zack Certa, Kenneth Chan, Carlyle Chan, Jonathan K Chandra, Prakash

Chanen, Andrew Chang, Charlene Chang, Hun Soo Chao, Fave

Chapman, Daniel P. Chaudhary, Ayesha

Cheema, Faiz A Chen, Donna Cheon, Jin Sook Chiasson, Ann Marie Childress, Anna Rose

Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois Chung, Bowen Clark, David Clarkin, John Clayton, Paula Cloninger, C. Robert Cobb Robert Coconcea, Cristinel

Coenson, Craig Coffey, C. Edward Coffey, M. Justin Cohen, Carl I. Cohen, Lewis Cohen, Mitchell Cole, Steven Compton III, Wilson Condon, Timothy Conrad, Erich Constant, Eric E

Copen, John Cora, Gabriella Cornblatt, Barbara Courchesne, Eric Cournos, Francine Cristancho, Pilar Croca, Marc-Antoine Crone, Catherine Crowley, Thomas

Çuhadaroglu-Çetin, Füsun

Curtis, Laurie Cutrone, Candace Dackis, Charles Dalack, Gregory Daniels, Allen Dannon, Pinhas Daskalakis, Zafiris Davidoff, Donald Davidson, Laurie Davies, Gordon Davis, Jeri Daviss, Steven

De Beaurepaire, Renaud De Blécourt, Carel De Jonghe, Frans De la Fuente, Camilo Declan, Barry

Degruy, Frank Deisseroth, Karl Dekker, Jack Dekleva. Kenneth Delgado, Mauricio Delgado, Pedro Deligiannidis, Kristina Dell'osso, bernardo Denisco, Richard DeSalvo Karen Desseilles, Martin Deutsch, Stephen Devlin, Michael Devulapalli, Kavi K Dewan, Mantosh Dhand, Sara Diaz, David Dickstein, Leah Dierker, Lisa Dike, Charles Diller, Kathleen C Dimaggio, Giuseppe Giancarlo Dobbins, Mary Domnitei, Diana Domschke, Katharina Donovan, Abigail Dorrepaal, Ethy Downey, Jennifer Drescher, Jack Drevets, Wayne Drury, Stacy Druss, Benjamin Duckworth, Kenneth S. Duffy, Farifteh Dunn, Laura Durden, Emily Duval, Fabrice Dwaikat, Sameh Dzirasa, Erikka Eells, Gregory Eld, Beatrice Ellis, Robert Elsayed, Yasser El-Shafei, Ahmed Embley, Scott Engel, Charles C. Eraslan, Defne Erten, Evrim

Fernandez, Francisco Ferreira, Luiz K Fetterolf, Frank A. Fier Jennifer Fine, Carla Finnerty, Molly Fiorillo, Andrea Fitelson, Elizabeth Fitzpatrick, Kathleen Flynn, Christopher Flynn, David Flynn, Meredith B Fochtmann, Laura Fonagy, Peter Forero, Jorge Forstein, Marshall Fosdick, Cara Foulks, Edward Foundas, Anne Franch Pato, Clara Franco, Kathleen Frank Julia Frascella, Joseph Freedman, Robert Friedman, Joshua Friedman, Matthew J. Friedman, Nora Friedman, Richard Friedman, Susan Hatters Frometa, Ayme Fujii, Ryuichi Fung, Kenneth Furukawa, Toshiaki A. Gabbard, Glen Gable, Mary S Galanter, Marc Gallion, Joan E. Galvez, Juan F. Galynker, Igor Garrett, Michael Gaspar, Enrique Gastelum, Emily Gathright, Molly Gaudiano, Brandon Geddes, John Geller, Jeffrey Georges, Hebert Georgieva, Galina J Gerbarg, Patricia Gerbert, Barbara Germain, Anne Gerschwind, Daniel

Ghanem, Mohamed

Giedd, Jay

Gillece, Joan

Ginzburg, Harold

Girard. Kristine Gitlin, David Glenn, Tasha Glick, Rachel Gluck, Mark Goethe, John Gold, Mark Goldberg, David Goldman, Howard Goldman, Marina Goldstein, Stacia Goldstein, Tina Gonzalez, Hector Goodman, Jeanne Gopal, Arun Gordy, Tracy Gorelick, David Graber, Cheryl Gracious, Barbara L Grady-Weliky, Tana Granacher, Robert Grant, Steven Grau, Arturo Gray, Sheila Hafter Green, Stephen Greenfield, Shelly Griffin, Margaret L Griffith, Ezra Griffith, James Gunderson, John Gunter, Gariane Gupta, Aarti A-G Gupta, Swapnil Gur, Raquel Gurrera, Ronald J Ha, Ju-Won Habl, Samar Hackman, Ann Haeri, Sophia SH Hales, Deborah Halfon, Olivier Hall. James Halmi, Katherine Halpern, John Haltzman, Scott Halverson, Jerry Hamlin, Ed Han, Doug Hyun Han, Sang Ick Haney, Margaret Hankins, Brandi Haq, Fasiha Hare, Todd Harpel, Joanne

Hassan, Farah S Hatters Friedman, Susan Hatti, Shivkumar Heckel, Sally Heim, Christine Helmer, Amanda Henderson, Melinda Hendriksen, Mariëlle Herazo, Edwin Herbert, Sarah Herbst. Luis G. Herman, Barry Hernández-Ribas, Rosa Herring, Matthew P. Heru, Alison Hien, Denise Hilderbrand, Richard Hilty, Donald Hinton, Devon Hinton, Ladson Hira-Brar, Shabneet Hlastala, Stefanie Hoffman, Perry Hoffman, William F Hoffpauir, Sarah Hoge, Steven Hoglend, Per Hong, Chang Hyung Hong, Elliot Hong, Minha Hong, Yang Hong, Youjin Honore, Russel Hoogenboom, Wouter S Hoop, Jinger Horey, Jonathan Horowitz, Mardi Houchins, Rachel A Houston, Michael Howe, Edmund Hristov. Svetoslav Hsiung, Robert Huang, David Huang, Rex Huang, Tiao-Lai Huguelet, Philippe Hunt, Justin Hunter, Jon Huremovic, Damir Hurley, Robin Hurwitz, Thomas Husain, Arshad Husni, Mariwan Harris, Toi Hussain, Arshad Harvey, Renee Hutchens, Steven

Hasin, Deborah S.

Evans, Liz

Everett, Anita

Faulkner, Larry

Feeny, Norah

Fenley, Gareth

Fauman, Beverly

Fernandez, Antony

# DISCLOSURE INDEX

Hwang, Soonjo Hyun, Aerin larovici, Doris Ibrahim, Fayaz

Inczedy-Farkas, Gabriella

Insel. Thomas Isenberg, Keith Islam, Sadaf Ismail Mostafa Jadresic, Enrique

Jaffe, Eli

Janardhanan. Thulasiram

Javed Oaiser Javier, Peña

Jeevarakshagan, Shamala

Jennings, Gillian Jensen, Signe Jeong-Ho, Seok Jermendy, Agnes Jimenez-Trevino, Luis Jimerson, David Jisun Kim Johnson, Paula Johnson, Sarah Johnston, Megan Johnstone, Eve Jones, Ashley B Jones, Cheryl W. Jones, Hendree

Jorge, Rita Jørgensen, Anders Jorgenson, Linda Joseph, Robert C. Jun, Tae-Youn Jung, Han-Young Juna. Seunaho Jung, Wooyul Juthani, Nalini Kahn, Tara A Kaitin, Kenneth

Kalivas, Peter Kalkay, Asli Funda Kalman, Thomas Kanner, Andres Kaplan, Allan Karasu, Sylvia Karnik, Niranjan Katz, Curren E. Katz. Maor

Katz-Bearnot, Sherry Katzman, Martin Kaufmann, Walter

Kautz, Mary Kav. Jerald Kaye, Walter Kelly, Meredith Kennedy, Robert Kent, Laura

Kernberg, Otto Kerner, Melissa Kesebir, Sermin Kessler, David Khalil, Afaf Khan, Arif Khan, Rizwan Kilpatrick, Michael Kim, Eun Jin

Kim Jin-woo Kim, Jun Won Kim, Scott Kim, Shin Gyeom Kim, Yong-Hwan King, Alisha E King, Bryan

Kim, Hwanglyong

King, Jeffrey King-Casas, Brooks Kingdon, David Kinzie, John David

Kissel, Olga

Knobler, Haim

Knoll, James Ko, Young-Hoon Koenig, Barbara Koenigsberg, Harold Kogan, Richard Koh. Steve

Kolling, Pieternel Kontis, Dimitrios Koo, Bon-Hoon Kool, Simone Kopelowicz, Alex

Kohrt, Brandon

Koszycki, Diana Krain, Lewis Krakowski, Menahem

Kramer, Milton Kramer, Peter Krasnik, Catherine Kravos, Matej Krishna, Sowmya Kukoyi, Oladipo

Kulkarni, Gaurav Kumar, Anand Kung, Simon Kunik, Mark Kupfer, David Kyung Yeol, Bae LaBar, Kevin

LaFrance, Jr., W. Curt Landsberger, Sarah A Laor, Nathaniel

Lapid, Maria Le Grange, Daniel LeBourgeois III, H

Lee. Elliott Lee, Hwa-Young Lee, Jonathan C Lee, Leilani

Lecours, Serge

Lee, Sang Kyu Lehman, Anthony Leibowitz, Scott Leight, Kristin Leistedt, Samuel

Lentz, Vanessa León-Andrade, Carlos Lester, Natalie A

Leszcz, Molyn

Leli, Ubaldo

Leung, Joey Shuk Yan JSY

Levander, Eric Levenson, Hanna Levin, Frances Levine, Ruth Levine, Stephen Levinson, Douglas Levv. Kenneth Levy, Norman Lewis, Janet

Lewis, Jerry Lewy, Colleen S Lim, Russell Lin, Chin-Chuen Lin, Jin-Jia Lindberg, Marc A Lindeman, Jeffrey Lineberry, Timothy Link, Patrick Lipsitt, Don

Liu. Zhifen Livesley, John Lobo Antonio LoboPrabhu, Sheila

Liu, Timothy

Lock, James Lomax, James Low, Yinghui Yh

Lowe, Matthew Lowenkopf, Eugene

Lu, Francis Lukas, Scott E Luna, Beatriz Luo, John Luty, Suzanne Lynch, Minda Lysaker, Paul

Mabe, P. Alex

Mack, Avram Mackey, Sean

Madaan, Vishal Maddox, Jill Maffei. Cesare Mago, Rajnish

Maj, Mario Maki, Pirjo H. Maldonado, Jose Malmquist, Carl Manalai, Partam Manber, Rachel

Manepalli, Jothika Mankad, Mehul Mannelli, Paolo Mantovani, Antonio Manzardo, Ann Marcu, Jahan

Marella, Srimannarayana MargeryBertoglia, Solange

Marissen, Marlies Markov, Dimitri Marks, Saul

Maruvama, Nancy C

Matharu, Yogi Matorin, Anu Matthews, Annette Mayers-Elder, Chanda McCann, David McCarron Robert McCarthy, Malia

McClellan, Andrew McCormick, Laurie McCormick, Richard McElroy, Susan McFarlane William

McGee, Michael McGraw, Deven McIntyre, Kathryn McLay, Robert McLean, Alexandra McNicholas Laura

McNulty, Karen Meesala, Anil AM Mehl-Madrona, Lewis Meier, Linda

Mendez, Mario Mendonca James D Mensah, Jason Menvielle, Edgardo Mercader, Carolina Merkel, Richard Meyer, Donald Meyer, Fremonta Meyers, Diana

Mian, Ayesha

Miciano Armando S Miettunen, Jouko Mihai, Adriana Miller, Earl Miller, Gary Miller, Gregory Min, Jungwon Miner,, Lucinda Mintz. David Mirza, Bushra F Misra, Sahana Mittal, Sukriti Moamai, Javad Moen, Richelle Moffic, Evan Mohandas, E. Montoya, Ivan Morse, Eric Morse, Gary Mosier, Jessica Moutier, Christine Mucic Davor Muñoz San José, Ainoa Munoz, Kristine

Munoz, Rodrigo A. Musalek, Michael Mushatt, David Musher, Jeremy Myers, Michael Myers, Wade Na, Haeran Hrn Nace, David Nadelson, Carol Naeem, Faroog Nanda, Aarti Nardi, Antonio Narrow, William Nascimento, Antonio Nasr, Mohamed Naylor, Magdalena Nejad, Shamim Neltner, Matthew Nemat. Ali Newton, Thomas

Noel Richard Nordon, Clementine CN Noteboom, Annemieke Notman, Malkah Nunes, Edward

Nicol, Ginger E

Nino, Johanna

Nicolo, Giuseppe

Nivoli, Alessandra

Nunes, Sandra Odebrecht Vargas SOVN

Nurenberg, Jeffry R

Nyhus, Nadine Ochsner, Kevin Odlaug, Brian L Oepen, Godehard Oh, Hyun Young Oldham, John Olsen, John L Ong, Jason Osinski, Alphonse Oslin, David Osofsky, Howard Osofsky, Joy

Ospina, Jorge Ostrow, David O'Sullivan, Michael Owen, Randall Pain, Clare Palmer, Brian Pang, Peng Pardes, Herbert Paris, Joel Park, Han Kyul Passik, Steve Patil, Uday Pato, Michele Paulsen, Jane Payne, Kate Pechnick, Robert Pedersen, Charlotte Peeters, Frenk Pelaez, Clara Peluso, Erica Penninx, Brenda Penska, Keith Perkins, Matthew Perlick, Deborah A.

Perroud, Nader Perry, Dana Peselow, Eric Peteet, John Peterson, Bradley Petrini, Mark Pflanz, Steven Pinals, Debra Pincus, Harold Plakun, Eric Pleak, Richard Plovnick, Robert

Pollack, David Poncelet, Jean Luc Pontius, Edward Pope. Kayla Potash, Mordecai Powsner, Seth Prabhakar, Deepak Preston, Kenzie

Preven. David Primm, Annelle Prudent, Vasthie Prudic, Joan Puchalski, Christina Quintanilla, Beatriz Rachal, Funmilayo Ragins, Mark Ramanathan, Anita Ramirez, Luis Randhawa, Jyoti

Rao, Nyapati Ronningstam, Elsa Rappaport, Lance M Rosario, Vernon Rappaport, Nancy Rosee, Richard Rasic, Daniel Rosenberg, Ilyse IR Rasmussen, Andrew Rasyidi, Ernest Rosenthal, Richard Rathod, Shanaya Ross, Stephen Ravitz, Paula Roy-Byrne, Peter Ravven, Simha E Ruditis, Ilze Rawkins, Sian Rue, David Rawlings, Joseph

Reardon, Claudia Reba-Harrelson, Lauren Recupero, Patricia Redish, A. David Reed, Geoffrey Reed, Hannah E Regier, Darrel A. Reich, James Reichborn-Kjennerud, Ted Reid, William

Reider, Eve Reifler, Burton V. Reiss, Allan Rei. Soham Remedi, Carolina Ren, Yan Resnick, Phillip Reus, Victor Reusche, Christian Reyes, Raymond Riba, Erica Riba, Michelle Richane, Abderrahmane AR

Richards, Lawrence Richardson, Jarrett Richeimer, Steven Richter, Peggy Riefer, Melody Rigamer, Elmore Riggio, Silvana Ritchie, Elspeth Robert, R. Roberts, Kimberly Roberts, Laura W.

Robinowitz, Carolyn B. Robinson, David Robinson, Donald Robinson, Gail Robinson, Robert G. Roca, Robert Rogers, Hollister Rohde, Paul

Roman Mazuecos, Eva Romanowicz, Magdalena

Rondon, Marta Rosenquist, Peter B.

Rueda-Jaimes, German E Rueda-Lara, Maria Adelaida Ruiz. Amanda

Ruiz, Pedro Ruminjo, Anne Rundell, James Runnels, Patrick Russakoff, L. Mark Rutherford, Bret R Ryan, Deirdre Rychik, Abe Saad, Emma Sachdeva, Shilpa Sacks, Stanley Sadiq, Afia

Saeed, Sy Safar, Laura Safer, Debra Safran, Marc Salzer, Alicia Samuel Janine Sands, Diana Savin, Daniel Saxon, Andrew Schlozman, Steven Schmidt, Chester Schmidt, Winsor Schnurr, Paula Schoener, Gary Schottenfeld, Richard Schubmehl, James Schuckit, Marc Schulden, Jeffrey Schuppert, Marieke

Schuster, James

# DISCLOSURE INDEX

Schwartz Michael Schwartz, Robert Schwartz, Victor Scott, Charles Scully, Jr., James Secin. Ricardo Seo Wan Seok Seppala, Jussi KM Seritan, Andreea Sesack, Susan Shaffer, David Shah, Amy Shahabuddin, Arif Shamal, Amin

Shannahoff-Khalsa, David Shapiro, Edward Sharfstein, Joshua Sharfstein, Steven Shim. Ruth Shin, Chul-Jin Shinfuku, Naotaka Shinozaki, Gen Shiroma, Paulo Shovinka, Sosunmolu

Shyu, Irene Sibrava, Nicholas J. Siefert, Caleb J Siggins, Lorraine Silberman, Edward

Silk, Kenneth R. Silva, Hernán Silva, Paula Silverman, Morton Simon, Robert Simpson, George G-S

Sinha, Rajita Sklar, Pamela Skodol, Andrew Slotema, Christina C

Small, Dana Smith, Delaney Smith, Dwight Smith, Gwenn Smith, Mary Kay Smith, Tyler Smither, Jane E. Snyder, Solomon Sohi, Manmohandeep

Soloff, Paul Soltys, Stephen Song, Young-Heon Sood, Aradhana Sorel, Eliot Sorensen, Roger Sorrentino, Erica Sorrentino, Renee

Spear, Linda Speier, Anthony Sperber, Jacob Spiegel, David Spila, Bozena Spinelli, Margaret

Spitznas, Cecelia Springgate, Benjamin Spurgeon, Joyce Stankowski, Joy Stanley, Barbara H. Stenback, Karis A Stevens, Anne Stewart, Jonathan

Stoddard, Frederick Stoddard Joel Stotland, Nada L. Strain, James Strasburg, Kate

Streeter, Chris C

Sudak, Donna Suetsugi, Masatomo Sullivan, Maria Summers, Richard Summers, Scott M

Sun, Ning Susman, Virginia L. Sussman, Matthew Sutcliffe, James Swedo, Susan Sylvia, Louisa G Szabo, Steven T Szarek, Bonnie Szegedi, Armin Szigethy, Eva Szycik, Gregor R Tackett, Jennifer Taintor, Zebulon Talbott, John Tandon, Rajiv Tapert, Susan Tasleem, Hina Tasman, Allan

Taylor, Craig Te Wildt, Bert T Tellez-Vargas, Jorge Temporini, Humberto Teshima, John Tewari, Nidhi Theochari, Eirini Thielman, Samuel Thomaes, Kathleen Thommi, Sairah

Thompson, Christopher Thompson, Kenneth Thomson, Captane

Thongdy, Tavi Thorpe, Michelle Thorsen, Poul Tillman, Jane Titchenal, Kay Tjoa, Christopher Trestman, Robert L. Trivedi, Reena

Truong, Kiet Tseng, Kuan-Chiao Tsuang, Ming Tucker, Phebe Turell, Jeffrey M Tzuang, Dan Uemura, Vivian Ursano, Robert Vaidya, Swapna Vaillant, George Vaks, Yakir K

Van Boeijen, Christine Van den Oord, Edwin Van Wattum, Pieter Joost

Van Wel. Bas Van, Henricus Vannucci, Elizabeth Vavrusova, Livia Vela, Ricardo Velásquez, Elvia Vemuri, Mytilee Venter Jacob Verdela, Helena Verduin, Marcia Vermani, Monica Vilhauer, Jennice Vinson, Sarah Volkow. Nora Volman, Susan Volpp, Serena

Walaszek, Art Warner, Christopher Waseem, Atif Washington, Harriet Wass, Caroline Watanabe, Norio Weber, Natalya S Webster, Cecil R

Wahlbeck, Kristian

Weinberger,, Daniel R. Weine, Stevan Weiner, Richard Weingeroff, Jolie Weinstein, Aviv Weinstein, Faye Weinstein Henry Weiss, Mitchell Weiss,, Susan R.B.

Wells, Kenneth Wells, Trevor

Westermeyer, Joseph Wetherington, Cora Lee Wexler, Micaela P Wheelis, Joan Wilk, Joshua Williams, Deidre Wills. Celia

Winhusen, Theresa Winstead, Nathaniel

Wise. Inae Wolf, Robert Wong, Felicia Wonseok, Choi Wrenn, Glenda Wulsin, Lawson R. Wynn. Pe S Xu, Yong

Yager, Joel Yang, Hyunjoo Yang, Chunxia Yang, Jun Yaseen, Zimri Yehuda, Rachel Yeomans, Frank Yeung, Albert Yildirim, Yilmaz Yoon, Jin-Sang Young, Melinda Yudofsky, Stuart Zachar, Peter Zanarini, Mary Zarate, Carlos Zarif, Nashwa

Zhang, Jing Zhao, Bing Ziedonis, Douglas Zimbrean, Paula Zimmerman, Mark Zonana, Howard Zorick, Todd Zucker, Kenneth Zurowski. Mateusz

# **LEXAPRO:** Proven efficacy in MDD in adolescents aged 12 to 17, and in MDD and GAD in adults<sup>1-5</sup>





Lexapro (escitalopram oxalate) is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and adolescents aged 12-17 years. Lexapro is also indicated for the acute treatment of generalized anxiety disorder (GAD) in adults.

#### IMPORTANT SAFETY INFORMATION

#### **Warnings and Precautions**

- All patients treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality and unusual changes in behavior, especially within the first few months of treatment or when changing the dose. Consideration should be given to changing the therapeutic regimen, including discontinuing medication, in patients whose depression is persistently worse, who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Families and caregivers of patients treated with antidepressants should be alerted about the need to monitor patients daily for the emergence of agitation, irritability, unusual changes in behavior, or the emergence of suicidality, and report such symptoms immediately. Prescriptions for Lexapro should be written for the smallest quantity of tablets, consistent with good patient management, in order to reduce the risk of overdose.
- A major depressive episode may be the initial presentation of bipolar disorder. In patients at risk for bipolar disorder, treating such an episode with an antidepressant alone may increase the likelihood of precipitating a mixed/manic episode. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine if they are at risk for bipolar disorder. Lexapro should be used cautiously in patients with a history of mania or seizure disorder. Lexapro is not approved for use in treating bipolar depression.
- The concomitant use of Lexapro with other SSRIs, SNRIs, triptans, tryptophan, antipsychotics or other dopamine antagonists is not recommended due to potential development of life-threatening serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reactions. Reactions have been reported with SNRIs and SSRIs alone, including Lexapro, but particularly with drugs that impair metabolism of serotonin (including MAOIs). Management of these events should include immediate discontinuation of Lexapro and the concomitant agent and continued monitoring.
- Patients should be monitored for adverse reactions when discontinuing treatment with Lexapro. During marketing of Lexapro and other SSRIs and SNRIs, there have been spontaneous reports of adverse events occurring upon discontinuation, including dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias), anxiety, confusion, headache, lethargy, emotional lability, insomnia and hypomania. A gradual dose reduction rather than abrupt cessation is recommended whenever possible.
- SSRIs and SNRIs have been associated with clinically significant hyponatremia. Elderly patients and patients taking diuretics or who are otherwise volume-depleted appear to be at a greater risk. Discontinuation of Lexapro should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.
- SSRIs (including Lexapro) and SNRIs may increase the risk of bleeding. Patients should be cautioned that concomitant use of aspirin, NSAIDs, warfarin or other anticoagulants may add to the risk.
- Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Lexapro does not affect their ability to engage in such activities.
- Lexapro should be used with caution in patients with severe renal impairment or with diseases or conditions that alter metabolism or hemodynamic responses. In subjects with hepatic impairment, clearance of racemic citalopram was decreased and plasma concentrations were increased. The recommended dose of Lexapro in hepatically impaired patients is 10 mg/day.
- For pregnant or nursing mothers, Lexapro should be used only if the potential benefit justifies the potential risk to the fetus or child.

#### **Adverse Reactions**

- In clinical trials of MDD, the most common adverse reactions in adults treated with Lexapro (approximately 5% or greater and at least twice the incidence of placebo) were nausea (15% vs 7%), insomnia (9% vs 4%), ejaculation disorder (9% vs <1%), fatigue (5% vs 2%), somnolence (6% vs 2%), and increased sweating (5% vs 2%). In pediatric patients, the overall profile of adverse reactions was similar to that seen in adults; however, the following additional adverse reactions were reported at an incidence of at least 2% for Lexapro and greater than placebo: back pain, urinary tract infection, vomiting, and nasal congestion.
- In clinical trials of GAD, the most common adverse reactions in adults treated with Lexapro (approximately 5% or greater and at least twice the incidence of placebo) were nausea (18% vs 8%), ejaculation disorder (14% vs 2%), insomnia (12% vs 6%), fatigue (8% vs 2%), decreased libido (7% vs 2%) and anorgasmia (6% vs <1%).


References: 1. LEXAPRO [package insert]. St. Louis, Mo: Forest Pharmaceuticals, Inc.; 2009. 2. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry. 2009; 48:721-729. 3. Burke WJ, Gergel I, Bose A, Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002; 63:331-336. 4. Davidson JRT, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety. 2004;19:234-240. 5. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2002;17:95-102.



# See the effect of LEXAPRO

Proven efficacy in MDD in adolescents aged 12 to 17, and in MDD and GAD in adults<sup>1-5</sup>

In adolescents aged 12 to 17 with Major Depressive Disorder (MDD)\*1









- Significantly improved MDD symptoms in adolescents<sup>2</sup>
- Significantly higher rates of response and remission vs placebo in MDD and GAD in adults<sup>4,5</sup>

#### There is no generic available for LEXAPRO

\*LEXAPRO is indicated as an integral part of a total treatment program for MDD. Drug treatment may not be indicated for all adolescents with this syndrome.

#### **WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS**

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Lexapro or any other antidepressant in a child, adolescent or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Lexapro is not approved for use in pediatric patients less than 12 years of age.

#### **Contraindications**

- Lexapro is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). There have been reports of serious, sometimes fatal, reactions with some cases resembling neuroleptic malignant syndrome (NMS) and serotonin syndrome. Features may include hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued SSRI treatment and have been started on an MAOI. Serotonin syndrome was reported for two patients who were concomitantly receiving linezolid, an antibiotic which has MAOI activity. Lexapro should not be used in combination with an MAOI or within 14 days of discontinuing an MAOI. MAOIs should not be initiated within 14 days of discontinuing Lexapro.
- Lexapro is contraindicated in patients taking pimozide or with hypersensitivity to escitalopram or citalopram.

Please see additional Important Safety Information on preceding page.

Forest Pharmaceuticals, Inc.



Drief Summary: For complete details, please see full Prescribing Information for Lexapro.

WARNINGS: SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDDI) and other psychiatric disorders. Anyone considering the use of Lexapro or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults aged 55 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and careqivers should be advised of the need for close observation and communication with the prescriber. Lexapro is not approved for use in pediatric patients less than 12 years of age. (See Warnings and Precautions: Clinical Worsening and Suicide Risk, Patient Counseling Information. Information for Patients, and Used in Specific Populations. Pediatric Usens.

INDICATIONS AND USAGE: Major Depressive Disorder-Lexapro (escitalopram) is indicated for the acute and maintenance treatment of majo INDICATIONS AND USAGE: Major Depressive Disorder-Lexapro (escitalopram) is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [see Clinical Studies]. A major depressive episode (DVH) implies a prominent and relatively persistent (nearly very day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersonmia, psychomotor agitation or retardation, increased fatigue, fellings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance.

CONTRAINDICATIONS: Monoamine oxidase inhibitors (MAOIs) Foocominant use in patients taking monoamine oxidase inhibitors (MAOIs) is contraindicated [see Warnings and Precautions]. Primazide-Concomitant use in patients taking pimozide is contraindicated [see Drug Interactions]. Primazide-Concomitant use in patients taking pimozide is contraindicated [see Drug Interactions]. Primazide-Concomitant use in patients taking pimozide is contraindicated [see Drug Interactions]. Primazide concomitant use in patients with a hypersensitivity to escitalopram or citalopram - craw of the inactive ingredients in Lexagno.

WARNINGS AND PRECAUTIONS: Clinical Worsening and Suicide Risk-Palients with major depressive disorder (MDD), both adult and pediatric, may experience vorsening of their depression and offer the emergence of suicidal idention and behavior, (suicidality) or unsuitable changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders hemselves are the strongest predictors discide. There has been a long-standing concern, however, that antidepressants may have a role in inducing vorsening of depression and of the emergence of suicidality in entire patients during the early plasses of treatment. Pooled analyses of short-term placebo-controlled trials entidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal hinking and behavior (suicidality) in children, adolescents, and upung adults lages 18-24) with major depresses disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults age to a disorder. Short-term studies did not show an increase in the violed analyses of placebo-controlled risks in children and delicesters with the propriet of placebo of adults and adolescents with observed computive disorder (DCD), or other psychiatric disorders included a total of 24 short-term trials of antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled risk in adults with MDD or other psychiatric disorders included a total of 24 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in ricrease in the younger patients for almost all drugs studied. There were difference so disuble risk of suicidality among strata and across so indications. With the highest incidence in MDD. The risk differences (drug vs. placebo) WARNINGS AND PRECAUTIONS: Clinical Worsening and Suicide Risk-Patients with major depressive disorder (MDD), both adult and pedi-

TABLE 1		
Age Range	Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated	
	Increases Compared to Placebo	
<18	14 additional cases	
18-24	5 additional cases	
	Decreases Compared to Placebo	
25-64	1 fewer case	
>65	6 fewer cases	

No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide. It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from pacebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression. All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months recurrence of depression. All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months recurred to the propriate of the propri recurrence of depression. All patients being treated with antidepressants for any indication should be monitored appropriately and observed charges in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, insomnia, irribability, aggressiveness, implisitivity, adhabisa (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric, abit the being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric, adhough a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of sucidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. Consideration should be given to changing the threapenduric regimen, including possibly discontinuing the medication, in patients whose depression persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. If the decision has been to discontinuite the decision has been decision of the decision has been decision and the discontinuition in section of the decision has been decision of the decision has been decision and the discontinuition in the decision has been decision and the discontinuition in the decision has been decision of the decision has been decision and the discontinuition of the decision Discontinuation of Treatment with Lexapro-During marketing of Loxapro and other SSRs and SMRs (secretorin and nopreinpehrine reuptate inhibitors), there have been spontaneous reports of adverse wents occurring upon discontinuation of these drugs, particularly when adrugt, including the following dysphoric mood, irritability, agitation, disciness, sensory disturbances (e.g., paresthesias such as electric shock sensor) and continuation of these drugs, particularly when adrugt, including the following dysphoric mood, irritability, agitation, disciness, sensory disturbances (e.g., paresthesias such as electric shock sensor) and continuation of the mode and the state of the sensor of judgment, thinking, or motor skills, however, patients should be cautioned about operating hazardous machinery, including automobiles, lettle year reasonably certain that Levapro therapy does not affect their ability to engage in such activities. Use in Patients with Concomitant Illness-Clinical experience with Lexapro in patients with certain concomitant systemic illnesses is limited. Caution is advisable in using Lexapro in patients with diseases or conditions that produce altered metabolism or hemodynamic responses. Lexapro has not been systematically evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were generally excluded from clinical studies during the product's premarketing testing. In subjects with hepatic impairment, clearance of reaemictopram was decreased and plasma concentrations were increased. The recommended dose of Lexapro in hepatically impaired patients is 10 mg/day [see Dosage and Administration]. Because escitalopram is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. Until adequate numbers of patients with severe renal impairment have been evaluated during chronic treatment with Lexapro, however, it

should be used with caution in such patients [see Dosage and Administration]. Potential for Interaction with Monoamine Oxidase Inhibitors In patients receiving serotonin reuptake inhibitor drugs in combination with a monoamine oxidase inhibitor (MAOI), there have been reported in serious, sometimes fatal, reactions including hyperhermal, rigidity, mycolorus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued SSRI treatment and have been started on an MAOI. Some cases presented with fears resembling neuroleptic malignant syndrome. Furthermore, limited animal data on the effects of combined use of SSRIs and MAOIs suggest that these drugs may act synergistically to elevable blood pressure and evice behavioral existation. Therefore, it is recommended that Lexagno should not be used in combination with an MAOI, or within 14 days of discontinuing treatment with an MAOI. Similarly, at least 14 days should be allowed after stopping Lexagno before starting and MAOI. Servicinis syndrome has been reported in two patients who were concomitantly receiving linezolid, an antibiotic which is a reversible non-selective MAOI.

ADVERSE REACTIONS: Clinical Trials Experience-Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Clinical Trial bas Sources, Pediatrics, 6-17 years/Adverse events were collected in 576 pediatric patients (286 Lexapro, 290 patients) with major depressive disorder in double-blind placebo-controlled studies. Safety and effectiveness of Lexapro in pediatric patients less than 12 years of age has not been established. Adults-Adverse events information for Lexapro was collected from 715 patients with major depressive disorder who were exposed to be established. Adults-Adverse events information for Lexapro was collected from 715 patients with major depressive disorder who were exposed to pacebo in double-blind placebo-controlled trials. Adverse events during exposed to placebo in double-blind, placebo-controlled trials. Adverse event surface and provide private provider and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, standard World Health Organization (WHO) terminology has been used to classify reported adverse events. The state for requencing adverse events without first proportion of individuals who experiencial event categories. In the tables and tabulations that follow, standard World Health Organization (WHO) terminology has been used to classify reported adverse events. The state for requencing expects in the proportion of individuals who experiencial experien ADVERSE REACTIONS: Clinical Trials Experience-Because clinical studies are conducted under widely varying conditions, adverse reaction 20 mg/day Lexapro was 10%, which was significantly different from the rate of discontinuation for adverse events in patients receiving 10 mg/day Lexapro (4%) and placebo (3%). Adverse events that were associated with the discontinuation of at least 1% of patients readed with Lexapro, the continuation of at least 1% of patients treated with Lexapro, and for which the rate was at least twice that of placebo, were nausea (2%) and ejaculation disorder (2% of male patients). Generalized Anxiety of the continuation of the continuat least 1% of patients treated with Lexapro, and for which the rate was at least twice the placebo rate, were nausea (2%), insomnia (1%), and fatigue (1%). Incidence of Adverse Reactions in Placebo-Controlled Clinical Trials; Major Depressive Disorder; Pediatrics (6 -17 years)-The sague 1/19), muleined of interest reactions in factor commonitor distinct mates, might object assessed instruct, managed to you end profile of deviews reactions in pediatric patients was generally similar to that seen in adult studies, as shown in Table 2. However, the following adverse reactions (excluding those which appear in Table 2 and these seen which the code determs were uninformative or misleading were reported at an incidence of at least 2% for Lexapro and greater than placebor back pain, urinary tract informative or misleading congestion. Adults-The most commonly observed adverse reactions in Lexapro patients (incidence of approximately 5% or greater and approximately twice the incidence in placebor patients) were insomina, algorithm district material type delay, natures, averalting increased, fatigue, and sommolence. Table 2 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred among 715 depressed patients who received Lexapro at doses ranging from 10 to 20 mg/day in placebo-controlled trials. Events included are those occurring in 2% or more of patients treated with Lexapro and for which the incidence in patients treated with Lexapro was greater than the incidence in placebo-treated patients.

TABLE 2			
Treatment-Emergent Adverse Reactions Observed with a Frequency of ≥ 2% and Greater Than Placebo for Major Depressive Disorder			
Adverse Reaction	<u>Lexapro</u> (N=715)	Placebo (N=592)	
Autonomic Nervous System Disorders	` '	` '	
Dry Mouth	6%	5%	
Sweating Increased	5%	2%	
Central & Peripheral Nervous System Disorders			
Dizziness	5%	3%	
Gastrointestinal Disorders			
Nausea	15%	7%	
Diarrhea	8%	5%	
Constipation	3%	1%	
Indigestion	3%	1%	
Abdominal Pain	2%	1%	
General			
Influenza-like Symptoms	5%	4%	
Fatique	5%	2%	
Psychiatric Disorders			
Insomnia	9%	4%	
Somnolence	6%	2%	
Appetite Decreased	3%	1%	
Libido Decreased	3%	1%	
Respiratory System Disorders			
Rhinitis	5%	4%	
Sinusitis	3%	2%	
Urogenital			
Ejaculation Disorder <sup>1,2</sup>	9%	<1%	
Impotence <sup>2</sup>	3%	<1%	
Anorgasmia <sup>3</sup>	2%	<1%	

1Primarily eiaculatory delay

<sup>3</sup>Penominator used was for males only (N=225 Lexapro; N=188 placebo). <sup>3</sup>Denominator used was for females only (N=490 Lexapro; N=404 placebo).

Generalized Anxiety Disorder, Adults-The most commonly observed adverse reactions in Lexapro patients (incidence of approximately 5% or greater and approximately twice the incidence in placebo patients) were nausea, ejeculation disorder (primarily ejeculatory delay), insomit affatigue, decreased libido, and anongsamia. Table 3 enumerates the incidence, rounded to the nearest percent of treatment—emergent adverse events that occurred among 429 GAD patients who received Lexapro 10 to 20 mg/day in placebo-controlled trials. Events included are the courring in 2% or more of patients treated with Lexapro and for which the incidence in patients treated with Lexapro and segretare than the

·	TABLE 3	
Treatment-Emergent Adverse Reactions Observed with a Frequency of ≥ 2% and Greater Than Placebo for Generalized Anxiety Disorder		
Adverse Reactions	<u>Lexapro</u> (N=429)	Placebo (N=427)
Autonomic Nervous System Disorders	•	
Dry Mouth	9%	5%
Sweating Increased	4%	1%
Central & Peripheral Nervous System Disorders		
Headache	24%	17%
Paresthesia	2%	1%
Gastrointestinal Disorders		
Nausea	18%	8%
Diarrhea	8%	6%
Constipation	5%	4%
Indigestion	3%	2%
Vomiting	3%	1%
Abdominal Pain	2%	1%
Flatulence	2%	1%
Toothache	2%	0%
General		
Fatigue	8%	2%
Influenza-like Symptoms	5%	4%
Musculoskeletal System Disorder		
Neck/Shoulder Pain	3%	1%
Psychiatric Disorders		
Somnolence	13%	7%
Insomnia	12%	6%
Libido Decreased	7%	2%
Dreaming Abnormal	3%	2%
Appetite Decreased	3%	1%
Lethargy	3%	1%

#### LEXAPRO® (escitalopram oxalate) TABLETS/ORAL SOLUTION

TABLE 3  Treatment-Emergent Adverse Reactions Observed with a Frequency of ≥ 2% and Greater Than Placebo for Generalized Auxiety Disorder (continued)			
Adverse Reactions	<u>Lexapro</u> (N=429)	<u>Placebo</u> (N=427)	
Respiratory System Disorders			
Yawning	2%	1%	
Urogenital			
Ejaculation Disorder <sup>1,2</sup>	14%	2%	
Anorgasmia <sup>3</sup>	6%	<1%	
Menstrual Disorder	2%	1%	

<sup>1</sup>Primarily ejaculatory delay. <sup>2</sup>Denominator used was for males only (N=182 Lexapro; N=195 placebo). <sup>3</sup>Denominator used was for females only (N=247 Lexapro; N=232 placebo).

Dose Dependency of Adverse Reactions-The potential dose dependency of common adverse reactions (defined as an incidence rate of ≥5% in either the 10 mg or 20 mg Lexapro groups) was examined on the basis of the combined incidence of adverse events in two fixed-dose trials. The overall incidence rates of adverse events in 10 mg Lexapro-treated patients (66%) was similar to that of the placebo-treated patients (61%) while the incidence rate in 20 mg/day Lexapro-treated patients was greater (86%). Table 4 shows common adverse reactions that occurred in the 20 mg/day Lexapro incidence that was approximately twice that of the 10 mg/day Lexapro group with an incidence that was approximately twice that of the 10 mg/day Lexapro group and approximately twice that

TABLE 4 Incidence of Common Adverse Reactions in Patients with Major Depressive Disorder			
Adverse Reaction	Placebo (N=311)	10 mg/day	20 mg/day
	(N=311)	Lexapro (N=310)	Lexapro (N=125)
Insomnia	4%	7%	14%
Diarrhea	5%	6%	14%
Dry Mouth	3%	4%	9%
Somnolence	1%	4%	9%
Dizziness	2%	4%	7%
Sweating Increased	<1%	3%	8%
Constipation	1%	3%	6%
Fatigue	2%	2%	6%
Indigestion	1%	2%	6%

Male and Female Sexual Dystunction with SSRIs-Although changes in sexual desire, sexual performance, and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of pharmacologic treatment. In particular, some evidence suggests that SSRIs can cause such untoward sexual experiences. Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in product labeling are likely to under estimate their actual incidence.

TABLE 5			
Incidence of Sexual Side Effects in Placebo-Controlled Clinical Trials			
Adverse Event	Lexapro	Placebo	
	In	Males Only	
	(N=407)	(N=383)	
Ejaculation Disorder			
(primarily ejaculatory delay)	12%	1%	
Libido Decreased	6%	2%	
Impotence	2%	<1%	
	In Females Only		
	(N=737)	(N=636)	
Libido Decreased	3%	1%	
Anorgasmia	3%	<1%	

There are no adequately designed studies examining sexual dysfunction with escitalonram treatment. Prianism has been reported with all SSRIs Inere are no adequately designed studies examining sexual dystinction with eschalopram freatment. Praignsm has been reported with all SSW thille it is difficult to know the precise risk of sexual dysfunction associated with the use of SSRIs, physicanis should routherly inquire about such possible side effects. Vital Sign Changes-Loxapro and placebo groups were compared with respect to (1) mean change from baseline vital signs; pulse, systolic blood pressure, and disctolic blood pressure) and (2) the incidence of patients meeting criteral for potentially clinically significant changes from baseline in these variables. These analyses did not reveal any clinically important changes in vital signs associated with Lexapro treatment. In addition, a comparison of supine and standing vital sign measures in subjects receiving Lexapro indicated that vital signs (pulse, systolic blood pressure, and disastolic blood pressure) and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses did not reveal any clinically important changes in vital signs associated with Lexapro treatment. In addition, a comparison of supine and standing vital sign measures in subjects receiving Lexapro indicated that Lexapro treatment is not associated with orthostaclic changes. Weight Changes-Patients treated with Lexapro in controlled Irid doit offler from placebo-treated patients with repart to clinically important change in body weight. Laboratory Changes-Lexapro and placebo groups were compared with respect to (1) mean change from baseline in various serum chemistry, hematology, and urinalysis variables, and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed not clinically important changes in laboratory test parameters associated with Lexapro treatment. Edg. Changes-Electrocardiograms from Lexapro (Il-e25), racemic citalopram (Il-e351), and placebo (Il-e327) groups were compared with respect to (1) mean change from baseline in various Economic (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in various Economic (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in various Economic (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in various Economic (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed (1) a decrease in local reveal of 2.9 minor test of 2.9 minor tes choreoathetosis, cerebrovascular accident, dysarthria, dyskinesia, dystonia, extrapyramidal disorders, grand mal seizures (or convulsions choreachteosis, cerebrovascular accident, dysarthria, dyskinesia, dystonia, extrapyramidal disorders, grand mal seizures (or convulsions, phypoaethesia, mycolorus, instagmus, Parkinsonism, restless legs, seziures, synope, tardive dyskinesia, tremor. Preprancy, Puerperium and Perinatal Conditions: spontaneous abortion. Psychiatric Disorders: acute psychosis, aggression, agitation, anger, anxiety, apathy, completed suicide, confusion, depersonalization, depression aggravated, delirium, delusion, disorientation, feeling unreal, hallucinations (visual and auditory), mood swings, nervousness, nightmare, panio reaction, paranoia, restlessness, self-harm or thoughts of self-harm, suicide attempt, suicide latenders, Repriatory, Thoracci and Medisatianal Disorders: (Sypena, epistass), pulmonary emblosim, pulmonary hypertension of the newborn. Skin and Subcutaneous Tissue Disorders: alopecia, angioedema, dermatitis, ecchymosis, erythema multiforme, photosensitivity reaction, Stevens, Johnson Syndromer, toxic epidermal necrolysis, urticaria. Vascular Disorders: deep vein thromosis, flushing, hypertensive crisis, hypotension, orthostatic hypotension, phibitis, thrombosis.

hypetensive crisis, hypotension, orthosataic hypotension, phibbitis, thrombosis.

DRUG INTERACTIONS: Serotonergic Drugs-Based on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential for serotonin syndrome, caution is advised when Lexapro is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an ambitiotic which is a reversible non-selective MAOI), lithium, tramadol, or SL John's Wort [see Warmins and Prezautions]. The concomitant use of Lexapro with their SSRIs, SNRIs or tryptophas is not recommended. Triptans-Thee have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan. If concomitant treatment of Lexapro with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and does increases [searchings and Prezautions], CNS Drugs-Given the primary CNS effects of escitaloppam, caution should be used when it is taken in combination with other centrally acting drugs. Alechol-Although Lexapro did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking Lexapro is not recommended. Monoamine Oxidase Inhibitors (MAOIs)-[see Contraindications and Varanings and Prezautions]. Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)-Serotonin release by platelets plays an important role in hemostasis. Explementological Studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin release and the occurrence of upper gastrointestinal bleeding have

#### LEXAPRO® (escitalopram oxalate) TABLETS/ORAL SOLUTION

also shown that concurrent use of an NSAID or aspirin may potentiate the risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SWRIs are coadministered with varfain. Patients receiving warfain therapy should be cardly monitored when Lexapro is initiated or discontinued. Climetidine-in subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and C..., of 43% and 39%, respectively. The cinical significance of these findings is undrown. Dipostrien subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and dipoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram and dipoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram of will make the citalopram of citalopram of citalopram or difference in the pharmacokinetics of citalopram or illhium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the sentioneryic effects of esclalopram citalopram of with appropriate adjustment to the lithium of the citalopram of with particular should be excrised when Lexapro and lithium are coadministered. Pimozitie and Celeza-in a controlled study, a single dose of pimozide 2 mg co-daministered with racemic citalopram 40 mg pieve nonce daily for 11 days was associated with a aream increase in OTC values proximately 10 msec compared to pimozide given alone. Racemic citalopram (40 mg/day for 21 days) and the CVP142 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of citalopram was not evaluated. Warfarin-Administration of 40 mg/day road carbamazepine in CyP34A substrate in chinal proximal particular solved in a destribution of 10 mg/day for 14 days) and carbamazepine in given and metoprolol had no clinically significant effects on blood pressure or heart rate. **Electroconvulsive Therapy (ECT)**-There are no clinical studies of the combined use of ECT and escitalopram.

Subtles of the combined use of ECT and escitaloprani. Our pressure of the art has. Executivation and the combined use of ECT and escitaloprani. Our pressure of the combined use of ECT and escitaloprani. Our pressure of the combined use of ECT and escitaloprani. Our pressure of the combined use of the comb effects or facemic citalopriam were observed at a maternally toxic dose in the rat and were not observed in the racin White hemale rats were treated with recenic citaloprian (4, 12.8, or 32 mg/kg/day) from late gestation through wealing, increased offspring mortality and 4 days after birth and persistent offspring growth retardation were observed at the highest dose. The no-effect dose was 12.8 mg/kg/day, Similar felects on offspring mortality and growth were seen when dams were treated throughout gestation and early lactation at doses ≥ 24 mg/kg/day. A no-effect dose was not determined in that study. There are no adequate and well-controlled studies in pregnant women, therefore, escitalopriam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy-Nonteratogenic Effect Nonates exposed to Lexapor and other SSRIs or SNRIs, tale in the third trinseter, have developed complications requiring prolonged hospital-ization, respiratory support, and tube feeding, Such complications can arrise immediately upon delivery. Reported clinical findings have included receivator, dictore, cornocies and present such productive including the hospital-ization, respiratory support, and tube feeding. Such complications can arrise immediately upon delivery. Reported clinical findings have included receivator, dictore, cornocies and present such productive including have included hospitals. pram should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy-Vionteratogenic Libera Roenales exposed to Lexapra and other SSRIs or SMRIS, late in the third trimseter, have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical indings have include respiratory distress, cyanosis, apena, seizures, temperature instability, feeding difficulty, vomiting, hypoplycemia, hypotronia, hyperforia, hyperreflexia, tremor, litteriness, irritability, and constant crying. These features are consistent with retired toxic effect of SSRIs and SMRIs, possibly, a drug discontinuation syndrome. It should be noted that, is some cases, the clinical pluruse is consistent with serior on somistent with servotion is syndrome (SPRIs) proposition and provided in the consistent with servotion is syndrome (SPRIs) provided in the newborn (PPHN). PPHN occurs in 1-2 per 1000 live britts in the general population and is associated with subtainal enomability and mortality, in a retrospective, case-control study of 377 women whose infants were born healthy, the risk for developing PPHN was approximately six-fold higher for infants exposed to SSRIs after the 20th was reported to infants who had not been exposed to antidepressants during pregnancy. There is currently no corroborative evidence reparding the six for PPHN following exposure to SSRIs is pregnancy, this six the first study that has investigated the potential risk. The study of data is investigated the potential risk. The study for this cinvestigated the potential risk. The study for the similar proparative evidence reparding the country of the propagative propagative propagative propagative propagative propagative propagative propagative propagative propagat

suspects and younger subjects, and other reported clinical experience has not identified differences in responses between the elider and younger patients, but again, greater sensitivity of some elderly individuals cannot be ruled out.

PRISA BAUSE AND DEPENDENCE: abuse and Opendence; Physical and Psychological Dependence-Animal studies suggest that the abuse lability of racemic citalopram is low. Lexapro has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence. The premarketing clinical experience with Lexapro did not reveal any drug-seeking behavior. However, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a OKS-active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully exhaulte Lexapro patients for history of drug abuse and follow supplements of tolerance, incrementations of dose, drug-seeking behavior).

OVERDOSAGE: Human Experience-In clinical trials of escitalopram, there were reports of escitalopram overdose, including overdoses of over 1000 mg have been reported. As with other SSRIs, a fatal outcome in a patient who has taken an overdose of escitalopram has been rarely reported. Surphorns most often accompanying escitalopram overdose, alone or in combination with other drugs and/or alone, including corrudosers, or overdose, including overdoses of over 1000 mg have been reported. As with other SSRIs, a fatal outcome in a patient who has taken an overdose of escitalopram has been rarely reported. Surphorns most often accompanying everdose, alone or in combination with other drugs and/or alone, including corrudosers, or overdose. In the prolongation and very rare cases of torsade de pointests. Acute renal failure has been very rearly reported accompanying overdooh, included convulsions, coma, diziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including OT prolongation and ver

Forest Pharmaceuticals, Inc Subsidiary of Forest Laboratories, Inc. St. Louis, MO 63045 USA Licensed from H. Lundbeck A/S

© 2009 Forest Laboratories, Inc.

Rev 05/09



Ranked first among all freestanding psychiatric hospitals...

U.S. News & World Report



# Research

# A Full Continuum of Psychiatric Care For All Ages

- Inpatient
- Acute and longer-term residential
- Partial hospitalization
- Outpatient services
- Specialized schools and camp

Leading Through Excellence and Innovation

Belmont, Mass. mclean.harvard.edu 800.333.0338

PARTNERS

# Engage, Interact, and Learn from the Experts! **Association 163rd Annual Meeting**

Saturday, May 22 - Wednesday, May 26

#### **Master Courses**

Attend a Master Course at the 2010 American Psychiatric Association Annual Meeting and receive an accompanying reference as part of your admission!



Price for Each Master Course: \$350.00 Onsite **Book Included in Each Course!** 

#### Child and Adolescent Psychopharmacology



Saturday, May 22 9:00am-4:00pm Presented by Christopher J. Kratochvil, M.D., with John T. Walkup, M.D., Christopher J. McDougle, M.D., and Karen Dineen Wagner, M.D., Ph.D.

#### **Cutting-Edge Psychopharmacology**



Saturday, May 22 9:00am-4:00pm Presented by Alan F. Schatzberg, M.D., and Ira D. Glick, M.D., with Charles DeBattista, M.D., Terrence Ketter, M.D., Kiki Chang, M.D., and Natalie Rasgon, M.D.

#### **Practical Cognitive-Behavior Therapy**



Sunday, May 23 9:00am-4:00pm

Director: Jesse Wright, M.D., Ph.D., with Judith Beck. Ph.D., Robert Goisman, M.D., and Donna Sudak, M.D.



#### Practical Psychodynamic Psychotherapy

Sunday, May 23 9:00am-4:00pm

Director: Glen O. Gabbard, M.D., with Robert Michels, M.D., John Gunderson, M.D., and Gabrielle Hobday, M.D.



#### **Neuropsychiatry for Veterans**

Wednesday, May 26 8:00am-12:00pm

Presented by Stuart C. Yudofsky, M.D., and Thomas Kosten, M.D., with Thomas Newton, M.D., Kimberly Arlinghaus, M.D., and Robin Hurley, M.D.

### **Additional Courses by APPI Authors**

Price for Each Course: \$250.00 Onsite **Book Included in Each Course!** 

#### **Advances in Neuropsychiatry** The Neuropsychiatry of Emotion and Its Disorders



Monday, May 24 8:00am-12:00pm

Presented by C. Edward Coffey, M.D., and Randolf B. Schiffer, M.D., with Matthew Menza, M.D., Michael Trimble, M.D., and Robert G. Robinson, M.D.



Purchase books and journals published by APPI at www.appi.org



Psychopharmacologic, ECT, and **Psychotherapeutic Treatment of Psychotic** (Delusional) Depression

Monday, May 24 1:00pm-5:00pm

Presented by Anthony J. Rothschild, M.D., with Brandon Guadiano, Ph.D.



### **How to Practice Evidence-Based Psychiatry**

**Principles and Case Studies** 

Tuesday, May 25 8:00am-12:00pm

Presented by C. Barr Taylor, M.D.

The First and Last Word in Psychiatry Priority code AH1017

# Engage, Interact, and Learn from the Experts!

# at the American Psychiatric Association

**163rd Annual Meeting** 

Saturday, May 22 - Wednesday, May 26

#### **Advances In Sessions**

Advances In Sessions provide meeting attendees with an opportunity to gain in-depth information on clinical and research advances in specific areas of psychiatry. These 3-hour didactic lecture series feature well-known experts presenting clinical and research findings and allowing time for questions and answers. No registration is necessary for these sessions.





#### **Advances in Correctional Psychiatry**

Monday, May 24 9:00am-12:00pm Chairperson: Charles L. Scott, M.D.



#### **Advances in Psychosomatic Medicine**

Monday, May 24 9:00am-12:00pm Chairperson: James L. Levenson, M.D.



#### **Advances in Forensic Psychiatry**

Monday, May 24 2:00pm-5:00pm Chairperson: Robert I. Simon, M.D.



#### **Advances in Psychotherapeutic Treatments**

Monday, May 24 2:00pm-5:00pm Chairperson: Glen O. Gabbard, M.D.



The First and Last Word in Psychiatry www.appi.org


Phone: 1-800-368-5777 • Email: appi@psych.org

Find us on f and Priority code AH1018



#### Advances in the Use of Antipsychotic **Medications**

9:00am-12:00pm Tuesday, May 25 Co-Chairpersons: Anthony J. Rothschild. M.D., Kristina Deligiannidis, M.D.



#### Advances in Personality Disorders

Tuesday, May 25 2:00pm-5:00pm Co-Chairpersons: John M. Oldham, M.D., Andrew E. Skodol, M.D.



#### **Advances in Substance Abuse Treatment**

Tuesday, May 25 2:00pm-5:00pm Co-Chairpersons: Marc Galanter, M.D., Herbert D. Kleber, M.D.

#### **APPI Bookstore**

Be sure to stop by the APPI bookstore to check out APPI's latest selections, from the newest textbooks, clinical manuals, and journals, to electronic products for your handheld, smartphone, or iPad.

#### **Bookstore Hours:**

Saturday, May 22 to Tuesday, May 25, 10:00am - 4:00pm

# CONTENTS

FORMAT DESCRIPTIONS
DAILY ATTENDANCE LOG60
SATURDAY SESSIONS
SUNDAY SESSIONS75
Monday Sessions85
TUESDAY SESSIONS103
Wednesday Sessions
TOPIC INDEX126

#### ADVANCES IN SERIES

These sessions are intended to highlight important new advances occurring in the field of psychiatry involving selected disorders or treatments. Some of these sessions are chaired by editors of recent textbooks published by the American Psychiatric Publishing, Inc. (APPI), and feature selected chapter authors from these texts. The books discussed at these sessions may be purchased at the APPI bookstore or online. During the Advances in Research Session, leading clinical researchers present the latest developments in research. Other types of advances in sessions include topics designed to provide psychiatrists with the latest in clinical developments in other areas of medicine. The intent is to give the audience an update from a physician in a particular specialty. These sessions will help attendees keep pace with the rapidly expanding knowledge base and technology in various branches of medicine.

#### CASE CONFERENCES

During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case.

These sessions are open to apa members only. A blue registration badge or an APA membership card are required for admittance.

#### COURSES MASTER COURSES)

Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (halfday), six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Attendees must be registered for the meeting and purchase tickets to attend.

#### FOCUS LIVE

These 90-minute sessions allow attendees to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. By using the ARS, attendees will feel like they are involved in a small group consultation with an expert clinician, even though the session is being attended by a large number of people. Experts, who served as guest editors of FOCUS, will lead lively multiple choice question-based discussions, and the audience will enter their answers using hand-held devices. The results are instantly tallied and projected on the screen.

#### FORUMS

These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists and other mental health professionals. Speakers and panel members are chosen by the Scientific Program Committee for their expertise and leadership in the field.

#### LECTURES

Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers. Award lectures are selected by the various APA Award Boards and/or Councils. All award lecturers are approved by the Board of Trustees.

#### NEW RESEARCH

This format allows for presentation of very recent findings. Posters, which are visual, are self-explanatory presentations. Two poster sessions on Monday will be designated as Young Investigators' Poster Sessions, which will contain poster presentations from young investigators, residents, medical students, and research or clinical fellows.

#### SCIENTIFIC AND CLINICAL REPORTS

Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with discussion from the audience following the presentation of each paper. There is no formal discussant.

#### SEMINARS

Seminars are designed to emphasize in-depth learning experiences that actively involve participants and include the opportunity for informal exchange with the presenters. Offered in four-hour (half-day) sessions, seminars either review basic concepts in a special subject area or present advanced material on a circumscribed topic.

#### SMALL INTERACTIVE SESSIONS

This 90-minute format allows small groups to meet informally with either selected experts in psychiatry to discuss topics chosen by the expert; to obtain consultations for problems in research from senior researchers; or utilize clinical material offered by the attendee and hear, clinically-based seminars presented by outstanding educators. Small Interactive Sessions are reserved for residents only. These sessions are limited to 25 attendees on a first-come, first-served basis.

# SYMPOSIA (INDUSTRY-SUPPORTED AND PRESIDENTIAL)

Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment on a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as Industry-Supported Symposia in this Program Book.

#### WORKSHOPS (MEDIA)

Workshops are 90-minute sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive. Media Workshops are three-hour sessions where a feature-length film is shown and discussed.

# HEW DEVELOPMENTS IN SCHIZOPHRENIA RESEARCH ND PRACTICE: From the Pipeline to the Clinic

SATURDAY, MAY 22, 2010 5:30PM Dinner and Sign-in 6:00PM-8:00PM Educational Activity

HILTON NEW ORLEANS RIVERSIDE First Level, Grand Ballroom A/B New Orleans, Louisiana

5:30pm DINNER AND SIGN-IN

WELCOME AND OVERVIEW
Prakash Masand, MD
Activity Chairperson
Duke University School of Medicine
Durham, North Carolina

6:05PM S DRUG DEVELOPMENT meth I. Kaitin, PhD s University School of Medicine on, Massachusetts 6:25PM
DOES PHARMACOGENETICS
HAVE A ROLE IN TREATING
SCHIZOPHRENIA?

SCHIZOPHRENIA? Roy H. Perlis, MD, MSc Massachusetts General Hospital Harvard Medical School Boston, Massachusetts

6:45pm SWITCHING ANTIPSYCHOTIC THERAPY: LESSONS FOR THE CLINICIAN Prokash Masand, MD Activity Chairperson

7:05em
INNOVATIVE STRATEGIES
TO IMPROVE ADHERENCE
IN SCHIZOPHRENIA
Mehul V. Mankad, MD
Duke University School of Medicine
Durham Veterans Affairs
Medical Central

7:25pm QUESTION AND ANSWER SESSION

Medical Center Durham, North Carolina

8:00pm ADJOURNMENT

WNO SKOULD PARTICIPATE
This activity is designed for clinical psychiatrists and other healthcare professionals interested in the management and treatment of schizophrenia.

#### LEARNING OBJECTIVES

- At the conclusion of this activity, participants should be able to

  1. Describe the challenges of CNS drug development; understand the time, cost, and risk of bringing new neuropharmocologic agents to market.

  2. Explain the process to translate a genetic association study into a clinically
- 3. Describe the clinical risks and benefits of switching antipsychotic medications and apply evidence-based strategies to adjusting therapeutic regimens.

  4. Discuss strategies to increase patient adherence to clinical recommendations in the treatment of psychosis.

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation
Council for Continuing Medical Education to provide continuing medical education

#### CREDIT DESIGNATION STATEMENT

The APA designates this educational activity for a maximum of 2 AMA PRA Category 1 Gedits<sup>10</sup>. Physicians should only daim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURE STATEMENT
Participating faculty will disclose any industry offiliations, sponsorships, honoraria, monetary support, and other potentially biasing factors to the audience.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA tall free at 1.888.357.7924 (within the US or Canada) or 703.907.7300.



Sponsored by the American Psychiatric Association



Novel Approaches to Assessing and Treating











A Symposium Held During the APA 2010 Annual Meeting in the MEDICALLY ILL

MONDAY, MAY 24, 2010 • 6:30 PM Dinner and Sign-in • 7:00 PM-9:00 PM Educational Activity HILTON NEW ORLEANS RIVERSIDE • First Level, Grand Ballroom A/B • New Orleans, Louisiana

# 6:30<sub>PM</sub> Dinner and Sign-in

7:05<sub>PM</sub>
Assessing Mood and
Somatic Symptoms in
the Medically III Patient
With Depression
Richard C. Shelton, MD
Vanderbilt University
School of Medicine
Nashville, Tennessee

7:25<sub>PM</sub>
Pathophysiology of Somatic
Symptoms and Major
Depressive Disorder in
Medically III Populations
Janet Witte, MD, MPH
Harvard Medical School
Clinical Trials Network
and Institute

7:45mM Managing Depression in the Medically III: An Up-to-Date Evidence-Based Guide Bradley N. Gaynes, MD, MPH Activity Chairperson

Management of Treatment-Resistant Patients With Somatic Symptoms and Medical Illness

8:25<sub>PM</sub> Question and Answer Session

8:55<sub>PM</sub> Closing Remarks

Adjournment

WHO SHOULD PARTICIPATE
This activity is designed for clinical psychiatrists and other healthcare professionals interested in the assessment and management of major depressive disorder in medically ill patients.

#### ACCREDITATION STATEMENT

#### FACULTY DISCLOSURE STATEMENT

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on flist-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1.888.357.7924 (within the US or Canada) or 703.907.7300.



#### FOR YOUR RECORDS

163RD ANNUAL MEETING OF THE AMERICAN PSYCHIATRIC ASSOCIATION MAY 22-26, 2010 • NEW ORLEANS, LA

This form is for your records and not for submission. Use this page to keep track of your attendance. Reporting is on an honor basis, claim one credit for each hour of participation.

All scientific sessions listed in the Annual Meeting Program Book are designated for AMA PRA Category 1 Credits<sup>™</sup>, except for New Research Poster Sessions.

DATE, HOURS	TITLE OF SESSION	# OF HOURS
	TOTAL	

# SATURDAY

Program changes are printed each day in the Daily Bulletin. You can pick up the **Daily Bulletin** in Exhibit Halls B/C, First Level, Morial Convention Center and at many other locations throughout the convention center

#### 8:00 A.M. SESSIONS COURSES 1-3





Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C, First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

#### COURSE 1

8:00 A.M.-NOON Room 221, Second Level, Morial Convention Center

NEUROPSYCHIATRIC MASQUERADES: MEDICAL AND NEUROLOGICAL DISORDERS THAT PRESENT WITH PSYCHIATRIC **Symptoms** 

Academy of Psychosomatic Medicine

#### Co-Directors:

Jose R. Maldonado, M.D. Paula Trzepacz, M.D.

#### COURSE 2

#### 8:00 A.M.-NOON

Room 235, Second Level, Morial Convention Center

#### LOSING A PATIENT TO SUICIDE

#### Director:

Michael F. Myers, M.D.

#### **Faculty:**

Carla Fine, M.S. Frank R. Campbell, Ph.D., L.C.S.W.

#### COURSE 3

#### 8:00 A.M.-NOON

Room 351, Third Level, Morial Convention Center

EXAMINING PROFESSIONAL **BOUNDARIES: WEIGHING** RISKS VERSUS **OPPORTUNITIES** 

#### Director:

Gail E. Robinson, M.D.

#### Faculty:

Gary R. Schoener, M.A. Linda M. Jorgenson, J.D., M.A. Howard E. Book, M.D.

#### SEMINARŞ 1-2 SEMINAR 1

#### 8:00 A.M.-NOON

Room 220, Second Level, Morial Convention Center

MANAGING MALPRACTICE **RISK FOR PSYCHIATRISTS:** THE BASICS AND BEYOND

#### Co-Chairs:

Jacqueline M. Melonas, J.D., R.N. Donna Vanderpool, J.D., M.B.A.

#### **Presenter:**

Denita Neal, J.D.

This seminar will be repeated today in the same room at 1:00 p.m.

#### SEMINAR 2

#### 8:00 A.M.-NOON

Room 342, Third Level, Morial Convention Center

#### **EVIDENCE-BASED** PSYCHOTHERAPY FOR CHRONIC MAJOR Depression





#### Co-Chairs:

Eric Levander, M.D., M.P.H. Toshiaki A. Furukawa, M.D., Ph.D.

#### 9:00 A.M. SESSIONS LECTURE 1

#### 9:00 A.M.-10:30 A.M.

Rooms R07-R09, Second Floor, Morial Convention Center

#### TRANSLATIONAL RESEARCH IN SCHIZOPHRENIA: CHALLENGES AND PROMISES

Distinguished Psychiatrist Lecture





#### **SESSION TRACKS**

- Affective Disorders (Mood and Anxiety)
- Personality Disorders
- Psychopharmacology
- Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- NIDA
- DSM-5

#### Raquel E. Gur, M.D., Ph.D.

Sukriti Mittal, M.D.



Raquel E. Gur, M.D. Ph.D., is professor of psychiatry, neurology and radiology at the University of Pennsylvania

in Philadelphia. Her academic career has been devoted to the study of brain function in schizophrenia. Dr. Gur has directed the Neuropsychiatry Section and the Schizophrenia Research Center and has established an interdisciplinary program dedicated to advancing the understanding of the pathophysiology of this complex disorder through the application of diverse strategies, from neurobehavioral to molecular. The research has been supported by NIMH, including a Mental Health Clinical Research Center, a MERIT Award, a Senior Scientist Award, a Conte Center for Neuroscience of Mental Disorders, and a training grant. Over the years, the research findings have been presented in professional meetings and published in leading scientific journals. This work has been carried out in large and well-characterized samples of research participants, with commitment to advancing knowledge while meeting patient care needs.

# WORKSHOPS 1-12

#### 9:00 A.M.-10:30 A.M.

Room 237, Second Level, Morial Convention Center

MANAGEMENT OF THE SUICIDAL OUTPATIENT: BEYOND THE CONTRACT FOR SAFETY

Jeanne Goodman, M.D.

#### Presenters:

Barbara H. Stanley, Ph.D. Mark J. Petrini, M.D., Ph.D.

#### WORKSHOP 2

9:00 A.M.-10:30 A.M.

Room 333, Third Level, Morial Convention Center

#### THE DEADLY YEARS: PREVENTING SUICIDE IN ASIAN-AMERICAN COLLEGE STUDENTS

Caucus of Asian-American **Psychiatrists** 

#### Co-Chairs:

Russell F. Lim, M.D. Velandy Manohar, M.D.

#### **Presenters:**

Dan Tzuang, M.D. Aradhana Sood, M.D., M.H.S.C. Kristine A. Girard, M.D. Jack Yen, M.D.

#### WORKSHOP 3

9:00 A.M.-10:30 A.M. Room 334, Third Level, Morial Convention Center

A MEDICINAL CANNABIS UPDATE FOR 2010: USE, ABUSE, NEW RESEARCH, NEW FORENSIC AND NEW POLITICAL REALITIES For APA Members Only

Lawrence K. Richards, M.D.

#### **Presenters:**

Ronald Abramson, M.D. David G. Ostrow, M.D., Ph.D. John H. Halpern, M.D. Jahan Marcu

#### WORKSHOP 4

9:00 A.M.-10:30 A.M. Room 336, Third Level, Morial Convention Center

Unconscious Projections: THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILM

#### Chair:

Steven E. Pflanz, M.D.

#### WORKSHOP 5

9:00 A.M.-10:30 A.M. Room 337, Third Level, Morial Convention Center

PSYCHIATRIC CARE AT THE END OF LIFE

Jonathan T. Stewart, M.D.

#### WORKSHOP 6

9:00 A.M.-10:30 A.M.

Room 340, Third Level, Morial Convention Center

#### ENHANCING RISK-ASSESSMENT ACROSS SERVICES IN MENTAL HEALTH

Amresh Shrivastava, M.D., D.P.M.

#### **Presenter:**

Megan Johnston, M.A.

#### WORKSHOP 7

9:00 A.M.-10:30 A.M. Room 341, Third Level, Morial Convention Center THE "NEGATIVE OUTCOME" IN PSYCHOTHERAPY: WHO IS RESPONSIBLE AND How?



#### Chair:

Janet L. Lewis, M.D.

#### WORKSHOP 8

9:00 A.M.-10:30 A.M. Room 346, Third Level, Morial Convention Center

**COGNITIVE THERAPY** FOR PERSONALITY **DISORDERS** 





#### Chair:

Judith S. Beck, Ph.D.

#### WORKSHOP 9

9:00 A.M.-10:30 A.M.

Room 347, Third Level, Morial Convention Center

THE IMG JOURNEY: SNAPSHOTS ACROSS THE PROFESSIONAL LIFESPAN

#### Co-Chairs

Vishal Madaan, M.D., M.B.B.S. Durga Bestha, M.B.B.S.

#### **Presenters:**

Renato D. Alarçon, M.D. Shamala Jeevarakshagan, M.D., B.S.

#### WORKSHOP 10

9:00 A.M.-10:30 P.M. Room 348, Third Level, Morial Convention Center

A Discussion About WEIGHT GAIN DURING MEDICATION TREATMENT FOR SCHIZOPHRENIA: HOW MUCH AND WHAT TO DO ABOUT IT



Peter F. Buckley, M.D.

#### **Presenter:**

Peter F. Buckley, M.D.

#### WORKSHOP 11

9:00 A.M.-10:30 A.M.

Room 349, Third Level, Morial Convention Center

A PROGRAM OF PSYCHOTHERAPY FOR COMBATANTS' DEPENDENTS-THE EFFECT ON RECALL RATES: "THEY ARE NOT GOING FOR THREE WEEKS AND THE FIGHTING HAS BEGUN!"

Michael Jan Wise, M.B.B.S., M.S.C.

#### **Presenter:**

Inge Wise

#### WORKSHOP 12

9:00 A.M.-10:30 A.M. Room 350, Third Level, Morial Convention Center

New APA Practice Guideline FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER

#### Co-Chairs:

Joel Yager, M.D. Alan J. Gelenberg, M.D.

#### **Presenter:**

Laura J. Fochtmann, M.D.



#### SYMPOSIA 1-13

MOVED TO MONDAY

#### 9:00 A.M.-NOON

Room 208/209, Second Level, Morial Convention Center

PTSD in Military Populations: TRANSLATING RESEARCH INTO PRACTICE

Darrel A. Regier, M.D., M.P.H.

#### Discussant:

Elspeth C. Ritchie, M.D., M.P.H.

- 1. PTSD in Military Populations: Scope and Treatment Challenges? Robert J. Ursano, M.D.
- 2. Current Evidence-Based Treatment **Recommendations for PTSD** Matthew J. Friedman, M.D.
- 3. What Is Known and What **Needs to Be Learned About Sociodemographic Factors** in PTSD? Paula Schnurr, Ph.D.
- 4. Treating PTSD and Other **Mental Health Conditions** in Military Populations Joshua Wilk, Ph.D. Charles W. Hoge, M.D. Joyce C. West, Ph.D., M.P.P. Farifteh F. Duffy, Ph.D.
- 5. Re-Engineering Systems of Primary Care Treatment for PTSD and Depression in the U.S. Military: Program, Description and Implementation Charles C. Engel, M.D. Thomas Oxman, M.D. Sheila Barry, B.A. Patrice Stewart, Ph.D. Kurt Kroenke, M.D., Col (Ret), M.C. John W. Williams, Jr., M.D., M.P.H.

Allen J. Dietrich, M.D.





6. APA/APIRE PTSD Performance in Practice Tools Farifteh F. Duffy, Ph.D. Thomas Craig, M.D.

Eve K. Moscicki, Sc.D., M.P.H. Joyce C. West, Ph.D., M.P.P. Laura J. Fochtmann, M.D.

#### SYMPOSIUM 2

9:00 A.M.-NOON

Room 218, Second Level, Morial Convention Center

RECENT RESEARCH ON **EATING DISORDERS** 

#### Co-Chairs:

James E. Mitchell, M.D. Walter Kaye, M.D.

- 1. Recent Findings in the **Longitudinal Assessment** of Bariatric Surgery (LABS) Study James E. Mitchell, M.D.
- 2. Neurocircuitry of Anorexia Nervosa Walter Kaye, M.D.
- 3. Bariatric Surgery in **Adolescents: Clinical** Characteristics and **Eating Behavior** Michael J. Devlin, M.D.
- 4. Stress Response to Food Portion Size in Anorexia Nervosa Katherine A. Halmi, M.D.

#### SYMPOSIUM 3

9:00 A.M.-NOON

Room 223, Second Level, Morial Convention Center

SMOKING AND PSYCHIATRIC **DISORDERS: CLUES ABOUT** CAUSAL PATHWAYS AND INNOVATIVE TREATMENT APPROACHES National Institute



Co-Chairs:

on Drug Abuse

Jeffrey D. Schulden, M.D. Wilson M. Compton III, M.D.

- 1. Psychiatric Disorders as Signals of Sensitivity for Nicotine Dependence Lisa Dierker, Ph.D. Jennifer Rose, Ph.D. Robin Mermelstein, Ph.D.
- 2. Nicotine Receptors and Their Genes in Psychosis Robert Freedman, M.D.
- 3. Integrating Tobacco Dependence **Treatment Into Mental Health** and Addiction Treatment

Douglas M. Ziedonis, M.D., M.P.H. David Kalman, Ph.D. David Smelson, Psy.D. Sarah Baker Greg Seward, MSHCA, CTTS Leon Sawh, M.P.H. Sun Kim, Ph.D., R.N.

#### SYMPOSIUM 4

9:00 A.M.-NOON

Room 224, Second Level, Morial Convention Center

SHARED DECISION MAKING IN MENTAL HEALTH CARE: A RECOVERY AND PERSON-CENTERED APPROACH

#### Co-Chairs:

Celia E. Wills, Ph.D. Kenneth S. Thompson, M.D.

- 1. Shared Decision-Making in Mental Health Care Melody J. Riefer, M.S.W.
- 2. Supporting Consumers' Recovery **Through Joint Consumer** and Clinician Use of Shared **Decision-Making Tools** James Schuster, M.D., M.B.A.
- 3. Shared Decision-Making: Making Recovery Real in Mental Health Laurie C. Curtis, M.A.

#### SYMPOSIUM 5

9:00 A.M.-NOON Room 239, Second Level, Morial Convention Center

NEW DEVELOPMENTS IN INTERPERSONAL PSYCHOTHERAPY (IPT)





#### Chair:

John C. Markowitz, M.D.

- 1. Interpersonal Psychotherapy: A Three-Session Evaluation, Support and Triage (IPT-EST) Helena Verdela, M.D.
- 2. Interpersonal Psychotherapy for Depressed Women Undergoing Fertility Treatment: A Randomized **Controlled Trial** Diana Koszycki, Ph.D.

Jean-Claude Bisserbe, M.D. Pierre Blier, M.D. Jacques Bradwejn, M.D. John C. Markowitz, M.D.

3. Interpersonal Psychotherapy for Patients With Chronic **Posttraumatic Stress** Disorder (IPT-PTSD) John C. Markowitz, M.D. Barbara Milrod, M.D. Kathryn Bleiberg, Ph.D. Randall D. Marshall, M.D.

- 4. Treating Depression With **Evidence-Based Interventions in** Routine Daily Practice: Results of a Pragmatic Effectiveness Trial Frenk Peeters, M.D., Ph.D. Marcus Huibers, Ph.D. Jeffrey Roelofs, Ph.D. Steve D. Hollon, Ph.D. John C. Markowitz, M.D. Jim van Os, M.D., Ph.D. Arnoud Arntz, Ph.D.
- 5. Interpersonal Psychotherapy for Community Patients With **Moderate to Severe Major** Depressive Disorder and **Multiple Comorbidities** Hasse Karlsson, M.D., Ph.D. Ulla Säteri, M.D. John C. Markowitz, M.D.

#### SYMPOSIUM 6

9:00 A.M.-11:00 A.M.

Room R01, Second Level, Morial Convention Center

UPDATE ON TREATMENTS FOR CHILD AND ADOLESCENT EATING **DISORDERS** 



#### Chair:

James Lock, M.D., Ph.D.

- 1. Family-Based Treatment for Child and Adolescent **Eating Disorders** Daniel le Grange, Ph.D.
- 2 Adolescent Focused Individual Therapy for Anorexia Nervosa James Lock, M.D., Ph.D.
- 3. Cognitive Remediation Therapy for Adolescent Anorexia Nervosa Kathleen K. Fitzpatrick, Ph.D.

#### SYMPOSIUM 7

9:00 A.M.-NOON

Room 338, Third Level, Morial Convention Center

NEURODEVELOPMENTAL DISORDERS IN DSM-5: AN UPDATE FROM THE WORK GROUP

Susan E. Swedo, M.D.

- 1. The Neurodevelopmental Disorders in DSM-5: What's Changed? What's Staying the Same? Susan E. Swedo, M.D.
- 2. DSM-5 and the Core Features of Autism Spectrum Disorders Catherine Lord, Ph.D. Eva Petkova, Ph.D. So Hyun Kim, M.A. Sanghan Lee, Ph.D.



A.M.

SATURDAY, MAY 22

- 3. Intellectual Disability in DSM-5 Walter E. Kaufmann, M.D. Bryan H. King, M.D., Ph.D. Sally J. Rogers, Ph.D.
- 4. Sex Differences in Autism Spectrum Disorder; Risk Factors, Changes Over Time, Early Signs and Core Autism Symptoms Poul Thorsen, M.D., Ph.D.
- 5. The Autism Spectrum: How Deep and How Wide? Bryan H. King, M.D., Ph.D.

#### SYMPOSIUM 8

9:00 A.M.-NOON

Room 339, Third Level, Morial Convention Center

AGGRESSIVE BEHAVIORS IN **GEROPSYCHIATRIC PATIENTS:** NEUROBIOLOGY, ASSESSMENT AND MANAGEMENT

American Association for Geriatric Psychiatry

#### Chair:

Helen H. Kyomen, M.D., M.S.

#### Discussant:

Mark E. Kunik, M.D., M.P.H.

- 1. The Neurobiology of Aggression Randy J. Nelson, Ph.D.
- 2. Non-Pharmacologic Assessment and Management of Aggressive Behaviors in **Geropsychiatric Patients** Patricia A. Arean, Ph.D. Liat Avalon, Ph.D. Leilani Feliciano, Ph.D.
- 3. Pharmacologic/Somatic Assessment and Management of Aggressive Behaviors in **Geropsychiatric Patients** Helen H. Kyomen, M.D., M.S.

#### SYMPOSIUM 9

9:00 A.M.-NOON

Rooms 343-345, Third Level, Morial Convention Center

ADVANCES IN THE MANAGEMENT OF TREATMENT-RESISTANT DEPRESSION



#### Co-Chairs:

Charles B. Nemeroff, M.D., Ph.D. Michael E. Thase, M.D.

1. The Neurobiology of Depression: **Implications for Treatment-**Resistant Depression and Personalized Medicine in Psychiatry Charles B. Nemeroff, M.D., Ph.D.

- 2. Unmet Needs in the **Treatment of Depression** Michael E. Thase, M.D.
- 3. Augmentation and **Combination Strategies in Treatment-Resistant Depression** Linda L. Carpenter, M.D.
- 4. Management of Comorbid **Depression and Substance Abuse** Ihsan M. Salloum, M.D., M.P.H.

#### SYMPOSIUM 10

9:00 A.M.-NOON

Room 353, Third Level, Morial Convention Center

#### CLINICAL TRENDS IN BIPOLAR DISORDERS



APA and the International Society of Bipolar Disorder

#### Co-Chairs:

Flavio Kapczinski, M.D. Benicio Frey, M.D.

- 1. The International Society of Bipolar Disorders (ISBD) Task Force on the Nomenclature of **Course and Outcome** in Bipolar Disorders Mauricio Tohen, M.D.
- 2. Evidence-Based **Treatment Guidelines** for Bipolar Disorder Lakshmi Yatham, M.B.B.S.
- 3. The Use of Biomarkers in Bipolar Disorder Flavio Kapczinski, M.D.
- 4. Redox Biology and **Glutathione: From** Pathophysiology to Novel Treatments in **Bipolar Disorder** Michael Berk, M.D.
- 5. Women's Issues in Bipolar Disorder Aysegul Ozerdem, M.D.

#### SYMPOSIUM 11

9:00 A.M.-NOON

Room 354, Third Level, Morial Convention Center

**CULTURALLY SENSITIVE** ASSESSMENT OF PSYCHOLOGICALLY DISTRESSED ETHNIC AND Non-English Speaking **POPULATIONS** 

#### Co-Chairs:

Devon Hinton, M.D., Ph.D. Roberto Lewis-Fernández, M.D.

- 1. Change in Culturally Specific Complaints and **PTSD Severity Across Initial** Treatment: Results of a Psychiatric Clinic Survey of Cambodian **Refugee Patients** Devon Hinton, M.D., Ph.D. Mark H. Pollack, M.D.
- 2. Culturally Sensitive Care for Older Adults: A Critical Examination of the DSM-IV Cultural Formulation Ladson Hinton, M.D.
- 3. Cultural Sensitivity and External Validity of Mental Health and **Psychosocial Assessments for** Child Soldiers in Nepal Brandon A. Kohrt, M.D., Ph.D.
- 4. Dissociation, Traumatic Exposure, and Self-Reported Psychotic Symptoms in U.S. Latinos Roberto Lewis-Fernández, M.D.
- 5. Assessing Family Conflict in **West African Immigrant Families** Andrew Rasmussen, Ph.D. Adeyinka Akinsulure-Smith, Ph.D. Tracy Chu, Ph.D.

#### SYMPOSIUM 12

9:00 A.M.-NOON Room 355, Third Level, Morial Convention Center

#### ANXIETY TREATMENT: New Research Findings FOR THE CLINICIAN





#### Co-Chairs:

Peter Roy-Byrne, M.D. Murray B. Stein, M.D., M.P.H.

- 1. Acute Treatment for Chronic PTSD: Prolonged Exposure **Versus Sertraline** Norah C. Feeny, Ph.D.
- 2. Social Anxiety Pharmacotherapy Improvement (SAPIENT): **Response to Initial SSRI Treatment** Murray B. Stein, M.D., M.P.H.

#### SESSION TRACKS

- Affective Disorders (Mood and Anxiety)
- Personality Disorders
- Psychopharmacology
- Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- NIDA
- DSM-5





A.M.

- 3. DCS: A Novel Pharmacological Strategy to Enhance CBT for Anxiety Mark H. Pollack, M.D.
- 4. CALM: Improving Primary **Care Anxiety Outcomes** Peter Roy-Byrne, M.D.

#### SYMPOSIUM 13

9:00 A.M.-NOON

Rooms 356/357, Third Level, Morial Convention Center

FAMILY AND BEHAVIORAL **GENETIC STUDIES** OF BORDERLINE PERSONALITY DISORDER



Chair:

Joel Paris, M.D.

Discussant:

John M. Oldham, M.D., M.S.

- 1. Behavioral Genetics of **Borderline Personality Disorder** Ted Reichborn-Kjennerud, M.D. Steven H. Aggen, Ph.D. Nikolai Czajkowski, M.A., M.S. Kristian Tambs, Ph.D. Espen Røysamb, Ph.D. Ragnhild E. Ørstavik, M.D. Michael C. Neale, Ph.D. Svenn Torgersen, Ph.D.
- 2. Childhood Adversity Associated With Adolescent-**Onset Borderline Personality** Disorder

Kenneth S. Kendler, M.D.

Mary C. Zanarini, Ed.D. Marianne S. Goodman, M.D.

- 3. Outcome in Women Diagnosed With Borderline Personality Disorder in Adolescence Robert Biskin, M.D., B.S. Joel Paris, M.D. Joanne Renaud, M.D. Amir Raz, Ph.D. Phyllis Zelkowitz, Ed.D.
- 4. Trauma and Psychopathology in Patients With Borderline Personality Disorder and **Their Sisters** Joel Paris, M.D. Lise Laporte, Ph.D. Herta Guttman, M.D.
- 5. Vulnerability to Depressive **Symptoms Among Children of Parents** With Major Depressive Disorder With or Without Comorbid Borderline Personality Disorder John Abela, Ph.D., B.A. Philippe Adams Warren Lewin

#### COURSES 4-7

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C. First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

#### COURSE 4

9:00 A.M.-4:00 P.M.

Rooms 231/232, Second Level, Morial Convention Center

AN OVERVIEW OF SLEEP MEDICINE FOR THE MENTAL HEALTH PROVIDER

**Co-Directors**:

R. Robert Auger, M.D. Thomas D. Hurwitz, M.D.

Faculty: Elliott K. Lee, M.D. Max Hirshkowitz, Ph.D.

#### COURSE 5

9:00 A.M.-4:00 P.M. Room 238, Second Level, Morial Convention Center

A PRACTICAL APPROACH TO RISK ASSESSMENT

Director:

William H. Campbell, M.D., M.B.A.

#### COURSE 6

9:00 A.M.-4:00 P.M.

Room R06, Second Level, Morial Convention Center

CHILD AND ADOLESCENT PSYCHIATRY FOR THE GENERAL PSYCHIATRIST

**Co-Directors:** 

Robert L. Hendren, D.O. Malia McCarthy, M.D.

#### COURSE 7

9:00 A.M.-4:00 P.M.

Room 352, Third Level, Morial Convention Center

COMPLEMENTARY AND INTEGRATIVE **TREATMENTS** FOR STRESS, DEPRESSION, ANXIETY, PTSD, MASS TRAUMA, **COGNITIVE** FUNCTION, ADD, AND SCHIZOPHRENIA



Co-Directors:

Patricia L. Gerbarg, M.D. Richard P. Brown, M.D.

Faculty:

Monica Vermani, M.A., Psy.D. Martin Katzman, M.D.

# MASTER COURSES 1-2

9:00 A.M.-4:00 P.M.

Rooms R02/R03, Second Level, Morial Convention Center

UPDATE ON PEDIATRIC **PSYCHOPHARMACOLOGY** 



Director:

Christopher J. Kratochvil, M.D.

Faculty:

John T. Walkup, M.D. Christopher J. McDougle, M.D. Karen D. Wagner, M.D., Ph.D.

MASTER COURSE 2

9:00 A.M.-4:00 P.M.

Rooms R04/R05, Second Level, Morial Convention Center

ESSENTIAL **PSYCHOPHARMACOLOGY** 



**Co-Directors:** 

Alan F. Schatzberg, M.D. Ira Glick, M.D.

Faculty:

Kiki Chang, M.D. Terence A. Ketter, M.D. Natalie L. Rasgon, M.D., Ph.D. Charles DeBattista, M.D.

#### 10:00 A.M.-4:00 P.M.

APA Member Center and Publishers' Book Fair Are Open.

Exhibit Halls B-D, First Level, Morial Convention Center

## 11:00 A.M. SESSIONS LECTURES

11:00 A.M.-12:30 P.M.

Rooms R07-R09, Second Floor, Morial Convention Center

THE FUTURE OF DEPRESSION RESEARCH International Lecture



Florian Holsboer, M.D.

Chair:

Madhukar Trivedi, M.D.



Florian Holsboer,

M.D. was born in Munich, Germany, and studied chemistry and medicine at the University of Munich, where he

completed his residency in psychiatry. His areas of study include: affective disorders, depression, anxiety, central regulation of stress hormones, sleep physiology, molecular and clinical psychopharmacology, pharmacogenetics and personalized medicine. In 1989 Professor Holsboer became director of the Max Planck Institute for Psychiatry. The institute is a research center for disorders of the central nervous system. Research is conducted by 28 research groups in a broad range of areas: molecular biology, pharmacology, human and mouse genetics, proteomics and chemical genomics. With his extensive knowledge and research of mental health issues, he will give attendees an overview of how current research trends are shaping the future of mental health research.

# WORKSHOPS 13-24

11:00 A.M.-12:30 P.M. Room 237, Second Level, Morial Convention Center

CHALLENGES AND OPPORTUNITIES IN TEACHING NEUROLOGY TO PSYCHIATRY RESIDENTS

#### Co-Chairs:

Claudia L. Reardon, M.D. Art Walaszek, M.D.

#### **Presenters:**

Stacey Burpee, D.O., M.P.H. Sheldon Benjamin, M.D. Michelle B. Riba, M.D., M.S. Kayla Pope, M.D., J.D. M. Justin Coffey, M.D.

#### WORKSHOP 14

11:00 A.M.-12:30 P.M.

Room 333, Third Level, Morial Convention Center

DEALING WITH THE DIFFICULT PROFESSIONAL **EMPLOYEE: EFFECTIVE** PERSONNEL MANAGEMENT **STRATEGIES** 

#### Chair:

Stephen M. Soltys, M.D.

**Presenter:** Kay H. Titchenal

#### WORKSHOP 15

11:00 A.M.-12:30 P.M. Room 334, Third Level, Morial Convention Center

MUNCHAUSEN REVISITED: FACTITIOUS DISORDER IN THE AGE OF THE Internet and DSM-5

#### Co-Chairs:

Damir Huremovic, M.D., M.P.P. Shabneet Hira-Brar, M.D.

#### **Presenters:**

Jacob E. Sperber, M.D. Sameh Dwaikat, M.D. Reena Trivedi, M.D.

#### WORKSHOP 16

11:00 A.M.-12:30 P.M.

Room 336, Third Level, Morial Convention Center

TELEPSYCHIATRY EDUCATION: TEACHING TO THE NEAR AND FAR ENDS

#### Chair.

John S. Teshima, M.D., M.Ed.

#### WORKSHOP 17

11:00 A.M.-12:30 P.M. Room 337, Third Level, Morial Convention Center

PREPARING INTERNATIONAL MEDICAL GRADUATE PSYCHIATRY RESIDENTS FOR A CAREER IN ACADEMIC PSYCHIATRY APA/GlaxoSmithKline Fellows

#### Co-Chairs:

Sosunmolu O. Shoyinka, M.B.B.S. Oladipo Kukoyi, M.D., M.S.

#### **Presenters:**

Richard Balon, M.D. Charles C. Dike, M.D., M.P.H. Milton Kramer, M.D. Ezra E. Griffith, M.D. Nalini V. Juthani, M.D. Paulo Shiroma, M.D.

#### WORKSHOP 18

11:00 A.M.-12:30 P.M. Room 340, Third Level,

Morial Convention Center

Is That an Unconscious FANTASY OR A CORE BELIEF? A RESIDENT'S PERSPECTIVE ON LEARNING MULTIPLE THERAPIES SIMULTANEOUSLY



#### Co-Chairs:

Emily Gastelum, M.D. Aerin Hyun, M.D., Ph.D.

#### **Presenters:**

Donna M. Sudak, M.D. David Goldberg, M.D. Deborah Cabaniss, M.D. Barbara H. Stanley, Ph.D.

#### WORKSHOP 19

11:00 A.M.-12:30 P.M. Room 341, Third Level, Morial Convention Center

#### TRANSPLANT PSYCHIATRY UPDATE

#### Co-Chairs:

Paula Zimbrean, M.D. Swapna Vaidya, M.D.

#### WORKSHOP 20

11:00 A.M.-12:30 P.M.

Room 346, Third Level, Morial Convention Center

WHEN DISORDER HITS HOME: DEALING WITH SERIOUS PSYCHIATRIC DISORDERS IN OUR **OWN FAMILIES** American Group Psychotherapy Association

Julia B. Frank, M.D.

#### **Presenters:**

Mitchell J.M. Cohen, M.D. Kathryn McIntyre, M.D.

#### WORKSHOP 21

11:00 A.M.-12:30 P.M. Room 347, Third Level, Morial Convention Center

LOST IN TRANSLATION: **GENERATIONAL ISSUES** AND MENTAL HEALTH Association of Women Psychiatrists

Tana A. Grady-Weliky, M.D.

#### **Presenters:**

Doris M. Iarovici, M.D. Leah J. Dickstein, M.D., M.A.

#### WORKSHOP 22

11:00 A.M.-12:30 P.M.

Room 348, Third Level, Morial Convention Center

DIAGNOSIS AND TREATMENT OF PSYCHOGENIC NONEPILEPTIC SEIZURES: WHAT DOES A PSYCHIATRIST Do Once the Diagnosis Is MADE?

#### Co-Chairs:

W. Curt LaFrance, Jr., M.D., M.P.H. Andres M. Kanner, M.D.



#### WORKSHOP 23

11:00 A.M.-12:30 P.M. Room 349, Third Level, Morial Convention Center

ORAL BOARDS BOOT CAMP 2010: FOCUS ON DIAGNOSTIC INTERVIEWING

#### Co-Chairs:

Elvse D. Weiner, M.D. Eric D. Peselow, M.D.

#### WORKSHOP 24

11:00 A.M.-12:30 P.M.

Room 350, Third Level, Morial Convention Center

THE BEHAVIORAL HEALTH ACTION NETWORK: REORGANIZING THE BEHAVIORAL HEALTH DELIVERY SYSTEM IN POST-KATRINA **NEW ORLEANS** 

#### Chair.

Elmore F. Rigamer, M.D., M.P.A.

#### **Presenters:**

Candace A. Cutrone, M.D. Craig J. Coenson, M.D. Sarah Hoffpauir, L.C.S.W. Jose Calderon-Abbo, M.D.

#### 1:00 P.M. SESSIONS COURSES 8-10

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C, First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

#### COURSE 8

1:00 P.M.-5:00 P.M.

Room 221, Second Level, Morial Convention Center

**BRAIN STIMULATION** THERAPIES IN **PSYCHIATRY** 

**Director:** 

Ziad H. Nahas, M.D.

**Faculty:** 

Linda L. Carpenter, M.D. Darin D. Dougherty, M.D. Husain Mustafa, M.D.

#### COURSE 9

1:00 P.M.-5:00 P.M.

Room 235, Second Level, Morial Convention Center

NEUROANATOMY OF BEHAVIOR: AN INTRODUCTION

#### **Co-Directors:**

David L. Clark, Ph.D. Nash N. Boutros, M.D.

#### Faculty:

Mario F. Mendez, M.D., Ph.D.

#### COURSE 10

1:00 P.M.-5:00 P.M.

Room 351, Third Level, Morial Convention Center

TIME-LIMITED DYNAMIC PSYCHOTHERAPY: AN ATTACHMENT BASED/RELATIONAL/ EXPERIENTIAL APPROACH



Director:

Hanna Levenson, Ph.D.

# SEMINARS 3-4

1:00 P.M.-5:00 P.M.

Room 220, Second Level, Morial Convention Center

MANAGING MALPRACTICE **RISK FOR PSYCHIATRISTS:** THE BASICS AND BEYOND

#### Co-Chairs:

Jacqueline Melonas, J.D. Donna Vanderpool, J.D., M.B.A.

#### **Presenter:**

Denita Neal, J.D.

#### SEMINAR 4

1:00 P.M.-5:00 P.M.

Room 342, Third Level, Morial Convention Center

INFIDELITY AND MARITAL RELATIONSHIPS: DEATH KNELL OR WAKE-UP CALL?



Scott D. Haltzman, M.D.

#### 1:30 P.M. SESSIONS WORKSHOPS 25-32

#### WORKSHOP 25

1:30 P.M.-3:00 P.M. Room 237, Second Level, Morial Convention Center

ADULT PERVASIVE DEVELOPMENTAL DISORDER: FOR BETTER Understanding and Treatment

#### Co-Chairs:

Soonjo Hwang, M.D. Mathew Brams, M.D.

#### WORKSHOP 26

1:30 P.M.-3:00 P.M. Room 333, Third Level, Morial Convention Center

BRIDGING THE CULTURAL DIVIDE: **CHALLENGES OF FIRST-GENERATION** IMMIGRANTS WITH CHILDREN WITH MENTAL ILLNESS

APA/SAMHSA Minority Fellows

#### Co-Chairs:

Timothy C. Liu, M.D. Steve Koh, M.D., M.P.H.

#### **Presenters:**

Arshad Husain, M.D. David S. Rue, M.D. Kiet T.V. Truong, M.D. Ranjan Avasthi, M.D.

#### WORKSHOP 27

1:30 P.M.-3:00 P.M.

Room 334, Third Level, Morial Convention Center

EVALUATION AND MANAGEMENT OF PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS IN PSYCHIATRIC PRACTICE

#### Chair

Dimitri D. Markov, M.D.

#### **Presenters:**

Karl Doghramji, M.D. Nidhi Tewari, M.D.

#### WORKSHOP 28

1:30 P.M.-3:00 P.M.

Room 336, Third Level, Morial Convention Center

VULNERABILITY AND RESILIENCE: KATRINA'S WIDESPREAD IMPACT ON FIRST RESPONDERS, CLINICIANS, YOUTH AND RELOCATED SURVIVORS

#### SESSION TRACKS

Affective Disorders (Mood and Anxiety)

Personality Disorders

Psychopharmacology

Psychotherapy

Schizophrenia and Other Psychotic Disorders

NIDA

DSM-5

#### Co-Chairs:

Phebe M. Tucker, M.D. Howard J. Osofsky, M.D., Ph.D.

#### **Presenter:**

Joy D. Osofsky, Ph.D.

#### WORKSHOP 29

1:30 P.M.-3:00 P.M. Room 337, Third Level, Morial Convention Center

WHEN ADULTS WITH PERVASIVE **DEVELOPMENTAL DISORDERS** PRESENT IN A COMMUNITY MENTAL HEALTH SETTING American Association of Community Psychiatrists

#### Chair:

Ann L. Hackman, M.D.

#### **Presenters:**

Theodora G. Balis, M.D. Curtis N. Adams, Jr., M.D. Steven E. Hutchens, M.D.

#### WORKSHOP 30

1:30 P.M.-3:00 P.M. Room 340, Third Level, Morial Convention Center

FROM OUTREACH TO ASSERTIVE COMMUNITY TREATMENT: TRANSFERRING RESEARCH TO PRACTICE IN COMPREHENSIVE CARE FOR UNDERSERVED PEOPLE LIVING WITH HIV/AIDS

#### Chair:

Gary Morse, Ph.D.

#### **Presenters:**

John Winn, L.C.S.W. Maurice Redden, M.D. Sheila Jackson

#### WORKSHOP 31

1:30 P.M.-3:00 P.M.

Room 341, Third Level, Morial Convention Center

SEXUAL MINORITY YOUTH: **CLINICAL COMPETENCIES** AND TRAINING NEEDS FOR THE 21ST CENTURY

American Academy of Child & Adolescent Psychiatry

Scott Leibowitz, M.D.

#### Presenters:

Edgardo J. Menvielle, M.D., M.S. Joel Stoddard, M.D.

#### WORKSHOP 32

Withdrawn

#### 2:00 P.M. SESSIONS PRESIDENTIAL SYMPOSIUM 1

2:00 P.M.-5:00 P.M. Rooms R07-R09, Second Floor, Morial Convention Center

THE EMERGING NEUROBIOLOGY OF ANTIDEPRESSANT TREATMENT RESPONSE



APA and the Society of Biological Psychiatry

#### Co-Chairs:

Katharina Domschke, M.D., M.A. Yvette Sheline, M.D.

- 1. Connectivity of the Subgenual Cortex and HPA Axis in Depression Alan F. Schatzberg, M.D.
- 2. Prediction of Antidepressant Treatment Response: A Pharmaco- and Imaging **Genetic Contribution** Katharina Domschke, M.D.
- 3. The Role of the Default Mode Network (DMN) in **Understanding Emotional** Circuitry in MDD Preand Post-Antidepressant **Treatment** Yvette Sheline, M.D.
- 4. Resetting Chemical **Dysbalance to Modulating** Networks: Lessons on the Neurobiology of Treatment-**Resistant Depression From Deep Brain Stimulation** Thomas Schlaepfer, M.D.

# SYMPOSIA 14-30

2:00 P.M.-4:00 P.M.

Room 210, Second Level, Morial Convention Center

**EXAMINING THE OUTCOME** CONTINUUM OF **SCHIZOPHRENIA** INTO LATER LIFE

#### Co-Chairs:

Carl I. Cohen, M.D. Sukriti Mittal, M.D.

#### Discussant:

Kenneth S. Thompson, M.D. 1. Community Integration

and Associated Factors **Among Older Adults** With Schizophrenia Chadi Abdallah, M.D. Carl I. Cohen, M.D. Miguel Sanchez-Almira, M.D. Pia Reyes, M.D. Paul M. Ramirez, Ph.D.

- 2. Successful Aging in Older Adults With Schizophrenia: Prevalence and Associated Factors Fayaz A. Ibrahim, M.D. Carl I. Cohen, M.D. Paul M. Ramirez, Ph.D.
- 3. Clinical Remission and Recovery in Schizophrenia Carl I. Cohen, M.D. Richa Pathak, M.D. Paul M. Ramirez, Ph.D.
- 4. Well-Being and Associated Factors: Quality of Life and **Subjective Successful Aging** in Older Persons With Schizophrenia Sukriti Mittal, M.D. A.O. Bankole, M.D. Carl I. Cohen, M.D. Paul M. Ramirez, Ph.D.

#### SYMPOSIUM 15

2:00 P.M.-5:00 P.M. Room 218, Second Level, Morial Convention Center

SPIRITUALITY AND MENTAL HEALTH: WHAT IS THE **PSYCHIATRIST'S ROLE?** 

#### Chair:

John R. Peteet, M.D.

- 1. The Evolving Role of Meditation and Other **Mindfulness Practices** in Psychotherapy William M. Greenberg, M.D.
- 2. Positive Emotions: Psychiatry's Great Blind Spot George E. Vaillant, M.D.
- 3. Introducing Spirituality **Into Psychiatric Education** and Care Marc Galanter, M.D.
- 4. Spiritual Aspects of the **Treatment of Personality** Disorders C. Robert Cloninger, M.D.
- 5. Spiritual Healing: The Psychiatrist as a **Facilitator of Integration** Nadine J. Nyhus, M.D., M.A.

#### SYMPOSIUM 16

2:00 P.M.-5:00 P.M. Room 223, Second Level, Morial Convention Center

BURN PSYCHIATRY: TREATMENT AND OUTCOMES

#### Chair:

Frederick J. Stoddard, M.D.







- 1. Trauma and Grief After the **Coconut Grove and Station** Nightclub Fires, 1942 and 2003 Frederick J. Stoddard, M.D.
- 2. Psychopharmacology of Neuropsychiatric Disorders in Burn Patients Shamim H. Nejad, M.D.
- 3. An Intervention to Reduce Stress in 0- to 5-Year Olds With Burns

Erica Sorrentino, M.A. Frederick J. Stoddard, M.D. J. Michael Murphy, Ed.D. David Chedekel, Ed.D. Glenn Saxe, M.D. Gwyne White, B.A. Jenny K.M. Man, B.S. Katia Canenguez, Ed.M. Diana Buterbaugh, R.N. Teresa Doyne, R.N. Taya Zbell, LICSW Stephanie Clark, M.T.-B.C., C.C.L.S. Robert Sheridan, M.D. Ronald G. Tompkins, M.D., Sc.D.

4. Pain Management During Acute **Burn Treatment in Children:** A Multicenter Study and **Psychosocial Outcome Analysis** Tolga A. Ceranoglu, M.D. Frederick J. Stoddard, M.D. Michael J. Murphy, Ed.D. Gwyne White, B.A. Erica Sorrentino, M.A.

#### SYMPOSIUM 17

2:00 P.M.-5:00 P.M. Room 224, Second Level, Morial Convention Center

UPDATE ON Interventions for ADULT EATING DISORDERS



Chair:

James Lock, M.D., Ph.D.

- 1. Stepped Care Versus **Best-Available Treatment** for Patients With Bulimia Nervosa James Mitchell, M.D.
- 2. Dialectical Behavior Therapy for Bulimia Nervosa and Binge **Eating Disorder** Debra L. Safer, M.D.
- 3. Cognitive Remediation Therapy for Adults With Anorexia Nervosa James Lock, M.D., Ph.D.
- 4. How to Prevent **Eating Disorders** Craig B. Taylor, M.D.

5. Pharmacotherapy of Eating Disorders: Established **Agents and New Directions** Allan S. Kaplan, M.D.

#### SYMPOSIUM 18

2:00 P.M.-5:00 P.M. Room 239, Second Level, Morial Convention Center

TRANSLATING THE **PSYCHOPHARMACOLOGY EVIDENCE BASE INTO** PRACTICE: A SAMPLER FROM THE AMERICAN SOCIETY OF CLINICAL **PSYCHOPHARMACOLOGY** 



#### Co-Chairs:

Michael D. Jibson, M.D., Ph.D. Ira Glick, M.D.

- 1. Quality of Care in Psychopharmacology: Doing an Actual Visit John M. Kane, M.D.
- 2. Combination Therapy: Psychopharmacology and Psychotherapy Ira Glick, M.D.
- 3. Focus on a Specific Patient **Group: Geriatric Patients** James M. Ellison, M.D., M.P.H.
- 4. An Ethical Framework for Clinician/Industry Interactions Michael D. Jibson, M.D., Ph.D.

#### SYMPOSIUM 19

2:00 P.M.-5:00 P.M. Room R01, Second Level, Morial Convention Center

PATHOPHYSIOLOGY OF PSYCHOTIC AND MOOD DISORDERS: Do WE HAVE ANY SOLID EVIDENCE OF INTEREST TO CLINICIANS?





#### Chair:

Mario Maj, M.D., Ph.D.

- 1. What Do We Know for Sure About the Pathophysiology of Schizophrenia? Stephen M. Lawrie, M.D.
- 2. Clinically Relevant Neurobiological Findings in Depression Gregor Hasler, M.D.
- 3. What Do We Know About the Causes of Bipolar Disorders? Stephen M. Strakowski, M.D.
- 4. Shared and Distinct Neurogenetic Mechanisms for Schizophrenia and Bipolar Disorder Andreas Meyer-Lindenberg, M.D.

#### SYMPOSIUM 20

2:00 P.M.-5:00 P.M. Room 338, Third Level, Morial Convention Center

UPDATING THE APA GUIDELINES FOR THE TREATMENT OF BORDERLINE PERSONALITY DISORDER Association for Research in Personality Disorders

James H. Reich, M.D., M.P.H.

#### Discussant:

Donald W. Black, M.D.

- 1. Updating the APA Guidelines for the Treatment of Borderline **Personality Disorder:** Neurobiology and Genetics of Borderline **Personality Pathology** Simone S. Kool, M.D., Ph.D. Moniek Thunnissen, M.D., Ph.D.
- 2. Emergency Management of Suicidal Crises in **Patients With Borderline** Personality Disorder Paul S. Links, M.D. Yvonne Bergmans, M.S.W., R.S.W.
- 3. Approaches to Prioritizing Treatment of Borderline Personality Disorder in the **Presence of Other Significant** Axis I and Axis II Disorders James H. Reich, M.D., M.P.H.
- 4. New Considerations in the Pharmacologic Treatment of **Borderline Personality Disorder** Kenneth R. Silk, M.D.
- 5. Psychotherapy for Borderline Personality Disorder John Livesley, M.D.

#### SYMPOSIUM 21

2:00 P.M.-5:00 P.M. Room 339, Third Level, Morial Convention Center

How to Get the Corner OFFICE: PRACTICAL LEADERSHIP STRATEGIES FOR WOMEN **PSYCHIATRISTS** 

Association of Women Psychiatrists

#### Chair:

Tana A. Grady-Weliky, M.D.

- 1. Thriving—Not Just Surviving as a Clinical Researcher Eva Szigethy, M.D., Ph.D.
- 2. Ditching the Corner Office to Address Global Health Mary Kay Smith, M.D.

3. Women in Organizational Leadership: What, When, and How? Carolyn B. Robinowitz, M.D.

#### SYMPOSIUM 22

2:00 P.M.-5:00 P.M. Rooms 343-345, Third Level, Morial Convention Center

CULTURE AND PSYCHIATRIC DIAGNOSIS: IMPLICATIONS FOR THE INTERNATIONAL IMPACT OF DSM-5



#### Chair:

Renato D. Alarçon, M.D.

- 1. Cultural Perspectives on the Current DSM-5 Work Renato D. Alarçon, M.D.
- 2. The Outline for Cultural **Formulation: Current Status** and DSM-5 Revision Roberto Lewis-Fernández, M.D.
- 3. Cultural Syndromes Around the World and in *DSM-5*: Why and How Should They Be Included? Joseph Westermeyer, M.D., Ph.D.

#### SYMPOSIUM 23

2:00 P.M.-5:00 P.M. Room 346, Third Level, Morial Convention Center

RECENT CHANGES TO ACUTE PSYCHIATRIC CARE: AN INTERNATIONAL PERSPECTIVE

#### Co-Chairs:

Julian Beezhold, M.D. Abigail L. Donovan, M.D.

- 1. Coercive Measures in **Acute Psychiatric Care:** An Italian Perspective Andrea Fiorillo, M.D., Ph.D.
- 2. Recent Changes in **Acute Psychiatric Care:** A Romanian Perspective Adriana A. Mihai, M.D., Ph.D.



#### SESSION TRACKS

- Affective Disorders (Mood and Anxiety)
- Personality Disorders
- Psychopharmacology
- Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- NIDA
- DSM-5

- 3. Acute Psychiatric Care in Turkey Defne Eraslan, M.D. Aytul Karabekiroglu, M.D. Ozgur Ozturk, M.D.
- 4. Acute Psychiatric Care in the U.S. Abigail L. Donovan, M.D.
- 5. Introduction of a Hospitalist System in a Large, Acute Psychiatric Service: Evaluating the Impact Julian Beezhold, M.D. Pete Williams Andy Harris Jenny Taylor Sumati Kandasamy, M.D. James Currie, M.D.

#### SYMPOSIUM 24

2:00 P.M.-5:00 P.M. Room 347, Third Level, Morial Convention Center

PREVENTION OF PTSD: RECENT ISRAELI PRACTICES



#### Co-Chairs:

Hiam Y. Knobler, M.D., M.A. Yoram Barak, M.D., M.H.A.

- 1. The IDF PTSD Prevention Program for Combat Medical Teams Yoram Barak, M.D., M.H.A.
- 2. Follow-Up of an Acutely Traumatized Reserve Unit for the Prevention of Combat PTSD Nathaniel Laor, M.D., Ph.D. Yoram Ben Yehuda, M.A. Leo Wolmer, M.A. Yoram Barak, M.D., M.H.A. Haim Y. Knobler, M.D., M.A.
- 3. Chronic Follow-Up of Traumatized **Reserve Units for Prevention** and Treatment of Combat PTSD Haim Y. Knobler, M.D., M.A.
- 4. A Model for Preventing PTSD **Symptoms Among Adolescent Volunteers on Ambulance Teams Exposed to Terrorism** Eli Jaffe, Ph.D. Avishy Goldberg, Ph.D. Einat Aviel, Ph.D. Moshe Z. Abramowitz, M.D., M.P.H. Haim Y. Knobler, M.D., M.A.

#### SYMPOSIUM 25

2:00 P.M.-5:00 P.M. Room 349, Third Level, Morial Convention Center

**PSYCHIATRY ACROSS BORDERS:** WORKING FOR THE U.S. GOVERNMENT IN THE DEPARTMENT OF STATE AS A **PSYCHIATRIST** 

#### Chairperson:

Herbert L Campbell, M.D., M.P.H.

#### Presenters:

Samuel Thielman, M.A., Ph.D., Joseph Rawlings, M.D., M.B.A., Paul Beighley, M.D., Kenneth Dekleva, M.D., Christopher Flynn, M.D.

#### SYMPOSIUM 26

2:00 P.M.-5:00 P.M. Room 350, Third Level, Morial Convention Center

TRANSCULTURAL PSYCHIATRY FOR MENTAL HEALTH IN A CHANGING WORLD

#### Chair:

Richard L. Merkel, M.D., Ph.D.

- 1. Cultural Psychiatry Issues in Schizophrenia Robert Kohn, M.D.
- 2. Cultural Contexts of Patient and Family Explanations of Suicidal Behavior Mitchell G. Weiss, M.D., Ph.D. Shubhangi R. Parkar, M.D. Arabinda N. Chowdhury, M.D. Anita Riecher, M.D.
- 3. Transcultural Psychiatry John David Kinzie, M.D.
- 4. Integrating Traditional and Western Mental Health Care Richard L. Merkel, M.D., Ph.D.

#### SYMPOSIUM 27

2:00 P.M.-5:00 P.M. Room 353, Third Level, Morial Convention Center

Non-Psychotic Issues of SCHIZOPHRENIC **PATIENTS** 

Chair: S. Charles Schulz, M.D.

- 1. Cognitive Rehabilitation of Schizophrenia: Treatment and Research Raquel E. Gur, M.D., Ph.D. Irene Hurford, M.D. Ruben C. Gur, Ph.D.
- 2. Smoking and Schizophrenia: **Efficacy of New Treatments** S. Hossein Fatemi, M.D., Ph.D. Timothy D. Folsom, M.S. Stephanie Liesch, M.S. Rachel Kneeland, B.A.
- 3. Schizophrenia and **Substance Abuse** Alan I. Green, M.D. Mary F. Brunette, M.D.
- 4. Approaches to Suicide in Schizophrenia Lawrence Adler, M.D.





#### SYMPOSIUM 28

2:00 P.M.-5:00 P.M. Room 354, Third Level, Morial Convention Center

**DOPING IN ATHLETES:** THE ROLE OF THE SPORT PSYCHIATRIST International Society for Sport Psychiatry

Antonia L. Baum, M.D.

Discussant: Richard Hilderbrand, Ph.D.

- 1. The Ethics in Doping Control Eric D. Morse, M.D.
- 2. Helping the Athlete Through the Therapeutic **Use Exemption Process** David O. Conant-Norville, M.D. Richard Hilderbrand, Ph.D.
- 3. Doping Control in Elite Athletics Saul I. Marks, M.D.

#### SYMPOSIUM 29

2:00 P.M.-5:00 P.M. Room 355, Third Level, Morial Convention Center

**EXECUTIVE FUNCTION** AS A BRAIN SYSTEM FOR SELF-CONTROL: THE NEUROCIRCUITRY OF PSYCHIATRIC DISORDERS AND ADDICTION National Institute on Drug Abuse



Mary A. Kautz, Ph.D. Minda R. Lynch, Ph.D.

- 1. Prefrontal Circuits for Rules, Concepts, and **Cognitive Control** Earl K. Miller, Ph.D.
- 2. Basic Neurobiology of Self-**Control in Decision Making** Todd Hare, M.D.
- 3. Key Circuits and Regions Implicated in Executive **Dysfunction and** Disruptions of Cognitive Control in Schizophrenia: Genetic Influences and **Dopamine Regulation** Karen Faith Berman, M.D.
- 4. Core Cognitive Systems for Controlling Craving and Negative Emotion in Substance Abuse and **Psychiatric Disorders** Kevin N. Ochsner, Ph.D.

#### SYMPOSIUM 30

2:00 P.M.-5:00 P.M. Rooms 356/357, Third Level, Morial Convention Center

ADDICTION RESEARCH, PREVENTION AND TREATMENT IN THE U.S. AND FRANCE: VIVE LA DIFFERENCE!

Co-Chairs:

National Institute

on Drug Abuse

John A. Talbott, M.D. Francois C. Petitjean, M.D.

**Discussant:** 

Alexandra B. McLean, M.D.

- 1. Progress in Addiction Research Nora D. Volkow, M.D.
- 2. Patterns of Addiction in High School and **University Students** Marc-Antoine Crocq, M.D. Alexis Boehrer, Psy.D.
- 3. The FDA and Tobacco Regulation Joshua Sharfstein, M.D.
- 4. Do Psychiatric **Patients Smoke to** Self-Medicate, or Is It for Other Reasons? Renaud de Beaurepaire, M.D., Ph.D.
- 5. The State of Treatment of Addictive Disorders in the United States David Oslin, M.D.
- 6. Organization and **Health Care Networks** for Cannabis Treatment in France Amine Benyamina, M.D. Lisa Blecha, M.D. Michel Reynaud, M.D., Ph.D.

# 3:30 P.M. SESSIONS WORKSHOPS 33-40 WORKSHOP 33

3:30 P.M.-5:00 P.M. Room 237, Second Level, Morial Convention Center

MAKING THE MOST **OF YOUR TWENTY-**MINUTE HOUR: MAXIMIZING THE THERAPEUTIC EXPERIENCE

Co-Chairs:

Frederick G. Guggenheim, M.D. Robert J. Boland, M.D.

#### WORKSHOP 34

3:30 P.M.-5:00 P.M. Room 333, Third Level, Morial Convention Center

PATIENT SUICIDE DURING **PSYCHIATRY RESIDENCY:** A Workshop Discussion

#### Co-Chairs:

Allison S. Baker, M.D. Christina V. Mangurian, M.D.

#### **Presenters:**

Andrew Booty, M.D. Meredith A. Kelly, M.D. Aerin Hyun, M.D., Ph.D. Emily Gastelum, M.D.

### WORKSHOP 35

Withdrawn

#### WORKSHOP 36

3:30 P.M.-5:00 P.M. Room 336, Third Level, Morial Convention Center

MEDITATION AND **PSYCHIATRY** 



Michael D. McGee, M.D.

#### WORKSHOP 37

3:30 P.M.-5:00 P.M. Room 337, Third Level, Morial Convention Center

PUBLISHING BOOKS FOR THE GENERAL PUBLIC

#### Chair:

Lewis M. Cohen, M.D.

#### WORKSHOP 38

3:30 P.M.-5:00 P.M. Room 340, Third Level, Morial Convention Center

ETHICAL, CLINICAL AND LEGAL CHALLENGES CREATED BY Information Technology

#### Co-Chairs:

Malkah T. Notman, M.D. Elissa P. Benedek, M.D.

#### **Presenters:**

Carl P. Malmquist, M.D. Jeffrey W. King, J.D., LL.M. Wade Myers, M.D.

#### WORKSHOP 39

3:30 P.M.-5:00 P.M. Room 341, Third Level, Morial Convention Center

WHERE SCIENCE AND SOCIAL JUSTICE MEET: THE EXAMPLE **OF SMOKING IN PERSONS** WITH BIPOLAR DISORDER

#### Chair:

Annette M. Matthews, M.D.

#### WORKSHOP 40

3:30 P.M.-5:00 P.M. Room 348, Third Level, Morial Convention Center

COGNITIVE-BEHAVIORAL THERAPY: TROUBLESHOOTING **COMMON CHALLENGES** 



Chair:

Donna M. Sudak, M.D.

**Presenters:** 

Judith S. Beck, Ph.D. Jesse H. Wright, M.D., Ph.D.

#### 6:00 P.M. SESSION SYMPOSIUM 1

6:00 P.M.-8:00 P.M.

Grand Ballrooms A/B, First Level, Hilton New Orleans Riverside

**NEW DEVELOPMENTS** IN SCHIZOPHRENIA RESEARCH AND PRACTICE: FROM THE PIPELINE TO THE CLINIC Supported by an Education



Chair:

Prakash S. Masand, M.D.

Grant from DSPA

- 1. Obstacles and Opportunities in New CNS Drug Development Kenneth Kaitin, Ph.D.
- 2. Do Pharmacogenetics Have a Role in Treating Schizophrenia? Roy H. Perlis, M.D., M.S.C.
- 3. Switching Antipsychotic Therapy: Lessons for the Clinician Prakash S. Masand, M.D.
- 4. Innovative Strategies to Improve Adherence in Schizophrenia Mehul V. Mankad, M.D.

#### SESSION MEDIA WORKSHOP 1

7:00 P.M.-10:00 P.M.

Grand Salon B, First Level, Hilton New Orleans Riverside

ISN'T ALL HORROR PSYCHOLOGICAL?

Horror film director, George Romero, and Steven Schlozman, M.D., discuss Polanski's classic film, "Repulsion."



Steven Schlozman, M.D.







VISIT THE EXHIBITS Publishers Book Fair and APA Member Center NEW ORLEANS, Open Saturday 10 am - 4:00 pm PRIDE & PROMISE: All Exhibits Open **TOWARD A NEW** PSYCHIATRY Sunday 10:00 am - 4:00 pm Monday 10:00 am - 4:00 pm Tuesday 10:00 am - 4:00 pm 163RD ANNUAL MEETING AMERICAN PSYCHIATRIC ASSOCIATION **Exhibit Hall Reception** NOTE: Final closing of exhibits is Tuesday at 4:00 pm Monday 12:30 – 1:30 pm

# Experience the Southern Elegance of New Orleans with the

# American Psychiatric Foundation

# "A Night in New Orleans"


Monday, May 24, 2010 7:00 - 10:00 pm **Grand Oaks Mansion at Mardi Gras World** 

The American Psychiatric Foundation invites you to our annual fundraising event, "A Night in New Orleans" a special evening at the Grand Oaks Mansion at Mardi Gras World. Enjoy tasty



cuisine and live music in this festive venue. The evening's program includes a silent auction and the presentation of the Awards for Advancing Minority Mental Health. Event proceeds support the foundation's grants, programs, research funding and awards that advance public understanding that mental illnesses are real and treatable. Tickets only cost \$150 and are available in the Member Center during Exhibit Hall hours, or at the door of the event.

# "Conversations" featuring Terry Bradshaw



Tuesday, May 25, 2009 5:30 - 6:30 pm Hall A, New Orleans Convention Center

Don't miss our 9th annual "Conversations" event, an interactive series that offers meeting attendees an opportunity to hear unique perspectives on mental illness. Conversations is free to all APA Annual Meeting attendees.

> "Conversations" is supported by a charitable contribution from AstraZeneca to the American Psychiatric Foundation

# SUNDAY

Program changes are printed each day in the Daily Bulletin. You can pick up the **Daily Bulletin** in Exhibit Halls B/C, First Level, Morial Convention Center and at many other locations throughout the convention center

#### 8:00 A.M. SESSIONS COURSES 11-18

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C, First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

#### COURSE 11

8:00 A.M.-NOON Room 224, Second Level, Morial Convention Center

How to Give a More **EFFECTIVE LECTURE:** Punch, Passion AND POLISH

Director Phillip J. Resnick, M.D.

#### COURSE 12

8:00 A.M.-NOON

Rooms 225/226, Second Level, Morial Convention Center

#### **EMERGENCY PSYCHIATRY:** THEORY TO PRACTICE

American Association for Emergency Psychiatry

#### **Director:**

Anthony T. Ng, M.D.

#### Faculty:

Seth Powsner, M.D. Ion S. Berlin, M.D. Rachel L. Glick, M.D.

#### COURSE 13

8:00 A.M.-NOON

Rooms 228/229, Second Level, Morial Convention Center

PSYCHIATRIC DISORDERS IN PREGNANT AND POSTPARTUM Women: Infant Morbidity AND MORTALITY

#### **Co-Directors:**

Margaret Spinelli, M.D. Katherine L. Wisner, M.D., M.S.

#### COURSE 14

8:00 A.M.-NOON

Room 230, Second Level, Morial Convention Center

MOTIVATIONAL INTERVIEWING FOR ROUTINE PSYCHIATRIC PRACTICE



#### **Director:**

Steven Cole, M.D.

#### COURSE 15

8:00 A.M.-NOON

Room 238, Second Level, Morial Convention Center

COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA COMORBID WITH DEPRESSIVE AND ANXIETY DISORDERS

#### **Director:**

Rachel Manber, Ph.D.

#### Faculty:

Anne Germain, Ph.D. Jack D. Edinger, Ph.D. Colleen E. Carney, Ph.D. Jason Ong, Ph.D.

#### COURSE 16

8:00 A.M.-NOON

Room 239, Second Level, Morial Convention Center

MOOD DISORDERS IN LATER LIFE



#### **Co-Directors:**

James M. Ellison, M.D., M.P.H. Yusuf Sivrioglu, M.D.

#### **Faculty:**

Brent P. Forester, M.D. Donald A. Davidoff, Ph.D. Patricia A. Arean, Ph.D.

#### **SESSION TRACKS**

- Affective Disorders (Mood and Anxiety)
- Personality Disorders
- Psychopharmacology
- Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- NIDA
- DSM-5

#### COURSE 17

8:00 A.M.-NOON

Room 336, Third Level, Morial Convention Center

MENTAL HEALTH CARE OF UNIVERSITY STUDENT POPULATIONS: A PRACTICAL OVERVIEW FOR PSYCHIATRISTS

#### **Co-Directors:**

Doris M. Iarovici, M.D. Ayesha Chaudhary, M.D.

#### Faculty:

Hollister Rogers, M.D.

#### COURSE 18

8:00 A.M.-NOON

Room 337, Third Level, Morial Convention Center

#### RESEARCH AND PUBLISHING ON A SHOESTRING BUDGET

#### **Director:**

Mantosh J. Dewan, M.D.

#### Faculty:

Michele T. Pato, M.D. Edward K. Silberman, M.D.

### 9:00 A.M. SESSIONS

#### WORKSHOPS 41-47 WORKSHOP 41

9:00 A.M.-10:30 A.M.

Room 236, Second Level, Morial Convention Center

AFTER A PARENT'S SUICIDE: CHILDREN'S **GRIEF AND HEALING** 



#### Chair:

Nancy Rappaport, M.D.

#### **Presenters:**

Joanne Harpel, J.D. Diana Sands, Ph.D.

#### WORKSHOP 42

9:00 A.M.-10:30 A.M.

Room 237, Second Level, Morial Convention Center

FROM NARRATIVE AND THEORY TO EVIDENCE-BASED SUPPORT FOR PSYCHIATRISTS WORKING UNDER EXTREME STRESS APA Lifers

#### Chair:

Sheila Hafter Gray, M.D.

#### **Presenters:**

Milton Kramer, M.D. Jane G. Tillman, Ph.D. Leah J. Dickstein, M.D., M.A. Captane P. Thomson, M.D.

John C. Bradley, M.D. David Huang, M.D.

#### WORKSHOP 43

9:00 A.M.-10:30 A.M. Room 333, Third Level, Morial Convention Center

PHYSICIAN HEAL THYSELF: SCANDALS, SUICIDES, AND SUBSTANCE ABUSE AMONG US

#### Co-Chairs:

Margaret Bishop-Baier, M.D. Scott Embley, L.C.S.W.

#### WORKSHOP 44

9:00 A.M.-10:30 A.M. Room 346, Third Level, Morial Convention Center

MOOD DISORDERS IN WOMEN OF REPRODUCTIVE AGE



Natalie L. Rasgon, M.D., Ph.D.

#### WORKSHOP 45

9:00 A.M.-10:30 A.M. Room 347, Third Level, Morial Convention Center

COGNITIVE-BEHAVIORAL STRATEGIES FOR WEIGHT LOSS



#### Co-Chairs:

Sarah B. Johnson, M.D., M.S.C. Joyce A. Spurgeon, M.D.

#### WORKSHOP 46

9:00 A.M.-10:30 A.M.

Room 350, Third Level, Morial Convention Center

**CHANGING PARADIGMS OF** PSYCHIATRIC PRACTICE IN AN ERA OF HEALTH CARE REFORM

APA Council on Advocacy & Government Relations

#### Co-Chairs:

Javeed Sukhera, M.D. Sarah Vinson, M.D.

#### **Presenters:**

Catherine E. Krasnik, M.D., Ph.D. Margaret Balfour, M.D., Ph.D. Peter S. Martin, M.D., M.P.H. Robin Reed, M.D.

#### WORKSHOP 47

9:00 A.M.-10:30 A.M.

Room 351, Third Level, Morial Convention Center

AMBULATORY MEDICAL CLINICS AS TRAINING SITES FOR RESIDENTS AND FELLOWS IN PSYCHOSOMATIC MEDICINE

#### Chair:

Robert C. Joseph, M.D., M.S.

#### **Presenters:**

Arun Gopal, M.D., B.A. Fremonta Meyer, M.D. Amy M. Bauer, M.D., M.S.

# SYMPOSIA 31-35

#### 9:00 A.M.-NOON

Room R01, Second Level, Morial Convention Center

Understanding Personality DISORDERS IN CHILDREN AND ADOLESCENTS: **CURRENT STATUS AND FUTURE DIRECTIONS** 



#### Chairs:

Paul S. Links, M.D. Joel F. Paris, M.D.

- 1. Advancing From Understanding Personality Disorders in Young **People Toward Early Detection** and Intervention Andrew M. Chanen, M.B.B.S.
- 2. Measurement and Assessment of PD Precursors: Links to Normal Personality and Axis I Problems Jennifer Tackett, M.D.
- 3. Why and Under What Circumstances Should We Make the Diagnosis of Personality Disorders in Children and Adolescents? Joel F. Paris, M.D.

#### SYMPOSIUM 32

9:00 A.M.-NOON

Rooms R04/R05, Second Level, Morial Convention Center

TREATMENT OF DEPRESSION IN ETHNIC MINORITIES



#### Co-Chairs:

Julio Licinio, M.D. William B. Lawson, M.D., Ph.D.

- 1. Disparity in Depression Treatment Among Racial and **Ethnic Minority Populations** in the United States Alegria Margarita, Ph.D.
- 2. Diagnosing Depression in People of African Ancestry: National and **International Perspectives** William B. Lawson, M.D., Ph.D.
- 3. Ethical and Cultural **Considerations in Treating** Depression in Patients of Chinese Background Albert Yeung, M.D., Sc.D.

4. Depression Care in the **United States Among Ethnic** and Racial Minorities Hector M. Gonzalez, Ph.D. William A. Vega, Ph.D. David R. Williams, Ph.D. Wassim Tarraf, M.A. Harold W. Neighbors, Ph.D.

#### SYMPOSIUM 33

9:00 A.M.-NOON

Room 348, Third Level, Morial Convention Center

APPROACHES TO SCHIZOPHRENIA THROUGH PHASES OF THE ILLNESS

#### Chair:

S. Charles Schulz, M.D.

- 1. Early Identification of the **Psychosis Prodrome and Clinical Practice** Kristin S. Cadenhead, M.D.
- 2. Management of First Episode Schizophrenia John M. Kane, M.D.
- 3. Approaches to Schizophrenia Peter Weiden, M.D.
- 4. Evaluation and Intervention for the Persistently Ill Schizophrenic Person S. Charles Schulz, M.D. Peter Milev, M.D., Ph.D.

#### SYMPOSIUM 34

9:00 A.M.-NOON

Room 349, Third Level, Morial Convention Center

DIAGNOSING AND TREATING THE NARCISSISTIC PERSONALITY DISORDER: AWAITING DSM-5

*International Society for the* Study of Personality Disorders

#### Co-Chairs:

Elsa Ronningstam, Ph.D. Giuseppe Giancarlo Dimaggio, M.D.

#### Discussant:

Kenneth N. Levy, Ph.D.

- 1. Observing Narcissistically **Vulnerable Traits** Mardi Horowitz, M.D.
- 2. Treatment Implications of the Proposed DSM-5 Representation of Narcissism Donna S. Bender, Ph.D.
- 3. A Self-Regulatory Model and Strategies for Treatment of Narcissistic Personality Disorder Elsa Ronningstam, Ph.D.





A.M.

4. Promoting Awareness of **Mental States and Their** Triggers and Reducing Feelings of Rejection in **Treatment of Narcissistic Pathology** 

Giuseppe Giancarlo Dimaggio, M.D. Giuseppe Nicolò, M.D. Giampaolo Salvatore, M.D. Michele Procacci, M.D.

5. Implications of Research on Trait Narcissism for the Conceptualization of **Narcissistic Personality** W. Keith Campbell, Ph.D. Joshua D. Miller, Ph.D.

#### SYMPOSIUM 35

9:00 A.M.-NOON

Room 353, Third Level, Morial Convention Center

SEX/GENDER DIFFERENCES AND WOMEN-SPECIFIC **ISSUES IN DRUG ABUSE:** PREDICTING AND IMPROVING TREATMENT OUTCOMES National Institute on Drug Abuse



Cora Lee Wetherington, Ph.D. Shelly F. Greenfield, M.D., M.P.H.

- 1. Gender Differences in **Psychiatric Comorbidity** With Substance Use **Disorder: Implications** "Telescoping" and Treatment Kathleen Brady, M.D.
- 2. Significant Role of Sex-**Based Biology in Predicting Relapse and Clinical Outcomes** in Drug Abuse Rajita Sinha, Ph.D. Helen Fox, Ph.D. Peter Morgan, M.D., Ph.D. Keri Bergquist, Psy.D.
- 3. Women-Focused Treatment for Substance Use Disorders: Results From the Women's **Recovery Group Study** Shelly F. Greenfield, M.D., M.P.H.
- 4. Substance-Abusing Women With PTSD: **How Best to Treat?** Denise Hien, Ph.D.
- 5. The Use of Motivational **Enhancement Therapy** and Vouchers to Improve **Treatment Utilization** and Outcome in Pregnant **Substance Users** Theresa Winhusen, Ph.D.

# COURSES 19-31

9:00 A.M.-4:00 P.M.

Room 210, Second Level, Morial Convention Center

ESSENTIALS OF ASSESSING AND TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN ADULTS AND CHILDREN

Director:

Thomas E. Brown, Ph.D.

**Faculty:** 

Jefferson B. Prince, M.D. Anthony L. Rostain, M.D., M.A.

#### COURSE 20

9:00 A.M.-4:00 P.M.

Room 219, Second Level, Morial Convention Center

How to Blog, Tweet, FRIEND, WIKI, AND NOT GET ADDICTED: 21ST CENTURY **INTERNET TECHNOLOGIES** FOR BEGINNERS American Association for Technology in Psychiatry

**Director:** 

Robert C. Hsiung, M.D.

**Faculty:** 

Jerald J. Block, M.D. Steven R. Daviss, M.D.

#### COURSE 21

9:00 A.M.-4:00 P.M.

Room 223, Second Level, Morial Convention Center

EEG FEEDBACK IN **PSYCHIATRY: CLINICAL** APPLICATIONS

Co-Directors:

Thomas M. Brod, M.D. Michael Cohen, B.S.

**Faculty:** 

Ed Hamlin, Ph.D. Anne W. Stevens, Ph.D. Stephen E. Buie, M.D.

#### COURSE 22

9:00 A.M.-4:00 P.M.

Room 227, Second Level, Morial Convention Center

BASIC CONCEPTS IN **ADMINISTRATIVE** PSYCHIATRY I

American Association of Psychiatric Administrators

**Co-Directors:** 

Barry K. Herman, M.D. Douglas M. Brandt, M.D. **Faculty:** 

L. Mark Russakoff, M.D. Shivkumar S. Hatti, M.D., M.B.A. David K. Nace, M.D. Sy A. Saeed, M.D., M.S.

#### COURSE 23

9:00 A.M.-4:00 P.M.

Room 235, Second Level, Morial Convention Center

WHAT IS PSYCHIATRY? PHILOSOPHIES AND PRACTICES

**Co-Directors:** 

S. Nassir Ghaemi, M.D., M.P.H. David H. Brendel, M.D.

#### COURSE 24

9:00 A.M.-4:00 P.M.

Room R06, Second Level, Morial Convention Center

TREATMENT OF SCHIZOPHRENIA





Director:

Philip G. Janicak, M.D.

Faculty:

Stephen R. Marder, M.D. Rajiv Tandon, M.D. Morris B. Goldman, M.D.

#### COURSE 25

9:00 A.M.-4:00 P.M. Room 338, Third Level, Morial Convention Center

SPIRITUALITY IN PSYCHIATRY

Director:

Michael D. McGee, M.D.

Faculty:

James L. Griffith, M.D. Christina Puchalski, M.D.

#### COURSE 26

9:00 A.M.-4:00 P.M.

Room 339, Third Level, Morial Convention Center

Understanding the PERSON BEHIND THE ILLNESS: AN APPROACH TO PSYCHODYNAMIC FORMULATION

Director:

William H. Campbell, M.D., M.B.A.

COURSE 27

9:00 A.M.-4:00 P.M.

Room 340, Third Level, Morial Convention Center

MINDFULNESS: PRACTICAL APPLICATIONS FOR PSYCHIATRY

Director:

Susan E. Abbey, M.D.

#### COURSE 28

9:00 A.M.-4:00 P.M. Room 352, Third Level, Morial Convention Center

YOGA OF THE EAST AND West: Integrating Breath WORK AND MEDITATION INTO CLINICAL PRACTICE

#### **Co-Directors:**

Patricia L. Gerbarg, M.D. Richard P. Brown, M.D.

#### Faculty:

Monica Vermani, M.A., Psy.D. Martin Katzman, M.D.

#### COURSE 29

9:00 A.M.-4:00 P.M. Room 354, Third Level, Morial Convention Center

TRANSFERENCE-FOCUSED **PSYCHOTHERAPY** FOR BORDERLINE PERSONALITY



#### Co-Directors:

Frank E. Yeomans, M.D., Ph.D. Otto F. Kernberg, M.D.

#### Faculty:

Eve Caligor, M.D. John F. Clarkin, Ph.D.

#### COURSE 30

9:00 A.M.-4:00 P.M. Room 355, Third Level, Morial Convention Center

#### ADVANCED INTERVIEWING **TECHNIQUES**

#### Director:

Shawn C. Shea, M.D.

#### COURSE 31

#### 9:00 A.M.-4:00 P.M.

Rooms 356/357, Third Level, Morial Convention Center

AUTISM SPECTRUM **DISORDERS: DIAGNOSTIC** CLASSIFICATION, NEUROBIOLOGY, **BIOPSYCHOSOCIAL** Interventions and **PHARMACOLOGIC** 



#### MANAGEMENT **Co-Directors:**

Kimberly A. Stigler, M.D. Alice R. Mao, M.D.

#### **Faculty:**

James Sutcliffe, Ph.D. Mathew Brams, M.D. Eric Courchesne, Ph.D. Nora Friedman, M.D. Stephanie Hamarman, M.D. Julie A. Chilton, M.D.

#### MASTER COURSES 3-4

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C. First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

#### MASTER COURSE 3

9:00 A.M.-4:00 P.M.

Rooms R02/R03, Second Level, Morial Convention Center

#### PSYCHODYNAMIC PSYCHOTHERAPY

Director:

Glen O. Gabbard, M.D.

#### Faculty:

Robert Michels, M.D. Gabrielle Hobday, M.D. John G. Gunderson, M.D.

#### MASTER COURSE 4

9:00 A.M.-4:00 P.M. Rooms R07/09, Second Floor, Morial Convention Center

#### PRACTICAL COGNITIVE-BEHAVIOR THERAPY



#### **Director:**

Jesse H. Wright, M.D., Ph.D.

#### Faculty:

Robert M. Goisman, M.D. Donna M. Sudak, M.D. Judith S. Beck, Ph.D.

# SEMINARS

#### 9:00 A.M.-4:00 P.M.

Room 342, Third Level, Morial Convention Center

#### THE IMG INSTITUTE

Nyapati R. Rao, M.D., M.S. Deborah J. Hales, M.D.

#### **Presenters:**

Michael D. Jibson, M.D., Ph.D. Milton Kramer, M.D. Peter F. Buckley, M.D. Priyanthy Weerasekera, M.D., M.Ed. Larry R. Faulkner, M.D. Jacob E. Sperber, M.D. Ramotse Saunders, M.D. Mantosh J. Dewan, M.D. Gerald Whalen, M.D. Jeffrey Goldberg, D.O.

Joan M. Aniza, M.D. Damir Huremovic, M.D., M.P.P.

#### 10:00 A.M.-4:00 P.M.

Exhibit Hall. APA Member Center and Publishers' Book Fair Are Open.

Exhibit Halls B-D, First Level, Morial Convention Center

#### :00 A.M. SESSIONS CIENTIFIC AND CLINICAL REPORTS: SESSION 1

#### 11:00 A.M.-12:30 P.M.

Room 351, Third Level, Morial Convention Center

#### Addiction Psychiatry

#### Chair: TBD

1. Mediation as Treatment Modality in Active Duty Service Members Participating in Residential **Substance Abuse Rehabilitation** Amy Canuso, D.O. Lyn Waelde, Ph.D. Robert McLay M.D., Ph.D. Mary Rusher, M.D. Chris Johnson, Ph.D. Scott Johnston, Ph.D.



A.M.

- 2. "Full Blown" Tramadol Dependence: Case Report and Review of Literature Durga Bestha, M.B.B.S. Vishal Madaan, M.D. Amy Kathryn Anderson, M.D.
- 3. An Update on Testing for Drugs of Abuse: Scientific Background and **Practical Clinical Concerns** Dwight Smith, M.D. Ashish Anand, M.D. Ronald Bugaoan, M.D. John Renner, M.D.

# WORKSHOPS 48-53 WORKSHOP 48

#### 11:00 A.M.-12:30 P.M.

Room 236, Second Level, Morial Convention Center

#### STREET TO HOME: SHAME IN HOMELESSNESS

#### Co-Chairs:

Prakash Chandra, M.D. Hina Tasleem, M.B.B.S.

#### **Presenters:**

Melissa Kerner, M.S.W. Jill Maddox, M.D.

#### WORKSHOP 49

11:00 A.M.-12:30 P.M. Room 237, Second Level, Morial Convention Center

I'M VIOLENT; ADMIT ME IF YOU DARE: HOW AND WHERE TO MANAGE POTENTIALLY VIOLENT INDIVIDUALS WITH UNCLEAR DIAGNOSES PRESENTING TO **EMERGENCY SERVICES** 

Co-Chairs:

Kenneth M. Certa, M.D. Jessica Mosier, M.D.

**Presenter:** 

Solange Margery Bertoglia, M.D.

WORKSHOP 50

11:00 A.M.-12:30 P.M.

Room 333, Third Level, Morial Convention Center

PSYCHIATRIC CARE IN LATIN AMERICA: CURRENT CHALLENGES AND FUTURE PERSPECTIVES

Co-Chairs:

Pedro Ruiz, M.D. Rodrigo A. Muñoz, M.D.

**Presenters:** 

Alfredo H. Cía, M.D. Enrique Camarena, M.D. Silvia Gaviria, M.D. Edgard Belfort, M.D.

WORKSHOP 51

11:00 A.M.-12:30 P.M.

Room 346, Third Level, Morial Convention Center

UPDATE ON PARASOMNIAS: A REVIEW FOR PSYCHIATRIC PRACTICE

Co-Chairs:

Dimitri D. Markov, M.D. Marina Goldman, M.D.

Presenter:

Nidhi Tewari, M.D.

WORKSHOP 52

11:00 A.M.-12:30 P.M.

Room 347, Third Level, Morial Convention Center

**CULTURAL DIVERSITIES:** THE IMPACT ON MENTAL HEALTH TREATMENT AND **EVALUATION IN JAILS** AND PRISONS

APA Council on Psychiatry & Law

Chair:

Henry C. Weinstein, M.D.

WORKSHOP 53

11:00 A.M.-12:30 P.M. Room 350, Third Level,

Morial Convention Center

SCOPE OF PRACTICE CHALLENGES: EXPERIENCES, SUCCESSES, AND TRIBULATIONS FROM ACROSS THE COUNTRY

Co-Chairs:

Jerry L. Halverson, M.D. Claudia L. Reardon, M.D.

**Presenters:** 

John T. Bailey, D.O. Joan M. Anzia, M.D. Harold M. Ginzburg, M.D., J.D. Paula Johnson, Ph.D. Jenny Boyer, M.D. Melinda L. Young, M.D.

12:30 P.M.

APA BUSINESS MEETING

(For Voting APA Members Only\*) 12:30 P.M.-1:30 P.M.

La Louisiane Rooms A/B, First Level, Morial Convention Center

\*Members-in-Training, General Members, Distinguished Fellows, Fellows, Life Fellows, Distinguished Life Fellows, and Life Members. Registration badge and/or APA membership card necessary for admission. No cameras or tape recorders are permitted in this meeting.

CALL TO ORDER

Alan F. Schatzberg, M.D. President

MEMORIAL TO **DECEASED MEMBERS** 

ANNOUNCEMENT OF **ELECTION RESULTS** 

Eliot Sorel, M.D.

Chair, Committee of Tellers

REPORTS TO THE MEMBERSHIP

David Fassler, M.D.

Secretary-Treasurer

Gary S. Weinstein, M.D. Speaker

Bruce A. Hershfield, M.D. Speaker-Elect

John O. Gaston, M.D. Chair, By-Laws Committee Kathleen M. Mogul, M.D.

Chair, Elections Committee

Joseph E.V. Rubin, M.D. Chair, Membership Committee

James H. Scully, Jr., M.D. Medical Director

**Chairs of Councils** 

(written reports only)

ANNUAL FORUM

ADJOURNMENT

:00 P.M. SESSIONS COURSES 32-40

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C, First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

COURSE 32

1:00 P.M.-5:00 P.M. Room 224, Second Level, Morial Convention Center

MULTIDISCIPLINARY TREATMENT OF CHRONIC PAIN

**Co-Directors:** 

Vladimir Bokarius, M.D., Ph.D. Steven Richeimer, M.D.

Faculty:

Yogi Matharu, D.P.M. Ali Nemat, M.D. Karen McNulty, O.T.D., O.T.R./L. Faye M. Weinstein, Ph.D.

COURSE 33

1:00 P.M.-5:00 P.M.

Rooms 225/226, Second Level, Morial Convention Center

NEUROANATOMY OF EMOTIONS

Director:

Ricardo M. Vela, M.D.

COURSE 34

1:00 P.M.-5:00 P.M.

Rooms 228/229, Second Floor, Morial Convention Center

MANAGEMENT OF PSYCHIATRIC DISORDERS IN PREGNANT AND POSTPARTUM WOMEN

**Co-Directors:** 

Shaila Misri, M.D. Diana Carter, M.D.

Faculty:

Shari I. Lusskin, M.D. Deirdre Ryan, M.D.

#### COURSE 35

1:00 P.M.-5:00 P.M.

Room 230, Second Level, Morial Convention Center

MENTALIZATION-BASED TREATMENT FOR BORDERLINE PERSONALITY DISORDER: INTRODUCTION

TO CLINICAL PRACTICE





**Co-Directors:** 

Anthony W. Bateman, M.B.B.S., M.R.C. Peter Fonagy, Ph.D.

#### COURSE 36

1:00 P.M.-5:00 P.M.

Room 238, Second Level, Morial Convention Center

FOSTERING ADHERENCE то Рѕусноткоріс MEDICATIONS: A PRACTICAL RESOURCE FOR CLINICIANS



**Co-Directors:** 

Luis F. Ramirez, M.D. Richard A. McCormick, Ph.D.

**Faculty:** 

David Robinson, M.D.

#### COURSE 37

1:00 P.M.-5:00 P.M.

Room 239, Second Level, Morial Convention Center

INTERPERSONAL **PSYCHOTHERAPY** 



Director:

John C. Markowitz, M.D.

#### COURSE 38

1:00 P.M.-5:00 P.M.

Room R01, Second Level, Morial Convention Center

INTERNAL MEDICINE **UPDATE: WHAT PSYCHIATRISTS** NEED TO KNOW

**Co-Directors:** 

Monique Yohanan, M.D. Michele T. Pato, M.D.

Faculty:

Robert Cobb, M.D.

#### COURSE 39

1:00 P.M.-5:00 P.M.

Room 336, Third Level, Morial Convention Center

MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP AND OTHER **BODY CLOCK DISORDERS** 

#### Director:

Alfred J. Lewy, M.D., Ph.D.

#### COURSE 40

1:00 P.M.-5:00 P.M.

Room 337, Third Level, Morial Convention Center

#### **COUNTER-INTUITIVES** IN MEDICAL ETHICS

**Director:** 

Edmund G. Howe, M.D., J.D.

#### SEMINAR 6

1:00 P.M.-5:00 P.M.

Room 334, Third Level, Morial Convention Center

OVERVIEW OF RECOVERY FOR PSYCHIATRISTS

Chair:

Mark Ragins, M.D.

#### :30 P.M. SESSIONS SCIENTIFIC AND CLINICAL REPORTS: SESSIONS 2-3

1:30 P.M.-3:00 P.M.

Room 236, Second Level, Morial Convention Center

#### MOOD DISORDERS



Chair:

Chadi Abdallah, M.D.

4. Significant Bipolar Risk Factors in Patients Presenting a Current Major Depressive Episode Charles Bowden, M.D.

J. Angst, Ph.D. J.M. Azorin, Ph.D. G. Perugi, M.D. E. Vieta, Ph.D. Allan H. Young, Ph.D.

5. The Prevalence and Clinical **Consequences of Concurrent** Hypertension in Patients with Bipolar Disorder Dale D'Mello, M.D.

6. Association of Medication Adherence with Therapeutic Alliance in Individuals with Bipolar Disorder Louisa G. Sylvia, Ph.D.

Aleena C. Hay, B.A. Andrew A. Nierenberg, M.D.



- Affective Disorders (Mood and Anxiety)
- Personality Disorders
- Psychopharmacology
- Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- NIDA
- DSM-5

Michael J. Ostacher, M.D., M.P.H. Thilo Deckersbach, Ph.D. David J. Miklowitz, Ph.D. Michael E. Thase, M.D. Gary S. Sachs, M.D. Roy H. Perlis, M.D., M.Sc.

#### SCR 3

1:30 P.M.-3:00 P.M.

Room 349, Third Level, Morial Convention Center

#### **PSYCHOPHARMACOLOGY**



Chair: TBD

- 7. Carcinogenesis of Psychopharmacological Treatments Prescribed in General Psychiatry: A Systematic Review Juan F. Galvez, M.D. Hussain Khrad, M.D., M.A. Hadani Gouta, M.D. S. Nassir Ghaemi, M.D., M.P.H.
- 8. Clozapine Treatment Causes Oxidation of Proteins Involved in Energy Metabolism in Lymphoblastoid Cells: Possible **Mechanism for Metabolic Alterations** Muhammad R. Baig, M.D., M.S.
- 9. Meta-Analysis of Placebo Response in Antipsychotic Trials Ofer Agid, M.D. Steven Potkin, M.D. Gary Remington, M.D. Shitij Kapur, M.D., Ph.D. Eric Watsky, M.D. Douglas Vanderburg, M.D., M.P.H., Cynthia Siu, Ph.D.

#### | WORKSHOPS 54-56 WORKSHOP 54

1:30 P.M.-3:00 P.M.

Room 237, Second Level, Morial Convention Center

MAKING THE MOST OF YOUR CHIEF YEAR: CHIEF RESIDENTS' FORUM, PART I



Rex W. Huang, M.D. Jonathan T. Horey, M.D.

#### **Presenters:**

Allison S. Baker, M.D. Laura K. Kent, M.D. Belinda S. Bandstra, M.D. Maor Katz, M.D.

#### WORKSHOP 55

1:30 P.M.-3:00 P.M. Room 333, Third Level, Morial Convention Center

**PROMOTING** International MEDICAL GRADUATES: PSYCHOSOCIAL SUPPORT **DURING RESIDENCY TRAINING** 

#### Co-Chairs:

Anu A. Matorin, M.D. Pedro Ruiz, M.D.

#### **Presenters:**

R. Rao Gogineni, M.D. Ashutosh Atri, M.D., M.S. Sadaf Islam, M.D. Ayesha Mian, M.D.

#### WORKSHOP 56

1:30 P.M.-3:00 P.M. Room 346, Third Level, Morial Convention Center

MAINTENANCE TREATMENT FOR OPIATE DEPENDENCE: TERMINABLE OR INTERMINABLE? National Institute on Drug Abuse

#### Co-Chairs:

Ivan D. Montoya, M.D., M.P.H. Herbert D. Kleber, M.D.

#### Presenters.

Kenzie L. Preston, Ph.D. Robert P. Schwartz, M.D. Steven L. Batki, M.D.



2:00 P.M.-3:30 P.M.

Rooms R04/R05, Second Level, Morial Convention Center

PATIENT VIOLENCE AGAINST MENTAL HEALTH CLINICIANS: SAFETY ASSESSMENT AND PREVENTION Manfred S. Guttmacher Award Lecture

Robert I. Simon, M.D. and Kenneth J. Tardiff, M.D., M.P.H.

#### Chair:

Marilyn Price, M.D., C.M.



Robert I. Simon, M.D., is a clinical professor of psychiatry and director of the Program in Psychiatry and Law at Georgetown

University School of Medicine. He is chair-elect of the Department of Psychiatry at Suburban Hospital, Johns Hopkins Medicine, and maintains a private practice in Potomac, MD. Dr. Simon is a Diplomate of the American Board of Psychiatry and Neurology with added qualifications in forensic psychiatry, and of the American Board of Forensic Psychiatry. He is a past president of the American Academy of Psychiatry and the Law. Dr. Simon is the author and editor of more than 20 books, 46 book chapters, and 80 articles regarding clinical and forensic psychiatry. Dr. Simon has received many honors for his teaching, research, and writing in the field of forensic psychiatry, including the Isaac Ray Award, the Seymour Pollack Award, and the Golden Apple Award. This is his third Manfred S. Guttmacher Award (1993, 2005, and 2010).

# BIO

Kenneth J. Tardiff, M.D., M.P.H., is professor of psychiatry and public health and attending psychiatrist at the Payne Whitney

Clinic, the New York Hospital—Cornell Medical Center, New York, where he is also past clinical director for the Department of Psychiatry. Dr. Tardiff was trained at the Massachusetts General Hospital and the Harvard School of Public Health. He has received research funding for decades and has published over 130 papers in peer-reviewed journals and over 75 books and book chapters on violence, suicide, psychopharmacology, and other topics in psychiatry. This is his second Manfred S. Guttmacher Award (1985 and 2010).

# SYMPOSIA 36-40

2:00 P.M.-5:00 P.M. Room 347, Third Level, Morial Convention Center

TREATING CHRONIC PAIN AND Co-Occurring Addiction in SUBSTANCE ABUSE PATIENTS National Institute on Drug Abuse



Richard A. Denisco, M.D., M.P.H. Will M. Aklin, Ph.D.

- 1. Why Do Some Patients Have Persistent Pain and Persistent Opioid Use Following Surgery? An Inception Cohort Study Ian R. Carroll, M.D., M.S. Peter Barelka, M.D. Charlie Kiat Meng Wang, B.S. Bing Mei Wang Rebecca McCue, B.A. Jarred Younger, Ph.D. Jodie Trafton, Ph.D. Keith Humphreys Stuart B. Goodman, M.D., Ph.D. Fredrick M. Dirbas, M.D. Richard I. Whyte, M.D., M.B.A. Jessica S. Donnington, M.D. Walter B. Cannon, M.D. Sean C. Mackey, M.D., Ph.D.
- 2. Clinical Aspects of Risk Management in Opioid Therapy Steve Passik, Ph.D.
- 3. Behavioral Treatment for **Co-Occurring Chronic** Pain and Opioid Addiction Declan Barry, Ph.D.
- 4. Results of the Prescription Opioid Addiction Treatment Study: A Multi-Site Trial of the NIDA Clinical Trials Network Roger D. Weiss, M.D. Jennifer Sharpe Potter, Ph.D. M.P.H. Petra Jacobs, M.D. Scott Provost, M.S.W. Pearl Zakroysky, B.A. Zhen Huang, M.S. Robert Lindblad, M.D. Walter Ling, M.D.
- 5. Overview of the Treatment of Acute and Chronic Pain in the Patient With a History of Addiction Sean Mackey, M.D., Ph.D.

#### SYMPOSIUM 37

2:00 P.M.-5:00 P.M. Room 348, Third Level, Morial Convention Center

CULTURALLY SENSITIVE TREATMENT OF PSYCHOLOGICALLY DISTRESSED ETHNIC AND NON-ENGLISH-SPEAKING POPULATIONS

#### Co-Chairs:

Devon Hinton, M.D., Ph.D. Roberto Lewis-Fernández, M.D.

1. Efficacy of a Culturally Adapted Parent-Training Program for **Ethnic Minority Families From Low-Income Communities** Esther J. Calzada, Ph.D.

- 2. Culturally Sensitive Treatment of Traumatized Refugees and Ethnic **Populations: Emotion Regulation** Therapy for PTSD Devon Hinton, M.D., Ph.D.
- 3. Psychosocial Treatments for Mexican Americans With Schizophrenia Alex Kopelowicz, M.D.
- 4. Using Culturally Adapted **Motivational Interviewing** to Improve Retention of Latino Outpatients in **Antidepressant Therapy** Roberto Lewis-Fernández, M.D.
- 5. Preventive Interventions for Refugee Families in Resettlement Stevan Weine, M.D.

#### SYMPOSIUM 38

2:00 P.M.-5:00 P.M. Room 350, Third Level, Morial Convention Center

NEUROENDOCRINE AND Neuroimmunological CORRELATES OF BIPOLAR DISORDER IN WOMEN

#### Co-Chairs:

Natalie L. Rasgon, M.D., Ph.D. Roger S. McIntyre, M.D.

- 1. Reproductive Endocrine **Function in Women With Bipolar Disorder and Control** Natalie L. Rasgon, M.D., Ph.D.
- 2. Should Bipolar Disorder Be Reclassified as Metabolic **Syndrome Type II?** Roger S. McIntyre, M.D.
- 3. Inflammatory and Oxidative Pathways in Mood Disorders: Novel Mechanisms and Therapeutic Opportunities Michael Berk, M.D., Ph.D.
- 4. Serum B<sub>12</sub> Levels and Thyroid Function in Bipolar Disorder: Is There a Gender Difference? Aysegul Ozerdem, M.D.

#### SYMPOSIUM 39

2:00 P.M.-4:00 P.M.

Room 351, Third Level, Morial Convention Center

THE MEDICAL HOME: Is There a Place for PSYCHIATRY IN IT? APA Council on Children, Adolescents & Their Families

#### Chair:

Eliot Sorel, M.D.

- 1. A Primary Care Perspective Frank Degruy, M.D.
- 2. The Pediatric Medical Home: Where Does the Child and Adolescent Psychiatrist Fit In? Michael Houston, M.D.
- 3. Psychiatry and Primary Care Integration: Challenges and Opportunities Eliot Sorel, M.D.

#### SYMPOSIUM 40

2:00 P.M.-4:00 P.M.

Room 353, Third Level, Morial Convention Center

#### PRIVACY IN ELECTRONIC MEDICAL RECORDS

#### Co-Chairs:

Zebulon Taintor, M.D. Laura J. Fochtmann, M.D.

#### Discussant:

Edward Pontius, M.D.

- 1. Privacy Violations and Consequences Zebulon Taintor, M.D.
- 2. Privacy and Control in **Health Information Exchanges:** More Than an Illusion? Glenn A. Martin, M.D.
- 3. The Perspective of Family Members on Privacy in **Electronic Medical Records** Edward F. Foulks, M.D.
- 4. Health IT and Privacy: Critical Pathways to **Improving Mental Health Care** Deven C. McGraw, J.D., M.P.H.
- 5. General Medical Views of Electronic Medical Record Privacy Laura J. Fochtmann, M.D.

#### SESSIONS SCIENTIFIC AND CLINICAL REPORTS: SESSIONS 4-5

#### 3:30 P.M.-5:00 P.M.

Room 236, Second Level, Morial Convention Center

#### CHILD AND ADOLESCENT PSYCHIATRY

#### Chair:

TBD

10. School-Based Intervention for **K**—Second Graders Presenting With Disruptive Behavior Jacob Venter, M.D. Linda Wiskerchen, M.S.W.

- Melissa Shaw, M.A. Alicia Ledesma, M.A. Sara DeSimone, M.S.W. Anne Marie Cardinal, M.S.W.
- 11. Clinical Predictors of Cardiometabolic Risk in Children Treated With Antipsychotic Medications John W. Newcomer, M.D. G.E. Nicol, M.D. M.D. Yingling, B.S.
- 12. Prevalence of Mental Illness and Substance Abuse Among Child and **Adolescent Suicide Victims** Yilmaz Yildirim, M.D. Ummuhan Yesil-Dagli, Ph.D. Richard Bloch, Ph.D.

#### SCR 5

3:30 P.M.-5:00 P.M. Room 349, Third Level, Morial Convention Center

**PSYCHOSOMATIC** MEDICINE AND HEALTH SERVICES RESEARCH

Josephine Mokonogho, M.D.

- 13. Psychiatric Vital Signs Mark Zimmerman, M.D. Diane Young, Ph.D. Iwona Chelminski, Ph.D. Kristy Dalrymple, Ph.D. Janine Galione, B.S.
- 14. Characteristics of Delirium in the Severely Medically Ill **Cancer Population** Soenke Boettger, M.D. Steven Passik, Ph.D. William Breitbart, M.D.
- 15. Pilot of Measurement-Based Care for Depression in an **HIV Outpatient Clinic** Julie Adams, M.D. R. Scott Pollard, L.C.S.W. Kristen G. Shirey, M.D. Brian W. Pence, Ph.D.

# WORKSHOPS 57-58 WORKSHOP 57

3:30 P.M.- 5:00 P.M. Room 237, Second Level, Morial Convention Center

MAKING THE MOST **OF YOUR CHIEF YEAR:** CHIEF RESIDENTS' FORUM, PART II

#### Co-Chairs:

Rex W. Huang, M.D. Jonathan T. Horey, M.D.





Allison S. Baker, M.D. Laura K. Kent, M.D. Belinda S. Bandstra, M.D. Maor Katz, M.D.

#### WORKSHOP 58

3:30 P.M.- 5:00 P.M. Room 346, Third Level, Morial Convention Center

**PPHARMACOLOGICAL** APPROACHES TO AUTISM SPECTRUM DISORDERS FOR CLINICIANS



Chair:

Christopher J. McDougle, M.D.

# OPENING SESSION

4:30 P.M.-5:45 P.M. Hall A, First Level, Morial Convention Center

CALL TO ORDER

Alan F. Schatzberg, M.D. President, American Psychiatric Association

Introduction of STAGE GUESTS

Introduction of SCIENTIFIC PROGRAM **COMMITTEE** 

Julio Licinio, M.D. Donald Hilty, M.D. Co-Chairs, Scientific Program Committee

Introduction of VISITING DIGNITARIES

PRESIDENTIAL ADDRESS

Alan F. Schatzberg, M.D. Introduced by David J. Kupfer, M.D.

RESPONSE FROM THE PRESIDENT-ELECT

Carol A. Bernstein, M.D. Introduced by Carol C. Nadelson, M.D.

ADJOURNMENT

#### 6:00 P.M. SESSION MIND GAMES

6:00 P.M.-7:00 P.M.

Rooms 343-345, Third Level, Morial Convention Center

**Moderator:** Glen O. Gabbard, M.D.

MindGames is a national team competition for residents that tests the depth and breadth of their knowledge of psychiatry. This final round pits the three

top-scoring residency programs

#### Finalists for the 2010 Championship:

Boston University Medical Center

against each other.

- Brown University (Butler Hospital)
- Carilion Clinic-Virginia Tech School of Medicine

#### 7:00 P.M. SESSIONS

MEDIA WORKSHOP 2

7:00 P.M.-10:00 P.M. Grand Salon B, First Level, Hilton New Orleans Riverside

VOICING THE UNSPEAKABLE: REFLECTIONS ON, AND DISCUSSION ABOUT, OVERCOMING LOSS BY SUICIDE

Chair:

Sally Heckel, B.A., M.F.A.

**Presenters:** 

Michael F. Myers, M.D. Carla Fine, M.S.



163rd Annual Meeting | American Psychiatric Association

# **FISHER**

# DON'T MISS THIS YEAR'S **CONVOCATION SPEAKER!**

The Convocation will take place on Monday, May 24, 2010 in Hall A, Level One, Morial Convention Center, 5:30-6:30, p.m.

- Recognized for her role as Princess Leia in Star Wars and the sequels.
- Just completed a major run of her hit autobiographical one-woman show, Wishful Drinking.
- She is also a leading mental health advocate.

# MONDAY

Program changes are printed each day in the Daily Bulletin. You can pick up the **Daily Bulletin** in Exhibit Halls B/C, First Level, Morial Convention Center and at many other locations throughout the convention center

#### 8:00 A.M. SESSIONS COURSES 41-48

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C, First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

#### COURSE 41

8:00 A.M.-NOON Bayside Room B, Fourth Floor, Sheraton New Orleans

SHORT-TERM **PSYCHODYNAMIC** SUPPORTIVE **PSYCHOTHERAPY** FOR DEPRESSION



**Co-Directors:** 

Henricus Van, M.D. Frans F. De Jonghe, M.D., Ph.D.

#### Faculty:

Simone S. Kool, M.D., Ph.D. Annemieke A. Noteboom, M.S.C. Mariëlle M. Hendriksen, M.A. Jack Dekker, M.S.C., Ph.D.

#### COURSE 42

8:00 A.M.-NOON

Bayside Room C, Fourth Floor. Sheraton New Orleans

EXPLORING **TECHNOLOGIES** IN PSYCHIATRY

American Association for *Technology in Psychiatry* 

**Co-Directors:** 

Robert S. Kennedy, M.A. John Luo, M.D.

Faculty: Carlyle H. Chan, M.D.

#### COURSE 43

8:00 A.M.-NOON

Nottoway Room, Fourth Floor, Sheraton New Orleans

**PSYCHIATRIC** CONSULTATION IN LONG-TERM CARE: ADVANCED COURSE

**Co-Directors:** 

Abhilash K. Desai, M.D. George T. Grossberg, M.D.

#### COURSE 44

8:00 A.M.-NOON

Grand Ballroom A, Fifth Floor, Sheraton New Orleans

STREET DRUGS AND MENTAL DISORDERS: OVERVIEW AND TREATMENT OF DUAL **DIAGNOSIS PATIENTS** 

**Director:** 

John W. Tsuang, M.D.

**Faculty:** 

Todd Zorick, M.D., Ph.D. Stephen Ross, M.D. Sara Dhand, M.D.

#### COURSE 45

8:00 A.M.-NOON Grand Ballroom B, Fifth Floor,

Sheraton New Orleans

THE DETECTION OF MALINGERED MENTAL ILLNESS

**Director:** 

Phillip J. Resnick, M.D.

#### COURSE 46

8:00 A.M.-NOON

Grand Ballroom D, Fifth Floor, Sheraton New Orleans

ADVANCES IN NEUROPSYCHIATRY: THE NEUROPSYCHIATRY OF EMOTION AND ITS DISORDERS

#### SESSION TRACKS

- Affective Disorders (Mood and Anxiety)
- Personality Disorders
- Psychopharmacology
- Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- NIDA
- DSM-5

#### **Co-Directors:**

C. Edward Coffey, M.D. Randolph B. Schiffer, M.D.

Robert G. Robinson, M.D. Matthew A. Menza, M.D. Michael Trimble, M.D.

#### COURSE 47

8:00 A.M.-NOON

Salons 825/829, Eighth Floor, Sheraton New Orleans

TREATING MEDICAL STUDENTS AND PHYSICIANS

**Co-Directors:** 

Michael F. Myers, M.D. Leah J. Dickstein, M.D., M.A.

Faculty:

Penelope Ziegler, M.D.

#### COURSE 48

8:00 A.M.-NOON

Salons 816/820, Eighth Floor, Sheraton New Orleans

CULTURALLY APPROPRIATE ASSESSMENT MADE **INCREDIBLY CLEAR:** A SKILLS-BASED COURSE WITH HANDS-ON EXPERIENCES

Director:

Russell F. Lim, M.D.

Faculty:

Francis Lu, M.D. Anita S. Ramanathan, M.D.

#### 9:00 A.M. SESSIONS ADVANCES IN MEDICINE 1

9:00 A.M.-10:30 A.M.

Rooms 217-219, Second Level, Morial Convention Center

DELIRIUM: NEUROBIOLOGY, PREVENTION AND TREATMENT APPROACHES

Jose R. Maldonado, M.D.

#### FOCUS LIVE 1

9:00 A.M.-10:30 A.M.

Rooms 343-345, Third Level, Morial Convention Center

PSYCHOTHERAPY



Presented by:

Priyanthy Weerasekera, M.D., M.Ed.

**Moderators:** 

Deborah J. Hales, M.D. Mark H. Rapaport, M.D.



A.M.



# LECTURES 4-5

#### 9:00 A.M.-10:30 A.M.

La Louisiane Rooms A/B, First Level, Morial Convention Center

#### WHY I TEACH

APA/NIMH Vestermark Award Lecture

Glen O. Gabbard, M.D.

#### Co-Chairs:

Frederick G. Guggenheim, M.D. David Goldberg, M.D.



Glen O. Gabbard, M.D., is the Brown Foundation Chair of Psychoanalysis and a professor of psychiatry at Baylor College of Medicine in Houston, Tx. He

is the former joint editor-in-chief of the International Journal of Psychoanalysis and a former Associate Editor of American Journal of Psychiatry. He is the author or editor of 22 books, including *Psychodynamic Psychiatry* in Clinical Practice: 4th Edition, Gabbard's Treatments of Psychiatric Disorders: 4th Edition, and The American Psychiatric Publishing Textbook of Psychotherapeutic *Treatments.* He is the author of 290 papers and book chapters and has received numerous honors. These include the 2000 Mary Sigourney Award for outstanding contributions to psychoanalysis, the 2004 American Psychiatric Association Adolf Meyer Award, and the 2008 Cornell-Westchester Borderline Personality Disorder Resource Center Award for distinguished contributions to the field of severe personality disorders.

#### LECTURE 5

#### 9:00 A.M.-10:30 A.M.

Rooms 353-355, Third Level, Morial Convention Center

THE PERPLEXITIES AND PROVOCATIONS OF EATING DISORDERS Distinguished Psychiatrist Lecture

Katherine A. Halmi, M.D.

#### Chair:

Barton Blinder, M.D.

# NEW RESEARCH/ YOUNG INVESTIGATORS POSTER SESSION 1

#### 9:00 A.M.-10:30 A.M.

La Louisiane C, First Level, Morial Convention Center

> For further information on New Research/Young Investigator submissions please refer to the New Research Program section in the back of this book.

#### IENTIFIC AND CLINICAL REPORTS: SESSIONS 6-7

#### 9:00 A.M.-10:30 A.M.

Rooms 228-229, Second Floor, Morial Convention Center

#### PSYCHOTHERAPY AND DEPRESSION

#### Chair:

Dilipkumar Patel, M.D.

- 16. Short-Term Psychodynamic **Psychotherapy Versus Pharmacotherapy Versus** Pill Placebo for Major Depressive Disorder in an Urban, Disadvantaged Sample Jacques P. Barber, Ph.D. Marna S. Barrett, Ph.D. Robert Gallop, Ph.D. Moira Rynn, M.D. Karl Rickels, M.D.
- 17. Sudden Gains in Supportive-Expressive Psychotherapy in Depression: A Replication and Extension Dahlia Mukherjee, M.A. Jacques P. Barber, Ph.D.
- 18. The Relation of Specific, Common, and Unintended **Factors to Outcome** in Psychodynamic Therapy for Depression



**Dr. Halmi** is board certified in both pediatrics and psychiatry. She began her eating disorder research career while on the faculty in the Department of Psychiatry at the University of Iowa and later moved to Cornell University Medical College and The New York Hospital: Westchester Division in 1979. She established a clinical research and treatment program for eating disorders and is a professor of psychiatry at Cornell. Dr. Halmi is a past president of the American Psychopathological Association, past president of the Society of Biological Psychiatry, past president of

Psychiatric Research Society, and past president of Eating Disorder Research Society. Dr. Halmi is conducting a multicenter family therapy study on the treatment of adolescent anorexia nervosa. She is also part of a multicenter genetic study of eating disorders.

Kevin S. McCarthy, M.A. Jacques P. Barber, Ph.D.

#### SCR 7

9:00 A.M.-10:30 A.M.

Room R01, Second Level, Morial Convention Center

BORDERLINE PERSONALITY DISORDER AND EMOTION **Dysregulation** 

#### Chairs:

Derya Iren Akbiyik, M.D. Sukriti Mittal, M.D.

19. Neural Sensitization as a Possible Mechanism of Emotional Reactivity: A Comparison of Borderline and Avoidant Personality **Disorder Patients and Healthy Control Subjects** Harold W. Koenigsberg, M.D. Jin Fan, Ph.D. Xun Liu, Ph.D. Kevin Guise Kevin Ochsner, Ph.D. Stephanie Guerreri Antonia S. New, M.D. Marianne Goodman, M.D. Larry J. Siever, M.D.

20. Short- Versus Long-Term **Dialectical Behavior Therapy for Patients** With Borderline **Personality Disorder: Predictors of** Response and **Elements of Choice** Nader Perroud, M.D. Huguelet Philippe, M.D.

21. Dysregulated Brain Networks in the **Cognitive Control** of Emotion in **Borderline Personality** Disorder: An fMRI Study Harold W. Koenigsberg, M.D. Jin Fan, Ph.D. Kevin Ochsner, Ph.D. Xun Liu, Ph.D. Scott Pizzarello Kevin Guise Stephanie Guerreri Lucia Tecuta Antonia S. New, M.D. Marianne Goodman, M.D. Larry J. Siever, M.D.

#### SMALL INTERACTIVE SESSIONS 1-4

These sessions are limited to 50 participants on a first-come first-served basis.





#### SI 1

9:00 A.M.-10:30 A.M. Room 236, Second Level, Morial Convention Center

#### DIAGNOSIS AND EVIDENCE-BASED TREATMENT OF BIPOLAR DISORDER



Chair

Terence A. Ketter, M.D.

9:00 A.M.-10:30 A.M.

Room 237, Second Level, Morial Convention Center

SUCCESSFUL COGNITIVE AND EMOTIONAL AGING: How can We get There?

Chair:

Dilip V. Jeste, M.D.

9:00 A.M.-10:30 A.M.

Room 336, Third Level, Morial Convention Center

THE CRISIS OF ACCESS TO PSYCHIATRISTS IN AN ERA OF HEALTH REFORM

Chair:

Steven S. Sharfstein, M.D.

#### SI 4

9:00 A.M.-10:30 A.M.

Room 337, Third Level, Morial Convention Center

SUICIDE AND SUICIDE RISK ASSESSMENT: PRACTICAL INFORMATION AND APPLICATION

Timothy Lineberry, M.D.

# WORKSHOPS 59-71 WORKSHOP 59

9:00 A.M.-10:30 A.M.

Room 210, Second Level, Morial Convention Center

PSYCHOLOGICAL ASPECTS OF BIOLOGIC, CHEMICAL, AND NUCLEAR TERRORISM

Chair:

M. Caroline Burton, M.D.

#### WORKSHOP 60

9:00 A.M.-10:30 A.M. Room 223, Second Level, Morial Convention Center

Interviewing Patients Who Hate or Fear **PSYCHIATRISTS** 

#### Chair:

James L. Griffith, M.D.

#### WORKSHOP 61

9:00 A.M.-10:30 A.M. Room 224, Second Level, Morial Convention Center

PATIENTS AS PRACTICE **PARTNERS: CATALYZING** RECOVERY THROUGH COLLABORATION

Peter F. Buckley, M.D.

**Presenters:** 

Gareth Fenley, M.S.W. P. Alex Mabe, Ph.D.

#### WORKSHOP 62

9:00 A.M.-10:30 A.M.

Rooms 225/226, Second Level, Morial Convention Center

DISASTER PREPAREDNESS, **EVACUATION AND REBUILDING:** LESSONS LEARNED FROM KATRINA APPLIED TO GUSTAV AND IKE

Erich J. Conrad, M.D.

#### **Presenters:**

Howard J. Osofsky, M.D., Ph.D. Mark H. Townsend, M.D., M.S. Ruth E. Levine, M.D.

#### WORKSHOP 63

9:00 A.M.-10:30 A.M. Room 227, Second Level, Morial Convention Center

THE EXPLOSION OF SOCIAL MEDIA: Why, Where, When AND HOW CAN **PSYCHIATRISTS CATCH UP WITH** THE TREND? APA Council on

Communications

Gabriella Cora, M.D., M.B.A.

#### **Presenters:**

Roberto A. Blanco, M.D. Gariane Gunter, M.D. Felicia K. Wong, M.D.

#### WORKSHOP 64

9:00 A.M.-10:30 A.M.

Room 230, Second Level, Morial Convention Center

TREATING THE AGGRESSIVE CHILD AND TEEN: INTEGRATED TECHNIQUES FOR MANAGEMENT AND INTERVENTION

#### Co-Chairs:

Niranjan S. Karnik, M.D., Ph.D. Hans Steiner, M.D.

#### WORKSHOP 65

9:00 A.M.-10:30 A.M. Room 235, Second Level, Morial Convention Center

**GUIDED SELF-HELP:** A NEW INTERVENTION TO OVERCOME ANXIETY **COMPLAINTS** 



Chair:

Christine A. Van Boeijen, M.D., Ph.D.

#### WORKSHOP 66

9:00 A.M.-10:30 A.M.

Room 335, Third Level, Morial Convention Center

PREVENTING LATE-LIFE SEQUELAE RESULTING FROM EARLY-LIFE TRAUMA



Erikka Dzirasa, M.D., M.P.H.

**Presenters:** 

Joy D. Osofsky, Ph.D. Stacy S. Drury, M.D., Ph.D. Charles Zeanah, M.D.

#### WORKSHOP 67

9:00 A.M.-10:30 A.M. Rooms 340/341, Third Level, Morial Convention Center

BEHAVIORAL COMPLICATIONS OF DEMENTIA: A COMPREHENSIVE MULTIDISCIPLINARY TREATMENT APPROACH

Chair:

Sanjay Vaswani, M.D.

**Presenters:** 

Amita R. Patel, M.D.

#### WORKSHOP 68

9:00 A.M.-10:30 A.M.

Room 342, Third Level, Morial Convention Center

CORE COMPETENCIES AND Maintenance of Competency IN EUROPE AND THE UNITED STATES OF AMERICA: AN EDUCATIONAL MODEL

Co-Chairs:

Pedro Ruiz, M.D. Deborah J. Hales, M.D.

#### **Presenters:**

Cyril Hoschl, M.D., D.Sc. Livia Vavrusova, M.D., Ph.D. Michael Musalek, M.D. Wolfgang Gaebel, M.D.





#### WORKSHOP 69

9:00 A.M.-10:30 A.M. Rooms 346/347, Third Level, Morial Convention Center WRITING FOR THE BLUE JOURNAL: THE RESIDENTS' AND FELLOWS' **EDITION OF THE AMERICAN** JOURNAL OF PSYCHIATRY

#### Chair:

Robert Freedman, M.D.

#### WORKSHOP 70

9:00 A.M.-10:30 A.M.

Rooms 348/349, Third Level, Morial Convention Center

A RESIDENT'S GUIDE TO BORDERLINE PERSONALITY DISORDER FROM THE EXPERTS: PART I For Residents Only



Chair:

John G. Gunderson, M.D.

#### **Presenters:**

Kenneth R. Silk, M.D. Perry D. Hoffman, Ph.D. John M. Oldham, M.D., M.S. Brian A. Palmer, M.D., M.P.H. James Hall, B.S.

#### WORKSHOP 71

9:00 A.M.-10:30 A.M. Rooms 350/351, Third Level, Morial Convention Center

"IF PATIENTS GOOGLE ME, WHAT WILL THEY FIND?"-THE INFORMATION AGE AND ITS IMPACT ON RESIDENCY TRAINING

#### Co-Chairs:

Donald M. Hilty, M.D. Deborah Cabaniss, M.D.

#### **Presenters:**

Allan S. Kaplan, M.D. Carol A. Bernstein, M.D. Leah J. Dickstein, M.D., M.A. Edward K. Silberman, M.D.

# ADVANCES IN SERIES 1-2

#### 9:00 A.M.-NOON

Rooms 238-239, Second Level, Morial Convention Center

ADVANCES IN CORRECTIONAL **PSYCHIATRY: FROM PROVISION** OF CARE TO MALPRACTICE PREVENTION

Charles Scott, M.D.

1. Conducting Mental Health **Assessments in Correctional Settings** Humberto D. Temporini, M.D.

- 2. Continuous Quality Improvement and Documentation Amanda Ruiz, M.D.
- 3. Juvenile Offenders and **Correctional Mental Health** Christopher Thompson, M.D.
- 4. Legal Issues Regarding the Provision of Care in a Correctional Setting Charles Scott, M.D.
- 5. Managing the Disruptive or Aggressive Inmate Robert L. Trestman, M.D.
- 6. Supermax Units and Death Row James Knoll, M.D.

#### ADVANCES IN SERIES 2

9:00 A.M.-NOON

Rooms R06-R09, Second Level, Morial Convention Center

#### ADVANCES IN PSYCHOSOMATIC MEDICINE



James L. Levenson, M.D.

- 1. Psychiatric Issues in the Care of Obstetric and **Gynecologic Patients** Donna E. Stewart, M.D.
- 2. Legal Issues at the Interface of Psychiatry and Medicine Rebecca W. Brendel, M.D., J.D.
- 3. Psychiatric Issues in Pain Management Michael R. Clark, M.D., M.P.H.
- 4. Psychopharmacology in the Medically Ill James L. Levenson, M.D.
- 5. Psychosis, Mania, and Catatonia in the Medically Ill Oliver Freudenreich, M.D.

#### CASE CONFERENCE 1

9:00 A.M.-10:30 A.M.

Room 338/339, Third Level, Morial Convention Center

This session is open to APA members only. Blue registration badge or APA membership card required for admittance.

#### PTSD AND THE AMERICAN SOLDIER TODAY



Col. Elspeth C. Ritchie, M.D., M.P.H.

#### **Presenters:**

Col. John Bradley, M.D. Lt. Col. Brett Schneider, M.D. Maj. Scott Moran, M.D.

#### PRESIDENTIAL SYMPOSIUM 2

9:00 A.M.-NOON

Room 352, Third Level, Morial Convention Center

COMPARATIVE EFFECTIVENESS OF PSYCHOTROPIC DRUGS: WHAT CAN WE LEARN FROM PRACTICAL **CLINICAL TRIALS?** 



Jeffrey A. Lieberman, M.D.

- 1. Bipolar Affective Disorder: Lithium **Anticonvulsant Comparative** Evaluation(BALANCE): An International, Open-Label **Randomized Clinical Trial** John Geddes, M.D.
- 2. Effectiveness of Treatment **Strategies for Depression** Madhukar H. Trivedi, M.D.
- 3. Lithium Moderate-Dose Study (LiTMUS): A Practical Clinical Trial for Bipolar Disorder Andrew A. Nierenberg, M.D.
- 4. Practical Clinical Trials in Schizophrenia T. Scott Stroups, M.D.
- 5. Practical Clinical Trials in Child and Adolescent Psychiatry John Walkup, M.D. John S. March, M.D.
- 6. The FDA's Perspective on Comparative Efficacy and Safety Jing Zhang, M.D.

# SYMPOSIA 41-42 SYMPOSIUM 41

#### 9:00 A.M.-NOON

Rooms 333/334, Third Level, Morial Convention Center

HEALTH AND MENTAL HEALTH AROUND THE WORLD: ARE ALL SYSTEMS GO?

#### Co-Chairs:

Gisèle Apter, M.D., Ph.D. Nada L. Stotland, M.D., M.P.H.

- 1. The Canadian Health Care **System: Pros and Cons** Gail E. Robinson, M.D.
- 2. The Swiss Health System: Private Insurance and Solidarity Are Possible Olivier Halfon, M.D.





A.M.


- 3. The French System: "Health Security" for All? Gisèle Apter, M.D., Ph.D.
- 4. Mental Health Care in the United Kingdom Dinesh Bhugra, M.B.B.S., Ph.D.

#### SYMPOSIUM 42

9:00 A.M.-NOON

Rooms 356/357, Third Level, Morial Convention Center

UPDATE ON MEDICATIONS **DEVELOPMENT: PROMISING** NEW TREATMENTS FOR



Co-Chairs:

Nora D. Volkow, M.D. David J. McCann, Ph.D.

Discussant:

Herbert D. Kleber, M.D.

- 1. Modafinil as a Novel Medication in the Treatment of Cocaine Addiction Charles P. O'Brien, M.D., Ph.D. Charles Dackis, M.D. Kyle Kampman, M.D.
- 2. D-Cycloserine in the Treatment of Cocaine and Nicotine Dependence Kathleen Brady, M.D., Ph.D. Kimber Price, Ph.D. Aimee McRae, Pharm.D. Mike Saladin, Ph.D.
- 3. Bupropion for the Treatment of **Methamphetamine Addiction** David J. McCann, Ph.D. Shou-Hua Li, Ph.D. Ahmed M. Elkashef, M.D.
- 4. Dronabinol for Cannabis **Addiction Treatment** Frances R. Levin, M.D.
- 5. NicVAX: An Innovative Vaccine Treatment for Nicotine Addiction Raafat Fahim, Ph.D.

#### COURSES 49-56

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C, First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

#### COURSE 49

9:00 A.M.-4:00 P.M.

Borgne Room, Third Floor, Sheraton New Orleans

**COGNITIVE-BEHAVIOR** THERAPY FOR SEVERE MENTAL ILLNESS





**Director:** 

Jesse H. Wright, M.D., Ph.D.

**Faculty:** 

Douglas Turkington, M.D. Michael E. Thase, M.D. David G. Kingdon, M.D.

#### COURSE 50

9:00 A.M.-4:00 P.M.

Bayside Room A, Fourth Floor, Sheraton New Orleans

BASIC CONCEPTS IN Administrative Psychiatry II

American Association of Psychiatric Administrators

**Co-Directors:** 

Douglas M. Brandt, M.D. Barry K. Herman, M.D.

**Faculty:** 

Alan Axelson, M.D. Arthur L. Lazarus, M.D., M.B.A. Ieri Davis, M.B.A. William H. Reid, M.D., M.P.H. Robert M. Atkins, M.D., M.P.H.

#### COURSE 51

9:00 A.M.-4:00 P.M.

Gallier Rooms A/B, Fourth Floor, Sheraton New Orleans

SEEING THE FOREST AND THE TREES: AN APPROACH TO BIOPSYCHOSOCIAL FORMULATION

Director:

William H. Campbell, M.D., M.B.A.

#### COURSE 52

9:00 A.M.-4:00 P.M.

Oak Alley Room, Fourth Floor, Sheraton New Orleans

TRAUMATIC BRAIN INIURY: NEUROPSYCHIATRIC ASSESSMENT

American Academy of Psychiatry & Law

**Director:** 

Robert P. Granacher, M.D., M.B.A.

#### COURSE 53

9:00 A.M.-4:00 P.M.

This course has been moved to Tuesday at 9:00 a.m.

ADULT SEXUAL LOVE AND INFIDELITY

Chair:

Stephen B. Levine, M.D.



SESSION TRACKS

- Affective Disorders (Mood and Anxiety)
- Personality Disorders
- Psychopharmacology
- Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- NIDA
- DSM-5

#### COURSE 54

9:00 A.M.-4:00 P.M.

Grand Couteau Room, Fifth Floor, Sheraton New Orleans

A PSYCHODYNAMIC APPROACH TO TREATMENT-RESISTANT MOOD **DISORDERS: BREAKING** THROUGH COMPLEX COMORBID TREATMENT RESISTANCE BY Focusing on Axis I



Director:

Eric M. Plakun, M.D.

Faculty:

Edward R. Shapiro, M.D., M.A. David L. Mintz, M.D.

#### COURSE 55

9:00 A.M.-4:00 P.M.

Salons 817/821, Eighth Floor, Sheraton New Orleans

IMPROVING PSYCHOTHERAPY EFFECTIVENESS: MAKING THERAPEUTIC USE OF Countertransference AND MENTALIZING



Director:

Paula Ravitz, M.D.

Faculty:

Jon J. Hunter, M.D. Clare Pain, M.D.

#### COURSE 56

9:00 A.M.-4:00 P.M

Cornet Room, Eighth Floor, Sheraton New Orleans

DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC PSYCHOTHERAPY IN CLINICAL PRACTICE

Director:

James Q. Schubmehl, M.D.

#### 10:00 A.M.-4:00 P.M.

Exhibit Hall, APA Member Center and Publishers' Book Fair Are Open

Exhibit Halls B-D, First Level, Morial Convention Center

#### 10:30 A.M. SESSIONS ADVANCES IN RESEARCH 1

10:30 A.M.-12:30 P.M.

Rooms R02-R05, Second Level, Morial Convention Center

ADVANCES IN RESEARCH





#### Chair:

Herbert Pardes, M.D.

- 1. Update on Clinical Research in Schizophrenia Stephen R. Marder M.D.
- 2. The Search for Brain-Based Biomarkers of Childhood **Psychiatric Disorders** Bradley S. Peterson M.D.
- 3. Fear and Anxiety: Neurocircuitry and Genetics Kerry Ressler M.D., Ph.D.
- 4. Research Advances and the **Treatment of Mood Disorders** Jerrold F. Rosenbaum M.D.

#### 11:00 A.M. SESSIONS ADVANCES IN MEDICINE 2

11:00 A.M.-12:30 P.M.

Rooms 217-219, Second Level, Morial Convention Center

TOP 10 MEDICAL ARTICLES OF 2009: A COMPREHENSIVE AND PRACTICAL REVIEW OF WHAT WE NEED TO KNOW

Chair:

Monique Yohanan, M.D.

#### FOCUS LIVE 2

11:00 A.M.-12:30 P.M.

Rooms 343-345, Third Level, Morial Convention Center

**GENETICS AND GENOMICS** 

Presented by:

Michele T. Pato, M.D. Carlos N. Pato, M.D.

**Moderators:** 

Deborah I. Hales, M.D. Mark H. Rapaport, M.D.

# FORUMS 1-2

11:00 A.M.-12:30 P.M.

Rooms 220-222, Second Level, Morial Convention Center

CHOPIN AT 200: HIS MIND AND His Music

Chair: Richard Kogan, M.D.

#### FORUM 2

11:00 A.M.-12:30 P.M.

Room 224, Second Level, Morial Convention Center

DSM-5: PROGRESS IN RESEARCH AND DEVELOPMENT

David J. Kupfer, M.D.

#### **Presenters:**

Darrel A. Regier, M.D., M.P.H. Lawson R. Wulsin, M.D. Jack D. Burke, M.D., M.P.H. Geoffrey M. Reed, Ph.D. Jane S. Paulsen, Ph.D.

# LECTURES 6-7

11:00 A.M.-12:30 P.M.

La Louisiane Rooms A/B, First Level, Morial Convention Center

**OPTOGENETICS:** DEVELOPMENT AND APPLICATION

Frontiers of Science Lecture National Institute on Drug Abuse

Karl Deisseroth, M.D., Ph.D.

Chair:

Mark George, M.D.



Karl Deisseroth, M.D., Ph.D., is an associate professor of bioengineering and psychiatry at Stanford University. Dr. Deisseroth received

his bachelor's degree from Harvard in 1992, his Ph.D. from Stanford in 1998, and his M.D. from Stanford in 2000. He completed postdoctoral training, medical internship, and adult psychiatry residency at Stanford, and he was board certified by the American Board of Psychiatry and Neurology in 2006. He is a faculty member in the Bioengineering and Psychiatry Departments at Stanford as well as in the interdisciplinary Bio-X and Neurosciences Programs.

#### LECTURE 7

11:00 A.M.-12:30 P.M.

Rooms 353-355, Third Level, Morial Convention Center

NEUROIMAGING CLUE TO THE CAUSES OF BIPOLAR DISORDER: WHERE WE ARE AND WHERE We're Going Distinguished Psychiatrist Lecture

Stephen M. Strakowski, M.D.

Chair:

Josephine Mokonogho, M.D.



Stephen M. Strakowski, M.D., is the Dr. Stanley and Mickey Kaplan Professor and Chair of Psychiatry at the University of Cincinnati,

College of Medicine, and the chief of psychiatry at University Hospital. He is also the director of the Center for Imaging Research, a core human research MRI center for the university. He completed his residency training at McLean Hospital/Harvard University School of Medicine in 1992. Upon completing residency, he moved to the University of Cincinnati. Dr. Strakowski has received a number of awards, most notably the Gerald L. Klerman Award from the NDMDA and the Best Doctors in America for a number of years. He has written over 200 peer-reviewed publications and a number of chapters, published abstracts, and solicited reviews. He serves on several editorial boards and as the field editor for Neuroimaging for Bipolar Disorders.





### SCIENTIFIC AND CLINICAL REPORTS: SESSION 8

11:00 A.M.-12:30 P.M.

Rooms 228/229, Second Floor, Morial Convention Center

BORDERLINE PERSONALITY DISORDER

Chair

Derya Iren Akbiyik, M.D.

22. Gender Differences in the Development of Borderline **Personality Disorder** Uday Patil, M.A. Joseph Triebwasser, M.D. Marianne Goodman, M.D.



A.M.

- 23. Recurrent Suicide Attempts and Medical Lethality in Borderline **Personality Disorder** Paul H. Soloff, M.D.
- 24. Time-to-Attainment of Recovery From Borderline Personality Disorder and Its Stability: A Ten-Year Prospective Follow-Up Study Mary C. Zanarini, Ed.D. Frances R. Frankenburg, M.D. D. Bradford Reich, M.D. Garrett Fitzmaurice, Sc.D.

#### SCR 9

11:00 A.M.-12:30 P.M.

Room R01, Second Level, Morial Convention Center

#### CHILDHOOD ABUSE

#### Chair

Prakash Chandra, M.D.

- 25. Clinical Phenomenology of Childhood Abuse-Related **Complex PTSD Patients: Differential Patterns** of Personality Disturbance Ethy E. Dorrepaal, M.D. Kathleen K. Thomaes, M.D. Johannes H. Smit, Ph.D. Adriaan W. Hoogendoorn, Ph.D. Dick J. Veltman, M.D., Ph.D. Anton J.L.M. van Balkom, M.D., Ph.D. Nel Draijer, Ph.D.
- 26. Effect of Cognitive Behavioral **Stabilizing Group Treatment on** Brain Activity in Childhood Abuse-Related Complex PTSD Patients Kathleen K. Thomaes, M.D. Ethy E. Dorrepaal, M.D. Nel Draijer, Ph.D. Michiel B. de Ruiter, Ph.D. Bernet M. Elzinga, Ph.D. Johannes H. Smit, Ph.D. Anton J.L.M. van Balkom, M.D., Ph.D. Dick J. Veltman, M.D., Ph.D.
- 27. Childhood Maltreatment in Women With Binge-Eating **Disorder: Associations With** Psychiatric Comorbidity, Psychological Functioning, and Eating Pathology Daniel F. Becker, M.D. Carlos M. Grilo, Ph.D.

#### SMALL INTERACTIVE SESSIONS 5-8

These sessions are limited to 50 participants on a first-come, first-served basis.

11:00 A.M.-12:30 P.M. Room 236, Second Level, Morial Convention Center

ANTIPSYCHOTIC POLYPHARMACY: AN EVIDENCE-BASED PERSPECTIVE



Chair:

Donald C. Goff, M.D.

11:00 A.M.-12:30 P.M.

Room 237, Second Level, Morial Convention Center

THE GRAVITY OF WEIGHT: THE IMPOSSIBLE **HEAVINESS OF BEING** 

Co-Chairs:

Sylvia R. Karasu, M.D. T. Byram Karasu, M.D.

#### SI 7

11:00 A.M.-12:30 P.M.

Room 336, Third Level, Morial Convention Center

CHILD PSYCHO-PHARMACOLOGY: SSRIS, STIMULANTS AND SAFETY ISSUES



Chair:

Barbara Coffey, M.D.

11:00 A.M.-12:30 P.M. Room 337, Third Level,

Morial Convention Center

**DELIRIUM ASSESSMENT** AND MANAGEMENT

Chair:

James R. Rundell, M.D.

# WORKSHOPS 72-83 WORKSHOP 72

11:00 A.M.-12:30 P.M.

Room 210, Second Level, Morial Convention Center

AMERICAN BOARD OF PSYCHIATRY AND **NEUROLOGY UPDATE:** CERTIFICATION IN PSYCHIATRY AND ITS SUBSPECIALTIES

Chair:

Larry R. Faulkner, M.D.

**Presenters:** 

Beth Ann Brooks, M.D., M.S. Victor I. Reus, M.D. David A. Mrazek, M.D.

#### WORKSHOP 73

11:00 A.M.-12:30 P.M. Rooms 225/226, Second Level, Morial Convention Center

TRANSCRANIAL MAGNETIC STIMULATION IN **CLINICAL PRACTICE:** A PRAGMATIC APPROACH TO A NEW PSYCHIATRIC **PROCEDURE** 



Timothy H. Derstine, M.D.

**Presenters:** 

Carl M. Wahlstrom, M.D. Karl I. Lanocha, M.D. Todd M. Hutton, M.D.

#### WORKSHOP 74

11:00 A.M.-12:30 P.M.

Room 227, Second Level, Morial Convention Center

To File or not to FILE: GUARDIANSHIP FOR OLDER ADULTS WITH DEMENTIA

Co-Chairs:

Asghar-Ali A. Ali, M.D. Sheila M. LoboPrabhu, M.D.

**Presenters:** 

Jeffrey B. Lindeman, Psy.D. Ellen F. Barr, M.S.N.

#### WORKSHOP 75

11:00 A.M.-12:30 P.M. Room 230, Second Level, Morial Convention Center

THE VICISSITUDES OF THE DOCTOR-PATIENT RELATIONSHIP IN MODERN MEDICINE: ENDURANCE, Erosion or TRANSFORMATION

Robert C. Joseph, M.D., M.S.

**Presenters:** 

Donald R. Lipsitt, M.D., M.A. Malkah T. Notman, M.D. Donald J. Meyer, M.D.

#### WORKSHOP 76

11:00 A.M.-12:30 P.M.

Room 235, Second Level, Morial Convention Center

WHEN IS PSYCHIATRIC **ILLNESS TERMINAL?** 

Co-Chairs:

Melinda S. Henderson, M.D. Kate Payne, J.D., R.N.

#### WORKSHOP 77

11:00 A.M.-12:30 P.M. Room 335, Third Level, Morial Convention Center

NEONATICIDE: **PHENOMENOLOGY** AND PREVENTION

#### Chair:

Renee M. Sorrentino, M.D.

#### **Presenters:**

Susan Hatters Friedman, M.D. Joy Stankowski, M.D.

#### WORKSHOP 78

11:00 A.M.-12:30 P.M.

Rooms 338/339, Third Level, Morial Convention Center

**INTEGRATING COMPLEMENTARY** ALTERNATIVE MEDICINE (CAM) IN PSYCHIATRIC CARE: NEW PARADIGMS AND PERSPECTIVES

Simon Chiu, M.D., Ph.D.

#### **Presenters:**

Zack Z. Cernovsky, Ph.D. John Copen, M.D., M.S.C. Michael A. Woodbury-Farina, M.D. Mariwan Husni, M.D.

#### WORKSHOP 79

11:00 A.M.-12:30 P.M.

Rooms 340/341, Third Level. Morial Convention Center

THE USE OF RESEARCH MEASURES IN CLINICAL PRACTICE

#### Chair:

Joan Busner, Ph.D.

#### **Presenters:**

Stuart L. Kaplan, M.D. Nicholas Greco IV, M.S.

#### WORKSHOP 80

11:00 A.M.-12:30 P.M.

Room 342, Third Level, Morial Convention Center

"TAKING IT PERSONAL": Integrating **PHARMACOGENETICS** INTO THE MANAGEMENT OF DEPRESSION

#### Chair:

Sheldon H. Preskorn, M.D.

**Presenters:** 

Melvin G. McInnis, M.D.

#### **WORKSHOP 81**

11:00 A.M.-12:30 P.M. Rooms 346/347, Third Level, Morial Convention Center

TELEPSYCHIATRY AND THE CHANGING FACE OF Access for Rural AMERICA'S CHILDREN AND ADOLESCENTS APA Council on Children, Adolescents & Their Families

L. Charolette Lippolis, D.O., M.P.H.

#### **Presenters:**

Michael Houston, M.D. Mary I. Dobbins, M.D. Daniel M. Savin, M.D. Paula Zuccano, F.N.P.

#### WORKSHOP 82

11:00 A.M.-12:30 P.M.

Rooms 348/349, Third Level, Morial Convention Center

GUARDIANSHIP AND Powers of Attorney: Issues in Geriatric **PSYCHIATRY** 

#### Co-Chairs:

David A. Casey, M.D. Robert P. Roca, M.D., M.P.H.

#### **Presenters:**

Helen H. Kyomen, M.D., M.S., Winsor C. Schmidt, J.D., LL.M.

#### **WORKSHOP 83**

11:00 A.M.-12:30 P.M.

Rooms 350/351, Third Level, Morial Convention Center

#### PRACTICAL. **PHARMACOTHERAPY** OF MOOD DISORDERS





#### Co-Chairs:

Gary E. Miller, M.D. Richard L. Noel, M.D.

#### SESSION TRACKS

- Affective Disorders (Mood and Anxiety)
- Personality Disorders
- Psychopharmacology
- Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- NIDA
- DSM-5

#### 12:30 P.M.-1:30 P.M.

#### EXHIBIT HALL RECEPTION

Exhibit Halls B-D, First Level, Morial Convention Center

This reception is open to all registrants. A registration badge is required to attend.

# NEW RESEARCH/ OUNG INVESTIGATORS POSTER SESSION 2

#### 12:30 P.M.-2:00 P.M.

La Louisiane C, First Level, Morial Convention Center

> For further information on New Research/Young Investigator submissions please refer to the New Research Program section.

#### 1:00 P.M. SESSIONS COURSES 57-64

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C, First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

#### COURSE 57

1:00 P.M.-5:00 P.M. Bayside Room B, Fourth Floor, Sheraton New Orleans

PAIN AND PALLIATIVE CARE IN PSYCHOGERIATRICS

#### Director:

Abhilash K. Desai, M.D.

#### Faculty:

George T. Grossberg, M.D. Jothika Manepalli, M.D.

#### COURSE 58

1:00 P.M.-5:00 P.M.

Bayside Room C, Fourth Floor, Sheraton New Orleans

#### REEL PSYCHIATRY

#### Co-Directors:

Luis F. Ramirez, M.D. David Robinson, M.D.



P.M.

#### COURSE 59

1:00 P.M.-5:00 P.M. Nottoway Room, Fourth Floor, Sheraton New Orleans

#### **PSYCHIATRIC PHARMACOGENOMICS**



**Director:** 

David A. Mrazek, M.D.

#### COURSE 60

1:00 P.M.-5:00 P.M.

Grand Ballroom A, Fifth Floor, Sheraton New Orleans

PSYCHOPHARMACOLOGIC, ECT AND PSYCHOTHERAPEUTIC TREATMENT OF PSYCHOTIC (DELUSIONAL) DEPRESSION



Director:

Anthony J. Rothschild, M.D.

Faculty:

Brandon A. Gaudiano, Ph.D.

#### COURSE 61

1:00 P.M.-5:00 P.M. Grand Ballroom B, Fifth Floor, Sheraton New Orleans

THE PSYCHIATRIST AS **EXPERT WITNESS** 

Director: Phillip J. Resnick, M.D.

#### COURSE 62

1:00 P.M.-5:00 P.M.

Grand Ballroom D, Fifth Floor, Sheraton New Orleans

ADVANCED ASSESSMENT AND TREATMENT OF ATTENTION-DEFICIT/ Hyperactivity Disorder

Director:

Thomas E. Brown, Ph.D.

**Faculty:** 

Jefferson B. Prince, M.D. Anthony L. Rostain, M.D., M.A.

#### COURSE 63

1:00 P.M.-5:00 P.M.

Salon 801, Eighth Floor, Sheraton New Orleans

CURRENT PROCEDURAL TERMINOLOGY: CODING AND DOCUMENTATION

**Co-Directors:** 

Chester W. Schmidt, M.D. Tracy R. Gordy, M.D.

**Faculty:** 

Ronald M. Burd, M.D. David K. Nace, M.D. Jeremy S. Musher, M.D. Allan A. Anderson, M.D.

#### COURSE 64

1:00 P.M.-5:00 P.M. Salons 816/820, Eighth Floor, Sheraton New Orleans

A PRIMER ON ACCEPTANCE AND **COMMITMENT THERAPY** 



**Co-Directors:** 

Kenneth D. Fung, M.D., M.S. Mateusz Zurowski, M.D., M.S.

#### 1:30 P.M. SESSIONS FOCUS LIVE 3

1:30 P.M.-3:00 P.M.

Rooms 343-345, Third Level, Morial Convention Center

DISORDERS OF SEX AND SLEEP

Presented by:

Stephen B. Levine, M.D.

**Moderators:** 

Deborah J. Hales, M.D. Mark H. Rapaport, M.D.

# LECTURES 8-9

1:30 P.M.- 3:00 P.M.

La Louisiane Rooms A/B, First Level, Morial Convention Center

THE AUDACITY PRINCIPLE IN SCIENCE *Adolf Meyer Award Lecture* 



Solomon H. Snyder, M.D.

David Baron, MSEd., D.O.



Solomon H. Snyder was born in Washington, D.C., and received his undergraduate and medical training at Georgetown University;

research associate training with Julius Axelrod at NIH (1963-1965); and psychiatric training at the Johns Hopkins Hospital (1965-1968). In 1966, he joined the faculty of the Johns Hopkins University School of Medicine (Asst Professor Pharmacology, 1966-1968; Associate Professor Pharmacology/Psychiatry, 1968-1970; Professor, 1970). In 1980 he established the Department of Neuroscience and served as Director (1980-2006). He is presently Distinguished Service Professor of Neuroscience, Pharmacology and Psychiatry.

#### LECTURE 9

1:30 P.M.- 3:00 P.M.

Rooms R02-R05, Second Level, Morial Convention Center

"YOUR BIPOLAR DAD IS A BAD REASON TO BECOME A PSYCHIATRIST": ADVOCACY ADVENTURES OF A BEWILDERED BOY WHO GREW UP TO BECOME NAMI'S MEDICAL DIRECTOR Patient Advocacy Award Lecture

Kenneth S. Duckworth, M.D.

#### Chairs:

Stephen M. Goldfinger, M.D. Josephine Mokonogho, M.D.



Ken Duckworth. M.D., serves as the medical director for the National Alliance on Mental Illness. He is triple board certified by the American Board

of Psychiatry and Neurology in adult, child and adolescent, and forensic psychiatry and has extensive experience in the public health arena. Dr. Duckworth is an assistant professor at Harvard University Medical School and serves as a board member of the American Association of Community Psychiatrists. Dr. Duckworth has served as a school consultant for a decade and, in addition to his role with NAMI, works in community mental health with Vinfen Corporation in Boston as its medical director. Dr. Duckworth attended the University of Michigan, where he graduated with honors, and Temple University School of Medicine, where he was named to the medical honor society. While at Temple, he won awards for his work in psychiatry and neurology.

# CIENTIFIC AND CLINICAL PORTS: SESSIONS 10-11

1:30 P.M.-3:00 P.M.

Room 230, Second Level, Morial Convention Center

COGNITIVE DISORDERS

Saleem Ismail, M.D.

28. Incidence Rates and Probability to Develop Dementia and Alzheimer's Disease in a **Southern European City:** The Zarademp Project Antonio Lobo, M.D., Ph.D. Raul Lopez-Anton, M.Sc. Pedro Saz, M.D., Ph.D.

Javier Santabarbara, M.Sc. Concepcion de-la-Camara, M.D., Ph.D. Tirso Ventura, M.D., Ph.D. Jose L. Dia, M.D., Ph.D. Miguel A. Quintanilla, M.D., Ph.D. Juan F. Roy, Ph.D. Antonio J. Campayo, M.D. Elena Lobo, Ph.D. Antonio Lobo-Escolar, M.D., Ph.D. Maria F. Barcones, M.D., Ph.D. Guillermo Marcos, M.D., Ph.D.

- 29. Art and Dementia: Pathological and Clinical **Features of Different** Subtypes of Dementia, With a Focus on the **Changes in Art Production** Laura Safar, M.D., M.A.
- 30. Metacognitive Capacity Mediates of the Impact of Neurocognitive Deficits on Function in Schizophrenia Paul H. Lysaker, Ph.D. Amanda M. Shea, B.A. Giancarlo Dimaggio, M.D. Giuseppe Nicolò, M.D. Kevin L. Rand, Ph.D.



#### SCR 11

1:30 P.M.-3:00 P.M. Rooms 348/349, Third Level, Morial Convention Center

#### DIAGNOSTIC ISSUES AND DSM-5



#### Chair:

Elias Shaya, M.D.

- 31. Intellectual Disability in DSM-5 Walter E. Kaufmann, M.D. Bryan H. King, M.D., Ph.D. Sally J. Rogers, Ph.D.
- 32. Adding Dimensional Assessments of Psychopathology to Psychiatric Diagnoses: Implications for DSM-5 William E. Narrow, M.D., M.P.H. Joyce C. West, Ph.D., M.P.P. Donald S. Rae, M.A. Maritza Rubio-Stipec, Sc.D. Eve K. Moscicki, Sc.D., M.P.H.



#### SESSION TRACKS:

- Affective Disorders (Mood and Anxiety)
- Personality Disorders
- Psychopharmacology
- Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- NIDA
- DSM-5

Farifteh F. Duffy, Ph.D. Darrel A. Regier, M.D., M.P.H.

33. Nosology for Beginners: Historical and Current Perspectives on the Fundamental Issues and Problems in the Classification of Psychiatric Disorders Avram H. Mack, M.D.

#### WORKSHOPS 84-85 WORKSHOP 84

#### 1:30 P.M.-3:00 P.M.

Room 235, Second Level, Morial Convention Center

MALPRACTICE DEFENSE: STRATEGIES FOR SUCCESS

#### Co-Chairs:

Abe M. Rychik, J.D. Eugene Lowenkopf, M.D.

#### WORKSHOP 85

1:30 P.M.-3:00 P.M. Room 335, Third Level, Morial Convention Center

THE PSYCHIATRIST'S ROLE IN INTEGRATING PRIMARY CARE AND BEHAVIORAL **HEALTH CARE: FRIEND OR FOE?** 

#### Chair:

Ruth S. Shim, M.D., M.P.H.

#### **Presenter:**

Benjamin Druss, M.D., M.P.H.

# 2:00 P.M. SESSIONS ADVANCES IN SERIES 3-4

#### 2:00 P.M.-5:00 P.M.

Rooms 238/239, Second Level, Morial Convention Center

#### ADVANCES IN FORENSIC **PSYCHIATRY**

#### Chair:

Robert I. Simon, M.D.

- 1. Cutting-Edge Issues in the **Evaluation of Malingering** H. W. LeBourgeois III, M.D.
- 2. Forensic Civil Competency Issues Alan A. Abrams, M.D., J.D.
- 3. Forensic Psychiatry and the Internet Patricia R. Recupero, M.D., J.D.
- 4. Quality Assurance Review of **Suicide Risk Assessments:** Reality and Remedy Robert I. Simon, M.D.
- 5. Thinking About Delinquency Peter Ash, M.D.

#### ADVANCES IN SERIES 4

2:00 P.M.-5:00 P.M. Rooms R06/09, Second Level, Morial Convention Center

#### ADVANCES IN PSYCHOTHERAPEUTIC **TREATMENTS**

#### Chair:

Glen O. Gabbard, M.D.

- 1. Critical Hallucinations and Bizarre Delusions in Schizophrenia: A Series of Cognitive Therapy Role Plays Douglas Turkington, M.D.
- 2. Psychotherapy Induces **Proliferation of Brain Serotonin** 5-HT<sub>1a</sub> Receptors in Patients With Major Depressive Disorder Hasse Karlsson, M.D., Ph.D.
- 3. Psychotherapy of Body **Dysmorphic Disorder** Katharine A. Phillips, M.D.
- 4. When, How Much, for Whom, and How Is Transference Work Useful in Dynamic Psychotherapy? Per Høglend, M.D., Ph.D.
- 5. Abandonment, Termination, and **Evidence-Based Therapies for Borderline Personality Disorder** John G. Gunderson, M.D.

# MEDIA WORKSHOPS

#### 2:00 P.M.-5:00 P.M.

Rooms 208/209, Second Level, Morial Convention Center

"Patrik, Age 1.5": A Swedish FILM ABOUT UNEXPECTED AND GAY ADOPTION American Academy of Child &

#### Chair:

Richard R. Pleak, M.D.

Adolescent Psychiatry

#### **Presenters:**

Edgardo J. Menvielle, M.D., M.S. Sarah E. Herbert, M.D., M.S.W.

# PRESIDENTIAL SYMPOSIA

#### 2:00 P.M.-5:00 P.M.

Rooms 220-222, Second Level, Morial Convention Center

CAN BASIC AND TRANSLATIONAL NEUROSCIENCE IMPROVE TREATMENT IN PSYCHIATRY? National Institute on Drug Abuse

#### Co-Chairs:

Alan F. Schatzberg, M.D. Karl Deisseroth, M.D.



Discussant: Thomas Insel, M.D.

- 1. Translational Studies in **Genetics: Genetic Tools** in Animal Models to **Understand Heritable Risk Factors in Depression** and Posttraumatic Stress Disorder Kerry Ressler, M.D., Ph.D.
- 2. Emotion Regulation: Toward a Neurobiological Understanding of **Psychotherapy** Amit Etkin, M.D., Ph.D.
- 3. Optogenetics: Development and Application Karl Deisseroth, M.D.
- 4. Using Optogenetic Tools and Information Theory to Elucidate Prefrontal **Microcircuit Dysfunction** in Schizophrenia Vikaas Sohal, M.D.

# SYMPOSIA 43-59 SYMPOSIUM 43

2:00 P.M.-5:00 P.M. Room 210, Second Level, Morial Convention Center

EARLY DETECTION AND Intervention in SCHIZOPHRENIA: An Idea Whose TIME HAS COME



Chair: Jeffrey A. Lieberman, M.D.

- 1. Early Intervention in Psychiatry: **Lessons From Psychosis** Patrick McGorry, M.D., Ph.D.
- 2. Why Treating Early, Treating Well, and **Treating for Life** Is Important in Schizophrenia Rene S. Kahn, M.D., Ph.D.
- 3. Selective and Indicated Prevention for Schizophrenia: An NIMH Perspective on Current and **Future Possibilities** Robert K. Heinssen, Ph.D.
- 4. Portland Identification and Early Referral (PIER): Prevention of Psychosis as a Public **Health Intervention** William R. McFarlane, M.D.

- 5. At Clinical High Risk for Psychosis: What Is the Outcome? Jean M. Addington, Ph.D.
- 6. Early Detection and Intervention in **Psychotic Disorders:** Making It Ready for "Prime Time" Jeffrey A. Lieberman, M.D.

#### SYMPOSIUM 44

2:00 P.M.-5:00 P.M. Rooms 217-219, Second Level, Morial Convention Center

#### AN EXAMINATION OF CNS TRIAL METHODOLOGIES

#### **Co-Chairs:**

Maurizio Fava, M.D. Steven D. Targum, M.D.

- 1. Placebo Response Is Not Necessarily Response to Placebo: Factors **Inflating Placebo Response in CNS Trials** Armin Szegedi, M.D.
- 2. Does De-Coupling of Entry Criteria **Improve Outcomes** in CNS Trials? Charlotte Kremer, M.D., M.B.A. Eric J. Watsky, M.D. Ilise D. Lombardo, M.D.
- 3. Comparison of Site-**Based Versus Centralized** Ratings in a Study of Generalized **Anxiety Disorder** Judith Dunn, Ph.D.
- 4. Evaluation of Centralized Ratings in a Clinical **Trial of Major Depressive Disorder** Steven D. Targum, M.D. Leo Bleicher, Ph.D. Andrew Nierenberg, M.D.
- 5. The Use of Independent Assessments for Patient **Eligibility for CNS Trials** Maurizio Fava, M.D. Steven D. Targum, M.D.

#### SYMPOSIUM 45

2:00 P.M.-5:00 P.M. Room 223, Second Level, Morial Convention Center

INTERPERSONAL AND SOCIAL RHYTHM THERAPY (IPSRT) FOR BIPOLAR DISORDER: NEW APPLICATIONS. NEW POPULATIONS, AND NEW EVIDENCE

#### Co-Chairs:

Holly A. Swartz, M.D. Ellen Frank, Ph.D.

#### Discussant:

John C. Markowitz, M.D.

- 1. Comparison of IPSRT Monotherapy and Quetiapine for the **Treatment of Bipolar II Depression:** A Proof of Concept Trial Holly A. Swartz, M.D.
- 2. Early Intervention for Adolescent Offspring of Parents With Bipolar **Disorder: Pilot Study** of IPSRT Tina Goldstein, Ph.D.
- 3. IPSRT for Adolescents With Bipolar Disorder: Treatment Development and Results From an Open Trial Stefanie A. Hlastala, Ph.D.
- 4. IPSRT for Bipolar Disorder in the Perinatal Period Suzanne Luty, Ph.D., M.B.B.S.
- 5. Group Interpersonal and Social Rhythm (IPSRT) Therapy Across the Continuum of Care in Routine Practice Settings Ellen Frank, Ph.D.

#### SYMPOSIUM 46

2:00 P.M.-5:00 P.M. Room 224, Second Level, Morial Convention Center

Ensuring a Public HEALTH IMPACT: PARTNERING WITH CONSUMERS AND COMMUNITY STAKEHOLDERS TO IMPROVE Access and Quality of CARE FOR MENTAL **DISORDERS** 

Kenneth B. Wells, M.D., M.P.H.

#### Discussant:

Diana Meyers, B.S.N.

- 1. A Public Health Initiative to Address Depression and Posttraumatic Stress Disorder in a Post-Disaster Setting Benjamin Springgate, M.D., M.P.H.
- 2. CBPR in the Arkansas Delta: Developing an Implementation Partnership With Rural Under-served **Community Health Centers** Justin B. Hunt, M.D. Angie Shaffner, R.N., L.N.C. Geoff Curran, Ph.D. John Fortney, Ph.D.

- 3. A Partnership for Wellness: Addressing Stress and Violence in West and Southwest Philadelphia Glenda Wrenn, M.D. Jane Jue, M.D. Lorraine Thomas
- 4. GROOVI Care: A Community Coalition to Engage With **Veterans of Operations Enduring Freedom and** Iraqi Freedom About Their Mental Health Patrick E. Link, M.D., M.P.H. Casey MacGregor, M.S.W. Lawrence A. Palinkas, Ph.D. Kenneth B. Wells, M.D., M.P.H. Michael Kilmer, M.S.W. Barbara Powell, M.A. Isabel Moriarty, M.S.W. Alexander Young, M.D., M.S.H.S.
- 5. Using a Community **Partnered Participatory** Research Approach to Implement a Randomized **Controlled Trial: Designing of Community** Partners in Care Bowen Chung, M.D., M.S. Loretta Jones, M.A. Elizabeth Dixon, Ph.D., R.N. Jim Gilmore, M.B.A. Kenneth B. Wells, M.D., M.P.H. Jeanne Miranda, Ph.D.

#### SYMPOSIUM 47

2:00 P.M.-5:00 P.M. Rooms 225/226, Second Level, Morial Convention Center

NEW STUDIES TO APPEAR IN THE **JUNE ISSUE OF THE AMERICAN JOURNAL OF PSYCHIATRY:** PRESENTATIONS BY THE **AUTHORS AND EDITORS** 

Robert Freedman, M.D.

Authors of the American Journal of Psychiatry papers that will appear in the June issue will present overviews of their findings, with discussion of why the papers were selected for publication by the editor, Robert Freedman, M.D. Among the presenters are **David** Spiegel, M.D., (evidence for a dissociative subtype of PTSD); Mary C. Zanarini, Ed.D., (recovery from borderline personality disorder and its stability); and Alexandre Dombrovski, M.D., (reward/ punishment reversal learning in older suicide attempters).

#### SYMPOSIUM 48

2:00 P.M.-5:00 P.M. Room 227, Second Level, Morial Convention Center

REDUCING HARM: SAFER INJECTION AND OTHER **STRATEGIES** 

#### Chair:

Curtis N. Adams, Jr., M.D.

#### Discussant:

David A. Pollack, M.D.

1. Creating an Inclusive Drug Strategy: The Experience of **Establishing Vancouver's Supervised Injection Site** Liz Evans, B.S.N.

#### SYMPOSIUM 49

2:00 P.M.-5:00 P.M. Rooms 228/229, Second Floor, Morial Convention Center

ADVANCES IN THE TREATMENT OF BIPOLAR DISORDER



#### Co-Chairs:

Terence A. Ketter, M.D. Po W. Wang, M.D.

- 1. Advances in Maintenance Treatment of Bipolar Disorder Terence A. Ketter, M.D. Po W. Wang, M.D.
- 2. Advances in the Treatment of Bipolar Depression Po W. Wang, M.D. Terence A. Ketter, M.D.
- 3. Treatment of Children and Adolescents With **Bipolar Disorder** Kiki Chang, M.D.
- 4. Treatment of Pregnant Women With Bipolar Disorder Mytilee Vemuri, M.D., M.B.A.
- 5. Management of Bipolar Disorders in Older Adults John O. Brooks, M.D., Ph.D.

#### SYMPOSIUM 50

2:00 P.M.-5:00 P.M. Room R01, Second Level, Morial Convention Center

CHALLENGES IN PROVIDING MENTAL HEALTH CARE FOR COLLEGE AND UNIVERSITY STUDENTS

APA Council on Children, Adolescents & Their Families Co-Chairs:

Jerald Kay, M.D. Victor I. Schwartz, M.D.

#### Discussant:

Beverly J. Fauman, M.D.

- 1. The Magnitude of Clinical Demands Jerald Kay, M.D.
- 2. The Ethical and Legal Issues in Providing College Mental Health Care Victor I. Schwartz, M.D.
- 3. Psychiatric Hospitalization and Follow-Up Care of the College Student Rachel L. Glick, M.D.
- 4. Violence Assessment and **Administrative Responses** Gregory T. Eells, Ph.D.
- 5. Managing the Suicidal College Student Morton Silverman, M.D.

#### SYMPOSIUM 51

2:00 P.M.-5:00 P.M. Rooms 333/334, Third Level, Morial Convention Center

GERIATRIC PSYCHOPHARMACOLOGY **OF LATE-LIFE MOOD DISORDERS:** FOCUS ON THE USE OF BIOMARKERS AS PREDICTORS OF RESPONSE

#### Chair:

Helen Lavretsky, M.D., M.S.

- 1. Psychopharmacology of Geriatric Depression: The Use of Aging Biomarkers to Predict Treatment Response Helen Lavretsky, M.D., M.S.
- 2. Geriatric Bipolar Disorder: Clinical Diagnosis and Treatment Martha Sajatovic, M.D.
- 3. The Use of Structural MRI as **Predictor of Antidepressant** Response in Older Adults Yvette Sheline, M.D.
- 4. Amygdala Activation to Emotional Faces in Geriatric Depression as a Marker of Treatment Response Howard Aizenstein, M.D.
- 5. Serotonin Transporter Occupancy and the Functional Neuroanatomic Effects of Citalopram in Geriatric Depression Gwenn Smith, Ph.D.





P.M.

#### SYMPOSIUM 52

2:00 P.M.-5:00 P.M Rooms 338/339, Third Level, Morial Convention Center

Innovations in Integrated TREATMENT OF SUBSTANCE USE AND PSYCHIATRIC **DISORDERS** 

National Institute on Drug Abuse

#### Co-Chairs:

Ivan D. Montoya, M.D., M.P.H. Wilson M. Compton III, M.D.

**Discussant:** 

Stanley Sacks, Ph.D.

- 1. Integrated Treatment of **Depression and Substance** Use Disorders in Adolescents Paul Rohde, Ph.D. Holly Waldron, Ph.D. Charles Turner, Ph.D. Janet Brody, Ph.D. Jenel Jorgensen, M.A.
- 2. Posttraumatic Stress Disorder and Drug Abuse: Etiology and Treatment Linkages Kathleen Brady, M.D., Ph.D. Sudie Back, Ph.D. Therese Killeen, Ph.D., R.N.
- 3. Integrated Group Therapy for Patients With Co-Occurring **Bipolar Disorder and Substance Use Disorder** Roger D. Weiss, M.D. Margaret L. Griffin, Ph.D. William B. Jaffee, Ph.D. Garrett M. Fitzmaurice, Ph.D.
- 4. Advances in Pharmacotherapy for Comorbid Depression and Addictions Edward V. Nunes, M.D.
- 5. Treatment of Cannabis **Use Disorder in Patients** With Schizophrenia Alan I. Green, M.D.

#### SYMPOSIUM 53

2:00 P.M.-5:00 P.M. Rooms 340/341, Third Level, Morial Convention Center

GENOTYPES AND BIOMARKERS: THE NEW DECISION MAKERS FOR TAILORED TREATMENT

#### Co-Chairs:

Florian Holsboer, M.D. Julio Licinio, M.D.

1. Genetic and Other Biomarkers of **Antidepressant Outcome** Francis McMahon, M.D.

- 2. Individualized Antipsychotic Therapy for Schizophrenic Patients Edwin J.C.G. van den Oord, Ph.D.
- 3. Gene Expression Profile in Persons Exposed to the Attack on the World Trade Center With and Without PTSD Rachel Yehuda, Ph.D.
- 4. Gene x Environment Interactions **Underlying Risk Versus Resilience** for Stress-Related Disorders Kerry Ressler, M.D., Ph.D.

#### SYMPOSIUM 54

2:00 P.M.-5:00 P.M. Room 342, Third Level, Morial Convention Center

SUBSTANCE RELATED **DISORDERS IN DSM-5:** PROGRESS REPORT



National Institute on Drug Abuse

**Co-Chairs:** 

Charles P. O'Brien, M.D., Ph.D. Deborah S. Hasin, Ph.D.

- 1. The Search for Specific Criteria: A Report From the Criterion Subcommittee Marc Schuckit, M.D.
- 2. Abuse and Dependence: Combining the Disorders Into a Single Category Deborah S. Hasin, Ph.D. Bridget F. Grant, Ph.D. Guilherme Borges, Sc.D. Kathleen Bucholz, Ph.D. Tulshi Saha, Ph.D. Katherine Keyes, M.P.H. Arpana Agrawal, Ph.D. Cheryl Beseler, Ph.D.
- 3. Non-Substance Related Addictions: Their Place in DSM-5 Nancy M. Petry, Ph.D. Eric Hollander, M.D. Thomas Kosten, M.D. Charles P. O'Brien, M.D. Wim van de Brink, Ph.D. Nora D. Volkow, M.D.
- 4. Terminology of Substance Use Disorders for DSM-5 Wilson M. Compton III, M.D. Marc Auriacombe, M.D. Alan J. Budney, Ph.D. Thomas J. Crowley, M.D. Bridget F. Grant, Ph.D. Deborah Hasin, Ph.D. Walter Ling, M.D. Charles P. O'Brien, M.D. Nancy Petry, Ph.D.
- 5. Severity of Substance **Use Disorders** Thomas J. Crowley, M.D. Marc Auriacombe, M.D.

Alan Budney, Ph.D. Wilson M. Compton II, M.D. Bridget F. Grant, Ph.D. Deborah Hasin, Ph.D. Walter Ling, M.D. Howard Moss, M.D. Marc Schuckit, M.D.

#### SYMPOSIUM 55

2:00 P.M.-5:00 P.M. Rooms 346/347, Third Level,

Morial Convention Center

DSM-5 UPDATE SERIES, PART I: REPORTS FROM THE WORK GROUPS



Chair:

Darrel A. Regier, M.D., M.P.H.

- 1. Approaches to the Diagnosis and Classification of Eating Disorders in DSM-5 B. Timothy Walsh, M.D.
- 2. Key Recommendations From the DSM-5 Sexual and Gender Identity **Disorders Workgroup** Kenneth J. Zucker, Ph.D.
- 3. Update From the Somatic Symptoms Workgroup Joel E. Dimsdale, M.D.
- 4. Towards a Better, Practical Understanding of Sleep Disturbances in People Living With or at Risk for Mental Illness Charles Reynolds, M.D.
- 5. Neurocognitive Disorders in DSM-5 Dilip V. Jeste, M.D. Deborah Blacker, M.D. Dan Blazer, M.D., Ph.D., M.P.H. Mary Ganguli, M.D. Igor Grant, M.D. Jane Paulsen, Ph.D. Ronald C. Petersen, M.D., Ph.D. Perminder Sachdev, M.D.

#### SYMPOSIUM 56

2:00 P.M.-5:00 P.M.

Rooms 350/351, Third Level, Morial Convention Center

FOCAL BRAIN STIMULATION FOR PSYCHIATRIC DISORDERS: CLINICAL UPDATE

Paul Holtzheimer, M.D.

1. The Clinical Safety and **Efficacy of Transcranial** Magnetic Stimulation: Results From Recent **Pivotal Clinical Trials** William M. McDonald, M.D.

- 2. Clinical Update on Magnetic Seizure Therapy (MST) Sarah H. Lisanby, M.D.
- 3. Clinical Update on Vagus Nerve Stimulation (VNS) Linda L. Carpenter, M.D.
- 4. The Promise of Direct **Epidural Cortical** Stimulation in **Refractory MDD:** The PROSPECT **Experience** and **Future Directions** Jerry L. Halverson, M.D. Brian Kopell, M.D. Douglas Kondziolka, M.D. Darin Dougherty, M.D. Robert Howland M.D. Harold Harsch, M.D. Emad Eskandar, M.D. Michael Thase, M.D.
- 5. Deep Brain Stimulation for Psychiatric Disorders: Clinical Update Paul Holtzheimer, M.D.

#### SYMPOSIUM 57

2:00 P.M.-5:00 P.M. Room 352, Third Level, Morial Convention Center

#### DEPRESSION, METABOLIC SYNDROME AND OBESITY



Co-Chairs: Julio Licinio, M.D. Anand Kumar, M.D.

- 1. Depression and **Abdominal Obesity** Brenda Penninx, Ph.D.
- 2. Depression and Diabetes: A Potentially Lethal Comorbidity Wayne Katon, M.D.
- 3. Brain Correlates of **Comorbid Diabetes** and Geriatric Depression Anand Kumar, M.D.
- 4. Depression Is Associated With Increased Severity of Comorbidities in **Bariatric Surgical** Candidates Mohamed Ali, M.D.
- 5. Should Mood Syndromes Be Reclassified as Metabolic Syndrome Type II? Roger S. McIntyre, M.D.

#### SYMPOSIUM 58

Withdrawn

#### SYMPOSIUM 59

2:00 P.M.-5:00 P.M. Rooms 356/357, Third Level, Morial Convention Center

**NEUROBIOLOGY OF OBESITY:** WHY WE CAN GET TOO MOTIVATED TO EAT National Institute on Drug Abuse

#### Co-Chairs:

Nora D. Volkow, M.D. Joseph Frascella, Ph.D.

- 1. Overeating and Obesity: Any End in Sight to Our "Addiction" to Food? David Kessler, M.D.
- 2. Central Control of Food Intake: Appetite Control and the Reward-Driven Brain Hans-Rudolf Berthoud, Ph.D.
- 3. Sweetness as a Super Reward: Comparison With Cocaine and Heroin Serge H. Ahmed, Ph.D.
- 4. Individual Differences in the Neurophysiology of Reward and the Obesity Epidemic Nora D. Volkow, M.D.
- 5. Neurocircuitry of Addiction and Obesity Nora D. Volkow, M.D.

# :00 P.M. SESSIONS

OSTER SESSION

3:00 P.M.- 5:00 P.M. La Louisiane C, First Level, Morial Convention Center

> For further information on New Research submissions, please refer to the New Research Program section of this book.

# 3:30 P.M. SESSIONS LECTURES 10-11

3:30 P.M.- 5:00 P.M La Louisiane Rooms A/B, First Level, Morial Convention Center

THE SIMPLE TRUTH ABOUT THE GENETIC COMPLEXITY OF SCHIZOPHRENIA Distinguished Psychiatrist Lecture

Daniel R. Weinberger, M.D.

#### Chair:

David Baron, MSEd., D.O.



Daniel R. Weinberger, M.D., is chief of the Clinical Brain Disorders Branch of the Intramural Research Program, director of the

Genes, Cognition and Psychosis Program, National Institute of Mental Health, National Institutes of Health in Bethesda. MD. He attended college at Johns Hopkins University, medical school at the University of Pennsylvania, and residencies in psychiatry at Harvard Medical School and in neurology at George Washington University. He is board certified in both psychiatry and neurology. He is a past president of the Society of Biological Psychiatry, past president of the American College of Neuropsychopharmacology and a member of the Institute of Medicine of the National Academy of Sciences.

#### LECTURE 11

3:30 P.M.- 5:00 P.M. Rooms R02-R05, Second Level, Morial Convention Center

SOLOMON CARTER FULLER: WHAT WOULD HE SAY ABOUT RACIAL POLITICS IN AMERICAN PSYCHIATRY TODAY? Solomon Carter Fuller Award Lecture

Donna M. Norris, M.D.



Donna M. Norris, M.D., is a child, adolescent and forensic psychiatrist in private practice in Massachusetts and a member of the Program in

Psychiatry and the Law at Beth Israel/ Deaconess Hospital, Harvard Medical School. She has written or cowritten articles on African-American children and loss, the impact of culture and race on the development of African Americans, countertransference, health care fraud, clergy sexual abuse, firearms and the roles of psychiatrists, and custody and parental fitness. Dr. Norris is a Distinguished Fellow of the American Psychiatric Association and has been the recipient of a number of awards, including the Women of Courage and Conviction Award of the National Council of Negro Women, Massachusetts Outstanding Psychiatrist Award for the Advancement of the Profession, and Special APA Presidential Commendations (2002) and 2008). She is a Fellow of the American College of Psychiatrists and is listed in both Who's Who Among Black Americans and Who's Who Among Women in America.



P.M.

#### CIENTIFIC AND CLINICAL REPORTS: SESSIONS 12-13

#### 3:30 P.M.- 5:00 P.M.

Room 230, Second Level, Morial Convention Center

#### PSYCHOSOMATICS AND CARDIAC VULNERABILITY

Derya Iren Akbiyik, M.D.

34. Sex Differences in the **SADHART-CHF Trial** 

Jonathan C. Lee, M.D. Maragatha Kuchibhatla, Ph.D. Michael Cuffe, M.D. Shelby Ladd, B.A. Christopher M. O'Conner, M.D. Ranga R. Krishnan, M.D. Wei Jiang, M.D.

35. Psychosomatic Medicine and the Philosophy of Life Michael A. Schwartz, M.D. Osborne P. Wiggins, Ph.D.



36. Broken Hearts: Cardiovascular and Emotional Stress Measures in Relocated Katrina Survivors

Phebe M. Tucker, M.D. Hattie Jeon-Slaughter, Ph.D. Betty Pfefferbaum, M.D., J.D. Qaiser Khan, M.P.H.


#### SCR 13

3:30 P.M.- 5:00 P.M.

Rooms 348/349, Third Level, Morial Convention Center

ADDICTIVE BEHAVIOR National Institute on Drug Abuse





- 38. Pathological Gambling: An Impulse Control Disorder? Measurement of Impulsivity Through Neurocognitive Tests Pinhas N. Dannon, M.D. Netta Shoenfeld, B.A. Semion Kertzman, M.D. Oded Rosenberg, M.D. Moshe Kotler, M.D.
- 39. Quitting Cannabis Use Without Formal Treatment in Adults David A. Gorelick, M.D., Ph.D. Kenneth H. Levin, B.A. Marc L. Copersino, Ph.D. Stephen J. Heishman, Ph.D. Fang Liu, M.S. Deanna L. Kelly, Pharm.D. Douglas L. Boggs, Pharm.D.

#### WORKSHOPS 86-87 WORKSHOP 86

3:30 P.M.- 5:00 P.M.

Room 235, Second Level, Morial Convention Center

#### TEACHING PSYCHIATRY IN **NEW MEDICAL SCHOOLS**

Zebulon Taintor, M.D.

#### **Presenters:**

Kathleen S. Franco, M.D., M.S. Daniel Castellanos, M.D. David F. Briones, M.D. Marcia L. Verduin, M.D.

#### WORKSHOP 87

3:30 P.M.- 5:00 P.M.

Room 335, Third Level, Morial Convention Center

DEAFNESS, DISABILITY OR DIFFERENCE? THE CULTURAL AND CLINICAL NEEDS OF **DEAF PATIENTS** APA/SAMHSA Minority Fellows

#### Co-Chairs:

Neil K. Aggarwal, M.D., M.B.A. Christopher W. Tjoa, M.D., B.S.

#### **Presenters:**

Jason O. Mensah, D.O. Deyadira Baez-Sierra, M.D. Sosunmolu O. Shoyinka, M.B.B.S. David R. Diaz, M.D. Kimberly J. Roberts, M.D. Sarah Anne Landsberger, M.D.

#### :30 P.M.

# CONVOCATION OF DISTINGUISHED FELLOWS

5:30 P.M.-6:30 P.M.

Hall A, First Level, Morial Convention Center

> All Distinguished Life Fellows, Distinguished Fellows, Life Fellows, International Fellows, APA Members, and Registered Guests Are Invited to Attend.

#### **Presiding:**

Alan F. Schatzberg, M.D. APA President

#### **Grand Marshals:**

Howard J. Osofsky, M.D., Ph.D. Daniel K. Winstead, M.D.

#### Marshals:

Edward F. Foulks, M.D. Stephen M. Goldfinger, M.D.



- Affective Disorders (Mood and Anxiety)
- Personality Disorders
- Psychopharmacology
- Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- NIDA
- DSM-5

#### Introduction of **DISTINGUISHED LIFE FELLOWS** Carol A. Bernstein, M.D. APA Presdent-Elect

#### INDUCTION OF DISTINGUISHED FELLOWS

Carol A. Bernstein, M.D. APA Presdent-Elect

INTRODUCTION OF 50-YEAR DISTINGUISHED LIFE FELLOWS, 50-YEAR LIFE MEMBERS, AND INTERNATIONAL FELLOWS Alan F. Schatzberg, M.D. APA President

#### Introduction of Fellows Alan F. Schatzberg, M.D. APA President

INTRODUCTION OF THE MEMBERSHIP COMMITTEE'S CHAIR AND Award Board Chairs

Alan F. Schatzberg, M.D. APA President

PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS Alan F. Schatzberg, M.D. APA President

#### PRESENTATION OF DISTINGUISHED SERVICE AWARDS Alan F. Schatzberg, M.D.

APA President

#### Presentation of Awards Alan F. Schatzberg, M.D. APA President

- APA Lilly Resident Research Awards
- APIRE/Kempf Fund Awards for Research Development in Psychobiological Psychiatry
- Human Rights Awards
- Blanche F. Ittleson Award for Research in Child Psychiatry
- Agnes Purcell McGavin Award for a Distinguished Career in Child and Adolescent Psychiatry
- Isaac Ray Award



Jack Weinberg Memorial Award for Geriatric Psychiatry

# WILLIAM C. MENNINGER MEMORIAL CONVOCATION

Carrie Fisher

#### 7:00 P.M. SESSIONS MEDIA WORKSHOP 4

7:00 P.M.-10:00 P.M.

Grand Salon B, First Level, Hilton New Orleans Riverside

NATIONAL DISASTERS: DEVELOPING A ROAD MAP FOR PREPAREDNESS AND Interventions World Psychiatric Association

Chair:

Arshad Husain, M.D.

**Presenters:** 

Russell D'Souza, M.D. E. Mohandas, M.D.

# INDUSTRY-SUPPORTED SYMPOSIUM 2

7:00 P.M.-9:00 P.M.

Grand Ballrooms A/B, First Level, Hilton New Orleans Riverside

#### NOVEL APPROACHES TO ASSESSING AND TREATING DEPRESSION IN THE MEDICALLY-ILL

Supported by an education grant from Lilly USA

Chair:

Bradley Gaynes, M.D.

Since her feature debut opposite Warren Beatty in "Shampoo" in 1975, Carrie Fisher has been a compelling force in the film industry. She attained international recognition as Princess Leia, a role that made her a cultural icon, in the box-office sensation "Star Wars" and the smash hit sequels "The Empire Strikes Back" and "Return of the Jedi." Other acting credits include "The Blues Brothers," "Garbo Talks," "When Harry Met Sally," and "Austin Powers" to name a few. Carrie became a sensation with the New York Times bestseller, Postcards From the Edge, for which she won the Los Angeles Pen Award for Best First Novel. Three additional best-selling novels, Surrender the Pink, Delusions of Grandma, and Wishful Drinking, followed. Fisher also wrote the screenplay based on Postcards from the Edge, which starred Meryl Streep and Shirley MacLaine. Ms.



Fisher's fourth novel, The Best Awful, received rave reviews and she is currently adapting it for Lifetime and Sony, with producers Bruce Cohen and Dan Jinks. Ms. Fisher completed a major run of her hit autobiographical onewoman show, Wishful Drinking at The Geffen Playhouse in Los Angeles in 2006 and most recently on Broadway at the Roundabout Theatre Company's Studio 54. Carrie Fisher's experience with mental illness and addiction has made her a popular speaker on the lecture circuit. She has appeared on the Senate floor urging state legislators to increase government funding for medication for people living with mental health issues. She has received dozens of awards for her courage and commitment to fighting mental illness and the stigmas associated with it.

- 1. Assessing Mood and Somatic Symptoms in the Medically-Ill **Depressed Patient** Gregory Simon, M.D., Ph.D.
- 2. Pathophysiology of Somatic Symptoms and Major Depressive Disorder in Medically-Ill **Populations** Janet Witte, M.D., M.P.H.
- 3. Managing Depression in the Medically-Ill: An Up-to-Date **Evidence-Based Guide** Bradley Gaynes, M.D.
- 4. Management of Treatment-**Resistant Patients with** Somatic Symptoms and Medical Illness Maurizio Fava, M.D.

# 2010 APA Annual Meeting



# **ONLINE & DVD-ROM HIGHLIGHTS**

Order yours during the meeting and save up to


#### SALES BOOTHS:

- Lobby B1
- Exhibit Hall B2, Near the Registration Area

\*On-site price expires May 26, 2010. Residents/Students save \$500, other attendees save \$400.









#### Editors: Deborah Hales, M.D., and Mark Hyman Rapaport, M.D.

*FOCUS* is the best system for recertification, self-assessment, and lifelong learning. In one easy subscription, FOCUS provides a comprehensive review of current clinical practice based on the content outlined by the ABPN recertification exam. Each issue offers: Clinical Reviews, Patient Management Exercise, Seminal Articles, and a CME guiz with 20 hours of CME per year for the journal (20 additional hours can be earned through completion of the Self-Assessment Exam). All current and back issues are accessible online with available CME credits for your subscription year.

The FOCUS Self-Assessment Exam is an annual 100-question, multiple-choice supplement written by practicing psychiatrists and academic experts that allows you to earn 20 CME credits and the opportunity to anonymously compare your knowledge to that of your peers either online or on paper. Each question is similar to those used in board-type exams. The FOCUS Self-Assessment Exam is listed by the ABPN as an approved self-assessment activity that fulfills the requirement of psychiatrists applying for and taking the recertification examination.

FOCUS addresses the core content in psychiatry in four-vear cycles.

Each issue briefs you on new developments and reviews the current state of practice in that topic area through:

- Clinical synthesis articles and reviews
- Interactive Patient Management Exercise and "Ask-the-Expert" column
- Influential publications: reprints of new, and classic articles that influence practice

*FOCUS* updates you in core content areas:

- **Volume VI** (2008): Major Depressive Disorder and Suicide; Schizophrenia: Cognition and Outcomes; Child and Adolescent Psychiatry; Panic and Social Phobia
- Volume VII (2009): Geriatric Psychiatry; HIV AIDS Psychiatry and Psychosomatic Medicine; PTSD and Disaster Psychiatry; Sleep, Eating, and Sexual Disorders
- **Volume VIII** (2010): Psychotherapy; Personality Disorders and Temperament; Psychiatric Genetics and Genomics; Psychopharmacology
- Volume IX (2011): Addiction Psychiatry; Bipolar Disorder; Anxiety Disorders; Ethics and Professionalism

The American Board of Psychiatry and Neurology has reviewed FOCUS: The Journal of Lifelong Learning in Psychiatry and the FOCUS Self-Assessment Examination and has approved this program as part of a comprehensive lifelong learning and self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification.

ABPN approval is time limited to 3 years for each FOCUS CME course. Refer to APA's CME website for ABPN approval status of each course.

The FOCUS Self-Assessment Program is approved for up to 20 hours of continuing professional development per year under Section 3 of the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Psychiatric Association designates the FOCUS educational program for a maximum of 40 AMA PRA Category 1 Credits". Physicians should only claim credit commensurate with the extent of their participation in the activity

#### Visit the APPI Bookstore to purchase your subscription

#### One-Year Prices:

■ U.S. APA Members: \$2,96 **\$246** 

International Member: \$3/3 \$323

APA MIT (Online Only): \$96 \$46

■ U.S. Non-Member price: \$476 \$426 ■ International Non-Members: \$552 \$502



The First and Last Word in Psychiatry

American Psychiatric Publishing, Inc.

Web: www.appi.org and focus.psychiatryonline.org

Email: appi@psych.org

Phone: 1-800-368-5777 | 703-907-7322 | Fax: 703-907-1091

When ordering, please reference priority code AH1022

# TUESDAY

Program changes are printed each day in the Daily Bulletin. You can pick up the **Daily Bulletin** in Exhibit Halls B/C, First Level, Morial Convention Center and at many other locations throughout the convention center

#### 8:00 A.M. SESSIONS COURSES 65-68

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C, First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

#### COURSE 65

8:00 A.M.-NOON Bayside Room A, Fourth Floor, Sheraton New Orleans

How to Practice Evidence-BASED PSYCHIATRY: PRINCIPLES AND **CASE STUDIES** 

Director: Craig B. Taylor, M.D.

#### COURSE 66

8:00 A.M.-NOON

Oak Alley Room, Fourth Floor, Sheraton New Orleans

RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.

#### COURSE 67

8:00 A.M.-NOON

*Grand Ballroom B, Fifth Floor,* Sheraton New Orleans

ECT PRACTICE UPDATE FOR THE GENERAL PSYCHIATRIST

Director: Jerry L. Lewis, M.D., M.S.

Faculty:

Laurie McCormick, M.D. Peter Rosenquist, M.D. Andrew Krystal, M.D. Charles Kellner, M.D.

#### COURSE 68

8:00 A.M.- 5:00 P.M. Grand Ballroom A, Fifth Floor, Sheraton New Orleans

OFFICE-BASED BUPRENORPHINE TREATMENT OF OPIOID-DEPENDENT PATIENTS

**Director:** 

Petros Levounis, M.D., M.A.

**Faculty:** 

Andrew Saxon, M.D. Laura McNicholas, M.D., Ph.D. John Renner, M.D.

# 9:00 A.M. SESSIONS ADVANCES IN MEDICINE

9:00 A.M.-10:30 A.M. Rooms 217-219, Second Level, Morial Convention Center

MOVEMENT DISORDERS IN PSYCHIATRIC PATIENTS

Co-Chairs:

Laura Marsh, M.D. Joseph H. Friedman, M.D.

# ADVANCES IN SERIES 5-6

9:00 A.M.-NOON

Room R01, Second Level, Morial Convention Center

FAMILY ASSESSMENT AND INTERVENTION FOR PSYCHIATRISTS



Chair:

Gabor I. Keitner, M.D.

- 1. A Comprehensive **Approach to Patient** Care: The Problem-**Centered Systems** Therapy of the Family (PCSTF) Gabor I. Keitner, M.D.
- 2. The Assessment of Families Alison M. Heru, M.D.

#### **ADVANCES IN SERIES 6**

9:00 A.M.-NOON

Rooms 356/357, Third Level, Morial Convention Center

ADVANCES IN THE USE OF ANTIPSYCHOTIC MEDICATIONS



**Co-Chairs:** 

Anthony J. Rothschild, M.D. Kristina Deligiannidis, M.D.

- 1. An Evidence-Based Approach to the Use of Antipsychotic Medications in the Treatment of Mood and Anxiety Disorders Kristina Deligiannidis, M.D.
- 2. Antipsychotic Medication Use in Personality Disorders Kenneth R. Silk, M.D.
- 3. Use of Antipsychotic Medications in Schizophrenia and Schizoaffective Disorder Jayendra Patel, M.D.
- 4. Use of Antipsychotic Medications in the Medically Ill David Gitlin, M.D.

# CASE CONFERENCES

9:00 A.M.-10:30 A.M.

Rooms 228-229, Second Floor, Morial Convention Center

This session is open to APA members only. Blue registration badge or APA membership card required for admittance.

#### DEATH OF A PHYSICIAN BY SUICIDE

Chair:

Michael F. Myers, M.D.

# FORUMS

9:00 A.M.-10:30 A.M.

Room 224, Second Level, Morial Convention Center

Is a Game-Changing Рѕусноткоріс Тоо MUCH TO EXPECT?



Chair:

Philip T. Ninan, M.D.

**Presenters:** 

Philip Ninan, M.D. Amir Kalali, M.D. Jeffrey Lieberman, M.D. Stephen Stahl, M.D., Ph.D.

#### LECTURES 12-13 LECTURE 12

9:00 A.M.-10:30 A.M. Hall A, First Level,

Morial Convention Center

ADDICTION: CONFLICT BETWEEN BRAIN CIRCUITS

Frontiers of Science Lecture National Institute on Drug Abuse

Nora D. Volkow, M.D.

Chair:

Herbert D. Kleber, M.D.







Nora D. Volkow, M.D., became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. NIDA

supports most of the world's research on the health aspects of drug abuse and addiction. Dr. Volkow's work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects of drugs and their addictive properties. Her studies have documented changes in the dopamine system affecting the actions of frontal brain regions involved with motivation, drive, and pleasure and the decline of brain dopamine function with age. She has also made important contributions to the neurobiology of obesity, ADHD, and the behavioral changes that occur with aging.

#### LECTURE 13

9:00 A.M.-10:30 A.M.

Rooms R02-R05, Second Level, Morial Convention Center

FROM CIRCUITS TO CELLS TO MOLECULAR REGULATION:
IDENTIFYING NOVEL TARGETS FOR THE TREATMENT OF PSYCHOTIC DISORDERS
Frontiers of Science Lecture

Francine M. Benes, M.D.



Dr. Benes is the William P. and Henry B. Test Professor of Psychiatric Neuroscience at Harvard Medical School and Director of the Program in

Structural and Molecular Neuroscience and the Harvard Brain Tissue Resource Center, both located at McLean Hospital. She has served on the editorial boards or been a Section Editor of many neuroscience and psychiatry journals (i.e., Biotechniques, Schizophrenia Bulletin, Development and Psychopathology, American Journal of Psychiatry, Neuropsychopharmacology, Schizophrenia Research, Current Opinion in Psychiatry, Neuroscience.Net and Clinical Schizophrenia and Related Psychoses). She has also been invited to speak at many national and international meetings, including those sponsored by the NIH, the World Health Organization, the College de France, the National Academy of Sciences, Cold Spring Harbor Research Institute and the Nobel Committee in Stockholm.

Chair: Sukriti Mittal, M.D.

#### SCIENTIFIC AND CLINICAL REPORTS SCR 14

#### 9:00 A.M.-10:30 A.M.

Room 227, Second Level, Morial Convention Center

#### ANXIETY DISORDERS



#### Chair:

Derya Iren Akbiyik, M.D.

- **40.** The Long-Term Treatment of Obsessive Compulsive Disorder Afia Sadiq, M.D. Stepan Shannon, Ph.D. Eric D. Peselow, M.D.
- 41. Acute Treatment of Panic Disorder
  With Clonazepam or Paroxetine:
  A Randomized
  Naturalistic
  Open Study

Antonio E Nardi, M.D., Ph.D. Alexandre M. Valença, M.D. Rafael C. Freire, M.D. Roman Amrein, M.D. Aline Sardinha, M.Sc. Michelle N. Levitan, Psv.D. Isabella Nascimento, M.D. Valfrido L. de Melo Neto, M.D. Anna L. King, M.Sc. Adriana Cardoso, Ph.D. Gastão L. Soares-Filho, M.D. Rafael T. da Costa, Psv.D. Marco A. Mezzasalma, M.D. Marcele R. de Carvalho, M.Sc. Ana C. de Cerqueira, M.D. Marcio Versiani, M.D.

42. Recurrence of Panic Attacks
Following Medication
Discontinuation
Svetoslav Hristov, M.D.
Shannon Stepan, Ph.D.
Eric Peselow, M.D.

#### PRESIDENTIAL SYMPOSIA 4-5 PRESIDENTIAL SYMPOSIUM 4

#### 9:00 A.M.-NOON

Rooms 338/339, Third Level, Morial Convention Center

RECENT ADVANCES IN PSYCHIATRIC GENETICS: FROM FUNDAMENTAL DISCOVERY TO CLINICAL IMPLICATION

#### Co-Chairs:

Alan F. Schatzberg, M.D. Solomon Snyder, M.D.

1. Opportunities and Pitfalls in Psychiatric Genetics in 2010: Clinical Implications
Douglas F. Levinson, M.D.

- **2.** The Genetics of Autism Daniel Gerschwind, M.D.
- 3. A TOMM-40 Variable Length polyT Repeat Polymorphism, Inherited Through Evolution, Determines the Age of Onset Distribution of Late-Onset Alzheimer's Disease Allen Roses, M.D.
- 4. New Directions in the Genetics of Bipolar Disorder Pamela Sklar, M.D., Ph.D.
- **5. Progress in Schizophrenia Genetics** Patrick Sullivan, M.D.
- 6. Genomics of Ethnic Minority Groups: Pharmacogenomics of Depression in Mexican-Americans Julio Licinio, M.D.

#### PRESIDENTIAL SYMPOSIUM 5

9:00 A.M.-NOON

Rooms 353-355, Third Level, Morial Convention Center

#### HEALTH REFORM AND PSYCHIATRY

#### Chair

Steven S. Sharfstein, M.D.

#### Discussant:

James H. Scully, Jr., M.D.

- 1. What Will Be the Role of the Public Sector Following Health Reform? Howard H. Goldman, M.D.
- 2. The Impact of Health Reform on Inpatient and Outpatient Psychiatric Practice Steven S. Sharfstein, M.D.
- 3. Health Care Reform: An Academic Exercise? Anthony Lehman, M.D.
- 4. The Role of Managed Care in Health Care Reform Henry Harbin, M.D.



#### SESSION TRACKS

- Affective Disorders (Mood and Anxiety)
- 2 Personality Disorders
- 3 Psychopharmacology
- 4 Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- 6 NIDA
- 7 DSM-5



5. The Impact of Health Reform on Psychotherapy by Psychiatrists Eric M. Plakun, M.D.

#### MALL INTERACTIVE SESSIONS 9-13

These sessions are limited to 50 participants on a first-come, first-served basis.

#### SI 9

#### 9:00 A.M.-10:30 A.M.

Room 236, Second Level, Morial Convention Center

#### NEUROPSYCHIATRIC ASSESSMENT FOR GENERAL PSYCHIATRISTS

#### Chair:

Sheldon Benjamin, M.D.

#### 9:00 A.M.-10:30 A.M.

Room 237, Second Level, Morial Convention Center

#### WHAT'S NEW IN CHILD AND ADOLESCENT PSYCHIATRY?

#### Chair:

Mina K. Dulcan, M.D.

#### SI 11

#### 9:00 A.M.-10:30 A.M.

Room 335, Third Level, Morial Convention Center

#### REQUESTS TO EVALUATE PATIENTS' DECISIONAL CAPACITY IN THE MEDICAL SETTING: WHAT ARE THEY REALLY ASKING FOR?

Philip R. Muskin, M.D., M.A.

#### 9:00 A.M.-10:30 A.M.

Room 336, Third Level, Morial Convention Center

#### CAREER DEVELOPMENT FOR WOMEN IN PSYCHIATRY: RESIDENTS-CHALLENGES AND SOLUTIONS

#### Chair:

Carol C. Nadelson, M.D.

#### 9:00 A.M.-10:30 A.M.

Room 337, Third Level, Morial Convention Center

#### PSYCHIATRIC ISSUES IN PALLIATIVE CARE

Jarrett W. Richardson, M.D.

#### SYMPOSIA 60-68 SYMPOSIUM 60

#### 9:00 A.M.-NOON

Rooms 220/222, Second Level, Morial Convention Center

#### THE POTENTIAL AND PITFALLS OF CREATING A BIPOLAR GENOMIC BIOBANK

#### Chair:

Mark Frye, M.D.

- 1. Mayo Clinic Individualized Medicine Biobank for Bipolar Disorder: Overview Joachim Benitez, M.D.
- 2. Antidepressant-Induced Mania: The Need for **Rigorous Phenotypic** Assessment Mark Frye, M.D.
- 3. Retrospective Pharmacogenomic **Treatment Response** Susan McElroy, M.D.
- 4. Advocacy Collaboration **Into Biobanks** Allen Daniels, Ed.D.
- 5. Biobanking: New **Ethical Challenges?** Barbara A. Koenig, Ph.D.

#### SYMPOSIUM 61

#### 9:00 A.M.-NOON

Room 223, Second Level, Morial Convention Center

#### PSYCHIATRISTS IN THE WORLD: ADVOCATING FOR LGBT MENTAL HEALTH

#### Chair:

Mary E. Barber, M.D.

#### Discussants:

Annelle B. Primm, M.D., M.P.H. Nada L. Stotland, M.D., M.P.H

- 1. The Psychiatrist as Advocate: The Case of AGLP Mary E. Barber, M.D. Ubaldo Leli, M.D.
- 2. The GAP Online Curriculum on LGBT Mental Health Vernon A. Rosario, M.D. Serena Y. Volpp, M.D.
- 3. A Picture's Worth a **Thousand Words: Using Film for Mental** Health Advocacy and Activism Alicia J. Salzer, M.D.

4. Talking to the Media: **Teaching Psychiatrists to Embrace the Sound Bite** Jack Drescher, M.D.

#### SYMPOSIUM 62

#### 9:00 A.M.-NOON

Rooms 225/226, Second Level, Morial Convention Center

The Public Health and **Clinical Interface Between** HIV, STDs, and Mental Health

#### Chair:

Marshall Forstein, M.D.

- 1. The Public Health Interface Between HIV, Sexually Transmitted Diseases, and Mental Illness Marc A. Safran, M.D.
- 2. The Clinical Interface Between HIV, Sexually Transmitted Diseases, and Mental Illness Marshall Forstein, M.D.
- 3. The Impact of Neuropsychiatric Syndromes on the Course of Treatment in HIV Stephen J. Ferrando, M.D.

#### SYMPOSIUM 63

9:00 A.M.-11:00 A.M. Rooms 238/239, Second Level, Morial Convention Center

ADOLESCENT POTENTIAL: EXPLORING THE **DEVELOPING** BRAIN AND Understanding PATHWAYS OF ADDICTION National Institute

#### Co-Chairs:

on Drug Abuse

Cheryl Anne Boyce, Ph.D. Joseph Frascella, Ph.D.

- 1. The Developing Brain, Adolescence and Alcohol/ Drug Use: An Evolutionary Approach Linda Patia Spear, Ph.D.
- 2. The Teen Brain: Insights From Neuroimaging Jay N. Giedd, M.D.
- 3. Vulnerabilities in Adolescent **Decision Making: Neuroimaging Evidence of Immaturities** in Cognitive Control, Reward Processing, and Brain Connectivity Beatriz Luna, Ph.D.



Charles Geier, Ph.D. Katerina Velanova, Ph.D. Miya Asato, M.D. Kai Hwang Aarthi Padmanabhan Robert Terwilliger, M.S.

4. Brain Functioning in Adolescent Substance-Using Boys and Girls Susan F. Tapert, Ph.D. Sunita Bava, Ph.D. Krista Lisdahl Medina, Ph.D. Omar Mahmood, Ph.D. Joanna Jacobus, M.S.

#### SYMPOSIUM 64

#### 9:00 A.M.-NOON

Rooms 343/345, Third Level, Morial Convention Center

THE 2010 APA TASK FORCE REPORT ON THE PRACTICE OF ELECTROCONVULSIVE THERAPY: EVIDENCE BASED GUIDELINES FOR THE PRACTICING CLINICIAN Sponsored by: The APA Council on Research and Quality Care



William M. McDonald, M.D.

- 1. The History of the Classification of ECT and the Challenges for the Future Richard Weiner, M.D.
- 2. The Medical Evaluation and Consent Process for **Patients Undergoing ECT** Husain Mustafa, M.D.
- 3. Optimal Electrode Placement in the Administration of ECT Sarah H. Lisanby, M.D.
- 4. Emerging Data on the Importance of Pulse Width in ECT Joan Prudic, M.D.
- 5. Maintenance Treatment in ECT Charles H. Kellner, M.D.

#### SYMPOSIUM 65

9:00 A.M.-NOON

Rooms 346/347, Third Level, Morial Convention Center

**DSM-5** Examined: NOSOLOGY OF MOOD DISORDERS





S. Nassir Ghaemi, M.D., M.P.H.

Discussant:

Michael B. First, M.D.

1. How Do We Classify the Mood Disorders? Michael A. Schwartz, M.D.

- 2. Depression: When Sadness is "Lost," What Is Gained? Peter D. Kramer, M.D.
- 3. Pediatric Bipolar Disorder: More Than a Social Construction, Less Than a Natural Kind Peter Zachar, Ph.D.
- 4. Major Depressive Disorder **Deconstructed: Neurotic Depression and Mixed States** S. Nassir Ghaemi, M.D., M.P.H.
- 5. An Update From the DSM-5 Workgroup on Mood Disorder: A Focus on Bipolar Symptoms Trisha Suppes, M.D.

#### SYMPOSIUM 66

9:00 A.M.-NOON

Rooms 348/349, Third Level, Morial Convention Center

DSM-5 UPDATE SERIES. PART II: REPORTS FROM THE WORK GROUPS





#### Chair:

David J. Kupfer, M.D.

- 1. Balancing Conservation and Innovation in DSM-5: **Update on Attention-Deficit** Hyperactivity Disorder Xavier Castellano, M.D.
- 2. Reconsidering the Disruptive Behavior Disorders for DSM-5 David Shaffer, M.D. Paul J. Frick, Ph.D. Terrie E. Moffitt, Ph.D. Prudence W. Fisher, Ph.D. Michelle L. Gallagher, M.A.
- 3. Developing a New Model of Personality Disorders for DSM-5 Andrew E. Skodol, M.D.

#### SYMPOSIUM 67

9:00 A.M.-NOON.

Rooms 350-351, Third Level, Morial Convention Center

REVISITING PHARMACOLOGICAL TREATMENTS TO PREVENT SUICIDE



#### Co-Chairs:

Stephen Koslow, M.D. Paula J. Clayton, M.D.

#### Discussant:

Joseph Calabrese, M.D.

1. The Evidence for and Potential Impact of Clozapine on Suicide Risk in Schizophrenia: So How Do We Get Psychiatrists to Prescribe It? Herbert Y. Meltzer, M.D.

- 2. Mortality in Schizophrenia: An Eleven-Year Follow-Up Study of the Total Finnish Population (Fin11 Study) Kristian Wahlbeck, M.D. Jouko Lönnqvist, M.D., Ph.D. Timo Klaukka, M.D., Ph.D. Leo Niksanen, M.D. Antti Tanskanen, Ph.Lic. Jari Haukka, Ph.D.
- 3. Translating Suicide **Endophenotypes Shared** by Humans and Mice: Novel Strategies to Understand the Mechanism of Lithium's **Antisuicidal Efficacy** Todd Gould, M.D. Colleen E. Kovacsics, B.S. Irving I. Gottesman, Ph.D.
- 4. Association Between Consistent Purchase of Anticonvulsants or Lithium and Suicide Risk: A Longitudinal Cohort Study From Denmark, 1995-2001 Eric G. Smith, M.D.

#### SYMPOSIUM 68

9:00 A.M.-NOON Room 352, Third Level, Morial Convention Center

REWARD NEUROCIRCUITRY IN SUBSTANCE DEPENDENCE AND OTHER PSYCHIATRIC DISORDERS: WHAT DOES **BRAIN RESEARCH TELL US?** National Institute



#### Co-Chairs:

on Drug Abuse

Susan Volman, Ph.D. James M. Bjork, Ph.D.

- 1. Reward Neurocircuitry in **Preclinical Models: Foundations** and Alterations With Drug Use Susan R. Sesack, Ph.D.
- 2. Functional Neuroimaging of **Neural Circuits Regulating Aversive Emotional Reactions** and Expectations of Reward Mauricio Delgado, Ph.D.
- 3. Neuroimaging Studies of **Reward Processing in Major** Depressive Disorder Wayne C. Drevets, M.D.
- 4. Association of Nicotine Addiction and Nicotine's Actions With **Separate Cingulate Cortex Functional Circuits** Elliot Hong, M.D.
- 5. PET Evaluation of Neurocircuitry Related to **Etiology and Treatment** of ADHD





A.M.

James M. Swanson, Ph.D. Gene Jack Wang, M.D. Tim Wigal, Ph.D. Scott Kollins, Ph.D. Jeff Newcorn, M.D. Frank Telang, M.D. Jean Logan, Ph.D. Wei Zhu, Ph.D. Yeming Ma, Ph.D. Chris Wong, M.S. Kith Pradhan, M.S. Joanna Fowler, Ph.D. Nora D. Volkow, M.D.

# WORKSHOPS 88-93

9:00 A.M.-10:30 A.M. Room 210, Second Level, Morial Convention Center

AGING HEROICALLY IN AN URBAN SETTING: THE DIARY OF **JESSIE SYLVESTER** "THE BEAUTIFUL HILLS of Brooklyn"

Chair: David W. Preven, M.D.

#### WORKSHOP 89

9:00 A.M.-10:30 A.M. Room 230, Second Level, Morial Convention Center

TRANSCRANIAL MAGNETIC STIMULATION (TMS) IN THE TREATMENT OF MAJOR DEPRESSION: A New Therapeutic TOOL FOR PSYCHIATRY



Chair: John O'Reardon

**Presenters:** Amanda Helmer, R.N.

#### WORKSHOP 90

9:00 A.M.-10:30 A.M. Room 235, Second Level, Morial Convention Center

Understanding CPT CODING AND HOW FEES ARE CALCULATED

Sponsored by: The APA Committee on RBRVS, Codes and Reimbursement

Chair: Ronald M. Burd, M.D.

Presenters: Chester Schmidt, M.D. Tracy Gordy, M.D. David Nace, M.D. Jeremy Musher, M.D. Allan Anderson, M.D.

#### WORKSHOP 91

9:00 A.M.-10:30 A.M. Rooms 333/334, Third Level, Morial Convention Center

PRACTICAL CHALLENGES FOR PSYCHIATRISTS IMPLEMENTING THE RECOVERY MODEL

#### Chair:

Mark Ragins, M.D.

#### WORKSHOP 92

9:00 A.M.-10:30 A.M. Rooms 340/341, Third Level, Morial Convention Center

COGNITIVE-BEHAVIORAL AND PSYCHODYNAMIC APPROACHES TO MEDICATION ADHERENCE IN SEVERE MENTAL ILLNESS

#### Co-Chairs:

Jesse H. Wright, M.D., Ph.D. Glen O. Gabbard, M.D.

#### Presenters:

Douglas Turkington, M.D. Allan Tasman, M.D. Sarah Johnson, M.D., M.S.C.

#### WORKSHOP 93

9:00 A.M.-10:30 A.M. Room 342, Third Level, Morial Convention Center

**BOUNDARY CROSSINGS AS BOUNDARY ACCOMMODATIONS:** THE PHYSICIAN/PATIENT RELATIONSHIP WITH MEDICALLY ILL PATIENTS

#### Co-Chairs:

James W. Lomax, M.D. Catherine C. Crone, M.D.

#### **Presenters:**

Andreea Seritan, M.D. John Oldham, M.D., M.S.

# COURSES <u>53, 69-74</u>

9:00 A.M.-4:00 P.M.

Grand Ballroom E, Fifth Floor, Sheraton New Orleans

ADULT SEXUAL LOVE AND INFIDELITY



**Director:** 

Stephen B. Levine, M.D.

#### COURSE 69

9:00 A.M.-4:00 P.M. Borgne Room, Third Floor, Sheraton New Orleans

**PSYCHODYNAMIC** PSYCHOPHARMACOLOGY: APPLYING PRACTICAL PSYCHODYNAMICS TO IMPROVE PHARMACOLOGIC **OUTCOMES WITH** 

TREATMENT-RESISTANT PATIENTS





Director.: David L. Mintz, M.D.

#### Faculty:

Barri Belnap, M.D. Samar Habl, M.D. Anne Carter, M.D. David Flynn, M.D.

#### COURSE 70

9:00 A.M.-4:00 P.M.

Bayside Room C, Fourth Floor, Sheraton New Orleans

KUNDALINI YOGA MEDITATION TECHNIQUES FOR SCHIZOPHRENIA, THE PERSONALITY DISORDERS, AND AUTISM

#### Director:

David Shannahoff-Khalsa, B.A.

#### COURSE 71

9:00 A.M.-4:00 P.M.

*Gallier Rooms A/B, Fourth Floor,* Sheraton New Orleans

COGNITIVE-BEHAVIORAL ANALYSIS SYSTEM OF PSYCHOTHERAPY (CBASP): HOPE FOR CHRONIC DEPRESSION

#### **Co-Directors:**

Paula Ravitz, M.D. Sian Rawkins, M.D.

#### Faculty:

Molyn Leszcz, M.D.

#### COURSE 72

9:00 A.M.-4:00 P.M.

Nottoway Room, Fourth Floor, Sheraton New Orleans

NARRATIVE HYPNOSIS FOR PSYCHIATRY: EMPHASIS ON PAIN MANAGEMENT



**Director:** 

Lewis Mehl-Madrona, M.D., Ph.D.

Ann Marie Chiasson, M.D., M.P.H.

#### COURSE 73

9:00 A.M.-4:00 P.M.

Grand Couteau Room, Fifth Floor, Sheraton New Orleans

TRAUMA-INFORMED CARE: PRINCIPLES AND IMPLEMENTATION

#### Director:

Sylvia Atdjian, M.D.

#### **Faculty:**

Tonier Cain, Joan Gillece, Ph.D.

#### COURSE 74

9:00 A.M.-4:00 P.M.

Cornet Room, Eighth Floor, Sheraton New Orleans Hotel

THERAPEUTIC INTERVENTIONS IN **EATING DISORDERS: BASIC PRINCIPLES** 

#### Director:

David C. Jimerson, M.D.

#### Faculty:

Joel Yager, M.D. Katherine Halmi, M.D. Michael Devlin, M.D. James Mitchell, M.D.

# :00 A.M. SESSIONS ADVANCES IN MEDICINE

11:00 A.M.-12:30 P.M.

Room 217/219, Second Level, Morial Convention Center

AGING AND DEMENTIA: AN UPDATE ON NEUROSCIENCE AND BRAIN IMAGING

Chair: Anne L. Foundas, M.D.

#### CASE CONFERENCES CASE CONFERENCE

11:00 A.M.-12:30 P.M. Rooms 228/229, Second Level, Morial Convention Center

This session is open to APA members only. Blue registration badge or APA membership Card Required for Admittance.

#### HELPING PARENTS OF A FIRST-**EPISODE PSYCHOTIC PATIENT**



#### Director.:

S. Charles Schulz, M.D.

#### **Presenters:**

Richelle Moen, Ph.D. Michael O'Sullivan, M.D.

#### LECTURES 14-15 LECTURE 14

#### 11:00 A.M.-12:30 P.M.

Rooms R02/R05, Second Level, Morial Convention Center

CO-MORBIDITY OF **PSYCHIATRIC DISORDERS** Frontiers of Science Lecture

Ronald C. Kessler, Ph.D.

Chair: Richa Pathak, M.D.



Ronald Kessler is a Professor of Health Care Policy at Harvard Medical School. He received his Ph.D. in Medical Sociology from NYU in 1975. He then did postdoctoral

training at the New York State Psychiatric Institute and the University of Wisconsin in psychiatric epidemiology before joining the faculty at the University of Michigan in 1979. He became a Professor in the Department of Sociology and a Program Director in Michigan's Institute for Social Research. He moved to his current position as Professor of Health Care Policy at Harvard Medical School in 1997. Kessler's research deals broadly with the social determinants of mental health and illness as studied from an epidemiological perspective. He is the author of over 500publications and the recipient of many awards for his research, including Senior Scientist and MERIT awards from the National Institute of Mental Health. Kessler has been rated by the ISI as the most widely cited researcher in the field of psychiatry in the world for each of the last nine years.

#### LECTURE 15

11:00 A.M.-12:30 P.M. Rooms R06/R09, Second Level, Morial Convention Center

#### HIGHLIGHTS AND LESSONS FROM **40-PLUS YEARS IN PSYCHIATRY** International Guest Lecture



Eve C. Johnstone, M.D.



Eve Johnstone was born and brought up in Scotland. She qualified MBChB (Glasgow) in 1967 and trained as a psychiatrist in Glasgow. She went

to London in 1974 to work for the Medical Research Council in their Clinical Research Centre at Northwick Park. While there she conducted many studies of the course, treatment and biological basis of schizophrenia, including the first controlled study of cerebral ventricular size in schizophrenia using modern imaging published in the Lancet 1976. In 1989 she was appointed as Professor and Head of Department of Psychiatry in the University of Edinburgh. Since then she has been involved in family and cohort studies of psychotic illness, especially schizophrenia. She is the author of more than 300 journal articles, 9 books, and numerous other publications. Over her career she has won various prizes and awards and is involved in extensive committee work for the Medical Research Council and other governmental bodies.

#### Chair:

Rodrigo A. Munoz, M.D.

# CIENTIFIC AND CLINICAL PORTS: SESSIONS 15-16

#### 11:00 A.M.-12:30 P.M.

Room 227, Second Level, Morial Convention Center

Information TECHNOLOGY

#### Chair:

Jerrold J. Block, M.D.

- 44. Web-Based Access to **Medicaid Data to Support** the Implementation of Best Practices in Pharmacotherapy in a Large Scale Quality Matthew Perkins, M.D., M.P.H. Edith Kealey, M.S.W. Emily Leckman-Westin, Ph.D.
- 45. International Telepsychiatry in Cross-Cultural Related Mental Health Care Davor Mucic, M.D.

#### SCR 16

11:00 A.M.-12:30 P.M. Room 230, Second Level, Morial Convention Center

SIDE EFFECTS OF PSYCHOTROPIC MEDICATION



#### Chair.

David W. Preven, M.D.

- 46. Risk of Low Bone Mineral **Density Associated** With Psychotropic **Medications and Mental** Disorders: A Population-**Based Analysis** James M. Bolton, B.S.C., M.D. Laura E. Targownik, M.D. Stella Leung, M.Sc. Jitender Sareen, M.D. William D. Leslie, M.Sc., M.D.
- 47. Metabolic Syndrome in **Psychiatric Inpatients:** The Role of Valproate and Lithium Bonnie L. Szarek, R.N., John W. Goethe, M.D.
- 48. A Novel, Patient-Rated **Scale for Side Effects: Prospective Proof-of-Concept Study** Rajnish Mago, M.D. Angelica Kloos, D.O. Constantine Daskalakis, Sc.D. Michelle Shwarz, M.S. Ed. Barry Rovner, M.D.





# SMALL INTERACTIVE SESSIONS 14-18

These sessions are limited to 50 participants on a first-come, first-served basis.

#### SI 14

#### 11:00 A.M.-12:30 P.M.

Room 236, Second Level, Morial Convention Center

MEET THE EDITORS: PRINCIPLES AND PRACTICE OF CHILD AND ADOLESCENT FORENSIC MENTAL HEALTH

#### Chair:

Elissa P. Benedek, M.D.

#### **Presenters:**

Peter Ash, M.D. Charles L.Scott, M.D.

#### SI 15

#### 11:00 A.M.-12:30 P.M.

Room 237, Second Level, Morial Convention Center

#### ADDICTION AND THE BRAIN

National Institute on Drug Abuse

#### Chair:

Nora D. Volkow, M.D.

#### SI 16

#### 11:00 A.M.-12:30 P.M.

Room 335, Second Level, Morial Convention Center

# ETHICAL ISSUES IN PSYCHIATRY

#### Chair:

Paul S. Appelbaum, M.D.

#### SI 17

## 11:00 A.M.-12:30 P.M.

Room 336, Third Level, Morial Convention Center

# PSYCHIATRIC PHARMACOGENOMICS



#### Chair:

David A. Mrazek, M.D.

#### SI 18

#### 11:00 A.M.-12:30 P.M.

Room 337, Third Level, Morial Convention Center

#### PSYCHIATRIC ISSUES RELATED TO RETURNING VETS FROM IRAQ AND AFGHANISTAN

# 1

#### Chair

Elspeth C. Ritchie, M.D., M.P.H.

# WORKSHOP 94

#### 11:00 A.M.-12:30 P.M.

Room 210, Second Level, Morial Convention Center

# ETHICAL DILEMMAS IN PSYCHIATRIC PRACTICE

Sponsored by: The Ethics Committee

#### Chair:

Wade Myers, M.D.

#### **Presenters:**

Burton V. Reifler, M.D. Stephen Green, M.D., M.A. Elissa Benedek, M.D.

#### WORKSHOP 95

#### 11:00 A.M.-12:30 P.M.

Room 224, Second Level, Morial Convention Center

#### CAM OR SCAM FOR MOOD DISORDERS: HERBALS AND BEYOND!



#### **Co-Chairs:**

Vishal Madaan, M.D., M.B.B.S. Diana S. Domnitei, M.D.

#### **Presenters:**

Nalini V. Juthani, M.D.

#### WORKSHOP 96

11:00 A.M.-12:30 P.M. *Room 235, Second Level.* 

Room 235, Second Level, Morial Convention Center

#### A RESIDENT'S GUIDE TO BORDERLINE PERSONALITY DISORDER: FROM THE

EXPERTS (PART II)
(For Residents Only)

#### Chair

John G. Gunderson, M.D.

#### **Presenters:**

Kenneth R. Silk, M.D. Perry Hoffman, Ph.D. John Oldham., M.D., M.S. Brian Palmer, M.D., M.P.H. James Hall, B.S.

#### WORKSHOP 97

#### 11:00 A.M.-12:30 P.M.

Rooms 333/334, Third Level, Morial Convention Center

#### PSYCHIATRIC PROFESSIONAL LIABILITY 2009: THE YEAR IN REVIEW

#### Co-Chairs:

Donna Vanderpool, J.D., M.B.A. Martin G. Tracy, J.D.

#### **Presenters:**

Jacqueline Melonas, J.D., R.N.

#### WORKSHOP 98

11:00 A.M.-12:30 P.M.

Rooms 340/341, Third Level, Morial Convention Center

#### THE TRAIN HAS LEFT THE STATION: NATIONAL INCENTIVES AND DEVELOPMENTS IN ELECTRONIC HEALTH RECORDS

#### Chair:

Laura J. Fochtmann, M.D.

#### **Presenters:**

Zebulon Taintor, M.D. Robert Plovnick, M.D., M.S. Steven Daviss, M.D. Marc Graff, M.D.

#### WORKSHOP 99

#### 11:00 A.M.-12:30 P.M.

Room 342, Third Level, Morial Convention Center

#### COGNITIVE THERAPY FOR PSYCHOSIS IN PRACTICE: BASIC TECHNIQUES FOR PSYCHIATRISTS





#### Chair:

Shanaya Rathod, M.D.

#### **Presenters:**

Douglas Turkington, M.D. David Kingdon, M.D.

#### NEW RESEARCH/ POSTER SESSION 4

#### NOON-2:00 P.M.

La Louisiane C, First Level, Morial Convention Center

For further information on New Research submissions, please refer to the **New Research Program** section of this book.

# 1:30 P.M. SESSIONS ADVANCES IN MEDICINE ADVANCES IN MEDICINE 5

#### 1:30 P.M.-3:00 P.M.

Rooms 343/345, Third Level, Morial Convention Center

MEDICAL MYSTERIES AND PRACTICAL MEDICAL PSYCHIATRIC UPDATES: IS IT MEDICAL, PSYCHIATRIC, OR A LITTLE OF BOTH?

#### Chair:

Robert M. McCarron, D.O.

#### COURSES 75-76 COURSE 75

#### 1:00 P.M.-5:00 P.M.

Bayside Room A, Fourth Floor, Sheraton New Orleans Hotel

#### THE STANDARD EEG IN PSYCHIATRIC PRACTICE

#### **Directors:**

Nash N. Boutros, M.D. Silvana Riggio, M.D.

#### COURSE 76

#### 1:00 P.M.-5:00 P.M.

Grand Ballroom B, Fifth Floor, Sheraton New Orleans Hotel

#### EVIDENCE-BASED PSYCHODYNAMIC THERAPY



#### Co-Chairs:

Richard F Summers, M.D. Jacques P Barber, Ph.D.

# LECTURES 16-17

#### 1:30 P.M.-3:00 P.M.

Rooms R02-R05, Second Level, Morial Convention Center

#### New Directions in Drug Policy: PRESIDENT OBAMA'S NATIONAL **DEMAND REDUCTION PRIORITIES**

Special Guest Lecture National Institute on Drug Abuse

#### A. Thomas McLellan, Ph.D.

Deputy Director and Chief Scientist White House Office of National Drug Control Policy

#### Chair:

Charles O'Brien, M.D.



#### In 2009, A. Thomas McLellan, Ph.D.,

was sworn in as the Deputy Director of the Office of National Drug Control Policy. Dr. McLellan brings 35 years of addiction

treatment research to the position, most recently at the Treatment Research Institute, and the University of Pennsylvania. He is the recipient of several distinguished awards including the Life Achievement Awards of the American and British Societies of Addiction Medicine (2001 & 2003); the Robert Wood Johnson Foundation Innovator Award (2005); and awards for Distinguished Contribution to Addiction Medicine from the Swedish and Italian Medical Associations (2002). In his career he has published over 400 articles and chapters on addiction research and served as editor-in-chief of the Journal of Substance Abuse Treatment. Dr. McLellan has contributed to the advancement of substance abuse research and the application of research findings to treatment systems and public policy. Dr. McLellan holds a B.A. from Colgate University and his Ph.D. from Bryn Mawr College. He received postgraduate training in psychology at Oxford University in England.

#### LECTURE 17

1:30 P.M.-3:00 P.M.

Rooms R06/R09, Second Level, Morial Convention Center

TOWARD A NEW PSYCHIATRY: VALUING THE POSITIVE EMOTIONS Oskar Pfister Award Lecture

George E. Vaillant, M.D.

#### Co-Chairs:

James Lomax, M.D. Clark Aist, Ph.D.



Dr. Vaillant is

a Professor of Psychiatry at Harvard Medical School and the Department of Psychiatry, Brigham and Women's Hospital. Dr. Vaillant

has spent his research career charting adult development and the recovery process of schizophrenia, heroin addiction, alcoholism, and personality disorder. He has spent the last 35 years as Director of the Study of Adult Development at the Harvard University Health Service. The study has prospectively charted the lives of 824 men and women for almost 70 years. His published works include Adaptation to Life, 1977, The Wisdom of The Ego, 1993, The Natural History of Alcoholism-Revisited, 1995, and Aging Well, 2002. His most recent book on the positive emotions, Spiritual Evolution was published by Doubleday Broadway in 2008. Dr. Vaillant has received the Foundations Fund Prize for Research in Psychiatry from the American Psychiatric Association, the Strecker Award from The Institute of Pennsylvania Hospital, and the Jellinek Award for research in alcoholism. Most recently he received The Distinguished Service Award from the American Psychiatric Association.

## SCIENTIFIC AND CLINICAL REPORTS: SESSIONS 17-19

#### 1:30 P.M.-3:00 P.M.

Room 227, Second Level, Morial Convention Center

WEIGHT GAIN AND PSYCHIATRIC ILLNESS

#### Co-Chairs:

Jeffrey C. Fetter, M.D. Saleem Ismail, M.D.

49. Biochemical Risk Factors for Development of Obesity in First-Episode Schizophrenia Robert Bodén, M.D. Arvo Haenni, M.D., Ph.D. Leif Lindström, M.D., Ph.D. Johan Sundström, M.D., Ph.D.

- 50. Relationship Between Cholesterol **Levels and Cognitive Function** in Patients with Schizophrenia Randomized to Clozapine, Olanzapine and Haloperidol Menahem I. Krakowski, M.D., Ph.D. Pal Czobor, Ph.D.
- 51. Oatmeal Versus Donuts: Treating Metabolic Syndrome/ Obesity Using CBT/DBT in an **Inner City SPMI Population** Joanne Caring, M.D.

#### SCR 18

#### 1:30 P.M.-3:00 P.M.

Room 230, Second Level, Morial Convention Center

#### SUICIDE

Chair: Meera Vaswani, M.D., Ph.D.

- 52. The Relationship Between Anxiety **Disorders and Suicide Attempts:** Findings from the National **Epidemiologic Survey on Alcohol** and Related Conditions James M. Bolton, B.S.C., M.D. Josh Nepon M.D. Shay Lee Belik M.Sc. Jitender Sareen M.D.
- 53. Religion, Spirituality and Risk of **Suicidal Ideation and Attempts:** An Epidemiological Perspective Daniel T. Rasic, B.S., M.D. Jennifer Robinson, M.A. Jitender Sareen, M.D.
- 54. A Multi-Site Review of **Post-Discharge Suicides** Virginia L. Susman, M.D. Fritz Engstrom, M.D. Joseph Gold, M.D. Theodore Mucha, M.D. Robert Roca, M.D. Lisa Shea, M.D. Gail Tsimprea, Ph.D. Sharon Chaput, R.N. Barbara Charen, R.N. Judi Giorgi-Cipriano, R.N. Gail Nelson, R.N. Mary Brimson, R.N.

#### SCR 19

#### 1:30 P.M.-3:00 P.M.

Room 235, Second Level, Morial Convention Center

ATTENTION DEFICITS AND PSYCHOSTIMULANTS



#### Chair:

Vishal Madaan, M.D., M.B.B.S.

55. Double-Blind, Placebo-Controlled Efficacy and Safety Study of Lisdexamfetamine Dimesylate in Adolescents with Attention-Deficit/Hyperactivity Disorder





Ann C. Childress, M.D. Andrew J. Cutler, M.D. Maria Gasior, M.D., Ph.D. Mohamed Hamdani, M.S. Celeste Ferreira-Cornwell, Ph.D. Liza Squires, M.D. Robert L. Findling, M.D.

- 56. Is Deficient Emotional Self Regulation a Comorbid or Integral Feature of Attention-Deficit Hyperactivity Disorder in Adults? A Controlled Study Craig B. Surman, M.D. Joseph Biederman, M.D. Thomas Spencer, M.D. Carolyn A. Miller, B.A. Stephen V. Faraone, Ph.D.
- 57. Adjunctive Armodafinil for Major Depression Associated With Bipolar I Disorder: A Randomized, Double-Blind, Placebo Controlled Study Joseph R. Calabrese, M.D. Terence A. Ketter, M.D. James M. Youakim, M.D. Jane Tiller, FRCPsych Ronghua Yang, Ph.D. Mark A. Frye, M.D.

#### WORKSHOPS WORKSHOP 100

1:30 P.M.-3:00 P.M. Room 352, Third Level, Morial Convention Center

# RESPONDING TO THE IMPACT OF SUICIDE ON CLINICIANS

#### Chair:

Eric M Plakun, M.D.

#### **Presenters:**

Jane Tillman, Ph.D. Edward Shapiro, M.A., M.D.

#### 2:00 P.M. SESSIONS ADVANCES IN SERIES 7-8 ADVANCES IN SERIES 7

2:00 P.M.-5:00 P.M.

Rooms 353/355, Third Level, Morial Convention Center

ADVANCES IN SUBSTANCE ABUSE TREATMENT

National Institute on Drug Abuse

#### Co-Chairs:

Marc Galanter, M.D. Herbert D. Kleber, M.D.

- 1. The Treatment of Perinatal Addiction Hendree Jones, M.D.
- 2. The Use of Buprenorphine in the Treatment of Opioid Dependence
  John A. Renner, M.D.

- Affective Disorders (Mood and Anxiety)
- 2 Personality Disorders
- 3 Psychopharmacology
- 4 Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- 6 NIDA
- 7 DSM-5
- 3. Treatment of Anabolic-Androgenic Steroid Abuse Harrison Pope, M.D.
- 4. Treatment of Marijuana Abuse and Dependence Mark Gold, M.D.
- 5. Treatment of the Dually Diagnosed Richard K. Ries, M.D.

#### **ADVANCES IN SERIES 8**

2:00 P.M.-5:00 P.M. Rooms 356/357, Third Level, Morial Convention Center

#### ADVANCES IN PERSONALITY DISORDER



Co-Chairs: John M. Oldham., M.D., M.S. Andrew E. Skodol, M.D.

- 1. A Current Review of the Literature on Borderline Personality Disorder John M. Oldham., M.D.
- Behavioral Genetics of DSM-IV Personality Disorder Ted Reichborn-Kjennerud, M.D.
- 3. Mentalization and Mentalization-Based Treatment for Antisocial Personality Disorder Anthony W. Bateman, M.D.
- 4. Neuroimaging Social Behavior in Borderline Personality Disorder Brooks King-Casas, M.D.
- 5. Personality Disorders in *DSM-5*: Emerging Perspectives Andrew E. Skodol, M.D.
- 6. Psychodynamic Psychiatry of Obsessive-Compulsive Personality Disorder Glen O. Gabbard, M.D.

#### SYMPOSIA 69-84 SYMPOSIUM 69

2:00 P.M.-5:00 P.M. Room 210, Second Level, Morial Convention Center

IMPLEMENTING THE STEPPS\*
PROGRAM FOR BORDERLINE
PERSONALITY DISORDER
(\*SYSTEMS TRAINING FOR
EMOTIONAL PREDICTABILITY
AND PROBLEM SOLVING)



Chair: Donald W. Black, M.D.

**Discussant:** Paul Links, M.D.

- 1. Implementing the STEPPS Program in Iowa Prisons Nancee S. Blum, M.S.W. Bruce Sieleni, M.D. Jeff Allen, Ph.D.
- 2. VERS: A Randomized Controlled Trial of a Dutch Version of STEPPS for Borderline Personality Disorder Bas E.B. van Wel, M.D. Elisabeth H. Bos, Ph.D. Martin T. Appelo, Ph.D. Marc J.P.M. Verbraak, Ph.D.
- 3. Implementing STEPPS in the United Kingdom Renee Harvey, M.A.
- 4. Emotion Regulation Training (an adaptation of STEPPS) for Adolescents With Borderline Personality Symptoms
  Marieke H.M. Schuppert, M.D. Josephine Giesen Bloo, Ph.D. Tonny G. van Gemert, M.D. Herman M. Wiersema, M.D. Ruud B. Minderaa, Ph.D. Paul M.G. Emmelkamp, Ph.D. Maaike H. Nauta, Ph.D.

#### SYMPOSIUM 70

2:00 P.M.-5:00 P.M.

Rooms 217/219, Second Level, Morial Convention Center

EVIDENCE-BASED TREATMENTS (EBT) FOR BORDERLINE PERSONALITY DISORDER: EMPIRICAL CLARITY MEETS CLINICAL REALITY



Chair:

Lois W. Choi-Kain, M.D., M.Ed.

Discussant:

John G. Gunderson, M.D.

1. Development and Implementation of Transference-Focused Psychotherapy (TFP)
Otto F. Kernberg, M.D.



- 2. Integrating Mentalization-Based Treatment With Other Evidence-**Based Treatments for Borderline** Personality Disorder: Lethal Cocktail or Super Therapy? Anthony W. Bateman, M.B.B.S. Peter Fonagy, Ph.D.
- 3. The Trials and Tribulations of **Implementing Dialectical Behavior** Therapy Joan Wheelis, M.D.
- 4. Dialectical Behavioral Therapy and Mentalization-**Based Treatment: An Integration** of Two Empirically Validated **Treatments for BPD** Lois W. Choi-Kain, M.D.

Withdrawn

#### SYMPOSIUM 72

2:00 P.M.-5:00 P.M.

Room 223, Second Level, Morial Convention Center

THE NUTS AND BOLTS OF THE PERINATAL PSYCHIATRIC CONSULTATION

#### Co-Chair:

Allison S. Baker, M.D. Carolyn A. Broudy, M.D., M.S.

- 1. Evaluation of Mood and **Anxiety Disorders During** Pregnancy and the **Postpartum Period** Ruta M. Nonacs, M.D. Adele Viguera, M.D. Margaret Spinelli, M.D. Kristin Leight, M.D. Elisabeth M. Fitelson, M.D.
- 2. Staying Informed and Afloat: How to Approach **Evidence-Based Practice** in the Psychiatric Treatment of Pregnant and Postpartum **Patients** Elizabeth M. Fitelson, M.D.
- 3. Psychotherapy Treatments
- Margaret Spinelli, M.D. Jean Endicott Ph.D.
- 4. The Perinatal Psychiatric Consultation: Medication Treatment Adele C. Viguera M.D.
- 5. Putting It All Together: The Last Movement of the Perinatal Psychiatric Consultation Kristin Leight, M.D.

#### SYMPOSIUM 73

Withdrawn

#### SYMPOSIUM 74

2:00 P.M.-5:00 P.M. Rooms 225/226, Second Level, Morial Convention Center

THE TREATMENT OF PSYCHIATRIC DISORDERS WITH RTMS: NEW RESEARCH AND CLINICAL FINDINGS

#### Chair:

Allan S. Kaplan, M.D.

- 1. Repetitive Transcranial Magnetic **Stimulation for Auditory** Hallucinations in Schizophrenia Zafiris J. Daskalakis, M.D.
- 2. Transcranial Magnetic Stimulation (TMS) for Major Depression: Past, **Present and Future Challenges** Yechiel Y.L. Levkovitz, M.D. Abraham Zangen, Ph.D.
- 3. Can rTMS Help Obsessive-Compulsive Disorder? Peggy Richter, M.D. Zafiris J. Daskalakis, M.D. Eliza Burroughs, B.A. Melissa Daigle, B.A.
- 4. A Meta-Analytic Study Evaluating Brain Activation and Response to rTMS in Anorexia Nervosa Allan S. Kaplan, M.D. Kate Strasbury, M.D. Paul B. Fitzgerald, M.B.B.S., Ph.D. Angela R. Laird, Ph.D. Jerome Maller, Ph.D.

#### SYMPOSIUM 75

2:00 P.M.-5:00 P.M. Rooms 228/229, Second Floor, Morial Convention Center

THE TATTERED SAFETY NET: THE PUBLIC MENTAL HEALTH CRISIS IN AN ECONOMIC RECESSION Sponsored by: The APA Council on Minority Mental Health & Health Disparities

#### Chair:

Russell F. Lim, M.D.

#### Discussant:

Jeffrey Geller, M.D., M.P.H

- 1. Who Cares? Can We Afford to **Reduce Expenditures for Mental** Health Services in Times of Need? Anita S. Everett, M.D.
- 2. The Economic Downturn, Mental Health, Mental Illness: **Prospects for Recovery** Kenneth Thompson, M.D.
- 3. Mental Health Consequences of the U.S. Economic Downturn: What Do we Know and What can Be Done?

Lisa M. Bates, S.M. Kenneth S. Thompson, M.D.

- 4. Sacramento County, California: Budget Cuts, Work-Arounds, and **Unintended Consequences** Russell F. Lim, M.D.
- 5. Adding Insult to Injury: The Public Mental Health Crisis in Regions of Long-**Term Economic Stagnation** Patrick S. Runnels, M.D.
- 6. An Action Plan for Public Mental Health During an **Economic Recession** David A. Pollack, M.D.

#### SYMPOSIUM 76

2:00 P.M.-5:00 P.M.

Rooms 238/239, Second Level, Morial Convention Center

LESSONS FROM HURRICANE KATRINA: RESPONSE, RECOVERY AND REBUILDING

Howard J. Osofsky, M.D., Ph.D.

#### Discussant:

James H. Scully, Jr., M.D.

- 1. Charting the Course of **Recovery from Mental** Disorders in Hurricane Katrina Ronald C. Kessler, Ph.D.
- 2. The Federal Crisis **Counseling Program: Lessons From New Orleans** Kenneth Thompson, M.D.
- 3. Louisiana Spirit: Catastrophic Impact and Psychological Recovery Anthony Speier, Ph.D.
- 4. Mental Health and Recovery Following Hurricane Katrina Howard J. Osofsky, M.D., Ph.D. Joy D. Osofsky, Ph.D.

#### SYMPOSIUM 77

2:00 P.M.-5:00 P.M.

Room R01, Second Level, Morial Convention Center

TOWARD A NEW MODEL FOR MENTAL HEALTH SERVICES IN THE UNIVERSITY COMMUNITY Sponsored by: The APA Council on Children, Adolescents & Their Families

#### Co-Chairs:

Jerald Kay, M.D. Victor I. Schwartz, M.D.

#### Discussant:

Victor I. Schwartz, M.D.





- 1. The Need for a Community Mental Health Model Paul J. Barreira, M.D.
- 2. Contributions From the Public Health Orientation Laurie Davidson, M.A.
- 3. Integrating the Student's Family Into College Mental Health Kristine A. Girard, M.D.
- 4. The Campus as Community: Working With Administration Lorraine D. Siggins, M.D.
- 5. Psychiatry Residents in the College Mental Health Service Jerald Kay, M.D.

2:00 P.M.-5:00 P.M. Rooms 333/334, Third Level, Morial Convention Center

DSM-5 UPDATE SERIES, PART III:
REPORTS FROM
THE WORK GROUPS



Darrel A. Regier, M.D., M.P.H.

- 1. DSM-5 Update on Anxiety Disorders and Obsessive-Compulsive Spectrum Disorders Katharine A. Phillips, M.D.
- 2. Major Issues Concerning Mood Disorders in *DSM-5* Jan Fawcett, M.D.
- 3. Anticipating DSM-5: Schizophrenia and Related Psychoses William T. Carpenter, M.D.
- 4. Looking Towards *DSM-5:* PTSD and Dissociative Disorders Matthew J. Friedman, M.D.
- 5 Update from the Mood Disorders Workgroup, Bipolar Disorder Subcommittee Trisha Suppes, M.D.

#### SYMPOSIUM 79

2:00 P.M.-5:00 P.M. Rooms 338/339, Third Level, Morial Convention Center

THE CHALLENGE OF COGNITIVE ENHANCERS IN MEDICINE National Institute

on Drug Abuse

Co-Chairs: Nora D. Volkow, M.D. Ruben D. Baler, Ph.D., M.S.C.

- 1. 5-HT Receptors as Targets for Cognitive Enhancement in Schizophrenia Herbert Y. Meltzer, M.D.
- 2. ADHD Treatment, Comorbidity With SUDs, and COGS Related Diversion Nora D. Volkow, M.D.
- 3. Modafinil's Abuse
  Potential and Possible
  Role in Cocaine Dependence
  Charles Dackis, M.D.
- 4. Nonimpaired Elders, Cognitive Enhancers, and the Boundaries of Usual and Customary Practice James M. Ellison, M.D.
- 5. Pharmacological Cognitive Enhancement in Neuropsychiatric Disorders and in Healthy People Barbara Sahakian, M.D. Herbert Meltzer, M.D.

#### SYMPOSIUM 80

2:00 PM-5:00 P.M. Rooms 340/341, Third Level, Morial Convention Center

SEX AND PSYCHODYNAMICS: CONTEMPORARY APPROACHES TO CLINICAL ISSUES THROUGH THE LIFECYCLE Sponsored by: The American Academy of Psychoanalysis

#### Chair:

Sherry P. Katz-Bearnot, M.D.

and Dynamic Psychiatry

#### Discussant:

Richard C. Friedman, M.D.

- 1. Breaking the Silence: Discussing Sex With Teens in Psychotherapy Eugene Beresin, M.D.
- 2. Psychodynamics of Hypersexuality in Children and Adolescents With Bipolar Disorder Stewart L. Adelson, M.D.
- 3. Driven Sexual Behavior in Adults With "Soft Bipolarity:" A Psychodynamic Perspective Jennifer I. Downey, M.D.
- 4. The Role of Sexual History-Taking in Improving Psychotherapeutic Treatment Matthew Neltner, M.D.
- 5. Menopause, Depression, and Decreased Sexual Desire: A Psychodynamic Contribution Sherry P. Katz-Bearnot, M.D.

#### SYMPOSIUM 81

2:00 P.M.-5:00 P.M. Room 342, Third Level, Morial Convention Center

PROGRESS AND PROMISE: PREVENTING THE FIRST EPISODE OF PSYCHOSIS



#### Chair:

William R. McFarlane, M.D.

- 1. Cognitive & fMRI Studies in Clinical High Risk and Early Psychosis: Understanding Mechanisms and Predicting Risk Carter S Cameron, M.D. Tara Niendam Ph.D. J. Daniel Ragland Ph.D. Andrea Auther Ph.D. Barbara Cornblatt Ph.D. William Cook Ph.D. William McFarlane M.D.
- 2. Pattern of Neurocognitive
  Deficits in Individuals at
  Clinical High Risk for Psychosis
  Barbara Cornblatt, Ph.D.
  Ricardo Carrion, Ph.D.
  Terry Goldberg, Ph.D.
  Danielle McLaughlin, M.A.
  Andrea Auther, Ph.D.
  William Cook, Ph.D.
  William McFarlane, M.D.
- 3. Transitioning from First Episode to Prodrome: Learning from the EAST Program Robert Wolf, M.D., Tamara Sale, M.A. Roderick Calkins, Ph.D. Ryan Melton, L.P.C.
- 4. Portland Identification and Early Referral (PIER): Conversion and Incidence Outcomes in a Catchment Area-Wide Psychosis Prevention Program William R. McFarlane, M.D. William L. Cook, Ph.D. Donna Downing M.S., O.T.R./L Ezra Susser, M.D., Ph.D.

#### SYMPOSIUM 82

2:00 P.M.-5:00 P.M. Rooms 346/347, Third Level, Morial Convention Center

REPRODUCTIVE ISSUES AND WOMEN'S MENTAL HEALTH: HOW TO UNTIE THE GORDIAN KNOT?



#### Chair:

Gisèle Apter, M.D., Ph.D.

#### Discussant:

Carol Nadelson, M.D.

 Why Psychiatry and Abortion? Nada L. Stotland, M.D.





- 2. Dilemmas Concerning Miscarriage and Genetic Terminations Gail Erlick Robinson M.D., D.Psych, F.R.C.P. (C)
- 3. The Right to Health: The Need to Uphold Sexual and Reproductive Health to Promote Mental Health in Latin America Marta B. Rondon, M.D.
- 4 What if Motherhood Cannot Chase All the Blues Away? Gisèle Apter, M.D.

2:00 P.M.-5:00 P.M.

Rooms 348/349, Third Level, Morial Convention Center

TREATMENT OF DEPRESSION WITH TMS: An Overview of Findings FROM THE OPTIMIZATION OF TMS FOR THE TREATMENT OF DEPRESSION TRIAL (OPT-TMS)

#### Co-Chairs:

William M. McDonald, M.D. Mark S. George, M.D.

- 1. Introduction and State of the Current Practice and Knowledge Mark S. George, M.D.
- 2. Clinical Results From the Randomized OPT-TMS Trial Paul Holtzheimer, M.D.
- 3. How Do These Results **Relate to Clinical Practice** and How Do We Decide Who to Treat and for How Long? William M. McDonald, M.D.
- 4. How Do You Create a TMS Sham? Sarah H. Lisanby, M.D.
- 5. How Long Do the TMS **Clinical Effects Last?** Antonio Montavani, M.D.
- 6. How Does Prefrontal TMS Work to Treat Depression? Ziad H. Nahas, M.D.

#### SYMPOSIUM 84

2:00 P.M.-5:00 P.M.

Rooms 350/351, Third Level, Morial Convention Center

Mood, Memory and Myths: What REALLY HAPPENS AT MENOPAUSE?

#### Co-Chairs:

C. Neill Epperson, M.D. Ellen Freeman, Ph.D.

1. Depression and Other Symptoms: Risks in the Transition to Menopause Ellen Freeman, Ph.D.

- 2. Hot Flashes and Sleep Disturbances **During Menopause Transition: Exploring Effective Treatment Strategies** Claudio N. Soares, M.D.
- 3. Sexuality in Transition: Menopause and Aging Anita H. Clayton, M.D.
- 4. Where Did I Put My Keys? The Ongoing Saga of Estrogen, Serotonin, Mood and Memory at Menopause C. Neill Epperson, M.D.

# WORKSHOPS

2:00 P.M.-5:00 P.M.

Rooms 208/209, Second Level, Morial Convention Center

#### NOVEL PROGRAMS TO PROMOTE MENTAL WELLNESS IN MEDICAL STUDENTS

Sponsored by: The American Foundation for Suicide Prevention

#### Co-Chairs:

Iulie A Chilton, M.D. Leah J. Dickstein, M.D., M.A.

#### **Presenters:**

Leah Dickstein, M.D., M.A. Christine Moutier, M.D. Julie Chilton, M.D.

# NEW RESEARCH/ POSTER SESSION 5

3:00 P.M.-5:00 P.M.

La Louisiane C, First Level, Morial Convention Center

> For further information on New Research submissions, please refer to the New Research Program section of this book.

# FORUMS

30 P.M. SESSIONS

#### 3:30 P.M.-5:00 P.M.

Rooms 343/345, Third Level, Morial Convention Center

#### GLOBAL DISASTERS: LESSONS LEARNED FROM HAITI & NEW ORLEANS

*Sponsored by: The American* Psychiatric Association, Pan American Health Organization/World Health Organization, World Psychiatric Association Conflict Management and Resolution Section

#### Chair:

Eliot Sorel, M.D.

#### Presenters:

Russel Honore, M.D. Jean Luc Poncelet, M.D. Karen DeSalvo, M.D., M.P.H. Naotaka Shinfuku, M.D. Yueqin Huang, Ph.D. Eliot Sorel, M.D.

#### LECTURES LECTURE 18

3:30 P.M.- 5:00 P.M.

R02/R05 Second Level, Morial Convention Center

#### PREVENTION INITIATIVES IN SCHIZOPHRENIA

Research Award Lecture

Thomas H. McGlashan, M.D.

#### Chair:

Stuart C. Yudofsky, M.D.



Thomas H. McGlashan M.D., is currently Professor of Psychiatry in the Department of Psychiatry at the Yale University School of Medicine.

He enjoys a national and international reputation for his work on the course and outcome of schizophrenia. Dr. McGlashan conducted the now classic Chestnut Lodge Follow-Up Study and his work examining suicide, gender differences, the predicting of outcomes in schizophrenia, as well as the phenomenology and natural history of negative symptoms, obsessive compulsive symptoms, and spontaneous dyskinesia has been especially productive. His nosologic investigations of schizophrenia subtypes has informed his participation on the APA's workgroup to draft the DSM-IV diagnostic criteria for psychotic disorders and his being invited twice to be a member of the APA committee to draft the Practice Guidelines for Schizophrenia. Dr. McGlashan's work has had a substanial impact on the way we describe, diagnose, track, treat, and think about schizophrenia and severe personality disorders.

## CIENTIFIC AND CLINICAL REPORTS: SESSIONS 20-21 SCR 20

3:30 P.M.-5:00 P.M.

Room 227, Second Level, Morial Convention Center

INPATIENT PSYCHIATRY: Admissions and Readmissions

#### Chair:

Hina Tasleem, M.D.





- 58. The Association Between **Pre-Admission Suicidality** and Readmission is Modified by Patient Experiences, Feelings and Characteristics Stephen B. Woolley, D.Sc., M.P.H. John W. Goethe, M.D. Bonnie L. Szarek, R.N.
- 59. Effectiveness of Peer Support in Reducing Readmissions Among People with Multiple **Psychiatric Hospitalizations** William H. Sledge, M.D. Martha Lawless Dave Sells, Ph.D. Melissa Wieland, Ph.D. Maria O'Connell, Ph.D. Larry Davidson, Ph.D.
- **60.** Inpatients With Psychotic Versus Nonpsychotic MDD: Prevalence and Clinical Characteristics John W. Goethe, M.D. Bonnie L. Szarek, R.N.

#### SCR 21

3:30 P.M.-5:00 P.M.

Room 230, Second Level, Morial Convention Center

SCALES AND SCREENING MEASURE

#### Chair:

Elias Shaya, M.D.

- 61. Feasibility and Effectiveness of Using E-mail to Screen College Students for Depression Irene Shyu, B.A. Soo Jeong Youn, B.A. Maurizio Fava, M.D. Albert Yeung, M.D.
- 62. The Valuation of Impairment: Relative Values on the Psychiatric Impairment Rating (PIRS) Subscales Gordon R. Davies, M.B., B.S.
- 63. Are Screening Scales for Bipolar Disorder Good Enough to be **Used in Clinical Practice?** Mark Zimmerman, M.D.

Janine N. Galione, B.A. Camilo J. Ruggero, Ph.D. Iwona Chelminski, Ph.D. Kristy Dalrymple, Ph.D. Diane Young, Ph.D.

# WORKSHOPS 101-102

3:30 P.M.-5:00 P.M.

Room 235, Second Level, Morial Convention Center

ETHICAL CHALLENGES IN END-OF-LIFE CARE IN THE HOSPITALIZED ELDERLY

#### Chair:

Maria I. Lapid, M.D.

#### **Presenters:**

Jarrett Richardson, M.D. Maria I. Lapid, M.D. M. Caroline Burton, M.D.

#### WORKSHOP 102

3:30 P.M.-5:00 P.M.

Room 352, Third Level, Morial Convention Center

DYNAMIC THERAPY WITH SELF-**DESTRUCTIVE BORDERLINE PATIENTS:** AN ALLIANCE-BASED Intervention for Suicide

#### Co-Chairs:

Eric M. Plakun, M.D. Edward Robert Shapiro, M.A., M.D.

#### 4:00 P.M. SESSIONS **LECTURES**

4:30 P.M.-5:30 P.M.

Grand Salon A, First Level, Hilton New Orleans Riverside

DEPRESSION AND SUICIDAL BEHAVIOR IN LATINO POPULATIONS Simon Bolivar Award Lecture

Maria Oquendo, M.D.

Andres Pumariega, M.D.



Maria A. Oquendo, M.D., is Professor of Clinical Psychiatry at Columbia University, Training Director for the Residency

Program, and Vice-Chair for Education in the Department of Psychiatry at Columbia University and the New York State Psychiatric Institute (NYSPI). She is a Fellow of the American Psychiatric Association and the President of the American Society of Hispanic Psychiatrists. Her areas of expertise include the diagnosis, pharmacologic treatment, and neurobiology of bipolar disorder and major depression with a special emphasis on suicidal behavior, as well as Cross Cultural Psychiatry. Dr. Oquendo is the principal investigator on a NIMH-funded prospective study of suicidal behavior in patients with affective disorders and on a Conte Center project on candidate genes and HPA axis function in mood-disordered suicide attempters. She was recently awarded an R25 grant to create a research track in the residency-training program together with Drs. Gordon and Pincus. She has authored or co-authored over 200 peer-reviewed articles, chapters, and editorials.

# :00 P.M. SESSIONS

# WORKSHOPS

7:00 P.M.-10:00 P.M.

Grand Salon B, First Level, Hilton New Orleans Riverside

BOY INTERRUPTED



#### Co-Chairs:

Nancy Rappaport, M.D. Joanne Harpel, J.D.

#### **Presenters:**

Dana Perry





# WEDNESDAY

Program changes are printed each day in the **Daily Bulletin**. You can pick up the **Daily Bulletin** in Exhibit Halls B/C, First Level, Morial Convention Center and at many other locations throughout the convention center.

# 8:00 A.M. SESSIONS MASTER COURSES MASTER COURSE 5

#### 8:00 A.M.-NOON

Grand Ballroom C, Fifth Floor, Sheraton New Orleans Hotel

# NEUROPSYCHIATRY FOR VETERANS

#### Director(s):

Stuart C. Yudofsky, M.D. Thomas Kosten, M.D., M.A.

#### Faculty:

Robin Hurley, M.D. Thomas Kosten, M.D., M.A. Thomas Newton, M.D. Kimberly Arlinghaus, M.D.

# 9:00 A.M. SESSIONS CASE CONFERENCES CASE CONFERENCE 4

#### 9:00 A.M.-NOON

Rooms 338/339, Third Level, Morial Convention Center

This session is open to APA members only. Blue registration badge or APA membership card required for admittance.



#### THE SELF-DEFEATING PATIENT

#### Chair:

Glen O. Gabbard, M.D.

#### **Presenters:**

Funmilayo Rachal, M.D.



## COURSE 77

#### 9:00 A.M.- 4:00 P.M.

Grand Ballroom E, Fifth Floor, Sheraton New Orleans Hotel

KUNDALINI YOGA MEDITATION FOR ANXIETY DISORDERS INCLUDING OCD, DEPRESSION, ATTENTION-DEFICIT/HYPERACTIVITY DISORDER, AND POST-TRAUMATIC STRESS DISORDER

#### Director:

David Shannahoff-Khalsa, B.A.

# LECTURES

#### 9:00 A.M.-10:30 A.M.

Rooms R02-R05, Second Level, Morial Convention Center

#### So you Want to Be a Physician Executive

Administrative Psychiatry Award Lecture

#### Arthur L. Lazarus, M.D., M.B.A.

#### Chair:

Barry K. Herman, M.D.



Arthur Lazarus, M.D., M.B.A., is senior director of clinical research for AstraZeneca Pharmaceuticals in Wilmington, Del. He is responsible

for establishing AstraZeneca as the gold standard for medical research by developing and managing strategic clinical trials for pharmaceutical products and ensuring their successful utilization in the U.S. Dr. Lazarus has more than 20 years of experience in health care practice and administration. Previously, he served as director and medical research specialist for Pfizer, Inc. Earlier, he led quality management and care delivery programs at Humana, Prudential Health Care and Independence Blue Cross. Dr. Lazarus earned his medical and business degrees from Temple University in Philadelphia. He also has published over 100 articles in scientific and professional journals and cowrote or edited four books. He resides in Chadds Ford, Pa., with his wife and four children.

#### SCIENTIFIC AND CLINICAL REPORTS: SESSIONS 22-25 SCR 22

#### 9:00 A.M.-10:30 A.M.

Room 223, Second Level, Morial Convention Center

#### **GENETICS**

#### Chair:

Meera Vaswani, Ph.D.

64. Longer Hospitalization Associated With Combinatorial CYP450
Drug Metabolism Deficiencies
Gualberto Ruano, M.D., Ph.D.
David Villagra, B.A.
Bonnie L. Szarek, R.N.
Andreas Windemuth, Ph.D.
Mohan Kocherla M.S.
John W. Goethe, M.D.

- 65. Psychiatric Phenotype in Fragile X-Associated Tremor/ Ataxia Syndrome (FXTAS) Andreea L. Seritan, M.D. James A. Bourgeois, O.D., M.D. E. Melina Casillas, B.A. David Hessl, Ph.D. Andrea Schneider, Ph.D. Ying Yang, M.S. Inderjeet Kaur, M.B.B.S. Jennifer B. Cogswell, B.A. Danh V. Nguyen, Ph.D. Randi J. Hagerman, M.D.
- 66. Association of Seropositivity
  for Influenza and Coronaviruses
  With History of Mood Disorders
  and Suicide Attempts
  Olaoluwa O. Okusaga, M.D.
  Robert H. Yolken, M.D.
  Patricia Langenberg, Ph.D.
  Manana Lapidus, M.D.
  Timothy A. Arling, B.A.
  Faith B. Dickerson, Ph.D.
  Debra A. Scrandis, M.D.
  Johanna A. Cabassa, M.D.
  Theodora Balis, M.D.
  Teodor T. Postolache, M.D.

#### SCR 23

#### 9:00 A.M. -10:30 A.M.

Room 227, Second Level, Morial Convention Center

#### Issues in Child and Adolescent Psychiatry

#### Chair

Vishal Madaan, M.D., M.B.B.S.

- 67. Childhood and Adolescence **Predictors of Psychosis in General** Population in the Northern Finland 1986 Birth Cohort Pirjo H. Maki, M.D., Ph.D. Jouko Miettunen, Ph.D. Irma Moilanen, M.D., Ph.D. Marika Kaakinen, M.Sc. Anja Taanila, Ph.D. Tuula Hurtig, Ph.D. Graham Murray, M.D., Ph.D. Peter B. Jones, M.D., Ph.D. Matti Joukamaa, M.D., Ph.D. Markus Heinimaa, M.D., Ph.D. Sebastian Therman, M.Psych. Juha Veijola, M.D., Ph.D.
- 68. The Use of Video Feedback to Improve the Mother-Infant Relationship in Women With Postnatal Depression Anne Buist, M.D. Justin Bilszta Ph.D. Nur Rusydina Zulkefli Fandy Wang
- 69. Medical Comorbidity in Bipolar Children With Rapid Cycles: Is It Different Relative to Non-Rapid-Cycling Children? Ruby C. Castilla-Puentes, M.D., D.P.H.

Wilma I. Castilla-Puentes, M.D. Sandra R. Castilla-Puentes, M.D. Carlos Sanchez-Russi, Ph.D. Miguel E. Habeych, M.D.

#### SCR 24

9:00 A.M.-10:30 A.M.

Rooms 231/232, Second Level, Morial Convention Center

Antidepressant RESPONSE AND AUGMENTATION



#### Chair:

Tana A. Grady-Weliky, M.D.

- 70. Quetiapine Augmentation of **Antidepressant Treatment in Elderly Depressed Patients** Yoram Barak, M.D., M.H.A. Shelly Tadger, M.D. Diana Paleacu, M.D.
- 71. Do Adjunctive Stimulants **Destabilize Mood in Patients** With Bipolar Disorders? Findings From the STEP-BD Joseph F. Goldberg, M.D. John O. Brooks, III, M.D., Ph.D. Terence A. Ketter, M.D. Joseph R. Calabrese, M.D. Michael E. Thase, M.D.
- 72. Difference Between Morning and Evening TRH Tests Could **Predict Antidepressant Response** Fabrice Duval, M.D. Marie-Claude Mokrani, Ph.D. Felix Gonzalez Lopera, M.D. Thanh Son Diep, M.D. Hassen Rabia, M.D. Saïd Fattah, M.D.

#### SCR 25

9:00 A.M.-10:30 A.M.

Room 335, Third Level, Morial Convention Center

**PSYCHOPHARMACOLOGY** 



#### Chair: TBD

73. Tolerability of High-Dose Venlafaxine XL in Depressed

> Faouzi F.D. Alam, M.D., Psy.D. Patrick Mbaya, M.B.B.S., M.R.C.Psych., Krishna Soywmya, M.B.B.S., M.R.C.Psych. Javed Qaisar, M.B.B.S., M.R.C.Psych.

74. Twelve-Month Herbal Medicine Use for Mental Health From the **National Comorbidity Survey:** Replication (NCS-R) Simha E. Ravven, M.D. M. Bridget Zimmerman, Ph.D. Susan K. Schultz, M.D. Robert B. Wallace, M.D., M.S.

75. Relationship Between Serum Venlafaxine, Its Metabolite Levels (O-Desmethylvenlafaxine) and **Treatment Response in Patients** With Refractory Depression Qaiser Q. Javed, M.B.B.S. Alam F. M.R.C. Psych. Geetha Jaganathan, M.D.

These sessions are limited to 50 participants on a first-come, first-served basis.

9:00 A.M.-10:30 A.M.

Room 236, Second Level, Morial Convention Center

#### ALTERNATIVE TREATMENTS IN PSYCHIATRY



#### Chair:

David Mischoulon, M.D., Ph.D.

#### SI 20

9:00 A.M.-10:30 A.M.

Room 237, Second Level, Morial Convention Center

RESEARCH AND CLINICAL MANAGEMENT OF PATIENTS WITH TREATMENT-RESISTANT Depression

#### Chair:

Carlos Zarate, M.D.

9:00 A.M.-10:30 A.M.

Room 336, Second Level, Morial Convention Center

#### How to get Your PAPER PUBLISHED

#### Chair:

Julio Licinio, M.D.

#### SESSION TRACKS

- Affective Disorders (Mood and Anxiety)
- Personality Disorders
- Psychopharmacology
- Psychotherapy
- Schizophrenia and Other Psychotic Disorders
- NIDA
- DSM-5

9:00 A.M.-10:30 A.M.

Room 337, Third Level, Morial Convention Center

#### TREATMENT OF COMPLEX Mood Disorders



Chair:

Pedro L. Delgado, M.D.

#### SYMPOSIA 85-98 SYMPOSIUM 85

#### 9:00 A.M.-NOON

Rooms 220/222, Second Level, Morial Convention Center

#### Women's Mental Health IN LATIN AMERICA: PRESENT AND FUTURE RESEARCH



Co-Chairs:

Wilma I. Castilla-Puentes, M.D. Silvia Gaviria, M.D.

#### Discussant:

Maria Adelaida Rueda-Lara, M.D.

- 1. Depression Among Women With Cancer in Ecuador Carlos León-Andrade, M.D.
- 2. Childhood Sexual and **Physical Abuse History** in a Gynecology Outpatient Clinic in Colombia: How **Abuse Impacts Menopausal Symptoms**

Ruby C. Castilla-Puentes, M.D. Wilma I. Castilla-Puentes, M.D. Sandra R. Castilla-Puentes, M.D. Ivan Gomez, M.D. Carlos Sanchez-Russi, Ph.D. Miguel Habeych, M.D.

- 3. Improving the Treatment of Depression in Chilean Women Enrique Jadresic, M.D. Graciela Rojas, M.D.
- 4. Clinical Presentation and Treatment of Girls With Attention-Deficit/Hyperactivity Disorder in Chile and Argentina Arturo P. Grau, M.D. Roberto Yunes, M.D.
- 5. Women's Mental Health in Latin America: Present and Future Elvia Velásquez, M.D. Silvia Gaviria, M.D.
- 6. Differences and Similarities in Mental Health Issues Between Men and Women in Latin America Jorge Forero, M.D.

German Rueda, M.D. Christian Munoz, M.D. Castulo Cisneros, M.D.



7. Suicidal Behavior and Substance Abuse Among Sexually Abused Girls in Ecuador Emma Saad, M.D.

#### SYMPOSIUM 86

9:00 A.M.-NOON

Room 224, Second Level, Morial Convention Center

How Dysfunction of Learning and Memory Circuits Contribute to Substance Abuse and Other Psychiatric Disorders National Institute on Drug Abuse



#### Co-Chairs:

Roger G. Sorensen, Ph.D., M.P.A. Steven Grant, Ph.D.

- 1. Selective Impairments in Reward Versus Punishment Learning in Psychiatric Disorders Mark A. Gluck, Ph.D.
- 2. Addiction as Dysfunction in Learning- and Memory-Based Decision Systems: Multiple Potential Failure Points Leading to Multiple Addiction Endophenotypes A. David Redish, Ph.D.
- 3. Impaired Modulation of Learned Motivational Responses to Cues: Common Core Dysfunctions in Addiction—and in PTSD Anna Rose Childress, Ph.D.
- 4. Neuroplasticity in Prefrontal Regulation of the Basal Ganglia Underlies Vulnerability to Relapse Peter W. Kalivas, Ph.D. Haowei Shen, Ph.D. Khaled Moussawi, B.S.
- 5. Emotional Influences on Memory Circuits in Posttraumatic Stress Disorder and Healthy Adults Kevin S. LaBar, Ph.D.

#### SYMPOSIUM 87

9:00 A.M.-NOON

Rooms 225-226, Second Level, Morial Convention Center

Advances in Psychiatric Ethics: New Approaches that Inform Psychiatric Practice

#### Co-Chairs:

Philip J. Candilis, M.D. Jinger G. Hoop, M.D., M.F.A.

#### Discussant:

Laura W. Roberts, M.D.

1. Neuroethics: An Introduction for the Clinical Psychiatrist

Jinger G. Hoop, M.D. Ryan Spellecy, Ph.D.

- 2. Ethical Considerations
  From Military Psychiatry
  Christopher H. Warner, M.D.
  George N. Appenzeller, M.D., LTC,
  MC, USA
  Thomas Grieger, M.D., CAPT (RET),
  MC, USN
  David M. Benedek, M.D., LTC, MC,
  USA
  Laura W. Roberts, M.D., M.A.
- 3. What Do Forensic Ethics Mean for General Psychiatry? Philip J. Candilis, M.D.
- 4. Research Ethics and the Practicing Psychiatrist: The Brave New World of Research in One's Private Practice Donna T. Chen, M.D. Lois L. Shepherd, J.D.
- 5. Psychiatric Ethics Through the Prism of Geriatric Research Sahana Misra, M.D.

#### SYMPOSIUM 88

9:00 A.M.-NOON Rooms 228/229 Second Level, Morial Convention Center

ADHD FAQs: PRACTICAL Answers for the Office-Based Practitioner

#### Chair:

Gabriel Kaplan, M.D.

- 1. How Do I Identify and Treat Adult ADHD?
  Gabriel Kaplan M.D.
- Cardiovascular Effects of Stimulants—Is There Cause for Concern? Donald Greydanus, M.D.
- 3. How Do I Approach the Bipolar Versus ADHD Issue? Christopher K. Varley, M.D.
- 4. How Do I Manage the ADHD/SUD Comorbidity? Atilla Turgay, M.D.

#### SYMPOSIUM 89

9:00 A.M.-NOON

Room 230, Second Level, Morial Convention Center

AUTONOMY IN THE PROLONGATION AND CURTAILMENT OF LIFE

#### Co-Chairs:

Norman B. Levy, M.D. James J. Strain, M.D.

- 1. The Balance Between
  Suicide and Autonomous
  End-of-Life Decisions:
  A Model Based on
  Chronic Kidney
  Disease and Dialysis
  Lewis M. Cohen, M.D.
- 2. Existential Resilience in Metastatic Breast Cancer: Choosing Life While Facing Death David Spiegel, M.D. Chin-Po Paul Yang, M.D., Ph.D., M.P.H. Michael Norden, M.D. Amitava Biswas, M.D.
- 3. Ethics and Judao-Christian Views of Suicide and Life Extension Norman B. Levy, M.D.
- 4. Ethics in Suicide Not Associated With Psychiatric Illness James J. Strain, M.D. Rosamond Rhodes, Ph.D.

#### SYMPOSIUM 90

9:00 A.M.-NOON

Rooms 238/239, Second Level, Morial Convention Center

New Perspectives on Intergenerational Transmission of BPD



#### Chain.

John G. Gunderson, M.D.

- 1. Genetic and Environmental Contributions to Borderline Personality Disorder John Livesley, M.D.
- 2. Familial Aggregation and Heritability of Borderline Personality Disorder and Its Component Traits Mary C. Zanarini, Ed.D.
- 3. Rejection Sensitivity as a Core Trait of Borderline Personality Disorder
  Lois W. Choi-Kain, M.D.
  John G. Gunderson, M.D.
  James Hudson, M.D.
  Mary Zanarini, Ed.D.
- 4. Familiality of Candidate Phenotypes John G. Gunderson, M.D.
- 5. Infantile Hypersensitivity to the Social Environment and Potential Developmental Failure in Affect Regulation, Effortful Control and Mentalization Peter Fonagy, Ph.D.





9:00 A.M.-NOON

Room R01, Second Level, Morial Convention Center

**NEW CANMAT GUIDELINES** FOR DEPRESSION AND BIPOLAR DISORDER: **COMBINING EVIDENCE** WITH CLINICAL PRACTICE



Roumen V. Milev, M.D., Ph.D.

- 1. CANMAT Clinical Guidelines for Mood & Anxiety Disorders-**History and Development** Sidney H. Kennedy, M.D.
- 2. CANMAT Clinical Guidelines for Management of Adults With **Major Depressive Disorder** Raymond W. Lam, M.D.
- 3. CANMAT Guidelines for Management of Bipolar Depression Lakshmi N. Yatham, M.B.B.S.
- 4. Combining Evidence-Based Psychiatry With Clinical Practice—CANMAT and Other Recent Guidelines Sagar Parikh, M.D.

#### SYMPOSIUM 92

9:00 A.M.-NOON Rooms 340/341, Third Level, Morial Convention Center

#### UPDATE ON CANNABIS Use Disorders

#### Chair:

David A. Gorelick, M.D., Ph.D.

- 1. Marijuana Abuse and Dependence in the General Population: Risk Factors, Symptom Structure, and Axis I and Axis II Comorbidity **Effects on Persistence** Deborah S. Hasin, Ph.D. Efrat Aharonovich, Ph.D. Katherine Keyes, M.P.H. Timothy Geier, B.A.
- 2. Neurobiology and Brain Imaging of Cannabis Dependence Aviv Weinstein, B.S.C.
- 3. Advances in the Development of Behavioral Treatments for **Cannabis Use Disorders** Alan Budney, Ph.D.
- 4. Advances in the Development of Pharmacological Treatments for Cannabis Use Disorders Margaret Haney, Ph.D.
- 5. Medical and Psychiatric Effects Associated With Cannabis Use David A. Gorelick, M.D.

#### SYMPOSIUM 93

9:00 A.M.-NOON Room 342, Third Level, Morial Convention Center

CULTURAL ADAPTATION OF **COGNITIVE-BEHAVIOR** THERAPY FOR ETHNIC/ MINORITY PATIENTS



#### Co-Chairs:

Stephen M. Goldfinger, M.D. Shanaya Rathod, M.D.

#### Discussant:

Toshiaki A. Furukawa, M.D., Ph.D.

- 1. Cognitive-Behavior Therapy Across Cultures David G. Kingdon, M.D.
- 2. Developing Culturally Sensitive Cognitive-Behavior Therapy for Psychosis: A United Kingdom-Based Study Shanaya Rathod, M.D. David G. Kingdon, M.D. Peter Phiri
- 3. Developing Culturally Sensitive **CBT Project, Southampton:** Adaptation of CBT for Depression in Pakistan Farooq Naeem, M.R.C. Mary Gobbi, M.D. Mohammed Ayub, M.B.B.S. David G. Kingdon, M.D.
- 4. Implementing CBT for Psychosis in the Treatment of Ethnic Minorities in the United States Michael Garrett, M.D.

#### SYMPOSIUM 94

9:00 A.M.-NOON

Rooms 346/347, Third Level, Morial Convention Center

#### CHOOSING THE RIGHT TREATMENT FOR SUBSTANCE ABUSE

Chair: Herbert D. Kleber, M.D.

- 1. Choosing the Right Treatment for Cocaine Dependence Adam Bisaga, M.D.
- 2. Choosing Treatments for Cannabis Dependence: What Are the Options? Frances R. Levin, M.D.
- 3. Principles of Combining Medications and Psychosocial Interventions in the Treatment of Substance Dependence Edward V. Nunes, M.D.
- 4. Pain and Addiction: Substance Use Disorders in the **Context of Opioid Therapy** Maria A. Sullivan, M.D.

#### SYMPOSIUM 95

9:00 A.M.-NOON Rooms 348/349, Third Level, Morial Convention Center

SHOULD "RISK SYNDROME OF PSYCHOSIS" BE INCLUDED IN DSM-5 AS A DIAGNOSIS? A ROAD TOWARD PREVENTIVE PSYCHIATRY





Amresh Shrivastava, M.D., D.P.M.

#### Discussant:

William Carpenter, M.D.

- 1. Risk Syndrome of Psychosis as a Diagnosis in DSM-5: Is the Question Legitimate? Amresh Shrivastava, M.D. John John, M.D. Megan Johnston, M.A.
- 2. Inclusion of the Psychosis Risk Syndrome in *DSM-5*: An Argument for Placing It in the Appendix Cheryl Corcoran, M.D.
- 3. An Overview of the Current Status of Risk Syndrome for Psychosis Ming T. Tsuang, M.D. Larry J. Seidman, Ph.D.
- 4. Risk Syndrome for Psychosis: A Reliable and Valid Diagnosis Scott W. Woods, M.D.
- 5. Inclusion of the Psychosis At-Risk Category in DSM-5: Is It Premature? Barbara Cornblatt, Ph.D.

#### SYMPOSIUM 96

9:00 A.M.-NOON

Room 352, Third Level, Morial Convention Center

BASIC SCIENCE IN PSYCHIATRY: A Move Toward Translational MEDICINE

#### Chair:

Mark H. Rapaport, M.D.

- 1. Synaptic Biology of Depression: G Proteins, Lipid Rafts, and the Search for a Biomarker Mark M. Rasenick, Ph.D.
- 2. Animal Models: Cell Cycle Regulators and Neurobehavioral Disorders Robert N. Pechnick, Ph.D.
- 3. Altered Brain Bioenergetics: A Reflection of Mitochondrial **Dysfunction During the Treatment** of Major Depressive Disorder Dan V. Iosifescu, M.D.





4. Neurogenesis Assays Prospectively Identify a Novel Clinically Efficacious Combination for the Treatment of Major Depressive Disorder Carrolee Barlow, M.D.

#### SYMPOSIUM 97

9:00 A.M.-NOON

Rooms 353/355, Third Level, Morial Convention Center

THE SUPREME COURT AND PSYCHIATRY IN THE 21ST CENTURY

#### Chair:

Paul S. Appelbaum, M.D.

#### Discussant:

Richard Bonnie, J.D.

- 1. Atkins v. Virginia: Mental Retardation and the Death Penalty Paul S. Appelbaum, M.D.
- 2. Clark v. Arizona: The Supreme Court Considers the Insanity Defense and Psychiatric Testimony Steven K. Hoge, M.D.
- 3. Panetti v. Quarterman (2007)
  Competence to be Executed:
  An Ethical Challenge for
  Psychiatrists and the Evolution
  of the Legal Standard
  Howard V. Zonana, M.D.
- 4. Indiana v. Edwards:
  Competence to Represent Oneself
  Debra Pinals, M.D.
  Howard Zonana, M.D.
  S. Kenneth Hoge, M.D.
  Richard Bonnie, L.L.B.
  Paul S. Appelbaum, M.D.

#### SYMPOSIUM 98

9:00 A.M.-NOON

Rooms 356/357, Third Level, Morial Convention Center

Novel Tools for Preventing and Treating Substance Use and Comorbidities in the Military and Returning Veterans

RETURNING VETERANS
National Institute
on Drug Abuse

#### Co-Chairs:

Cecelia M. Spitznas, Ph.D. Eve E. Reider, Ph.D.

#### **Discussant:**

Michael Kilpatrick, B.A., M.D.

1. Understanding Long-Term Tobacco and Alcohol Use and Comorbid Mental Health Symptoms in Military Service Members and Veterans: The Millennium Cohort Study Tyler C. Smith, Ph.D.

- 2. Automated Interactive Voice Response as a Therapeutic Tool for Chronic Pain Reduction and Opioid Medication Use Decrease Magdalena R. Naylor, M.D., Ph.D. Shelly Naud, Ph.D. Bart Brigidi, Ph.D. Michele Comette, B.A. Francis J. Keefe, Ph.D. John E. Helzer, M.D.
- 3. Virtual Reality and D-Cycloserine for Exposure-Based Therapy Barbara Rothbaum, Ph.D.
- 4. The Video Doctor Approach:
  Potential Applications to
  Psychiatric Practices Serving
  Patients Impacted by War
  Barbara Gerbert, Ph.D.
- 5. Computer-Based Training in Cognitive-Behavior Therapy: New Findings and Applications for Military Personnel Kathleen M. Carroll, Ph.D. Samuel A. Ball, Ph.D. Steve Martino, Ph.D. Charla Nich, M.S. Bruce J. Rounsaville, M.D.

#### WORKSHOP 103-106 WORKSHOP 103

9:00 A.M.- 10:30 A.M. Room 210, Second Level, Morial Convention Center

MAKING YOUR PRESENTATION MORE INTERACTIVE: THE BETTER WAY!

#### Chair:

Jon J.D. Davine, M.D.

#### WORKSHOP 104

9:00 A.M.-10:30 A.M.

Room 235, Second Level, Morial Convention Center

FIGHTING STIGMA: WHEN
PSYCHIATRISTS WHO HAVE
BEEN IN TREATMENT SPEAK OUT

#### Co-Chairs:

Michael F. Myers, M.D. Leah J. Dickstein, M.D., M.A.

#### **Presenters:**

Alphonse Osinski, M.D. Raymond Reyes, M.D. Suzanne E. Vogel-Scibilia, M.D. Francine Cournos, M.D.

#### WORKSHOP 105

9:00 A.M.-10:30 A.M. Room 333/334 Third Level, Morial Convention Center

THE AWKWARD PROCESS OF RECRUITING YOUR OWN

#### Chair:

Lewis Krain, M.D.

#### **Presenters:**

Brandi Hawkins, Ph.D. Gregory Dalack, M.D. Michael Jibson, M.D., Ph.D. Molly Gathright, M.D.

#### WORKSHOP 106

9:00 A.M.-10:30 A.M.

Rooms 350/351, Third Level, Morial Convention Center

ASSESSMENT OF CAPACITY: DEVELOPMENTS, DOCUMENTATION AND DEFENDABILITY

#### Chair:

Michael Jan Wise, M.B.B.S, M.S.C.

#### **Presenters:**

Julian Beezhold, M.D.

#### MEDIA WORKSHOP 7

9:00 A.M.-NOON

Rooms 208/209, Second Level, Morial Convention Center

BUILDING BRIDGES: THE INTERSECTION BETWEEN FAITH AND MENTAL HEALTH

#### Co-Chairs:

Asghar-Ali A. Ali, M.D. Cecil R. Webster, M.D.

#### **Presenters:**

Toi Harris, B.A., M.D. Annelle Primm, M.D., M.P.H. Valdesha Ball, M.D. Chanda Mayers-Elder, M.D.

# 11:00 A.M. SESSIONS ADVANCES IN MEDICINE ADVANCES IN MEDICINE 6

11:00 A.M.-12:30 P.M. Rooms 217/219, Second Level, Morial Convention Center

AN UPDATE ON GASTRO-ENTEROLOGY AND HEPATOLOGY FOR PSYCHIATRISTS AND MENTAL HEALTH PRACTITIONERS

#### Chair:

Nathaniel S. Winstead, M.D., M.P.H.

# LECTURES LECTURE 21

11:00 A.M.-12:30 P.M.

Rooms R02-R05, Second Level, Morial Convention Center

SEEK AND TREAT FOR OPTIMAL PREVENTION OF HIV/AIDS-STOP HIV/AIDS Frontiers of Science Lecture

National Institute on Drug Abuse



Julio Montaner, M.D.

Annette M. Matthews, M.D.



**Julio Montaner**. M.D. received his M.D. with honors in 1979 at the University of Buenos Aires, Argentina. In 1981, he joined the

University of British Columbia as a postdoctoral fellow, completed a residency in internal medicine and respiratory medicine and was chief resident for the Department of Medicine in 1986/1987. In 1987 Dr. Montaner joined the faculty at St. Paul's Hospital/University of British Columbia (SPH/UBC) as the director of the AIDS Research Program and the Infectious Disease Clinic. He is the director of clinical activities at the BC Centre for Excellence in HIV/AIDS and a founding co-director of the Canadian HIV Trials Network. He held a National Health Research Scholar of Health Canada for 10 years starting in 1988. In 1996 he successfully competed for the Endowed Chair on AIDS at SPH/UBC. In 1997, he was appointed professor of medicine at UBC.

## SCIENTIFIC AND CLINICAL REPORTS: SESSIONS 26-29

#### 11:00 A.M.-12:30 P.M.

Room 223, Second Level, Morial Convention Center

#### **PSYCHOSIS**



#### Chair

Douglas L. Noordsy, M.D.

- 76. Catatonia: A "Frozen Condition"? **New Treatment Options Based on Case Reports** and Literature Review Cristinel M. Coconcea, M.D.
- 77. Racial Differences in Major Depressive Disorder With **Psychotic Features** Karen Bullock, Ph.D. Bonnie L. Szarek, R.N. John W. Goethe, M.D.
- 78. Toward a Better Understanding of the Interaction Between Religious Delusions and the Clinical and **Religious Background of Patients** With Schizophrenia Philippe Huguelet, M.D. Rieben Isabelle, M.A. Mohr Sylvia, Ph.D.

11:00 A.M.-12:30 P.M. Room 227, Second Level, Morial Convention Center

#### Issues in Mood Disorders



James Ellison, M.D.

- 79. Minor Mixed Depression (Formerly Mixed Affective State): A Treatable Condition in Violent Court-Ordered **Detention Patients With a Personality Disorder** Carel C.V. De Blécourt, M.D., Ph.D. Tjoe I. Oei, M.D., Ph.D.
- 80. Psychosocial Impairment Associated With Dysthymic Disorder in the NESARC Study David J. Hellerstein, M.D. Vito Agosti, C.S.W. Sarah Black, M.A. Monica Bosi, M.D.
- 81. Increased Mortality and **Hospital Readmissions** in Patients Depressed at the Time of Discharge From Medical Wards Antonio Campayo, M.D. Antonio Bulbena, M.D., Ph.D. Joan DePablo, M.D., Ph.D. Josep Maria Farré, M.D., Ph.D. Eduardo García-Camba M.D., Ph.D. Javier García-Campayo, M.D., Ph.D. Manuel Girón, M.D., Ph.D. María Carlos Mingote, M.D., Ph.D. Luís Salvador-Carulla, M.D., Ph.D. F. Barcones, B.Sc. Javier Santabárbara, B.Sc. Pedro Saz, M.D., Ph.D. Aurora Sarasola, M.D., Ph.D. Antonio Lobo, M.D., Ph.D.

#### SCR 28

11:00 A.M.-12:30 P.M.

Rooms 231/232, Second Level, Morial Convention Center

#### EPIDEMIOLOGY, SLEEP, AND MEDICAL SCREENING

#### Chair:

Daniel Chapman, M.D.

- 82. Laboratory Evaluation of Psychiatric Patients in the **Emergency Room** Leslie Zun, M.D., M.B.A. Lavone Downey, Ph.D.
- 83. STOP-BANG Sleep Apnea Screening Evinces a High Risk **Among Patients Admitted to Psychiatric Units** Sam Al-Saadi, M.D., M.S. Thomas Newmark M.D. Karl Doghramji, M.D.

84. Schizotypal Personality Disorder in the United States: Prevalence and Correlates in a Representative **General Population Sample** Vanessa Lentz, M.S., B.S., Jennifer Robinson, B.A. (Hons) James M. Bolton, M.D.

#### SCR 29

11:00 A.M.-12:30 P.M.

Room 335, Third Level, Morial Convention Center

IMPORTANT BUT INFREQUENTLY ADDRESSED TOPICS

#### Chair:

Elias K. Shaya, M.D.

85. Overdiagnosis of Bipolar Disorder and **Disability Payments** Mark Zimmerman, M.D. Janine N. Galione, B.A. Camilo J. Ruggero, Ph.D. Iwona Chelminski, Ph.D. Kristy Dalrymple, Ph.D. Diane Young, Ph.D.

- 86. Can We Talk? Do Psychotherapists and Prescribing Psychiatrists Communicate With Each Other **About Their Mutual Patients?** Thomas P. Kalman, M.D., M.S. Jolie Avena, B.A.
- 87. The Economic Impact of **Medication-Access Problems Among Medicaid Psychiatric Patients in Ten States** Joyce C. West, Ph.D., M.P.P. Donald S. Rae, M.S. Maritza Rubio-Stipec, Sc.D. Haiden Huskamp, Ph.D. Darrel A. Regier, M.D., M.P.H.

# WORKSHOPS 107-109 WORKSHOP 107

11:00 A.M.-12:30 P.M.

Room 235, Second Level, Morial Convention Center

TAI CHI EXERCISE, A CONTROLLABLE PHYSICAL INTERVENTION TO ENHANCE MINDFULNESS AND BEHAVIORAL ACTIVATION IN CBT GROUP TREATMENT FOR DEPRESSED PATIENTS

Co-Chairs:

Jun Yang, M.D., Ph.D. Jennice Vilhauer, Ph.D.

**Presenters:** 

Ernest Rasyidi, M.D.

#### WORKSHOP 108

11:00 A.M.-12:30 P.M. Rooms 333/334, Third Level, Morial Convention Center



Using the DSM-IV-TR Outline FOR CULTURAL FORMULATION FOR CULTURALLY APPROPRIATE ASSESSMENT: A SKILLS-BASED APPROACH WITH DVD CASES

Russell F. Lim, M.D.

#### WORKSHOP 109

11:00 A.M.-12:30 P.M.

Rooms 350/351, Third Level, Morial Convention Center

#### CHILDREN OF PSYCHIATRISTS

#### Co-Chairs:

Michelle B. Riba, M.D., M.S. Leah J. Dickstein, M.D., M.A.

#### **Presenters:**

Evan Moffic Erica Riba Stacia Goldstein, B.S., M.Ed.

## NOON SESSIONS NEW RESEARCH/ POSTER SESSION 6

NOON- 2:00 P.M.

La Louisiane C, First Level, Morial Convention Center

> For further information on New Research submissions, please refer to the **New** Research Program section of this book.

## 1:00 P.M. SESSIONS SEMINARS

1:00 P.M.- 5:00 P.M.

Room 223, Second Level, Morial Convention Center

PRACTICAL GUIDE TO THE PERFORMANCE OF THE MENTAL STATUS EXAMINATION

#### Chair:

Stephen I. Deutsch, M.D., Ph.D.

Richard B. Rosse, M.D. Stephen I. Deutsch, M.D., Ph.D.

# WORKSHOPS 110-112

1:30 P.M.- 3:00 P.M. Room 235, Second Level, Morial Convention Center

GAMES PEOPLE PLAY: WHAT EVERY PSYCHIATRIST NEEDS TO KNOW ABOUT VIDEO GAMES

#### Co-Chairs:

Deidre E. Williams, M.D., M.Ed. Faye Chao, M.D.

#### **Presenters:**

Jason Caplan, M.D.

#### WORKSHOP 111

1:30 P.M.- 3:00 P.M. Room 335, Third Level, Morial Convention Center

How to Implement Cardio-METABOLIC MONITORING ACROSS LARGE PUBLIC HEALTH SYSTEMS

#### Co-Chairs:

Laura K. Kent, M.D. Christina V. Mangurian, M.D.

#### **Presenters:**

Gregory Miller, M.D., M.B.A. Aaron Chapman, M.D.

#### WORKSHOP 112

1:30 P.M.- 3:00 P.M. Rooms 343/345, Third Level,

Morial Convention Center FEEDBACK ON CRITERIA AND TERMINOLOGY IN DSM-5



#### Co-Chairs:

David J. Kupfer, M.D. Darrel A. Regier, M.D.

## 2:00 P.M. SESSIONS SYMPOSIA 99-105

2:00 P.M.- 5:00 P.M.

Rooms 333/334, Third Level, Morial Convention Center

HOT TOPICS IN AFRICAN-AMERICAN MENTAL HEALTH: IMPACT OF PAST AND CURRENT PREJUDICES; WOMEN'S MENTAL HEALTH; HIV; AND UNIQUE PSYCHO-**PHARMACOLOGICAL FINDINGS** 





#### Chair:

David W. Smith, M.D.

- 1. History of Racism in Mental **Health: Seeds of Distrust** Harriet A. Washington
- 2. Pseudoscientific Literature Promotes **Racial Prejudice Among Physicians** Zack Z. Cernovsky, Ph.D.
- 3. Black Women and Depression: The Role of Stigma as a **Barrier to Treatment** Janet E. Taylor, M.D.
- 4. HIV and African-American Mental Health David W. Smith, M.D.

5. Response and Tolerability of Psychotropics in African-Americans William B. Lawson, M.D.

#### SYMPOSIUM 100

2:00 P.M.- 5:00 P.M. Rooms 340/341, Third Level, Morial Convention Center

Dysfunctions in Mentalization OR METACOGNITION IN PERSONALITY **DISORDERS: EMPIRICAL EVIDENCE** AND IMPLICATIONS FOR PATHOLOGY, TREATMENT AND RESEARCH

Chair: Giuseppe Nicolo, M.D.

#### Discussants:

Giancarlo Dimaggio, M.D. Cesare Maffei, M.D., Ph.D.

- 1. Impaired Metacognition and Correlations With Symptoms, Social Functioning, and Overall Personality Disorder Severity Giuseppe Nicolo, M.D. Antonino Carcione, M.D. Michele Procacci, M.D. Antonio Semerari M.D. Giuseppe Giancarlo Dimaggio M.D. Stefania D'Angerio Ph.D. Raffaele Popolo M.D.
- 2. Improving Mentalization in Borderline Patients in Transference-Focused Psychotherapy (TFP) John F. Clarkin, Ph.D.
- 3. Verbal Elaboration of Distinct Affect Categories in BPD Serge Lecours, Ph.D. Marc-André Bouchard, Ph.D.

#### SYMPOSIUM 101

Withdrawn

#### SYMPOSIUM 102

2:00 P.M.- 5:00 P.M.

Rooms 346/347, Third Level, Morial Convention Center

TREATING BORDERLINE PERSONALITY DISORDER: CURRENT **PSYCHODYNAMIC** PERSPECTIVES

#### Chair:

Eve Caligor, M.D.

#### Discussant:

Peter Fonagy, Ph.D.

- 1. Key Clinical Interventions of **Mentalization-Based Treatment** Anthony W. Bateman, M.D. Peter Fonagy Ph.D
- 2. Transference-Focused Psychotherapy in Theory and in Practice Frank E. Yeomans, M.D.



- 3. Overview of Expressive Supportive Psychotherapy John G. Gunderson, M.D.
- 4. An Overview of Integrated Psychotherapy for BPD Glen O. Gabbard, M.D.

2:00 P.M.- 5:00 P.M. Rooms 348/349, Third Level, Morial Convention Center

#### COMPREHENSIVE HIV PSYCHIATRY UPDATE



Chair: Karl Goodkin, M.D., Ph.D.

- 1. HIV/AIDS Medical Update David Mushatt, M.D.
- 2. Neuropsychiatric Overview Mordecai Potash, M.D.
- 3. Neurocognitive Decline Karl Goodkin, M.D.
- 4. Psychopharmacology Francisco Fernandez, M.D.

#### SYMPOSIUM 104

2:00 P.M.- 5:00 P.M. Rooms 350/351, Third Level, Morial Convention Center

Understanding Comorbidity OF HEART DISEASE WITH DEPRESSION AND **ANXIETY DISORDERS** 

#### Co-Chairs:

Ruby C. Castilla-Puentes, M.D., D.P.H. Maria A. Oquendo, M.D.

#### Discussant:

Carlos León-Andrade, M.D.

- 1. Depression-Anxiety Comorbidity: Clinical Aspects Jose Luis Ayuso, M.D.
- 2. Treatment of Anxiety Disorders Is Associated With a Significantly Lower **Prevalence of Secondary Depression** Leo Russo, Ph.D.
- 3. Neurobiological Mechanisms in Anxiety/Depression and the **Impact on Coronary Heart Disease** Jorge Tellez-Vargas, M.D.
- 4. Understanding Comorbidity of Heart Disease With Depression and Anxiety Disorders Ricardo Secin, M.D.
- 5. Depression and Panic **Disorders Significantly Increase** the Risk for Heart Disease: One More Piece of Evidence Ruby C. Castilla-Puentes, M.D.

Andres Gomez-Caminero, Ph.D. William A. Blumentals, Ph.D. Leo J. Russo, Ph.D.

- 6. Association Study Between Blood Pressure and Personality, Anxiety and Depression Jorge Ospina, M.D.
- 7. Strategies for Optimizing Treatment of Depression and Panic Disorder: What to Do When SSRIs Fail? Carolina Remedi, M.D. Carlos A. Soria, M.D.

#### SYMPOSIUM 105

2:00 P.M.- 5:00 P.M.

Rooms 353/355, Third Level, Morial Convention Center

#### THE ETHICS OF INNOVATIVE INTERVENTIONS IN PSYCHIATRY

#### Co-Chairs:

Paul S. Appelbaum, M.D. Laura B. Dunn, M.D.

#### Discussant:

Scott Kim, M.D., Ph.D.

1. Ethical Issues in DBS Research for Psychiatric Disorders

Laura B. Dunn, M.D. Paul E. Holtzheimer III, M.D. Jinger G. Hoop, M.D., M.F.A. Helen Mayberg, M.D. Laura W. Roberts, M.D., M.A. Paul S. Appelbaum, M.D.

- 2. The Ethics of Genetic Screening for Psychiatric Disorders Paul S. Appelbaum, M.D.
- 3. Ethical Issues Related to the **Use of Transcranial Magnetic** Stimulation and Vagus Nerve Stimulation in Psychiatry Paul E. Holtzheimer, M.D.
- 4. Ethical Issues in Pharmacologic Enhancement Jinger G. Hoop, M.D. Ryan Spellecy, Ph.D.

#### **WORKSHOPS** MEDIA WORKSHOP 8

2:00 P.M.- 5:00 P.M.

Rooms 208/209, Second Level, Morial Convention Center

#### RACHEL IS GETTING MARRIED, KYM IS GETTING SOBER, EVERYONE IS LOSING IT

*Sponsored by: The American* Academy of Addiction Psychiatry

Chair: Petros Levounis, M.D., M.A.

#### **Presenters:**

Richard Rosenthal, M.D.

Hunter McQuistion, M.D. Andrew Anson, M.D. Stephen Ross, M.D. Kimberly Roberts, M.D.

# 3:00 P.M. SESSIONS

3:00 P.M. -5:00 P.M.

La Louisiane C, First Level, Morial Convention Center

> For further information on New Research submissions. please refer to the New Research Program section of this book.

# 3:30 P.M. SESSIONS WORKSHOPS 113-115 WORKSHOP 113

3:30 P.M.- 5:00 P.M. Room 227, Second Level, Morial Convention Center

MAINTENANCE OF CERTIFICATION FOR DIPLOMATES OF THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY

Chair: Larry R. Faulkner, M.D.

#### **Presenters:**

Beth Ann Brooks, M.D., M.S. Victor Reus, M.D. David Mrazek, M.D.

#### WORKSHOP 114

3:30 P.M.- 5:00 P.M. Room 235, Second Level, Morial Convention Center

#### SUICIDE BOMBERS: PSYCHOLOGY, PSYCHOPATHOLOGY AND CULTURAL VIEWS

#### Co-Chairs:

Mostafa K. Ismail, M.D., M.R.C. Afaf H. Khalil, M.D., M.R.C.

#### **Presenters:**

Ahmed El-Shafei, M.D. Mohamed Ghanem, M.D., M.R.C. Yasser Elsayed, M.D., M.S. Nashwa Zarif, M.S., M.D.

## WORKSHOP 115

3:30 P.M.- 5:00 P.M. (REPEAT OF WORKSHOP 112) Rooms 343/345, Third Level, Morial Convention Center


#### FEEDBACK ON CRITERIA AND TERMINOLOGY IN DSM-5



#### Co-Chairs:

David J. Kupfer, M.D. Darrel A. Regier, M.D.





				Ì
	ADDICTION PSYCHIATRY		92 Update on Cannabis Use Disorders	121
	ADVANCES IN	112	94 Choosing the Right Treatment for Substance Abuse Symposium	121
	7 Advances in Substance Abuse Treatment	112	98 Novel Tools for Preventing and Treating Substance Use and	
	COURSES		Comorbidities in the Military and Returning Veterans	122
4	4 Street Drugs and Mental Disorders: Overview and Treatment of Dual Diagnosis Patients	86	WORKSHOP	
6	8 Office-based Buprenorphine Treatment of	00	Maintenance Treatment for Opiate Dependence:	
	Opioid-Dependent Patients	104	Terminable or Interminable?	82
L	LECTURES			
	2 Addiction: Conflict between Brain Circuits	104	AIDS AND HIV	
	6 New Directions in Drug Policy: President Obama's National Demand Reduction Priorities	111	21 Seek and Treat for Optimal Prevention of	
			HIV/AIDS: STOP HIV/AIDS	122
	MEDIA WORKSHOP  8 Rachel is Getting Married,		SYMPOSIA	
	Kym is Getting Sober, Everyone is Losing it	125	103 Comprehensive HIV Psychiatry Update	125
	COLEMETICS AND OF MICH DEPORTS		62 The Public Health and Clinical Interface Between HIV,	106
	SCIENTIFIC AND CLINICAL REPORTS  1 Addiction Psychiatry	79	STDs, and Mental Health	106
1		100	WORKSHOP	
	SMALL INTERACTIVE SESSION		30 From Outreach to Assertive Community Treatment: Transferring Research to Practice in Comprehensive Care for	
1		110	Underserved People Living With HIV/AIDS	69
	3 Smoking and Psychiatric Disorders: Clues About		ANXIETY DISORDERS	
	Causal Pathways and Innovative Treatment Approaches	64	CASE CONFERENCE	
2	9 Executive Function as a Brain System for Self-Control: The Neurocircuitry of Psychiatric Disorders and Addiction	72	1 PTSD and the American Soldier Today	89
3	O Addiction Research, Prevention and Treatment in	12	COURSE	
0	the U.S. and France: Vive la Difference!	72	7 Complementary and Integrative Treatments for Stress, Depression,	
3	5 Sex/Gender Differences and Women-Specific Issues in Drug Abuse: Predicting and Improving Treatment Outcomes	78	Anxiety, PTSD, Mass Trauma, Cognitive Function, ADD, and Schizophrenia	66
3	6 Treating Chronic Pain and Co-Occurring		cognitive ranction, 110 D, and octilizophicina	00
4	Addiction in Substance Abuse Patients  Update on Medications Development:	82	SCIENTIFIC AND CLINICAL REPORT	105
Ċ	Promising New Treatments for Drug Addiction	90	14 Anxiety Disorders	105
4 5	, ,	97	SYMPOSIA	
J	2 Innovations in Integrated Treatment of Substance Use and Psychiatric Disorders	98	1 PTSD in Military Populations: Translating Research Into Practice	63
	4 Substance Related Disorders in DSM-5: Progress Report	98	12 Anxiety Treatment: New Research Findings for the Clinician 24 Prevention of PTSD: Recent Israeli Practices	65 71
5 6	<ul> <li>9 Neurobiology of Obesity: Why We Can Get Too Motivated to Eat</li> <li>3 Adolescent Potential: Exploring the Developing Brain and</li> </ul>	99	104 Understanding Comorbidity of Heart Disease with	
	Understanding Pathways of Addiction	106	Depression and Anxiety Disorders	125
6	0 0	107	WORKSHOP	
Ü	Psychiatric Disorders: What Does Brain Research Tell Us?	107	65 Guided Self-Help:	0.0
7		114	A new Intervention to Overcome Anxiety Complaints	88
8	6 How Dysfunction of Learning and Memory Circuits Contribute to Substance Abuse and Other Psychiatric Disorders	120		
	,		ATTENTION SPECTRUM DISORDERS COURSE	
	GUIDE TO USING THE TOPIC INDEX		19 Essentials of Assessing and Treating Attention Deficit	
			Hyperactivity Disorder in Adults and Children	78
	You can use this index to find sessions of interest to		62 Advanced Assessment and Treatment of Attention Deficit Hyperactivity Disorder	94
	you. Listed below are all of the topic areas contained in the scientific program. Listed under each topic			
	you will find the title of the individual session listed by		SCIENTIFIC AND CLINICAL REPORT  10 Attention Deficite and Psychoetimulants	111
	number. The listing will also show the page number		19 Attention Deficits and Psychostimulants	111
	where the session appears in this book. Look up the		SYMPOSIUM	
	page number for further details about the session.		88 ADHD FAQs: Practical Answers for	

the Office-Based Practitioner

120

		PAGE*		OAG!
В	EHAVIOR AND COGNITIVE THERAPIES	_	MASTER COURSE	V.
	DURSES		1 Update on Pediatric Psychopharmacology	6
14	Motivational Interviewing for Routine Psychiatric Practice	76	COURNITIES AND OUNION DEPORTS	
15	Cognitive Behavioral Therapy for Insomnia Co-morbid With	76	SCIENTIFIC AND CLINICAL REPORTS  Mood Disorders	8
49	Depressive and Anxiety Disorders Cognitive-Behavior Therapy for Severe Mental Illness	76 90	19 Attention Deficits and Psychostimulants	11
64	A Primer on Acceptance and Commitment Therapy	94		
71	Cognitive-Behavioural Analysis Systems of	, .	SMALL INTERACTIVE SESSIONS	
	Psychotherapy (CBASP): Hope for Chronic Depression	108	7 Child Psychopharmacology: SSRIs, Stimulants and Safety Issues	9
			What's New in Child and Adolescent Psychiatry?	10
MA	ASTER COURSE	=0	14 Meet the Editors: Principles and Practice of Child and Adolescent Forensic Mental Health	11
4	Practical Cognitive-Behavior Therapy	79	Clind and Adolescent Potensic Wentai Health	11
SC	CIENTIFIC AND CLINICAL REPORT		SYMPOSIA	
7	Borderline Personality Disorder and Emotion	87	6 Update on Treatments for Child and Adolescent Eating Disorders	6
			7 Neurodevelopmental Disorders in DSM-5:	
SE	MINAR		An Update from the Work Group  31 Understanding Personality Disorders in	6
2	Evidence Based Psychotherapy for Chronic Major Depression	62	Children and Adolescents: Current Status and Future Directions	7
1416			57 Depression, Metabolic Syndrome and Obesity	9
8	ORKSHOPS  Cognitive Therapy for Personality Disorders	63	63 Adolescent Potential: Exploring the Developing Brain and	
36	Meditation and Psychiatry	72	Understanding Pathways of Addiction	10
40		73		
99	Cognitive Therapy for Psychosis in Practice:		WORKSHOPS	6
	Basic Techniques for Psychiatrists	110	<ul><li>21 Lost in Translation: Generational Issues and Mental Health</li><li>25 Adult Pervasive Developmental Disorder:</li></ul>	6
107			For Better Understanding and Treatment	6
	Enhance Mindfulness and Behavioral Activation in CBT Group Treatment for Depressed Patients	123	26 Bridging the Cultural Divide: Challenges of First	
	CD1 Group Treatment for Depressed Fatients	123	Generation Immigrants With Children With Mental Illness	6
			64 Treating the Aggressive Child and Teen:	
В	IOLOGICAL PSYCHIATRY AND		Integrated Techniques for Management and Intervention	8
	EUROSCIENCE		<ul> <li>Preventing Late Life Sequelae Resulting from Early Life Trauma</li> <li>Telepsychiatry and the Changing Face of</li> </ul>	8
	DURSES		Access for Rural America's Children and Adolescents	9
9	Neuroanatomy of Behavior: An Introduction	68	109 Children of Psychiatrists	12
33	Neuroanatomy of Emotions	80	•	
	CTURE		COCKUTIVE DISCORDEDS	
13	From Circuits to Cells to Molecular Regulation:		COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, ETC.)	
	Identifying Novel Targets for the Treatment of Psychotic Disorders	105	ADVANCES IN MEDICINE	
	, ,		1 Delirium: Neurobiology, Prevention and Treatment Approaches	8
PF	RESIDENTIAL SYMPOSIUM		4 Aging and Dementia:	O
3	Can Basic and Translational Neuroscience	0.5	An Update on Neuroscience and Brain Imaging	10
	Improve Treatment in Psychiatry?	95		
SY	MPOSIA		COURSE	
19	Pathophysiology of Psychotic and Mood Disorders:		52 Traumatic Brain Injury: Neuropsychiatric Assessment	9
	Do We Have any Solid Evidence of Interest to Clinicians?	70	COLEMETIC AND CHANCAL DEPORT	
29	Executive Function as a Brain System for Self-Control:		SCIENTIFIC AND CLINICAL REPORT  10 Cognitive Disorders	9
	The Neurocircuitry of Psychiatric Disorders and Addiction	72	Cognitive Disorders	
53	Genotypes and Biomarkers: The New Decision Makers for Tailored Treatment	98	SMALL INTERACTIVE SESSIONS	
56	Focal Brain Stimulation for Psychiatric Disorders: Clinical Update	98	2 Successful Cognitive and Emotional Aging:	
68	Reward Neurocircuitry in Substance Dependence and	70	How Can We Get There?	8
	Other Psychiatric Disorders: What Does Brain Research Tell Us?	107	8 Delirium Assessment and Management	9
79	The Challenge of Cognitive Enhancers in Medicine	114	MODICION	
86	How Dysfunction of Learning and Memory Circuits Contribute to	100	WORKSHOP 67 Behavioral Complications of Dementia:	
96	Substance Abuse and Other Psychiatric Disorders Basic Science in Psychiatry:	120	A Comprehensive Multi-Disciplinary Treatment Approach	8
90	A Move Toward Translational Medicine	121	To compression or state 2 sooffman y troumout approach	
W	ORKSHOP		COMBINED PHARMACOTHERAPY &	
3	A Medicinal Cannabis Update for 2010:		PSYCHOTHERAPY COURSE	
	Use, Abuse, New Research, New Forensic and New Political Realities	63		
			69 Psychodynamic Psychopharmacology:	
	HILD AND ADOLESCENT PSYCHIATRY	7	Applying Practical Psychodynamics to Improve Pharmacologic Outcomes with Treatment Resistant Patients	10
	DURSES		Outcomes with freatment resistant Patients	10
6	Child and Adolescent Psychiatry for the General Psychiatrist	66	WORKSHOPS	
19	Essentials of Assessing and Treating Attention Deficit	30	33 Making the Most of Your Twenty-minute Hour:	
	Hyperactivity Disorder in Adults and Children	78	Maximizing the Therapeutic Experience	7
31	Autism Spectrum Disorders: Diagnostic Classification, Neurobiology,		92 Cognitive-Behavioral and Psychodynamic Approaches to	
	Biopsychosocial Interventions and Pharmacologic Management	79	Medication Adherence in Severe Mental Illness	10

		PAGE*	PR	GE
		Y	SYMPOSIA	
	COMPUTERS, TECHNOLOGY, INTERNET & RELATED COURSES		11 Culturally Sensitive Assessment of Psychologically Distressed Ethnic and Non-English Speaking Populations	65
2	How to Blog, Tweet, Friend, Wiki, and not get Addicted:		22 Culture and Psychiatric Diagnosis: I mplications for the International Impact of DSM-5	71
	21st Century Internet Technologies for Beginners	78	1	71 71
4	42 Exploring Technologies in Psychiatry	86	30 Addiction Research, Prevention and	
ì	SCIENTIFIC AND CLINICAL REPORT			72 77
	15 Information Technology	109	37 Culturally Sensitive Treatment of Psychologically	//
	SMALL INTERACTIVE SESSION		Distressed Ethnic and Non-English Speaking Populations	82
	21 How to get Your Paper Published	119	<ul><li>Women's Mental Health in Latin America: Present and Future Research</li><li>Cultural Adaptation of Cognitive Behaviour</li></ul>	19
				21
	SYMPOSIUM  10 Primary in Floatnessia Madical Records	0.2	99 Hot Topics in Afro-American Mental Health;	
-	40 Privacy in Electronic Medical Records	83	Impact of Past and Current Prejudices; Womens' Mental Health; HIV; Unique Psychopharmacological Findings	24
	WORKSHOPS		Till 1, omque 10, onophum mucologicum 1 mumbo	
	Telepsychiatry for Education and Psychotherapy:	67	WORKSHOPS	
	Teaching to the Near and Far Ends  The Explosion of Social Media: Why, Where,	67	2 The Deadly Years: Preventing Suicide in Asian-American College Students 6	62
	When and How can Psychiatrists Catch up with the Trend?	88		63
8	Telepsychiatry and the Changing Face of Access for	0.2	17 Preparing IMG (International Medical Graduate)	
8	Rural America's Children and Adolescents  Teaching Psychiatry in New Medical Schools	93 100	Psychiatry Residents for a Career in Academic Psychiatry  Bridging the Cultural Divide: Challenges of First Generation	67
	The Train has Left the Station: National Incentives and		0 0	68
	Developments in Electronic Health Records	110	85 The Psychiatrist's Role in Integrating Primary Care and	
	110 Games People Play: What Every Psychiatrist Needs to Know About Video Games	124	Behavioral Health Care: Friend or Foe?  87 Deafness - Disability or Difference?	95
	Allow resource Calling	121	,	00
	COUPLE AND FAMILY THERAPIES		108 Using the DSM-IV-TR Outline for Cultural Formulation for Culturally	
	ADVANCES IN		11 1	23 25
	5 Family Assessment and Intervention for Psychiatrists	104	5 Suicide Bollibers. Esychology, Esychopathology and Cultural views	23
	COURCE		DIAGNOSTIC ISSUES	
	COURSE  53 Adult Sexual Love and Infidelity	108	ADVANCES IN MEDICINE	
	,		5 Medical Mysteries and Practical Medical Psychiatric Updates:	
	SEMINAR	60	Is it Medical, Psychiatric, or a Little of Both?	10
	4 Infidelity and Marital Relationships: Death Knell or Wake-up Call?	68	COURSES	
	CDEATIVITY AND THE ADTO		26 Understanding the Person Behind the Illness:	
	CREATIVITY AND THE ARTS			78
Ę	Reel Psychiatry	93	/ 11 1	86
			51 Seeing the Forest and the Trees:	
	FORUM	0.1	An Approach to Biopsychosocial Formulation	90
	1 Chopin at 200: His Mind and His Music	91	FORUM	
	MEDIA WORKSHOP		2 DSM-5: Progress in Research and Development	91
	1 Isn't All Horror Psychological? Horror Film Director George Romero and	72	COLENITIES AND OLINIOAL DEPORTS	
	Steve Schlozman, MD Discuss Polanski's Classic Film "Repulsion"	73	SCIENTIFIC AND CLINICAL REPORTS  11 Diagnostic Issues and DSM-5	95
ı	WORKSHOPS			16
	4 Unconscious Projections:	(2	CEMINAR	
2	The Portrayal of Psychiatry in Recent American Film  41 After a Parent's Suicide: Children's Grief and Healing	63 76	SEMINAR 7 Practical Guide to the Performance of the Mental Status Examination 12	24
	Publishing Books for the General Public	72		
			SMALL INTERACTIVE SESSION	0.0
	CROSS-CULTURAL AND		9 Neuropsychiatric Assessment for General Psychiatrists 10	06
1	MINORITY ISSUES COURSE		SYMPOSIA	
			7 Neurodevelopmental Disorders in DSM-5:	
4	48 Culturally Appropriate Assessment Made Incredibly Clear: A Skills-Based Course With Hands-On Experiences	86		64 96
	r		54 Substance Related Disorders in DSM-5: Progress Report	98
	LECTURES		55 DSM-5 Update Series, Part I: Reports from the Work Groups	98
	11 Solomon Carter Fuller: What Would He Say About Racial Politics in American Psychiatry Today?	99	67	07 07
	Depression and Suicidal Behavior in Latino Populations	116		07 14
	MEDIA WORKSHOP  7 Building Bridges: The Intersection Between Faith and Mental Health	122	WORKSHOPS 79 The Use of Research Measures in Clinical Practice	93
	. Daniella Diageo. The intersection between I aim and Memai Health	144	THE OSC OF RESCARCIT PIERSUIES III CHINEAU FTACILE	,,

		PAGE*		PAGE
112	Using the DSM-IV-TR Outline for Cultural Formulation for Culturally Appropriate Assessment: A Skills Based Approach with DVD Cases AM Session: Feedback on Criteria and Terminology in DSM-5 PM Session: Feedback on Criteria and Terminology in DSM-5	123 124 125	<ul> <li>COURSES</li> <li>A Practical Approach to Risk Assessment</li> <li>Psychiatric Disorders in Pregnant and Postpartum Women: Infant Morbidity and Mortality</li> <li>The Detection of Malingered Mental Illness</li> <li>The Psychiatrist As Expert Witness</li> </ul>	66 76 86 94
E	ATING DISORDERS		66 Risk Assessment for Violence	104
74	Therapeutic Interventions in Eating Disorders: Basic Principles	109	LECTURE 3 Patient Violence Against Mental Health Clinicians:	
LE <sup>0</sup>	CTURE The Perplexities & Provocations of Eating Disorders	87	Safety Assessment and Prevention  MASTER COURSE	82
SN 6	IALL INTERACTIVE SESSION  The Gravity of Weight: The Impossible Heaviness of Being	92	2 Essential Psychopharmacology	66
	MPOSIA		SCIENTIFIC AND CLINICAL REPORT  18 Issues in Mood Disorders	123
2 6 17 57 59	Recent Research on Eating Disorders Update on Treatments for Child and Adolescent Eating Disorders Update on Interventions for Adult Eating Disorders Depression, Metabolic Syndrome and Obesity Neurobiology of Obesity: Why We Can Get Too Motivated to Eat	64 64 70 99 99	<ul> <li>SEMINARS</li> <li>AM Session: Managing Malpractice Risk for Psychiatrists:         <ul> <li>The Basics and Beyond</li> </ul> </li> <li>PM Session: Managing Malpractice Risk for Psychiatrists:         <ul> <li>The Basics and Beyond</li> </ul> </li> </ul>	62 68
SC	PIDEMIOLOGY EIENTIFIC AND CLINICAL REPORT		<ul> <li>SMALL INTERACTIVE SESSION</li> <li>11 Requests to Evaluate Patients' Decisional Capacity in the Medical Setting: What are They Really Asking For?</li> </ul>	106
23	Issues in Child and Adolescent Psychiatry	118	SYMPOSIUM	100
SY 84	MPOSIUM  Mood, Memory and Myths: What Really Happens at Menopause?	115	97 The Supreme Court and Psychiatry in the 21st Century	122
40 ME	THICS AND HUMAN RIGHTS DURSE  Counter-Intuitives in Medical Ethics  EDIA WORKSHOP	81	<ul> <li>WORKSHOPS</li> <li>A Medicinal Cannabis Update for 2010: Use, Abuse,         New Research, New Forensic and New Political Realities</li> <li>Ethical, Clinical and Legal Challenges         Created by Information Technology</li> <li>Cultural Diversities: The Impact on Mental Health         Treatment and Evaluation in Jails and Prisons</li> </ul>	63 72 80
3	Patrik, Age 1.5: A Swedish Film About Unexpected and Gay Adoption	95	<ul> <li>Neonaticide: Phenomenology and Prevention</li> <li>Guardianship and Powers of Attorney: Issues in Geriatric Psychiatry</li> </ul>	93
16	IALL INTERACTIVE SESSION Ethical Issues in Psychiatry	110	<ul><li>84 Malpractice Defense: Strategies for Success</li><li>106 Assessment of Capacity:</li></ul>	93 95
SY 28 40 87 97 105	MPOSIA Doping in AthletesThe Role of the Sport Psychiatrist Privacy in Electronic Medical Records Advances in Psychiatric Ethics: New Approaches that Inform Psychiatric Practice The Supreme Court and Psychiatry in the 21st Century The Ethics of Innovative Interventions in Psychiatry	72 83 120 122 125	Developments, Documentation & Defendability  GENETICS  COURSE  59 Psychiatric Pharmacogenomics	94
7	DRKSHOPS The "Negative Outcome" in Psychotherapy: Who Is Responsible and How? Transplant Psychiatry Undata	63	LECTURES  6 Optogenetics - Development and Application  10 The Simple Truth About the Genetic Complexity of Schizophrenia	91 99
19 38 74 76 94 101	Transplant Psychiatry Update Ethical, Clinical and Legal Challenges Created by Information Technology To File or Not to File: Guardianship for Older Adults with Dementia When Is Psychiatric Illness Terminal? Ethical Dilemmas in Psychiatric Practice Ethical Challenges in End of Life Care in the Hospitalized Elderly	72 92 92 110 116	PRESIDENTIAL SYMPOSIUM  4 Recent Advances in Psychiatric Genetics: From Fundamental Discovery to Clinical Implication  SCIENTIFIC AND CLINICAL REPORT  22 Genetics	105 118
F/	ACTITIOUS DISORDERS		SMALL INTERACTIVE SESSION  17 Psychiatric Pharmacogenomics	110
15	Münchausen Revisited: Factitious Disorder in the Age of the Internet and DSM-5	67	SYMPOSIA  13 Family and Behavioral Genetic Studies of BPD	66
F(	ORENSIC PSYCHIATRY		60 The Potential and Pitfalls of Creating a Bipolar Genomic Biobank	106
1	Advances in Correctional Psychiatry: From Provision of Care to Malpractice Prevention Advances in Forensic Psychiatry	89 95	GERIATRIC PSYCHIATRY ADVANCES IN MEDICINE  4 Aging and Dementia: An Update on Neuroscience and Brain Imaging	109

		PAGE		PAGE
16 43 57	DURSES  Mood Disorders in Later Life Psychiatric Consultation in Long-term Care: Advanced Course Pain and Palliative Care in Psychogeriatrics	76 86 93	111 How to Implement Cardiometabolic Monitoring Across Large Public Health Systems  HISTORICAL QUESTIONS	124
10 24	CIENTIFIC AND CLINICAL REPORTS  Cognitive Disorders  Antidepressant Response and Augmentation	94 119	COURSE  23 What Is Psychiatry? Philosophies and Practices  SCIENTIFIC AND CLINICAL REPORTS	78
SN 13	MALL INTERACTIVE SESSION Psychiatric Issues in Palliative Care	106	11 Diagnostic Issues and DSM-5 12 Psychosomatics and Cardiac Vulnerability	95 100
SY 14 51	MPOSIA  Examining the Outcome Continuum of Schizophrenia Into Later Life Geriatric Psychopharmacology of Late-Life Mood Disorders: Focus on the use of Biomarkers as Predictors of Response Aggressive Behaviors in Geropsychiatric Patients: Neurobiology, Assessment and Management	69 97 65	WORKSHOP 75 The Vicissitudes of the Doctor-Patient Relationship in Modern Medicine: Endurance, Erosion or Transformation  IMPULSE CONTROL DISORDERS COURSE	92
5 67	ORKSHOPS Psychiatric Care at the End of Life Behavioral Complications of Dementia:	63	20 How to Blog, Tweet, Friend, Wiki, and not get Addicted: 21st Century Internet Technologies for Beginners	78
74 82	A Comprehensive Multi-Disciplinary Treatment Approach To File or Not to File: Guardianship for Older Adults with Dementia Guardianship and Powers of Attorney: Issues in Geriatric Psychiatry	88 92 93	SCIENTIFIC AND CLINICAL REPORT  Issues in Mood Disorders	123
101	Aging Heroically in an Urban Setting: The Diary of Jessie Sylvester "The Beautiful Hills of Brooklyn" Ethical Challenges in End of Life Care in the Hospitalized Elderly	108 116	INDIVIDUAL PSYCHOTHERAPIES ADVANCES IN 4 Advances in Psychotherapeutic Treatments	95
2 SYY 69 WC 11	ROUP THERAPY DIENTIFIC AND CLINICAL REPORT Mood Disorders  MPOSIUM Implementing the STEPPS* Program for Borderline Personality Disorder (*Systems Training for Emotional Predictability and Problem Solving)  DRKSHOPS A Program of Psychotherapy for Combatants' Dependents - The Effect on Recall Rates: "They Are Not Going for Three Weeks and the Fighting Has Begun!" Tai Chi Exercise, a Controllable Physical Intervention to Enhance Mindfulness and Behavioral Activation in CBT Group Treatment for Depressed Patients  EALTH SERVICES RESEARCH	81 112 63 123	<ul> <li>COURSES</li> <li>Time-Limited Dynamic Psychotherapy:</li></ul>	68 79 79 81 86 90 90 108 108 111
2	RESIDENTIAL SYMPOSIUM  Comparative Effectiveness of Psychotropic Drugs: hat can We Learn From Practical Clinical Trials?	89	MASTER COURSE  3 Psychodynamic Psychotherapy	79
3 15 29	Psychopharmacology Information Technology Important but Infrequently Addressed Topics	81 109 123	SCIENTIFIC AND CLINICAL REPORT 6 Psychotherapy and Depression  SYMPOSIUM 5 New Developments in Interpersonal Psychotherapy (IPT)	87 64
5Y 1 46 76 80	PTSD in Military Populations: Translating Research Into Practice Ensuring a Public Health Impact: Partnering with Consumers and Community Stakeholders to Improve Access and Quality of Care for Mental Disorders Lessons from Hurricane Katrina: Response, Recovery and Rebuilding Sex and Psychodynamics: Contemporary Approaches to	96 113	WORKSHOPS 7 The "Negative Outcome" in Psychotherapy: Who Is Responsible and How? 93 Boundary Crossings as Boundary Accommodations: The Physician/Patient Relationship with Medically Ill Patients 102 Dynamic Therapy With Self-Destructive Borderlines: An Alliance Based Intervention for Suicide	63 108 116
6 46	Clinical Issues Through the Lifecycle  ORKSHOPS  Enhancing Risk-Assessment Across Services in Mental Health Changing Paradigms of Psychiatric Practice in	63	LESBIAN/GAY/BISEXUAL/ TRANSGENDER ISSUES MEDIA WORKSHOP  3 Patrik, Age 1.5: A Swedish Film About Unexpected and Gay Adoption	95
78	an Era of Health Care Reform Integrating Complementary Alternative Medicine (CAM) in Psychiatric Care: New Paradigms and Perspectives	77 93	SYMPOSIUM 61 Psychiatrists in the World: Advocating for LGBT Mental Health	106

		PAGE*		PAGE
1010		Qr.		Qr.
31	DRKSHOP Sexual Minority Youth: Clinical Competencies and		5 New Developments in Interpersonal Psychotherapy (IPT)	64
01	Training Needs for the 21st Century	69	9 Advances in the Management of Treatment-Resistant Depression	65
	running receasion the 21st century	0,5	10 Clinical Trends in Bipolar Disorders	65
			19 Pathophysiology of Psychotic and Mood Disorders:	
M	ANAGED CARE & L		Do We Have any Solid Evidence of Interest to Clinicians?	70
	EALTH CARE FINANCING		38 Neuroendocrine and Neuroimmunological Correlates of	
			Biopolar Disorder in Women	83
63	Current Procedural Terminology Coding and Documentation	94	45 Interpersonal and Social Rhythm Therapy (IPSRT) for Bipolar Disorder: New Applications, New Populations, and New Evidence	96
			49 Advances in the Treatment of Bipolar Disorder	97
	RESIDENTIAL SYMPOSIUM	105	51 Geriatric Psychopharmacology of Late-Life Mood Disorders:	,
5	Health Reform and Psychiatry	105	Focus on the use of Biomarkers as Predictors of Response	97
C1	MALL INTERACTIVE SESSION		60 The Potential and Pitfalls of Creating a Bipolar Genomic Biobank	106
3	The Crisis of Access to Psychiatrists in an Era of Health Reform	88	65 DSM-5 Examined: Nosology of Mood Disorders	107
	The office of recess to regenation in an Dra of realing reform	00	91 New CANMAT Guidelines for Depression and	
SY	MPOSIA		Bipolar Disorder: Combining Evidence with Clinical Practice	121
41	Health and Mental Health Around the World? Are all Systems go?	89	WORKSHOPS	
75	The Tattered Safety Net:		12 New APA Practice Guideline for the Treatment of	
	The Public Mental Health Crisis in an Economic Recession	113	Patients with Major Depressive Disorder	63
			39 Where Science and Social Justice Meet:	
	DRKSHOP	100	The Example of Smoking in Persons With Bipolar Disorder	72
90	Understanding CPT Coding and How Fees are Calculated	108	73 Transcranial Magnetic Stimulation in Clinical Practice:	
			A Pragmatic Approach to a New Psychiatric Procedure	92
M	OOD DISORDERS		83 Practical Pharmacotherapy of Mood Disorders	93
CC	DURSES		89 Transcranial Magnetic Stimulation (TMS) in the Treatment of Major Depression: A New Therapeutic Tool for Psychiatry	108
16	Mood Disorders in Later Life	76	95 CAM or sCAM for Mood Disorders: Herbals and Beyond!	110
34	Management of Psychiatric Disorders in		Office of Softer for Mood Disorders, Herbais and Defond.	110
	Pregnant and Postpartum Women	80		
37	Interpersonal Psychotherapy (IPT)	81	NEUROPSYCHIATRY	
39	Melatonin and Light Treatment of SAD, Sleep and Other Body Clock Disorders	81	ADVANCES IN MEDICINE	
41	Short-Term Psychodynamic Supportive	01	3 Movement Disorders in Psychiatric Patients	104
	Psychotherapy for Depression	86		
54	A Psychodynamic Approach to Treatment Resistant Mood Disorders:		COURSES	
	Breaking Through Complex Comorbid Treatment		1 Neuropsychiatric Masquerades: Medical and Neurological Disorders	(2)
	Resistance by Focusing on Axis I	90	That Present With Psychiatric Symptoms  46 Advances in Neuropsychiatry:	62
60	Psychopharmacologic, ECT and Psychotherapeutic Treatment of	0.4	The Neuropsychiatry of Emotion and Its Disorders	86
67	Psychotic (Delusional) Depression ECT Practice Update for the General Psychiatrist	94 104	52 Traumatic Brain Injury: Neuropsychiatric Assessment	90
07	ECT Fractice Optiate for the General Psychiatrist	104	75 The Standard EEG in Psychiatric Practice	110
INI	DUSTRY SUPPORTED SYMPOSIUM			
2	Novel Approaches to Assessing and Treating Depression	101	LECTURE	
			12 Addiction: Conflict between Brain Circuits	104
LE	CTURES		MASTER COURSE	
2	The Future of Depression Research	66	5 Neuropsychiatry for Veterans	118
7	Neuroimaging Clue to the Causes of Bipolar Disorder:	0.1	rearopsychiatry for veteralis	110
14	Where We Are and Where We're Going Co-Morbidity of Psychiatric Disorders	91 109	SMALL INTERACTIVE SESSIONS	
19	Depression and Suicidal Behavior in Latino Populations	116	9 Neuropsychiatric Assessment for General Psychiatrists	106
			15 Addiction and the Brain	110
ME	EDIA WORKSHOP			
6	Boy Interrupted	116	SYMPOSIUM	
			8 Aggressive Behaviors in Geropsychiatric	65
	CIENTIFIC AND CLINICAL REPORTS		Patients: Neurobiology, Assessment and Management	65
4	Child and Adolescent Psychiatry	83 87	WORKSHOPS	
6 20	Psychotherapy and Depression Inpatient Psychiatry: Admissions and Readmissions	115	13 Challenges and Opportunities in Teaching	
21	Scales and Screening Measures	116	Neurology to Psychiatry Residents	67
22	Genetics	118	22 Diagnosis and Treatment of Psychogenic Nonepileptic Seizures:	
24	Antidepressant Response and Augmentation	119	What Does a Psychiatrist Do Once the Diagnosis Is Made?	67
25	Psychopharmacology	119		
			OTHER SOMATIC THERAPIEC	
	MINAR	(2)	OTHER SOMATIC THERAPIES ADVANCES IN MEDICINE	
2	Evidence Based Psychotherapy for Chronic Major Depression	62	2 Top 10 Medical Articles of 2009:	
CI.	MALL INTERACTIVE SESSIONS		A Comprehensive and Practical Review of What We Need to Know	91
1	Diagnosis and Evidence-Based Treatment of Bipolar Disorder	88	1	
20	Research and Clinical Management of Patients with		COURSES	
	Treatment-Resistant Depression	119	21 EEG Feedback in Psychiatry: Clinical Applications	78
22	Treatment of Complex Mood Disorders	119	38 Internal Medicine Update: What Psychiatrists Need to Know	81

		PAGE*		PAGE
67	ECT Practice Update for the General Psychiatrist	104	PERSONALITY DISORDERS	Ø,
7	Complementary and Integrative Treatments for Stress, Depression, Anxiety, PTSD, Mass Trauma, Cognitive Function, ADD, and Schizophrenia	66	ADVANCES IN  8 Advances in Personality Disorders	112
70	Kundalini Yoga Meditation Techniques for Schizophrenia, the Personality Disorders, and Autism	108	,	
77	Kundalini Yoga Meditation for Anxiety Disorders Including OCD, Depression, Attention Deficit Hyperactivity Disorder, and Posttraumatic Stress Disorder	118	COURSES  10 Time-Limited Dynamic Psychotherapy: An Attachment-based/Relational/Experiential Approach	68
8	Brain Stimulation Therapies in Psychiatry	68	<ul> <li>Transference-Focused Psychotherapy for Borderline Personality</li> <li>Mentalization Based Treatment (MBT) for Borderline</li> </ul>	79
SY	MPOSIA		Personality Disorder (BPD): Introduction to Clinical Practice	81
56 64	Focal Brain Stimulation for Psychiatric Disorders: Clinical Update The 2010 APA Task Force Report on the Practice of Electroconvulsive	98	MEDIA WORKSHOP	
01	Therapy: Evidence-based Guidelines for the Practicing Clinician	107	8 Rachel is Getting Married, Kym is Getting Sober, Everyone is Losing it	125
WC	DRKSHOPS		SCIENTIFIC AND CLINICAL REPORT	
73	Transcranial Magnetic Stimulation in Clinical Practice: A Pragmatic Approach to a New Psychiatric Procedure	92	7 Borderline Personality Disorder and Emotion	87
89	Transcranial Magnetic Stimulation (TMS) in the Treatment of	72	8 Borderline Personality Disorder 9 Child Abuse	91 92
	Major Depression: A New Therapeutic Tool for Psychiatry	108		
P	AIN MANAGEMENT		SYMPOSIA  13 Family and Behavioral Genetic Studies of BPD	66
	DURSES		20 Updating the APA Guidelines for the Treatment of	
32 57	Multidisciplinary Treatment of Chronic Pain Pain and Palliative Care in Psychogeriatrics	80 93	Borderline Personality Disorder  31 Understanding Personality Disorders in Children and	70
72	Narrative Hypnosis for Psychiatry: Emphasis on Pain Management	108	Adolescents: Current Status and Future Directions	77
CN	IALL INTERACTIVE SESSION		34 Diagnosing and Treating the Narcissistic Personality Disorder: Awaiting DSM-5	77
13	Psychiatric Issues in Palliative Care	106	69 Implementing the STEPPS* Program for Borderline Personality Disorder (*Systems Training for Emotional Predictability and Problem Solving)	112
CV	MPOCIA		70 Evidence-based Treatments (EBT) for Borderline Personality Disorder:	112
10	MPOSIA Clinical Trends in Bipolar Disorders	65	Empirical Clarity Meets Clinical Reality  New Perspectives on Intergenerational Transmission of BPD	112 120
16 36	Burn Psychiatry: Treatment and Outcomes Treating Chronic Pain and Co-Occurring Addiction in	69	100 Dysfunctions in Mentalization or Metacognition in	120
30	Substance Abuse Patients	82	Personality Disorders: Empirical Evidence and Implications for Pathology, Treatment and Research	124
			102 Treating Borderline Personality Disorder:	
P/ CA	ATIENT SAFETY & SUICIDE		Current Psychodynamic Perspectives	124
2	Death of a Physician by Suicide	104	WORKSHOPS	
	NIDCEC		<ul><li>8 Cognitive Therapy for Personality Disorders</li><li>70 A Resident's Guide to Borderline Personality</li></ul>	63
12	Emergency Psychiatry: Theory to Practice	76	Disorder From the Experts: Part I  96 A Resident's Guide to Borderline Personality Disorder:	89
2 5	Losing a Patient to Suicide A Practical Approach to Risk Assessment	62 66	From the Experts (Part II)	110
Ü	A Fractical Approach to Risk Assessment	00		
	Voicing Unspeakable: Reflections on, and Discussion About,		POLITICAL QUESTIONS	
	Overcoming Loss by Suicide	84	PRESIDENTIAL SYMPOSIUM  5 Health Reform and Psychiatry	105
6	Boy Interrupted	116	Treath reform and royellading	103
	IENTIFIC AND CLINICAL REPORT	111	LECTURE  16 New Directions in Drug Policy:	
18	Suicide	111	President Obama's National Demand Reduction Priorities	111
	ALL INTERACTIVE SESSION		SYMPOSIA	
4	Suicide and Suicide Risk Assessment: Practical Information and Application	88	39 The Medical Home: Is There a Place for Psychiatry in It?	83
CV	MPOCIA		41 Health and Mental Health Around the World? Are all Systems go?	89
67	MPOSIA Revisiting Pharmacological Treatments to Prevent Suicide	107	WORKSHOPS	
75	The Tattered Safety Net: The Public Mental Health Crisis in an Economic Recession	113	39 Where Science and Social Justice Meet: The Example of Smoking in Persons With Bipolar Disorder	72
89	Autonomy in the Prolongation and Curtailment of Life	120	53 Scope of Practice Challenges: Experiences, Successes, and Tribulations From Across the Country	80
WC	DRKSHOPS		Tibulations from Across the Country	30
1	Management of the Suicidal Outpatient: Beyond the Contract for Safety	62	PRACTICE MANAGEMENT	
2	The Deadly Years: Preventing Suicide in Asian-American College Students	62	COURSE	
41	After a Parent's Suicide: Children's Grief and Healing	76	63 Current Procedural Terminology Coding and Documentation	94
	Responding to the Impact of Suicide on Clinicians Dynamic Therapy With Self-Destructive Borderlines:	112	SCIENTIFIC AND CLINICAL REPORT	
	An Alliance Based Intervention for Suicide	116	3 Psychopharmacology	81

		PAGE*		PAGE
W	DRKSHOPS		SYMPOSIA	
90 98	Understanding CPT Coding and How Fees are Calculated The Train has Left the Station:	108	25 Psychiatry Across Borders: Working for the U.S. Government in the Department of State as a Psychiatrist	71
90	National Incentives and Developments in Electronic Health Records	110	50 Challenges in Providing Mental Health Care for	
			College and University Students 77 Toward a New Model for Mental Health Services in the	97
Р	ROFESSIONAL & PERSONAL ISSUES	5	University Community	113
2	SE CONFERENCE  Death of a Physician by Suicide	104	WORKSHOPS	
	Death of a r hysician by Suicide	104	14 Dealing with the Difficult Professional Employee:	
2	DURSES Losing a Patient to Suicide	62	Effective Personnel Management Strategies  46 Changing Paradigms of Psychiatric Practice in	67
3	Examining Professional Boundaries:		an Era of Health Care Reform	77
18	Weighing Risks Versus Opportunities Research and Publishing on a Shoe-String Budget	62 76	50 Psychiatric Care in Latin America: Current Challenges and Future Perspectives	80
27	Mindfulness: Practical Applications for Psychiatry	78	61 Patients as Practice Partners: Catalyzing Recovery Through Collaboration	88
47 50	Treating Medical Students and Physicians Basic Concepts in Administrative Psychiatry II	86 90	Catalyzing Recovery Infough Conaboration	00
53	Adult Sexual Love and Infidelity	108	PSYCHIATRIC EDUCATION	
LE	CTURES		COURSES	
17	Toward a New Psychiatry: Valuing the Positive Emotions	111	<ul><li>How to Give a More Effective Lecture: Punch, Passion and Polish</li><li>What Is Psychiatry? Philosophies and Practices</li></ul>	76 78
20 9	So You Want To Be A Physician Executive Your Bipolar Dad is a Bad Reason to Become a Psychiatrist:	118	58 Reel Psychiatry	93
	Advocacy Adventures of a Bewildered Boy Who Grew up to Become NAMI's Medical Director	94	LECTURE	
	Grew up to become wayn's medical Director	24	4 Why I Teach	87
SE 1	MINARS  AM Session: Managing Malpractice Risk for Psychiatrists:		MEDIA WORKSHOP	
	e Basics and Beyond	62	4 National Disasters:	101
3	PM Session: Managing Malpractice Risk for Psychiatrists: The Basics and Beyond	68	Developing a Road Map for Preparedness and Interventions	101
	,	00	SEMINAR The IMC Institute	70
SN 12	MALL INTERACTIVE SESSIONS  Career Development for Women in Psychiatry:		5 The IMG Insitute	79
	Residents - Challenges and Solutions	106	SYMPOSIUM	
21	How to get Your Paper Published	119	21 How to Get the Corner Office: Practical Leadership Strategies for Women Psychiatrists	70
	MPOSIA		WORKSHOPS	
21	How to Get the Corner Office: Practical Leadership Strategies for Women Psychiatrists	70	13 Challenges and Opportunities in	
28	Doping in AthletesThe Role of the Sport Psychiatrist	72	Teaching Neurology to Psychiatry Residents  16 Telepsychiatry for Education and Psychotherapy:	67
WC	DRKSHOPS		Teaching to the Near and Far Ends	67
104	Fighting Stigma: When Psychiatrists Who Have Been in Treatment Speak Out	122	17 Preparing IMG (International Medical Graduate) Psychiatry Residents for a Career in Academic Psychiatry	67
	Children of Psychiatrists	124	18 Is That an Unconscious Fantasy or a Core Belief? A Resident's	
113	Maintenance of Certification for Diplomates of the American Board of Psychiatry and Neurology	125	Perspective on Learning Multiple Therapies Simultaneously Lost in Translation: Generational Issues and Mental Health	67 67
20	When Disorder Hits Home: Dealing With		31 Sexual Minority Youth:	60
42	Serious Psychiatric Disorders in Our Own Families From Narrative and Theory to Evidence-based Support for	67	Clinical Competencies and Training Needs for the 21st Century  Ambulatory Medical Clinics as Training Sites for	69
	Psychiatrists Working Under Extreme Stress	76	Residents and Fellows in Psychosomatic Medicine  Disaster Preparedness, Evacuation and Rebuilding:	77
43	Physician Heal Thyself: Scandals, Suicides, and Substance Abuse Among Us	77	Lessons Learned from Katrina Applied to Gustav and Ike	88
72	American Board of Psychiatry and Neurology Update:		68 Core Competencies and Maintenance of Competency in Europe and the United States of America: An Educational Model	88
75	Certification in Psychiatry and Its Subspecialities The Vicissitudes of the Doctor-Patient Relationship in	92	71 "If a Patient Googles Me, What Will They Find?" –	
91	Modern Medicine: Endurance, Erosion or Transformation Practical Challenges for Psychiatrists	92	The Information Age and Its Impact on Residency Training  86 Teaching Psychiatry in New Medical Schools	89 100
	Implementing the Recovery Model	108	100 Responding to the Impact of Suicide on Clinicians	112
97	Psychiatric Professional Liability 2009: The Year in Review	110	<ul><li>Making Your Presentation More Interactive: The Better Way!</li><li>The Awkward Process of Recruiting Your Own</li></ul>	122 122
	200 200 III ACTON	110	Č	
P	SYCHIATRIC ADMINISTRATION &		PSYCHIATRIC REHABILITATION SEMINAR	
S	ERVICES: PUBLIC, PRIVATE & UNIVERS DURSES	SITY	6 Overview of Recovery for Psychiatrists	
17	Mental Health Care of University Student Populations:			
	A Practical Overview for Psychiatrists	76 78	PSYCHOANALYSIS CASE CONFERENCE	
22 50	Basic Concepts in Administrative Psychiatry I Basic Concepts in Administrative Psychiatry II	78 90	4 The Self-Defeating Patient	118


	PAGE*		PAGE
PSYCHOPHARMACOLOGY ADVANCES IN	Q*	ADVANCES IN MEDICINE  1 Delirium: Neurobiology, Prevention and Treatment Approaches	86
6 Advances in the Use of Antipsychotic Medications	104	2 Top 10 Medical Articles of 2009:	
COURSES		A Comprehensive and Practical Review of What We Need to Know  6 Advances in Medicine	91 122
24 Treatment of Schizophrenia	78	COURSES	
36 Fostering Adherence to Psychotropic Medications: A Practical Resource for Clinicians	81	1 Neuropsychiatric Masquerades: Medical and Neurological	
		Disorders That Present With Psychiatric Symptoms  38 Internal Medicine Update: What Psychiatrists Need to Know	62 81
FORUM  3 Is a Game Changing Psychotropic Too Much to Expect?	104	43 Psychiatric Consultation in Long-term Care: Advanced Course	86
LECTURE		SCIENTIFIC AND CLINICAL REPORT	
8 The Audacity Principle in Science?	94	12 Psychosomatics and Cardiac Vulnerability	100
MASTER COURSE		SMALL INTERACTIVE SESSIONS	0.0
2 Essential Psychopharmacology	66	8 Delirium Assessment and Management 11 Requests to Evaluate Patients' Decisional Capacity in	92
PRESIDENTIAL SYMPOSIUM		the Medical Setting: What are They Really Asking For?	106
2 Comparative Effectiveness of Psychotropic Drugs:	00	SYMPOSIA	
What can We Learn From Practical Clinical Trials?	89	<ul><li>Burn Psychiatry: Treatment and Outcomes</li><li>Autonomy in the Prolongation and Curtailment of Life</li></ul>	69 120
SCIENTIFIC AND CLINICAL REPORT	100	104 Understanding Comorbidity of Heart Disease with	
16 Side Effects of Psychotropic Medication	109	Depression and Anxiety Disorders	125
SMALL INTERACTIVE SESSIONS	110	WORKSHOPS	
<ul><li>19 Alternative Treatments in Psychiatry</li><li>5 Antipsychotic Polypharmacy:</li></ul>	119	15 Münchausen Revisited: Factitious Disorder in the Age of the Internet and DSM-5	67
An Evidence-based Perspective	92	47 Ambulatory Medical Clinics as Training Sites for Residents and Fellows in Psychosomatic Medicine	77
SYMPOSIUM		85 The Psychiatrist's Role in Integrating Primary Care and	
18 Translating the Psychopharmacology Evidence Base Into Practice: A Sampler From the American Society of Clinical Psychopharmacology	70	Behavioral Health Care: Friend or Foe?	95
			2
WORKSHOPS  10 A Discussion About Weight Gain During Medication Treatment for		RELIGION, SPIRITUALITY, & PSYCHIATRY COURSES	•
Schizophrenia: How Much and What to do about it Pharmacological Approaches to	63	25 Spirituality in Psychiatry	78
Autism Spectrum Disorders for Clinicians	84	70 Kundalini Yoga Meditation Techniques for Schizophrenia, the Personality Disorders, and Autism	108
80 "Taking It Personal": Integrating Pharmacogenetics into the Management of Depression	93	77 Kundalini Yoga Meditation for Anxiety Disorders Including OCD, Depression, Attention Deficit Hyperactivity Disorder, and	
95 CAM or sCAM for Mood Disorders: Herbals and Beyond!	110	Posttraumatic Stress Disorder	118
Herbas and beyond:	110	LECTURE	
SCIENTIFIC AND CLINICAL REPORTS  14 Anxiety Disorders	105	17 Toward a New Psychiatry: Valuing the Positive Emotions	111
17 Weight Gain and Psychiatric Illness	111	MEDIA WORKSHOP	
<ul><li>25 Psychopharmacology</li><li>29 Important but Infrequently Addressed Topics</li></ul>	119 123	7 Building Bridges: The Intersection Between Faith and Mental Health	122
SYMPOSIA			122
42 Update on Medications Development:		SCIENTIFIC AND CLINICAL REPORTS  1 Addiction Psychiatry	79
Promising New Treatments for Drug Addiction  49 Advances in the Treatment of Bipolar Disorder	90 97	26 Psychosis	123
WORKSHOPS		SYMPOSIUM	
WORKSHOPS  19 Transplant Psychiatry Update	67	15 Spirituality and Mental Health: What Is the Psychiatrist's Role?	69
78 Integrating Complementary Alternative Medicine (CAM) in Psychiatric Care: New Paradigms and Perspectives	93	WORKSHOP	
,		36 Meditation and Psychiatry	72
SYMPOSIUM  80 Sex and Psychodynamics:		RESEARCH ISSUES	
Contemporary Approaches to Clinical Issues Through the Lifecycle	114	ADVANCES IN RESEARCH	
WORKSHOP		Advances in Research	91
83 Practical Pharmacotherapy of Mood Disorders	93	COURSE	76
		18 Research and Publishing on a Shoe-String Budget	76
PSYCHOSOMATIC MEDICINE ADVANCES IN		LECTURES  2 The Future of Depression Research	66
2 Advances in Psychosomatic Medicine	89	15 Highlights and Lessons from 40 Years in Psychiatry	109

	PAGE*		PAGE
PRESIDENTIAL SYMPOSIA  1 The Emerging Neurobiology of Antidepressant Treatment Respons 4 Recent Advances in Psychiatric Genetics: From Fundamental Discovery to Clinical Implication		<ul> <li>Approaches to Schizophrenia Through Phases of the Illness</li> <li>Early Detection and Intervention in Schizophrenia:         <ul> <li>An Idea Whose Time has Come</li> </ul> </li> <li>Progress and Promise: Preventing the First Episode of Psychosis</li> <li>Should 'Risk syndrome of Psychosis' be</li> </ul>	77 96 114
<ul> <li>SYMPOSIA</li> <li>An Examination of CNS Trial Methodologies</li> <li>New Studies to Appear in the June Issue of the American Journal of Psychiatry: Presentations by the Authors and Editors</li> <li>Treatment of Depression with TMS: An Overview of Findings from to Optimization of TMS for the Treatment of Depression Trial (Opt-TMS)</li> <li>The Ethics of Innovative Interventions in Psychiatry</li> </ul>		Included in DSM 5 as a Diagnosis? A road Towards Preventive Psychiatry  WORKSHOPS  10 A Discussion About Weight Gain During Medication Treatment for Schizophrenia: How Much and What to do about it When Adults with Pervasive Developmental Disorders Present in a Community Mental Health Setting  99 Cognitive Therapy for Psychosis in Practice:	121 63 69
RESIDENT & MEDICAL STUDENT CONCERNS MEDIA WORKSHOP		Basic Techniques for Psychiatrists	110
5 Novel Programs to Promote Mental Wellness in Medical Students	s 115	SLEEP DISORDERS COURSES	
<ul> <li>SYMPOSIUM</li> <li>Toward a New Model for Mental Health Services in the University Community</li> <li>WORKSHOPS</li> <li>The IMG Journey: Snapshots Across the Professional Lifespan</li> <li>Oral Boards Boot Camp 2010: Focus on Diagnostic Interviewing</li> <li>Making the Most of Your Twenty-minute Hour:</li> </ul>	113 63 68	4 An Overview of Sleep Medicine for the Mental Health Provider 15 Cognitive Behavioral Therapy for Insomnia Co-morbid With Depressive and Anxiety Disorders 39 Melatonin and Light Treatment of SAD, Sleep and Other Body Clock Disorders  WORKSHOPS	66 76 81
Maximizing the Therapeutic Experience Patient Suicide During Psychiatry Residency: A Workshop Discussion Making the Most of Your Chief Year: Chief Residents' Forum, Part Promoting International Medical Graduates Psychosocial Support During Residency Training	I 81 82	<ul> <li>Evaluation and Management of Patients with         Excessive Daytime Sleepiness in Psychiatric Practice     </li> <li>Update on Parasomnias:         A Review for Psychiatric Practice     </li> </ul>	68 80
<ul> <li>Making the Most of Your Chief Year: Chief Residents' Forum, Part</li> <li>Writing for the "Blue Journal": The Residents' and Fellows' Edition of the American Journal of Psychiatry</li> <li>A Resident's Guide to Borderline Personality Disorder from the Experts: Part I</li> </ul>	II 83 89 89	SOCIAL & COMMUNITY PSYCHIATRY COURSE  12 Emergency Psychiatry: Theory to Practice	76
<ul> <li>"If a Patient Googles Me, What Will They Find?" –         The Information Age and Its Impact on Residency Training     </li> <li>American Board of Psychiatry and Neurology Update:         Certification in Psychiatry and Its Subspecialities     </li> <li>A Resident's Guide to Borderline Personality Disorder:         From the Experts (Part II)     </li> </ul>	89 92 110	FORUM 4 Global Disasters Forum: Lessons Learned from Chile, Haiti & New Orleans  SCIENTIFIC AND CLINICAL REPORT 28 Epidemiology, Sleep, and Medical Screening	115
SCHIZOPHRENIA & OTHER PSYCHOTIC DISORDERS		SEMINAR 6 Overview of Recovery for Psychiatrists	123
3 Helping Parents of a First Episode Psychotic Patient	109	SYMPOSIA 23 Recent Changes to Acute Psychiatric Care: An International Perspective	71
COURSE  24 Treatment of Schizophrenia  INDUSTRY SUPPORTED SYMPOSIUM	78	<ul> <li>Psychiatry Across Borders: Working for the U.S. Government in the Department of State as a Psychiatrist</li> <li>Treatment of Depression in Ethnic Minorities</li> <li>Psychiatrists in the World: Advocating for LGBT Mental Health</li> <li>Lessons from Hurricane Katrina: Response, Recovery and Rebuilding</li> </ul>	71 77 106 113
New Developments in Schizophrenia Research and Practice:     From the Pipeline to the Clinic  LECTURES	73	WORKSHOPS 6 Enhancing Risk-Assessment Across Services in Mental Health	63
1 Translational Research in Schizophrenia: Challenges and Promis 10 The Simple Truth About the Genetic Complexity of Schizophreni 13 From Circuits to Cells to Molecular Regulation: Identifying Novel Targets for the Treatment of Psychotic Disorde 18 Prevention Initiatives in Schizophrenia	a 99	<ul> <li>The Behavioral Health Action Network: Reorganizing the Behavioral Health Delivery System in Post-Katrina New Orleans</li> <li>When Adults with Pervasive Developmental Disorders Present in a Community Mental Health Setting</li> <li>Street to Home: Shame in Homelessness</li> <li>I'm Violent, Admit Me if you Dare: How and Where to Manage Potentially Violent Individuals With Unclear Diagnoses</li> </ul>	68 69 79
5 Psychosomatic Medicine and Health Services Weight Gain and Psychiatric Illness Issues in Child and Adolescent Psychiatry Psychosis	83 111 118 123	Presenting to Emergency Services Practical Challenges for Psychiatrists Implementing the Recovery Model  SOMATOFORM DISORDERS WORKSHOPS	80 108
SYMPOSIA  14 Examining the Outcome Continuum of Schizophrenia Into Later L  27 Non-Psychotic Issues of Schizophrenic Patients	ife 69	<ul> <li>Assessment of Capacity: Developments, Documentation &amp; Defendability</li> <li>Diagnosis and Treatment of Psychogenic Nonepileptic Seizures:</li> <li>What Does a Psychiatrist Do Once the Diagnosis Is Made?</li> </ul>	122 67

		PAGE*		akek
STIGI	MA/ADVOCACY	\$1	WORKSHOPS	Ø,
	WORKSHOPS		56 Maintenance Treatment for Opiate Dependence: Terminable or Interminable?	82
	All Horror Psychological? Horror Film Director George Romero and e Schlozman, MD Discuss Polanski's Classic Film "Repulsion"	73	60 Interviewing Patients Who Hate or Fear Psychiatrists	88
	el Programs to Promote Mental Wellness in Medical Students	115	64 Treating the Aggressive Child and Teen:	0.0
			Integrated Techniques for Management and Intervention  65 Guided Self-Help: A new Intervention to Overcome Anxiety Complaints	88 88
	SHOPS  uting Stigma:		duded our resp. They mervenion to overcome runner, companies	00
	en Psychiatrists Who Have Been in Treatment Speak Out	122	VIOLENCE TO ALIMA & VICTIMIZATION	
	en Disorder Hits Home: Dealing With	<b>6</b> 7	VIOLENCE, TRAUMA & VICTIMIZATION COURSES	
	ous Psychiatric Disorders in Our Own Families et to Home: Shame in Homelessness	67 79	66 Risk Assessment for Violence	104
<b>63</b> The	Explosion of Social Media: Why, Where,		73 Trauma-Informed Care: Principles and Implementation	108
Whe	en and How can Psychiatrists Catch up with the Trend?	88	FORUM	
			4 Global Disasters Forum:	
STRE			Lessons Learned from Chile, Haiti & New Orleans	115
	CONFERENCE D and the American Soldier Today	89	LECTURE	
1 113	D and the American soldier roday	0)	3 Patient Violence Against Mental Health Clinicians:	
COURS			Safety Assessment and Prevention	82
	dfulness: Practical Applications for Psychiatry a of the East and West: Integrating Breath Work and	78	MEDIA WORKSHOP	
	litation Into Clinical Practice	79	4 National Disasters: Developing a Road Map for	
			Preparedness and Interventions	101
SYMPC 24 Prev	OSIA vention of PTSD: Recent Israeli Practices	71	SCIENTIFIC AND CLINICAL REPORT	
	el Tools for Preventing and Treating Substance Use and	, 1	9 Child Abuse	92
Com	norbidities in the Military and Returning Veterans	122	CMALL INITEDACTIVE CECCIONI	
WORK	SHOPS		SMALL INTERACTIVE SESSION  18 Psychiatric Issues Related to Returning Vets From Iraq and Afghanistan	110
	nerability and Resilience: Katrina's Widespread Impact on			
	t Responders, Clinicians, Youth and Relocated Survivors	68	WORKSHOPS  Wylnorphility and Position on Verting's Wideenroad Impact on	
	n Narrative and Theory to Evidence-based Support for hiatrists Working Under Extreme Stress	76	28 Vulnerability and Resilience: Katrina's Widespread Impact on First Responders, Clinicians, Youth and Relocated Survivors	68
62 Disa	ster Preparedness, Evacuation and Rebuilding:		49 I'm Violent, Admit Me if you Dare:	
Less	ons Learned from Katrina Applied to Gustav and Ike	88	How and Where to Manage Potentially Violent Individuals With Unclear Diagnoses Presenting to Emergency Services	80
			59 Psychological Aspects of Biologic, Chemical, and Nuclear Terrorism	88
TRE	ATMENT TECHNIQUES & COME STUDIES		114 Suicide Bombers: Psychology, Psychopathology and Cultural Views	125
ADVAN	ICES IN			
4 Adva	ances in Psychotherapeutic Treatments	95	WOMEN'S HEALTH ISSUES	
			13 Psychiatric Disorders in Pregnant and Postpartum Women:	
COURS	SES mining Professional Boundaries:		Infant Morbidity and Mortality	76
	ghing Risks Versus Opportunities	62	34 Management of Psychiatric Disorders in	
	ering Adherence to Psychotropic Medications:	0.1	Pregnant and Postpartum Women	80
	ractical Resource for Clinicians v to Practice Evidence Based Psychiatry:	81	SYMPOSIA	
Prin	ciples and Case Studies	104	Sex/Gender Differences and Women-Specific Issues in Drug Abuse:	76
	hodynamic Psychopharmacology: Applying Practical Psychodynamics nprove Pharmacologic Outcomes with Treatment Resistant Patients	108	Predicting and Improving Treatment Outcomes  Neuroendocrine and Neuroimmunological Correlates of	78
	ima-Informed Care: Principles and Implementation	108	Biopolar Disorder in Women	83
			72 The Nuts and Bolts of the Perinatal Psychiatric Consultation 82 Reproductive Issues and Women's Mental Health:	113
SYMPC 4 Shar	OSIA red Decision Making in Mental Health Care:		How to Untie the Gordian Knot?	114
	covery and Person-centered Approach	64	Mood, Memory and Myths: What Really Happens at Menopause?	115
	ating the APA Guidelines for the Treatment of	70	Women's Mental Health in Latin America: Present and Future Research	119
	derline Personality Disorder ovations in Integrated Treatment of	70	WORKSHOPS	
Subs	stance Use and Psychiatric Disorders	98	44 Mood Disorders in Women of Reproductive Age	77
	2010 APA Task Force Report on the Practice of Electroconvulsive rapy: Evidence-based Guidelines for the Practicing Clinician	107	<ul><li>Cognitive Behavioral Strategies for Weight Loss</li><li>Neonaticide: Phenomenology and Prevention</li></ul>	77 93
	lence-based Treatments (EBT) for Borderline Personality Disorder:	107	<b>.</b> ,	
	pirical Clarity Meets Clinical Reality	112		
	Treatment of Psychiatric Disorders with rTMS:  Research and Clinical Findings	113		
93 Cult	ural Adaptation of Cognitive Behaviour Therapy for			
	nic/Minority Patients functions in Mentalization or Metacognition in	121		
	onality Disorders: Empirical Evidence and			
Impl	lications for Pathology, Treatment and Research	124		

# American Psychiatric Publishing, Inc.

# The First and Last Word in Psychiatry



#### Sunday, May 23

11:00am - 12:00pm

Alan F. Schatzberg, M.D.

Manual of Clinical Psychopharmacology, Seventh Edition

The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition

11:00am - 12:00pm

Charles B. Nemeroff, M.D., Ph.D.

The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition

11:00am - 12:00pm

Terence A. Ketter, M.D.

Handbook of Diagnosis and Treatment of Bipolar Disorders

#### Monday, May 24

11:00am - 12:00pm

Glen O. Gabbard, M.D.

Long-Term Psychodynamic Psychotherapy:

A Basic Text, Second Edition

#### Tuesday, May 25

11:00am - 12:00pm

Mina K. Dulcan, M.D.

Dulcan's Textbook of Child and Adolescent **Psychiatry** 

11:00am - 12:00pm

Jesse H. Wright, M.D., Ph.D.

High-Yield Cognitive-Behavior Therapy for Brief Sessions: An Illustrated Guide

Priority code AH1015



The First and Last Word in Psychiatry

# Psychiatry Online.com


# Online access to a premier collection of psychiatric resources

## Visit the APPI Bookstore for a demo!

PsychiatryOnline.com is a powerful website that features DSM-IV-TR® and The American Journal of Psychiatry as the cornerstones of an unsurpassed collection of psychiatric references, including books, journals, and self-assessment tools. Much more than simply books and journals presented online, PsychiatryOnline. com features sophisticated searching and indexing tools that enable you to quickly target all the information you need.

Whether your needs are clinical, learning, or research, **PsychiatryOnline.com** provides access to the information critical to your work and everyday practice with convenient features such as:

- Search and linking tools that let you find relevant book chapters and journal articles quickly.
- Unlimited downloads to PDA so you can take book sections with you wherever you go.
- Copy and paste functions for easy creation of tables and presentations.
- Citation exports to most reference manager formats.
- Printer-friendly views that mean no reformatting when you need a hard copy.
- Saved searches and bookmarked chapters to make it easy to return to topics of interest.
- Email page feature that allows you to share the information with colleagues.



Interested in an institutional subscription? Please contact us at: 1-703-907-8538, ext. 8538 or institutions@psych.org.

Also Sample APPI Content on Four Different E-Book Readers!

• iPad • Kindle • Edge • Nook

#### **APPI Bookstore Hours**

Saturday, May 22 to Tuesday, May 25 10:00 am – 4:00 pm



The First and Last Word in Psychiatry

American Psychiatric Publishing, Inc. 1-800-368-5777 or 703-907-7322 appi@psych.org

Priority Code AH1019

Find us on facebook and Ewilker



#### 9:00 A.M.-10:30 A.M.

#### YOUNG INVESTIGATORS' POSTER SESSION 1

LA LOUISIANE C, MORIAL CONVENTION CENTER

#### **Moderator:**

Daniel P. Chapman, Ph.D.

#### NR1-1

MEDIATION AS TREATMENT MODALITY IN ACTIVE DUTY SERVICE MEMBERS PARTICIPATING IN RESIDENTIAL SUBSTANCE ABUSE REHABILITATION

Amy Canuso, D.O. Lyń Waelde, Ph.D. Robert McLay M.D., Ph.D. Mary Rusher, M.D. Chris Johnson, Ph.D. Scott Johnston, Ph.D.

#### NR1-2

STRAWS: SCHEDULED TAPER RECOMMENDED FOR ALCOHOL WITHDRAWAL SYNDROME Cheryl Graber, M.D. Anthony Tobia, M.D. Shannon Parks, D.O.

#### NR1-3

**CORRELATION BETWEEN** CHRONIC COCAINE USE AND Hypoglycemia in Patients ADMITTED TO THE HOSPITAL

Faiz A. Cheema, M.D. Ferhana Nadeem, M.D. Summer Jaffrey, M.D. Ghulam Bajwa, M.D. David Chiapaikeo, B.S. Yoshie Umemura, B.S. Amel Badr, M.D. Joan Wynn, M.B.A. Javed Iqbal, M.D.

#### NR1-4

SAFETY AND EFFICACY OF VARENICLINE IN SCHIZOPHRENIA: PRELIMINARY DATA Iohanna Nino, M.D. A. Eden Evins, M.D., M.P.H.

CLINICAL CORRELATES OF ATTRITION AT A RESIDENTIAL SUBSTANCE ABUSE THERAPEUTIC COMMUNITY PROGRAM Jonathan C. Lee, M.D.

Douglas M. Burgess, M.D. Karen Kelley, Kevin McDonald Kathleen S. Peindl, Ph.D. *Julie L. Adams M.D.* Ashwin Patkar, M.D.

COLLECTIVISTIC AND SOSIOTROPIC TENDENCY OF PATIENTS WITH ALCOHOL DEPENDENCE IN KOREA Jungwon Min, M.D. Jung-Ho Shin, M.D. Min-Hyuk Kim, M.D.

#### NR1-7

SEXUAL DYSFUNCTION IN PATIENTS DIAGNOSED WITH SUBSTANCE USE DISORDER Neslihan Akkisi Kumsar, M.D. Nesrin Dilbaz

#### NR1-8

SUBSTANCE USE AND TRAUMA: A RETROSPECTIVE CHART **REVIEW OF TRAUMA PATIENTS** IN THE URBAN SOUTH Rachel A. Houchins, M.D. Kristin Arthur, M.D. Mark A. Jones, M.D.

#### NR1-9

THE CONTRIBUTING FACTORS ON THE PROBLEM DRINKING **OF WORKERS** Sang Kyu Lee, M.D. Hong-Seock Lee, M.D., Ph.D.

COMPARISON OF BEHAVIORAL, PSYCHOLOGICAL CHARACTERISTIC FEATURES AND SEVERITY BETWEEN GAMBLERS IN LEGAL AND ILLEGAL GAMBLING PLACES Sang Kyu Lee, M.D. Hong-Seock Lee, M.D. Ph.D.

#### NR1-11

PSYCHIATRY RESIDENTS' ATTITUDES ON SUBSTANCE **ABUSE: CHANGES IN ATTITUDES** POST-SBIRT TRAINING Victoria Balkoski, M.D. Tavi Thongdy, M.D.

#### NR1-12

WITHDRAWAL AND ABSTINENCE-RELATED PSYCHIATRIC SYMPTOMS IN ABSTINENT METHAMPHETAMINE-**DEPENDENT SUBJECTS** Todd Zorick, M.D., Ph.D. Karen Miotto, M.D. Gerhard Hellemann, Ph.D. Catherine Sugar, Ph.D. Rick Rawson, Ph.D. Edythe London, Ph.D.

#### NR1-13

ASSOCIATION STUDY BETWEEN PANIC DISORDER AND 5-HT1A GENE C(-1019)G **POLYMORPHISM** 

Choi Wonseok, B.A. Yong-Ku Kim, M.D., Ph.D. Bun-Hee Lee, M.D., Ph.D. Ho-Kyoung Yoon, M.D., Ph.D.

#### NR1-14

ASSOCIATION STUDY BETWEEN PANIC DISORDER AND -874 A/T INTERFERON-GAMMA GENE **POLYMORPHISM** Choi Wonseok, B.A. Ho-Kyung Yoon, M.D., Ph.D. Yong-Ku Kim, M.D., Ph.D.

#### NR1-15

COMPARISON OF ANXIETY-RELATED TRAITS BETWEEN EARLY AND LATE-ONSET PANIC DISORDER Eun Jin Kim, M.D. Ju-Won Ha, M.D. Se-Won Lim, M.D. Kang-Seob Oh, M.D., Ph.D.

#### NR1-16

THE EFFECT OF TEMPERAMENT AND CHARACTER ON THE TREATMENT OUTCOME AFTER 24-WEEK **PHARMACOTHERAPY** WITH ESCITALOPRAM IN PATIENTS WITH PANIC DISORDER Haeran Na, M.D. Yoon-Jae Song, M.D. Eun-Ho Kang, M.D. Bum-Hee Yu, M.D., Ph.D.

#### NR1-17

BRAIN GLUCOSE METABOLISM AND TEMPERAMENT AND CHARACTER IN PATIENTS WITH PANIC DISORDER: AN [18]FDG-PET STUDY Haeran Na, M.D. Sang-Wook Kim, M.D. Eun-Ho Kang, M.D. Bum-Hee Yu, M.D., Ph.D.

#### NR1-18

EFFICACY OF KOREAN-TYPE COGNITIVE-BEHAVIORAL GROUP THERAPY FOR SOCIAL ANXIETY DISORDER

Ju-Won Ha, M.D. Eun-Jin Kim, M.D. Se-Won Lim, M.D. Kang-Seob Oh, M.D.

#### NR1-19

ASSOCIATION OF THE C-1019G POLYMORPHISM OF SEROTONIN 1A RECEPTOR GENE AND ABNORMAL **EATING BEHAVIOR IN KOREAN** FEMALE ADOLESCENTS Ju-Won Ha, M.D. Eun-Jin Kim, M.D. Se-Won Lim, M.D. Dong-Won Shin, M.D. Hee-Yeon Woo, M.D.

#### NR1-20

Kye-Hyun Kim, M.D.

AN OPEN-LABEL, RATER BLINDED 6-WEEK PILOT TRIAL OF ESCITALOPRAM FOR GAD AMONG PATIENTS WITH HIV

Manmohandeep Sohi, M.D. Haresh Tharwani, M.D. Chi-Un Pae, M.D. Prakash Masand, M.D. Meera Narasimhan, M.D. Ashwin A Patkar, M.D.

### NR1-21

### COGNITIVE MODULATION OF FRONTO-STRIATAL NETWORKS IN PATIENTS WITH OCD

Martin Desseilles, M.D., Ph.D. Alice Muselle, M.D. Christel Devue, Ph.D. Virginie Sterpenich, Ph.D. Thien Thanh Dang-Vu, M.D., Ph.D. Genevieve Albouy, Ph.D. Christina Schmitd, Ph.D. Christian Degueldre, Christophe Phillips, Ph.D. Marc Ansseau, M.D. Pierre Maquet, M.D., Ph.D. Sophie Schwartz, Ph.D.

### NR1-22

**EXERCISE TRAINING REDUCES** ANXIETY SYMPTOMS AMONG PATIENTS WITH A CHRONIC MEDICAL ILLNESS

Matthew P. Herring, M.S., M.Ed., Patrick I. O'Connor, Ph.D. Rodney K. Dishman, Ph.D.

### NR1-23

COMPARISON OF THE INFLUENCE OF PSYCHOSOCIAL AND GENETIC FACTORS ON ADOLESCENT SUICIDAL IDEATION: A POPULATION-BASED STUDY Hoyoung An, M.D. Joon-Ho Ahn, M.D., Ph.D. Soo-Young Bhang, M.D., M.P.H.

### NR1-24

THE PREVALENCE AND SEVERITY OF NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE AND SUBCORTICAL VASCULAR DEMENTIA: THE CREDOS STUDY

Hoyoung An, M.D. Chan-Seung Chung Joongsun Lee Doh Kwan Kim Byung-Hoon Oh Jae-Hong Lee SangYun Kim Seul-Hee Han Duk-Lyul Na Seong-Yoon Kim

### NR1-25

DELIRIUM IN THE OLDEST-OLD: SOCIODEMOGRAPHIC AND **EPIDEMIOLOGIC FEATURES AND** RESPONSE TO TREATMENT

Antonio Nascimento, M.D. Gilberto Sousa Alves, M.D. Markus Salomão Miguel, M.D. Juliano Victor Luna, M.D.

Marcelo Ciuffo, D.Sc.

FOCUS: The Journal of Lifelong Learning in Psychiatry

Tel: 800-368-5777

### NR1-26

COMPARISON ON THE EFFICACY OF RISPERIDONE VERSUS HALOPERIDOL IN THE TREATMENT OF DELIRIUM: PROSPECTIVE, RANDOMIZED, DOUBLE **BLIND TRIAL** 

Wooyul Jung, Han-Yong Jung, M.D., Ph.D. Soyoung Irene Lee, M.D., Ph.D. Shin Gyeom Kim, M.D. Eun Young Shin, M.D. Joonho Park, Ph.D. Mihee Park, M.D.

### NR1-27

AGE AT ONSET OF FIRST SUICIDE ATTEMPT IN MEN AND WOMEN: FURTHER EVIDENCE FOR TWO **SUBGROUPS** 

Hilario Blasco-Fontecilla, M.D., Ph.D. Analucia A. Alegria, B.S. M. Mercedes Perez-Rodriguez, M.D., Ph.D. David Delgado-Gomez, M.D. Teresa Legido-Gil, B.S. Jorge Lopez-Castroman, M.D., Ph.D. Jeronimo Saiz-Ruiz

### NR1-28

**OLFACTORY REFERENCE SYNDROME:** PART OF THE OCD SPECTRUM OR PSYCHOSIS? A DISCUSSION ILLUSTRATED WITH A CASE Juliana Brum Moraes, M.D. Vivian Uemura, M.D. Rogério Paysano Marrocos, M.D., M. Sc.

### NR1-29

DIFFERENTIATING PARANEOPLASTIC SYNDROMES FROM PSYCHOSIS OF A PSYCHIATRIC ETIOLOGY Mary S. Gable, M.D., M.P.H. Shilpa Gavali, M.P.H. Allen Radner, M.D. D. Tilley, M.D. B. Lee, M.D. Lauralee Dyner, M.D.

A. Collins, M.D. Anna Dengel, M.D. Josep Dalmau, Ph.D., M.D. Carol Glaser, M.D.

### NR1-30

THE DIAGNOSTIC STABILITY OF BRIEF PSYCHOTIC DISORDER

Youjin Hong, M.D. Joongsun Lee, M.D. Imyel Kim, M.D. Jung-Seo Yi, M.D. Byung-Su Kin, M.D. Jong-Han Lim, M.D. Yeon-Ho Joo. M.D.

# NR1-31

USE OF BODY IMAGE SOFTWARE TO EVALUATE BODY IMAGE DISTORTION IN PATIENTS WITH ANOREXIA NERVOSA Jennifer Fier, B.A.

Jennifer Hagman, M.D. Jane Gralla, Ph.D. Rick Gardner, Ph.D.

### NR1-32

QUALITY OF LIFE IN INDIVIDUALS WITH TRICHOTILLOMANIA AND PATHOLOGICAL SKIN PICKING Brian L. Odlaug, B.A. Jon E. Grant, J.D., M.D., M.P.H.

### NR1-33

LATEST CLINICAL TRIALS FOR MDD: WHAT KINDS OF DRUGS AND WHAT KINDS OF TRIALS? Aarti Gupta, M.B.B.S. Rajnish Mago, M.D.

### NR1-34

GENDER DIFFERENCES IN CLINICAL FEATURES AND PREDOMINANT POLARITY AMONGST BIPOLAR DISORDERS Alessandra Nivoli, M.D. F. Colom, PsyD, M.Sc., Ph.D. A. Murru, M.D. I. Pacchiarotti, M.D. M. Reinares, PsyD, M.Sc., Ph.D. C. M. Bonnin, PsyD, M.Sc. E. Vieta, M.D., Ph.D.

### NR1-35

Episodes are not DISTINCT FROM SPONTANEOUS EPISODES: IMPLICATIONS FOR DSM-5 Alessandra Nivoli, M.D. I. Pacchiarotti, M.D. E. Popova, M.D. A. Murru, M.D. C. Torrent A. R. Rosa M. Valentí, M.D.

F. Colom, Psy.D., M.Sc., Ph.D.

E. Vieta, M.D., Ph.D.

POST-PARTUM BIPOLAR

### NR1-36

ABNORMALITIES DURING RESTING STATE FUNCTIONAL MAGNETIC SONANCE IMAGING IN TREATMENT-NAIVE PATIENTS WITH MDD Bing Zhao, B.S.C.

Jon E. Grant, M.D., J.D., M.P.H.

### NR1-37

THE COMBINED EFFECTS OF THE BDNF AND GSK3B GENES MODULATE THE RELATIONSHIP BETWEEN NEGATIVE LIFE EVENTS AND MDD

Chunxia Yang, B.S.C. Hong Yang, M.Sc. Yong Xu, M.Sc. Ning Sun, M.Sc. Zhifeng Liu, M.Sc. Yan Ren, M.Sc. Xiaohua Cao, Ph.D. Kerang Zhang, M.D.





### NR1-38

CONTRASTING PATTERNS OF **DEFICITS IN VISUOSPATIAL** MEMORY AND EXECUTIVE FUNCTION IN PATIENTS WITH Major Depression, with AND WITHOUT ECT REFERRAL Eirini Theochari, M.D. Stamatina Kalogerakou, M.Sc. Vassiliki-Maria Papakosta, B.Sc. Dimitrios Kontis, M.D., Ph.D. Marinela Koutroumpi, B.Sc. Eleni Anyfandi, B.Sc. Ioannis Michopoulos, M.D., Ph.D. Evangelos Karapoulios, M.D. George Papadimitriou, M.D., Ph.D.

### NR1-39

A CLINICAL COMPARISON BETWEEN EARLY (< 15 YEARS) AND LATE-ONSET PATIENTS WITH BIPOLAR DISORDER

Panagiotis Oulis, M.D., Ph.D.

Eleftheria Tsaltas, Ph.D.

Farah S. Hassan, M.D. Elizabeth C. Penick, Ph.D. Ekkehart Othmer, M.D., Ph.D. Elizabeth J. Nickel, M.A. Cheryln DeSouza, M.D. E. N. Hunter, Ph.D. William F. Gabrielli, M.D., Ph.D.

### NR1-40

DEPRESSIVE SYMPTOMS IN ANXIETY DISORDERS AND MDD Hyunjoo Yang, M.D. Hong Yang Yan Ren

### NR1-41

A COMPARISON OF MEDICAL COMORBIDITIES IN ELDERLY VERSUS YOUNGER BIPOLAR PATIENTS Ilyse Rosenberg, D.O., B.S. J. Prosser, M.D. K. Shah, M.D.

I. Galvnker, M.D. L. Cohen, Ph.D. M. Lantz, M.D.

### NR1-42

FEASIBILITY AND EFFECTIVENESS OF USING E-MAIL TO SCREEN COLLEGE STUDENTS FOR DEPRESSION

Irene Shyu, B.A., Soo Jeong Youn, B.A. Maurizio Fava, M.D. Albert Yeung, M.D., Sc.D.

### NR1-43

SEASONAL VARIATION OF MOOD AND BEHAVIOR IN BIPOLAR I AND BIPOLAR II DISORDERS

Jungmi Choi, M.D. Jihae Noh, M.A., Ji Hyun Baek, M.D. Ji Sun Kim, M.D. Ji Sun Choi, RN-BSN Hee Jung Nam, M.D. Dongsoo Lee, M.D., Ph.D. Kyung Sue Hong, M.D., Ph.D.

APA 2010 ANNUAL MEETING ONLINE:

- · Special onsite pricing
- Earn CME Credit for top lectures and symposia online
- For more information: <psych.org/amlibrary>

### NR1-44

COMORBID ANXIETY AND MOOD DISORDERS IN A TERTIARY **CARE OUTPATIENT SETTING** Kavi K. Devulapalli, B.A. Keming Gao, M.D., Ph.D

### NR1-45

DIAGNOSTIC STABILITY OF FIRST-EPISODE PSYCHOSES RETROSPECTIVELY ASSESSED AFTER RECURRENCE OF PSYCHOTIC EPISODES Ii Sun Kim, M.D. Ji Sun Choi Kyung Sue Hong, M.D., Ph.D.

### NR1-46

ATR AS A PREDICTOR OF RESPONSE TO REBOXETINE

Marissa Caudill, M.D., Ph.D. Ian A. Cook, M.D. Aimee M. Hunter, Ph.D. Andrew F. Leuchter, M.D.

GENETIC ASSOCIATION OF THE INTERACTION BETWEEN THE BDNF AND GSK3B GENES AND MDD in a Chinese Population Ning Sun, B.S.C. Chunxia Yang, M.Sc. Yong Xu, M.Sc. Hong Yang, M.Sc. Jinli Liu, M.Sc. Kerang Zhang, M.D. Qi Xu, Ph.D. Yan Shen, M.Sc.

### NR1-48

How to Use Adverse **EVENTS LISTED IN THE PDR** FOR ANTIDEPRESSANTS? Srimannarayana Marella, M.B.B.S. Rajnish Mago, M.D.

### NR1-49

ACTIVATION/INHIBITION RESPONSE, EFFICACY, SAFETY OF OLANZAPINE IN ACUTE **BIPOLAR PATIENTS: SECONDARY** OUTCOMES OF A 24-WEEKS OPEN-LABEL SINGLE-ARM TRIAL Stephanie Gerard, Pharm.D. Chantal Henry, M.D. Amandine Luquiens, M.D. Christophe Lancon, M.D., Ph.D. Hélène Sapin, Elena Perrin, M.D. Bruno Falissard, M.D., Ph.D. Stephanie Gerard, Pharm.D. Michael Lukasiewicz, M.D., Ph.D.

### NR1-50

RESTING-STATE SPONTANEOUS NEURAL ACTIVITIES IN PATIENTS WITH A FIRST-EPISODE OF MDD AND THEIR FIRST-DEGREE RELATIVES Xiaohua Cao, Ph.D. Zhifen Liu, M.Sc. Bing Zhao, M.Sc. Cheng Xu, B.M. Lijuan Bai, M.Sc. Chongxi Du, B.M. Kerang Zhang, M.D.

### NR1-51

DECREASED REGIONAL HOMOGENEITY IN INSULA AND CEREBELLUM: A RESTING-STATE FMRI STUDY IN PATIENTS WITH DEPRESSION AND SUBJECTS AT RISK FOR DEPRESSION Zhifen Liu, B.S.C. Chong-Xi Du

### NR1-52

DOES GENDER IMPACT THE RELATIONSHIP BETWEEN PARENTAL MALTREATMENT AND PERSONALITY PATHOLOGY IN ADULTHOOD?

Aarti Nanda, M.D. Michelle Foster Winter Halmi Cristina Nesci Igor Galynker, M.D. Lisa J. Cohen, Ph.D..

### NR1-53

RISK FACTORS FOR OBESITY IN PATIENTS WITH BPD OVER 10 YEARS OF PROSPECTIVE FOLLOW-UP Jolie Weingeroff, M.A. Frances R. Frankenburg, M.D. Garrett Fitzmaurice, Sc.D. Mary C. Zanarini, Ed.D.

### NR1-54

PREVALENCE OF PERSONALITY DISORDERS IN ADULT GAY, LESBIAN, BISEXUAL, AND TRANSGENDER PATIENTS IN AN INPATIENT CHEMICAL DEPENDENCY TREATMENT PROGRAM

Meredith B. Flynn, M.D. Winter Halmi Aarti Naanda, M.D. Cristina Nesci Igor Galynker, M.D. Lisa J. Cohen, Ph.D.

### NR1-55

REDUCTION OF TYPICAL GENDER DIFFERENCES AMONG PSYCHIATRIC **OUTPATIENTS WITH ASPD** 

Micaela P. Wexler, D.O. Elizabeth C. Penick, Ph.D. Elizabeth J. Nickel, M.A. Ekkehart Othmer, M.D. Ph.D. Marsha M. Read, Ph.D. Cherilyn M. DeSousa, M.D. Barry Liskow, M.D. William F. Gabrielli, M.D., Ph.D.

### NR1-56 Withdrawn

### NR1-57

QUALITY OF CARE AND **CRIME RATES AMONG PATIENTS** WITH SCHIZOPHRENIA: A NATIONWIDE POPULATION-BASED FOLLOW-UP STUDY Charlotte Pedersen, Merete Nordentoft, Ph.D. Søren Paaske Johnsen, Ph.D. Jan Mainz, Ph.D.

### NR1-58

THE EFFICACY OF LOW-FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION TREATMENT FOR AUDITORY VERBAL HALLUCINATIONS MAY BE LOW Christina C. Slotema, M.D., D.Phil. Ian Dirk Blom, Ph.D. Hans W. Hoek, M.D., Ph.D. René S. Kahn, M.D., Ph.D. Iris E.C. Sommer, M.D., Ph.D.

### NR1-59

METABOLIC AND CARDIOVASCULAR RISK IN PSYCHOTIC PATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS

Clara Franch Pato Juan I. Franch Valderde, Ph.D. Gema Medina Ojeda, Ph.D. Ana I. Ledo Rubio, M.D.

### NR1-60

"How Long Should I Take This Medicine?" A Literature REVIEW OF THE DURATION OF MAINTENANCE TREATMENT IN **SCHIZOPHRENIA** 

Durga Bestha, M.B.B.S. Vishal Madaan, M.D. Babuji Gandra, M.B.B.S.

### NR1-61

**BEYOND SMOKING CESSATION:** VARENICLINE IN SCHIZOPHRENIA? Durga Bestha, M.B.B.S. Vishal Madaan, M.D. Namita Dhiman, M.B.B.S.

FACIAL EMOTION RECOGNITION IN CHINESE WITH FIRST-**EPISODE SCHIZOPHRENIA: EMOTION SPECIFIC DEFICIT** AND ERROR PATTERN Joey Shuk Yan Leung, M.B.B.S.

### NR1-63

Previous Offending **AMONG FIRST EPISODE PSYCHOSIS** PATIENTS: PREVALENCE AND **CLINICAL CORRELATES** Laila Asmal, M.D., M.Med. Robin A. Emsley, MB.Ch.B, M.Med, M.D. Piet Oosthuizen, MB.Ch.B, M.Med, M.D. Bonginkosi Chiliza, MB.Ch.C.

### NR1-64

ANTIPSYCHOTICS AND LONG-TERM OUTCOME IN SCHIZOPHRENIA: MILAN-STANFORD **COLLABORATIVE PROJECT** 

Massimiliano Buoli, M.D. Filippo Dragogna, M.D. Massimo Carlo Mauri, M.D. Giobbio Gian Marco, M.D. Bernardo Dell'Osso, M.D. Carlo Altamura, M.D. Ira D. Glick, M.D.

### NR1-65

**EXACERBATION OF** PSYCHOSIS IN RELATION TO MENSTRUAL CYCLE IN Women: Role of Estrogen Michelle Thorpe, M.D. Sadia Ghaffar, M.D. Anuradha Seshadri, B.S. Sutapa Dube, B.S. Amel Badr, M.D. Joan Wynn, MBA Javed Iqbal, M.D.

### NR1-66

DELUSIONS, DELUSIONAL CONVICTION AND METACOGNITIVE IMPAIRMENTS IN PATIENTS WITH **SCHIZOPHRENIA** 

Nicolas Bruno, M.D. Nadia Sachs, Ph.D. Nicolas Franck, M.D., Ph.D. Elisabeth Pacherie, Ph.D

### NR1-67

PREDICTORS OF FUNCTIONAL DISABILITY AND NUMBER OF HOSPITALIZATIONS IN SCHIZOPHRENIA: RELATIONS WITH NEUROCOGNITION, SYMPTOMS, AND PREMORBID ADJUSTMENT Iavier Peña, Ph.D. Pedro Manuel Sánchez, M.D. Natalia Ojeda, Ph.D. Edorta Elizagarate, M.D. Jesus Ezcurra, M.D. Miguel Gutiérrez, M.D.

### NR1-68

COMPARATIVE ANALYSIS OF INVOLUNTARY ADMISSION AND VOLUNTARY ADMISSION IN SCHIZOPHRENIA: A THREE-YEAR FOLLOW-UP Seung-Ho Jung, M.D. Young-Su Lee, M.D. Chul-Eung Kim, Ph.D.

### NR1-69

CARBON DIOXIDE-INDUCED PANIC IN SCHIZOPHRENIA WITH AUDITORY HALLUCINATIONS Tara A. Kahn Jeffrey P. Kahn, M.D. Adam Savitz, M.D., Ph.D.

### NR1-70

THREE DIMENSIONAL ELECTROENCEPHALOGRAPHIC MAPPING WITH ELORETA **DURING SLEEP ONSET PERIOD** Chul-Jin Shin, M.D., Ph.D. Jae Young Park, M.D. Doo-Heum Park M.D.

### NR1-71

STUDY COMPARING PSG DATA IN INSOMNIA PATIENTS WITH HIV VERSUS MATCHED CONTROLS WITH INSOMNIA Yinghui Yh. Low, B.S.C. Toma Omonuwa, M.D. Jack Edinger, Ph.D. Harold Goforth, M.D. Xavier Preud'homme, M.D. Colleen Carney, Ph.D. Andrew Krystál, M.D.

### NR1-72

DECREASES IN SOLUBLE CD40 LIGAND ARE ASSOCIATED WITH IMPROVEMENTS IN SEVERITY OF INSOMNIA IN HIV-INFECTED PATIENTS: A PILOT STUDY Yinghui Low, B.S.C. Edward C. Suarez, Ph.D. Harold Goforth, M.D. Toma Omonuwa, M.D. Andrew Krystal, M.D.

### NR1-73

PERCEIVED STRESS AND PSYCHO-PATHOLOGY IN SCHIZOPHRENIA

Anders Jørgensen, M.D. Anders Fink-Jensen, M.D., DMSci Henrik Enghusen Poulsen, M.D., DMSci Martin Balslev Jørgensen, M.D., DMSci

### 12:30 P.M.-2:00 P.M.

YOUNG INVESTIGATORS' **POSTER SESSION 2** 

LA LOUISIANE C, MORIAL CONVENTION CENTER

### Moderator:

Barton Blinder, M.D.

EXPLORING THE RELATIONSHIP BETWEEN SLEEP AND AN ANXIETY-RELATED ENDOPHENOTYPE: ACTIVE AVOIDANCE LEARNING INCREASES REM SLEEP Frank A. Fetterolf, B.S. Helene S. Porte, Ph.D.

### NR2-2

THE SECOND DIGIT TO THE FOURTH DIGIT LENGTH RATIO AND ITS PERSONALITY AND TEMPERAMENT CHARACTERISTIC Hyun Young Oh, M.D. Hwang Lyong Kim, M.D. Hyun Joo Yang, M.D. Suk Hyun Kim, M.D., Ph.D. Yong Chon Park, M.D., Ph.D.





### NR2-3

### Loss of Heart Rate COMPLEXITY IN MEN WITH DEPRESSION

Samuel Leistedt, M.D. Paul Linkowski, M.D., Ph.D. Jean-Pol Languart, Ph.D. Chung-Kang Peng, Ph.D. Joseph E. Mietus, Ph.D. Ary L. Goldberger, M.D. Madalena D. Costa, Ph.D.

### NR2-4

Neurobiologic CORRELATES OF LOW PLAN/IMPULSIVE SUICIDE ATTEMPT: A REVIEW Sarah Berkson, B.A. Lauren M. Klayman, B.A. Lance M. Rappaport Lisa J. Cohen, Ph.D. Serena J. Fox, M.D. Igor I. Galynker, M.D., Ph.D.

### NR2-5

**Up-Regulation in** SERUM TROPOMYOSIN-RELATED KINASE B PROTEIN LEVEL IN ACUTE STAGE OF MAJOR DEPRESSION Tiao-Lai Huang, M.D. Yi-Yung Hung, M.D. Chia-Ju Lin

### NR2-6

ASSOCIATION STUDY OF PERSONALITY AND BRAIN **EVOKED POTENTIALS IN HEALTHY CHINESE** Yan Ren, B.S.C. Hong Yang Kerang Zhang

### NR2-7

Huijun Duan

STRUCTURAL VOLUMES OF THE CEREBELLAR VERMIS IN A PEDIATRIC **BIPOLAR POPULATION** WITH COMORBID ADHD Amy Shah, M.D. David E. Fleck, Ph.D. Melissa P. DelBello, M.D. Neil P. Mills, B.S.

### NR2-8

NEURAL REPRESENTATION OF VISUAL PROCESSING OF ATTACHMENT FIGURES IN YOUNG ADULT WOMEN Using FMRI

Curren E. Katz, Ed.M. Joy Hirsh Ph.D. Steve Dashnaw Leo Bierman B.A. Gillian Jennings, B.A. Janine Samuel B.A. Cristina Nesci, M.S. Hellen Mayberg, M.D. Arnold Winston, M.D. Igor Galynker, M.D., Ph.D.

### NR2-9

A COMPARISON STUDY BETWEEN VISUAL INTERPRETATION AND STATISTICAL PARAMETRIC MAPPING (SPM) ANALYSIS **OF SPECT IMAGES IN PATIENTS** WITH TRAUMATIC BRAIN INJURY Hwang Lyong Kim, M.D.

### NR2-10

RELATIONSHIP BETWEEN RCBF AND NEUROPSYCHIATRIC SYMPTOMS IN TRAUMATIC BRAIN INJURY AT THE CHRONIC STAGE: A SPECT STUDY WITH SPM ANALYSIS

Hwang Lyong Kim, M.D. Hyun Joo Yang, M.D. Hyun Young Kim, M.D. Yong Chon Park, M.D., Ph.D. Dong Hoon Oh, M.D.

### NR2-11

THE LINK BETWEEN TOURETTE'S SYNDROME AND BIPOLAR DISORDER: A CLOSER LOOK Atif Waseem, B.S.

Gulam A Noorani, M.D., M.P.H. Javed Igbal, M.D.

### NR2-12

IMPROVEMENT IN MULTIPLE SYMPTOM DOMAINS IN Youth Following 12 WEEKS OF ATYPICAL ANTIPSYCHOTIC TREATMENT FOR IRRITABILITY AND AGGRESSION

Cara Fosdick, B.A. Ginger Nicol, M.D. Michael Yingling, B.S. John Newcomer, M.D.

### NR2-13

ZIPRASIDONE-INDUCED GALACTORRHEA IN AN **ADOLESCENT FEMALE:** A CASE REPORT Fasiha Haq, M.D. Shakeel Raza, M.D.

### NR2-14

INTELLIGENCE AND NEUROCOGNITIVE FUNCTIONING BY KPI-C PROFILE Type in Children with ADHD Han Kyul Park, M.D. Wanseok Seo, M.D., Ph.D. Bon-Hoon Koo, M.D., Ph.D. Kwangheun Lee, M.D., Ph.D. Kyung-Keun Kim, M.D.

### NR2-15

**CHRONIC DEPRESSION** IN AN 11-YEAR-OLD ASTHMATIC MALE: A CASE REPORT AND LITERATURE REVIEW Matthew Lowe, D.O., M.S. Leanne Strack, D.O. Amy Hoisington-Stabile, M.D.

### NR2-16

WELL-BEING AND PSYCHIATRIC STATUS OF PARENTS OF CHILDREN WITH MENTAL RETARDATION IN **PAKISTAN** 

Muhammad Waqar Azeem, M.D. Imtiaz Dogar, M.D. Imran Haider, M.D. Marianne Wudarsky, M.D., Ph.D. Alia Asmat, M.Sc. Madeeha Akbar, M.Sc. Sumira Kousar, M.Sc.

### NR2-17

REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION AND OLANZAPINE VERSUS OLANZAPINE ALONE IN THE TREATMENT OF ADOLESCENTS WITH BIPOLAR MANIA Ram Jeevan Bishnoi, D.P.M. Venu Gopal Jhanwar, M.D.

### NR2-18

NEUROFEEDBACK: AN EFFECTIVE AND SAFE TREATMENT OPTION FOR CHRONIC TENSION TYPE HEADACHES Ram Jeevan Bishnoi, D.P.M.

### NR2-19

PREVALENCE OF MENTAL ILLNESS AND SUBSTANCE ABUSE AMONG CHILD AND ADOLESCENT SUICIDE VICTIMS Yilmaz Yildirim, M.D. Ummuhan Yesil-Dagli, Ph.D. Richard Bloch, Ph.D.

### NR2-20

THE JOKER: A DARK NIGHT FOR DEPICTIONS OF MENTAL ILLNESS Cecil R. Webster, M.D. John Coverdale, M.D.

MIGRATION PSYCHIATRIC DISORDERS AT AN ACUTE PSYCHIATRIC UNIT Eva Roman Mazuecos, M.D. Jesús J. Marín Lozano, M.D. Ainoa Muñoz S. Jose, M.D. David López Gómez, M.D. Belén Bardón Rivera, M.D. Mª Fé Bravo Ortiz, M.D., Ph.D.

Is She Bipolar? Considering CONTRIBUTIONS OF A CULTURAL BACKGROUND FROM A SPANISH-SPEAKING PATIENT AND BILINGUAL MENTAL HEALTH TREATMENT TEAM Kristine Munoz, M.D. Iason Bennett, M.D.

### NR2-23

THE IMPACT OF RACE, ETHNICITY, AND CULTURE ON THE DIAGNOSIS OF BIPOLAR DISORDER: A REVIEW Sophia Haeri, B.A. J. Williams, B.A. A. Newmark, B.A. I. Kopeykina, B.A. L. Cohen, Ph.D. I. Galynker, M.D. Ph.D.

### NR2-24

CLINICAL AND DEMOGRAPHICAL CHARACTERISTICS AMONG PSYCHIATRIC PATIENTS IN AN EMERGENCY SERVICE Ainoa Muñoz San José, M.D. Jesús J. Marín, M.D. Mª Eva Román, M.D. Mª Victoria Bonan, M.D. David López, M.D. Marifé Bravo, Ph.D.

### NR2-25

FAMILIAL RELATION OF OBSESSIVE-COMPULSIVE AND SCHIZOID/ SCHIZOTYPAL TRAITS TO AUTISM TRAITS IN PEDIATRIC OCD

Hannah E. Reed, B.A. Kelley Anderson, B.A. Sarah Davarya, B.A. Ariana Tart-Zelvin Kathryn Mills Pedro Alvarez Marco Grados, M.D., M.P.H.

### NR2-26

OUTPATIENT PSYCHOTHERAPY USE PREVALENCE, CORRELATES AND EXPENDITURES: A Systematic Review Paula Silva, M.D. Sergio L. Blay, M.D., Ph.D.

### NR2-27

CAN ECONOMIC CRISES TURNS **DEADLY? MENTAL HEALTH EMERGENCIES IN TIMES OF ECONOMIC CRISIS IN A GENERAL** HOSPITAL IN MADRID Susana S. Cebolla, M.D. Juan J. De Frutos, M.D. Belén Bardón, M.D. Maria F. Bravo, Ph.D.

# NR2-28

MENTAL HEALTH CHANGE IN FLOODED DISTRICT CITIZEN: Two Years Follow-Up Young Ju Cho, M.D. Seongho Min, M.D., Ph.D. Min-Hyuk Kim, M.D.

Too Many Duties, Too Few RIGHTS: ETHICAL DILEMMAS IN PSYCHIATRIST'S RIGHTS VIS-À-VIS PATIENTS RIGHTS: PROPOSAL FOR AN **INTERNATIONAL CONSENSUS** Mohamed Nasr, M.D. Hani Hamed, M.D. Dalal Amer, M.D. Nahed Khairy, M.D.

### NR2-30

FREQUENCY OF THIRD PARTY NOTIFICATION FOLLOWING A THREAT IN AN INPATIENT STATE PSYCHIATRIC HOSPITAL POPULATION Delaney Smith, M.D. Tara Mayes, M.D.

### NR2-31

NEUROCHEMICAL CHARACTERISTICS Co-Vary with Personality TRAITS: FORENSIC PSYCHIATRIC FINDINGS REPLICATED IN THE GENERAL POPULATION Sara Bromander, M.D. Thomas Nilsson, Ph.D. Rolf Anckarsäter, M.D. Marianne Kristiansson, M.D., Ph.D. Anders Forsman, M.D., Ph.D. Kaj Blennow, M.D., Ph.D. Henrik Zetterberg, M.D., Ph.D, Henrik Anckarsäter, M.D, Ph.D. Caroline Wass, Ph.D.

### NR2-32

T3111C CLOCK SNP AND MOOD DISORDERS: A SYSTEMATIC REVIEW Enrique Gaspar, M.D. Raffaella Calati, Ph.D. Carlos S. Cruz-Fuentes, Ph.D. Diana De Ronchi, M.D., Ph.D.

### NR2-33

NEUROPSYCHOLOGICAL AND **PSYCHIATRIC ALTERATIONS** CAUSED BY MUTATIONS OF THE MITOCHONDRIAL DNA Gabriella Inczedy-Farkas, M.D.

Alessandro Serretti, M.D., Ph.D.

Agnes Meszaros Monika Andrejkovics Aniko Gal, Ph.D. Viktoria Remenyi Maria Judit Molnar, M.D., Ph.D.

### NR2-34 DENTAL CARE AND ASSOCIATED

**FACTORS AMONG OLDER ADULTS** WITH SCHIZOPHRENIA Thulasiram Janardhanan, M.D. Stanley Kim, D.D.S. Jean-Claude Desrosiers, M.D. Nikhil Palekar, M.D. Susan Pugliese, D.D.S. Iasvir Singh, M.D. Batool F Rizvi, D.D.S. Paul Ramirez, Ph.D.

### NR2-35

Carl I Cohen, M.D.

BARRIERS IN METABOLIC SCREENING FOR PEOPLE WITH SEVERE MENTAL ILLNESSES IN COMMUNITY BEHAVIORAL HEALTH CLINICS IN SAN FRANCISCO AND NEW YORK CITY Charlene Chang, B.A. Sharat Parameswaran, M.D. Karimi Mailutha, M.D., M.P.H. Lisa Dixon, M.D., M.P.H. Christina Mangurian, M.D.

### NR2-36

IMPROVING FOLLOW UP AFTER INPATIENT CARE: STAFF PERSPECTIVES Jane N. Kogan, Ph.D. Shari L. Hutchison, M.S. Emily A. Magee, B.A. Bradley D. Stein, M.D., Ph.D.

### NR2-37

PILOT OF MEASUREMENT-BASED CARE FOR DEPRESSION IN AN HIV OUTPATIENT CLINIC Julie Adams, M.D. R. Scott Pollard, L.C.S.W. Kristen G. Shirey, M.D. Brian W. Pence, Ph.D.

### NR2-38

TRIAGING PSYCHIATRIC PATIENTS IN THE EMERGENCY DEPARTMENT: EFFECTIVENESS OF A BRIEF **SCREENING TOOL** Kathleen C. Diller, M.D. Olga Achildi, M.D. William R. Dubin, M.D.

### NR2-39

THE CHRONIC PAIN PATIENT IN 5D: BETTER CARE THROUGH Understanding of Five Core COMPLICATING ISSUES IN THE TREATMENT OF CHRONIC PAIN PATIENTS Mitchell J.M. Cohen, M.D. Muhammed A. Abbas, M.D.

### NR2-40

VARIATIONS IN CANCER CARE AND OUTCOMES IN OLDER ADULTS WITH MENTAL ILLNESS: RESULTS FROM THE HEALTH AND RETIREMENT STUDY Simha E. Ravven, M.D. Susan K. Schultz, M.D. Robert B. Wallace, M.D., M.S.

### NR2-41

LANGUAGE, COMMUNICATION AND PSYCHIATRIC DISORDERS: A Case for Psycholinguistics Swapnil Gupta, M.D. Jatinder Mohan Chawla, M.D. Harshvardhan Reddy, M.D.

### NR2-42

COMBATING STIGMA IN MENTAL HEALTH: THE EFFECTS OF ETHNICITY AND EDUCATION ON MENTAL HEALTH LITERACY Christian Reusche, M.D. Cheryl Ann Kennedy, M.D. Jeffrey Borckardt, Ph.D.

META-ANALYSIS OF 123I-MIBG CARDIAC SCINTIGRAPHY FOR THE DIAGNOSIS OF A-Synucleinopathies Alisha E. King, M.D. Donald R. Royall, M.D. Jim Mintz, Ph.D.

### NR2-44

FIRST-ONSET PSYCHOTIC DISORDER CONCURRENT WITH A FIRST-ONSET SEIZURE DISORDER: A CASE REPORT Carolina Mercader, D.O. Amel Badr, M.D. Joan Wynn, M.B.A. Javed Iqbal, M.D.





P.M.

### NR2-45

PHANTOM LIMB AND PHANTOM PAIN SYNDROME IN COLOMBIAN MILITARY PERSONNEL AMPUTATED BY LANDMINES

Juliana Acosta-Uribe Ligia Eugenia Uribe, M.D. Francisco Lopera, M.D.

### NR2-46

FIREARMS USE, PSYCHIATRIC ILLNESS, AND NEUROPSYCHOLOGICAL FUNCTION Karis A. Stenback, M.D. Robert McLay, M.D. Ph.D. Heather Kurera, D.O. Massoud Nikkhoy, M.P.H.

### NR2-47

RELATIONSHIPS BETWEEN MULTIPLE SCLEROSIS AND DEPRESSION

Nancy Byatt, D.O., M.B.A. Anthony J. Rothschild, M.D. Peter Riskind, M.D., Ph.D. Carolina Ionete, M.D., Ph.D. Anne Hunt, Sc.D.

### NR2-48

THE RETROSPECTIVE STUDY OF THE EFFECT OF EEG BIOFEEDBACK IN CHILD AND ADOLESCENT PATIENTS WITH PSYCHIATRIC DISORDERS Bon-Hoon Koo, M.D., Ph.D. Wanseok Seo, M.D., Ph.D. Kwangheun Lee, M.D., Ph.D. Kyung-Keun Kim, M.D. Han Kyul Park, M.D.

### NR2-49

EARLY FAMILY FACTORS AND RISK OF ATTEMPTED SUICIDES OR SUICIDES IN OFFSPRING: THE NORTHERN FINLAND 1966 BIRTH COHORT STUDY

Antti Alaräisänen, M.D. Iouko Miettunen, Ph.D. Anneli Pouta, M.D., Ph.D. Matti Isohanni, M.D., Ph.D. Pirkko Räsänen, M.D., Ph.D. Pirjo Mäki, M.D., Ph.D.

### NR2-50

THE SUICIDE TRIGGER SCALE (STS-3): PRELIMINARY RESULTS FROM A PROSPECTIVE STUDY OF SUICIDAL PATIENTS IN THE ER

Zimri Yaseen, M.D. Lance M. Rappaport Dragos Serseni, M.D. Lisa I. Cohen, Ph.D. Igor Galynker, M.D., Ph.D.

### NR2-51

INCREASING THE USE OF RISPERDAL CONSTA AS A TREATMENT REGIMEN: A QUALITY IMPROVEMENT PROJECT Abderrahmane Richane, M.D. Carolina Mercader, D.O. Michelle Thorpe, M.D. Harpreet Kaur Amel Badr, M.D. J. Iqbal, M.D.

### NR2-52

Assessing Current PHYSICAL RESTRAINT PROTOCOLS AND THEIR Use on Psychiatric Patients Amin Shamal, M.D. Deepa Hasija, M.D. Melissa Oliver Sutapa Dube

### NR2-53

J. Iqbal, M.D.

Amel Badr, M.D.

A QUALITY IMPROVEMENT PROJECT TO ASSESS THE IMPORTANCE OF SCREENING VARIABLES IN PATIENTS BEING TREATED WITH LITHIUM Asad Amir, M.D. Gulam Noorani, M.D., M.P.H. Radha Agepati, M.D. Ayme Frometa, M.D. Deepa Hasija, M.D. Ioan Wynn, M.D. A. Hossain, M.D. Amel Badr, M.D. Javed Iqbal, M.D.

### NR2-54

ASSESSMENT OF THE IMPORTANCE OF SCREENING VARIABLES IN PATIENTS BEING TREATED WITH VALPROATE Avme Frometa, M.D. Asad Amir, M.D. Gulam A Noorani M.D. Radha Agepati, M.D. Deepa Hasija, M.D. Jonathan Chan, B.A. Vandana Parvatam, B.S. Jehan Murugaser, B.A. Joan Wynn, M.B.A. Amel Badr, M.D.

### NR2-55

Javed Iqbal, M.D.

IMPLEMENTATION OF Two Policies Reduces PATIENT WAIT TIME IN THE **EMERGENCY DEPARTMENT** Bushra F. Mirza, M.B.B.S, B.S. Irmute Usiene, M.D. Ferhana Nadeem, M.D. David Chiapaikeo Lulua Mandviwala Amel Badr, M.D. Joan Wynn, M.B.A. Javed Iqbal, M.D.

### NR2-56

ASSESSMENT OF APPROPRIATE PRESCRIBING PRACTICES OF **SECOND-GENERATION** ANTIPSYCHOTICS FOR PSYCHOTIC PATIENTS WITH COMORBID DIABETES MELLITUS Ionathan K. Chan, B.A. Vandana Parvatam, B.S. Gulam Noorani, M.D., M.P.H. Asghar Hossain, M.D. Javed M. Iqbal, M.D.

### NR2-57

CHOICE OF BRAND NAME VERSUS GENERIC MEDICATIONS PRESCRIBED BY PSYCHIATRIST IN THE OUTPATIENT CLINICAL SETTING Yakir K. Vaks, M.D. Bushra Mirza, M.D. Ferhana Nadeem, M.D. Lindi Zhuta Philip Silva Amel Badr, M.D. Joan Wynn, M.B.A. Javed Igbal, M.D.

### NR2-58

THERAPY BITES: PROMOTING COMPETENCY IN PSYCHOTHERAPY THROUGH AN EXPLORATION OF POPULAR FICTION

Ashley B. Jones, M.D. Leslie E. Frinks, M.D. Nioaka N. Campbell, M.D.

### NR2-59

Underutilization of Nonpharmacologic Interventions for Insomnia BY HEALTHCARE PROVIDERS Meghan L. Rieu-Werden, B.S. Kelly M. Sutton-Skinner, B.A. Sarah A. Romeo, B.A. John A. Fromson, M.D. Robert J. Birnbaum, M.D., Ph.D.

### NR2-60

POST PEDS PORTAL PROJECT: GENERATING WORKFORCE IN CHILD AND ADOLESCENT PSYCHIATRY Robert Ellis, M.D. Amy Kathryn Anderson, M.D. Vishal Madaan, M.D. Jamie Snyder, M.D.

### NR2-61

MENTAL HEALTH PROVIDERS' RESPONSES TO A CLINICAL CASE VIGNETTE: TRANSCULTURAL DIAGNOSTIC AND TREATMENT **DIFFERENCES** 

Sarah A. Romeo, B.A. Hongyu Tang, M.D. Ronghuan Jiang, M.D. Xin Yu, M.D. Hong Ma, M.D. Yanging Guo, M.D. Fanĥo Li, M.D. Jessica K. Miller, Ph.D. Albert Yeung, M.D. John A. Fromson, M.D. Robert J. Birnbaum, M.D., Ph.D.

### NR2-62

STUTTERING-ONSET ASSOCIATED WITH STREPTOCOCCAL INFECTION: A CASE SUGGESTING STUTTERING AS PANDAS Scott M. Summers, Ph.D. Gerald A. Maguire, M.D. Steven N. Viele, M.D. Sanjay Agarwal, M.D. Elliot Handler David Franklin, Psy.D.

### NR2-63

ATTITUDES TOWARDS MEDICATION Among Teenagers in a Residential TREATMENT PROGRAM

Agnes Jermendy, M.D. Vignatha Reddy Adam George Dora Werner C.D. Hanson, M.D., J.D.

### NR2-64

**CLOZAPINE-INDUCED DOUBLE INCONTINENCE: CASE REPORT** Anil Meesala, M.D. Patel Kajal, M.D.

Varagani Kanthi, M.D. George Vinu, M.D.

### NR2-65

THE EVIDENCE BASE FOR THE LONG-TERM USE OF ANTIDEPRESSANTS AS PROPHYLAXIS AGAINST **FUTURE DEPRESSIVE EPISODES** Brian Briscoe, M.D. Rif S. El-Mallakh, M.D.

### NR2-66

L-LYSINE TREATMENT NORMALIZED SUB-CORTICAL, ACOUSTICALLY **ELICITED, MASKING-RESPONSE IN** PATIENTS WITH SCHIZOPHRENIA Caroline Wass, Ph.D. E. Pålsson, Ph.D. D. Klamer, Ph.D. K. Fejgin, Ph.D. L. Svensson, Ph.D.

J.A. Engel Prof., J. Källstrand, M.Sc. S. Nehlstedt, M.Sc.

B. Rembeck, Ph.D., M.D.

### NR2-67

AN ASSOCIATION STUDY BETWEEN VARIOUS MONOAMINE TRANSPORTER GENE POLYMORPHISMS AND TREATMENT RESPONSE TO MIRTAZAPINE IN MAJOR DEPRESSION

Jin-Woo Kim, M.D. Shinn-Won Lim, M.S. Hong Choi, M.D. Su-Yeon Kim, Ph.D. Iae-Won Chung, M.D. Doh-Kwan Kim, M.D., Ph.D.

### NR2-68

ACUTE PSYCHOSIS ATTRIBUTED TO INTERACTION OF ANTITUSSIVE WITH ANTICONVULSANT AND STIMULANT MEDICATIONS Martin Blake, B.S.

### NR2-69

**CLOZAPINE TREATMENT CAUSES OXIDATION OF** PROTEINS INVOLVED IN ENERGY METABOLISM IN LYMPHOBLASTOID CELLS: POSSIBLE MECHANISM FOR METABOLIC ALTERATIONS Muhammad R. Baig, M.D., M.S.

### NR2-70

A Possible Role for ANTIDEPRESSANTS IN THE PREVENTION OF LITHIUM-INDUCED DIABETES INSIPIDUS? Soham Rej, M.D. Karl J. Looper, M.D., M.Sc. Marilyn Segal, M.D.

### NR2-71

ISONIAZID-INDUCED PSYCHOSIS Adekola Alao, M.D. S. Shrestha, M.D.

### NR2-72

**DIABETES AND DEPRESSION:** Is THERE A LINK? Arshad Hussain, M.D. Dr. Zeenat Faroog, D.G.O.

### NR2-73

CONVERSION DISORDER: A COMMON MISDIAGNOSIS OF PRIMARY DYSKINESIA? Mona Amini, M.D., M.B.A.

### NR2-74

MEDICAL STUDENT **EVALUATION OF PSYCHIATRY** RESIDENT TEACHING: DOES FEEDBACK MATTER? Sunny P. Aslam, M.D. Rachna Kenia

Alison Welch John Manring, M.D. Brian Johnson, M.D.

### NR2-75 A Systematic Review

OF COLLABORATIVE CARE MODELS IN THE TREATMENT OF MENTAL HEALTH CONDITIONS Hebert Georges, M.D. Mark S. Bauer, M.D. Amy M. Kilbourne, Ph.D., M.P.H. Brian E. Perron, Ph.D. Emily Woltman, M.S.W., Ph.D. Andrew Grogan-Kaylor, Ph.D.

### NR2-76

RESPONSE TO ECT IN PATIENTS WITH MOOD DISORDER RESISTANT TO THE PHARMACOLOGICAL TREATMENT: CAN IT BE PREDICTED? Magdalena Romanowicz, M.D. John Schmid, Ph.D.

## NR2-77

Victor Karpyak, M.D.

Ramon Solhkhah, M.D.

Tai Chi Chuan as an ALTERNATIVE TREATMENT FOR TEENAGERS WITH MENTAL ILLNESS: RESULTS FROM A 12-WEEK CONTROLLED PILOT STUDY Peng Pang, M.D. Alan Hilfer, Ph.D. Heather Fine Jennifer Shindman, B.A.

### NR2-78

CHARACTERISTICS OF A HIGH-RISK OBSTETRICS POPULATION REFERRED FOR PSYCHIATRIC EVALUATION Elizabeth Vannucci, M.D. Robert C. Kores, Ph.D. S. Taylor Williams, M.D.

### NR2-79

VALIDATION STUDY OF EDINBURGH POSTNATAL DEPRESSION SCALE (EPDS) AND PATIENT HEALTH QUESTIONNAIRE (PHQ9) IN MADAGASCAR Jyoti Randhawa, M.D. Ruqiya Shama Tareen, M.D.

Michael R. Liepman, M.D. Richard Roach, M.D. Gilbert Muma, G. K. Bedi, M.D. L. A. Reid, M.D. S. S. Randhawa, M.D.

# 3:00 P.M.-5:00 P.M.

POSTER SESSION 3 LA LOUISIANE C, MORIAL CONVENTION CENTER

Moderator: Maria I. Lapid, M.D.

A. S. Randhawa

NR3-1

**EFFICACY AND SAFETY OF** QUETIAPINE FOR DEPRESSIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA

Tae-Youn Jun, M.D., Ph.D. Yang-Whan Jeon, M.D., Ph,D. Hae-Kook Lee, M.D., Ph.D. Kyung-Uk Lee, M.D., Ph.D.

Epistasis Between a Set of VARIATIONS LOCATED IN THE TAAR6 AND HSP-70 GENES TOWARD SCHIZOPHRENIA AND RESPONSE TO ANTIPSYCHOTIC TREATMENT Tae-Youn Jun, M.D., Ph.D. Chi-Un Pae, M.D., Ph.D. Hyun-Jin Moon, M.D. Alessandro Serretti, M.D.

CHARACTERISTICS OF CHILDREN WITH ADHD WITH AND WITHOUT COMORBID READING DISORDER Trong K. Le, M.P.H., M.S. Peter Classi, M.S. Robert Bandy, M.S. Sarah Ward, B.S.P.H. Joe Johnston, M.D., M.Sc.

Obtain your Certificate of Attendance for the 2010 APA Annual Meeting at <www.psych. org/AnnualMeetingCME>





### NR3-4

THE ROLE OF ACETALDEHYDE IN HUMAN PSYCHOMOTOR FUNCTION: A DOUBLE-BLIND PLACEBO-CONTROLLED **CROSSOVER STUDY** Bae Kyung Yeol, M.D. Sung-Wan Kim, M.D., Ph.D. Hee-Young Shin, M.D., Ph.D. Jae-Min Kim, M.D., Ph.D. Il-Seon Shin, M.D., Ph.D. Tak Youn, M.D., Ph.D. Jin Kim, Ph.D. Jong-Keun Kim, M.D., Ph.D. Jin-Sang Yoon, M.D., Ph.D.

### NR3-5

THE ASSOCIATION BETWEEN OBESITY, SUICIDE, BRAIN-DERIVED NEUROTROPHIC FACTOR AND TYROSINCE KINASE B RECEPTOR PROTEIN LEVELS IN MAJOR DEPRESSION Chin-Chuen Lin, M.D. Tiao-Lai Huang, M.D.

# NR3-6

BIOCHEMICAL AND POLYSOMNOGRAPHIC STUDY OF PATIENTS WITH MDD and Somatoform PAIN DISORDERS Samah Afifi, M.D., Ph.D. Timothy Roehrs, Ph.D. Nash Boutros, M.D. Gamal Shamma, M.D. Tarek Asaad, M.D.

Aisha Abdullatif, M.D.

Elsayed Gad, M.D.

### NR3-7

PLASMA SEROTONIN LEVEL OF KOREAN VIETNAM WAR VETERANS WITH PTSD AND SYMPTOM SEVERITY Moon Young Chung, M.D., Ph.D. Suk-Hoon Kang, M.D.

# NR3-8

A CORRELATION AMONG PLASMA Aβ42, DEPRESSIVE SYMPTOM, AND COGNITIVE FUNCTION IN THE KOREAN ELDERLY Suk-Hoon Kang, M.D. Do Hoon Kim, M.D., Ph.D.

### NR3-9

EVIDENCE FOR INTERACTION BETWEEN BDNF PATHWAY GENES AND PERSONALITY IN CHINESE HAN **POPULATION** Yang Hong, B.S.C. Xuemei Liao, M.Sc. Fei Yu, M.Sc. Qiankun Yao, M.Sc. Kerang Zhang, M.D. Juyi Peng

### NR3-10

**COMPLEXITY: A GAP JUNCTION Hypothesis** Chadi Abdallah, M.D. Jeremy D. Coplan, M.D. Cheuk Y. Tang, Ph.D. Sanjay J. Mathew, M.D. Jose Martinez, M.A. Patrick R. Hof, M.D., Ph.D. Eric L.P. Smith, Ph.D. Andrew J. Dwork, M.D. Tarique D. Perera, M.D. Leonard A. Rosenblum, Ph.D. Dikoma C. Shungu, Ph.D. Ioel Gelernter, M.D. Arie Kaffman, M.D., Ph.D. Andrea Jackowski, Ph.D. Joan Kaufman, M.D. Amjad Hindi, M.D.

**DIFFUSION TENSOR IMAGING** 

IN STUDYING WHITE MATTER

### NR3-11

Jack M. Gorman, M.D.

**CORRELATIONS BETWEEN** MOOD AND BRAIN GAMMA-AMINOBYUTYRIC ACID LEVELS AFTER YOGA AND WALKING Chris C. Streeter, M.D. Theodore Hatch Whitfield, Sc.D. Tasha Rein, B.A. Domenic A. Ciraulo, M.D.

Perry F. Renshaw, M.D., Ph.D.

### NR3-12

J. Eric Jensen, Ph.D.

PLAYERS OF FIRST PERSON SHOOTER GAMES SHOW INCREASED ACTIVITY IN FRONTAL BRAIN IN DEFAULT-MODE NETWORK AS SHOWN BY FMRI Gregor R Szycik, Ph.D. Bahram Mohammadi, M.D. Thomas F Münte, M.D. Amir Samii, M.D. Wolfgang Dillo, M.D.

### NR3-13

Bert T te Wildt, M.D.

NATURE OR NURTURE?

PERSONALITY DIMENSIONS AND FMRI NEURAL REPRESENTATION OF ATTACHMENT Igor Galynker, M.D., Ph.D. Joy Hirsh, Ph.D. Steve Dashnaw Leo Bierman, B.A. Gillian Jennings, B.A. Ianine Samuel, B.A. Cristina Nesci, M.S. Hellen Mayberg, M.D. Arnold Winston, M.D. Curren Katz, Ed.M.

### NR3-14

PET-MEASURED OCCUPANCY OF THE D2 RECEPTOR: A COMPARISON OF QUETIAPINE FUMARATE IMMEDIATE- AND EXTENDED-RELEASE FORMULATIONS IN **HEALTHY SUBJECTS** Svante Nyberg, M.D.

### NR3-15

THE FEASIBILITY OF IMAGING HUMAN HIPPOCAMPAL SUBFIELDS IN YOUNG ADULTS AT 7 TESLA Vasthie Prudent, B.S. Arun Kumar, M.D. Songtao Liu, M.D. Graham Wiggins, Ph.D. Dolores Malaspina, M.D. Oded Gonen, Ph.D.

### NR3-16

THE SEROTONIN RECEPTOR 2A GENE POLYMORPHISM AND CHILD ABUSE HISTORY ASSOCIATED WITH A HISTORY OF SUICIDE ATTEMPTS Among Depressed Inpatients Gen Shinozaki, M.D. Magdalena Romanowicz, M.D. Simon Kung, M.D. David A. Mrazek, M.D.

### NR3-17

SERT AND BDNF POLYMORPHISMS IN BPD AND BIPOLAR DISORDER II Hernán Silva, M.D. Patricia Iturra, M.Sc. Sonia Jerez, M.D. Juana Villarroel, M.D. Cristian Montes Giovanna Otalora M. Leonor Bustamante, M.D., Ph.D.

### NR3-18

NR<sub>3</sub>C<sub>1+18</sub>3oC>G POLYMORPHISMS AND MIRTAZAPINE RESPONSES IN PATIENTS WITH MAJOR DEPRESSION Min-Soo Lee, M.D., Ph.D. Hun Soo Chang, Ph.D. Hwa-Young Lee, M.D. Byung-Joo Ham, M.D., Ph.D. Sang-Woo Hahn, M.D., Ph.D.

### NR3-19 POLIMORPHISMS OF THE LEP- AND

LEPR GENES, METABOLIC PROFILE AFTER PROLONGED CLOZAPINE ADMINISTRATION AND RESPONSE TO THE ANTIDIABETIC METFORMIN Trino J. Baptista, M.D., Ph.D. Erika Fernández, Ms.Sci. Edgardo Carrizo, M.D. Virginia Fernández, M.D. Ignacio Sandia, M.D. Dexy Prieto, M.D. Lisette Connell, Ms.Sci. Johana Mogollón, M.D. Dennys Valbuena, Ms.Sci. Iliana Fernández, Ms.Sci. Enma de Baptista, Ms.Sci.

### NR3-20

**GENETIC STUDIES OF** MICRORNAS IN SCHIZOPHRENIA Yong Xu, M.D. Fei Li, M.Sc. Bo Zhang, M.Sc. Fuquan Zhang, M.D. Xuezhu Huang, M.D. Kerang Zhang, M.D. Pozi Liu, M.D.

### NR3-21

PATIENT AND STAFF PERCEPTIONS OF THE IMPLEMENTATION OF AN ENHANCED **DISCHARGE PROCESS** FOR INPATIENT **PSYCHIATRIC SETTINGS** Bradley D. Stein, M.D., Ph.D. Jane N. Kogan, Ph.D. Shari L. Hutchison, M.S. Emily A. Magee, B.A.

### NR3-22

SUCCESSFUL IMPLEMENTATION OF A GLUCOSE MONITORING PROGRAM IN A COMMUNITY MENTAL HEALTH SETTING Ginger E. Nicol, M.D. Elaine H. Morrato, Dr.P.H. Mark C. Johnson, M.D. John W. Newcomer, M.D.

### NR3-23

TREATMENT ADHERENCE AND PERSISTENCE WITH **BRANDED ANTIDEPRESSANTS** Among Patients with MDD AND PAINFUL **CHRONIC DISEASES** Junling Wang, Ph.D., M.S. Xianchen Liu, M.D., Ph.D. C. Daniel Mullins, Ph.D.

Is "Home Treatment"

### NR3-24

FOR THE ACUTELY MENTALLY ILL IN A RURAL SOUTHERN GERMAN AREA AS EFFECTIVE AS THE USUAL INPATIENT TREATMENT? Karel J. Frasch, M.D. Miriam Ott Henriette Jahn, M.D. Annett Rauscher Christoph Piesbergen, Ph.D. Markus Jaeger, M.D. Thomas Becker, M.D. Reinhold Kilian, Ph.D. Isolde Munz

### NR3-25

FREQUENCY AND DURATION OF PHYSICAL RESTRAINTS IN GENERALIZED VERSUS SPECIALIZED EMERGENCY **ROOM SETTINGS** Natalie A. Lester, M.D. Ali Kazim, M.D.

### NR3-26

A DRUG INTERACTION STUDY OF DEXTROMETHORPHAN/ QUINIDINE: AN INVESTIGATIONAL AGENT FOR PSEUDOBULBAR AFFECT AND PAROXETINE Kerri Schoedel, Ph.D. Laura E. Pope, Ph.D. Randall Kaye, M.D. Adrian Hepner, M.D.

Edward M. Sellers, M.D., Ph.D.

### NR3-27

A STUDY OF POTENTIAL PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) Interactions Between DEXTROMETHORPHAN/ QUINIDINE AND MEMANTINE Laura Pope, Ph.D. Randall Kaye, M.D. Adrian Hepner, M.D. Kerri A. Schoedel, Ph.D. Cynthia Bartlett, M.Math Edward M. Sellers, M.D., Ph.D.

### NR3-28

EMPLOYEE PERSPECTIVES ON PATIENT SAFETY INSIDE A BEHAVIORAL HEALTH CLINIC: A CASE STUDY

Colleen S. Lewy, Ph.D. Celina Oliver, Ph.D. Holly Fussell, Ph.D. Bentson McFarland, M.D., Ph.D.

### NR3-29

PREDICTIVE VALIDITY OF THE REASONS FOR LIVING INVENTORY IN COLOMBIAN PSYCHIATRY PATIENTS WITH SUICIDE RISK German E. Rueda-Jaimes, M.D. Andres M. Rangel-Martinez-Villalba, M.D. Paul A. Camacho-Lopez, M.Sc.

### NR3-30

THE ROLE OF PERCEIVED SOCIAL SUPPORT AS A RISK FACTOR FOR ADOLESCENT SUICIDE ATTEMPTS: A Systematic Review Lance M. Rappaport Igor I. Galynker, M.D., Ph.D. Serena I. Fox, M.D.

FOR PSYCHIATRY: CHALLENGES IN THE NEONATAL INTENSIVE CARE UNIT Joshua Friedman, M.D., Ph.D. Susan Hatters Friedman, M.D. Marc Collin, M.D.

LIAISON OPPORTUNITIES

Richard Martin, M.D.

IMPROVING EFFICIENCY AND Access to Mental Health Care: INTEGRATING MENTAL HEALTH AND PRIMARY CARE SERVICES AT McGuire Veterans Affairs MEDICAL CENTER Chervl W. Jones, M.D. Steven Carter, F.N.P. Antony Fernandez, M.D.

### NR3-33

CLINICAL INDICES OF Institutional Stress in RELOCATING TO A NEW HOSPITAL Jeffry R. Nurenberg, M.D. Janet J. Monroe, R.N., M.A.S. David I. Mayerhoff, M.D. Steven J. Schleifer, M.D.

### NR3-34

Is There a Difference IN TRANSPORTATION OF PSYCHIATRIC PATIENTS TO THE EMERGENCY DEPARTMENT? Leslie Zun, M.D., M.B.A. Lavonne Downey, Ph.D.

### NR3-35

PHYSICIAN COMPLIANCE WITH REQUIRED TESTING ON PSYCHIATRIC PATIENTS IN THE EMERGENCY DEPARTMENT Leslie Zun, M.D., M.B.A. Lavonne Downey, Ph.D.

### NR3-36

ACUTE CARE MODEL: A NOVEL WAY OF SERVICE PROVISION IN ADULT PSYCHIATRIC SERVICES

Sowmya Krishna, M.D., Psy.D. Faouzi Alam, M.D. Geetha Jaganathan, M.D. Qaiser Javed, M.D.

# NR3-37

PREDICTORS OF PSYCHIATRIC DISORDERS **DURING PEG-INTERFERON** AND RIBAVIRIN THERAPY IN PATIENTS WITH CHRONIC HEPATITIS HCV-CORRELATED Bernardo Dell'osso, M.D. Massimiliano Buoli, M.D. Mariacarlotta Palazzo M.D. Marta Serati, M.D. Gianmaria Prati, M.D. Alessio Aghemo, M.D. Roberta D'Ambrosio, M.D. Maria Grazia Rumi, M.D. Massimo Colombo, M.D. A. Carlo Altamura, M.D.

### NR3-38

CHILDHOOD SEXUAL ABUSE BY PARENTS AND **OTHERS CAREGIVERS:** Intra-Familial Characteristics AND BIOMARKERS OF IMMUNE RESPONSE

Vivian Uemura, M.D. Juliana Brum Moraes, M.D. Sandra Odebrecht Vargas Nunes, M.D. Ph.D. Renato Moriya, M.D. Edna Maria Vissoci Reiche, Ph.D. Helena K. Morimoto, M.S. Maria Angélica Watanabe, Ph.D. Tiemi Matsuo, Ph.D.

### NR3-39

Hypersensitivity Pneumonitis SECONDARY TO CLOZAPINE THERAPY: A CASE REPORT Arif Shahabuddin, M.D. Gregory Stepanets, M.D. Beatrice Kovaznay, M.D. Victoria Balkoski, M.D.





P.M.

### NR3-40

TRANSLATIONAL PHARMACOLOGY OF QUETIAPINE AND NORQUETIAPINE: PRECLINICAL FINDINGS SUPPORT MULTIFUNCTIONAL PSYCHOTROPIC **PROPERTIES** 

Daniel Widzowski, Ph.D. Svante Nyberg

### NR3-41

PREDICTORS OF POST-DISCHARGE ADHERENCE TO ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN ADOLESCENT PSYCHIATRIC PATIENTS David L. Pogge, Ph.D. John Stokes, Ph.D. Philip D. Harvey, Ph.D.

### NR3-42

THE IMPACT OF PATIENTS' EXPECTATIONS ON CLINICAL RESPONSE: RE-ANALYSIS OF DATA FROM THE HYPERICUM DEPRESSION TRIAL STUDY GROUP David Mischoulon, M.D., Ph.D. Justin Chen, M.D. George I. Papakostas, M.D. Soo Jeong Youn, B.A. Lee Baer, Ph.D.

### NR3-43

Alisabet I. Clain, M.S.

Maurizio Fava, M.D.

SIMPLIFYING ANTIPSYCHOTIC POLYPHARMACY REGIMENS FOR PATIENTS WITH CHRONIC MENTAL **ILLNESS** 

David Mischoulon, M.D., Ph.D.

Galina J. Georgieva, M.D. Stepan Shannon, Ph.D. Eric D. Peselow, M.D. Andrew J. Kolodny, M.D.

### NR3-44

**EFFECTIVENESS OF SWITCHING FROM** ARIPIPRAZOLE TO ZIPRASIDONE IN PATIENTS WITH SCHIZOPHRENIA

Jin-Sang Yoon, M.D. Sung-Wan Kim, M.D., Ph.D. Il-Seon Shin, M.D., Ph.D. Jae-Min Kim, M.D., Ph.D. Kyung-Yeol Bae, M.D. Su-Jin Yang, M.D., Ph.D.

DRUG USE AMONG SOCIAL NETWORK MEMBERS OF PATIENTS WITH CO-OCCURRING SUBSTANCE USE DEPENDENCE AND BIPOLAR DISORDER

Margaret L. Griffin, Ph.D.

# NR3-46

L-METHYLFOLATE PLUS SSRI OR SNRI FROM TREATMENT INITIATION COMPARED TO SSRI OR SNRI MONOTHERAPY IN A MAJOR DEPRESSIVE EPISODE Lawrence D. Ginsberg, M.D. Alondra Y. Oubre, Ph.D. Yahya A. Daoud

"Principles of Psychodynamic Psychotherapy" A CD-ROM Course by Glen O. Gabbard, M.D., and Lucy J. Puryear, M.D. To order: <a href="http://www.appi.">http://www.appi.</a> org/book.cfm?id=2348>

### NR3-47

RESPONSE AND SYMPTOMATIC REMISSION WITH OPEN-LABEL Co-Administration of GUANFACINE EXTENDED RELEASE AND STIMULANTS FOR ADHD Lawrence D. Ginsberg, M.D. Rakesh Jain, M.D. William Rory Murphy, M.D., M.P.H. Andrew Lyne, M.Sc., C.Stat. Jonathan Rubin, M.D.

### NR3-48

EFFECT OF AGE ON ARMODAFINIL PHARMACOKINETICS IN HEALTHY SUBJECTS

Mary Kirby, M.S., M.B.A. Mona Darwish, Ph.D. Edward T. Hellriegel, Ph.D. Ronghua Yang, Ph.D. Philmore Robertson, Jr., Ph.D.

### NR3-49

AN OPEN-LABEL, EIGHT-WEEK, FLEXIBLE DOSE TRIAL OF **ESCITALOPRAM IN COMORBID** Major Depression with MULTIPLE SCLEROSIS

Meera Narasimhan, M.D. Suzanne Hardeman, APRN-BC Davit Mrelashvili, M.D. Kimberly Rudd, M.D. Shilpa Srinivasan, M.D. Ashwin Patkar, M.D. Kathi Peindl, Ph.D.

### NR3-50

EFFECT OF ARMODAFINIL ON QUETIAPINE PHARMACOKINETICS IN PATIENTS WITH SCHIZOPHRENIA

Mona Darwish, Ph.D. Mary Kirby, M.S. Edward T. Hellriegel, Ph.D. Ronghua Yang, Ph.D. Philmore Robertson, Jr., Ph.D.

### NR3-51

BETAHISTINE SAFELY MITIGATES **OLANZAPINE ADVERSE: ROLE** OF HISTAMINE RECEPTORS IN WEIGHT GAIN AND SOMNOLENCE Nir Barak, M.D.

### NR3-52

AN IN-DEPTH CARDIOVASCULAR STUDY OF LONGER-TERM LISDEXAMFETAMINE (LDX) TREATMENT IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) Paul G. Hammerness, M.D.

### NR3-53

POINT OF CARE LITHIUM MONITORING: QUANTITATIVE **DETECTION OF LITHIUM** Using Microchip Capillary **ELECTROPHORESIS** Pieternel Kolling, M.D. Ralph W. Kupka, Ph.D., M.D. Arjan Floris, M.Sc. Steven S. Staal, M.Sc. Albert van den Berg, Prof.

### NR3-54

THE MAINTENANCE RATE OF ARIPIPRAZOLE AMONG SCHIZOPHRENIC PATIENTS WITH DIFFERENT ILLNESS DURATION AND EXPERIENCE OF NEUROLEPTICS **DURING SIX MONTHS** 

Sae-Heon Jang, M.D. Young-Myo Jae, M.D., Ph.D. Dae-Su Lee M.D.

### NR3-55

Influnce of Antipsychotics AUGMENTATION ON TREATMENT ADHERENCE IN TREATMENT OF MDD with Antidepressants Sae-Heon Jang, M.D. Young-Myo Jae, M.D., Ph.D.

Dae-Su Lee, M.D. Jin-Hyug Choi, M.D.

### NR3-56

PANAX GINSENG AUGMENTATION OF SUBSYNDROMAL DEPRESSIVE SYMPTOMS (SSD) IN SCHIZOPHRENIA: A MULTI-SITE RCT STUDY Simon Chiu, M.D., Ph.D. Zack Cernovsky, Ph.D. Mariwan Husni, M.D., MRC John Copen M.D, M.Sc. Robbie Campbell Jr., M.D.

### NR3-57

Jason Carr, Ph.D.

Long-Term Weight Loss Effect OF ADJUNCTIVE ZONISAMIDE IN PSYCHIATRIC PATIENTS: A RETROSPECTIVE CHART REVIEW Young-Hoon Ko, M.D., Ph.D. Jaehyoung Lim, M.D. Sook-Haeng Joe, M.D., Ph.D. Changsu Han, M.D., Ph.D. Ho-Kyoung Yoon, M.D., Ph.D. Hwa-Young Lee, M.D., Ph.D.

### NR3-58

MENTAL STATUS IN NMS Varadaraj Velamoor, M.D. Ronald Gurrera M.D. Zack Z. Cernovsky, Ph.D.

### NR3-59

Women's and Men's Depressive SYMPTOMS AND FUNCTIONAL RECOVERY FOLLOWING CORONARY ARTERY GRAFT (CAG) SURGERY James D. Mendonca, Ph.D. Ronald R. Holden, Ph.D. Zack Z. Cernovsky, Ph.D.

### NR3-60

PSYCHOLOGICAL DISTRESS IN WOMEN WITH DUCTAL CARCINOMA IN SITU AND EARLY INVASIVE **BREAST CANCER** Nancy C. Maruyama, M.D. Khyati Shah, M.D.

### NR3-61

Does a Self-Report Measure (RSQ) AND THE AAI EVALUATE THE SAME DIMENSION OF SECURE **ADULT ATTACHMENT?** 

Gillian Jennings, B.A. Curren Katz, M.Ed. Leo Bierman Elizabeth Menaker, B.A. Lisa I Cohen, Ph.D. Arnold Winston, M.D. *Igor Galynker, M.D., Ph.D.* 

### NR3-62

ECONOMY AND SUICIDE IN COLOMBIA: RELATIONSHIP BETWEEN MACROECONOMIC VARIABLES AND SUICIDE RATE Edwin Herazo, M.D., M.S.C. Andrea C. Acevedo Adalberto Campo-Arias, M.D., M.Sc.

### NR3-63

FROM WINDY STORM TO TOTAL DARKNESS: THE EFFECT OF A COMMUNITY-WIDE BLACKOUT ON ED VISITS AND PSYCHIATRIC Admissions to an Urban University Hospital Jeffrey M. Turell, M.D., M.P.H. Parikshit Deshmukh, M.D.

### NR3-64

Joseph Calabrese, M.D.

Withdrawn

### NR3-65

A COMPARISON OF RAPID TITRATION QUETIAPINE AND HALOPERIDOL IN AGITATED ADULTS IN AN **EMERGENCY SETTING** George Simpson, M.D. Akikur Reza Mohammad Sved Fauzia Marius Campaneau Eugene Laska Rebecca Ninah

### NR3-66

Joseph Wanderling

George Simpson

Use of a Predictive Algorithm AND AN AUTOMATED TELEPHONE SCREENER TOOL IN IDENTIFYING MISDIAGNOSED BIPOLAR DISORDER PATIENTS Keith Isenberg, M.D. C. Fang

E. Tafesse S. A. Kamat

# NR3-67

METHODOLOGIC APPROACHES TO THE NATURALISTIC ASSESSMENT OF CLINICAL UTILIZATION AND OUTCOME OF A DEVICE-BASED TREATMENT IN CLINICAL PRACTICE Mark Demitrack, M.D.

### NR3-68

MEDICATION ADHERENCE AND PERSISTENCE AND PSYCHIATRIC HOSPITALIZATION IN PATIENTS WITH MDD

Xianchen Liu, M.D., Ph.D. Ping Tepper, M.D., Ph.D. Peter Watson, M.P.H. Steven Able, Ph.D. Michael Happich, Ph.D.

### NR3-69

NICOTINE DEPENDENCE, ADAPTIVE FUNCTIONING, AND PSYCHOPATHOLOGY AMONG PSYCHIATRIC INPATIENTS Mariwan Husni, M.D. Zach Cernovsky, Ph.D. Simon Chiu, M.D.

### NR3-70

COMPLEMENTARY USE OF TAI CHI IMPROVES RESILIENCE, QUALITY OF LIFE, AND COGNITIVE FUNCTION IN **DEPRESSED OLDER ADULTS** Helen Lavretsky, M.D., M.S. Michael Irwin, M.D.

### NR3-71

ARIPIPRAZOLE AND HALOPERIDOL IN THE TREATMENT OF DELIRIUM AND ITS SUBTYPES Soenke Boettger, M.D.

William Breitbart, M.D. Steven Passik, Ph.D.

### NR3-72

FACTORS ASSOCIATED WITH LOW **DELIRIUM RESOLUTION RATES** Soenke Boettger, M.D. Steven Passik, Ph.D. William Breitbart, M.D.

### NR3-73

META-ANALYSIS OF PLACEBO RESPONSE IN ANTIPSYCHOTIC TRIALS Ofer Agid, M.D. Steven Potkin, M.D. Gary Remington, M.D. Shitij Kapur, M.D., Ph.D. Eric Watsky, M.D. Douglas Vanderburg, M.D., M.P.H. Cynthia Siu, Ph.D.

American Psychiatric Assocation **164th Annual Meeting** 

Honolulu, Hawaii May 14 - 18, 2011



Transforming Mental Health Through Leadership, Discovery and Collaboration

# CALL FOR ABSTRACTS

Don't miss the opportunity to submit your proposed presentation for a symposium, workshop, course, and/or other scientific sessions.

Visit our website on June 15th for further information regarding submissions. www.psych.org

### NOON-2:00 P.M. POSTER SESSION 4: MOOD DISORDERS

LA LOUISIANE C, MORIAL CONVENTION CENTER

### **Moderator:**

David A. Baron, Ms.Ed., D.O.

### NR4-1

EVALUATION OF THE EFFICACY OF EXTENDED RELEASE QUETIAPINE FUMARATE FOR THE TREATMENT OF PATIENTS WITH MDD

Amir H. Kalali, M.D. Stuart Montgomery, M.D. Willie Earley, M.D. Johan Szamosi, M.Sc., Hans Eriksson, M.D., Ph.D., M.B.A.

### NR4-2

EFFICACY AND TOLERABILITY OF VILAZODONE, A DUAL-ACTING SEROTONERGIC ANTIDEPRESSANT, IN THE TREATMENT OF PATIENTS WITH MDD

Arif Khan, M.D. Andrew J. Cutler, M.D. Daniel Kajdasz, Ph.D. Maria Athanasiou, Ph.D. Donald S. Robinson, M.D. Heidi Whalen, M.H.S. Carol R. Reed, M.D.

### NR4-3

A SIX-WEEK RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF ZIPRASIDONE FOR THE ACUTE DEPRESSIVE MIXED STATE

Ashwin A. Patkar, M.D. William Gilmer, M.D. Manmohandeep Sohi, M.D. Elizabeth Whitham, B.A. Sairah Thommi, B.S. Anthony Loebel, M.D. Prakash Masand, M.D. S. Nassir Ghaemi, M.D., M.P.H. Chi-un Pae, M.D., Ph.D.

### NR4-4

EFFECT OF CHILDHOOD TRAUMA ON THE COURSE OF BIPOLAR DISORDER Asli Funda Kalkay, M.D. Evrim Erten, M.D. Omer Saatcioglu, M.D.

Timucin Oral, M.D. Duran Çakmak, M.D.

### NR4-5

OSTEOPOROSIS RISK BURDEN IN
DEPRESSED MID-LIFE OUTPATIENTS

Barbara L. Gracious, M.D. Melissa N. Parkhurst, B.S. Teresa L. Finucane, M.S.

Obtain your Certificate of Attendance for the 2010 APA Annual Meeting at <a href="https://www.psych.org/AnnualMeetingCME">www.psych.org/AnnualMeetingCME</a>

### NR4-6

EXTENDED RELEASE QUETIAPINE
FUMARATE AS ADJUNCT TO
ANTIDEPRESSANTS IN MDD: POOLED
ANALYSIS IN PATIENTS WITH LOW AND
HIGH LEVELS OF BASELINE ANXIETY
Borwin Bandelow, M.D.
Eduard Vieta, M.D.
Nizar El-Khalili, M.D.
Mattias Udd, M.Sc.
Urban Gustafsson. Ph.D.
Hans Eriksson, M.D., Ph.D., M.B.A.

### NR4-7

THE IMPACT OF STRESS FACTORS ON HPA FUNCTION IN PATIENTS WITH DEPRESSION AND NEUROSIS: A STUDY WITH THE USE OF DST

Bozena Spila, M.D. Halina Dubas-Slemp, M.D. Helena Donica, Ph.D. Beata Wojtysiak-Duma, Ph.D. Anna Urbanska

### NR4-8

EXPECTANCY EFFECTS AND TREATMENT OF DEPRESSION: COGNITIVE AND NEURAL MECHANISMS

Bret R. Rutherford, M.D. Steven P. Roose, M.D. Joel Sneed, Ph.D. Dev Devanand, M.D.

### NR4-9

IMPROVEMENTS IN COGNITIVE FUNCTIONING DURING INPATIENT HOSPITALIZATION FOR UNIPOLAR AND BIPOLAR DEPRESSION WITH AND WITHOUT PSYCHOTIC FEATURES Caleb J. Siefert, Ph.D.

John Matthews, M.D. Adrienne van Nieuwenhuizen, B.A. Rita Seabrook, B.A. Lauren House, M.A. Kaloyan Tanev, M.D. David Abramson, M.D. Maurizio Fava, M.D.

### NR4-10

COMPARISON OF SAFETY, EFFICACY, AND TOLERABILITY OF MODIFIED AND IMMEDIATE RELEASE ESCITALOPRAM AND PLACEBO IN ADULTS WITH MDD Carl Gommoll, M.S.,

Carl Gommoll, M.S., William M. Greenberg, M.D. Giovanna Forero, M.A. Qing Wang, Ph.D. Peter Werner, Ph.D.

### NR4-11

GENOTYPIC AND PHENOTYPIC CYP2D6 POOR METABOLIZER STATUS AMONG OUTPATIENTS WITH DEPRESSION TREATED WITH VENLAFAXINE

Cecelia Kane, M.D. Alice Nichols, Ph.D. Vaisali Chhaya Gina Buckley, M.T., M.S. Christine J. Guico-Pabia, M.D., M.B.A., M.P.H.

### NR4-12

ANALYSES OF THE EFFECT OF ZIPRASIDONE ON AGITATION IN ACUTE BIPOLAR MANIA USING CLINICIAN-RATED PANSS AND SADS-C PROXY MEASURES Cedric O'Gorman, M.D. Steven Potkin, M.D. Francine Mandel, Ph.D. Douglas Vanderburg, M.D.

### NR4-13

TREATMENT OUTCOMES-BASED ON DISEASE SEVERITY FOR SUBJECTS WITH BIPOLAR I DISORDER TREATED WITH ZIPRASIDONE PLUS A MOOD STABILIZER Charles Bowden, M.D. Balarama Gundapaneni, M.S. Cedric O'Gorman, M.D.

Balarama Gundapaneni, M.S. Cedric O'Gorman, M.D. Elizabeth Pappadopulos, Ph.D. Jeffrey Schwartz, Ph.D. Rodger Kobes, M.D. Onur Karayal, M.D.

### NR4-14

SIGNIFICANT BIPOLAR RISK FACTORS IN PATIENTS PRESENTING A CURRENT MAJOR DEPRESSIVE EPISODE Charles Bowden, M.D. J. Angst, Ph.D. J. M. Azorin, Ph.D. G. Perugi, M.D.

# NR4-15

E. Vieta, Ph.D.

Allan H. Young, Ph.D.

POOLED ANALYSIS OF THE EFFICACY OF DESVENLAFAXINE 50 MG COMPARED WITH PLACEBO IN THE PATIENTS WITH MODERATE OR SEVERE MDD

Christine J. Guico-Pabia, M.D., M.B.A. Jeff Musgnung, M.S. Ben Wang

### NR4-16

RURALITY, SUICIDE AND THE AVAILABILITY OF MENTAL HEALTH PROVIDERS Dale D'Mello, M.D.

### NR4-17

THE PREVALENCE AND CLINICAL CONSEQUENCES OF CONCURRENT HYPERTENSION IN PATIENTS WITH BIPOLAR DISORDER Dale D'Mello, M.D.

### NR4-18

Randall Owen, M.D.

EFFICACY OF ADJUNCTIVE
ARIPIPRAZOLE IN MDD:
A POOLED RESPONSE QUARTILE
ANALYSIS (CN138-139, CN138-163
AND CN138-165)
Daniel E. Casey, M.D.
Kimberly Laubmeier, Ph.D.
Ross A. Baker, Ph.D., M.B.A.
Sabrina Marler, M.S.
Robert A. Forbes. Ph.D.



NOON

**DULOXETINE 60 MG/DAY** FOR THE PREVENTION OF **DEPRESSIVE RECURRENCES:** POST-HOC ANALYSES FROM A RECURRENCE PREVENTION STUDY David Perahia, M.D., M.R.C. Michael Berk, M.D., Ph.D. Melissa Spann, Ph.D. Doron Sagman, M.D. Joel Raskin, M.D. Daniel Walker, Ph.D. Katarina Kelin, M.D.

### NR4-20

ON FUNCTIONAL IMPAIRMENT IN PATIENTS WITH MDD David V. Sheehan, M.D., M.B.A. Adam L. Meyers, M.S. Jonna Ahl, Ph.D. Apurva Prakash, B.A.

Tina Marie Myers Oakes, Ph.D.

EFFICACY OF DULOXETINE

### NR4-21

EFFECTS OF EXTENDED RELEASE QUETIAPINE FUMARATE ON LONG-TERM FUNCTIONING AND SLEEP QUALITY IN PATIENTS WITH GAD David V. Sheehan, M.D., M.B.A. Henrik Svedsäter, Ph.D. Julie Locklear, Pharm.D., M.B.A. Hans Eriksson, M.D., Ph.D, M.B.A.

### NR4-22

A ONE-YEAR OPEN-LABEL STUDY ASSESSING THE SAFETY AND TOLERABILITY OF VILAZODONE IN PATIENTS WITH MDD Donald Robinson, M.D.

Daniel Kajdasz, Ph.D. Susan Gallipoli, R.N. Heidi Whalen, M.H.S. Art Wamil, M.D., Ph.D. Carol R. Reed, M.D.

### NR4-23

ATTRIBUTES OF RESPONSE IN Depressed Patients Switched TO DULOXETINE TREATMENT

Doron Sagman, M.D. Diane McIntosh, M.D. Min Soo Lee, M.D. Huichun Li, M.D. Sandra Ruschel, M.D. Nadia Hussain, B.Sc. Renee Granger, Ph.D. Arier Lee, Ph.D. Joel Raskin, M.D.

### NR4-24

THE CORRELATION BETWEEN WHITE MATTER TRACT INTEGRITY OF ANTERIOR CINGULATE AND THYROID FUNCTION IN PATIENTS WITH MAJOR DEPRESSION

Doug Hyun Han, D.P.H. Doo Byung Park, Psy.D. Joon Mo Kang, M.D. Beom Woo Nam, M.D., Psy.D. Churl Na, Psy.D.

### NR4-25

CLINICAL CORRELATES OF **EATING DISORDERS COMORBIDITY** IN WOMEN WITH BIPOLAR DISORDER TYPE 1 Elisa Brietzke, M.D. Camila Moreira Ricardo Alexandre Toniolo, M.D. Beny Lafer, M.D., Ph.D.

### NR4-26

EFFICACY OF ADJUNCTIVE ARIPIPRAZOLE IN PATIENTS WITH MDD WITH MINIMAL OR PARTIAL RESPONSE TO ANTIDEPRESSANT THERAPY Elizabeth Bellocchio, Ph.D. Ross A. Baker, Ph.D., M.B.A. Linda M. Rollin, Ph.D. Robert D. McQuade, Ph.D. Ronald N. Marcus, M.D. Robert M. Berman, M.D. J. Craig Nelson, M.D.

### NR4-27

**EFFECTS ON COGNITION OF** ADJUNCTIVE ZIPRASIDONE VERSUS PLACEBO IN A LONG-TERM RANDOMIZED, DOUBLE **BLIND TRIAL IN SUBJECTS** WITH BIPOLAR I DISORDER *Elizabeth Pappadopulos, Ph.D.* Richard Keefe, M.D. Onur Karayal, M.D. Francine Mandel, Ph.D. Doug Vanderburg, M.D. Sonya Lewis, Ph.D. Michelle Stewart, Ph.D.

### NR4-28

HEALTHCARE UTILIZATION AND COSTS IN A COMMERCIAL POPULATION OF PATIENTS WITH TYPE I BIPOLAR DISORDER WHO RELAPSE FREQUENTLY Emily Durden, Ph.D. Iivoon Choi, Pharm.D. Érik Muser, Pharm.D. Erin Bagalman, M.S.W. Wayne Macfadden, M.D. Tom Haskins, Ph.D. Riad Dirani, Ph.D.

### NR4-29

**COST-EFFECTIVENESS OF** ADJUNCTIVE QUETIAPINE **EXTENDED-RELEASE TABLETS** WITH MOOD STABILIZERS IN THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER Eskinder Tafesse, Ph.D. Arthur Lazarus, M.D.

# NR4-30

**QUALITY OF LIFE IN SUBGROUPS** OF BIPOLAR I PATIENTS WHO HAD CHILDHOOD TRAUMA Evrim Erten, M.D. Asli Funda Kalkay, M.D. Omer Saatcioglu, M.D. Duran Çakmak, M.D.

### NR4-31

HPA Axis Dysfunction in REMITTED BIPOLAR PATIENTS Fabrice Duval, M.D. Marie-Claude Mokrani, Ph.D. Hassen Rabia, M.D. Felix Gonzalez, M.D. Claudia Alexa, M.D.

### NR4-32

Saïd Fattah, M.D.

EXTENDED RELEASE QUETIAPINE FUMARATE IN PATIENTS WITH MDD STRATIFIED BY BASELINE ANXIETY LEVEL: POOLED ANALYSIS OF DATA FROM Two Monotherapy Studies Hans Eriksson, M.D., Ph.D. Koen Demyttenaere, M.D., Ph.D. Michael E. Thase, M.D. Mattias Udd, M.Sc. Urban Gustafsson, Ph.D.

### NR4-33

VILAZODONE PHARMACOKINETICS IN SUBJECTS WITH MILD TO MODERATE RENAL IMPAIRMENT Harry Alcorn, Pharm.D.

### NR4-34

TREATMENT-EMERGENT SEXUAL DYSFUNCTION IN **OUTPATIENTS WITH MDD:** SIX-MONTH TREATMENT AND **FUNCTIONAL OUTCOMES** Hector J. Duenas, M.D. Saiyed Abdulrazak, M.D. Arier Lee, Ph.D. Amanda Lowry, Ph.D. Joel Raskin, M.D. Adam Meyers, M.A. Alan Brnabic, M.A. Martin Dossenbach, M.D.

### NR4-35

LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF EXTENDED RELEASE CARBAMAZEPINE IN A LARGE CLINICAL PRACTICE: A CHART REVIEW STUDY Lawrence D. Ginsberg, M.D. Herbert W. Harris, M.D., Ph.D.

# NR4-36

ASSOCIATION OF THE SEROTONIN TRANSPORTER INTRON 2 VNTR POLYMORPHISM WITH TREATMENT RESPONSE TO MIRTAZAPINE IN PATIENTS WITH MDD Min-Soo Lee, M.D., Ph.D. Sang-Woo Hahn, M.D., Ph.D. Hwa-Young Lee, M.D., Ph.D. Hun Soo Chang, Ph.D. Byung-Joo Ham, M.D., Ph.D. Jong-Woo Paik, M.D., Ph.D. Moon-Soo Lee, M.D., Ph.D.

Chang-su Han, M.D., Ph.D.

Young-Hoon Ko, M.D., Ph.D.





VILAZODONE PHARMACOKINETICS IN SUBJECTS WITH MILD TO MODERATE HEPATIC IMPAIRMENT

James Longstreth, Ph.D. Harry Alcorn, Jr., Pharm.D. Marijke H. Adams, Pharm.D., Ph.D. Carol R. Reed, M.D.

### NR4-38

LONG-TERM OUTCOME OF FIRST MANIC EPISODES: A RETROSPECTIVE REVIEW OF 354 INPATIENT CASES Javad Moamai, M.D., M.S.C. Jacques Seguin, M.D., Ph.D.

### NR4-39

PLACEBO RESPONSE IN TRIALS OF ANTI-DEPRESSANTS IN PATIENTS WITH MDD

Jeff Musgnung, M.S. Christine J. Guico-Pabia, M.D., M.B.A., M.P.H. Ron Pedersen, M.S. Philip T. Ninan, M.D.

### NR4-40

Incidence of Headache, Nausea, and Myalgia after ECT in Adolescents and Adults: Relation to Treatment Number and Patient Age

John L. Olsen, M.D. Howard Weeks, M.D. Lowry Bushnell, M.D. Kelly W. Smith, M.D.

### NR4-41

HIGH LEVELS OF COMORBID
PERSONALITY DISORDER PREDICT
NON-RESPONSE TO METHYLPHENIDATE
FOR ADULTS WITH ADHD

John L. Olsen, M.D. Barrie K. Marchant, M.S. Robert E. Strong, D.O. Reid J. Robison, M.D. Fred W. Reimherr, M.D.

### NR4-42

ASENAPINE AS ADJUNCTIVE
TREATMENT FOR BIPOLAR
MANIA: RESULTS OF A PLACEBOCONTROLLED 12-WEEK STUDY
AND 40-WEEK EXTENSION
Joseph Calabrese, M.D.
Let Stet, Ph.D.
Himanshu Kotari, Ph.D.
Jun Zhao, Ph.D.
Alex Kouassi, Ph.D.
Armin Szegedi, M.D., Ph.D.

### NR4-43

John Panagides, Ph.D.

HIGHER SCORES ON MOTOR
IMPULSIVITY AND LOWER SCORES ON
COOPERATIVENESS ARE ASSOCIATED
WITH HISTORY OF SUICIDE ATTEMPTS
IN BRAZILIAN OUTPATIENTS WITH
BIPOLAR DISORDER
Karla Almeida, M.D., L.N.

Karla Almeida, M.D., L.N. Abreu, M.D. B. Lafer, M.D., Ph.D.



Tel: 800-368-5777

### NR4-44

Comparison Between Clinical Characteristics of Suicide Attempters and Non-Attempters in a Sample of Bipolar Disorder Patients with Mania as First Episode Lena Abreu, M.D. Fabiano G. Nery, M.D., Ph.D. Elisa Brietzke, M.D. Pedro V.S. Magalhaes, M.D. Flavio Kapczinski, M.D., Ph.D. Beny Lafer, M.D., Ph.D.

### NR4-45

Association of Medication Adherence with Therapeutic Alliance in Individuals with Bipolar Disorder Louisa G. Sylvia, Ph.D. Aleena C. Hay, B.A., Andrew A. Nierenberg, M.D. Michael J. Ostacher, M.D., M.P.H. Thilo Deckersbach, Ph.D. David J. Miklowitz, Ph.D. Michael E. Thase, M.D.

### NR4-46

Gary S. Sachs, M.D.

Roy H. Perlis, M.D., M.Sc.

CORRELATION BETWEEN
FUNCTIONALITY AND SUBJECTIVE
WELL-BEING IN UNIPOLAR
DEPRESSIVE PATIENTS IN
REMISSION

Luis G. Herbst, M.D. Laura Lorenzo, M.D. Eduardo Leiderman, M.D. Anibal Goldchluk, M.D. Pedro Gargoloff, M.D. Damian Gargoloff, M.D.

### NR4-47

COMPARISON OF HOSPITALIZATIONS AND COSTS AMONG BIPOLAR PATIENTS WHO SWITCHED TO EXTENDED-RELEASE QUETIAPINE FROM IMMEDIATE-RELEASE QUETIAPINE

Mariam Hassan, Ph.D. Elise Pelletier, M.S. Daniel Smith, M.A. Berhanu Alemayehu Jennifer Kim, Pharm.D.

### NR4-48

A WEB-BASED SYSTEM FOR MEASURING OUTCOME IN THE TREATMENT OF DEPRESSION: RELIABILITY, VALIDITY, AND PATIENT ACCEPTANCE Mark Zimmerman, M.D. Janine Galione, B.S.

### NR4-49

DEPRESSED PATIENTS
PERSPECTIVES OF TWO
MEASURES OF OUTCOME:
THE QUICK INVENTORY OF
DEPRESSIVE SYMPTOMATOLOGY
& REMISSION FROM DEPRESSION
QUESTIONNAIRE
Mark Zimmerman, M.D.
Janine Galione, B.S.
Naureen Attiullah, M.D.
Michael Friedman, M.D.
Cristina Toba, M.D.
Daniela Boerescu, M.D.
Moataz Ragheb, M.D.

### NR4-50

THE RELATIONSHIP
BETWEEN CONTINUED USE OF
ANTIDEPRESSANTS AND ACUTE
PSYCHIATRIC EVENTS AMONG
PATIENTS WITH MANIC OR MIXED
BIPOLAR DISORDER EPISODES
Matthew Sussman, B.S.
M. Friedman
J.R. Korn
M. Hassan
J. Kim
J. Menzin

### NR4-51

EFFICACY OF ARIPIPRAZOLE IN
THE TREATMENT OF IRRITABILITY
IN PEDIATRIC PATIENTS (6-17 YEARS)
WITH AUTISTIC DISORDER: RESULTS
FROM A 52-WEEK STUDY
Meeta Patel, Pharm.D.
Randall Owen, M.D.
Patricia K. Corey-Lisle, Ph.D.
Raymond Mankoski, M.D., Ph.D.
Lisa Kamen, M.H.A.
George Manos, Ph.D.
Robert D. McQuade, Ph.D.
William H. Carson, M.D.
Ronald N. Marcus, M.D.

### NR4-52

Association of Age of Onset and Mood in Bipolar Disorder: Comparing Sub-Groups Identified by Cluster Analysis and Clinical Observation Michael Bauer, M.D., Ph.D. Tasha Glenn, Ph.D. Natalie Rasgon, M.D. Wendy Marsh, M.D. Kemal Sagduyu, M.D. Rodrigo Munoz, M.D. Peter C Whybrow, M.D.

### NR4-53

EFFECTS OF ADJUNCTIVE
EXTENDED RELEASE QUETIAPINE
FUMARATE ON SLEEP DISTURBANCE
AND QUALITY IN PATIENTS WITH
MDD: A POOLED ANALYSIS
Michael Bauer, M.D., Ph.D.
Roger S. McIntyre, M.D.
Johan Szamosi, M.Sc.
Hans Eriksson, M.D.





EFFICACY OF EXTENDED RELEASE QUETIAPINE FUMARATE MONOTHERAPY ACCORDING TO MDD SEVERITY: POOLED ANALYSIS OF DATA FROM FOUR ACUTE STUDIES Michael E. Thase, M.D. Stuart Montgomery, M.D. George Papakostas, M.D. Michael Bauer, M.D. Madhukar Trivedi, M.D. Henrik Svedsäter, Ph.D. Mattias Udd, M.Sc. Urban Gustafsson, Ph.D. Hans Eriksson, M.D., Ph.D., M.B.A.

### NR4-55

Assessing the True Treatment EFFECT OF ACTIVE TREATMENT VERSUS PLACEBO THERAPY IN PATIENTS WITH MDD

Michael E. Thase, M.D. K. G. Larsen S. H. Kennedy

### NR4-56

RISK FOR VIOLENCE AND ARREST IN BIPOLAR DISORDER: RESULTS FROM THE STEP-BD COHORT

Michael J. Ostacher, M.D., M.P.H. Christine I. Kansky, B.A. Andrew A. Nierenberg, M.D. Michael Thase, M.D. Gary Sachs, M.D. Roy H. Perlis, M.D. M.Sc.

### NR4-57

A 52-WEEK SAFETY AND TOLERABILITY STUDY OF ARIPIPRAZOLE FOR THE TREATMENT OF IRRITABILITY IN PEDIATRIC PATIENTS (6-17 YEARS) WITH **AUTISTIC DISORDER** Monique McCollough, Pharm.D. Randall Owen, M.D. Patricia K. Corev-Lisle, Ph.D. Raymond Mankoski, M.D., Ph.D. Lisa Kamen, M.H.A. George Manos, Ph.D. Robert D. McQuade, Ph.D. William H. Carson, M.D. Ronald N. Marcus, M.D.

### NR4-58

NEURAL CORRELATES OF CLINICAL IMPROVEMENT IN MDD: A PAIN-INDUCTION FUNCTIONAL MRI STUDY

Narcis Cardoner, M.D. Marina López-Solà, B.Sc. Jesus Pujol, M.D. Rosa Hernández-Ribas, M.D. Joan Deus, Ph.D. Hector Ortiz, M.S. Érika Martínez-Amoros, M.D. *Oren Contreras, B.Sc.* Carles Soriano-Mas, Ph.D. Ben J. Harrison, Ph.D. Iose M. Menchón, M.D.

### NR4-59

DESCRIPTIVE EPIDEMIOLOGY AND COMORBIDITY OF BIPOLAR DISORDER IN THE NATIONAL HOSPITAL **DISCHARGE SURVEY (NHDS)** Natalya S. Weber, M.D., M.P.H. Jared A. Fisher, M.P.H. David N. Cowan, Ph.D., M.P.H. David W. Niebuhr, M.D., M.P.H., M.S.

### NR4-60

TREATMENT-EMERGENT SEXUAL Dysfunction in Outpatients with MDD: Six-Month Treatment and **FUNCTIONAL OUTCOMES** 

Héctor Dueñas, M.D., M.B.A. Saiyed Abdulrazak Arier Lee, Ph.D. Amanda Lowry, Ph.D. Joel Raskin, M.D. Adam Meyers, M.A. Alan Brnabic, M.A. Martin Dossenbach, M.D., Ph.D.

### NR4-61

**BRIEF BEHAVIORAL THERAPY** FOR INSOMNIA FOR OUTPATIENTS WITH RESIDUAL DEPRESSION WITH COMORBID INSOMNIA: ASSESSOR-BLIND, RANDOMIZED CONTROLLED TRIAL

Norio Watanabe, M.D., Ph.D. Toshi A. Furukawa, M.D., Ph.D. Shinji Shimodera, M.D., Ph.D. Ippei Morokuma, M.D. Fujika Katsuki, R.N., Ph.D. Hirokazu Fujita, M.D., Ph.D. Megumi Sasaki, Ph.D. Chihiro Kawamura Michael L. Perlis, Ph.D.

### NR4-62

THE PROPHYLACTIC **EFFICACY OF SSRIS** Olga Kissel, M.D. Eric D. Peselow, M.D.

Rushaniya Khairova, M.D. Aditi Hajirnis, M.D. Mary Guardino, M.D.

### NR4-63

TREATMENT OUTCOMES-BASED ON DISEASE SEVERITY FOR SUBJECTS WITH BIPOLAR I DISORDER TREATED WITH ZIPRASIDONE PLUS A MOOD STABILIZER

Onur N. Karayal, M.D., M.P.H. Charles Bowden, M.D. Balarama Gundapaneni, M.S. Cedric O'Gorman, M.D. *Elizabeth Pappadopulos, Ph.D.* Jeffrey Schwartz, Ph.D. Rodger Kobes, M.D.

Obtain your Certificate of Attendance for the 2010 APA Annual Meeting at <www.psych. org/AnnualMeetingCME>

### NR4-64

ALLERGEN-SPECIFIC IGE AND ALLERGY SYMPTOMS ARE ASSOCIATED WITH DEPRESSION SCORES IN PATIENTS WITH MOOD DISORDERS EXPOSED TO SEASONAL POLLEN-PEAKS Partam Manalai, M.D. Robert G. Hamilton, Ph.D. Amar Slemi, M.D. Susan E. Kosisky, M.A. Manana Lapidus, M.D. Johanna A. Cabassa, M.D. Paula Strassle Patricia Langenberg, Ph.D. Teodor T. Postolache, M.D.

### NR4-65

PRESCRIBING PATTERNS AND PATIENT OUT-OF-POCKET EXPENSES AMONG BIPOLAR DISORDER PATIENTS RECEIVING EXTENDED-RELEASE QUETIAPINE OR ARIPIPRAZOLE Elise Pelletier, M.S. Daniel Smith, M.A. Mariam Hassan, Ph.D. Jennifer Kim, Pharm.D.

### NR4-66

LEFT DORSOLATERAL PREFRONTAL TRANSCRANIAL MAGNETIC STIMULATION (TMS): EFFECT ON SLEEP IN PATIENTS WITH PHARMACORESISTANT MDD Peter B. Rosenquist, M.D. Andrew Krystal, M.D. K. L. Heart M. Demitrack, M.D. W. Vaughn McCall, M.D., M.S.

### NR4-67

GLOBAL FUNCTIONING OF BIPOLAR PATIENTS IS INFLUENCED BY IMPULSIVITY AND TEMPERAMENT Piero I. Castro-Loli, M.D. Bàrbara Arias, Ph.D. Ester Jiménez, Psy. Lourdes Fañanás, Ph.D.

Eduard Vieta, M.D., Ph.D.

Antonio Benabarre, M.D., Ph.D.

### NR4-68

THE COMPARATIVE **EFFICACY AND SAFETY** OF ADJUNCTIVE ANTIPSYCHOTICS IN MDD PATIENTS WHO FAIL ANTIDEPRESSANT THERAPY

Pieter Drost, M.S.C., Pharm.D. William Pitchot, M.D. Roelien Postema, M.Sc., PharmD. Nathalie Houwing, M.Sc. Jean-Yves Loze, M.D. Maarten Treur, M.Sc. Pieter Drost, M.Sc., PharmD.





NOON 12

### NR4-69

EFFICACY OF ADJUNCTIVE ARIPIPRAZOLE TO LITHIUM OR VALPROATE IN THE LONG-TERM TREATMENT OF MANIA IN SUBJECTS WITH BIPOLAR I DISORDER (CN138-189) Randall Owen, M.D. Linda Rollin, Ph.D. Arif Khan, M.D. Raymond Sanchez, M.D. William Carson, M.D. Beth Morris, B.A. Karen Timko, B.S., M.B.A. Ronald Marcus, M.D.

### NR4-70

YMRS LINE ITEM ANALYSIS IN PEDIATRIC PATIENTS WITH BIPOLAR I DISORDER TREATED WITH ARIPIPRAZOLE

Raymond Mankoski, M.D., Ph.D. Joan Zhao, Ph.D. William H. Carson, M.D. Margaretta Nyilas, M.D. Suja Mathew, B.S. Robert A. Forbes, Ph.D

### NR4-71

ATTRIBUTES OF RESPONSE IN DEPRESSED PATIENTS SWITCHED TO **DULOXETINE TREATMENT** 

Doron Sagman, M.D. Diane McIntosh, M.D. Min Soo Lee, M.D. Huichun Li, M.D. Sandra Ruschel, M.D. Nadia Hussain, B.Sc. Renee Granger, Ph.D. Arier Lee, Ph.D. Joel Raskin, M.D.

### NR4-72

**DEPRESSION IN WOMEN:** CHARACTERISTICS OF A SAMPLE OF OUTPATIENTS OLDER THAN 40 YEARS WITH DEPRESSIVE DISORDER Rita Prieto, M.D. Celso Iglesias, Ph.D., M.D.

### NR4-73



**BRAIN IMAGING CORRELATES OF** ANTIDEPRESSANT RESPONSE TO REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN PATIENTS WITH DEPRESSION

Rosa Hernández-Ribas, M.D. Carles Soriano-Mas, Ph.D. Narcís Cardoner, M.D. Iesús Pujol, M.D. Ioan Deus, Ph.D. Cinto Segalàs, M.D. Marina López-Solà, B.Sc. Héctor Ortiz, M.S. Ben Harrison, Ph.D. José M. Menchón, M.D.

### NR4-74

DEVELOPMENT OF IN VITRO DIAGNOSTIC TEST FOR LITHIUM-SENSITIVE BIPOLAR DISORDER Sairah Thommi, B.S. Elizabeth Whitham, B.A. Hanady Gouta, M.D. Hussain Khrad, M.S. Sang Kil Lee, Ph.D. Connie Maddox, L.P.N. Suephy C. Chen, M.D. P. Michael Iuvone, Ph.D. S. Nassir Ghaemi, M.D. Chiaki Fukuhara, Ph.D.

### NR4-75

NATURAL KILLER T CELL IN DEPRESSED PATIENTS TREATED WITH SSRIS Sang Ick Han, Psy.D., Ph.D. Yang-Whan Jeon, Ph.D. E-Jin Park, Ph.D.

### NR4-76

AN OPEN-LABEL STUDY OF TRANSCRANIAL MAGNETIC STIMULATION COMBINED WITH ANTIDEPRESSANT MEDICATION FOR THE TREATMENT OF MDD Scott T. Aaronson, M.D.

### NR4-77

CHARACTERISTICS OF **EMOTIONAL RESPONSE** AND ITS RELATIONSHIP WITH EARLY-LIFE STRESS AND RESILIENCE IN MDD Seok Jeong-Ho, M.D., Ph.D.

### NR4-78

RELATIONSHIP OF PSYCHOPATHOLOGY WITH EARLY-LIFE STRESS AND RESILIENCE IN A YOUNG ADULTHOOD POPULATION Seok Jeong-Ho, M.D., Ph.D.

### NR4-79

CLOSE CORRELATION OF THE PHQ-9 AND BDI-II FOR DEPRESSION MEASUREMENT IN THE MOOD DISORDERS OUTPATIENT AND INPATIENT SETTINGS Simon Kung, M.D. Renato D. Alarcon, M.D., M.P.H. Kathleen A. Poppe, R.N. Mary Io Moore, R.N. Grant T. Bauer, L.I.C.S.W. Mark D. Williams, M.D.

### NR4-80

Mark A. Frye, M.D.

Peter Werner, Ph.D

EFFICACY OF LEVOMILNACIPRAN IN IMPROVING SYMPTOMS AND FUNCTIONAL IMPAIRMENT ASSOCIATED WITH MDD Stuart A. Montgomery, M.D. Yves Lecrubier, M.D. Lucilla Mansuy, M.D. Daniel Ventura, Ph.D. Dayong Li, Ph.D.

### NR4-81

ASSOCIATION BETWEEN MEDIAN FAMILY INCOME AND SELF-REPORTED MOOD IN BIPOLAR DISORDER Tasha Glenn, Ph.D. Michael Bauer, M.D. Natalie Rasgon, M.D. Wendy Marsh, M.D. Kemal Sagduyu, M.D. Rodrigo Munoz, M.D. Peter C. Whybrow, M.D.

### NR4-82

ANXIETY AS PREDICTOR OR MODERATOR FOR EFFECT OF ZIPRASIDONE COMBINED WITH MOOD STABILIZER IN MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

Terence A. Ketter, M.D. Douglas Vanderburg, M.D., M.P.H. Cynthia O. Siu, Ph.D. Elizabeth A. Pappadopulos, Ph.D. Onur Karayal, M.D., M.P.H.

### NR4-83

THE EFFECTS OF QUETIAPINE XR MONOTHERAPY ON SLEEP DISTURBANCE: POOLED DATA FROM FOUR ACUTE STUDIES IN PATIENTS WITH MDD Willie W. Earley, M.D. Borwin Bandelow, M.D. Koen Demyttenaere, M.D., Ph.D. George Papakostas, M.D. Madhukar Trivedi, M.D. Iohan Szamosi, M.Sc. Hans Eriksson, M.D., Ph.D., M.B.A.

### NR4-84

A LARGE-SCALE DTI

STUDY IN MDD: UTILITY OF LEGACY DATA Wouter S. Hoogenboom, M.S. Roy H. Perlis, M.D. Jordan W. Smoller, M.D., Sc.D. , Qing Zeng-Treitler, Ph.D. Vivian S. Gainer, M.S. Shawn N. Murphy, M.D., Ph.D. Susanne E. Churchill, Ph.D. Isaac Kohane, M.D., Ph.D. Martha E. Shenton, Ph.D. Dan V. Iosifescu, M.D., M.S.

# NR4-85

**BASELINE CHARACTERISTICS** OF PATIENTS WITH MDD FROM THE CLINICAL **OUTCOMES IN MEASUREMENT-**BASED TREATMENT (COMET) STUDY Yonghua Jing, Ph.D. Susan K. Brenneman, P.T., Ph.D. Jean Siebenaler, M.D., C.P.I. Jonathan Kurlander, M.S. Robert D. McQuade, Ph.D. Tony Hebden, Ph.D.

LONG-TERM SAFETY AND TOLERABILITY OF ADJUNCTIVE ARIPIPRAZOLE IN THE TREATMENT OF PATIENTS WITH MDD

Zachary Cain, Pharm.D. Ross A. Baker, Ph.D., M.B.A. Linda Rollin, Ph.D. Robert A. Forbes, Ph.D. Ronald N. Marcus, M.D. Robert M. Berman, M.D.

### NR4-87

CLINICAL FEATURES OF OLFACTORY REFERENCE SYNDROME

Katharine A. Phillips, M.D. William Menard, B.A.

### NR4-88

AGE AT ONSET AND CLINICAL CORRELATES IN BDD

Andri S. Bjornsson, Ph.D. Emily Stalker William Menard, B.A. Jon E. Grant, M.D. Katharine A. Phillips, M.D. (presenting)

### 3:00 P.M.-5:00 P.M. POSTER SESSION 5 LA LOUISIANE C, MORIAL CONVENTION CENTER

### Moderator:

Daniel P. Chapman, Ph.D.

### NR5-1

**EXTENDED-RELEASE** DEXMETHYLPHENIDATE IMPROVES PERMP MATH TEST PERFORMANCE THROUGHOUT THE LABORATORY-CLASSROOM DAY IN CHILDREN WITH ADHD

Andrew Cutler, M.D. Linda Pestreich Kevin McCague, Ph.D. Rafael Muniz, M.D.

### NR5-2

ADHD in Turkish Elementary SCHOOL STUDENTS: A TWO-YEAR LONGITUDINAL STUDY OF PREVALENCE

Cahide Aydin, M.D. Evup S. Ércan, M.D. Rasiha Kandulu, M.D. Erman Uslu, M.D. Günay Sagduyu, B.S.

### NR5-3

SAFETY PROFILE OF LISDEXAMFET-AMINE DIMESYLATE IN CLINICAL TRIALS IN CHILDREN, ADOLESCENTS, AND ADULTS WITH ADHD

David W. Goodman, M.D. Brian Scheckner, Pharm.D. Bryan Dirks, M.D. Thomas Babcock, D.O. Ben Adeyi, M.S. Robert Lasser, M.D. Maria Gasior, M.D. Robert Findling, M.D.

### NR5-4

COMPARATIVE EFFECTS OF LISDEXAMFETAMINE DIMESYLATE AND MIXED AMPHETAMINE SALTS EXTENDED RELEASE IN ADULTS WITH ADHD Dirks Bryan, M.D. Robert Lasser, M.D.

### NR5-5

Ben Adeyi, M.S.

Thomas Babcock, D.O.

RELIABILITY AND VALIDITY OF TURGAY DSM-IV-BASED DISRUPTIVE BEHAVIOR **DISORDERS RATING SCALE** TEACHER AND PARENT FORMS Eyüp Sabri Ercan, M.D. Atilla Turgay M.D. Elif Ercan, B.S. Rasiha Kandulu M.D. Erman Uslu M.D. Cahide Aydin M.D.

### NR5-6

IS DSM-IV-BASED ADHD SELF-REPORT SCALE VALID AND RELIABLE TOOL FOR EIGHT-YEAR-OLD CHILDREN? DEVELOPMENT OF A RELIABLE AND VALID SELF REPORT QUESTIONAIRE Elif Ercan, M.S.

Eyup Sabri Ercan, M.D. Cahide Aydin, M.D. Rasiha Kandulu, M.D. Erman Uslu, M.D.

### NR5-7 ADOLESCENTS WITH

CHILDHOOD DIAGNOSIS OF ADHD: COMORBIDITY, **EXECUTIVE FUNCTIONS,** ATTACHMENT AND IDENTITY Füsun Çuhadaroglu-Çetin, M.D. Tuna H. Ulay, M.D.

Gulser S. Dinç, M.D. Zevnep Tuzun, Ph.D. Gulin Evinc, Ph.D. Esra T. Çöp, M.D.

### NR5-8

EFFECT OF OROS METHYLPHENIDATE (MPH) TREATMENT ON BEHAVIOR AND PERFORMANCE IN CHILDREN WITH ADHD WITH AND WITHOUT COMORBID LEARNING DISABILITIES Harriette L. Starr, M.D. Robert B. Armstrong, M.D., C.V. Damaraju, Ph.D. Steve Ascher, Ph.D.

### NR5-9

I. Markov, M.A.

AGE AND GENDER CHARACTERISTICS OF ADHD COMORBIDITIES IN A LARGE CLINICAL SAMPLE Isaac Szpindel, M.D. A. Turgay, M.D. R. Ansari, M.D. D. Ng, M.D. L. Joseph, K. Bordbar, M.D.

### NR5-10

DIFFERENCES IN THE DIAGNOSIS AND TREATMENT OF CHILDHOOD ADHD PATIENTS WITH OR WITHOUT OPPOSITIONAL SYMPTOMS Jonathan Rubin, M.D. Robert Findling, M.D. Elizabeth J. Short, Ph.D. Cynthia Macahili Diana Conger Michael Manos, Ph.D.

### NR5-11

**EARLY IMPROVEMENTS** WITH ATOMOXETINE THERAPY PREDICT FINAL TREATMENT OUTCOME: A CLASSIFICATION AND REGRESSION TREE (CART) Analysis of Adult ADHD DATA Meihua Qiao, Ph.D. David Duesenberg, M.D. Fred Reimherr, M.D. Barrie K. Marchant, M.S.

### NR5-12

Stephen Ruberg, Ph.D.

Matthew Menza, M.D.

STIMULANT TREATMENT AND ACADEMIC GRADES OF URBAN CHILDREN AND ADOLESCENTS WITH ADHD Michael Durkin, M.S. Steven Marcus, Ph.D.

### NR5-13

ADHERENCE AND PERSISTENCE TO MEDICATIONS FOR ADHD IN CHILDREN AND ADOLESCENTS Peter Classi, M.S., B.A. Tomoko Sugihara, M.S. Anthony Zagar, M.S.

### NR5-14

EFFICACY OF LISDEXAMFETAMINE DIMESYLATE IN CHILDREN WITH ADHD AND SUBOPTIMAL RESPONSE TO METHYLPHENIDATE Rakesh Jain, M.D. Thomas Babcock, D.O. Teodor Burtea, M.D. Bryan Dirks, M.D. Ben Adevi, M.S.

### NR5-15

**EXAMINATION OF EFFECTS** OF LISDEXAMFETAMINE DIMESYLATE ON SLEEP QUALITY IN STUDIES OF ADULTS WITH ADHD Richard Weisler, M.D. David Goodman, M.D. Brian Scheckner, Pharm.D. Bryan Dirks, M.D. Thomas Babcock, D.O. Ben Adeyi, M.S. Robert Lasser, M.D. Thomas Roth, Ph.D.

Brian Scheckner, Pharm.D.

Robert Lasser, M.D.





### NR5-16

THE APPLICATION OF A COMPARATIVE EFFECTIVENESS TRIAL CRITERIA TO A COMMERCIALLY-Insured Population of CHILDREN WITH ADHD

Safiya Abouzaid, Pharm.D. Ioan Busner Michael Durkin Garu Schneider

### NR5-17

PSYCHOPATHOLOGY AND TEMPERAMENT IN PARENTS OF CHILDREN AND ADOLESCENTS WITH ADHD: A CONTROLLED STUDY

Sermin Kesebir, M.D. Y. Bilge Sair, M.D. I. Ferhan Dereboy, M.D.

### NR5-18

MENTAL STATUS OF CAREGIVERS AND TREATMENT ADHERENCE: COMPARISON OF CAREGIVERS OF BIPOLAR AND SCHIZOPHRENIC **PATIENTS** 

Sermin Kesebir, M.D. Enver Demirel Yilmaz, M.D. Ali Görkem Gencer, M.D. Mehmet Fatih Üstündag, M.D. Mustafa Bilici, M.D.

### NR5-19

EFFECT OF OROS METHYLPHENIDATE TREATMENT ON READING PERFORMANCE IN CHILDREN WITH ADHD

Sharon Wigal, Ph.D. Tim Wigal, Ph.D. Sabrina Schuck, Ph.D. David Williamson, Ph.D. Robert B. Armstrong, M.D. Matthew Brams, M.D. C.V. Damaraju, Ph.D. Steve Ascher, Ph.D. H. Lynn Starr, M.D.

### NR5-20

VISUAL MEMORY AS AN **ENDOPHENOTYPE IN ADHD:** EVIDENCE FROM THE CAMBRIDGE Neuropsychological TEST BATTERY Susan Shur-Fen Gau, M.D., Ph.D.

Chi-Yung Shang, M.D.

### NR5-21

CLINICAL UTILITY OF ADHD SYMPTOM THRESHOLDS TO ASSESS NORMALIZATION OF EXECUTIVE FUNCTION WITH LISDEXAMFETAMINE DIMESYLATE TREATMENT

Thomas E. Brown, Ph.D. Matthew Brams, M.D. Maria Gasior, M.D. Ben Adeyi, M.S. Bryan Dirks, M.D. Thomas Babcock, D.O., Brian Scheckner, Pharm.D. Robert Lasser, M.D. Timothy Wigal, Ph.D.

### NR5-22

WHAT PREDICTS SUBSTANCE ABUSE IN ADHD YOUTH? A 10-YEAR FOLLOW-UP STUDY

Timothy E. Wilens, M.D. MaryKate Martelon, M.P.H. Michael C. Monuteaux, Sc.D. Eric Mick, Sc.D. Maggie Evans, B.A. Clancey Bateman, B.A. Joseph B. Biederman, M.D.

### NR5-23

**CHANGES OF SLEEP PARAMETERS** AFTER TAKING METHYLPHENIDATE IN CHILDREN WITH ADHD

Wan Seok Seo, M.D., Ph.D. Bon Hoon Koo, M.D. Kwang-Hun Lee, M.D. Kyung-Keun Kim, M.D. Han-Kyul Park, M.D.

### NR5-24

**EFFECTS OF LONG-TERM OPEN-LABEL** CO-ADMINISTRATION OF GUANFACINE EXTENDED RELEASE AND STIMULANTS ON CORE SYMPTOMS OF ADHD

Bradley Vince, D.O. Floyd R. Sallee, M.D., Ph.D. Andrew Lyne, M.Sc., C.Stat. Sharon Youcha, M.D.

### NR5-25

CHANGES IN PARENTAL STRESS WITH GUANFACINE EXTENDED RELEASE IN CHILDREN WITH ADHD AND **OPPOSITIONAL SYMPTOMS** 

Daniel F. Connor, M.D. Floyd R. Sallee, M.D., Ph.D. Andrew Lyne, M.Sc., C.Stat. Sharon Youcha, M.D.

### NR5-26

SCHOOL-BASED INTERVENTION FOR K-Second Graders Presenting WITH DISRUPTIVE BEHAVIOR

Jacob Venter, M.D. Linda Wiskerchen, M.S.W. Melissa Shaw, M.A. Alicia Ledesma, M.A. Sara DeSimone, M.S.W. Anne Marie Cardinal, M.S.W.

### NR5-27

CLINICAL PREDICTORS OF CARDIOMETABOLIC RISK IN CHILDREN TREATED WITH ANTIPSYCHOTIC MEDICATIONS John W. Newcomer, M.D.

G. E. Nicol, M.D. M. D. Yingling, B.S.

### NR5-28

CONTINUITY OF DEPRESSIVE DISORDERS FROM CHILDHOOD AND ADOLESCENCE TO ADULTHOOD: A NATURALISTIC STUDY AT COMMUNITY MENTAL HEALTH CENTERS IN MADRID, SPAIN Juan J. Carballo, M.D., Ph.D. Laura Muñoz-Lorenzo L, Psy.D., Hilario Blasco-Fontecilla, M.D., Ph.D. Jorge Lopez-Castroman. M.D., Ph.D. M. Mercedes Perez-Rodriguez, M.D. Ph.D., Kanita Dervic, M.D. Maria A. Oquendo, M.D.

### NR5-29

PALIPERIDONE FOR IRRITABILITY IN ADOLESCENTS AND YOUNG ADULTS WITH AUTISTIC DISORDER

Kimberly A. Stigler, M.D. Craig A. Erickson, M.D. David J. Posey, M.D., M.S. Jennifer E. Mullett, R.N., C.C.R.P. Ion T. Diener, B.S. Arlene E. Kohn, B.A. Christopher J. McDougle, M.D.

### NR5-30

POLYPHARMACY REDUCTION LEADS TO POSITIVE EFFECTS ON BOTH TREATMENT OUTCOME AND HEALTHCARE COST: ANALYSES FROM A RESIDENTIAL TREATMENT CENTER Pieter Joost van Wattum, M.D., M.A. Caroline Fabius, M.S. Todd Johnson, L.C.S.W. Cheryl Smith, L.C.S.W. Daniel Lyga, L.C.S.W.

### NR5-31

EXTENDED-RELEASE DEXMETHYLPHENIDATE 30 MG IMPROVES LATE-DAY ADHD SYMPTOM CONTROL IN CHILDREN WITH ADHD: A RANDOMIZED, Double-Blind, Crossover Study Rafael Muniz, M.D. Linda Pestreich Kevin McCague, Ph.D. Americo Padilla, M.D. Matt Brams, M.D.

### NR5-32

Ann Childress, M.D.

DEFICIENT EMOTIONAL SELF-REGULATION IS A CORE DEFICIT THAT PREDICTS ADAPTIVE IMPAIRMENTS IN ADULTS WITH ADHD Russell A. Barkley, Ph.D. Kevin R. Murphy, Ph.D.

# PRACTICE GUIDELINE CME COURSES:

- Patient care strategies to assist psychiatrists in clinical decision making
- Earn up to 8 hours of AMA PRA Category 1 Credits™
- For more information: <apa.education.org>





### NR5-33

LONG-TERM SAFETY AND EFFECTIVENESS OF OPEN-LABEL COADMINISTRATION OF GUANFACINE EXTENDED RELEASE AND STIMULANTS FOR ADHD IN CHILDREN AND ADOLESCENTS Sharon Youcha, M.D. Keith McBurnett, Ph.D. Andrew Lyne, M.Sc., C.Stat. Jonathan Rubin, M.D.

### NR5-34

THERAPEUTIC ALLIANCE BUILDING DURING THE CHILD PSYCHIATRIC INTAKE: DOES VTC MAKE A DIFFERENCE?

Keith Penska, M.D. Robin Michael, Ph.D. Stephen C. Messer, M.A., Ph.D. Nancy B. Black, M.D.

### NR5-35

FAMILY-FOCUSED TREATMENT AND HEALTH-PROMOTING INTERVENTION: STABILIZING BIPOLAR MOOD SYMPTOMS THROUGH PROMOTING **SELF-CARE AMONG** FAMILY MEMBERS Deborah A. Perlick, Ph.D. David J. Miklowitz, Ph.D. Norma Lopez, L.C.S.W. Victoria Adzhiashvili, B.A. Carla Kalvin, B.A. James Chou, M.D.

### NR5-36

Andrew Aronson, M.D.

ENHANCING RESIDENCY TRAINING OF INTERNATIONAL MEDICAL **GRADUATES IN PSYCHIATRY** 

Antony Fernandez, M.D. Francis Sanchez, M.D. Milton Kramer, M.D. Fructuoso Irigoyen, M.D. Marie-Claude Rigaud, M.D. Khushro Unwalla, M.D.

### NR5-37

THE USE OF McGILL ILLNESS NARRATIVE INTERVIEW (MINI) IN FIBROMYALGIA PATIENTS Clara Pelaez, M.D. Luis Caballero, Ph.D.

### NR5-38

LATINOS AND WOMEN ARE LESS LIKELY TO RECEIVE EMERGENCY ANTIPSYCHOTIC MEDICATIONS **DURING ACUTE PSYCHIATRIC** HOSPITALIZATION

Linda Meier, M.A. Ricardo Ramirez, M.D. Meglani Megha, M.D. Katherine Hulbert, M.D. Behrouz Namdari, M.D. Benjamin Puliafito Isabel T. Lagomasino, M.D, M.S.H.S. Osama A. Abulseoud, M.D.

### NR5-39

WHAT DO PSYCHIATRIC PATIENTS MEAN BY BEING COERCED INTO HOSPITALIZATION?

Kuan-Chiao Tseng, M.D., Sc.D. Kevin Chien-Chang Wu, M.D., LL.B., LL.M., Ph.D.

### NR5-40

PREVENTING VIOLENCE: A FEMALE ADOLESCENT COMMITTING VIOLENT MURDER DUE TO PARANOID **DELUSIONS** 

Kulkarni Gaurav, M.D. Parikshit Deshmukh, M.D. Michael Sorter, M.D. Drew Barzman, M.D.

### NR5-41

**IDENTIFYING CORRELATES OF** COMPETENCY TO STAND TRIAL (CST) AMONG YOUTH ADMITTED TO A **JUVENILE MENTAL HEALTH COURT** Lauren Reba-Harrelson, M.A., Ph.D. Eraka Bath, M.D.

### NR5-42

CLINICAL AND DEMOGRAPHIC DIFFERENCES BETWEEN INVOLUNTARY AND VOLUNTARY Admissions in a National REFERENCE HOSPITAL IN BRAZIL Luiz K. Ferreira, M.D. Taís Michele Minatogawa-Chang, M.D. Montezuma Pimenta Ferreira, M.D. Edson Shiguemi Hirata, M.D., Ph.D.

### NR5-43

DIRECT TESTS OF THE ATTACHMENT HYPOTHESIS OF THE DEVELOPMENT OF CRIMINAL BEHAVIORS Marc A. Lindberg, Ph.D. Lindsay Lounder, Psy.D

### NR5-44

THE CURRENT STATUS OF FORENSIC PSYCHIATRY IN JAPAN Ryuichi Fujii, M.D., Ph.D. Takashi Tsuboi, M.D. Shohei Nishimon, M.D. Hideaki Tani, M.D. Keisuke Orimo, M.D. Jun Nakane, M.D.

### NR5-45

MENTAL ILLNESS IN A NATIONAL LEVEL SAMPLE IN NEW ZEALAND Susan Hatters Friedman, M.D. James Cavney, MBChB Brian McKenna, R.N., B.A., MHSc (Hons), Ph.D. Alexander Simpson, MBChB, FRANZCP

CHILD MURDER BY PARENTS AND

QUANTITATIVE ASSESSMENT OF PSYCHOSOCIAL DISTRESS OF ELDERLY INDIVIDUALS WITH COPD AND WITH CHRONIC PAIN, ACCORDING TO THE AMA Guides Sixth Edition Armando S. Miciano, M.D.

### NR5-47

EFFECT OF EXTENDED RELEASE QUETIAPINE FUMARATE ON QUALITY OF LIFE AND SLEEP IN ELDERLY PATIENTS WITH GAD Catherine Datto, M.D., M.S. Jean Endicott, Ph.D. Henrik Svedsäter, Ph.D. Julie Locklear, Pharm.D., M.B.A.

### NR5-48

RELATIONSHIP BETWEEN SLEEP QUALITY AND ANXIETY SYMPTOMS IN THE ELDERLY Chang Hyung Hong, M.D., Ph.D. Hyun-Chung Kim, M.D. Ki-Young Lim, M.D. Young-Ki Chung, M.D. Kang-Soo Lee, M.D. Yun-Hwan Lee, M.D. Jae-Seok Seo, M.D.

### NR5-49

WHITE MATTER CHANGE AND COGNITIVE DYSFUNCTION Han-Young Jung, M.D., Ph.D. Soyoung Irene Lee, M.D., Ph.D. Shin Gyeom Kim, M.D. Hee Yeun Jung M.D., Ph.D. Eun Young Shin, M.D. Wooyul Jung, M.D. Joonho Park, Ph.D. Mihee Park, M.D.

# NR5-50

Withdrawn

### NR5-51

FACTORS INFLUENCING ON THE SUICIDE-RELATED BEHAVIOR IN COMMUNITY-**DWELLING KOREAN ELDERS** *Jin Sook Cheon, M.D., Ph.D.* Byoung Hoon Oh, M.D., Ph.D.

### NR5-52

EFFECTS OF EXTENDED-RELEASE QUETIAPINE FUMARATE ON QUALITY OF LIFE AND SLEEP IN **ELDERLY PATIENTS** WITH MDD Julie Locklear, Pharm.D., M.B.A. Iean Endicott, Ph.D. Henrik Svedsäter, Ph.D.

Catherine Datto M.D., M.S.

NR5-53 MULTI-SITE, OPEN-LABEL, PROSPECTIVE TRIAL OF LAMOTRIGINE FOR GERIATRIC **BIPOLAR DEPRESSION** Martha Sajatovic, M.D. Ariel Gildengers, M.D. Rayan Al Jurdi, M.D. Laszlo Gyulai, M.D. Kristin A. Cassidy, M.A. Rebecca L. Greenberg, M.S. Thomas Ten Have, Ph.D.

Robert Young, M.D.





### NR5-54

CORRELATION OF WHITE MATTER CHANGES WITH BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS AND COGNITION IN ALZHEIMER'S DISEASE PATIENTS

Shin Gyeom Kim, M.D. Han-Yong Jung M.D., Ph.D. Soyoung Irene Lee, M.D., Ph.D. Hee Yeun Jung M.D., Ph.D. Eun Young Shin, M.D. Wooyul Jung, M.D. Mihee Park, M.D.

### NR5-55

THE EFFECT OF EXTENDED-RELEASE MEMANTINE ON BEHAVIORAL DOMAINS IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE Stephen M. Graham, Ph.D. Michael Tocco, Ph.D.

Hai-an Hsu, Ph.D. Lei Xie, Ph.D. James L. Perhach, Ph.D.

### NR5-56

SYNERGISTIC EFFECTS OF DEPRESSION AND APOLIPOPROTEIN E4 ON THE INCIDENCE OF DEMENTIA

Yong-Hwan Kim, M.D. Jae-Min Kim, M.D., Ph.D. Robert Stewart, M.D., Ph.D. Sung-Wan Kim, M.D., Ph.D. Kyung-Yeol Bae, M.D. Sun-Young Kim, M.D. Su-Jin Yang, M.D., Ph.D. Il-Seon Shin, M.D., Ph.D. Jin-Sang Yoon, M.D., Ph.D.

### NR5-57

TSH, COGNITIVE IMPAIRMENT, AND DEPRESSION IN AN OLDER KOREAN POPULATION

Young-Heon Song, M.D. Jae-Min Kim, M.D., Ph.D. Robert Stewart, M.D., Ph.D. Kyung-Yeol Bae, M.D. Sung-Wan Kim, M.D., Ph.D. Su-Jin Yang, M.D., Ph.D. Ho-Cheol Kang, M.D., Ph.D. Il-Seon Shin, M.D., Ph.D. Jin-Sang Yoon, M.D., Ph.D.

# NR5-58

WITCHCRAFT OR MENTAL ILLNESS? Beatriz Quintanilla, M.D., Ph.D.

### NR5-59

SOCIAL SUPPORT AND ACCULTURATION: PREDICTORS OF PSYCHOLOGICAL HEALTH OF INTERNATIONAL MEDICAL GRADUATES PURSUING PSYCHIATRIC RESIDENCIES Ashutosh Atri, M.S., M.D.

### NR5-60

**CHANGES IN EMPATHY DURING KOREAN MEDICAL** COLLEGE AND MEDICAL **SCHOOL EDUCATION:** 1-YEAR FOLLOW UP Minha Hong, M.D. Duk Soo Moon, M.D. Geon Ho Bahn, M.D., Ph.D. Won Hye Lee, Ph.D.

### NR5-61

**EMPATHY IN KOREAN** PSYCHIATRIC RESIDENTS Minha Hong, M.D. Geon Ho Bahn, M.D., Ph.D. Won Hye Lee, Ph.D. Min Young Lee, B.A.

### NR5-62

CORTEX AND CLINICAL SYMPTOMS IN PATIENTS WITH PTSD AFTER A TRAFFIC ACCIDENT Jun Won Kim, M.D. Han Doug Hyun, M.D., Ph.D. Beom Woo Nam, Ph.D. Churl Na, Ph.D.

VOLUME OF ORBITOFRONTAL

### NR5-63

Doo Byung Park, Ph.D.

ANTIDEPRESSANT MEDICATIONS IN PREGNANCY AND POSTPARTUM: ADHERENCE VERSUS DECLINE Diana Carter, M.D. Shaila Misri, M.D. Deirdre Ryan, M.D. Jasmin Abizadeh, B.A. Arjun Nanda


### NR5-64

AN OPEN-LABEL TRIAL OF ESCITALO-PRAM IN POSTPARTUM WOMEN WITH MOOD AND ANXIETY DISORDERS Shaila Misri, M.D. Karen Joe, B.Sc. (Hon.) Iasmin Abizadeh, B.A.

### NR5-65

Withdrawn







### LA LOUISIANE C, MORIAL CONVENTION CENTER

### Moderator:

Renato D. Alarcon, M.D., M.P.H.

### NR6-1

**Dose-Associated Changes in** SAFETY AND EFFICACY PARAMETERS OBSERVED IN A 24-WEEK MAINTENANCE TRIAL OF OLANZAPINE LONG-ACTING INJECTION IN PATIENTS WITH SCHIZOPHRENIA

Angela Gulliver, Pharm.D. Bin Sun, Ph.D. Jamie L. Karagianis, M.D. Fangyi Zhao, Ph.D. Susan B. Watson, Ph.D. David P. McDonnell, M.B.

### NR6-2

EFFICACY OF LURASIDONE IN SCHIZOPHRENIA: SUMMARY OF RESULTS FROM THE CLINICAL **DEVELOPMENT PROGRAM** 

Antony Loebel, M.D. Josephine Cucchiaro, Ph.D. Masaaki Ogasa, M.S. Robert Silva, Ph.D. Andrei A. Pikalov, M.D., Ph.D. Jay Hsu, Ph.D. Jane Xu, Ph.D

### NR6-3

GLUTAMATE QUANTIFICATION IN THE ASSOCIATIVE STRIATUM OF PATIENTS WITH SCHIZOPHRENIA BEFORE AND AFTER ANTIPSYCHOTIC TREATMENT Camilo de la Fuente, M.D., M.S. Rafael Favila, M.Sc. Pablo León-Ortíz, M.D. Leonardo Díaz-Galvis, M.D. Carmen Amezcua, M.D. Sylvana Stephano, M.D. Ariel Graff-Guerrero, M.D., Ph.D.

### NR6-4

**EVALUATION OF THE RELATIONSHIPS** Among Change in Function. SYMPTOMS, AND DURATION OF **SCHIZOPHRENIA** 

Chris Kozma, Ph.D. Riad Dirani, Ph.D. Deborah Nicholl, M.Sc. Kasem Akhras, Pharm.D.

### NR6-5

ONSET OF EFFICACY WITH PALIPERIDONE PALMITATE IN PATIENTS WITH ACUTELY **EXACERBATED SCHIZOPHRENIA** Cynthia Bossie, Ph.D. J. Thomas Haskins, Ph.D. Jennifer Kern Sliwa, Pharm.D. Yi-Wen Ma, Ph.D. Larry Alphs, M.D., Ph.D.

### NR6-6

THE CARDIOVASCULAR SAFETY OF INHALED LOXAPINE (AZ-004) Daniel A. Spyker, Ph.D., M.D. Mildred D. Gottwald, Pharm.D. Robert S. Fishman, M.D. James V. Cassella, Ph.D.

### NR6-7

LONG-TERM SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PALIPERIDONE PALMITATE: A ONE-YEAR, OPEN-LABEL STUDY IN PATIENTS WITH **SCHIZOPHRENIA** 

Danielle Coppola, M.D. Yanning Liu, M.S. Srihari Gopal, M.D. Bart Remmerie Mahesh Samtani, Ph.D. Gahan Pandina, Ph.D. David Hough, M.D. Isaac Nuamah, Ph.D. Ahmad Hatim Sulaiman, M.D.

### NR6-8

**EDUCATIONAL LEVEL OF THE** RATER PREDICTS QUALITY **OF SYMPTOM ASSESSMENT** INTERVIEWS IN SCHIZOPHRENIA CLINICAL TRIALS David Daniel, M.D. John Bartko, Ph.D. Norman Sartorius M.D., Ph.D. Eduard Vieta, M.D.

### NR6-9

INCREASED MATERNAL AGE AT BIRTH HAMPERS REVERSAL LEARNING IN SCHIZOPHRENIA Dimitrios Kontis, M.D., Ph.D. Eirini Theochari, M.D. Spiros Kleisas, M.D. Stamatina Kalogerakou, M.Sc. Angeliki Andreopoulou, M.Sc. Charalambos Karouzos, M.D. Eleftheria Tsaltas, Ph.D.

### NR6-10

PALIPERIDONE EXTENDED RELEASE AS MONOTHERAPY OR ADJUNCTIVE THERAPY TO MOOD STABILIZERS/ ANTIDEPRESSANTS IN SUBJECTS WITH SCHIZOAFFECTIVE DISORDER Dong-Jing Fu, M.D., Ph.D. Cynthia A. Bossie, Ph.D. Ibrahim Turkoz, M.S. Larry Alphs, M.D., Ph.D. Carla M. Canuso, M.D.

Obtain your Certificate of Attendance for the 2010 APA Annual Meeting at <www.psych. org/AnnualMeetingCME>

### NR6-11

**EMOTIONAL MUSICAL RECOGNITION DEFICITS IN PARANOID** SCHIZOPHRENIC PATIENTS

Eric E. Constant, M.D., Ph.D. Severine Samson, Ph.D. Pierre Philippot, Ph.D. Catherine De Graeuwe D'Aoust, Psy. Aline De Jaegere, M.P.H. Vincent Meert, M.D. Benoit Delatte, M.D. Benoit Gillain, M.D. Xavier De Longueville, M.D. Jean Delbeke, M.D. Isabelle Peretz, Ph.D.

### NR6-12

A RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF PALIPERIDONE PALMITATE AND RISPERIDONE LONG-ACTING THERAPY IN PATIENTS WITH SCHIZOPHRENIA Gahan Pandina, Ph.D. R. Lane, M.A.S. S. Gopal, M.D., M.H.S. C. Gassmann-Mayer, Ph.D. D. Hough, M.D. B. Remmerie, G. Simpson, M.D.

### NR6-13

PREDICTORS OF FAVORABLE LONG-TERM OUTCOME IN THE TREATMENT OF **SCHIZOPHRENIA** Haya Ascher-Svanum, Ph.D.

Gebra Cuyún Carter, Ph.D., M.P.H. Denái Milton, M.S. Douglas Faries, Ph.D.

### NR6-14

PATIENTS' EARLY PERCEPTIONS OF MEDICATIONS' BENEFITS PREDICT SUBSEQUENT RESPONSE IN THE TREATMENT OF SCHIZOPHRENIA Haya Ascher-Svanum, Ph.D. Allen W. Nyhuis, M.S. Douglas E. Faries, Ph.D.

Virginia L. Stauffer, Pharm.D. Sara Kollack-Walker, Ph.D. Bruce I. Kinon, M.D. Peter Weiden, M.D.

# NR6-15

LURASIDONE IN THE TREATMENT OF ACUTE SCHIZOPHRENIA: RESULTS OF THE DOUBLE-BLIND, PLACEBO-CONTROLLED PEARL 2 TRIAL Herbert Y. Meltzer, M.D. Josephine Cucchiaro, Ph.D. Robert Silva, Ph.D. Masaaki Ogasa, M.S. Jane Xu, Ph.D. Debra Phillips, B.A. Doreen Simonelli, Ph.D.

Amir Kalali, M.D.

Antony Loebel, M.D.





### NR6-16

EFFICACY, SAFETY, AND TOLERABILITY OF PALIPERIDONE EXTENDED RELEASE IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA Jaskaran Singh, M.D. Ujjwala Vijapurkar, Ph.D. Adelaide Robb, M.D. Isaac Nuamah, Ph.D. David Hough, M.D.

### NR6-17

**EFFECTS OF PALIPERIDONE** PALMITATE TREATMENT IN SCHIZOPHRENIA PATIENTS PREVIOUSLY TREATED WITH ORAL RISPERIDONE Jennifer Kern Sliwa, Pharm.D.

Cynthia A. Bossie, Ph.D. Yi-Wen Ma, Ph.D. Larry Alphs, M.D., Ph.D. I. Thomas Haskins, Ph.D.

### NR6-18

HEMATOLOGICAL CLOZAPINE MONITORING WITH A POINT-OF-CARE DEVICE Jimmi Nielsen, M.D. Christoph U. Correll, M.D.

### NR6-19

DIFFERENTIAL METABOLIC PROFILES OF LURASIDONE AND OLANZAPINE: DATA FROM A SIX-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED SCHIZOPHRENIA TRIAL Jonathan M. Meyer, M.D. Josephine Cucchiaro, Ph.D. Andrei Pikalov, M.D., Ph.D. Jay Hsu, Ph.D. Antony Loebel, M.D.

### NR6-20

SAFETY OF LURASIDONE: POOLED ANALYSIS OF FIVE PLACEBO-CONTROLLED TRIALS IN PATIENTS WITH SCHIZOPHRENIA

Josephine Cucchiaro, Ph.D. Andrei Pikalov, M.D., Ph.D. Masaaki Ogasa, M.S. Robert Silva, Ph.D. Jay Hsu, Ph.D. Jane Xu, Ph.D. Antony Loebel, M.D.

### NR6-21

TOLERABILITY OF PALIPERIDONE PALMITATE Initiation Doses in Subjects WITH RECENTLY DIAGNOSED SCHIZOPHRENIA

Larry D. Alphs, M.D. Cynthia Bossie, Ph.D. Jénnifer Kern Sliwa, Pharm.D. Yi-Wen Ma, Ph.D. I. Thomas Haskins, Ph.D.

### NR6-22

**GAMMA OSCILLATION** AND SERUM NITRIC OXIDE METABOLITES IN THE CHRONIC SCHIZOPHRENIC PATIENTS Masatomo Suetsugi, M.D., Ph.D. Yasushi Mizuki, M.D., Ph.D. Kumiko Hara, B.S. Yoshifumi Watanabe, M.D., Ph.D.

### NR6-23

CHANGE IN APPETITE AS A PREDICTOR OF WEIGHT CHANGES DURING OLANZAPINE TREATMENT Michael G. Case, M.S. Jamie Karagianis, M.D. Tamas Treuer, M.D. Vicki Poole-Hoffmann, Pharm.D.

### NR6-24

STRATEGY FOR SELECTION OF VARIOUS SWITCHING DOSES FOR OLANZAPINE LONG-ACTING INJECTION

Michael M. Witte, Ph.D. Holland Detke, Ph.D. Fangyi Zhao, Ph.D. Prajakti Kothare, Ph.D. Parag Garhyan, Ph.D. Janice Carlson, Ph.D. David McDonnell, MRCPsych

### NR6-25

COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE VERSUS ORAL ATYPICALS AND A CONVENTIONAL DEPOT FORMULATION IN THE U.S. Mirko Sikirica, Pharm.D. Concetta Crivera, Pharm.D., M.P.H. Riad Dirani, Ph.D.

### NR6-26

A MARKED-TO-SEVERE **EXACERBATION OF SCHIZOPHRENIA** Norris Turner, Ph.D., Pharm.D. Cynthia A. Bossie, Ph.D. I. Thomas Haskins, Ph.D. Jennifer Kern Sliwa, Pharm.D. Yi-Wen Ma, Ph.D. Larry Alphs, M.D., Ph.D.

EFFECTS OF PALIPERIDONE

PALMITATE IN ACUTELY

ILL SUBJECTS WITH

### NR6-27

Withdrawn

### NR6-28

A THREE ARM DOSE FINDING STUDY OF LURASIDONE: EFFICACY AND TOLERABILITY DATA Philip D. Harvey, Ph.D. Mitsukuni Murasaki, M.D. Masaaki Ogasa, M.D. Josephine Cucchiaro, Ph.D. Antony Loebel, M.D.

### NR6-29

LONG-TERM EFFICACY OF ASENAPINE IN PEOPLE WITH PERSISTENT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA Pilar Cazorla, Ph.D. John Panagides, Ph.D. Jun Zhao, Ph.D. Phillip Phiri, Ph.D. Larry Alphs, M.D., Ph.D. Niná Scĥooler, Ph.D. Armin Szegedi, M.D., Ph.D. Robert W. Buchanan, M.D.

### NR6-30

PRELIMINARY RESULTS ABOUT CAREGIVERS' QUALITY OF LIFE OF FIRST-EPISODE PSYCHOSIS PATIENTS IN BRAZIL Rita Jorge, M.D. Ana Cristina Chaves, Ph.D.

### NR6-31

CAREGIVERS EGO DEFENSE MECHANISMS IN FIRST-**EPISODE PSYCHOSIS** Rita Jorge, M.D. Ana Cristina Chaves, Ph.D.

THE SELECTIVE NK3 ANTAGONIST AZD2624 Does Not Improve SYMPTOMS OR COGNITION IN SCHIZOPHRENIA

Robert E. Litman, M.D. Mark Smith, M.D., Ph.D. Dhaval Desai, M.D. Thomas Simpson, Ph.D. Stephen Kanes, M.D., Ph.D.

### NR6-33

TREATING AGITATION WITH INHALED LOXAPINE (AZ-004): EFFICACY ANALYSES IN PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER

Robert S. Fishman, M.D. Daniel A. Spyker, Ph.D., M.D. James V. Cassella, Ph.D.

### NR6-34

**EFFICACY OF LONG-ACTING** RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA: A SIX-MONTH FOLLOW-UP FROM THE E-STAR DATABASE IN LATIN AMERICA Rogelio Apiquian, M.D., Ph.D. Rodrigo Córdoba, M.D. Mario Souza, M.D. Carlos Castillejos, M.D. Carmen Amezcua, M.D. Leonardo Diaz, M.D.

### NR6-35

PERSONALITY DIFFERENCES IN FIRST EPISODE SCHIZOPHRENIA AND BIPOLAR DISORDER Ronald J. Gurrera, M.D. Toni Mahowald, B.A. Dean Salisbury, Ph.D.





### NR6-36

New Diagnostic Criteria for NMS Using the Delphi Consensus TECHNIQUE AND AN INTERNATIONAL EXPERT PANEL

Ronald J. Gurrera, M.D. Stanley N. Caroff, M.D. Abigail Cohen, Ph.D.

Robin Emsley, M.D., Ph.D.

### NR6-37

LONG-TERM SAFETY AND EFFICACY OF ASENAPINE VERSUS OLANZAPINE IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER Schoemaker Joep, M.S.C. Let Stet, Ph.D. Dieter Naber, M.D., Ph.D. John Panagides, Ph.D.

### NR6-38

TIME TO NEGATIVE SYMPTOMS REMISSION AND PSYCHOSOCIAL FUNCTIONING IN SCHIZOPHRENIA: A 196-WEEK DOUBLE-BLIND STUDY OF ZIPRASIDONE VERSUS HALOPERIDOL Stephen Stahl, M.D., Ph.D. Ashok Malla, M.D. John W. Newcomer, M.D. Steven G. Potkin, M.D. Peter J. Weiden, M.D. Philip D. Harvey, Ph.D. Antony Loebel, M.D. Eric Watsky, M.D. Cynthia O. Siu, Ph.D. Steve Romano, M.D.

### NR6-39

SHORT-TERM TOLERABILITY, SAFETY, AND PHARMACOKINETIC PROFILE OF ASENAPINE IN OLDER PATIENTS WITH PSYCHOSIS Steven Dubovsky, M.D. Colleen Frobose, Ph.D.

Phillip Phiri, Ph.D. John Panagides, Ph.D.

### NR6-40

COMPARATIVE RECEPTOR BINDING PROFILE OF LURASIDONE AND OTHER FIRST AND SECOND **GENERATION ANTIPSYCHOTICS** 

Takeo Ishiyama, Ph.D. Antony Loebel, M.D. Josephine Cucchiaro, Ph.D. Tomoko Horisawa, B.S. Kumiko Tokuda, B.S. Maasaki Ogasa, M.S. Tadashi Ishibashi, Ph.D. Steven M. Stahl, M.D., Ph.D.

Cherilyn DeSouza, M.D.

### NR6-41

REDUCTION OF HOSPITALIZATION IN PATIENTS INITIATED ON RISPERIDONE LONG-ACTING INJECTION IN THE U.S., SPAIN, AUSTRALIA, AND BELGIUM Timothy Lambert, M.B.B.S, Ph.D. J.M. Olivares, M.D., Ph.D. J. Peuskens, M.D., Ph.D.

Chris M. Kozma, Ph.D. Patrick Otten Concetta Crivera, Pharm.D., M.P.H. An Jacobs Wayne Macfadden, M.D. Lian Mao, Ph.D. Stephen C. Rodrigue Riad G. Dirani, Ph.D. Kasem S. Akhras, Pharm.D.

### NR6-42

**EFFICACY AND SAFETY OF QUETIAPINE** FOR DEPRESSIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA

Tae-Youn Jun, Yang-Whan Jeon Hae-Kook Lee Kyoung-Uk Lee

### NR6-43

RATES OF LEUKOPENIA AND AGRANULOCYTOSIS ASSOCIATED WITH CLOZARIL TREATMENT DURING 19 YEARS OF BLOOD MONITORING BY THE CLOZARIL NATIONAL REGISTRY Vinod Kumar, M.D. Jonathan J. Salem

### 3:00 P.M.-5:00 P.M. POSTER SESSION 7 LA LOUISIANE C, MORIAL CONVENTION CENTER

### **Moderator:**

Annette Matthews, M.D.

GENDER SPECIFIC EFFECTS OF PREMATURE BIRTH ON THE RISK FOR ALCOHOLISM GREATER IN MALES THAN FEMALES: A 45-YEAR DANISH **BIRTH COHORT STUDY** Ann Manzardo, Ph.D.

Elizabeth C. Penick, Ph.D. Joachim Knop, M.D. Wendy Madarasz, M.P.E. Erik Lykke Mortensen, Cand. Psych. Holger J. Sorenson, M.D., Ph.D. Ulrik Becker, M.D. Elizabeth J Nickel, M.S. William F Gabrielli Jr., M.D., Ph.D.

### NR7-2

DIAGNOSTIC ASPECTS OF PATHOLOGICAL INTERNET USE: A PROSPECTIVE STUDY OF PSYCHIATRIC PHENOMENOLOGY AND COMORBIDITY OF INTERNET DEPENDENCY Bert T. te Wildt, M.D.

I. Putzig, M.D. M. Drews, M.D. F. Wedegaertner, M.D., M.P.H. G. R. Szycik, Ph.D.



### NR7-3

CHARACTERISTICS, PERSISTENCE AND OUTCOMES OF INSURED PATIENTS TREATED WITH EXTENDED-RELEASE NALTREXONE (XR-NTX) OR ORAL MEDICATIONS David R. Gastfriend, M.D. Henry R. Kranzler, M.D. Leslie Montejano, Ph.D. Tami Mark, Ph.D. Mady Chalk, Ph.D. David R. Gastfriend. M.D.

### NR7-4

MISIDENTIFIED CONTENT AND CONTAMINANTS: FURTHER RISKS OF UNDERGROUND ANABOLIC STEROID USE Dwight Smith, M.D. Troy Pulas, M.D. John Renner, M.D.

### NR7-5

AN UPDATE ON TESTING FOR DRUGS OF ABUSE: SCIENTIFIC BACKGROUND AND PRACTICAL CLINICAL CONCERNS Dwight Smith, M.D. Ashish Anand, M.D. Ronald Bugaoan, M.D. John Renner, M.D.

### NR7-6

EFFICACY AND SAFETY OF EXTENDED-RELEASE INJECTABLE NALTREXONE (XR-NTX) FOR THE TREATMENT OF **OPIOID DEPENDENCE** Evgeny Krupitsky Ari Illeperuma, M.S.

David R. Gastfriend, M.D. Bernard L. Silverman, M.D.

### NR7-7

LONGITUDINAL ASSOCIATIONS BETWEEN EARLY EMOTIONAL PROBLEMS, BEHAVIOURAL PROBLEMS, AND SUBSTANCE USE: 20 YEAR FOLLOW-UP OF A FINNISH BIRTH COHORT Jouko Miettunen, Ph.D. Graham K. Murray, M.R.C.Psych. Peter B. Jones, F.R.C.Psych. Pirjo Mäki, M.D., Ph.D. Hanna Ebeling, M.D., Ph.D. Anja Taanila, Ph.D. Matti Joukamaa, M.D., Ph.D. Jukka Savolainen, Ph.D. Sari Törmänen, B.Med. Marjo-Riitta Järvel

### NR7-8

CHARACTERISTICS, PERSISTENCE, AND OUTCOMES OF INSURED PATIENTS TREATED WITH EXTENDED-RELEASE NALTREXONE (XR-NTX) or Oral Medications Mady Chalk, Ph.D. Leslie Montejano, Ph.D. Tami Mark, Ph.D. Henry R. Kranzler M.D. David R. Gastfriend, M.D. Juna Veijola, M.D., Ph.D. Irma Moilanen, M.D., Ph.D.





# NR7-9

Withdrawn

# NR7-10

Withdrawn

### NR7-11

THE DIAGNOSTIC AND ABSTENTION SUPERVISION WITH MARKERS OF ALCOHOL DEPENDENCY Matej Kravos, M.D., Ph.D. Ivan Malešic

### NR7-12

PRELIMINARY EVALUATION OF EXTENDED-RELEASE NALTREXONE (XR-NTX) IN MICHIGAN AND Missouri Drug Courts Michael W. Finigan, Ph.D. Tamara Perkins, Ph.D.

### NR7-13

ALCOHOL USE AND ADDITION OF LOW DOSE NALTREXONE IN **OPIOID DETOXIFICATION** Paolo Mannelli, M.D. Kathleen Peindl, Ph.D. Ashwin A. Patkar, M.D.

Phyllis Zold-Kilbourn, Ph.D.

Haresh Tharwani, M.D. Li-Tzy Wu, Sc.D.

# NR7-14

Withdrawn

### NR7-15

AN ANALYSIS OF CO-OCURRING TOBACCO SMOKERS, DEPRESSION, AND SUBSTANCE USE Sandra Odebrecht Vargas Nunes, M.D., Ph D Juliana Brum Moraes, M.D. Vivian Uemura, M.D. Márcia Regina Pizzo de Castro, M.S. Tiemi Matsuo, Ph.D.

### NR7-16

EXTENDED-RELEASE INJECTABLE NALTREXONE (XR-NTX) REDUCES BRAIN RESPONSE TO ALCOHOL CUES IN ALCOHOL-**DEPENDENT VOLUNTEERS:** A BOLD FMRI STUDY

Heber Odebrecht Vargas, M.D.

Scott E. Lukas, Ph.D. Steven Lowen, Ph.D. David M. Penetar, Ph.D. Nina Conn Wendy Tartarini, M.A. John Rodolico, Ph.D. Gopi Mallya, M.D. Christopher Palmer, M.D. Bernard L. Silverman, M.D. David R. Gastfriend, M.D.

TREATMENT OF CHRONIC PAIN WITH BUPRENORPHINE IN A VETERAN WITH TRAUMATIC BRAIN INJURY Shilpa Sachdeva, M.D. Adekola Alao, M.D.

### NR7-18

MORTALITY FOLLOWING TREATMENT FOR CANNABIS, COCAINE, AMPHETAMINE, ECSTASY, AND OPIOID USE DISORDERS: A NATIONWIDE FOLLOW-UP STUDY FROM DENMARK Signe Jensen, M.S.C. Mikkel Arendt, MScPsych, Ph.D. Povl Munk-Jørgensen, M.D.

### NR7-19

TRANSLATIONAL DEVELOPMENT OF Novel Pharmacotherapeutic STRATEGIES FOR PSYCHOSTIMULANT DEPENDENCE

Steven T. Szabo, M.D., Ph.D. Ashwin Patkar, M.D. Barry Mangum, Pharm. D. Wayne F. Beyer, Ph.D. F. Joseph McClernon, Ph.D. Bruce K. Burnett, Ph.D. Tong H. Lee, M.D., Ph.D.

DrMedSc, Leo Sher, M.D.

### NR7-20

SUBSTANCE INTOXICATION SIGNIFICANTLY REDUCES SERUM THYROTROPIN (TSH) LEVELS IN **ACUTE PSYCHIATRIC PATIENTS:** PRELIMINARY RESULTS Trevor Wells M.D.

Elana Miller M.D. Linda Meier M.A., Shilla Nassi, M.D., Ph.D. Cheryl Vigen Ph.D. Osama A. Abulseoud M.D.

### NR7-21

BRAIN MECHANISMS OF DECISION MAKING DURING RECOVERY FROM METHAMPHETAMINE DEPENDENCE William F. Hoffman, M.D., Ph.D. D. Schwartz, B.A. A. Mitchell, B.A. D. Lahna, B.A. H. Luber, B.A. S. Mitchell, Ph.D. M. Huckans, Ph.D.

### NR7-22

A REVIEW OF PANIC DISORDER/ ATTACKS AND SUICIDAL ATTEMPTS IN THE ABSENCE OF MOOD DISORDERS Anne Ruminjo, M.D. Sadie Shin, B.A. Igor Galynker, M.D., Ph.D. Lisa J. Cohen, Ph.D.

### NR7-23

Does Early Improvement PREDICT ENDPOINT RESPONSE IN GAD PATIENTS TREATED WITH PREGABALIN OR VENLAFAXINE-XR? David Baldwin, D.M. Edward Schweizer, M.D. Yikang Xu, Ph.D. Gavin Lyndon, M.D.

Sean Donevan, Ph.D.

### NR7-24

EFFICACY OF PREGABALIN IN GENERALIZED SOCIAL ANXIETY DISORDER: RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE STUDY Douglas Feltner, M.D. Robert Bielski, M.D. Maria Liu-Dumaw, M.S.

### NR7-25

FUNCTIONAL AND HEALTH-RELATED QUALITY OF LIFE **OUTCOMES IN PATIENTS** WITH OCD: RELATIONSHIP TO TREATMENT RESPONSE AND SYMPTOM

Eric Hollander, M.D. Dan J. Stein, M.D. Naomi A. Fineberg, M.D. M. Marteau, Ph.D. Mark Legault, M.D.

### NR7-26

SWITCHING FROM LONG-TERM BENZODIAZEPINE THERAPY TO PREGABALIN IN PATIENTS WITH GAD: A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL Francine Mandel, Ph.D. Sean Donevan, Ph.D. Edward Schweizer, M.D.

### NR7-27

EFFICACY OF PREGABALIN IN PREVENTING RELAPSE IN GENERALIZED SOCIAL ANXIETY DISORDER: RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED 26-WEEK STUDY John Greist, M.D. Maria Liu-Dumaw, M.S. Douglas Feltner, M.D.

### NR7-28

THE USE OF THE INTERNET BY SOCIAL PHOBICS TO SEEK HEALTH INFORMATION Michael Van Ameringen, M.D. Catherine Mancini, M.D., F.R.C.P.C. William Simpson, B.Sc. Beth Patterson, B.Sc.N., B.Ed.

### NR7-29

HARM AVOIDANCE AND INCOMPLETENESS IN A CLINICAL SAMPLE OF OCD Nicholas J. Sibrava, Ph.D. Jane L. Eisen, M.D. Maria C. Mancebo, Ph.D. Steven A. Rasmussen, M.D.

# NR7-3<u>0</u>

INSOMNIA AND GAD: CLINICAL PRESENTATION AND DIFFERENTIAL RESPONSE TO THREE DRUG CLASSES Sean Donevan, Ph.D. Edward Schweizer, M.D. Yikang Xu, Ph.D. Gavin Lyndon, M.D.





### NR7-31

EFFECTS OF ORAL RIVASTIGMINE ON SUBSCALES OF THE SEVERE IMPAIRMENT BATTERY (SIB) IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE Jason T. Olin, Ph.D. Xiangyi Meng, Ph.D. Monique Somogyi, M.D.

### NR7-32

**BECK DEPRESSION INVENTORY** (BDI) AS A SCREENING TOOL FOR DEPRESSION: A POPULATION-BASED FINNISH COHORT STUDY

Jussi K.M. Seppala, M.D. Mauno Vanhala, M.D., Prof. Hannu Kautiainen, Ph.D. Salme Jarvenpaa, M.Sc. Johan Eriksson, M.D., Ph.D. Olli Kampman, M.D., Ph.D. Yrjo Ovaskainen, M.D. Merja Viikki, M.D., Ph.D. Hannu Koponen, M.D., Prof.

### NR7-33

Withdrawn

### NR7-34

INPATIENT PSYCHIATRIC TREATMENT OF DEAF AND SEVERELY HARD-OF-HEARING ADULTS: DEMOGRAPHIC AND DIAGNOSTIC COMPARISONS WITH HEARING INPATIENTS Sarah A. Landsberger, Ph.D. David R. Diaz, M.D.

### NR7-35

**EFFECTIVENESS OF EATING** DISORDER TREATMENT IN REAL WORLD SETTINGS: COMPREHENSIVE ASSESSMENT AND OUTCOME Godehard Oepen, M.D., Ph.D. Lane Gould-Hartline, A.P.R.N., B.C. Edward J. Federman, Ph.D. Emily Martinez Whitt, Psy.D. Roberto Norniella, M.D. Richard Akins, M.D., M.B.A.

### NR7-36

TESTS OF THE KOOB-KELLY-GOLD-VOLKOW-KESSLER HYPOTHESIS OF BMI INCREASES IN THE U.S.

Jennifer Cavender, B.A. Yulia Dementieva, Ph.D. Marc A, Lindberg, Ph.D.

### NR7-37

PSYCHOTROPIC DRUG USE IN OLDER PEOPLE AND RISK OF **DEATH DURING HEAT WAVES:** A FRENCH POPULATION-BASED **CASE-CONTROL STUDY** 

Clementine Nordon, M.D., M.S.C. Karin Martin-Latry, Ph.D. Laurence de Roquefeuil, Ms.C. Philippe Latry, Ms.C. Bernard Begaud, Ph.D. Bruno Falissard, Ph.D. Frederic Rouillon, Ph.D. Helene Verdoux, Ph.D.

### NR7-38

TWELVE-MONTH OUTPATIENT PSYCHOTHERAPY USE IN SÃO PAULO, **BRAZIL: FINANCIAL PATTERNS** Erica Peluso, Ph.D. Paula F. R. Silva, M.D. Sérgio L. Blay, M.D., Ph.D.

### NR7-39

CHANGES IN REGIONAL VARIATIONS IN LEADING SUICIDE METHOD IN TAIWAN: A SURGE OF CHARCOAL **BURNING FROM 2002 TO 2008** Jin-Jia Lin, M.D. Tsung-Hsueh Lu, M.D., Ph.D. Shusen Chang, M.D.

### NR7-40

MELANCHOLIA IN PATIENTS WITH PSYCHOTIC DEPRESSION: A 10-YEAR ANALYSIS OF CLINICAL SEVERITY AND OUTCOME Leilani Lee, M.D.

Laura Fochtmann, M.D. Evelyn Bromet, Ph.D.

### NR7-41

FREQUENT VERSUS INFREQUENT VISITORS TO A PSYCHIATRIC **EMERGENCY SERVICE** 

Luis Jimenez-Trevino, Ph.D. Javier Caballer-Garcia, M.D. Hilario Blasco, Ph.D. Javier Quintero-Gutierrez, Ph.D. Javier Correas-Lauffer, Ph.D. Pilar Saiz, Ph.D. Julio Bobes, Ph.D.

### NR7-42

ETHNIC SELF-IDENTITY AND SUICIDAL IDEATION: RESULTS FROM THE NATIONAL COMORBIDITY SURVEY REPLICATION

Rizwan Khan, D.O. Richard Walker, B.S. Iames Dias, Ph.D. Erick Messias, M.D., Ph.D.

### NR7-43

Nonmedical Use Surveillance AND SIGNAL IDENTIFICATION OF LISDEXAMFETAMINE DIMESYLATE: A Pro-Drug Stimulant for the TREATMENT OF ADHD

Sajan Varughese, Pharm.D., M.B.A. Susan Rosen, M.D. Michelle D. Ertischek, M.P.H. Mark A. Sembower, M.S. Emmanuelle St. Jean, M.P.H. Sidney H. Schnoll, M.D., Ph.D.

### NR7-44

Neurocognitive Predictors OF LAMOTRIGINE TREATMENT FOR PATHOLOGIC SKIN PICKING: A Double-Blind, Placebo-CONTROLLED TRIAL

Jon E. Grant, M.D., J.D. Brian L. Odlaug, B.A. Samuel R. Chamberlain, M.D., Ph.D. Suck Won Kim, M.D.

### NR7-45

**EKG Abnormalities During ECT:** A MATCHED CONTROLLED STUDY Pe S. Wynn, M.D., M.P.H. Mandeep Kaur, M.D. Jong Sun, M.D. Lalu George, R.N. Fabien Trémeau, M.D.

### NR7-46

LONG-TERM DURABILITY OF ACUTE RESPONSE TO TRANSCRANIAL MAGNETIC STIMULATION (TMS) IN THE TREATMENT OF PHARMACORESISTANT Major Depression

Philip G. Janicak, M.D. Ziad Nahas, M.D., M.S.C.R. Sarah H. Lisanby, M.D. H. Brent Solvason, M.D., Ph.D. Shirlene M. Sampson, M.D. William M. McDonald, M.D. Lauren B. Marangell, M.D. Peter Rosenquist, M.D. W. Vaughn McCall, M.D., M.S. James Kimball, M.D. John O'Reardon, M.D. Colleen Loo, FRANZCP, M.D. Mustafa H. Husain, M.D. Andrew Krystal, M.D. William Gilber, M.D. Sheila M. Dowd, Ph.D. Mark A. Demitrack, M.D. Alan F. Schatzberg, M.D.

### NR7-47

EFFECT OF MILNACIPRAN TREATMENT ON FATIGUE IN PATIENTS WITH FIBROMYALGIA: POOLED ANALYSES FROM THREE RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIALS Allan Spera, M.D.

Philip Mease, M.D. Robert H. Palmer, M.D. Yong Wang, Ph.D. R. Michael Gendreau, M.D., Ph.D.

### NR7-48

MILNACIPRAN IMPROVES PAIN, PGIC, PHYSICAL FUNCTION, AND DEPRESSIVE SYMPTOMS IN FIBROMYALGIA: RESULTS FROM A PLACEBO-CONTROLLED MILNACIPRAN TRIAL

Leslev M. Arnold, M.D. R. Michael Gendreau, M.D., Ph.D. Judy Gendreau, M.D. Allan Spera, M.D. Yong Wang, Ph.D.

# NR7-49

Serge Perrot, M.D.

FUNCTIONALITY AND QUALITY OF LIFE ARE IMPROVED IN FIBRO-MYALGIA PATIENTS TREATED WITH SODIUM OXYBATE: RESULTS FROM A PHASE 3 INTERNATIONAL TRIAL Robert M. Bennett, M.D. Norman Rosenthal, M.D. Chinglin Lai, Ph.D. Beverly Benson, Ph.D. Y. Grace Wang, M.D. Cayetano Alegre, M.D.





### NR7-50

INFLUENCE OF PARENTING STYLES ON TEMPERAMENT, NORMAL PERSONALITY TRAITS, AND PERSONALITY DISORDERS Janine Samuel, B.S. Allison Lee, M.D. Curren Katz, M.A. Gillian Jennings Leo Bierman Elizabeth Menaker Igor Galynker, M.D.

### NR7-51

PTSD: CLINICAL PERSONALITY DISORDERS THAT CORRELATE WITH THE ONSET OF COMBAT STRESS *Joan E. Gallion, B.S.* Marc A. Lindberg, Ph.D.

### NR7-52

FACIAL AFFECT RECOGNITION IN NARCISSISTIC PERSONALITY DISORDER Marlies Marissen, Ph.D.

Ingmar Franken, Prof.

### NR7-53

EFFECT OF ARMODAFINIL ON PATIENT FUNCTIONING AND FATIGUE IN PATIENTS WITH RESIDUAL EXCESSIVE SLEEPINESS ASSOCIATED WITH TREATED OSA AND COMORBID MDD Andrew D. Krystal, M.D. John Harsh, Ph.D. Ronghua Yang, Ph.D. Gregory A. Rippon, M.D., M.S. Alan Lankford, Ph.D.

### NR7-54

"What a Difference a KID MAKES": HOUSEHOLD **DEMOGRAPHICS AND** SLEEP IN THE U.S. Daniel P. Chapman, Ph.D., M.Sc. Anne G. Wheaton, Ph.D. Geraldine Perry, D.P.H. Stephanie L. Sturgis Tara W. Strine, M.A. Janet B. Croft, Ph.D.

### NR7-55

A RANDOMIZED, CONTROLLED TRIAL OF VIRTUAL REALITY EXPOSURE WITH AROUSAL CONTROL FOR ACTIVE **DUTY SERVICE MEMBERS** WITH COMBAT PTSD Robert McLay, M.D., Ph.D. Dennis P. Wood, Ph.D. Jennifer A. Webb-Murphy, Ph.D. James L. Spira, Ph.D. Mark D. Wiederhold, M.D. Jeff M. Pyne, M.D. Brenda K. Wiederhold, Ph.D.



# APA 2010 ANNUAL MEETING ONLINE:

- Special onsite pricing
- Earn CME Credit for top lectures and symposia online
- For more information: <psych.org/amlibrary>



There are significant direct consequences to the invasion of HIV into the nervous system that may present as neurological, neuropsychiatric, and/or psychiatric syndromes and disorders. These may arise acutely and require rapid evaluation and intervention, or they may be chronic and subtle and be accompanied by physical complaints.

> Know how to respond. To learn more contact the APA Office of HIV Psychiatry. We can help with your training and resource needs.



American Psychiatric Association • Office of HIV Psychiatry 703.907.8668 • aids@psych.org • www.psych.org/aids

### Addiction Psychiatry/Substance Use Disorders

NR1-1 to NR1-12, NR3-28, NR3-45, NR3-69, NR7-1 to NR7-8, NR7-11 to NR7-13, NR7-15 to NR7-21, NR7-36

### AIDS & HIV

NR2-37

### ANXIETY DISORDERS

NR1-13 to NR1-18, NR1-20 to NR1-22, NR1-69, NR2-1, NR4-21, NR7-21 to NR7-30

### ATTENTION SPECTRUM DISORDERS

NR2-77, NR4-41, NR5-1 to NR5-17, NR5-19 to NR5-23, NR5-32

### BEHAVIOR & COGNITIVE THERAPIES

NR2-18, NR3-1 to NR3-3

### BIOLOGICAL PSYCHIATRY & NEUROSCIENCE

NR1-70, NR2-1 to NR2-6, NR2-8, NR2-33, NR3-4 to NR3-7, NR3-9, NR3-10, NR3-12, NR4-8, NR4-31, NR6-6, NR6-33

### BRAIN IMAGING

NR1-50, NR1-51, NR2-7 to NR2-10, NR3-10 to NR3-15, NR4-24, NR4-58, NR4-73, NR4-84, NR5-62, NR6-3, NR7-16

### CHILD & ADOLESCENT PSYCHIATRY

NR1-23, NR2-7, NR2-11 to NR2-17, NR2-19, NR2-48, NR2-63, NR3-30, NR3-41, NR3-47, NR4-35, NR5-1, NR5-5, NR5-7, NR5-13, NR5-24 to NR5-34, NR5-40

### COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, ETC.)

NR1-24 ot NR1-26, NR3-71, NR3-72, NR4-9, NR7-31

### COMPUTERS, TECHNOLOGY, INTERNET & RELATED

NR2-46, NR4-49, NR5-34

### **COUPLE & FAMILY THERAPIES**

NR5-35

### CREATIVITY & THE ARTS

NR2-20, NR2-58

### CROSS-CULTURAL & MINORITY ISSUES

NR2-21 to NR2-23, NR2-79, NR5-36 to NR5-38, NR7-34

### **DIAGNOSTIC ISSUES**

NR1-15, NR1-27 to NR1-30, NR1-35, NR3-58, NR4-14, NR4-48, NR4-87, NR5-6, NR6-36, NR7-11, NR7-32 to NR7-34

### EATING DISORDERS

NR1-19, NR1-31, NR1-53, NR3-57, NR4-25, NR7-35, NR7-36

### **EPIDEMIOLOGY**

NR1-8, NR1-44, NR1-57, NR2-24 to NR2-28, NR2-49, NR3-62, NR3-63, NR4-16, NR4-38, NR4-59, NR5-2, NR7-32, NR7-37 to NR7-43, NR7-54

### ETHICS & HUMAN RIGHTS

NR2-29, NR5-39, NR5-42

### FORENSIC PSYCHIATRY

NR1-63, NR2-30, NR2-31, NR5-39 to NR5-45

### **GENDER ISSUES**

NR1-34, NR1-55, NR4-72, NR5-58, NR7-1, NR7-15

### GENETICS

NR1-13, NR1-14, NR1-19, NR2-32, NR2-33, NR2-67, NR3-16 to NR3-20, NR4-11, NR4-36

### GERIATRIC PSYCHIATRY

NR1-24, NR1-41, NR2-34, NR2-40, NR2-43, NR2-64. NR2-70, NR3-8, NR3-70, NR5-46 to NR5-57, NR7-31, NR7-37

### **GROUP THERAPY**

NR1-18, NR5-26

### **HEALTH SERVICES RESEARCH**

NR2-35 to NR2-40, NR2-75, NR3-21 to NR3-25, NR4-78, NR5-38, NR7-35

### HISTORICAL OUESTIONS

NR2-41, NR5-58

### IMPULSE CONTROL DISORDERS

NR1-10, NR1-32, NR5-43, NR7-2, NR7-21, NR7-44

# LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES

NR1-54

### Managed Care & Health Care Financing

NR5-18

### MEN'S HEALTH ISSUES

NR2-42

### MOOD DISORDERS

NR1-27, NR1-33 to NR1-51, NR2-3, NR2-5, NR2-23, NR2-32, NR2-47, NR2-76, NR3-5, NR3-16, NR3-18, NR3-42, NR3-49, NR3-55, NR3-67, NR3-67, NR3-68, NR3-70, NR4-1 to NR4-86, NR5-28, NR7-7, NR7-9

### NEUROPSYCHIATRY

NR1-21, NR2-41, NR2-43 to NR2-47, NR2-73, NR3-26, NR3-27, NR5-20, NR5-55, NR6-12, NR6-24, NR7-20

### OTHER SOMATIC THERAPIES

NR2-17, NR2-48, NR4-66, NR7-45, NR7-46

### PAIN MANAGEMENT

NR5-46, NR7-47 to NR7-49

### PATIENT SAFETY & SUICIDE

NR1-23, NR2-49, NR2-50, NR3-28 to NR3-30, NR7-22

### PERSONALITY DISORDERS

NR1-52 to NR1-55, NR3-13, NR4-41, NR6-35, NR7-50 to NR7-52

### PRACTICE MANAGEMENT

NR2-51 to NR2-57, NR3-32, NR3-53

### PROFESSIONAL & PERSONAL ISSUES

NR2-29. NR3-31

### **PSYCHIATRIC ADMINISTRATION & SERVICES:** PUBLIC, PRIVATE & UNIVERSITY

NR3-22, NR3-32 to NR3-34, NR3-36

### **PSYCHIATRIC EDUCATION**

NR1-59, NR2-58 to NR2-61, NR2-74, NR5-60

### **PSYCHOANALYSIS**

NR2-22, NR6-31

### **PSYCHOIMMUNOLOGY**

NR2-62, NR3-37, NR3-38, NR4-64, NR4-75

### **PSYCHOPHARMACOLOGY**

NR1-26, NR1-60, NR1-61, NR2-12, NR2-63 to NR2-70, NR3-19, NR3-39 to NR3-44, NR3-46, NR3-48 to NR3-58, NR4-10, NR4-42, NR4-80, NR5-9, NR5-23, NR5-27, NR5-30, NR6-1 NR6-2, NR6-5, NR6-7, NR6-8, NR6-15, NR6-16, NR6-18 to NT6-21, NR6-28, NR6-29, NR6-34, NR6-3

### PSYCHOSOMATIC MEDICINE

NR1-2, NR1-22, NR2-15, NR2-71 to NR2-73, NR3-31, NR3-59, NR3-60, NR4-5

### RELIGION, SPIRITUALITY, & PSYCHIATRY

### RESEARCH ISSUES

NR3-15, NR3-61, NR4-15, NR4-39

### RESIDENT & MEDICAL STUDENT CONCERNS

NR2-74, NR5-36, NR5-59 to NR5-61

### SCHIZOPHRENIA & OTHER PSYCHOTIC DISORDERS

NR1-4, NR1-30, NR1-57 to NR1-69, NR1-73, NR2-35, NR2-66, NR2-69, NR3-39, NR3-44, NR3-51, NR3-54, NR3-56, NR3-73, NR6-1 to NR6-43

### SLEEP DISORDERS

NR1-70 to NR1-73, NR3-6, NR4-61, NR7-53, NR7-54

### SOCIAL & COMMUNITY PSYCHIATRY

NR1-9, NR3-24, NR3-35, NR3-62, NR3-63, NR5-51, NR7-41

### SOMATOFORM DISORDERS

NR4-88

### STIGMA/ADVOCACY

NR1-11, NR2-20

### STRESS

NR1-73, NR3-11, NR3-33 NR4-7, NR4-77, NR4-78, NR7-55

### TREATMENT TECHNIQUES & OUTCOME STUDIES

NR1-58, NR2-18, NR2-75 to NR2-77, NR3-25, NR3-37, NR3-65 to NR3-68, NR4-43, NR4-74, NR5-35, NR6-13, NR6-14, NR7-55

### VIOLENCE, TRAUMA & VICTIMIZATION

NR1-52, NR2-45, NR2-78, NR3-38, NR4-56, NR5-45, NR5-62

### Women's Health Issues

NR1-48, NR2-78, NR2-79, NR5-63, NR5-64



All Exhibits Open

Sunday 10:00 am - 4:00 pm Monday 10:00 am - 4:00 pm

Tuesday 10:00 am - 4:00 pm

**Exhibit Hall Reception** Monday 12:30 – 1:30 pm



NOTE: Final closing of exhibits is Tuesday at 4:00 pm



Transforming Mental Health Through Leadership, Discovery and Collaboration



# CALLFORABSTRACTS

Don't miss the opportunity to submit your proposed presentation for a: symposium, workshop, course, iss and/or other scientific sessions.

Visit our website on June 15th for further information regarding submissions. www.psych.org

For more information about the APA Annual Meeting visit our website at: www.psych.org



# Moving Forward Together

SZ Magazine is a trusted resource, providing the essential information on treatment options and lifestyle enhancements necessary to move forward together.

Visit Booth #1931 to receive your complimentary copy of *SZ Magazine* and learn about the special subscription offer available exclusively to APA members.

# www.szmagazine.com

Ask us how you can receive the new digital version of




or visit www.anchormag.com to learn more.

Member of:







Have you ever wondered about the decision-making process used to determine which studies are published by *The American Journal of Psychiatry*?

At APA's 2010 annual meeting in New Orleans, you'll get some insight into the answer in a symposium led by AJP Editor Robert Freedman, M.D. He will use the upcoming June issue to explain how submission decisions are made as he highlights important research reported in that issue to be released the following week. Authors of papers that will be appearing in the June issue will also be on hand to present overviews of their findings.

Be a part of this exciting event in New Orleans!

Symposium 47: New Studies to Appear in the June Issue of *The American Journal of Psychiatry*: Presentations by the Authors and Editors
Chair: Robert Freedman, M.D.
Monday, May 24: 2:00 p.m.-5:00 p.m.
Rooms 225/226, Second Level, Morial Convention Center

AMONG THE PRESENTERS

**David Spiegel**, discussing evidence for a dissociative subtype of PTSD

Mary Zanarini, discussing recovery from borderline personality disorder and its stability

Alexandre Dombrovski, discussing reward/punishment reversal learning in older suicide attempters

**David Gardner**, discussing an international consensus study of antipsychotic dosing

Other articles of note in the June issue:

A Double-Blind, Placebo-Controlled Trial That Combines Sertraline and Naltrexone for Treating Co-Occurring Depression and Alcohol Dependence

Life-Threatening Danger Suppresses Attention Bias to Threat

# The NEW www.appi.org just debuted!

# The new www.appi.org offers:

- Special Discounts for American Psychiatric Association Members and Members-in-Training
- Detailed descriptions on more than 700 titles + subscription products
- My Account history with order and tracking information.
- Fast and easy navigation
- Enhanced search engine



### **APPI Bookstore Hours**

Saturday, May 22 to Tuesday, May 25 10:00 am – 4:00 pm

Extra Special Discount for Members at the APPI Bookstore!

15% Discount for APA Members

30% Discount for APA Members-in-Training



The First and Last Word in Psychiatry
American Psychiatric Publishing, Inc.
1-800-368-5777 or 703-907-7322
appi@psych.org


# American Psychiatric Association

# xhibits Guide

# CONTENTS

GENERAL INFORMATION
PRODUCT THEATERS177
Alphabetical List of Exhibitors183
EXHIBITORS WITH PRODUCT/ SERVICE DESCRIPTIONS
EXHIBITORS BY PRODUCT/SERVICE LISTING210
CAREER FAIR EXHIBITORS AND PUBLISHING BOOK FAIR EXHIBITORS214
Numerical List of Exhibitors by Booth Number218
EXHIBIT HALL FLOOR PLAN219







The APA Exhibits Program is an integral component of the overall Annual Meeting and provides an excellent opportunity for meeting registrants to obtain the latest information on products and services related to the psychiatric profession.

Please allow adequate time in your daily schedule to visit the exhibits, which are located in Exhibit Halls B-D, First Level of the Morial Convention Center. At the exhibits you participate in interactive computer programs and speak with the representatives of companies who provide services and products related directly to psychiatrists' professional and personal interests.

To assist in locating a particular company or product, a floor plan of the Exhibit Hall is included in the exhibits section of The Guide, along with a list of: 1) exhibitors with product/service description; 2) exhibitors by product/service listing; and 3) exhibitors listed alphabetically with booth numbers.

### HOSPITALITY LOUNGES

Two hospitality lounges, serving complimentary coffee are located throughout the Exhibit Hall. Please utilize these areas to relax and refresh during your time in the Hall.

### PUBLISHERS BOOK FAIR

Major publishers and book sellers, including the American Psychiatric Publishing, Inc., are located in this designated area. Participating companies are selling and taking orders for new and current professional books in the field of psychiatry.

### CAREER FAIR

Exhibitors in this area include: government agencies, hospitals, locum tenens, psychiatric



### **NEW THIS YEAR!**

Exhibit Hall Reception Open to All Registrants

### MONDAY, MAY 24, 2010 12:30-1:30 PM

Join us for fun and food. Meet colleagues and visit the exhibits.

facilities, and recruiters seeking psychiatrists to fill open positions. The American Psychiatric Association Job Bank, located in the Member Center. has the most comprehensive online listing of psychiatric positions for candidates to search for new employment opportunities.

### ENDORSEMENTS

Products and services displayed in the Exhibit Hall occur by the contractual arrangement between the American Psychiatric Association and participating companies. This arrangement does not constitute or imply an endorsement by the American Psychiatric Association of these products or services.

### EXHIBIT DATES AND HOURS

PUBLISHER'S BOOK FAIR (ONLY):

SATURDAY, MAY 22 10:00 A.M. - 4:00 P.M.

### ALL EXHIBITS:

### SUNDAY, MAY 23

10:00 A.M. - 4:00 P.M.

### MONDAY, MAY 24

10:00 A.M. - 4:00 P.M.

### TUESDAY, MAY 25

10:00 A.M. - 4:00 P.M.

### WEDNESDAY, MAY 26 10:00 A.M. - 4:00 P.M.





# Practice Management for Early Career Psychiatrists: A Reference Guide

Created by the American Psychiatric Association's Office of Healthcare Systems and Financing, this handbook provides APA members with an overview of many of the things they need to be aware of as a psychiatrist. Although specifically designed to meet the needs of **Residents** and **Early Career Psychiatrists** (ECPs), the information it contains may also be of value to those who have been in practice for years. Contents include:



# II. ESTABLISHING YOUR PRACTICE

5. Incorporation Options

Practice Options

I. STARTING OUT

6. Buying or Leasing Office Space and Equipment

Conducting an Effective Job or Practice Search

Negotiating an Employment Contract

Licensing and Board Certification

- 7. Medical Professional Liability Insurance
- 8. Hiring and Managing Administrative Staff
- 9. Selecting Computer Applications and Software
- 10. Marketing Your Practice Effectively
- 11. Putting Your Practice on a Budget



- 12. Managing Relationships with Other Clinicians
- 13. Managing Appointment Scheduling
- 14. Insurance Terminology
- 15. Verifying Benefit Coverage Accurately and Efficiently
- 16. Coordinating Benefits for Patients with More than One Source of Insurance Coverage
- 17. Implementing Electronic Billing Capabilities
- 18. Increasing the Success Rate of Collections Efforts
- 19. Avoiding Common Procedure Coding Problems

### IV. PATIENT CARE ISSUES

- 20. Confidentiality
- 21. Duty to Warn
- 22. Informed Consent
- 23. Civil Commitment
- 24. Medical Records
- 25. Conducting a Patient Satisfaction Survey

### V. MANAGED CARE ISSUES

- 26. Defining Managed Care
- 27. Getting on Managed Care Panels
- 28. Reviewing and Negotiating Contracts
- 29. Appealing Reimbursement Denials
- 30. Getting Paid
- 31. Maintaining Confidentiality in the Era of Managed Care
- 32. Handling Medical Record Reviews
- 33. Avoiding Deselection
- 34. Managed Care Resources

### VI. PROFESSIONAL ISSUES

- 35. Principles of Medical Ethics
- 36. Opinions of the Ethics Committee
- 37. Managing Relationships with Patients
- 38. Reducing Malpractice Risk
- 39. Practice Guidelines

### VII. LEGAL ISSUES

- 40. Medicare and Medicaid
- 40a. How to Appeal Decisions by Medicare Carriers
- 40b. Compliance Programs
- 41. Fraud and Abuse
- 41a. HIPAA
- 42. ERISA
- 43. An Overview of Antitrust Laws Affecting Physicians
- 44. The National Practitioner Data Bank



Access this valuable member benefit at www.psych.org

in the "Members Corner"





## **LEARN MORE ABOUT CHANTIX®** (varenicline) AT BOOTH 1816

CHANTIX is indicated as an aid to smoking cessation treatment in adults 18 and over. Patients may benefit from behavioral modification and support during their guit attempt. Patients should be encouraged to continue to attempt to guit if they have early lapses after guit day.

#### **IMPORTANT SAFETY INFORMATION**

All patients being treated with CHANTIX should be observed for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide. These symptoms, as well as worsening of pre-existing psychiatric illness and completed suicide have been reported in some patients attempting to quit smoking while taking CHANTIX in the post-marketing experience.

These events have occurred in patients with and without pre-existing psychiatric disease. Patients with serious psychiatric illness such as schizophrenia, bipolar disorder, and major depressive disorder did not participate in the pre-marketing studies of CHANTIX and the safety and efficacy of CHANTIX in such patients has not been established.

Advise patients and caregivers that the patient should stop taking CHANTIX and contact a healthcare provider immediately if agitation, hostility, depressed mood, or changes in behavior or thinking that are not typical for the patient are observed, or if the patient develops suicidal ideation or suicidal behavior. In many post-marketing cases, resolution of symptoms after discontinuation of CHANTIX was reported, although in some cases the symptoms persisted; therefore, ongoing monitoring and supportive care should be provided until symptoms resolve.

CHANTIX is contraindicated in patients with a history of serious hypersensitivity or skin reactions to CHANTIX.

Patients should be informed that there have been reports of serious skin reactions, such as Stevens Johnson Syndrome and Erythema Multiforme and of angioedema, with swelling of the face, mouth and neck that can lead to life-threatening respiratory compromise. Patients should be instructed to discontinue CHANTIX and immediately seek medical care if they experience these symptoms or at the first sign of rash with mucosal lesions or any other signs of hypersensitivity.

The most common adverse reactions include nausea (30%), sleep disturbance, constipation, flatulence, and vomiting. Patients should be informed that they may experience vivid, unusual, or strange dreams during treatment with CHANTIX. Patients should be advised to use caution driving or operating machinery or engaging in other potentially hazardous activities until they know how CHANTIX may affect them.

Safety and efficacy of CHANTIX in combination with other smoking cessation drug therapies have not been studied. Dosage adjustment with CHANTIX is recommended in patients with severe renal impairment or in patients undergoing hemodialysis.

Smoking cessation, with or without treatment with CHANTIX, may alter the pharmacokinetics or pharmacodynamics of some drugs, such as theophylline, warfarin, and insulin. Dosage adjustment for these drugs may be necessary.

## www.pfizerpro.com/chantix

Please see accompanying brief summary of Prescribing Information.



#### Brief summary of full Prescribing Information.

#### **CHANTIX®** (varenicline) Tablets

#### WARNING.

WARNING:
Serious neuropsychiatric events, including, but not limited to depression, suicidal ideation, suicide attempt and completed suicide have been reported in patients taking CHANTIX. Some reported cases may have been complicated by the symptoms of nicotine withdrawal in patients who stopped smoking. Depressed mood may be a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation, has been reported in smokers undergoing a smoking cessation attempt without medication. However, some of these symptoms have occurred in patients taking CHANTIX who continued to smoke.

All patients being treated with CHANTIX should be observed for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide. These symptoms, as well as worsening of pre-existing psychiatric illness and completed suicide have been reported in some patients attempting to quit manking which sking CHANTIX in the post-marketing experience. When symptoms were reported, most were during CHANTIX treatment, but some were following discontinuation of CHANTIX therapy.

These events have occurred in patients with and without pre-existing psychiatric disease. Patients with serious psychiatric illness such as schizophrenia, bipolar disorder, and major depressive disorder did not participate in the pre-marketing studies of CHANTIX and the safety and efficacy of CHANTIX in such patients has not been established.

Advise patients and caregivers that the patient should stop taking CHANTIX and contact a healthcare provider immediately if agitation, hostility, depressed mood, or changes in behavior or thinking that are not typical for the patient are observed, or if the patient develops suicidal ideation or suicidal behavior. In many post-marketing cases, resolution of symptoms after discontinuation of CHANTIX was reported, although in some cases the symptoms persisted; therefore, ongoing monitoring and supportive care should be provided until symptoms resolve.

The risks of CHANTIX should be weighed against the benefits of its use. CHANTIX has been demonstrated to increase the likelihood of abstinence from smoking for as long as one year compared to treatment with placebo. The health benefits of quitting smoking are immediate and substantial.

(See WARNINGS/Neuropsychiatric Symptoms and Suicidality, PRECAUTIONS/Information for Patients, and ADVERSE REACTIONS/Post-Marketing Experience)

#### INDICATIONS AND USAGE

CHANTIX is indicated as an aid to smoking cessation treatment

#### Neuropsychiatric Symptoms and Suicidality

Serious neuropsychiatric symptoms have been reported in patients being treated with CHANTIX (See **Boxed Warning, PRECAUTIONS/**Information for patients, and **ADVERSE REACTIONS/Post-Marketing Experience**). These post-marketing reports have included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, bronicidal ideation, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Some reported cases may have been complicated by the symptoms of nicotine withdrawal in patients who stopped smoking. Depressed mood may be a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation, has been reported in smokers undergoing a smoking cessation attendituthout medication. However, some of these symptoms have occurred in patients taking GHANTIX who continued to smoke. When symptoms were reported, most were during CHANTIX treatment, but some were following discontinuation of CHANTIX therapy.

These events have occurred in patients with and without pre-existing psychiatric disease; some patients have experienced worsening of their psychiatric illnesses. All patients being treated with CHANTIX should be observed for neuropsychiatric symptoms or worsening of pre-existing psychiatric illness. Patients with serious psychiatric illness such as schizophrenia, bipolar disorder, and major depressive disorder did not participate in the pre-marketing studies of CHANTIX and the safety and efficacy of CHANTIX in such patients has not been established.

Advise patients and caregivers that the patient should stop taking CHANTIX and contact a health care provider immediately if agitation, depressed mood, changes in behavior or thinking that are not typical for the patient are observed, or if the patient develops suicidal ideation or suicidal behavior. In many post-marketing cases, resolution of symptoms after discontinuation of CHANTIX was reported, although in some cases the symptoms persisted, therefore, ongoing monitoring and supportive care should be provided until symptoms resolve.

The risks of CHANTIX should be weighed against the benefits of its use. CHANTIX has been demonstrated to increase the likelihood of abstinence from smoking for as long as one year compared to treatment with placebo. The health benefits of quitting smoking are immediate and substantial.

#### Angioedema and Hypersensitivity Reactions.

There have been post-marketing reports of hypersensitivity reactions including angioedema in patients treated with CHANTIX (See ADVERSE REACTIONS/Post-Marketing Experience). Clinical signs included swelling of the face, mouth (tongue, lips, and gums), extremities, and neck (throat and larynx). There were infrequent reports of life-threatening angioedema requiring emergent medical attention due to respiratory compromise. Patients should be instructed to discontinue CHANTIX and immediately seek medical care if they experience these symptoms.

#### **Serious Skin Reactions**

There have been post-marketing reports of rare but serious skin reactions, including Stevens-Johnson Syndrome and Erythema Multiforme in patients using CHANTIX (See ADVERSE REACTIONS/Post-Marketing Experience) As these skin reactions can be life-threatening, patients should be instructed to stop taking CHANTIX and contact their healthcare provider immediately at the first appearance of a skin rash with mucosal lesions or any other signs of hypersensitivity.

#### PRECAUTIONS

General Nausea was the most common adverse event associated with CHANTIX treatment. Nausea was generally described as mild or moderate and often transient; however, for some subjects, it was persistent over several months. The incidence of nausea was dose-dependent. Initial dose-titration was beneficial in reducing the occurrence of nausea. Nausea was reported by approximately 30% of patients treated with CHANTX1 T in gBI Oaft era nitrital week of dose titration. In patients taking CHANTX in gBI Dit, the incidence of nausea was 16% following initial titration. Approximately 3% of subjects treated with CHANTIX 1 mg BID in studies involving 12 weeks of treatment discontinued treatment prematurely because of nausea. For patients with intolerable nausea, dose reduction should be considered.

Accidental Injury There have been post-marketing reports of traffic accidents, near-miss incidents in traffic, or other accidental injuries in patients taking CHANTIX. In some cases, the patients reported somnolence, dizziness, loss of consciousness or difficulty concentrating that resulted in impairment, or concern about potential impairment, in driving or operating machinery behavior advised to use caution driving or operating machinery or engaging in other potentially hazardous activities until they know to CHANTIX.

Effect of smoking cessation: Physiological changes resulting from smoking cessation, with or without treatment with CHANTIX, may alter the pharmacokinetics or pharmacodynamics of some drugs, for which dosage adjustment may be necessary (examples include ophylline, warfarin and insulin).

Drug Interactions Based on varenicline characteristics and clinical experience to date, CHANTIX has no clinically meaningful pharmacokinetic drug interactions (See Full Prescribing Information, CLINICAL PHARMACOLOGY, Drug-Drug Interactions).

Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis. Lifetime carcinogenicity studies were performed in CD-1 mice and Sprague-Dawley rats. There was no evidence of a carcinogenic effect in mice administered varenicline by oral gavage for 2 years at Oses up to 20 mg/kg/day (47 times the maximum recommended human daily exposure based on AUC). Rats were administered varenicline (1, 5, and 15 mg/kg/day) by oral gavage for 2 years. In male rats (1 = 65 per sex per dose group), incidences of hiberonna (tumor of the brown fat) were increased at the mid dose (1 tumor, 5 mg/kg/day, 23 times the maximum recommended human daily exposure based on AUC). The clinical relevance of this finding to humans has not been established. There was no evidence of carcinogenicity in female rats.

Mutagenesis. Varenicline was not genotoxic, with or without metabolic activation, in the following assays: Ames bacterial mutation assay;

mutagetiess. Varience was not getioud, will or window interaction; and in the following assays. Aries bacterian influence assay, and tests for cytogenetic aberations in vivo in ration white in human hyphocytes. Impairment of fertility. There was no evidence of impairment of fertility in either male or female Sprague-Dawley rats administered varencinies succinate up to 15 mg/kg/day (67 and 36 times, respectively, the maximum recommended human daily exposure based on AUC at 1 mg BID). However, a decrease in fertility was noted in the offspring of pregnant rats who were administered varenclines occinate at an oral dose of 15 mg/kg/day (86 times the maximum recommended human daily exposure based on AUC at 1 mg BID). This decrease in fertility in the offspring of treated female rats was not evident at an oral dose of 3 mg/kg/day (9 times the maximum recommended human daily exposure based on AUC at 1 mg BID). This decrease in fertility in the offspring of treated female rats was not evident at an oral dose of 3 mg/kg/day (9 times the maximum recommended human daily exposure based on AUC at 1 mg BID). This decrease in fertility in the offspring of treated female rats was not evident at an oral dose of 3 mg/kg/day (9 times the maximum recommended human daily exposure based on AUC at 1 mg BID). This decrease in fertility in the offspring of treated female rats was not evident at an oral dose of 3 mg/kg/day (9 times the maximum recommended human daily exposure based on AUC at 1 mg BID). daily exposure based on AUC at 1 mg BID).

daily exposure based on AUC at 1 mg BID).

Pregnancy Pregnancy Category C. Varenicinie succinate was not teratogenic in rats and rabbits at oral doses up to 15 and 30 mg/kg/day, respectively; 636 and 50-times the maximum recommended human daily exposure based on AUC at 1 mg BID, respectively. Nontreatogenic effects Varenicine succinate has been shown to have an adverse effect on the fetus in animal reproducing studies. Administration of varenicine succinate to pregnant rabbits resulted in reduced fetal weights at an oral dose of 30 mg/kg/day (50 times the human AUC at 1 mg BID); this reduction was not evident following treatment with 10 mg/kg/day (23 times the maximum recommended daily human exposure based on AUC, in addition, in the offspring of pregnant rats treated with varenicline succinate there were decreases in leftrillity and increases in auditory startle response at an oral dose of 15 mg/kg/day (36 times the maximum recommended human daily exposure based on AUC at 1 mg BID). There are no adequate and well-controlled studies in pregnant women. CHANTIX solutes be used during pregnancy only if the potential bareflit justifies the potential risk to the fetus. Nursing mothers Although it is not known whether this drug is excreted in human milk, animal studies have demonstrated that varenicine can be transferred to nursing purport of the ANTIX, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Labor and delivery The potential effects of CHANTIX on labor and delivery are not known. Pediatric Use

effectiveness of CHANTIX in pediatric patients have not been established; therefore, CHANTIX is not recommended for use in patients under 18 years of age. Geriatric Use: A combined single and multiple-dose pharmacokinetic study demonstrated that the pharmacokinetics of 1 mg varenicline given ID or BID to 16 healthy elderly male and female smokers (aged 65-75 yrs) for 7 consecutive days was similar that of younger subjects. No overall differences in sately or effectiveness were observed between these subjects and other reported clinical experience has not identified differences in responses between the elderly and younger subjects, and other reported clinical experience has not identified differences in estomator be substantially excreted by the kidned after responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be nuled out. Varenicline is known to be substantially excreted by the kidned the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in does selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION, Special Populations, Patients with impaired renal function). No dosage adjustment is recommended for elderly patients (see DOSAGE AND ADMINISTRATION, Special Populations).

#### Information for Patients:

- Patients should be instructed to set a date to quit smoking and to initiate CHANTIX treatment one week before the quit date.

  Patients should be advised that CHANTIX should be taken after eating, and with a full glass of water.

  Patients should be instructed how to titrate CHANTIX, beginning at a dose of 0.5 mg/day, Prescribers should explain that one 0.5 mg tablet should be taken aligh for the first three days, and that for the next four days, one 0.5 mg tablet should be taken in the morning and one 0.5 mg tablet should be taken in the evening.

  Patients should be advised that, after the first seven days, the dose should be increased to one 1 mg tablet in the morning and one 1 mg tablet in the morning and one
- 1 mg tablet in the evening.

  Patients should be encouraged to continue to attempt to quit if they have early lapses after quit day.
- Patients should also be provided with educational materials and necessary counseling to support an attempt at quitting smoking.
   Patients should be informed that nausea and insomnia are side effects of CHANTIX and are usually transient, however, patients should be advised that if they are persistently troubled by these symptoms, they should notify the prescribing physician so that a dose reduction can be considered
- Pedients should be informed that they may experience vivid, unusual or strange dreams during treatment with CHANTIX.

  Patients should be informed that quitting smoking, with or without CHANTIX, may be associated with nicotine withdrawal symptoms (including depression or agitation) or exacerbation of pre-existing psychiatric illness. Furthermore, some patients have experienced changes in mood (including depression and mania), psychosis, hallucinations, paramoia, delusions, homicidal ideation, aggression, anxiety, and panic, as well as suicidal ideation and suicide when attempting to quit smoking while taking CHANTIX. If patients develop agitation, hostility, depressed mood, or changes in behavior or thinking that are not typical for them, or if patients develop suicidal ideation or behavior, they should be urged to discontinue CHANTIX and report these symptoms to their healthcare provider immediately.

- Patients should be encouraged to reveal any history of psychiatric lillness prior to initiating treatment.
   Patients should be informed that some medications may require dose adjustment after quitting smoking.
   Patients intending to become pregnant or planning to breast-feed an infant should be advised of the risks of smoking and risks and benefits of smoking cessation with CHAVITIX.
- Patients should be advised to use caution driving or operating machinery until they know how quitting smoking with varenicline may
- aftect them.

  Patients should be informed that there have been reports of angioedema, with swelling of the face, mouth (lip, gurn, tongue) and neck (larynx and pharynx) that can lead to life-threatening respiratory compromise. Patients should be instructed to discontinue CHANTIX and immediately seek medical care if they experience these symptoms.

  Patients should be informed that serious skin reactions, such as Stevens Johnson Syndrome and Erythema Multiforme, were reported by some patients taking CHANTIX. They should be advised to stop taking CHANTIX at the first sign of rash with mucosal lesions or skin
- reaction and contact a health care provider immediately.

#### ADVERSE REACTIONS

During the premarketing development of CHANTIX, over 4500 individuals were exposed to CHANTIX, with over 450 treated for at least 24 weeks and approximately 100 for a year. Most study participants were treated for 12 weeks or less. In Phase 2 and 3 placebo-controlled studies, the treatment discontinuation rate due to adverse events in patients dosed with 1 mg BID was 12% for CHANTIX compared to 10% for placebo in studies of three months' treatment. In this group, the discontinuation rates for the most common adverse events in CHANTIX treated patients were as follows: nausea (3% vs. 0.5% for placebo), headache (0.6% vs. 0.9% for placebo), in adhornomal florams (0.3% vs. 0.2% for placebo). Adverse Events were categorized using the Medical Dictionary for Regulatory Activities (MedDRA, Version 7.1).

The most common adverse events associated with CHANTIX (>5% and twice the rate seen in placebo-treated patients) were nausea, sleep disturbance, constipation, flatulence, and vomiting. Smoking cessation, with or without treatment, is associated with nicotine withdrawal symptoms.

The most common adverse event associated with CHANTIX treatment is nausea. For patients treated to the maximum recommended dose of 1 mg BID following initial dosage titration, the incidence of nausea was 30% compared with 10% in patients taking a comparable placebo regimen. In patients taking CHANTIX 0.5 mg BID following initial titration, the incidence was 16% compared with 11% for placebo. Nausea was generally described as mild or moderate and often transient; however, for some subjects, it was persistent throughout the treatment period.

persistent unoughout on the treatment period.

Table 3 shows the adverse events for CHANTIX and placebo in the 12 week fixed dose studies with titration in the first week (Studies 2 (titrated arm only), 4, and 5). MedDRA High Level Group Terms (HLGT) reported in ≥ 5% of patients in the CHANTIX 1 mg BID dose group, and more commonly than in the placebo group, are listed, along with subordinate Preferred Terms (PT) reported in ≥ 1% CHANTIX patients (and at least. 0.5% more frequent than placebo). Closely related Preferred Terms such as 'Insomnia', 'Initial insomnia', 'Early morning awakening' were grouped, but individual patients reporting two or more grouped events are only counted once.

Table 3: Common Treatment Emergent AEs (%) in the Fixed-Dose, Placebo-Controlled Studies ( $\geq$  1% in the 1 mg BID CHANTIX Group, and 1 mg BID CHANTIX at least 0.5% more than Placebo)

SYSTEM ORGAN CLASS	CHANTIX	CHANTIX	Placebo
High Level Group Term Preferred Term	0.5 mg BID N=129	1mg BID N=821	N=805
GASTROINTESTINAL			
GI Signs and Symptoms Nausea Abdominal Pain* Flatulence Dyspeosia	16 5 9 5	30 7 6 5	10 5 3 3
Vomiting Gl Motility/Defecation Conditions	1	5	2
Constipation Gastroesophageal reflux disease Salivary Gland Conditions	5 1	8 1	3 0
Dry mouth	4	6	4
PSYCHIATRIC DISORDERS			
Sleep Disorders/Disturbances Insomnia** Abnormal dreams Sleep disorder Nightmare	19 9 2 2	18 13 5 1	13 5 3 0
NERVOUS SYSTEM			
Headaches Headache Neurological Disorders NEC	19	15	13
Dysgeusia Somnolence Letharqy	8 3 2	5 3 1	4 2 0
GENERAL DISORDERS			
General Disorders NEC Fatigue/Malaise/Asthenia	4	7	6
RESPIR/THORACIC/MEDIAST			
Respiratory Disorders NEC Rhinorrhea Dyspnoea Upper Respiratory Tract Disorder	0 2 7	1 1 5	0 1 4
SKIN/SUBCUTANEOUS TISSUE			
Epidermal and Dermal Conditions Rash Pruritis	1 0	3 1	2 1
METABOLISM & NUTRITION Appetite/General Nutrit. Disorders Increased appetite	4	3	2
Decreased appetite/Anorexia	i	2	1

<sup>\*</sup> Includes PTs Abdominal (pain, pain upper, pain lower, discomfort, tenderness, distension) and Stomach discomfort
\*\* Includes PTs Insomnia/Initial insomnia/Middle insomnia/Early morning awakening

The overall pattern, and the frequency of adverse events during the longer-term trials was very similar to that described in Table 3.

though several of the most common events were reported by a greater proportion of patients. Nausea, for instance, was reported in

BOUGH Several or united common revents were reported by a greater proportion or purposition reports. Readed, or market was 40% of placebot treated with CHANTIX 1 mg BID in a one-year study, compared to 8% of placebot created patients.

Following is a list of treatment-emergent adverse events reported by patients treated with CHANTIX during all clinical trials. The listing Following is a list of treatment-emergent anverse events reported by patients treated with clark in Cardinal clinical trials. The listing does not include those events already listed in the previous bables or elsewhere in labelling, those events for which a guase was remote, those events which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life-threatening. BLOOD AND LYMPHATIC SYSTEM DISRIDERS. Infrequent Anemia, Lymphadenopathy. Rare. Leukocytosis, Thrombocytopenia, Spienomegaly. CARDIAC DISORDERS. Infrequent Angina pectoris, Arrhythmia, Bradycardia, Ventricular extrasystoles, Myocardial infarction, Palpitations, Tachycardia. Rare. Atrial fibrillation, Cardinal Culture, Connary artery disease, Cor pulmonale, Acute coronary syndrome. EAR AND LASYRINTH DISORDERS. Infrequent Timilius, Vertigo, Rare. Deafness. Menier's disease. ENDOCRINE DISORDERS. Infrequent. Thyroid gland disorders. EYE DISORDERS. Intrequent: Conjunctivitis, Dry eye, Eye irritation, Vision blurred, Visual disturbance, Eye pain. Rare. Acquired night blindness, Blindness transient, Cataract subcapsular, Ocular vascular disorder, Photophobia, Vitreous floaters, GASTROINTESTINAL DISORDERS. Frequent Diarneb, Gingvilis. Intrequent: Dysphagia, Enterocolitis, Eurotation, Castribi, Gastrointestinal, Hemorrhage, Mouth ulceration, Esophagitis. Rare. Gastric ulcer, Intestinal obstruction, Pancreatitis acute. GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS. Frequent: Chest pain, Influenza like illness, Edema, Thirst. Infrequent: Chest discomfort. Chills, Pyrexia HEPATOBILLARY DISORDERS. Infrequent: Gall bladder disorder. IMMUNE SYSTEM DISORDERS. Infrequent: Hypersensitivity. Rare Drug hypersensitivity, INVESTIGATIONS. Frequent: Liver function test ahormati. Weight increased. Infrequent: Electocardiogram abnormat, Muscle enzyme increased, Urine analysis abnormat. METABOLISM AND NUTRITION DISORDERS. Infrequent: Diabetes abnormal, Muscle enzyme increased, Unne analysis abnormal, METABOLISM AND NUTRITION DISORDERS. Intrequent: Dislockerine interiplicational, Hydyockemia. Rare: Hyperaklemia, Hypoglycemia. MISCULLOSKELETAL AND COMMICTIVE TISSUE DISORDERS. Frequent. Arthritis, Osteoporosis. Rare: Myositis. NERVOUS SYSTEM DISORDERS. Frequent Disturbance in attention, Dizziness, Sensory disturbance. Intrequent: Arthritis, Osteoporosis. Rare: Myositis. NERVOUS SYSTEM DISORDERS. Frequent Disturbance in attention, Dizziness, Sensory disturbance. Intrequent: Armenia, Migraine, Parosmia, Psychomotro typeractivity, Restless legs syndrome, Syncope. Temor. Rare: Balance disorder, Beatines disorder, Carvalsent Cardischer, Carvalsent, Ca Nare staphynerial, Euponor mood, Nocturia, Unia abnormality, Ureal deaunon, Neinal, And Uninanty Dissurdian, requested Polyuria. Infrequent Nephriolithiasis, Nocturia, Unia abnormality, Ureal syndrome. Rare Renal failant acute, Urinary retention. Reproductive System And Breast Dissorbers. Frequent Menstrual disorder. Infrequent Erectile dysfunction. Rares exual dysfunction. Respiratory Reproductive New Polymora (Can Dissorbers). Frequent Enjatasis, Respiratory disorders. Infrequent: Asthma. Rare. Pleurisy, Pulmonary embolism. SKIN AND SUBCUTANEOUS TISSUE DISORDERS. Frequent Hyperhidrosis. Infrequent Acon. Dermatitis, Dry Skin, Ezerma. Erythema, Psoriasis, Uriclara. Rares Photosensitivity reaction. Vascular Disorders. Frequent Hyperterioris. Infrequent Acon. Prophers of Proph

#### Post-Marketing Experience:

The following adverse events have been reported during post-approval use of CHANTIX. Because these events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. There have been reports of depression, mania, psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide in patients attempting to quit smoking while taking CHAINTK (See Boxed Warning, WARNINGS/Neuropsychiatric Symptoms and Suicidality, PRECAUTIONS/TORMION Teatment is associated with nicotine withdrawal symptoms and the exacerbation of underlying psychiatric illness. Not all patients had known pre-existing psychiatric illness and not all had discontinued smoking.

 $There \ have \ been \ reports \ of \ hypersensitivity \ reactions, including \ angioedema \ (See \ \textbf{WARNINGS} \ and \ \textbf{PRECAUTIONS}).$ 

There have also been reports of serious skin reactions, including Stevens Johnson Syndrome and Erythema Multiforme in patients taking CHANTIX (See WARNINGS and PRECAUTIONS).

#### DRUG ABUSE AND DEPENDENCE

Controlled Substance Class Varenicline is not a controlled substance. <u>Humans</u>: Fewer than 1 out of 1000 patients reported euphoria in clinical trials with CHANTIX. At higher doses (greater than 2 mg), CHANTIX produced more frequent reports of gastrointestinal disturbances such as nausea and vomiting. There is no evidence of dose-escalation to maintain therapeutic effects in clinical studies which suggests that tolerance does not develop. Aburpt discontinuation of CHANTIX was associated with an increase in irritability and sleep disturbances in up to 3% of patients. This suggests that, in some patients, varenicline may produce mild physical dependence which is not associated with addiction. In a human laboratory abuse liability study, a single oral dose of 1 mg varenicing and increase in some positive subjective or negative subjective responses in smokers. In non-smokers, 1 mg varenicine produced an increase in some positive subjective effects, but this was accompanied by an increase in negative adverse effects, especially nausea. A single oral dose of 3 mg varenicline uniformly produced unpleasant subjective responses in both smokers and non-smokers. Animals: Studies in rodents have shown that varenicline produces behavioral responses similar to those produced by nicotine. In rats trained to discriminate nicotine from saline, varenicline produced full generalization to the nicotine cue. In self-administration studies, the degree to which varenicline substitutes for nicotine is dependent upon the requirement of the task. Rats trained to self-administer nicotine under easy conditions continued to self-administer varenicline to a degree comparable to that of nicotine, however in a more demanding task, rats self-administered varenicline to a lesser extent than nicotine. Varenicline pretreatment also reduced nicotine selfadministration.

#### OVERDOSAGE

In case of overdose, standard supportive measures should be instituted as required. Varenicline has been shown to be dialyzed in patients with end stage renal disease (see CLINICAL PHARMACOLOGY, Pharmacokinetics, Pharmacokinetics in Special Patient Populations), however, there is no experience in dialysis following overdose.

#### DOSAGE AND ADMINISTRATION

Usual Dosage for Adults Smiking essation therapies are more likely to succeed for patients who are motivated to stop smoking and who are provided additional advice and support. Patients should be provided with appropriate educational materials and counseling to support the quit attempt. The patient should set a date to stop smoking. CHANTIX dosing should start one week before this date. CHANTIX should be taken after eating and with a full glass of water. The recommended dose of CHANTIX is 1 mg twice daily following

Days 1-3:	0.5 mg once daily
Days 4-7:	0.5 mg twice daily
Days 8-End of treatment:	1 mg twice daily

Patients who cannot tolerate adverse effects of CHANTIX may have the dose lowered temporarily or permanently. Patients should be treated with CHANTIX for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with CHANTIX is recommended to further increase the likelihood long-term abstinence. Patients who do not succeed in stopping smoking during 12 weeks of initial therapy, or who relapse after treatment, should be encouraged to make another attempt once factors contributing to the failed attempt have been identified and addressed.

Patients with impaired renal function. No dosage adjustment is necessary for patients with mild to moderate renal impairment. For patients with severe renal impairment, the recommended starting dose of CHANTIX is 0.5 mg once daily. Patients may then titrate as needed to a maximum dose of 0.5 mg twice a day. For patients with end-stage renal disease undergoing hemodialysis, a maximum dose of 0.5 mg once daily may be administred if tolerated well (See CLINICAL PHARMACOLOGY, Pharmacokinetics, Pharmacokinetics in Special Populations, Renal impairment).

Dosing in elderly patients and patients with impaired hepatic function No dosage adjustment is necessary for patients with hepatic impairment. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (See PRECAUTIONS, Geriatric Use).

Use in children Safety and effectiveness of CHANTIX in pediatric patients have not been established; therefore, CHANTIX is not recommended for use in patients under 18 years of age.

Please see CHANTIX full Prescribing Information and patient Medication Guide at www.pfizerpro.com/chantix.

July 2009, Version 4.0



TOTAL RECOVERED FIBER

VCP01284

© 2010 Pfizer Inc.

All rights reserved.

Printed in USA/April 2010



# International psychiatrists –

## Join APA at the Annual Meeting and receive immediate member savings!

Are you planning to visit the American Psychiatric Publishing, Inc. (APPI) bookstore while in New Orleans to purchase your psychiatry, mental health and behavioral science books and journals? Join the APA before you buy to take advantage of member savings immediately. APA Members receive a special 15% discount for purchases made at the APPI Bookstore at the 2010 Annual Meeting. APA Members receive a 10% discount throughout the year.

## How do I join?

Complete an International membership application onsite (available at one of the membership desks in the Member Center or in the main registration hall) and submit it along with a copy of your medical license, psychiatry residency training certificate and your membership dues to the membership desk located in the main registration hall, next to the APA Store. APA staff will process your membership and issue your APA membership card. Show your card when making APPI purchases to receive your member discount!

## How much are International membership dues?


APA's International membership dues are based on your country of residence income group category defined by the World Bank. There are four categories:

Income Category	Group Category	APA Dues
High Income	HI	\$205 USD
Upper Middle Income	UMI	\$175 USD
Lower Middle Income	LMI	\$125 USD
Low Income	LI	\$50 USD

Defined by the World Bank As of July 2009







is unrivaled in the industry. Whether you are just completing your residency or currently have a successful practice, Psychiatric Solutions, Inc. welcomes the opportunity to explore ways to bring your expertise and leadership to one of our facilities.

Come visit us at **BOOTH #1832** to explore the possibilities we can offer.



WWW.PSYSOLUTIONS.COM

Product Theaters will again be held this year during the Annual Meeting. These infomercials are being held as an extension of the exhibit hall. Seating is limited to 200, and is on a first-come basis. They feature promotional programs supported by our exhibitors. CME credit is not provided for these sessions. The 30-minute sessions will be held in Room 231, Level Two of the Morial Convention Center. Sessions will be on Sunday, Monday, and Tuesday with three sessions each day at 8:30 a.m., 9:30 a.m., and 4:00 p.m. Light refreshments will be available. Topics may include treatment management, disease updates, and issues of interest to the supporting company. Supporters of the sessions include Alkermes, Boehringer Ingelheim, Janssen, Merck, Shire US, and Wyeth Legacy. Look for signs announcing the presenters and topics in the Convention Center, exhibit hall, and outside Room 231 and plan to attend.

#### SUNDAY, MAY 23 SESSIONS

#### 8:30 A.M.

Supported by Shire US Inc.

Managing ADHD in Adults BEYOND THE WORKDAY: INSIGHTS AND PERSPECTIVE FROM A LEADING EXPERT

#### Speaker:

Gregory W. Mattingly, M.D. Associate Clinical Professor, Department of Psychiatry Washington University School of Medicine

All Product Theaters are 30 minutes in length and are supported promotional presentations. Attendance is limited and on a first-come, first-served basis. Only registered APA Annual Meeting participants may attend the presentations.

#### 9:30 A.M.

Supported by: Boehringer-Ingelheim

It's Time to Talk: Recognizing FEMALE SEXUAL DYSFUNCTION AND DIAGNOSING HYPOACTIVE SEXUAL DESIRE DISORDER

#### Speaker:

Raymond C. Rosen, Ph.D., Professor, Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School, University of Medicine and Dentistry

#### 4:00 P.M.

Supported by Merck

#### IMPORTANT CLINICAL INFORMATION ABOUT BIPOLAR I DISORDER

#### Speaker:

Roger S. McIntyre, M.D., FRCPC *Associate Professor of Psychiatry* and Pharmacology, University of Toronto, Head, Mood Disorders Psychopharmacology Unit, University Health Network

APA Product Theaters are for informational and promotional purposes only, and do not offer CME credit. The information presented is provided by the supporting companies and does not represent any endorsement by the American Psychiatric Association of any company or product.

#### MONDAY, MAY 24 SESSIONS

#### 8:30 A.M.

Supported by Alkermes

**EVIDENCE-BASED MEDICINE** FOR THE TREATMENT OF ALCOHOL DEPENDENCE: ASSUMPTIONS VS. REALITIES

#### Speaker:

Hugh Myrick, M.D. Associate Professor of Psychiatry, Service Chief, Center for Drug and Alcohol Programs, Medical University of South Carolina

#### 9:30 AM

Supported by Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Invega Sustenna Product THEATER: RETHINKING SCHIZOPHRENIA MANAGEMENT: A ONCE-MONTHLY MEDICATION OPTION FOR SCHIZOPHRENIA

#### Speaker:

Henry A. Nasrallah, M.D. Professor of Psychiatry and Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio

#### 4:00 PM

Supported by Merck

#### IMPORTANT CLINICAL INFORMATION ABOUT SCHIZOPHRENIA

#### Speaker:

Steven G. Potkin, M.D. Professor of Psychiatry and Human Behavior Director of Research, Robert R. Sprague Endowed Chair in Brain Imaging, Director of UCI Brain Imaging Center, University of California

#### TUESDAY, MAY 25 SESSIONS

#### 8:30 AM

Supported by Wyeth Legacy

DISCUSSIONS IN DEPRESSION: HELPING PATIENTS TOWARD THEIR TREATMENT GOALS

#### Speaker:

To be announced

#### 9:30 AM

Supported by: Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

INVEGA PRODUCT THEATER: ACUTE TREATMENT OF SCHIZOAFFECTIVE DISORDER: ADDRESSING THE CLINICAL **CHALLENGES** 

#### Speaker:

Jelena L. Kunovac, M.D., M.S. Founder and Medical Director, Excell Research, Oceanside, California

## American Psychiatric Publishing, Inc.

# The First and Last Word in Psychiatry

# Visit the APPI Bookstore at the 2010 APA Annual Meeting

Be sure to stop by the APPI bookstore and check out APPI's latest selections, from the newest textbooks, clinical manuals, journals, and electronic products.

#### **APPI Bookstore Hours**

Saturday 10:00 am - 4:00 pm Sunday 10:00 am - 4:00 pm Monday 10:00 am - 4:00 pm Tuesday 10:00 am - 4:00 pm **Extra Special Discount for Members!** 

15% Discount for APA Members

30% Discount for APA **Members-in-Training** 



## Manual of Clinical Psychopharmacology, **Seventh Edition**

Alan F. Schatzberg, M.D., Jonathan O. Cole, M.D., and Charles DeBattista, D.M.H., M.D.

2010 · 704 pages · ISBN 978-1-58562-377-8 Paperback · \$92.00 · Item #62377



## **Essentials of Neuropsychiatry and Behavioral Neurosciences, Second Edition**

Edited by Stuart C. Yudofsky, M.D., and Robert E. Hales, M.D., M.B.A.


2010 · 640 pages · ISBN 978-1-58562-376-1 Paperback · \$129.00 · Item #62376



## Dulcan's Textbook of Child and Adolescent Psychiatry

Edited by Mina K. Dulcan, M.D.

2010 · 1104 pages · ISBN 978-1-58562-323-5 Hardcover · \$239.00 · Item #62323



## **Textbook of Anxiety Disorders, Second Edition**

Edited by Dan J. Stein, M.D., Ph.D., Eric Hollander, M.D., and Barbara O. Rothbaum, Ph.D., A.B.P.P.

2010 · 822 pages · ISBN 978-1-58562-254-2 Hardcover · \$125.00 · Item #62254



## **Long-Term Psychodynamic Psychotherapy**

Ю

A Basic Text, Second Edition

Core Competencies in Psychotherapy

Glen O. Gabbard, M.D.

2010 · 233 pages · ISBN 978-1-58562-385-3 Paperback \$65.00 · Item #62385



#### High-Yield Cognitive-Behavior Therapy for Brief Sessions

An Illustrated Guide

Jesse H. Wright, M.D., Ph.D., Donna M. Sudak, M.D., Douglas Turkington, M.D., and Michael E. Thase, M.D.


2010 · 432 pages · ISBN 978-1-58562-362-4 Paperback · \$74.00 · Item #62362



## The American Psychiatric Publishing Textbook of Forensic Psychiatry, Second Edition

Edited by Robert I. Simon, M.D., and Liza H. Gold, M.D.

2010 · 768 pages · ISBN 978-1-58562-378-5 Hardcover · \$120.00 · Item #62378



#### Textbook of Pediatric Psychosomatic Medicine

Edited by Richard J. Shaw, M.B., B.S., and David R. DeMaso, M.D.

2010 · 551 pages · ISBN 978-1-58562-350-1 Hardcover · \$125.00 · Item #62350




The First and Last Word in Psychiatry

American Psychiatric Publishing, Inc. • www.appi.org Phone: 1-800-368-5777 • Email: appi@psych.org

Priority code AH1015







# Candidates and Employers Connect through the APA Job Bank

- Visit APA Job Bank booth during the APA Annual Meeting to search the most comprehensive online listing of psychiatric positions and other career resources.
- ◆ Use APA Job Bank Conference Connection Tool to connect with prospective employers at the meeting.
- ◆ Visit <u>psych.org/jobbank</u> today and get your job posted in time for the meeting.
- ◆ Sign up for the Conference Connection and get a chance to win \$100 gift card.
- Ask APA Job Bank representatives for a demonstration of the redesigned and enhanced web site features.
- ◆ Visit the APA Job Bank today to find the ideal position!

#### Location:

APA Member Center, next to the APPI Bookstore in the Exhibit Hall.

> Saturday, May 22 10:00 am - 4:00 pm

> Sunday, May 23 10:00 am - 4:00 pm


> Monday, May 24 10:00 am - 4:00 pm

> Tuesday, May 25 10:00 am - 4:00 pm

For more information, contact: Lindsey Fox at 703.907.7331 or lfox@psych.org



# 



his four-day event will feature more than 200 expertly-led educational sessions on a variety of topics, popular networking events, and exhibits that complement the educational program. Further information can be found on the Web at www.psych.org/IPS.

#### Who Should Attend?

- All APA members, including early career psychiatrists and psychiatric residents (only \$75 for advance registration)
- International psychiatrists
- Physicians
- Mental health professionals from all disciplines

## Why Should You Attend?

- To earn CME credit (CEs have also been applied for)
- To improve patient care
- To learn about clinically-focused topics that offer specific skill sets
- To network with colleagues and obtain solutions for the challenges you face
- Because your return on investment will reap both personal and professional rewards

#### The IPS Has Gone "GREEN"

The Preliminary Program, which includes registration, housing, travel, and detailed program information is available online only at www.psych.org/IPS.



For more information, please contact: American Psychiatric Association 1000 Wilson Blvd., Suite 1825 Arlington, VA 22209-3901

Phone: 1-888-35-PSYCH or (703) 907-7300

Fax: (703) 907-1090 E-mail: apa@psych.org Web: www.psych.org/IPS



Co-sponsored by Drexel University College of Medicine/ Behavioral Healthcare Education

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.



established by

Fritz M. Klein, M.D. (1932-2006)

founder of the
Journal of Bisexuality
and creator of the
Klein Sexual Orientation Grid

inviting members of the American Psychiatric Association to share ideas with AIB and each other about bisexuality awareness.





Visit www.bibrain.org for new fMRI data

The American Institute of Bisexuality, Inc. (AIB) encourages, supports and assists research and education about bisexuality, through programs likely to make a material difference and enhance public knowledge and awareness.

www.bisexual.org

## **ICANotes**

The EMR for The Behavioral Health Profession

# Learn How ICANotes Creates, Organizes and Stores

Initial Evals, Progress Notes, Treatment Plans and Discharge Summaries With little or no Typing


## **Thinks Like a Psychiatrist**

Runs Like a Dream!

Free Test Drives

Booth 1736

www.icanotes.com 866-847-3590



15TH WORLD CONGRESS

OF PSYCHIATRY14 (IN LOBBY)	
	BASSETT HEALTHCARE NETWORK - BASSETT MEDICAL CENTER1904
A	BHR Corporation
A CICL D	
ACIGI RELAXATION/FUJIIRYOKI2302	BIOBEHAVIORAL DIAGNOSTICS COMPANY2413
ALCOHOLICS ANONYMOUS1234	BIOMED CENTRAL 1538
ALKERMES, INC	BOEHRINGER INGELHEIM PHARMACEUTICALS, INC818
ALL STAR RECRUITING2001	BORGESS HEALTH2002
Allina Hospitals and Clinics2009	BP MAGAZINE/ESPERANZA2134
American Academy of Psychiatry and the Law922	Bristol-Myers Squibb Company/ Otsuka America Pharmaceutical, Inc1032
American Association for Geriatric Psychiatry227	С
American Association of Community Psychiatrists1021	$\mathcal{C}$
	CAMBRIDGE UNIVERSITY PRESS1533
American Board of Psychiatry and Neurology, Inc919	Cannon Design
American College of Psychiatrists917	CAREERSTAFF UNLIMITED215
AMERICAN EXPRESS® OPEN737	CBR Youth Connect326
AMERICAN PHYSICIAN INSTITUTE FOR ADVANCED PROFESSIONAL STUDIES824	THE CENTER FOR EATING DISORDERS AT SHEPPARD PRATT1717
American Professional Agency, Inc2412	CENTER FOR FAMILY GUIDANCE (CFG) HEALTH NETWORK2006
AMERICAN PSYCHOLOGICAL ASSOCIATION1636	Christian Medical Association,
ANT - ADVANCED NEURO TECHNOLOGY2335	PSYCHIATRY SECTION936
ARMY HEALTHCARE RECRUITING2012	CLINICAL PSYCHIATRY NEWS720
ASP.MD, Inc2403	CNS Response, Inc
Association of Gay and	CNS VITAL SIGNS827
LESBIAN PSYCHIATRISTS	COMPHEALTH2109
Association of Women Psychiatrists 1023	CORRECTIONAL MEDICAL SERVICES2304
ASSURERX HEALTH2332	CURRENT PSYCHIATRY/QUADRANT HEALTHCOM1620
ASTRAZENECA PHARMACEUTICALS416	
ATLANTIC COASTAL SUPPLY, INC1835	D
AUSTEN RIGGS CENTER	
AUSTIN LAKES HOSPITAL,	DSP/Sepracor Inc2102
TEXAS NEURO REHAB AND HICKORY TRAIL2212	DEFENSE CENTERS OF EXCELLENCE (DCOE) FOR PSYCHO-
Avanir Pharmaceuticals, Inc538	LOGICAL HEALTH AND TRAUMATIC BRAIN INJURY2405

DEPARTMENT OF VETERANS AFFAIRS1804	HOGREFE PUBLISHING1630
DEY PHARMA, L.P2210	HOSPITAL CORPORATION OF AMERICA (HCA)2010
DOCTORS BEHAVIORAL HEALTH CENTER2312	AMERICA (HCA)2010
DULUTH CLINIC2011	
E	ICANOTES
ECNP Congress - European College of Neuropsychopharmacology12 (in lobby)	INTELLISPHERE, LLC
ELECTROMEDICAL PRODUCTS INTERNATIONAL, INC815	INTERNATIONAL MEDICAL RECRUITMENT1910
ELSEVIER	International Psychogeriatric Association (IPA)826
EMR-BEAR, LLC2313	
EXHIBITCHEK 2233	J
F	JACKSON & COKER1802
	JANSSEN, DIVISION OF ORTHO-MCNEIL-JANSSEN
FAVORITE PHYSICIANS 2113	PHARMACEUTICALS, INC
FDA/Division of Drug Marketing, Advertising, and Communications2136	JOHNS HOPKINS UNIVERSITY PRESS1430
FISHER WALLACE LABORATORIES1238	JONES & BARTLETT
FLOYD BEHAVIORAL HEALTH CENTER1905	_
FOREFRONT BEHAVIORAL TELECARE2103	K
FOREST PHARMACEUTICALS, INC434	Kaiser Permanente2005
	Karger Publishers1726
G	Kiwis STAT2306
GENESIS HEALTHCARE SYSTEM1837	
GLOBAL MEDICAL STAFFING1810	
GOULD FARM1933	La Amistad Foundation, Inc., Lakewood Center2206
GROUP HEALTH PERMANENTE2311	LA LETTRE DU PSYCHIATRE425
GUILFORD PUBLICATIONS1534	LEXICOR MEDICAL TECHNOLOGY, LLC828
-	Lilly USA, LLC
H	LIPPINCOTT WILLIAMS & WILKINS,
HAVEN BEHAVIORAL HEALTHCARE2105	Wolters-Kluwer
HEALTH MATCH BC1902	THE LITEBOOK COMPANY LTD634
HEALTHFORCEONTARIO MARKETING	LITTLE HILL - ALINA LODGE 2411
AND RECRUITMENT AGENCY1912	LOCUMTENENS.COM1729



M	Northern Light Technologies816
THE MAGSTIM COMPANY LIMITED726	NOVARTIS PHARMACEUTICALS
MagVenture A/S2138	
MASSACHUSETTS GENERAL HOSPITAL ACADEMY2310	O
MAXIM PHYSICIAN RESOURCES419	Oregon State Hospital1906
MAYO CLINIC	Oxford University Press1330
MBL Communications, Inc1730	
McLean Hospital	P
MECTA Corporation716	
MEDICAL ASSOCIATES CLINIC1901	PAMLAB, LLC415
MEDICAL BILLING PROFESSIONALS1337	PFIZER, INC. 1816
MEDICAL DOCTOR ASSOCIATES1738	PHILIPS CONSUMER LIFESTYLE1838
MEDNET TECHNOLOGIES, INC320	PHYSICIAN FINDERS
THE MENNINGER CLINIC2235	PHYSICIANS FOR A NATIONAL HEALTH PROGRAM923
MENTALNOTE	PIKES PEAK BEHAVIORAL HEALTH GROUP2404
MERCK	Pine Rest Christian Mental Health Services2013
MERRILL LYNCH2237	PRACTICEFUSION217
MHM Services, Inc1236	PRACTICELINK.COM1913
MINISTRY HEALTH CARE1814	PSYCHIATRIC SOLUTIONS, INC
	PSYCHIATRIC TIMES1821
N	PSYCHIATRISTS ONLY, LLC915
NARSAD AND NARSAD ARTWORKS938	THE PSYCHIATRISTS' PROGRAM916
NATIONAL DEATH INDEX534	
NATIONAL INSTITUTE OF MENTAL HEALTH	QTC Medical Services
NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA)1031	
NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)1033	R
Nature Publishing Group1331	RAPID PSYCHLER PRESS1336
NETSMART TECHNOLOGIES2303	THE READING HOSPITAL AND MEDICAL CENTER2309
Neuronetics, Inc	RECKITT BENCKISER PHARMACEUTICALS2330
NewYork-Presbyterian Hospital316	REGISTRY OF PHYSICIAN SPECIALISTS1724
THE NEW YORK TIMES1632	RiverValley Behavioral Health819
North Carolina Office of Rural Health	ROBERT YOUNG CENTER FOR COMMUNITY MENTAL HEALTH2003



ROSECRANCE HEALTH NETWORK636	T
ROUTLEDGE1438	
ROUTLEDGE JOURNALS1434	TEVA PHARMACEUTICALS172
ROYAL COLLEGE OF PSYCHIATRISTS1530	THERAMANAGER LLC
RVJ International LLC / Happy Feet, Inc	THE TOVA COMPANY
	U
S	U.S. ARMY CIVILIAN CORPS190
SECURE TELEHEALTH	U.S. DEPARTMENT OF STATE, OFFICE OF MEDICAL SERVICES
SEPRACOR INC. 2110	U.S. NAVY RECRUITING2202
SHEPPARD PRATT HEALTH SYSTEM1715	U.S. Public Health Service240
SHIRE PHARMACEUTICALS216	Uplift Technologies Inc
SINGING RIVER HOSPITAL BEHAVIORAL HEALTH SERVICES	V
, .	
SOCIAL SECURITY ADMINISTRATION2204	VA NORTHWEST HEALTH NETWORK211
SOCIEDAD ESPANOLA DE PATOLOGIA DUAL (SEPD)11 (IN LOBBY)	VALANT MEDICAL SOLUTIONS82
SOMATICS LLC	Validus Pharmaceuticals, LLC223
SOS Programs & Parents Press1633	VISTA STAFFING SOLUTIONS, INC123
SPARTANBURG REGIONAL2004	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
Staff Care, Inc924	W
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION (SAMHSA)926	W.W. Norton1529
SUITEMED, LLC2305	WILEY - BLACKWELL162.
SZ MAGAZINE1931	WORLD ASSOCIATION FOR SOCIAL PSYCHIATRY13 (IN LOBBY



CAMBRIDGE

**JOURNALS** 

# HOLOGICAI

Celebrating 40 years of publication

To mark this occasion, we are offering free online access\*, until the end of 2010 - unlocking 40 years of research.

Psychological Medicine is a leading international journal in the fields of psychiatry, clinical psychology and the related basic sciences.



To gain your free access, register your details at the Cambridge University Press stand.

\*this offer is available to a limited number of recipients



## **The Johns Hopkins University Press**

#### Addiction and Art

edited by Patricia B. Santora, Margaret L. Dowell, and Jack E. Henningfield \$29.95 hardcover



#### The Yipping Tiger and Other Tales from the **Neuropsychiatric Clinic**

Perminder Sachdev, M.D. \$24.95 hardcover

#### **Developmental** Disabilities from Childhood to Adulthood

What Works for Psychiatrists in Community and Institutional Settings edited by Roxanne C. Dryden-Edwards, M.D., and Lee Combrinck-Graham, M.D. \$65.00 hardcover

#### Practical Plans for Difficult **Conversations in Medicine**

Strategies That Work in Breaking Bad News Robert Buckman, M.D., Ph.D. \$30.00 paperback

**Forthcoming** 

#### **Trouble in Mind**

An Unorthodox Introduction to Psychiatry Dean F. MacKinnon, M.D. \$25.00 paperback

#### **Psychiatric Consultation** in Long-Term Care

A Guide for Health Care Professionals Abhilash K. Desai, M.D., FAPA, and George T. Grossberg, M.D. \$70.00 hardcover

#### Happy Pills in America


From Miltown to Prozac David Herzberg \$30.00 paperback

Booth 1430 • 1-800-537-5487 • press.jhu.edu



## New from Routledge

American Psychiatric Association 2010 Annual Meeting



## Get the Diagnosis Right

by Jerome S. Blackman 978-0-415-80155-3 - 265 pp.

"This book is an excellent addition to Dr. Blackman's previous 101 Defenses. Get the Diagnosis Right is characterized by a broad knowledge of the psychoanalytic literature, extensive references, and an exceptional capacity to convey difficult

concepts on the dynamic understanding of psychopathology and therapeutic approaches with ease and a touch of humor." -Cecilio Paniagua, MD, ScD, Madrid

Routledge Mental Health is pleased to offer a 20% discount and free shipping to attendees at our booth, #1438

For more information on this and all of our titles, visit

www.routledgementalhealth.com



We are pleased to announce that

#### PROFESSOR SIR MICHAEL RUTTER is the 2010 recipient of the

C. CHARLES BURLINGAME, M.D. AWARD

for his outstanding contributions to psychiatry.

Past Recipients

1988 Robert Kellner, M.D., Ph.D. 1989 William T. Carpenter, Jr., M.D. 1990 Dennis P. Cantwell, M.D. 1991 George E. Vaillant, M.D. 1992 A. John Rush, M.D. 1993 John C. Nemiah, M.D. 1994 Maurice J. Martin, M.D. 1995 Otto F. Kernberg, M.D. 1996 Charles P. O'Brien, M.D., Ph.D. 1997 Glen Owen Gabbard, M.D. 1998 Lissy F. Jarvik, M.D., Ph.D. 1999 Nancy C. Andreasen, M.D., Ph.D. 2000 Lewis L. Judd, M.D. 2001 Paul S. Appelbaum, M.D. 2002 Charles B. Nemeroff, M.D., Ph.D. 2003 Dilip V. Jeste, M.D. 2004 David H. Barlow, Ph.D. 2005 Herbert D. Kleber, M.D. 2006 Daniel N. Stern, M.D. 2007 Jerrold F. Rosenbaum, M.D. 2008 K. Ranga Rama Krishnan, M.D. 2009 David J. Kupfer, M.D.




200 Retreat Avenue Hartford, CT 06106 1-800-673-2411


# NewYork-Presbyterian Psychiatry



Columbia Psychiatry



Payne Whitney Manhattan



Payne Whitney Westchester

NewYork-Presbyterian Psychiatry provides a full continuum of expert diagnosis and treatment services for adults, adolescents and children with psychiatric, behavioral and emotional problems.

Accomplished specialists in psychiatry, psychopharmacology, clinical psychology and neurology work together to provide the highest quality of care, incorporating the most recent clinical and scientific advances. With proper diagnosis and treatment, every mental health condition can be effectively addressed.

The psychiatric services of NewYork-Presbyterian Hospital are ranked among the nation's best by *U.S. News & World Report* <sup>®</sup>.

To make a referral or for further information, please call: Columbia Psychiatry (212) 305-6001 Weill Cornell Psychiatry (888) 694-5700

Visit us at Booth #316

## www.nyppsychiatry.org

Columbia Psychiatry

Affiliate

Weill Cornell Psychiatry

NewYork-Presbyterian Hospital/ Columbia University Medical Center 622 West 168th Street New York, NY 10032 212-305-6001 The Allen Hospital 5141 Broadway New York, NY 10034 212-305-6001 New York State Psychiatric Institute 1051 Riverside Drive New York, NY 10032 212-543-5000 Payne Whitney Psychiatry The Westchester Division NewYork-Presbyterian Hospital/ Weill Cornell Medical Center 21 Bloomingdale Road White Plains, NY 10605 888-694-5700 Payne Whitney Psychiatry NewYork-Presbyterian Hospital/ Weill Cornell Medical Center 525 East 68th Street New York, NY 10065 888-694-5700

#### 15th WORLD CONGRESS OF PSYCHIATRY

Avenida Santa Fe 1970, First Floor, Of 1 Buenos Aires, CPC1123AAO, Argentina (Booth 14 - Exhibit Hall Lobby)

The 15th World Congress of Psychiatry will take place on September 18-22, 2011 in Buenos Aires, Argentina. For more information go to our website: <www.wpa-argentina2011.com.ar>



#### ACIGI RELAXATION/FUJIIRYOKI

4399 Ingot Street Fremont, CA 94538 (Booth 2302)

With over 55 years in the Medical Cyber Relax Massage Chair industry, Fujiiryoki developed professional techniques that remove accumulated strain even in your brain. The extreme mechanisms exquisite comfort approaches the deep, powerful, and pliant touch of real hands. Fuji helps massage and squeeze away tension, pain, and stress.

#### ALCOHOLICS ANONYMOUS

475 Riverside Drive, 11th Floor New York, NY 10115 (Booth 1234)

Alcoholics Anonymous is a fellowship of men and women who have found a solution to their drinking problem. The only requirement for membership is a desire to stop drinking. There are no dues or fees; A.A. is supported by voluntary contributions of its members, neither seeking nor accepting outside funding. Our members observe personal anonymity at the public level.

#### ALKERMES, INC.

852 Winter Street Cambridge, MA 02139 (Booths 1815, 2214)

Alkermes, Inc., is a fully integrated biotechnology company that uses proprietary technologies and know-how to create innovative medicines designed to yield better therapeutic outcomes for patients with serious disease, including alcohol dependence and other CNS disorders. For more information about Alkermes, please visit: <www. alkermes.com>. Please visit us at booths #1815 and #2214.

#### ALL STAR RECRUITING

4400 West Sample Road Coconut Creek, FL 33073 (Booth 2001)

All Star Recruiting specializes in the permanent recruitment of highly qualified pediatric, emergency medicine, primary care, and OB/GYN physicians, as well as surgeons, cardiologists, gastroenterologists, anesthesiologists, CRNAs, PAs, and NPs. We believe that every candidate needs personal attention while searching for the perfect opportunity. We have over 30 years of experience in placing physicians and nurses in jobs all over the country. Our experience in recruitment will help you find the perfect position! Please visit our website at <www.allstarrrecruiting.com> or call (800) 928-0229 for a complete listing of the current All Star Recruiting opportunities.

#### ALLINA HOSPITALS AND CLINICS

2925 Chicago Avenue Minneapolis, MN 55407-1321 (Booth 2009)

For more than 30 years, Allina Mental Health has helped children, adolescents, adults, and seniors work through times when the troubles of life interfere with their ability to function or cope. We serve people at hospitals and clinics throughout the Twin Cities and greater Minnesota. Stop by our booth or visit <www.allina.com/jobs> for information about our urban, suburban, and rural mental health practice opportunities.

## AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW

One Regency Drive Bloomfield, CT 06002 (Booth 922)

The American Academy of Psychiatry and the Law (APPL) is the association for members of the APA who are interested in the interface of psychiatry and the law. The purpose of this exhibit is to introduce attendees to the Academy and acquaint them with the advantage of membership.

## AMERICAN ASSOCIATION FOR GERIATRIC PSYCHIATRY

7910 Woodmont Avenue, Suite 1050 Bethesda, MD 20814 (Booth 227)

AGP is dedicated to serving its membership of geriatric psychiatrists and mental health professionals who work to improve the quality of life for older people with mental disorders. Members of AAGP's Board of Directors will be staffing our booth so stop by to meet our elected officials and learn about AAGP's services, products, and conferences. Join us at AAGP's 2011 Annual Meeting in San Antonio. TX.



P.O. Box 570218 Dallas, TX 75357 (Booth 1021)

The American Association of Community Psychiatrists (AACP) exhibit will present information for members and prospective members, including educational materials pertaining to the field of community psychiatry.

## AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY, INC.

2150 E. Lake Cook Road, Suite 900 Buffalo Grove, IL 60089 (Booth 919)

The American Board of Psychiatry and Neurology (ABPN) serves the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and maintenance of certification processes for psychiatry, addiction psychiatry, child and adolescent psychiatry, forensic psychiatry, geriatric psychiatry, hospice and palliative medicine, pain medicine, psychosomatic medicine, and sleep medicine. Please visit the ABPN booth for answers to your questions.

#### AMERICAN COLLEGE OF PSYCHIATRISTS

122 South Michigan Avenue, Suite 1360 Chicago, IL 60603 (Booth 917)

The American College of Psychiatrists is an honorary psychiatric association. The College develops and administers PRITE (for psychiatry residents) and PIPE, an online preparatory tool for recertification that also fulfills ABPN's selfassessment requirement.

#### AMERICAN EXPRESS® OPEN

200 Vessey Street New York, NY 10285 (Booth 737)

American Express® Business Cards give you automatic access to the tools and resources that American Express OPEN has to offer, including benefits that can help you save money, gain control over your practice expenses, earn valuable rewards and much more.

## AMERICAN PHYSICIAN INSTITUTE FOR ADVANCED PROFESSIONAL STUDIES

125 Windsor Drive, Suite 111 Oak Brook, IL 60523 (Booth 824)

The American Physician Institute provides comprehensive, guaranteed board preparation and medical education courses. For free study materials and for complete course listings and information, visit our website: <www. AmericanPhysician.com>.

#### AMERICAN PROFESSIONAL AGENCY, INC.

95 Broadway Amityville, NY 11701 (Booth 2412)

Please visit the American Professional Agency, Inc., exhibit for more information about their products and services that will be of interest to you.

#### AMERICAN PSYCHOLOGICAL ASSOCIATION

750 First Street, N.E. Washington, DC 20002

(Booth 1636)

American Psychological Association (APA) is the premier source for information in psychology. APA delivers this information through their expansive collection of books, journals, newsletters, electronic products, and on their website at <www.apa.org>.

#### ANT - ADVANCED NEURO TECHNOLOGY

Colosseum 22 7521 PT Enschede, The Netherlands (Booth 2335)

ANT- Advanced Neuro Technology is introducing Cognitrace, a comprehensive system for recording, analysis, and reporting of EEG and cognitive evoked potentials. It integrates high-quality data recording, online analysis, and reporting. Cognitrace provides EEG, AEP, VEP, P300, CNV, and other protocols that may be used with psychiatric disorders like schizophrenia, memory deficit, depressions, attention deficit, and alcoholism.

#### ARMY HEALTHCARE RECRUITING

Building 1307, 1307 Third Avenue Fort Knox, KY 40121 (Booth 2012)

The U.S. Army Medical Corps has a variety of dynamic opportunities available for talented doctors to serve their country. Visit the Army Medical Corps booth to learn more about full-time positions in the Army or part-time positions in the Army Reserves.

#### ASP.MD, INC.

229 Third Street Cambridge, MA 02142 (Booth 2403)

Developers of AMOS - totally web-based practice management and EHR, with no upfront costs and lower monthly fees than our competitors, AMOS offers more for less. AMOS + Stimulus = EHR in your office, and \$35,000 cash in your pocket. AMOS was designed by a physician, for a physician.

## ASSOCIATION OF GAY AND LESBIAN PSYCHIATRISTS

4514 Chester Avenue Philadelphia, PA 19143 (Booth 932)

The Association of Gay and Lesbian Psychiatrists (AGLP) is a professional organization of psychiatrists, psychiatrists in training, and other mental health professionals, which



serves as a voice for the concerns of lesbian, gay, bisexual, and transgendered (LBT) people within the psychiatric community. The Association is committed to fostering a more accurate understanding of sexual orientation and gender identify, opposing discriminatory practices against LGBT people, and promoting supportive, well informed mental health treatment for LGBT patients. The organization provides opportunities for affiliation and collaboration among people who share these concerns. Please visit the AGLP exhibit booth #932 to learn more about our mission, advocacy, and membership opportunities.

#### ASSOCIATION OF WOMEN PSYCHIATRISTS

P.O. Box 570218 Dallas, TX 75357-0218 (Booth 1023)

The Association of Women Psychiatrists (AWP) is a national organization of women psychiatrists working to: 1) form a national and international network of women psychiatrists; 2) improve communication and provide support to women psychiatrists; 3) promote women psychiatrists into leadership positions in all aspects of health care; 4) encourage and support activities and research in women's mental health issues; 5) advocate for just legislation for women; 6) encourage women psychiatrists to actively participate in the APA, both locally and nationally; and 7) influence the policy and procedures of the APA so it meets the needs of women. AWP maintains active liaison relationships with the Committee on Women under the APA Council on National Affairs and the APA Women's Caucus, providing representation in the APA Assembly.

#### ASSURERX HEALTH

(Booth 2332)

Please visit the AssureRx Health exhibit for more information about their products and services that will be of interest to you.

#### ASTRAZENECA PHARMACEUTICALS

1800 Concord Pike Wilmington, DE 19850 (Booth 416)

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology, and neuroscience products. Please stop by exhibit booth #416 for further information.

#### ATLANTIC COASTAL SUPPLY, INC.

4539 U.S. Highway 13 Greenville, NC 27834 (Booth 1835)

The Versi-Shower is a risk reducing addition to your facility and will pay for itself in water savings in just a few years and reduces the risk of suicide which will help reduce liability issues for your facility. Please visit the Atlantic Coastal Supply, Inc. exhibit for more information on the Suicide Resistant In Line Shower Unit.

#### AUSTEN RIGGS CENTER

25 Main Street, P.O. Box 962 Stockbridge, MA 01262 (Booth 1722)

The Austen Riggs Center is a nonprofit, hospitalbased continuum of care center offering intensive psychotherapy in a fully open therapeutic community setting. The Austen Riggs Center is a national referral center for treatment of refractory patients and is located on Main Street in Stockbridge, Massachusetts, two and one-half hours from Boston and three hours from New York City.

## AUSTIN LAKES HOSPITAL, TEXAS NEURO REHAB AND HICKORY TRAIL

1025 East 32nd Street Austin, TX 78705 (Booth 2212)

Austin Lakes Hospital, Texas Neuro Rehab and Hickory Trail are part of the psychiatric solutions family of hospitals. These three facilities are located in Central and North Texas and provide comprehensive psychiatric services for children, adolescents, adults and older adults. The Texas Neuro Rehab campus also houses a neurobehavioral program as well as chemical dependency treatment.

#### AVANIR PHARMACEUTICALS, INC.

101 Enterprise, Suite 300 Aliso Viego, CA 92656 (Booth 538)

Please visit the Avanir Pharmaceuticals, Inc. exhibit for more information about their products and services that will be of interest to you.



## BASSETT HEALTHCARE NETWORK -BASSETT MEDICAL CENTER

One Atwell Road Cooperstown, NY 13326 (Booth 1904)

Bassett Medical Center, is located in beautiful Cooperstown, NY, is seeking well-trained, BC/ BE adult psychiatrists to join our progressive multidisciplinary team of six psychiatrists. The Department of Psychiatry has inpatient, outpatient, and crisis facilities. Practice opportunities include combinations of inpatient, outpatient, and consultation-liaison psychiatry with education of medical residents and Columbia-Bassett medical students. Cooperstown is a small, historical community with excellent schools, unique cultural amenities, and four-season recreational activities. Please contact Colleen Donnelly, Bassett Medical Center, (607) 547-6982, email: colleen.donnelly@ bassett.org, or at <www.bassett.org>.

#### BHR CORPORATION

5674 Stoneridge Drive, Suite 116 Pleasanton, CA 94588 (Booth 1806)

BHR Corporation is an 11-year old behavioral healthcare management company. We provide psychiatric medication management and therapy services to medical groups, hospitals, county and state facilities, and commercial health care companies nationwide. Our services also include physician recruitment and management, clinical consultation, billing, intake, utilization management, appeals writing, strategic management, and mental health training. Visit and submit your CV through <www. bhrcorp.org>.

#### BIOBEHAVIORAL DIAGNOSTICS COMPANY

239 Littleton Road, Suite 6A Westford, MA 01886 (Booth 2413)

BioBehavioral Diagnostics Company is the developer of the Quotient™ ADHD system which measures motion and attention state to given an objective, clear picture of ADHD.

#### BIOMED CENTRAL

Floor 6, 236 Gray's Inn Road London, WC1X 8HL, United Kingdom (Booth 1538)

BioMed Central is the open access publisher committed to the free widespread dissemination of scientific research. BioMed Central publishes over 200 peer-reviewed, open access journals, including a range of psychiatry journals. All original research articles published are immediately and permanently available online without charge or any other barriers to access. Visit our booth to learn more about the journals and the benefits of open access publishing.

## BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

900 Ridgebury Road Ridgefield, CT 06877 (Booth 818)

Boehringer Ingelheim Pharmaceuticals, Inc., the U.S. subsidiary of Boehringer Ingelheim, headquartered in Germany, operates globally in 47 countries with approximately 39,800 employees. The company is committed to researching, developing, manufacturing, and marketing novel products of high therapeutic value for human and veterinary medicine.

#### BP MAGAZINE/ESPERANZA

374 Delaware Avenue, #302 Buffalo, NY 14202 (Booth 2134)

bp Magazine/esperanza are quarterly publications tailored to the unique interests and needs of people living with bipolar disorder, anxiety, and/or depression. Both magazines deliver cutting-edge research and news and are packed with in-depth features and real-life profiles to serve up as inspiration to

consumers and their extended communities. bp Magazine/ esperanza are distributed to psychiatrists' offices, consumer associations, and individual and bulk subscribers.

#### BORGESS HEALTH

1521 Gull Road Kalamazoo, MI 49048 (Booth 2002)

Borgess Medical Center is a 424-bed teaching hospital and Level 1 trauma center providing nationally recognized cardiac and neuro care with advanced capabilities in multiple specialties. Located in Kalamazoo, Michigan, Borgess offers a complete continuum of services to 1.1 million people living in 11 counties in southwest and south central Michigan.

## BRISTOL-MYERS SQUIBB COMPANY/ OTSUKA AMERICA PHARMACEUTICAL, INC.

777 Scudders Mill Road Plainsboro, NJ 08536 (Booth 1032)

Bristol-Myers Squibb welcomes you to New Orleans. We invite you to visit our exhibit and welcome you the opportunity to meet our representatives to discuss the products and services we have to offer.



#### CAMBRIDGE UNIVERSITY PRESS (Booth 1533)

Cambridge University Press is a leading publisher of professional books and journals in psychiatry and mental health. With dozens of new books in the past year, including more from Stephen Stahl, author of Stahl's Essential Psychopharmacology, Cambridge has cutting-edge material in everything from psychopharmacology to disaster psychiatry to many other fields. We also are offering free access to Stahl's Essential Psychopharmacology Online for APA attendees. Please use access code APA2010 to claim your limitedtime account at <stahlonline.cambridge.org>.

#### CANNON DESIGN

2170 Whitehaven Road Grand Island, NY 14072 (Booth 328)

Cannon Design is ranked among the leading international firms in planning and design for healthcare science and technology, education, sports and recreation, and government clients. At present, the firm employs a staff of over 1,000, delivering services in 17 offices throughout North America, as well as abroad in Shanghai, China, and Mumbai, India.

#### CAREERSTAFF UNLIMITED

6191 North State Highway 161, Suite 650 Irving, TX 75038 (Booth 215)

CareerStaff is one of the nation's leading providers of temporary and permanent healthcare staff, combining the resources of a national staffing service with the personal



touch of a local agency. CareerStaff offers rewarding career opportunities for healthcare professionals who want to combine exciting travel, personal growth, and professional excellence. Locum tenens or a long-term placement, CareerStaff can help you meet your career and lifestyle goals.

#### CBR YOUTH CONNECT

28071 Highway 109 LaJunta, CO 81050 (Booth 326)

CBR YouthConnect (CBRYC) is a national residential treatment facility that provides mental health services and education to at-risk boys, ages 10 to 21. Located on 340-acres, CBRYC serves youth who have coexisting psychiatric, behavioral, and educational problems that prevent them from successfully functioning at home. CBRYC's mission is to achieve excellence in providing troubled youth with the means to become hopeful and productive citizens.

## THE CENTER FOR EATING DISORDERS AT SHEPPARD PRATT

(Booth 1717)

The Center for Eating Disorders at Sheppard Pratt offers a comprehensive continuum of treatment services for adults, adolescents, and children with complex eating disorders. The continuum provides inpatient, day hospital, intensive outpatient services, and ongoing outpatient treatment, and boasts a team of more than 20 multi-disciplinary professionals with specialized experience. The program is designed to respond to both the psychiatric and medical aspects of eating disorders, with a comprehensive array of mental health and consultative medical reports.

## CENTER FOR FAMILY GUIDANCE (CFG) HEALTH NETWORK

765 East Route 70, Suite A100 Marlton, NJ 08053 (Booth 2006)

CFG Health System, LLC, is a comprehensive, physicianowned and operated, broad-based organization dedicated to providing quality, state-of-the-art, mental health services. These services are based upon a set of core beliefs: dignity, respect, and value of the individuals placed in our care. CFG recognizes the importance of multidisciplinary, multimodal treatment which addresses the physical, emotional and social needs of the individual. Please visit with us and learn of our innovation approach in patient care.

## CHRISTIAN MEDICAL ASSOCIATION, PSYCHIATRY SECTION

P.O. Box 33795 Decatur, GA 30033 (Booth 936)

The Christian Medical Association is part of the larger Christian Medical and Dental Associations (CMDA), a 15,000 member organization providing resources, networking, education, and a public voice for Christian healthcare professionals and students. The Psychiatry Section offers a forum for the interface of psychiatric practice and the Christian faith. APA participants are welcome to attend our concurrent programs. Visit <www.cmda. org/psychiatry> for more information.

#### CLINICAL PSYCHIATRY NEWS

60-B Columbia Road Morristown, NJ 07960 (Booth 720)

Clinical Psychiatry News is an independent newspaper that provides the practicing psychiatrist with timely and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and the physician's practice.

#### CNS RESPONSE, INC.

85 Enterprise, Suite 410 Aliso Viejo, CA 92656 (Booth 1825)

CNS Response has developed a patented data-analysis capability that, with the help of a simple, non-invasive EEG, will analyze a patient's brain waves and compare the results to an extensive patient outcomes database. The process produces an rEEG® report providing a psychiatrist with guidance to personalize medication regimens for a patient, based on the patient's own brain physiology. To read more about the benefits this patented technology provides physicians, patients, and insurers, please visit the CNS Response website, <www.cnsresponse.com>.

#### CNS VITAL SIGNS

1829 Franklin Street Chapel Hill, NC 27514 (Booth 827)

CNS Vital Signs is a world leader in the design and development of neurocognitive assessment tools. CNS Vital Signs gives practicing clinicians and researchers assessment platforms that provide the ability to detect subtle cognitive deficits while creating a baseline of cognitive function (measure) and track subtle cognitive changes (monitor).

#### COMPHEALTH

6440 South Millrock Dr., Suite 175 Salt Lake City, UT 84121 (Booth 2109)

CompHealth is one of the largest providers of healthcare staffing and recruiting services. For 30 years, we have offered physicians more locum tenens and permanent placement opportunities in more locations nationwide. Contact us about opportunities in your specialty. Call (800) 453-3030 or visit <www.comphealth.com/physician>.

#### CORRECTIONAL MEDICAL SERVICES (Booth 2304)

Please visit the Correctional Medical Services exhibit for more information about their products and services that will be of interest to you.

#### CURRENT PSYCHIATRY/QUADRANT HEALTHCOM

7 Century Drive, Suite 302 Parsippany, NJ 07054 (Booth 1620)

Sign up for a complimentary subscription to Current Psychiatry and learn more about the publication. Edited by Henry A. Nasrallah, M.D., Current Psychiatry provides peer-



reviewed, up-to-date practical advice by leading authorities emphasizing solutions to commonly seen clinical problems. In just eight years, this publication has become one of the leading journals among psychiatric practitioners. Published as an educational partnership with the University of Cincinnati, Department of Psychiatry, this journal is free to psychiatric practitioners who provide patient care, as well as residents and faculty members (U.S. only). Please visit <www. CurrentPsychiatry.com> for additional information.



#### DSP/SEPRACOR INC.

84 Waterford Drive Marlborough, MA 01752 (Booth 2102)

Dainippon Sumitomo Pharma Co., Ltd., (DSP) is a multibillion dollar Japanese company with a diverse portfolio of pharmaceuticals, animal health, food, and specialty products. In 2009, Sepracor Inc. became an indirect, wholly-owned U.S. subsidiary of DSP. Sepracor has several marketed products, including Lunesta® brand eszopiclone. The DSP-Sepracor U.S. pharmaceutical candidate pipeline is focused principally in the central nervous system and respiratory areas. Visit <www. sepracor.com>.

## DEFENSE CENTERS OF EXCELLENCE (DCOE) FOR PSYCHOLOGICAL HEALTH AND FOR PSYCHOLOGICAL HEA TRAUMATIC BRAIN INJURY

1401 Wilson Boulevard, Suite 400 Arlington, VA 22209 (Booth 2405)

Please visit the Defense Centers of Excellence (DCOE) exhibit for more information about their products and services that will be of interest to you.

#### DEPARTMENT OF VETERANS AFFAIRS (HRRO)

1555 Poydras Street, Suite 1971 New Orleans, LA 70112 (Booth 1804)

The Department of Veterans Affairs (HRRO) is focused on recruiting healthcare professionals and students throughout the U.S. to provide the best care for our nation's veterans. Promoting a diverse workforce and offering a wide array of employment benefits, scholarships and retention initiatives, the VA truly is a leader in our nation's health care industry. Join VA - Best Care - Best Careers.

#### DEY PHARMA, L.P.

110 Allen Road, 4th Floor Basking Ridge, NJ 07920 (Booth 2210)

Dey Pharma, L.P., a subsidiary of Mylan, Inc., (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing, and marketing of prescription drug products for the treatment of respiratory diseases, severe allergic reactions, and psychiatric disorders. The company puts patients first and facilitates effective partnerships with customers.

#### DOCTORS BEHAVIORAL HEALTH CENTER (Booth 2312)

Please visit the Doctors Behavioral Health Center exhibit for more information about their products and services that will be of interest to you.

#### DULUTH CLINIC

400 East Third Street Duluth, MN 55805 (Booth 2011)

We are searching for an adult and child/adolescent psychiatrist for the Duluth Clinic, part of the SMDC Health System, with 400+ physicians, a multi-specialty group, with 17 locations and 5 hospitals caring for over 460,000 people. An inpatient unit is adjacent to the clinic. The clinic offers Norman Rockwell living; four seasons of outdoor adventure on the shores of Lake Superior in the upper Midwest. Visit the Duluth Clinic exhibit for more information.



## OLLEGE OF

P.O. Box 85410 3508 AK Utrecht, The Netherlands (Booth 12 - Exhibit Hall Lobby)

The 23rd ECNP Congress will be held August 28-September 1, 2010, in Amsterdam, The Netherlands. Please visit the ECNP Congress exhibit for more information about this meeting.

#### ELECTROMEDICAL PRINTERNATIONAL, INC. RODUCTS

2201 Garrett Morris Parkway Mineral Wells, TX 76067 (Booth 815)

Since 1981, Alpha-Stim® cranial electrotherapy stimulation technology has proven safe and efficacious in the treatment of anxiety, insomnia, and depressions. Supported by more scientific research than any therapeutic device, there are over 55 studies abstracted at <www.alpha-stim.com>. The company offers free clinical support at (940) 328-0788 and a 60-day loan option for psychiatrists who would like to try it in their practice (first time customers only).

#### ELSEVIER

1600 John F. Kennedy Boulevard, Suite 1800 Philadelphia, PA 19103 (Booth 1429)

Please visit the Elsevier exhibit for more information about their products and services that will be of interest to you.



#### EMR-BEAR, LLC

15 Calle Esperanza Santa Fe, NM 87507 (Booth 2313)

EMR-Bear is a web-based electronic health record designed by and for behavioral health professionals. Come by our booth for a tour of the product and its features, such as clinical notes, assessments, and treatment plans, scheduling, electronic prescriptions, and much more. We will show you how easy and affordable it can be to take your private group practice, community mental health organization, or private practice paperless.

#### EXHIBITCHEK

20351 East LaSalle Place Aurora, CO, 80013 (Booth 2233)

EXHIBITCHEK is a specialized market research program designed to measure and enhance the educational value of exhibits at this meeting. We invite you to complete a brief survey, which will lead to more informative exhibits at future meetings.



#### FAVORITE PHYSICIANS

7255 West 98th Terrace, Building 5, Suite 150 Overland Park, KS, 66212 (Booth 2113)

Favorite Physicians, a locum tenens company, provides our clients and physicians a full service consultant, and we have on-site staff 24/7/365 to cover your requests. We specialize in family practice, hospitalists, internal medicine and psychiatry, and provide coverage from one week to one year.

## FDA/ DIVISION OF DRUG MARKETING, ADVERTISING, AND COMMUNICATIONS

10903 New Hampshire Avenue Silver Spring, MD 20993 (Booth 2136)

The purpose of this booth is to educate healthcare practitioners about prescription drug advertising regulations, how to identify misleading drug promotion, and what course of action to take if misleading drug promotion is observed. The booth will be staffed by the Division of Drug Marketing, Advertising, and Communications.

#### FISHER WALLACE LABORATORIES

515 Madison Avenue, Suite SW New York, NY 10022 (Booth 1238)

Fresh off a successful study at Harvard Medical School, Fisher Wallace Laboratories continues to pioneer the drugfree treatment of depression, insomnia, anxiety and stress. In addition to Harvard, our technology recently completed a successful pilot program at Phoenix House, the largest nonprofit drug and alcohol rehab center in the U.S. Please visit our booth to speak to our President, Chip Fisher.

#### FLOYD BEHAVIORAL HEALTH CENTER

306 Shorter Avenue Rome, GA 30165 (Booth 1905)

Floyd Behavioral Health Center is a 53-bed, voluntary receiving adult behavioral health center with psychiatry, chemical dependency, and geriatric programs. Located in Northwest Georgia, within an hour of Atlanta, Rome is a unique small city with a flourishing health care community of more than 350 practicing physicians. We are searching for a hospital-based psychiatrist and an office-based psychiatrist to join our team. To learn more, visit <www.floyd.org>.

#### FOREFRONT BEHAVIORAL TELECARE

2200 Powell Street, Suite 840 Emeryville, CA 94608 (Booth 2103)

Forefront Behavioral Telecare's telehealth network of independent psychiatrists provides behavioral health services to rural SNFs, health clinics, youth homes, and county jails where resources are scarce. Members can use their home/office PCs to use Forefront's live video conferencing service. Members set their telehealth hours weekly to take appointments in their specialties from networked facilities all over their state(s) of licensure. See <www.forefrontbt.com> for more details.

#### FOREST PHARMACEUTICALS, INC.

13600 Shoreline Drive St. Louis, MO 63045 (Booth 434)

Forest Pharmaceuticals, Inc., welcomes you to New Orleans! We invite you to visit our exhibit where our professional representatives will welcome the opportunity to discuss and answer any questions regarding our products Lexapro® (escitalopram oxalate) and Namenda® (memantine HCI). Please visit our website at <www.forestpharm.com>.



#### GENESIS HEALTHCARE SYSTEM

2951 Maple Avenue Zanesville, OH 43701 (Booth 1837)

Genesis Healthcare System, Zanesville, OH, is now recruiting psychiatrists for a facility of 24 adult beds, and 14 child/adolescent beds. A dedicated nursing team provides individualized treatments for each patient. Wide range of services offered include art/music therapy, group-family therapy, occupational therapy, therapeutic recreation, stress management and wellness education, alcohol/ substance abuse assessment and groups, and partial hospitalization.



#### GLOBAL MEDICAL STAFFING

4970 South 900 East, Suite J Murray, UT 84117 (Booth 1810)

Life enriching experiences through International and U.S. Locum Tenens! Being a locum tenens physician is a life-changing experience-whether you want a change of scenery or a change of pace, and whether you stay in your own back yard or travel the world. Global Medical and its staff pioneered the international locum tenens staffing industry and we are the benchmark for all other international staffing groups. Nearly 3,000 physicians have chosen us for their lifeenriching locum experience in Australia, New Zealand, the U.S. and beyond- and we can make it a reality for you now. The world is your practice. Where do you want to go? For more information call (800) 760-3174 or visit < www. gmedical.com>.

#### GOULD FARM

P.O. Box 157, 100 Gould Road Monterey, MA 01245 (Booth 1933)

Founded in 1913, Gould Farm is the first residential, therapeutic community in the Nation dedicated to helping adults living with mental illness move toward recovery, health, and greater independence through community living, meaningful work, and clinical support. Within this safe, family-like community, all members are accepted, respected, and celebrated as individuals.

#### GROUP HEALTH PERMANENTE

320 Westlake Avenue N Seattle, WA 98109 (Booth 2311)

Please visit the Group Health Permanente exhibit for more information about their products and services that will be of interest to you.

#### GUILFORD PUBLICATIONS

72 Spring Street New York, NY 10012 (Booth 1534)

New titles from Guilford Publications include: Barkley, Taking Charge of Adult ADHD; Miklowitz, Understanding Bipolar Disorder; Salekin, Handbook of Child and Adolescent Psychopathy; Leiblum, Treating Sexual Desire Disorders; Blaustein, Treating Traumatic Stress in Children and Adolescents; Millon, Contemporary Directions in Psychopathology; Maroda, Psychodynamic Techniques; Klonoff, Psychotherapy After Brain Injury; Butler, Cognitive-Behavioral Therapy for Anxiety Disorders; and Clark/ Beck, Cognitive Therapy of Anxiety Disorders.



#### HAVEN BEHAVIORAL HEALTHCARE

652 West Iris Drive Nashville, TN 37204 (Booth 2105)

Please visit the Haven Behavioral Healthcare, Inc. exhibit for more information about their products and services that will be of interest to you.

#### HEALTH MATCH BC

200-1333 West Broadway Vancouver, BC, V6H 4C6 Canada (Booth 1902)

Health Match BC is a free, province-wide, physician and allied health professional recruitment service funded by the government of British Columbia, Canada. Our experienced consultants will match your professional and lifestyle interests with opportunities throughout British Columbia. We'll guide you through licensing and immigration procedures, and support you in making a seamless transition to your new practice.

## HEALTHFORCEONTARIO MARKETING AND RECRUITMENT AGENCY

163 Queen Street East Toronto, Ontario M5A 1S1 Canada (Booth 1912)

Please visit the HealthForceOntario Marketing and Recruitment Agency exhibit for more information about their products and services that will be of interest to you.

#### HOGREFE PUBLISHING

875 Massachusetts Avenue, 7th Floor Cambridge, MA 02139 (Booth 1630)

Hogrefe has been publishing books, periodicals, and assessment tools in the fields of psychiatry, medicine, and psychology for over 75 years. They will be presenting the latest edition of their highly popular Clinical Handbook of Psychotropic Drugs, new releases in their series Advances in Psychotherapy, as well as their other recent releases. Visit their booth to find out more.

#### HOSPITAL CORPORATION OF AMERICA (HCA)

2 Maryland Farms, Suite 200 Brentwood, TN 37027 (Booth 2010)

Hospital Corporation of America (HCA) owns and operates 163 healthcare facilities in 20 states with opportunities coast to coast. HCA was one of the nation's first hospital companies. We are committed to the care and improvement of human life. We strive to deliver quality healthcare that meets the needs of the communities we serve.



#### ICANOTES, LLC

1600 St. Margarets Road Annapolis, MD 21409 (Booth 1736)

Over two million notes created and counting. ICANOTES is the most widely used Electronic Health Software (EHR, EMR) for psychiatrists and other mental health professionals. ICANOTES requires little or no typing and is available to any clinician with an internet connection. ICANOTES is by psychiatrists as well as nurses, social workers, counselors, etc., in both inpatient and outpatient settings.

#### INTELLISPHERE, LLC

666 Plainsboro Road Plainsboro, NJ 08536 (Booth 1435)

Connecting more than 200,000 physicians and specialists to current and emerging healthcare technology trends, hundreds of online resources, and the latest breakthroughs affecting their medical practice, the MDNG series of publications and custom publishing products offer the best healthcare and technology news and information for physicians, patients and their caregivers.

#### INTERIM PHYSICIANS

1040 Crown Pointe Parkway, Suite 120 Atlanta, GA 30338 (Booth 1823)

Interim Physicians has been serving physicians in all major specialties since 1979. Our dedicated team of professional consultants has over 35 years of combined experience placing psychiatrists in positions throughout the U.S.. Stop by our booth and allow one of our consultants to tell you about the exciting opportunities we have open today, or call us at (800) 226-6347 anytime!

#### INTERNATIONAL MEDICAL RECRUITMENT

Level 6, West Tower, 608 St. Kilda Road Melbourne, Victoria, Australia 3004 (Booth 1910)

Choose Australia's largest and most experienced medical recruitment company when it comes to securing your new career and life in Australia or New Zealand with: 1) a dedicated specialist psychiatry division; 2) access to hundreds of unadvertised jobs; 3) unlimited free advice on employment opportunities; 4) free registration and immigration processing; and 5) \$500 cash gift to all doctors taking jobs through us. Visit us at Booth #1910 for a confidential discussion about your individual needs. International: phone: +61 3 8506 0185, fax: +61 3 8648 6846, psychiatry@IMRmedical.com, <www. IMRpsychiatry.com or www.IMRmedical.com>.

# INTERNATIONAL PSYCHOGERIATRIC ASSOCIATION (IPA)

550 Frontage Road, Suite 3759 Northfield, IL 60093 (Booth 826)

With a mission to "improve mental health for older people," the International Psychogeriatric Association (IPA) is a

multidisciplinary professional healthcare association, with members from over 60 countries: psychiatrists, neurologists, geriatricians, psychologists, primary care physicians, scientists, nurses, social workers, and occupational therapists. IPA promotes research, offers education, advocates for better care, facilitates an international exchange of ideas, and fosters crosscultural understanding of the latest developments in the field.



#### JACKSON & COKER

2655 Northwinds Parkway Alpharetta, GA 30009 (Booth 1802)

Jackson & Coker (J&C) is among the most recognized physician recruitment firms in the nation, providing temporary (locum tenens) and permanent placement services to government and commercial hospitals, clinics, and other medical facilities. J&C has the unique distinction of being awarded certification from the National Committee for Quality Assurance (NCQA) in ten out of ten credentialing services, and from The Joint Commission as a "Gold Star" Certified Health Care Staffing Service.

# JANSSEN, DIVISION OF ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.

1125 Trenton-Harbourton Road Titusville, NJ 08560 (Booth 733)

Please visit the Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. exhibit for more information about their products and services that will be of service to you.

#### JOHNS HOPKINS UNIVERSITY PRESS

2715 North Charles Street Baltimore, MD 21218 (Booth 1430)

Johns Hopkins University Press publishes scholarly and general interest books in psychiatry. Recent titles include: The Rise and Fall of the Biopsychosocial Model, by Nassir Ghaeni; Eating Disorders, 2nd ed., by Philip Mehler and Arnold Andersen; Developmental Disabilities From Childhood to Adulthood, edited by Roxanne Dryden-Edwards and Lee Combrinck-Graham; and Addiction and Art, edited by Patricia Santora, Margaret Dowell, and Jack Henningfield.

#### JONES & BARTLETT

40 Tall Pine Drive Sudbury, MA 01779 (Booth 1629)

Founded in 1983, Jones and Bartlett is a world-leading provider of instructional, assessment and learningperformance management solutions for the post-secondary, career and professional markets. We endeavor to develop educational programs and services that improve learning outcomes and enhance student achievement across a broad spectrum of academic, vocational and professional fields. Our products and services uniquely combine authoritative content from academia and industry thought-leaders with innovative,

proven and engaging technology applications that enable anytime, anywhere learning—revolutionizing how instructors teach, professionals train, and students learn. About Jones and Bartlett (<www.jbpub.com>).



#### KAISER PERMANENTE

1800 Harrison Street, 7th Floor Oakland, CA 94612 (Booth 2005)

Kaiser Permanente believes their achievements are best measured by the health and wellness of the diverse communities they serve. That is why they provide a fully integrated system of care guided by values such as integrity, quality, service, and of course, results. That is also why they give their physicians the tools, flexibility, and freedom needed to get the best outcomes possible for their patients.

#### KARGER PUBLISHERS

26 West Avon Road, P.O. Box 529 Unionville, CT 06085 (Booth 1726)

Publications include: Chronotherapeutics for Affective Disorders; Lithium Treatment of Mood Disorders; Neurological Disorders in Famous Artists (Parts 1-3); the book series Advances in Biological Psychiatry; Advances in Psychosomatic Medicine; Key Issues in Mental Health; and Modern Trends in Pharmacopsychiatry; and the journals Dementia and Geriatric Cognitive Disorders, Human Development, Neurodegenerative Diseases, Neuropsychobiology, Psychopathology, and Psychotherapy and Psychosomatics.

#### KIWIS STAT

Unit 1/48 Lismore Street, Waltham Christchurch, 8011, New Zealand (Booth 2306)

Kiwis STAT is the largest medical recruitment company in New Zealand and Australia. We organize fixed-term contracts for doctors wanting working holidays in a "no-sue" health system, in "Lord of the Rings" country. We provide a professional service that focuses on your employment, family, and leisure needs. Come and meet us at our booth and talk to Kiwis about becoming a Kiwi or Aussie Doctor.



## FOUNDATION, INC.,

8400 La Amistad Cove Fern Park, FL 32730 (Booth 2206)

Owned and operated by La Amistad Foundation, Inc., Lakewood Center is a private, non-private, residential psychiatric treatment facility for adults with schizophrenia, autism, bipolar, and depression. The nursing, social work,

activities, work program, and personal care staff provide a safe and active community. In addition, their Transitional Program helps develop independent functioning.

#### LA LETTRE DU PSYCHIATRE

2, rue Sainte Marie Courbevoie, Cedex, 92418 France (Booth 425)

La Lettre du Psychiatre is a French publication specializing in psychiatry.

#### LILLY USA, LLC

Lilly Corporate Center Indianapolis, IN 46285 (Booth 734)

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answersthrough medicine and information-for some of the world's most urgent medical needs.

# LIPPINCOTT WILLIAMS & WILKINS, WOLTERS-KLUWER

530 Walnut Street Philadelphia, PA 19106 (Booth 1616)

Lippincott Williams & Wilkins, a Wolters-Kluwer Health Company, is a leading international publisher of medical books, journals, and electronic media. We proudly offer specialized publications and software for physicians, nurses, students, and clinicians. Please visit our booth to browse our comprehensive product line.

#### THE LITEBOOK COMPANY LTD.

#6, 941 South Railway Street, South Medicine Hat, Alberta T1A 2W3 Canada (Booth 634)

The Litebook Company pioneered portable light therapy in 2001 with the Litebook®. Their patented LED technology produces bright, yet safe, diffused white light in the optimum blue and green wavelengths. Litebook® is the only device with published data for SAD (Yale-led double-blind study). Litebook® Elite™ features a sleek design, rechargeable lithium battery and timer for improved patient comfort and increased compliance.

#### LITTLE HILL - ALINA LODGE

Box GBlairstown, NJ 07825 (Booth 2411)

Please visit the Little Hill - Alina Lodge exhibit for more information about their products and services that will be of interest to you.

#### LOCUMTENENS.COM

2655 Northwinds Parkway Alpharetta, GA 30009 (Booth 1729)

LocumTenens.com is a full-service agency providing temporary placement services for psychiatrists nationwide.



We offer excellent compensation, paid malpractice insurance, and the freedom and flexibility to decide when, where, and how often you want to work. To speak with a recruiter, call us at (800) 562-8663. Visit our website at <www.LocumTenens.com> and check out our Career Resource Center and free job board.



#### THE MAGSTIM COMPANY LIMITED

Spring Gardens, Whitland Carmarthenshire, Wales UK SA34 0HR (Booth 726)

Please visit The Magstim Company Limited exhibit for more information about their products and services that will be of interest to you.

#### MAGVENTURE, INC.

303 Perimeter Center North, Suite 300 Atlanta. GA 30346 (Booth 2138)

Please visit the MagVenture, Inc. exhibit for more information about magnetic stimulators for diagnostics and research.

# MASSACHUSETTS GENERAL HOSPITAL ACADEMY

383 Main Avenue Norwalk, CT 06851 (Booth 2310)

For healthcare professionals who value the highest standards of care, the Massachusetts General Hospital Psychiatry Academy provides world-renowned education that improves clinical practice and leads to better lives for patients and their families. Advanced teaching methods, an interactive learning format, and focus on solving real-world, practice-related challenges give the Academy international recognition for helping providers effectively treat psychiatric disorders. Visit <www.mghcme.org>.

#### MAXIM PHYSICIAN RESOURCES

(Booth 419)

Please visit the Maxim Physician Resources exhibit for more information about their products and services that will be of interest to you.

#### MAYO CLINIC

200 First Street, SW Rochester, MN 55905 (Booth 925)

The Mayo Clinic Innovations in Psychiatry exhibit booth provides a look into Mayo's multidisciplinary approach to the practice of psychiatry and psychology. Learn how translational research programs and pharmacogenomic testing provide novel treatment options for patients worldwide. Find details about Mayo Clinic's Intensive Addiction Program, Pain Rehabilitation Center, Mood Disorder Unit, and Child and adolescent inpatient services. Also, obtain registration information for continuing medical education courses. Make the Mayo Clinic exhibit your first stop at the conference.

#### MBL COMMUNICATIONS, INC.

333 Hudson Street, 7 Floor New York, NY 10013 (Booth 1730)

MBL Communications, Inc., an independent publishing and communications company, publishes the monthly peer-reviewed journals *Primary Psychiatry* and *CNS Spectrums* , *Primary Psychiatry - NP/PA Edition*, and *Psychiatry Weekly* , the nation's only weekly psychiatric news service. Since 1994, MBL has also developed CNS-based print, web, and live programs for its 115,000 monthly readers, including Expert Panel Supplements and webcasts, BlackBox<sup>™</sup> reference guides and related iPhone applications, and the biennial Alzheimer's Disease Summit™.

#### MCLEAN HOSPITAL

115 Mill Street Belmont, MA 02478 (Booth 1735)

McLean Hospital is an international center for psychiatric treatment, teaching, and research, founded in 1811. McLean offers state-of-the-art diagnostic and treatment services across a full continuum that includes inpatient, residential, partial hospital and outpatient services. McLean also offers an expanded array of specialized academic programs for children and adolescents as well as dedicated services for older adults with Alzheimer's and other dementias. McLean houses the largest research program of any private psychiatric hospital in the world. As a major teaching affiliate of Harvard Medical School, McLean continues to educate the best and brightest mental health providers.

#### MECTA CORPORATION

19799 SW 95th Avenue, Suite B Tualatin, OR 97062 (Booth 716)

MECTA, ECT Evidence Based Technology. Since 1973 MECTA has set the standard for unparalleled innovation based on research throughout four generations of electroconvulsive therapy (ECT) devices used for the treatment of depression. Exclusive features include an optimum 0.3 ms ultrabrief pulsewidth including easy to use titration methodology to reduce cognitive side effects, and RMSManager ECT database. Stop by the MECTA Corporation booth to view the Electronic Medical Records software program.

#### MEDICAL ASSOCIATES CLINIC

1500 Associates Drive Dubuque, IA 52002 (Booth 1901)

Please visit the Medical Associates Clinic exhibit for more information about their products and services that will be of interest to you.

#### MEDICAL BILLING PROFESSIONALS

P.O. Box 560 Royersford, PA 19468 (Booth 1337)

Let Medical Billing Professionals (MBP) submit your insurance claims for as little as \$1.49 per claim. MBP has expertise in behavioral health billing and guarantees accurate claim submission by the next business day at the latest. Visit our booth for more information about our services.

#### MEDICAL DOCTOR ASSOCIATES

145 Technology Parkway, N.W. Norcross, GA 30092 (Booth 1738)

Experience the difference quality makes. Medical Doctor Associates (MDA) is the quality leader in medical staffing. Whether you like a coastal, mountain, urban, or rural lifestyle, MDA has the opportunity for you. MDA provides the best protection in malpractice insurance available; and we are the largest organization that can. We have opportunities in all specialties and work with some of the largest healthcare networks in the industry. Call MDA today and find out how quality can start working for you. For more information contact (888) 383-6700 or <www.mdainc.com>.

#### MEDNET TECHNOLOGIES, INC.

1975 Linden Boulevard, Suite 407 Elmont, NY 11103 (Booth 320)

MedNet Technologies designs, hosts, and manages websites for medical practices, hospitals and other healthcare organizations. Clients range in size from small medical offices to teaching hospitals to medical societies. Developing and optimizing your web presence on the internet is our goal.

#### THE MENNINGER CLINIC

2801 Gessner Drive Houston, TX 77080 (Booth 2235)

The Menninger Clinic, Houston, is a specialty psychiatric center for the treatment of adolescents and adults with difficult-to-treat brain and behavioral disorders as well as co-occurring conditions. Treatment integrates evidencebased and biopsychosocial therapies with rehabilitation. Neuropsychiatric assessments are available for adults and adolescents. Menninger also trains mental health professionals, conducts collaborative research and is affiliated with Baylor College of Medicine.

#### MENTALNOTE™

31101 Bancroft Drive Novi, MI 48377 (Booth 633)

MentalNote<sup>™</sup> is the preferred stand-alone electronic documenting management software for behavior health professionals. Progress notes, patient history, letters, billing summaries, and prescriptions are all automatically generated to your specifications and personalized, professional touches with a click of a box. Learn more about our highly anticipated MentalNote™ On-line (MNOL), the EHR and web-based version of MentalNote™. Visit booth #633 or contact us at <www.MentalNoteOnline.com> for more information.

#### MERCK

2000 Galloping Hill Road Kenilworth, NJ 07033 (Booths 2216, 2314)

Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs that donate and deliver our products to the people who need them. Merck. Be Well. For more information, visit <www.merck.com>.

#### MERRILL LYNCH WEALTH MANAGEMENT

1400 Merrill Lynch Drive Pennington, NJ 08534 (Booth 2237)

Merrill Lynch is one of the world's premier providers of wealth management, securities trading and sales, corporate finance, and investment banking services. Working with our clients as strategic partners, we create and execute winning solutions based on five unwavering principles: client focus, respect for the individual, teamwork, responsible citizenship, and integrity.

#### MHM SERVICES, INC.

1593 Spring Hill Road, Suite 610 Vienna, VA 22182 (Booth 1236)

MHM Services, Inc., is a leading national provider of healthcare services to state and local government agencies. From mental health and long-term care to medical and forensic services, our employees are dedicated to providing the highest quality of care for every population they serve. Today we serve over 275,000 individuals in hundreds of facilities across 15 states.

#### MINISTRY HEALTH CARE

900 Illinois Avenue Stevens Point, WI 54481 (Booth 1814)

Ministry Health Care is currently looking for BC/BP psychiatrists to join our multi-specialty group in central and northern Wisconsin. We have different practices to fit your needs, with inpatient, outpatient, and child/ adolescent psychiatry positions at two different locations that work with different practice philosophies. You have the choice of working with a multi-disciplinary, team approach, or an independent, flexible group.



#### NARSAD AND NARSAD ARTWORKS

761 West Lambert Road Brea, CA 92821 (Booth 938)

NARSAD raises and distributes funds for scientific research into the causes, cures, treatments, and prevention of severe mental illnesses. NARSAD Artworks solicits art created by artists with mental illness and incorporates it into products such as note and holiday cards. NARSAD Artworks is the country's clearinghouse for such art.



#### NATIONAL DEATH INDEX

3311 Toledo Road, Room 7316 Hyattsville, MD 20782 (Booth 534)

The National Death Index (NDI) is a central computerized index of death record information on file in the state vital statistics offices. Working with these states, NCHS established the NDI as a resource to aid epidemiologists and other health and medical investigators with their mortality ascertainment activities.

#### NATIONAL INSTITUTE OF MENTAL HEALTH

6001 Executive Blvd., Room 8184, MSC 9663 Bethesda, MD 20892 (Booth 1025)

The National Institute of Mental Health (NIMH), a component of the National Institutes of Health, Department of Health & Human Services, conducts and supports research on mental health and mental disorders. NIMH offers many publications, at no cost, to help people with mental disorders, health care practitioners, researchers, and the general public to gain a better understanding of mental illnesses and NIMH research programs. Some materials are available in Spanish.

## NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

2107 Wilson Boulevard, #1000 Arlington, VA 22201 (Booth 1031)

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) exhibit highlights the importance of alcohol research, prevention, and treatment for maintaining the health of the individual, the family, and the nation. The NIAAA exhibit features publications appropriate for the public, research findings for professionals and for policy makers, and research grant opportunities available for biomedical and social science researchers. A direct link to NIAAA's web site will be available at this exhibit.

## NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)

6001 Executive Boulevard, Suite 5213 Bethesda, MD 20892 (Booth 1033)

The National Institute on Drug Abuse (NIDA) is a Federal agency charged with supporting research on the causes, prevention, and treatment of all aspects of drug abuse including AIDS. The results of the NIDA-funded research offer this country's best hope for solving the medical, social, and public health problems of drug abuse and addiction. Publications and research opportunities supporting these efforts will be made available.

#### NATURE PUBLISHING GROUP

75 Varick Street, Floor 9 New York, NY 10013 (Booth 1331)

Nature Publishing Group (NPG) brings leading scientific and medical research to your desktop. The NPG portfolio combines the continued excellence of Nature and its associated research and review journals, over 42 leading academic and society journals and eight Nature Clinical Practice journals. Visit Booth #1331 for free sample copies.

#### NETSMART TECHNOLOGIES

3500 Sunrise Highway Great River, NY 11739 (Booth 2303)

Helper offers affordable and comprehensive Practice Management, EMR, electronic claims, e-Prescribing, credit card processing, and e-Learning software designed specifically for behavioral health. Helper is a division of Netsmart Technologies, a leading behavioral health software provider with over 18,000 customers nationwide, from solo, private practices to over 300 community mental health cents and 35+ state systems. Please visit the Netsmart Technologies exhibit for more information about their products and services that will be of interest to you. For more information visit <www.ntst.com>.

#### NEURONETICS, INC.

31 General Warren Boulevard Malvern, PA 19355 (Booth 224)

Neuronetics is changing the way psychiatrists think about and treat major depression. Neuronetics' fastest-growing, noninvasive, non-systemic treatment is now provided by over 130 U.S. providers. Visit APA booth #224 for a one-on-one demonstration, product risk information, to meet the experts, and to find out how it can benefit your patients and your practice. You may also contact us at <www.NeuroStarTMS. com> or (877) 600-7555 for more information.

#### NEWYORK-PRESBYTERIAN HOSPITAL

333 E. 38th Street, 5th Floor, Marketing New York, NY 10016 (Booth 316)

NewYork-Presbyterian Hospital, Departments of Psychiatry, a recognized leader in clinical case, training, and research, offers a full continuum of expert diagnostic and treatment services for children, adolescents, adults, and the elderly with psychiatric, neuropsychiatric, behavioral, or emotional problems. Accomplished specialists in psychiatry, psychopharmacology, clinical psychology, and neurology provide the highest quality of care that includes the most recent scientific advances and stateof-the-art treatment options.

#### THE NEW YORK TIMES

613 South Avenue Weston, MA 02493 (Booth 1632)

The New York Times (NYT) newspaper is the largest metropolitan newspaper in the U.S. The NYT is frequently relied upon as the official and authoritative reference for modern events. Please visit the NYT exhibit for 25% off home delivery and receive a free gift with your subscription.

#### NORTH CAROLINA OFFICE OF RURAL HEALTH

2009 Mail Service Center Raleigh, NC 27699 (Booth 1911)

The North Carolina Office of Rural Health and Community Care provides quality mental health support to the rural and underserved areas of North Carolina. We offer placement in various facilities and practices

providing service to under-served populations in rural or metropolitan communities. Loan repayment and other incentive options are available for psychiatrists seeking employment opportunities.

#### NORTHERN LIGHT TECHNOLOGIES

8971 Henri Bourassa West Montreal, Quebec H4S 1P7 Canada (Booth 816)

Northern Light Technologies produces the TRAVELITE, the 10,000 Lux high-output SATELITE Desk Lamp, FLAMINGO Floor Lamp, BOXELITE, ceiling track mounted SHOWOFF and the new LUXOR table lamp. Preferred by thousands of healthcare professionals, Northern Light Technologies is the supplier of choice for affordable, versatile, and adjustable bright light sources. UV-clean, flicker-free, and operating on 110V to 220V current. Call (800) 263-0066 or visit us at <www. northernlighttechnologies.com>.

#### NOVARTIS PHARMACEUTICALS

One Health Plaza East Hanover, NJ 07936 (Booths 638, 1716, 2101, 2301)

Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing, and marketing prescription drugs that help meet our customers' medical needs and improve their quality of life.



#### OREGON STATE HOSPITAL

2600 Center Street, NE Salem, OR 97301 (Booth 1906)

Oregon State Hospital, in Salem, Oregon, is a new hospital incorporating state-of-the-art architecture, treatment space, and technology by 2011. It is surrounded by ocean beaches, snow-covered mountains, and world famous wineries. You can ski, raft, fish, hike, boat, gold, game, and taste-and just about everything you could imagine-all within an hour's drive. What more could you ask for? Please visit us at the Career Fair.

#### OXFORD UNIVERSITY PRESS

198 Madison Avenue New York, NY 10016 (Booth 1330)

The Oxford University Press will feature the following new books: Cutter, Psychiatry, Second Edition; North, Goodwin and Guze's Psychiatric Diagnosis, Sixth Edition; Mrazek, Psychiatric Pharmacogenomics; Zorumski, Demystifying Psychiatry; Starcevic, Anxiety Disorders in Adults, Second Edition; Frankland, The Little Psychotherapy Book; new Treatments That Work titles and the rest of Oxford's leading list in psychiatry. Sample copies of the journal Schizophrenia are also available.



#### PAMLAB, LLC

4099 Highway, 190 East Covington, LA 70470 (Booth 415)

Deplin is indicated for low plasma and/or low red blood cell folate with particular emphasis for those individuals who have a major depressive disorder that has not fully responded or may not fully respond to antidepressant therapy. Cerefolin® with NAC features N-acetylcysteine which targets the oxidative damage associated with mild cognitive impairment by reducing the neurotoxic effects of beta amyloid and hyperhomocysteinemia.

#### PFIZER, INC.

235 East 42nd Street New York, NY 10017 (Booth 1816)

Please visit the Pfizer, Inc., Worldwide Pharmaceutical exhibit featuring: Chantix<sup>™</sup> (varenicline), Goedon<sup>®</sup> (ziprasidone hydrochloride), and Pristiq® (desvenlaxine extended-release tablets).

#### PHILIPS CONSUMER LIFESTYLE

710 North, 900 East Pleasant Grove, UT 84062 (Booth 1838)

Winter blues affect an estimated 25 million Americans and light therapy is recommended by the APA as a first-line treatment. Philips Consumer Lifestyle (formerly Apollo Health) offers newly discovered blueware technology for fast relief. Come by booth 1838, call (801) 616-2850, or visit < www.lighttherapy. com> to learn about our medical professional demo units, authorization codes, and waiting room information kits.

## PHYSICIANS FOR A NATIONAL HEALTH PROGRAM

29 East Madison, Suite 602 Chicago, IL 60602 (Booth 923)

Physicians for a National Health Program (PNHP) is a non-profit research and education organization of 17,000 physicians, medical students, and health professionals who support single-payer national health insurance.

## PINE REST CHRISTIAN MENTAL HEALTH SERVICES

300 68th Street, S.E. Grand Rapids, MI 49501-0165 (Booth 2013)

Pine Rest Christian Mental Health Services is celebrating our 100th anniversary this year. Pine Rest is a leader in behavioral health care and is the fifth largest free-standing behavioral health care organization in the country providing a continuum of services for all ages: prevention and education; psychological assessment and testing; outpatient counseling and therapy at over 20 clinical locations; residential services; day treatment; inpatient hospitalization and more. Visit us at booth 2013 or <www. pinerest.org> to learn more about our opportunities and services.



#### PRACTICE FUSION

(Booth 217)

Please visit the Practice Fusion exhibit for more information about their products and services that will be of interest to you.

#### PRACTICELINK.COM

415 Second Avenue Hinton, WV 25951 (Booth 1913)

PracticeLink®.com - The Online Physician Job Bank™ Find more than 14,000 practice opportunities in all specialties, nationwide on <PracticeLink.com>. Visit the <www. PracticeLink.com> Physician Job Bank or call (800) 776-8383 to discuss opportunities with a PracticeLink On Call ™ Representative. PracticeLink is a free service for physicians. PracticeLink is not a search firm.

#### PSYCHIATRIC SOLUTIONS, INC.

6640 Carothers Parkway Franklin, TN 37067 (Booth 1832)

Psychiatric Solutions, Inc. (PSI) offers an extensive continuum of behavioral health programs to critically ill children, adolescents, and adults, and is the largest operator of owned or leased, freestanding psychiatric inpatient facilities with approximately 10,000 beds in 32 states, Puerto Rico, and the U.S. Virgin Islands.

#### PSYCHIATRIC TIMES

(Booth 1821)

Please visit the *Psychiatric Times* exhibit for more information about their products and services that will be of interest to you.

#### PSYCHIATRISTS ONLY, LLC

2970 Clairmont Road, Suite 650 Atlanta, GA 30329 (Booth 915)

Psychiatrists Only is a physician-owned and managed fullservice, nationwide locum tenens and psychiatrists' permanent placement agency. Full-service equals hassle-free service to their hospital, clinic, and mental health center clients and to their physicians. Their professional recruitment staff will keep on top of any issues and problems, and they will keep you fully informed during each step of the recruitment process.

#### THE PSYCHIATRISTS' PROGRAM

1515 Wilson Boulevard, Suite 800 Arlington, VA 22209 (Booth 916)

The Psychiatrists' Program offers medical malpractice insurance and risk management resources to individual psychiatrists and behavioral healthcare groups. Participants have access to the toll-free Risk Management Consultation Service helpline, complimentary risk management seminars, Online Education Center and more. Coverage includes administrative defense benefits and forensic psychiatric services. Discounts available include part-time, early career, moonlighting residents, child/adolescent, and risk management. Visit us online at <www.psychprogram.com>!



#### QTC MEDICAL SERVICES

21700 Copley Drive, Suite 200 Diamond Bar, CA 91765 (Booth 825)

QTC is the largest private provider of outsourced medical and disability examination services in the Nation. Built upon a focus of integrating information technology to achieve consistent, efficient, and accurate medical evaluations, our more than 28-year history has been marked by innovative, agency-focused services and positive working relationships. To learn more visit <www.QTCM.com>.



#### RAPID PSYCHLER PRESS

(Booth 1336)

Please visit the Rapid Psychler Press exhibit for more information about their products and services that will be of interest to you.

#### THE READING HOSPITAL AND MEDICAL CENTER

South 6th Avenue and Spruce Street West Reading, PA 19611 (Booth 2309)

The Reading Hospital and Medical Center is a 672-bed, notfor-profit healthcare center providing comprehensive acute care, post-acute rehabilitation, behavioral, and occupational health services to the people of Berks and adjoining counties. Located in scenic Berks County, the main West Reading campus consists of a 22-building complex located on a 36-acre suburban campus. Learn more about our opportunities at <www.readingdocs.org>.

#### RECKITT BENCKISER PHARMACEUTICALS

10710 Midlothian Turnpike, Suite 430 Richmond, VA 23235 (Booth 2330)

Reckitt Benckiser Pharmaceuticals is at the forefront providing educational resources and treatment options to physicians and patients dealing with the chronic relapsing disease of opioid dependence. Please visit their exhibit where Reckitt Benckiser clinical liaisons will be available to discuss the indications, and provide scientific information, and answer your questions about a unique treatment option.

#### REGISTRY OF PHYSICIAN SPECIALISTS

1299 Newell Hill Place, Suite 100 Walnut Creek, CA 94596 (Booth 1724)

The Registry of Physician Specialists is a preferred provider of psychiatric and medical services to correctional facilities within the California Department of Correction and Rehabilitation since 1988. The Registry of Physician Specialists is currently seeking

mental health and other medical providers to join and provide services within opportunities nationwide. Please call (800) 882-0686 and speak with a Registry of Physician Specialists recruiter for more information.

#### RIVERVALLEY BEHAVIORAL HEALTH

1100 Walnut Street Owensboro, KY 42301 (Booth 819)

RiverValley Consulting Services, a comprehensive healthcare provider located in Owensboro, Kentucky, provides the full range of outpatient behavioral healthcare services in seven surrounding counties and inpatient child/adolescent services. We provide various opportunities for physicians to develop their practices, in multiple sites utilizing telemedicine technology, while maintaining the autonomy of a private practice, making this corporation an ideal choice for any psychiatrist.

# ROBERT YOUNG CENTER FO COMMUNITY MENTAL HEALTH

4600 Third Street Moline, IL 61265 (Booth 2003)

Please visit the Robert Young Center for Community Mental Health exhibit for more information about their products and services that will be of interest to you.

#### ROSECRANCE HEALTH NETWORK

1021 Mulford Road Rockford, IL 61107 (Booth 636)

Rosecrance Treatment Centers, located in Rockford, IL, 70 miles northwest of Chicago, is a private, not-for-profit organization that has a documented history of providing quality substance abuse treatment and prevention services for children, adolescents, adults, and families. Services include detoxification, inpatient, partial hospitalization, outpatient, continuing care, and recovery homes for young men and women. You can visit our website at <www.rosecrance.org>.

#### ROUTLEDGE

270 Madison Avenue New York, NY 10016 (Booth 1438)

Routledge publishes an impressive portfolio of psychology textbooks, professional books, and journals. We are offering a special 20% discount and free shipping to all attendees who place orders at our booth #1438! Featuring Get the Diagnosis Right! By Jerome Blackman and Handbook of Clinical Sexuality for Mental Health Professionals edited by Stephen B. Levine, et al. For more information visit < www.routledgemenalhealth.com>.

#### ROUTLEDGE JOURNALS

325 Chestnut Street, Suite 800 New York, NY 10016 (Booth 1434)

For two centuries, Taylor & Francis has been fully committed to the publication of scholarly information. Under our Routledge imprint, we publish a wide variety of journals in

the psychiatric field. Visit the Routledge booth to view our products and to pick up free sample copies of our journals.

#### ROYAL COLLEGE OF PSYCHIATRISTS

17 Belgrave Square London, SW1X 8PG United Kingdom (Booth 1530)

This is the professional body for psychiatrists in the United Kingdom, but membership is available for overseas psychiatrists in the form of International Associateship. Journals include British Journal of Psychiatry and Advances in Psychiatric Treatment (see <www.rcpsych.org>). Please visit the exhibit to take free journal sample copies; get 20% off journal subscriptions; plus get 10% discount off book prices. To learn more about the College visit <www.rcpsych.ac.uk>.

#### RVJ INTERNATIONAL LLC / HAPPY FEET, INC.

6130 W. Flamingo Road, PMB 460 Las Vegas, NV 89103 (Booth 324)

Glycerin filled insoles provide cushion, massage, and arch support. It is thin enough to wear in any shoe, and is washable. Run, walk, or stand. Come by and try it today. It is the best on the market and take advantage of our show special.



#### SECURE TELEHEALTH

9150 Harmony Drive Pittsburgh, PA 15237 (Booth 223)

Please visit the Secure TeleHealth exhibit for more information about their products and services that will be of interest to you.

#### SEPRACOR INC.

84 Waterford Drive Marlborough, MA 01752 (Booth 2110)

Dainippon Sumitomo Pharma Co., Ltd., (DSP) is a multibillion dollar Japanese company with a diverse portfolio of pharmaceuticals, animal health, food, and specialty products. In 2009, Sepracor Inc. became an indirect, wholly-owned U.S. subsidiary of DSP. Sepracor has several marketed products, including Lunesta® brand eszopicione. The DSP-Sepracor U.S. pharmaceutical candidate pipeline is focused principally in the central nervous system and respiratory areas. Visit <www. sepractor.com>.

#### SHEPPARD PRATT HEALTH SYSTEM

6501 North Charles Street Baltimore, MD 21204 (Booth 1715)

Sheppard Pratt Health System (SPHS) is a private, nonprofit continuum of behavioral health and addiction services providing a full range of inpatients, partial, and



outpatient services for children, adolescents, adults, and older adults. Specialty programs are also offered for the treatment of trauma disorders, eating disorders, and neuropsychiatric disorders. In addition, Sheppard Pratt operates psychiatric rehabilitation programs, special education schools, residential treatment centers, and therapeutic and community housing programs; manages general hospital psychiatric services, and also provides psychiatric services to nursing homes and life care communities. For 19 consecutive years, SPHS has been ranked among the top psychiatric hospitals in the U.S. by U.S. News and World Report.

#### SHIRE PHARMACEUTICALS

725 Chesterbrook Boulevard Wayne, PA 19087 (Booth 216)

Shire is a leading global specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire centers its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. Shire's size and structure allows the company to target new therapeutic areas as opportunities arise through in-licensing and acquisition efforts focused on products in niche markets with strong intellectual property protection in the U.S. and Europe. Shire's carefully selected portfolio, aligned with a relatively small-scale sales force, delivers strong results. For further information on Shire, please visit: <www.shire.com>.

# SINGING RIVER HOSPITAL BEHAVIORAL HEALTH SERVICES

2809 Denny Avenue Pascagoula, MS 39581 (Booth 1909)

Singing River Hospital Behavioral Health Services has the following at its facility: a 14-bed medical/ psychiatric unit with senior track, Medicare-Medicaid, a 16-bed adult psychiatric unit, adult and senior structured outpatient programs; and a behavioral health outpatient physicians' practice. Located in Singing River Hospital as part of Singing River Health System Pascagoula, Ocean Springs, Mississippi. We can be contacted at (228) 809-2273 and (228) 249-3305.

#### SKYLAND TRAIL

1961 North Druid Hills Road Atlanta, GA 30329 (Booth 724)

Skyland Trail, an American Psychiatric Association's Gold Achievement Award winner, is a nationally recognized provider of high-quality, individualized, adult psychiatric services. It offers a full continuum of residential, partial, outpatient, and transitional services. Treatment encompasses care for individuals with cognitive, mood, and psychotic disorders, including dual diagnosis. Their primary care clinic also offers physical health services. For information call (404) 315-8333 or (866) 528-9593.

#### SOCIAL SECURITY ADMINISTRATION

6401 Security Boulevard, 3433 Annex Baltimore, MD 21235 (Booth 2204)

The Social Security Administration's award winning website, <www.socialsecurity.gov> provides a wealth of information. The website includes new and improved online applications for disability and retirement benefits. Today, more and more people are doing business online, and we will demonstrate our online services, promote the extra help with Medicare prescription drug costs, and distribute Social Security publications.

## PATOLOGIA DUAL (SEPD)

Londres, 17 Madrid 28028 Spain (Booth 11 - Exhibit Hall Lobby)

The 2nd International Congress Dual Disorders Addictive Behaviors and other Mental Disorders will take place October 5-8, 2011. This is a major meeting under the patronage of NIDA, WPA and other major institutions. This provides a platform for clinicians and researchers to exchange knowledge on a relevant topic. Visit the exhibit in the Exhibit Hall Lobby.

#### SOMATICS LLC

910 Sherwood Drive, Unit 23 Lake Bluff, IL 60044 (Booth 728)

Somatics LLC manufactures the Thymatron® System IV ECT instrument, now easier than ever to use (a single dial selects all functions), featuring the new Remote Treat Handle, ultrabrief 0.3 ms pulsewidth, Automatic Optimal Stimulus Selection at 0.3 and 0.5 ms, 4-channel monitor-printer, Postictal Suppression Index, automatic EEG Seizure Endpoint Detection, digital heart rate printout, and real-time on-screen monitoring via the GENIE™ IV, which also features newly-enhanced patient information software to interface with electronic record keeping systems and hospital networking platforms.

#### SOS PROGRAMS & PARENTS PRESS

1403 Mount Ayr Circle Bowling Green, KY 42103 (Booth 1633)

SOS is a cognitive therapy program for adults and teens, and a behavior therapy program for children. These programs in both English and Spanish are easily implemented by your staff and your patients. Treatment planning is made easier and is endorsed by Albert Ellis. Come to the Publishers' Book Fair for a brief DVD demo and free resources for psychiatrists. Visit <www.sosprograms.com> for more information.

#### SPARTANBURG REGIONAL

101 E. Wood Street Spartanburg, SC 29303 (Booth 2004)

Spartanburg Regional Healthcare System (SRHS) is an integrated healthcare delivery system anchored by Spartanburg Regional Medical Center, a 540-bed teaching and research hospital. The system offers a range of specialized healthcare services that is unrivaled in its five-county service region, featuring world-class specialty centers making SRHS the region's preferred provider of comprehensive healthcare services.

#### STAFF CARE, INC.

5001 Statesman Drive Irving, TX 75063 (Booth 924)

Staff Care, Inc. is the nation's leader in locum tenens staffing. Their role is to match qualified, independent contractor physicians with health care organizations requiring temporary physician services. Locum tenens physicians maintain patient care, referrals, and revenue by covering vacancies due to vacation/CME, staffing shortages, increased census, and other causes. Staff Care is also a proud sponsor of the Country Doctor of the Year award. Please visit their website at <www.staffcare.com> or call them at (800) 685-2272.

## SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION (SAMHSA)

One Choke Cherry Road Rockville, MD 20857 (Booth 926)

Substance Abuse and Mental Health Services (SAMHSA) is a public health agency within the Department of Health and Human Services. The agency is responsible for improving the accountability, capacity, and effectiveness of the Nation's substance abuse prevention, addictions treatment, and mental health services delivery system.

#### SUITEMED, LLC

333 Hegenberger Road, Suite 800 Oakland, CA 94621 (Booth 2305)

Please visit the SuiteMed, LLC exhibit for more information about their products and services that will be of interest to you.

#### SZ MAGAZINE

P.O. Box 59 Buffalo, NY 14205-0059 (Booth 1931)

SZ Magazine is a quarterly publication that provides information for health professionals and offers inspiration to individuals diagnosed with schizophrenia, their families, and caregivers. SZ Magazine features articles about schizophrenia therapies and medications, as well as personal stories. As a trusted source of information on mental wellness, readers learn coping techniques, industry trends, and treatment options.



#### TEVA PHARMACEUTICALS

1090 Horsham Road North Wales, PA 19454 (Booth 1723)

Teva Pharmaceuticals, the nation's leading generic manufacturer, markets over 320 products and 1,100 SKUs. The company manufactures products in all major therapeutic areas, including immunosuppressive agents to prevent the rejection of kidney, liver, and heart allograft, as well as atypical antipsychotics for the management of severely ill schizophrenic patients.

#### THERAMANAGER, LLC

98 Floral Avenue, Suite 202 New Providence, NJ 07974 (Booth 1719)

TheraManager is an all-in-one, easy-to-use practice management and EMR software that provides scheduling, electronic billing, EMR, and electronic prescriptions, including renewal requests. It is designed for both solo psychiatrists and large mental health practices. The EMR is exceptional with multiple options including templates, a unique form capability that speeds creating notes by at least a factor often, and even stores handwriting. Please check us out.



#### U.S. ARMY CIVILIAN CORPS

2050 Worth Road, Suite 6 Fort Sam Houston, TX 78234 (Booth 1903)

Vast Opportunities. Exceptional Benefits. Rewarding Careers. Practice your specialty with one of the largest health care and dental care networks in the world. The Army Medicine Civilian Corps provides world-class health and dental care at more than 70 facilities throughout the U.S., Europe, and the Pacific. With over 2,500 positions available, come meet our recruiters and explore your opportunities.

## U.S. DEPARTMENT OF STATE, OFFICE OF MEDICAL SERVICES

2401 E Street, NW, L-217 Washington, DC 20522 (Booth 1812)

The U.S. Department of State, Office of Medical Services offers a unique career in psychiatry in an overseas setting. They are looking for board-certified psychiatrists with at least five years of post-residency clinical experience in adult or child/adolescent psychiatry. The Department of State provides primary psychiatric care and preventative mental

health programs to U.S. diplomats and their families worldwide. Visit <www.careers.state.gov> for more information.

#### U.S. NAVY RECRUITING COMMAND

5722 Integrity Drive Millington, TN 38054 (Booth 2202)

With the U.S. Navy Medical Corps, become a leader within the medical world-with financial assistance available. Learn more at the Navy booth or visit <www.navy.com/healthcare>.

#### U.S. PUBLIC HEALTH SERVICE (Booth 2409)

Please visit the U.S. Public Health Service exhibit for more information about their products and services that will be of interest to you.

#### UPLIFT TECHNOLOGIES INC.

19-10 Morris Drive Dartmouth, NS B3B 1K8 Canada (Booth 423)

Since 1993, Uplift Technologies has provided Day-Light Bright Light Therapy Systems that have been clinically proven and used by researchers worldwide! Day-Lights help those suffering from seasonal and non-seasonal conditions: The Winter Blues, Circadian Sleep Disorders, Jet Lag, or Shift Work Adjustment. Day-Light Bright Light Therapy Systems are built to meet the guidelines leading experts recommend for effective therapy. Visit our booth for more information.



#### VA NORTHWEST HEALTH NETWORK

P.O. Box 1035 Portland, OR 97207 (Booth 2111)

The VA Northwest Health Network is a system of B medical centers and 31 clinics throughout Alaska, Idaho, Oregon, and Washington. We can offer you the rare opportunity to help our nation's veterans continue to lead strong, productive lives. We would love for you to join us. Visit <www.vacareers.va.gov> or email us at <visn20mentalhealthpositions@va.gov>.

#### VALANT MEDICAL SOLUTIONS

P.O. Box 21405 Seattle, WA 98111 (Booth 823)

"The Psychiatrist's EasyMR"—Valant is the first and only company to offer a 100% web-based electronic medical record (EMR) and practice management suite designed exclusively for psychiatrists. Stop by Booth #823 for a live demo and feature details.

Take home a free Netbook laptop with your EMR purchase!

#### VALIDUS PHARMACEUTICALS, LLC

119 Cherry Hill Road, Suite 310 Parsippany, NJ 07054 (Booth 2230)

Equetro<sup>®</sup> (carbamazepine extended release) Capsules: Effectively treats acute manic and mixed episodes associated with Bipolar 1 Disorder. Marplan® (isocarboxazid) Tablets: For the treatment of major depressive disorders.

#### VISTA STAFFING SOLUTIONS, INC.

275 East 200 South Salt Lake City, UT 84111 (Booth 1232)

VISTA Staffing Solutions helps you achieve your immediate career goals and plan your professional future. Find the perfect fit in locum tenens assignments, extended placements, or permanent positions in the U.S., or six- to twelve-month placements in Australia, New Zealand, Bermuda, and beyond. You control where, when, how, and how much you work. Visit <www.VistaStaff.com>, or call us at (800) 366-1884.



#### W.W. NORTON

500 574 Avenue New York, NY 10110 (Booth 1529)

Norton Professional Books publishes high-quality books for psychiatrists, psychotherapists, psychologists, and other mental health professionals. New titles include: The Neuroscience of Psychotherapy, Second Edition; Treating Child & Adolescent Mental Illness; The Dao of Neuroscience; The Behavioral Neuroscience of Adolescence; Kundalini Yoga for Complex Psychiatric Disorders; and many more.

#### WILEY - BLACKWELL (Booth 1624)

Please visit the Wiley - Blackwell exhibit for more information about their products and services that will be of interest to you.

# WORLD ASSOCIATION FOR SOCIAL PSYCHIATRY (WASP)

44 Avenue de l'Armee Royale Casablanca 20020 Morroco (Booth 13)

The WASP 2010 20th World Congress will be held October 23-27, 2010. Please visit the World Association for Social Psychiatry exhibit for more information about this meeting.



#### **EARLY MEETING REGISTRATION DISCOUNT:**

Register during the 2010 Annual Meeting for Hawaii in 2011, and receive the 2010 meeting registration rates for 2011.

Why YOU should attend this meeting:

- Update your knowledge base
- Earn Category 1 CME credits
- Network with colleagues and meet your peers and industry leaders
- Find the right products and the best deals on the exhibit floor
- Save money on next year's registration prices
- Take advantage of one of America's greatest destinations with earlier ending sessions

This offer is only available onsite from May 21-26, 2010.

#### **EARLY BIRD HOUSING:**

From May 20-26, 2010 Secure Your First Choice Hotel for Hawaii 2011!

During the 2010 Annual Meeting Only (May 20-26), housing reservations for 2011 will be open to 2010 APA attendees

When this year's Annual Meeting is closed, housing will be closed until December!

Visit www.psych.org (May 20-26, 2010 only) and click on the links for the 2011 Annual Meeting or visit the Travel Planners booth in Lobby B, The Morial Convention Center.

Get your questions answered. Learn about new programs.



Visit the

# APA Member Center

next to the APPI Bookstore in the Exhibit Hall, Morial Convention Center


Saturday, May 22 10:00 am - 4:00 pm Sunday, May 23 10:00 am - 4:00 pm Monday, May 24 10:00 am - 4:00 pm Tuesday, May 25 10:00 am - 4:00 pm











EXHIBITORS AS OF APRIL 16, 2010

ARCHITECTURAL/ENGINEERING FIRM	MentalNote	633
CANNON DESIGN328	Netsmart Technologies	2303
	SUITEMED, LLC	2305
COMPUTERIZED NEUROCOGNITIVE TESTING	THERAMANAGER LLC	1719
CNS VITAL SIGNS827	VALANT MEDICAL SOLUTIONS	823
CONSUMER MAGAZINE	FEDERAL GOVERNMENT	
SZ MAGAZINE1931	Defense Centers of Excellence (DCOE) for Psychological Health and Traumatic Brain Injury	2405
CORRECTIONAL HEALTH CARE		
MHM Services, Inc1236	FINANCIAL SERVICES  Merrill Lynch	2237
DIAGNOSTIC TOOLS	HOSPITAL/RESIDENTIAL AND	
ANT - Advanced Neuro Technology2335	OUTPATIENT CLINICS	
BIOBEHAVIORAL DIAGNOSTICS COMPANY2413	Austen Riggs Center	1722
MAGVENTURE A/S2138	Borgess Health	2002
	Haven Behavioral Healthcare	2105
ECT	McLean Hospital	1735
MECTA Corporation716	THE MENNINGER CLINIC	2235
SOMATICS LLC728	NewYork-Presbyterian Hospital	316
EDUCATIONAL NON-PROFIT ASSOCIATION	Pine Rest Christian Mental Health Services	2013
AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW922	THE READING HOSPITAL AND MEDICAL CENTER	2309
AMERICAN ASSOCIATION FOR GERIATRIC PSYCHIATRY 227	INSURANCE	
EDUCATIONAL/PROFESSIONAL	THE PSYCHIATRISTS' PROGRAM	916
SUPPORT ORGANIZATIONS	American Professional Agency	2412
American Association of Community Psychiatrists1021	LIFE SCIENCES DATA COMPANY	
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION (SAMHSA)926	CNS Response, Inc.	1825
ELECTRONIC HEALTH RECORDS/	LOCUM TENENS/RECRUITMENT	
ELECTRONIC MEDICAL RECORDS	FAVORITE PHYSICIANS	_
ASP,MD, INC2403	GLOBAL MEDICAL STAFFING	
EMR-BEAR, LLC2313	Interim Physicians	
ICANotes1736	MEDICAL DOCTOR ASSOCIATES	1738



# EXHIBITORS BY PRODUCT/SERVICE LISTING

MAGAZINE	PHARMACEUTICAL COMPANIES
BP MAGAZINE/ESPERANZA2134	ALKERMES, INC 1815, 2214
MARKET RESEARCH	ASTRAZENECA PHARMACEUTICALS416
MARKET RESEARCH EXHIBITCHEK2233	AVANIR PHARMACEUTICALS, INC538
EAHIBITCHER2233	BRISTOL-MYERS SQUIBB COMPANY/ OTSUKA AMERICA PHARMACEUTICAL, INC1032
MEDICAL BILLING SERVICE	DSP/Sepracor Inc2102
ELECTROMEDICAL PRODUCTS INTERNATIONAL, INC 815	
FISHER WALLACE LABORATORIES1238	DEY PHARMA, L.P
THE MAGSTIM COMPANY LIMITED726	Forest Pharmaceuticals, Inc
MEDICAL BILLING PROFESSIONALS1337	JANSSEN, DIVISION OF ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC733
Neuronetics, Inc. 224	LILLY USA, LLC734
	MERCK
MEDICAL DEVICE	Novartis Pharmaceuticals 638, 1716, 2101, 2301
ACIGI RELAXATION/FUJIIRYOKI2302	PAMLAB, LLC415
MEDICAL EDUCATION	PFIZER, INC. 1816
15 <sup>th</sup> World Congress of Psychiatry	RECKITT BENCKISER PHARMACEUTICALS2330
American Physician Institute for Advanced Professional Studies824	SEPRACOR INC2110
MASSACHUSETTS GENERAL	Shire Pharmaceuticals216
HOSPITAL ACADEMY	TEVA PHARMACEUTICALS1723
SOCIEDAD ESPANOLA DE PATOLOGIA DUAL (SEPD)11	Validus Pharmaceuticals, LLC2230
WORLD ASSOCIATION FOR SOCIAL PSYCHIATRY13	
	PHARMACEUTICAL, DISEASE STATE AWARENESS
NON-PROFIT SELF-HELP GROUP OR PROFESSIONAL ASSOCIATION	BOEHRINGER INGELHEIM PHARMACEUTICALS, INC818
Alcoholics Anonymous1234	
American Board of Psychiatry and Neurology, Inc919	PHOTOTHERAPY
American College of Psychiatrists	THE LITEBOOK COMPANY LTD634
	Northern Light Technologies816
Association of Women Psychiatrists1023	PHILIPS CONSUMER LIFESTYLE1838
CHRISTIAN MEDICAL ASSOCIATION, PSYCHIATRY SECTION936	UPLIFT TECHNOLOGIES INC423
International Psychogeriatric Association (IPA)826	PRACTICE MANAGEMENT
MAYO CLINIC925	American Express® OPEN737
NARSAD AND NARSAD ARTWORKS938	
National Institute of Mental Health1025	PROFESSIONAL SUPPORT
National Institute on	Association of Gay and Lesbian Psychiatrists932
ALCOHOL ABUSE AND ALCOHOLISM1031	ECNP Congress - European College of
Physicians for a National Health Program923	NEUROPSYCHOPHARMACOLOGY 12



### EXHIBITORS BY PRODUCT/SERVICE LISTING

PSYCHIATRIC FACILITIES	PSYCHIATRIC TIMES	.1821
Austin Lakes Hospital, Texas Neuro Rehab and Hickory Trail2212	RAPID PSYCHLER PRESS	.1336
Bassett Healthcare Network -	ROUTLEDGE JOURNALS	.1434
BASSETT MEDICAL CENTER1904	ROUTLEDGE	.1438
CBR YOUTH CONNECT326	ROYAL COLLEGE OF PSYCHIATRISTS	.1530
THE CENTER FOR EATING DISORDERS AT SHEPPARD PRATT1717	SOS Programs & Parents Press	.1633
Gould Farm1933	W.W. Norton	.1529
La Amistad Foundation, Inc.,	Wiley - Blackwell	.1624
LAKEWOOD CENTER2206		
PINE REST CHRISTIAN MENTAL HEALTH SERVICES2013	RECRUITMENT	
PSYCHIATRIC SOLUTIONS, INC	ALL STAR RECRUITING	
RIVERVALLEY BEHAVIORAL HEALTH819	Allina Hospitals and Clinics	_
SHEPPARD PRATT HEALTH SYSTEM1715	ARMY HEALTHCARE RECRUITING	
Singing River Hospital Behavioral	BHR Corporation	
HEALTH SERVICES1909	CAREERSTAFF UNLIMITED	
SKYLAND TRAIL724	CENTER FOR FAMILY GUIDANCE (CFG)	
	CompHealth	.2109
PUBLISHERS/BOOKSELLERS	DEPARTMENT OF VETERANS AFFAIRS	.1804
AMERICAN PSYCHOLOGICAL ASSOCIATION1636	DOCTORS BEHAVIORAL HEALTH CENTER	
BIOMED CENTRAL 1538	DULUTH CLINIC	.2011
CAMBRIDGE UNIVERSITY PRESS1533	FLOYD BEHAVIORAL HEALTH CENTER	
CLINICAL PSYCHIATRY NEWS720	GENESIS HEALTHCARE SYSTEM	
CURRENT PSYCHIATRY/QUADRANT HEALTHCOM1620	GROUP HEALTH PERMANENTE	
ELSEVIER1429	HEALTH MATCH BC	.1902
Guilford Publications1534	HEALTHFORCEONTARIO MARKETING AND RECRUITMENT AGENCY	.1012
HOGREFE PUBLISHING	Hospital Corporation of America (HCA)	
INTELLISPHERE, LLC1435	INTERNATIONAL MEDICAL RECRUITMENT	
JOHNS HOPKINS UNIVERSITY PRESS1430	JACKSON & COKER	
JONES & BARTLETT1629	KAISER PERMANENTE	
Karger Publishers1726	Kiwis STAT	_
La Lettre du Psychiatre425	LocumTenens.com	
Lippincott Williams & Wilkins, Wolters-Kluwer1616	MAXIM PHYSICIAN RESOURCES	
MBL Communications, Inc1730	MEDICAL ASSOCIATES CLINIC	
	LILLICAL HOSOCIATES CLIMIC	.1901
NATURE PUBLISHING GROUP 1221	MINISTRY HEALTH CARE	181
NATURE PUBLISHING GROUP1331 THE NEW YORK TIMES1632	MINISTRY HEALTH CARE	
NATURE PUBLISHING GROUP	MINISTRY HEALTH CARE  NETSMART TECHNOLOGIES  NORTH CAROLINA OFFICE OF RURAL HEALTH	.2303



### EXHIBITORS BY PRODUCT/SERVICE LISTING

PHYSICIAN FINDERS2429	NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)1033
PIKES PEAK BEHAVIORAL HEALTH GROUP2404	OREGON STATE HOSPITAL1906
PINE REST CHRISTIAN MENTAL HEALTH SERVICES2013	SOCIAL SECURITY ADMINISTRATION2204
PRACTICELINK.COM1913	U.S. DEPARTMENT OF STATE, OFFICE OF MEDICAL SERVICES1812
PSYCHIATRISTS ONLY, LLC915	OFFICE OF MEDICAL SERVICES1812
QTC Medical Services825	SUBSTANCE ABUSE
THE READING HOSPITAL AND MEDICAL CENTER2309	TREATMENT CENTERS
REGISTRY OF PHYSICIAN SPECIALISTS1724	ROSECRANCE HEALTH NETWORK636
ROBERT YOUNG CENTER FOR COMMUNITY MENTAL HEALTH2003	SUICIDE RESISTANT SOLUTIONS
Spartanburg Regional2004	ATLANTIC COASTAL SUPPLY, INC1835
Staff Care, Inc924	TELEHEALTH NETWORK
U.S. ARMY CIVILIAN CORPS1903	FOREFRONT BEHAVIORAL TELECARE2103
U.S. NAVY RECRUITING2202	TOREFRONT DEHAVIORAL TELECARE2103
U.S. Public Health Service2409	THERAPEUTIC MASSAGE EQUIPMENT
VA Northwest Health Network2111	ACIGI RELAXATION/FUJIIRYOKI2302
VISTA STAFFING SOLUTIONS, INC1232	RVJ International LLC /Happy Feet, Inc324
STATE/FEDERAL	WEBSITE DESIGN SEARCH
FDA/ Division of Drug Marketing, Advertising, and Communications2136	ENGINE OPTIMIZATION  MEDNET TECHNOLOGIES, INC320





# Monday, May 24 12:30 pm — 1:30 pm



### Exhibit Hall B-D, First Level, **Morial Convention Center**

Open to all registrants

Join us for fun, food, meet colleagues and visit the exhibits. Box lunch will be provided first come first served and soft drinks.

CAREER FAIR EXHIBITORS	ROBERT YOUNG CENTER FOR
ALL STAR RECRUITING2001	COMMUNITY MENTAL HEALTH2003
Allina Hospitals and Clinics2009	SINGING RIVER HOSPITAL BEHAVIORAL HEALTH SERVICES1909
U.S. Army Healthcare Recruiting2012	Spartanburg Regional
BASSETT HEALTHCARE NETWORK - BASSETT MEDICAL CENTER1904	U.S. ARMY CIVILIAN CORPS1903
BHR Corporation	U.S. DEPARTMENT OF STATE, OFFICE OF MEDICAL SERVICES1812
BORGESS HEALTH2002	VA Northwest Health Network2111
CENTER FOR FAMILY GUIDANCE (CFG) HEALTH NETWORK2006	PUBLISHER'S BOOK FAIR EXHIBITORS
COMPHEALTH2109	AMERICAN PSYCHOLOGICAL ASSOCIATION1636
DEPARTMENT OF VETERANS AFFAIRS1804	BIOMED CENTRAL 1538
DOCTORS BEHAVIORAL HEALTH CENTER2312	CAMBRIDGE UNIVERSITY PRESS1533
DULUTH CLINIC2011	CURRENT PSYCHIATRY/ QUADRANT HEALTHCOM1620
FAVORITE PHYSICIANS2113	ELSEVIER
FLOYD BEHAVIORAL HEALTH CENTER1905	GUILFORD PUBLICATIONS
GLOBAL MEDICAL STAFFING1810	HOGREFE PUBLISHING
HEALTH MATCH BC1902	INTELLISPHERE, LLC
HEALTHFORCEONTARIO MARKETING AND RECRUITMENT AGENCY	JOHNS HOPKINS UNIVERSITY PRESS
HOSPITAL CORPORATION OF AMERICA (HCA)2010	JONES & BARTLETT
International Medical Recruitment1910	LIPPINCOTT WILLIAMS & WILKINS, WOLTERS-KLUWER1616
JACKSON & COKER1802	
KAISER PERMANENTE2005	MBL Communications, Inc1730
Kiwis STAT2306	NATURE PUBLISHING GROUP1331
MEDICAL ASSOCIATES CLINIC1901	THE NEW YORK TIMES1632
MINISTRY HEALTH CARE	OXFORD UNIVERSITY PRESS1330
NETSMART TECHNOLOGIES2303	RAPID PSYCHLER PRESS1336
North Carolina Office of Rural Health1911	ROUTLEDGE JOURNALS1434
OREGON STATE HOSPITAL	ROUTLEDGE 1438
PINE REST CHRISTIAN	ROYAL COLLEGE OF PSYCHIATRISTS1530
MENTAL HEALTH SERVICES2013	SOS Programs & Parents Press1633
PRACTICELINK.COM1913	W.W. NORTON
THE READING HOSPITAL AND MEDICAL CENTER2309	WILEY - BLACKWELL 1624

# 44 EACH DAY IS CHALLENGING. EACH DAY IS EACH DAY IS



### BE A LEADER IN MENTAL HEALTH.



MEET WITH A COMMISSIONED CORPS OFFICER THE CONFERENCE.





### We're recruiting Psychiatrists. '



Where all your skills **come together** to treat the most complex needs.

We offer challenging and rewarding careers that allow you to enrich the futures of people who need you.

- > Loan repayment program
- Excellent health insurance benefits
- > State retirement package
- Paid malpractice

For career information, contact: Michael Taylor 1-800-533-8847 michael.taylor@dhhs.nc.gov www.dhhs.state.nc.us/dsohf/

Booth #1911



Division of State Operated Healthcare Facilities

### Now recruiting:

## Psychiatrist • Neuropsychologists • Mental Health Nurse Practitioner

The Reading Hospital and Medical Center in West Reading, PA, is seeking candidates to fill the following openings:

**Psychiatrist** - Full-time outpatient position at our Main Campus

Neuropsychologists - Full-time inpatient and full-time inpatient/outpatient for our Post-Acute Rehabilitation Hospital

Mental Health Nurse Practitioner -Full-time outpatient (with some inpatient consultation) for our Mental Health Center



Excellent schools and colleges and a multitude of cultural, recreational, shopping and sporting attractions are in the vicinity. You will enjoy country living with easy access to shore points, two airports and major metro areas, such as Philadelphia, Washington, DC and New York City.

> To apply, send your CV to: Maddie Wagner, Physician Recruiter, madeline.wagner@trhmg.org.

To learn more, visit our website: www.readingdocs.org

Visit us at Booth Number 2309 at the American Psychiatric Association Annual Meeting in New Orleans

### About Our Psychiatry Department

- 35+ year history
- 40-bed, state-of-the-art inpatient pavilion
- 2 partial-hospitalization programs
- Residential non-medical detoxification and rehabilitation center
- Intensive outpatient dual disorder program
- Multiple outpatient centers located throughout Berks County

### What We Offer

- · Competitive salary
- Medical/dental/life insurance
- · Occurrence-based malpractice insurance
- Generous paid time off
- CME allowance
- Retirement plans
- Student loan forgiveness programs



The Reading Hospital and Medical Center



### **Adult Psychiatry** St. George, Utah

Intermountain Healthcare is recruiting 1 BC/BE adult psychiatrist to join our Medical Group. Outpatient medicine with only 1 weekend per month of inpatient coverage. 4-day clinic week. Call: 1 in 4. Physician will assist in the management of patients with spine and pain disorders with concomitant psychiatric illnesses. Interest/ability in providing outpatient chemical dependency consultation/direction care for chemical dependency in a setting of chronic pain. Interest/ability in leading/directing the cognitive behavioral therapy component of a functional restoration program for spine and pain disorders is highly desirable. This is a key position, and in some cases the psychiatrist will function as the point person. The spine program is based on a one-stopshopping concept. Psych will be involved to perform psych eval if that is what is determined as a key need or if patients are chemically dependent. The spine clinic piece will start out as one day per week and as the program grows, will never exceed two days per week. The outpatient clinic is fully staffed and well managed. Employment with salary guarantee transitioning to productivity and bonuses. Full Intermountain benefits. Relocation provided.

Send/e-mail/fax CV to: Intermountain Healthcare Attn: Wilf Rudert, Physician Recruiting Dept. 36 S. State Street, 21st Floor, Salt Lake City, UT 84111 800-888-3134 | Fax: 801-442-2999 | PhysicianRecruit@imail.org

http://intermountain.net/docjobs





POSITION

### Director of Inpatient Psychiatric Services at the University of Miami Hospital and Assistant/Associate/ Professor of Psychiatry & Behavioral Sciences

The Department of Psychiatry and Behavioral Sciences of the University of Miami (UM) Miller School of Medicine is in an exciting phase of growth and expansion under the leadership of a new chairman, Charles B. Nemeroff, M.D., Ph.D.

We are recruiting for a new full time faculty member to serve as the Director of Inpatient Psychiatric Services at the prestigious University of Miami Hospital. The University of Miami Hospital, located in the heart of Miami, is an accredited 560-bed, full service hospital that provides acute care and private rooms for all patients. UMH is committed to education and success; remaining true to its mission, patients and community.

This individual will be responsible for leading and directing the UMH Inpatient Psychiatric Services and be involved in the evaluation and short-term treatment of patients who present to the unit, teaching of medical students, supervision of psychiatry residents, and opportunities for participation in research and other academic activities. We seek an experienced practitioner and administrator, able to handle the demands of this challenging opportunity.

The successful and dynamic candidate will be adept in handling all varieties of psychiatric services and must demonstrate excellent interpersonal and communication skills, which are essential to partnership with other departments and our community. Furthermore, a track record of mentoring is highly desirable. M.D. or M.D. / PhD is required as well as board certification in psychiatry and a current unrestricted Florida medical license.

The University of Miami offers competitive compensation and excellent benefit packages. Salary will be based upon education and experience, and hiring is dependent on meeting the requirements for Florida medical licensure, board certifications and credentialing with the University of Miami and affiliated

Interested candidates should send letter and CV addressed to Charles B. Nemeroff, M.D., Ph.D., Leonard M. Miller Professor and Chairman, Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, 1120 NW 14th Street, Suite 1455, Miami, Florida 33136 or email mgerdes@med.miami.edu.

### **Adult Psychiatrist:**

Cumberland, Maryland, needed to work 32-40 hours per week in modern JCAHO Accredited State of Maryland Psychiatric Hospital, located in the beautiful mountains of Western Maryland. This position would serve as a unit physician for a 22-bed adult unit. This position would also serve as the leader of a multi-disciplinary treatment team including psychologists, social workers, occupational therapists and nurses. Position requires minimal contact with Managed Care Providers. This is a contractual position paying \$110-\$113 per hour with the availability of health benefits and 401K plans. Additional income is available by working on-duty (evenings, nights and weekends) coverage if interested. Send CV to Thomas B. Finan Center, Clinical Director, PO Box 1722, Cumberland, MD 21501-1722. Interested psychiatrists may also inquire by calling 1-888-854-0035. The Thomas B. Finan Center is an Equal Opportunity Employer

# HUMAN RIGHTS = AWARD

→ PURPOSE ←

The Human Rights Award was established to recognize an individual and an organization whose efforts exemplify the capacity of human beings to act courageously and effectively to prevent human rights violations, to protect others from human rights violations and their psychiatric consequences, and to help victims recover from human rights abuses.

→ NOMINATION PROCEDURES ↔

APA members are asked to submit nominations by July 1, 2010 to:

Council on Psychiatry and Law American Psychiatric Association c/o Yoshie Davison, Staff Liaison 1000 Wilson Blvd., Suite 1825 Arlington, VA 22209 E-mail: advocacy@psych.org

The nomination letter should succinctly describe the contributions that are the basis for the nomination and be accompanied by a curriculum vitae of the nominee. The Council on Psychiatry and Law will serve as the award review panel in determining the recipients of this award. The recipients will receive a plaque which will be awarded during the Convocation at the APA's Annual Meeting in May 2011.

# Explore a practice opportunity unlike any other.

Since 1875, Pikes Peak Behavioral Health Group has created help and hope for residents of Colorado Springs and surrounding areas. We provide a broad range of services to meet individual and family needs in mental health, substance abuse, and much more. Nationally recognized for our philosophy of recovery, we have outstanding opportunities for:

### Licensed Psychiatrists (MD/DO)

If you share our vision of creating a mentally healthy community where the worth and dignity of every person is promoted and encouraged, we would like to talk with you. Stop by our booth to learn more about our dynamic team environment. We will be setting up interviews that will be conducted around the conference schedule.

Committed to being an employer of choice, Pikes Peak Behavioral Health Group offers a comprehensive benefits program in order to attract and retain the best employees. Feel free to contact Mariah McCarty, Manager of Recruiting at:  $\textbf{719-499-9540 or Mariah.} Mc Carty @ppbhg.org. \ Visit us online at www.ppbhg.org.$ 



### PHYSICIAN FINDERS

Nationwide Physician Placement - 800-229-9759

THE BRATTLEBORO RETREAT, located in Brattleboro, Vermont, is pleased to announce immediate opportunities for three medical staff positions in our comprehensive psychiatric facility. We are seeking leaders in the following positions:

· Inpatient adult psychiatry, Inpatient Psychiatry for LGBT patients and outpatient psychiatry.

http://www.brattlebororetreat.org - The Brattleboro Retreat webpage

PROVIDENCE BEHAVIORAL HEALTH HOSPITAL, located in Springfield, Massachusetts, is searching for a Medical Director in the following specialty areas, Substance Abuse Services, Adult Services and Child and Adolescent Services.

The facility has 124 inpatient beds and is comprised of 3 psychiatric units treating Adults, Older Adults, Child and Adolescents; a 30 bed inpatient Detoxification unit, an Acute Residential Treatment program for children and adolescents and a Methadone Maintenance Treatment

http://www.mercycares.com/pages.asp?id=514

SUNPOINTE HEALTH would like to announce our search for an additional psychiatrist to join our team of 9 psychiatrists and 37 providers in our privately owned practice in State College, Pennsylvania.

Our group, founded in 1998, has tripled in size in the last 6 years. We occupy 28k square feet of beautiful office space, which is one of 9 practice sites in which we maintain a presence. Currently, we see over 4k patient visits each month.

http://forabrighterfuture.com/


For information about these positions and others, please contact Gene.Corbett@physicianfinders.com.




EXHIBITORS A	AS OF	APRIL	16,	2010
--------------	-------	-------	-----	------

!	Exhibit Booths 11-14 are located	636	Rosecrance Health Network
	in the Exhibit Hall Lobby.	638	Novartis Pharmaceuticals
		716	MECTA Corporation
11	SOCIEDAD ESPANOLA DE PATOLOGIA DUAL (SEPD)	720	CLINICAL PSYCHIATRY NEWS
12	ECNP Congress - European College of	724	SKYLAND TRAIL
12	NEUROPSYCHOPHARMACOLOGY	726	THE MAGSTIM COMPANY LIMITED
13	World Association for Social Psychiatry	728	SOMATICS LLC
14	15TH WORLD CONGRESS OF PSYCHIATRY	733	Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
		734	LILLY USA, LLC
	The following booths are located	737	American Express® OPEN
	in the Exhibit Hall.	815	ELECTROMEDICAL PRODUCTS INTERNATIONAL, INC.
215	CAREERSTAFF UNLIMITED	816	Northern Light Technologies
216	SHIRE PHARMACEUTICALS	818	Boehringer Ingelheim Pharmaceuticals, Inc.
217	PRACTICEFUSION	819	RiverValley Behavioral Health
224	Neuronetics, Inc.	823	VALANT MEDICAL SOLUTIONS
227	American Association for Geriatric Psychiatry	824	American Physician Institute for Advanced Professional Studies
316	New York-Presbyterian Hospital	825	QTC Medical Services
320	MedNet Technologies, Inc.	826	International Psychogeriatric
324	RVJ International LLC / Happy Feet, Inc.		Association (IPA)
326	CBR Youth Connect	827	CNS VITAL SIGNS
328	CANNON DESIGN	828	LEXICOR MEDICAL TECHNOLOGY, LLC
415	Pamlab, LLC	915	Psychiatrists Only, LLC
416	ASTRAZENECA PHARMACEUTICALS	916	The Psychiatrists' Program
419	MAXIM PHYSICIAN RESOURCES	917	American College of Psychiatrists
423	Uplift Technologies Inc.	919	American Board of Psychiatry
425	La Lettre du Psychiatre	919	AND NEUROLOGY, INC.
434	Forest Pharmaceuticals, Inc.	922	American Academy of Psychiatry and the Law
534	NATIONAL DEATH INDEX	923	PHYSICIANS FOR A NATIONAL
538	AVANIR PHARMACEUTICALS, INC.	923	HEALTH PROGRAM
633	MENTALNOTE	924	STAFF CARE, INC.
634	THE LITEBOOK COMPANY LTD.	925	Mayo Clinic










# REGISTRATION







1837	GENESIS HEALTHCARE SYSTEM	2134	BP MAGAZINE/ESPERANZA
1838	PHILIPS CONSUMER LIFESTYLE	2136	FDA/ Division of Drug Marketing, Advertising, and Communications
1901	MEDICAL ASSOCIATES CLINIC	2138	MagVenture A/S
1902	HEALTH MATCH BC	2202	U.S. NAVY RECRUITING
1903	U.S. Army Civilian Corps	2202	Social Security Administration
1904	Bassett Healthcare Network - Bassett Medical Center	2204	La Amistad Foundation, Inc.,
1905	FLOYD BEHAVIORAL HEALTH CENTER	2200	LAKEWOOD CENTER
1905	OREGON STATE HOSPITAL	2210	Dey Pharma, L.P.
		2212	Austin Lakes Hospital, Texas Neuro Rehab and Hickory Trail
1909	Singing River Hospital Behavioral Health Services	0011	
1910	International Medical Recruitment	2214	ALKERMES, INC.
1911	North Carolina Office of Rural Health	2216	Merck
1912	HealthForceOntario Marketing	2230	VALIDUS PHARMACEUTICALS, LLC
	AND RECRUITMENT AGENCY	2233	EXHIBITCHEK
1913	PRACTICELINK.COM	2235	THE MENNINGER CLINIC
1931	SZ Magazine	2237	MERRILL LYNCH
1933	Gould Farm	2301	Novartis Pharmaceuticals
2001	ALL STAR RECRUITING	2302	ACIGI Relaxation/Fujiiryoki
2002	Borgess Health	2303	Netsmart Technologies
2003	ROBERT YOUNG CENTER FOR COMMUNITY MENTAL HEALTH	2304	CORRECTIONAL MEDICAL SERVICES
2004	Spartanburg Regional	2305	SUITEMED, LLC
2005	KAISER PERMANENTE	2306	Kiwis STAT
2005	CENTER FOR FAMILY GUIDANCE (CFG)	2309	THE READING HOSPITAL AND MEDICAL CENTER
2006	HEALTH NETWORK	2310	MASSACHUSETTS GENERAL HOSPITAL ACADEMY
2009	Allina Hospitals and Clinics	2311	GROUP HEALTH PERMANENTE
2010	HOSPITAL CORPORATION OF AMERICA (HCA)	2312	Doctors Behavioral Health Center
2011	DULUTH CLINIC	2313	EMR-BEAR, LLC
2012	ARMY HEALTHCARE RECRUITING	2314	Merck
2013	PINE REST CHRISTIAN MENTAL HEALTH SERVICES	2330	RECKITT BENCKISER PHARMACEUTICALS
2101	Novartis Pharmaceuticals	2332	AssureRx Health
2102	DSP/Sepracor Inc.	2335	ANT - Advanced Neuro Technology
2103	FOREFRONT BEHAVIORAL TELECARE	2403	ASP.MD, Inc.
2105	Haven Behavioral Healthcare	2405	Defense Centers of Excellence (DCOE) for
2109	СомрНеацтн		PSYCHOLOGICAL HEALTH AND TRAUMATIC BRAIN INJURY
2110	SEPRACOR INC.	2409	U.S. Public Health Service
2111	VA Northwest Health Network	2411	Little Hill – Alina Lodge
2113	FAVORITE PHYSICIANS	2413	BIOBEHAVIORAL DIAGNOSTICS COMPANY

# **SUBSCRIBE TO**

# **PSYCHIATRIC SERVICES**



- Evidence-based and best practices: delivering effective services and programs
- Recovery-oriented, client-centered care: how systems are being transformed
- Racial-ethnic disparities in care: how they arise and how to overcome them
- Criminal justice involvement and homelessness: diversion and housing programs
- Use of medications: improving adherence, monitoring trends and treatment adequacy
- Medicaid changes and recent court cases: what they mean for your practice

Visit the APPI Bookstore for more information or to subscribe.

Bookstore Hours: Saturday, May 22 to Tuesday, May 25, 10:00am - 4:00pm



The First and Last Word in Psychiatry

www.appi.org • Toll Free: 1-800-368-5777 • Fax: 703-907-1091 • Email: appi@psych.org

# **APA Member Benefits and Services** That Make a Difference!

RECEIVE DISCOUNTS ON QUALITY SERVICES for you and your practice with these additional benefits:

### Professional Benefits

Free Web Page on PsychSites.com

Promote your practice, career, and expertise to patients and colleagues

FDA-mandated drug Alerts by Email

Sign up for secure online drug and patient safety alerts through the Health Care Notification Network (HCNN)

Clinical Reference Applications at the Point-of-Care

Receive 20% discount off retail pricing on electronic subscription products through Epocrates

APA Job Bank

Online career search and recruitment

American Psychiatric Publishing, Inc. (APPI)

Receive a 10% discount on all APPI titles (Members-in-Training receive 25% off APPI titles)

### Financial Tools

Merrill Lynch Retirement and Investment Planning

Meet your short and long-term retirement and financial planning goals

Bank of America Credit Cards and Financial Tools

Earn WorldPoints™ Rewards

Solveras Payment Systems

Affordable tools to effectively manage patient payments

### ■ Professional Liability Insurance and Money Saving Legal Consultation

The Psychiatrists' Program

Medical malpractice insurance for psychiatrists

Legal Consultation

Find money-saving legal consultation with APA's Legal Information and Consultation Plan (separate fee)

### Personal Benefits

Car Rentals

Substantial discounts from Alamo, Avis, Budget, Hertz, or National

Magazine Subscriptions

Save up to 50% off regular subscription rates on magazines

Save on Office Expenses

Receive APA member discounts on FedEx shipping and Penny-Wise Office Supplies































Booth #	Company name	Page #
NE	American Institute of Bisexuality	182
2412	American Professional Agency, Inc.	170
2012	Army Healthcare Recruiting	217
153	Cambridge University Press	187
NE	Dainippon Sumitomo Pharma America, Inc	59
434	Forest Pharmaceuticals, Inc., Lexapro	52-55
1736	ICANotes	182
NE	Insitutue of Living, Hartford Hospital	187
NE	Intermountain Healthcare	216
733	Janssen, Division of Ortho McNeil-Janssen Pharmaceuticals, Inc	13
1430	John Hopkins University Press	187
734	Lilly, USA, Inc	19
1735	McLean Hospital	56
2216; 2314	Merck & Company, Inc	29
224	Neuronetics, Inc	21
316	New York Presbyterian Hospital	188
1911	North Carolina Department of Healthcare and Human Services	215
1816	Pfizer, Inc., Chantix	173-175
1816	Pfizer, Inc., Geodon	238-C4
1816	Pfizer, Inc., Pristiq	C2-3
2429	Physician Finders, Inc	217
2013	Pikes Peak Behavioral Health Group	217
2013	Pine Rest Christian Mental Health Services	20
1832	Psychiatric Solutions, Inc	176
916	The Psychiatrists' Program	31
2309	Reading Hospital and Medical Center	215
1438	Routledge Mental Health	187
1931	SZ Magazine	168
NE	Thomas B. Finnian Center	216
2012	U.S. Army Healthare Recruiting	217
2409	U.S. Public Health Service Commissioned Corps	215
NE	University of Miami Miller School of Medicine	216
NE	Yale New Haven Hospital	27

NE—designates advertisers not exhibiting as of 4/16/10

### APA ADVERTISEMENTS AND OPPORTUNITIES

American Journal of Psychiatry Symposium	Research Tab A
American Psychiatric Foundation Events	74
Annual Meeting Online	
APA Journal of Psychiatric Services	223
APA Isaac Ray and Human Rights Awards	3, 216
APA Membership Benefits, Services and New Member Savings	14, 25, 172, 175, 224
APA Member Center in Exhibit Hall	209
APA Office of HIV Psychiatry	164
APA Online Job Bank	
APA Store	11, 170
APPI Advances and Author Sessions	
APPI Bookstore; PsychiatryOnline.com1	178, Exhibit Tabs A and E
APPI NEW Website, www.appi.org	
CME Certificate of Attendance	
Exhibit Hall Hours and Events	73, 166, 213
FOCUS, Journal of Lifelong Learning Subscription Discount	102
Global Disaster Forum	182
International Psychiatrists—APA Discussion Groups and New Member Discounts	25, 26, 175
2010 Insitute of Psychiatric Services, Oct 14-17 in Boston	181
2011 Hawaii Annual Meeting Call for Abstracts and Early Registration Discount	149, 167, 208
Future Meetings of the American Psychiatric Association	180



### Δ

Aaronson, Scott T			1	54
Abbas, Muhammed A			1	43
Abbey, Susan E				78
Abdallah, Chadi	69	9, 81,	1	46
Abela, John				66
Abouzaid, Safiya			1	56
Abrams, Alan A				95
Abramson, Ronald				63
Abreu, Lena			1	52
Acosta-Uribe, Juliana			1	44
Adams, Curtis N., Jr		69	Э,	97
Adams, Julie				
Addington, Jean M				96
Adelson, Stewart L			1	14
Adler, Lawrence				
Afifi, Samah			1	46
Aggarwal, Neil K				
Agid, Ofer				
Ahmed, Serge H				
Aizenstein, Howard				
Akkisi Kumsar, Neslihan				
Aklin, Will M.				
Alam, Faouzi				
Alao, Adekola				
Alaräisänen, Antti				
Alcorn, Harry, Jr				
Ali, Asghar-Ali A				
Ali, Mohamed				
Almeida, Karla				
Alphs, Larry				
Al-Saadi, Sam				
Amini, Mona			1	45
Amir, Asad			1	44
An, Hoyoung			1	39
Anderson, Allan A				
Anson, Andrew				
Anzia, Joan M				
Apiquian, Rogelio				
Appelbaum, Paul S				
Apter, Gisèle89,				
Arean, Patricia A.				
Arlinghaus, Kimberly				
Arnold, Lesley M				
Ascher-Svanum, Haya				
Ash, Peter				
Aslam, Sunny P				
Asmal, Laila				
Atdjian, Sylvia				80
Atkins, Robert M				
Atri, Ashutosh				
Auger, R. Robert				
Avasthi, Ranjan				
Axelson, Alan				
Aydin, Cahide				
Ayuso, Jose Luis				
Azeem, Muhammad Waqar				
- I -				

### R

Baez-Sierra, Deyadira1	
Baig, Muhammad R81, 1	
Bailey, John T.	
Baker, Allison S72, 82, 84, 1	
Baldwin, David1	
Baler, Ruben D	
Balfour, Margaret	
Balis, Theodora G69, 1	
Balkoski, Victoria	
Ball, Samuel A.	
Ball, Valdesha	
Balon, Richard	
Bandelow, Borwin	
Bandstra, Belinda S	
Baptista, Trino J.	
Barak, Nir	
Barak, Yoram	
Barber, Jacques P	
Barber, Mary E	
Barkley, Russell A	
Barlow, Carrolee	
Baron, David A	
Barreira, Paul J	
Bateman, Anthony W	
Bates, Lisa M	
Batki, Steven L.	
Bauer, Amy M.	
Bauer, Michael	
Baum, Antonia L.	
Beck, Judith S63, 73,	79
Beck, Judith S	79 92
Beck, Judith S	79 92 22
Beck, Judith S	79 92 22 71
Beck, Judith S	79 92 22 71 80
Beck, Judith S	79 92 22 71 80 51
Beck, Judith S	79 92 22 71 80 51 08
Beck, Judith S	79 92 22 71 80 51 08 77
Beck, Judith S	79 92 22 71 80 51 08 77 10
Beck, Judith S	79 92 22 71 80 51 08 77 10 05
Beck, Judith S.       63, 73,         Becker, Daniel F.       —         Beezhold, Julian       71, 1         Beighley, Paul       —         Belfort, Edgard       —         Bellocchio, Elizabeth       1         Belnap, Barri       1         Bender, Donna S.       —         Benedek, Elissa P       72, 1         Benes, Francine M.       1         Benitez, Joachim       1	79 92 21 71 80 51 08 77 10 05 06
Beck, Judith S	79 92 21 80 51 08 77 10 05 06
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 22 71 80 51 08 77 10 05 06 63
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 22 71 80 51 08 77 10 05 06 06 63 72
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 22 71 80 51 08 77 10 05 06 06 63 72 14
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 22 71 80 51 08 77 10 05 06 63 72 14 51
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 22 71 80 51 08 77 10 05 06 63 72 14 51 42
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 22 71 80 51 08 77 10 05 06 63 72 14 51 42 76
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 22 71 80 51 05 05 06 63 72 14 51 42 76 72
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 21 71 80 51 05 06 06 63 72 14 51 42 76 72 00
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 21 71 80 51 05 06 06 63 72 74 51 42 76 72 00 99
Beck, Judith S.       63, 73,         Becker, Daniel F.       71, 1         Beezhold, Julian       71, 1         Beighley, Paul       8         Belfort, Edgard       1         Bellocchio, Elizabeth       1         Belnap, Barri       1         Bender, Donna S.       1         Benedek, Elissa P       72, 1         Benes, Francine M.       1         Benitez, Joachim       1         Benjamin, Sheldon       67, 1         Bennett, Robert M.       1         Benyamina, Amine       1         Bersin, Eugene       1         Berkson, Sarah       1         Berlin, Jon S.       1         Berman, Karen Faith       84, 89, 1         Bernstein, Carol A.       84, 89, 1         Berthoud, Hans-Rudolf       84, 89, 1	79 92 21 71 80 51 05 06 63 72 14 76 72 00 99 41
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 21 71 80 51 05 06 63 72 76 72 00 99 41 90
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 21 71 80 51 06 06 63 72 14 51 42 76 72 00 99 41 90 42
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 21 71 80 51 05 06 63 72 14 76 72 00 99 41 90 42 77 66
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 21 71 80 51 05 06 63 72 14 76 72 00 99 41 90 42 77 66
Beck, Judith S.       63, 73,         Becker, Daniel F.	79 92 22 71 80 51 05 06 06 63 72 14 51 42 76 72 00 99 41 90 42 77 66 07
Beck, Judith S.       63, 73,         Becker, Daniel F.       8eezhold, Julian       .71, 1         Beighley, Paul       .71, 1       8eighley, Paul         Belfort, Edgard       .72, 1         Bellocchio, Elizabeth       .1         Belnap, Barri       .1         Bender, Donna S.          Benedek, Elissa P       .72, 1         Benes, Francine M.       .1         Benjamin, Sheldon       .67, 1         Bennett, Robert M.       .1         Benyamina, Amine          Beresin, Eugene       .1         Berkson, Sarah          Berlin, Jon S.          Berman, Karen Faith          Bernstein, Carol A.       .84, 89, 1         Berthoud, Hans-Rudolf          Bestha, Durga       .63, 1         Bhugra, Dinesh          Bishnoi, Ram Jeevan          Bishop-Baier, Margaret          Biskin, Robert	79 92 22 71 80 51 05 06 06 63 72 14 51 42 76 09 94 19 94 19 45

Blasco-Fontecilla, Hilario	139, 156	Caplan, Jason	124
Block, Jerald J	78	Carballo, Juan J	156
Blum, Nancee S	112	Cardoner, Narcís	153, 154
Bodén, Robert	111	Caring, Joanne	111
Boettger, Soenke		Carney, Colleen E	
Bokarius, Vladimir		Carpenter, Linda L.	
Boland. Robert J.		· · · · · · · · · · · · · · · · · · ·	
		Carpenter, William T	
Bolton, James M		Carroll, Ian R	
Bonnie, Richard		Carroll, Kathleen M	
Book, Howard E	62	Carter, Anne	108
Booty, Andrew	72	Carter, Diana	81, 158
Bossie, Cynthia A.	159, 160	Case, Michael G	160
Boutros, Nash N		Casey, Daniel E.	
Bowden, Charles		Casey, David A.	
Boyce, Cheryl Anne		Castellano, Xavier	
Boyer, Jenny		Castellanos, Daniel	
Bradley, John C.	77, 89	Castilla-Puentes, Ruby C	118, 119, 125
Brady, Kathleen	78, 90, 98	Castilla-Puentes, Wilma I	118-119
Brams, Mathew	68, 79, 156	Castro-Loli, Piero I.	153
Brandt, Douglas M.		Caudill, Marissa	
Brendel, David H.		Cavender, Jennifer	
Brendel, Rebecca W.		Cazorla, Pilar	
Brietzke, Elisa		Cebolla, Susana S	
Briones, David F	100	Ceranoglu, Tolga A	
Briscoe, Brian	145	Cernovsky, Zack Z	93, 124, 148, 149
Brod, Thomas M	78	Certa, Kenneth M.	80
Bromander, Sara	143	Chalk, Mady	161
Brooks, Beth Ann		Chan, Carlyle H.	
Brooks, John O.		Chan, Jonathan	
Broudy, Carolyn A		Chandra, Prakash	
Brown, Richard P	66, 79	Chanen, Andrew M	77
Brown, Thomas E	78, 94, 156	Chang, Charlene	143
Brum Moraes, Juliana	139	Chang, Kiki	66, 97
Bruno, Nicolas	141	Chao, Faye	
Bryan Dirks	155		10/
Bryan, Dirks			124
Buckley, Peter F	63, 79, 88	Chapman, Daniel P	123, 138, 155, 164
Buckley, Peter F	63, 79, 88 98, 98, 121	Chapman, Daniel P Chaudhary, Ayesha	123, 138, 155, 164 76
Buckley, Peter F	63, 79, 88 98, 98, 121 78	Chapman, Daniel P Chaudhary, Ayesha Chaves, Ana Cristina	123, 138, 155, 164 76 160
Buckley, Peter F	63, 79, 88 98, 98, 121 78	Chapman, Daniel P Chaudhary, Ayesha	123, 138, 155, 164 76 160
Buckley, Peter F	63, 79, 88 98, 98, 121 78 118	Chapman, Daniel P Chaudhary, Ayesha Chaves, Ana Cristina	123, 138, 155, 164 76 160 138
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T.	123, 138, 155, 164 
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calabrese, Joseph R.		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calabrese, Joseph R.  Calderon-Abbo, Jose		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Classi, Peter Clayton, Anita H.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calderon-Abbo, Jose  Caligor, Eve		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter Clayton, Anita H. Clayton, Paula J.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calabrese, Joseph R.  Calderon-Abbo, Jose  Caligor, Eve  Calzada, Esther J.		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter Clayton, Anita H. Clayton, Paula J. Cloninger, C. Robert	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calderon-Abbo, Jose  Caligor, Eve		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter Clayton, Anita H. Clayton, Paula J.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calabrese, Joseph R.  Calderon-Abbo, Jose  Caligor, Eve  Calzada, Esther J.		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter Clayton, Anita H. Clayton, Paula J. Cloninger, C. Robert	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calderon-Abbo, Jose  Calzada, Esther J.  Camarena, Enrique  Cameron, Carter S.		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cia, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter Clayton, Anita H. Clayton, Paula J. Cloninger, C. Robert Cobb, Robert	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calderon-Abbo, Jose  Caligor, Eve  Calzada, Esther J.  Cameron, Carter S.  Campayo, Antonio J.		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Choi, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter Clayton, Anita H. Clayton, Paula J. Cloninger, C. Robert Coconcea, Cristinel M. Coenson, Craig J.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calabrese, Joseph R.  Calderon-Abbo, Jose  Calzada, Esther J.  Camarena, Enrique  Cameron, Carter S.  Campayo, Antonio J.  Cammena Buist Manne Busher S.  Burber Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Zachary  Calabrese, Joseph R.  Calderon-Abbo, Jose  Calzada, Esther J.  Camarena, Enrique  Cameron, Carter S.  Campayo, Antonio J.  Campbell, Frank R.		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Anna Choildress, Anna Cholidress, Anna Cholidre	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calabrese, Joseph R.  Calderon-Abbo, Jose  Caligor, Eve  Camarena, Enrique  Cameron, Carter S.  Campayo, Antonio J.  Campbell, Frank R.  Campbell, Herbert		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Anna Childress, Anna Childress, Anna Rose Chilton, Julie A. Choi, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter Clayton, Anita H. Clayton, Paula J. Cloninger, C. Robert Coconcea, Cristinel M. Coenson, Craig J. Coffey, Barbara Coffey, C. Edward	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calabrese, Joseph R.  Calderon-Abbo, Jose  Caligor, Eve  Calzada, Esther J.  Camarena, Enrique  Cameron, Carter S.  Campayo, Antonio J.  Campbell, Frank R.  Campbell, Herbert  Campbell, W. Keith		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Anna Childress, Anna Rose Chilton, Julie A. Choi, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter Clayton, Anita H. Clayton, Paula J. Cloninger, C. Robert Coconcea, Cristinel M. Coenson, Craig J. Coffey, Barbara Coffey, C. Edward Coffey, M. Justin	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calabrese, Joseph R.  Calderon-Abbo, Jose  Caligor, Eve  Camarena, Enrique  Cameron, Carter S.  Campayo, Antonio J.  Campbell, Frank R.  Campbell, Herbert		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter Clayton, Anita H. Clayton, Paula J. Cloninger, C. Robert Coconcea, Cristinel M. Coenson, Craig J. Coffey, Barbara Coffey, C. Edward Coffey, M. Justin Cohen, Carl I.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calabrese, Joseph R.  Calderon-Abbo, Jose  Caligor, Eve  Calzada, Esther J.  Camarena, Enrique  Cameron, Carter S.  Campayo, Antonio J.  Campbell, Frank R.  Campbell, Herbert  Campbell, W. Keith		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Anna Childress, Anna Rose Chilton, Julie A. Choi, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter Clayton, Anita H. Clayton, Paula J. Cloninger, C. Robert Coconcea, Cristinel M. Coenson, Craig J. Coffey, Barbara Coffey, C. Edward Coffey, M. Justin	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calabrese, Joseph R.  Calderon-Abbo, Jose  Caligor, Eve  Calzada, Esther J.  Camarena, Enrique  Cameron, Carter S.  Campayo, Antonio J.  Campbell, Frank R.  Campbell, Herbert  Campbell, W. Keith  Campbell, William H.		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Ann Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter Clayton, Anita H. Clayton, Paula J. Cloninger, C. Robert Coconcea, Cristinel M. Coenson, Craig J. Coffey, Barbara Coffey, C. Edward Coffey, M. Justin Cohen, Carl I.	
Buckley, Peter F.  Budney, Alan J.  Buie, Stephen E.  Buist, Anne  Bullock, Karen  Buoli, Massimiliano  Burd, Ronald M.  Burke, Jack D.  Burpee, Stacey  Burton, M. Caroline  Busner, Joan  Byatt, Nancy  Cabaniss, Deborah  Cadenhead, Kristin S.  Cain, Tonier  Cain, Zachary  Calabrese, Joseph R.  Calderon-Abbo, Jose  Caligor, Eve  Calzada, Esther J.  Camarena, Enrique  Cameron, Carter S.  Campbell, Frank R.  Campbell, Herbert  Campbell, William H.  Candilis, Philip J.		Chapman, Daniel P. Chaudhary, Ayesha Chaves, Ana Cristina Cheema, Faiz A. Chen, Donna T. Cheon, Jin Sook Chiasson, Ann Marie Childress, Anna Childress, Anna Rose Chilton, Julie A. Chiu, Simon Cho, Young Ju Choi, Jungmi Choi-Kain, Lois W. Chung, Bowen Chung, Moon Young Cía, Alfredo H. Clark, David L. Clark, Michael R. Clarkin, John F. Classi, Peter Clayton, Anita H. Clayton, Paula J. Cloninger, C. Robert Coconcea, Cristinel M. Coenson, Craig J. Coffey, Barbara Coffey, M. Justin Cohen, Carl I. Cohen, Lewis M.	

Cole Steven	76	Diller, Kathleen C	1	4:
	64, 98	Dimaggio, Giuseppe Giancarlo		
•	72	Dimsdale, Joel E		
	156	D'Mello, Dale		
	88	Dobbins, Mary I.		
	159	Doghramji, Karl		
	93, 148	Domnitei, Diana S		
· ·	159	Domschke, Katharina		
	88	Donevan, Sean		
	121	Donovan, Abigail L		
	114, 121	Dorrepaal, Ethy E		
	79	Dougherty, Darin D		
	122	Downey, Jennifer I		
	72	Drescher, Jack		
·	108	Drevets, Wayne C		
	98, 98	Drost, Pieter		
•	159, 160, 161	Drury, Stacy S.		
· ·		Druss, Benjamin		
	64	D'Souza, Russell		
	111–112, 150, 155	Dubovsky, Steven		
	68	Duckworth, Kenneth S		
,		Dueñas, Héctor		
		Duffy, Farifteh F.		
D		Dulcan, Mina K.		
		Dunn, Judith		
Dackie Charles	90, 114	Dunn, Laura B		
	122	Durden, Emily		
0 3		Durkin, Michael		
	106	Duval, Fabrice		
	100	Dwaikat, Sameh		
	148	Dzirasa, Erikka		
	113	22.464, 2.1144		-
	157			
	76	E		
	114	<b>—</b>		
	116	Earley, Willie	150 1	54
	122	Edinger, Jack D.		
	90	Eells, Gregory T.		
	78, 110	Ellis, Robert		
	72	Ellison, James M		
· ·	123	Elsayed, Yasser		
	86	El-Shafei, Ahmed		
0	159	Embley, Scott		
	66	Engel, Charles C.		
	82	Epperson, C. Neill		
	83	Eraslan, Defne		
0 3.	91, 95, 96	Ercan, Eyüp Sabri		
	86	Eriksson, Hans		
	71	Erten, Evrim		
	107	Etkin, Amit		
9	119	Evans, Liz		
0	104	Everett, Anita S		
•	141, 147			-
	163			
	149	F		
	82			
	92	Fahim, Raafat		90
	86, 93	Fatemi, S. Hossein		
	115	Faulkner, Larry R		
	139	Fauman, Beverly		
	124	Fava, Maurizio		
•	64, 109	Fawcett, Jan		
	140	Feeny, Norah C		
•	76, 79	Feltner, Douglas		
	86	Fenley, Gareth		
	100, 163	Fernandez, Antony		
	67, 76, 86, 89, 115, 122, 124	Fernandez, Francisco		
	64	Ferrando, Stephen J		
Dike Charles C	67	Ferreira Luiz K		57

Fetterolf, Frank A.	141	Gerbert, Barbara	122
Fier, Jennifer	139	Germain, Anne	76
Fine, Carla	62, 84	Gerschwind, Daniel	105
Finigan, Michael W	162	Ghaemi, S. Nassir	78, 81, 107, 150, 154
Fiorillo, Andrea	71	Ghanem, Mohamed	125
First, Michael B.	107	Giedd, Jay N	106
Fisher, Carrie	101	Gillece, Joan	109
Fishman, Robert S	159, 160	Ginsberg, Lawrence D	148, 151
Fitelson, Elisabeth M	113	Ginzburg, Harold M	80
Fitzpatrick, Kathleen K.	64	Girard, Kristine A	63, 114
Flynn, Christopher	71	Gitlin, David	104
Flynn, David,	108	Glenn, Tasha	152, 154
Flynn, Meredith B	140	Glick, Ira D	66, 70, 141
Fochtmann, Laura J	63, 64, 83, 110, 163	Glick, Rachel L	76, 97
Fonagy, Peter	81, 113, 120, 124	Gluck, Mark A	120
Forero, Jorge	119	Goethe, John W	109, 116, 118, 123
Forester, Brent P	76	Goff, Donald	92
Forstein, Marshall	106	Gogineni, R. Rao	82
Fosdick, Cara	142	Goisman, Robert M	79
Foulks, Edward F	83, 100	Gold, Mark	112
Foundas, Anne L	109	Goldberg, David	67, 87
Franch Pato, Clara	141	Goldberg, Jeffrey	79
Franco, Kathleen S	100	9	119
Frank, Ellen	96	Goldfinger, Stephen M	94, 100, 121
Frank, Julia B	67	Goldman, Howard H	105
Frascella, Joseph	99, 106	Goldman, Marina	80
Frasch, Karel J	147	Goldman, Morris B	78
Freedman, Robert	64, 89, 97	Goldstein, Stacia	124
Freeman, Ellen	115	Goldstein, Tina	96
Freudenreich, Oliver	89	Gommoll, Carl	150
Frey, Benicio	65	Gonzalez, Hector M	77
Friedman, Joseph H	104	Goodkin, Karl	125
Friedman, Joshua	147	Goodman, David W	155
Friedman, Matthew J	63, 114	Goodman, Jeanne	62
Friedman, Nora	79	Gopal, Arun	77
Friedman, Richard C.	114	Gordy, Tracy R	94, 108
Friedman, Susan Hatters	93, 147, 157	Gorelick, David A	100, 121
Frometa, Ayme	144	Gould, Todd	107
Frye, Mark A		Graber, Cheryl	138
Fu, Dong-Jing	159	Gracious, Barbara L	150
Fujii, Ryuichi	157	Grady-Weliky, Tana A	67, 70, 119
Fung, Kenneth D.	94	3	110
Furukawa, Toshiaki A			158
			90
		Granger, Renee	151, 154
G		9	
Si programme de la companya de la co			120
Gabbard, Glen O79, 84, 87, 95	, 108, 112, 118, 125		119
Gable, Mary S.			76
Gaebel, Wolfgang			93
Galanter, Marc			71, 98
Gallion, Joan E.			110
Galynker, Igor I140, 142, 144, 146	6, 147, 149, 162, 164	•	69, 150
Garrett, Michael		0	
Gaspar, Enrique			162
Gastelum, Emily			98, 148
Gastfriend, David R.			67
Gathright, Molly			
Gau, Susan Shur-Fen			
Gaudiano, Brandon A.		0.	72, 87
Gaviria, Silvia			150, 152
Geddes, John			159
Gelenberg, Alan J.		_	79, 89, 95, 110, 112, 120, 125
Geller, Jeffrey			88
George, Mark S.			139
Georges, Hebert		•	143
Georgieva, Galina J			71
Gerard Stephanie	140	Gurrera Ronald I	160 161

# PRESENTER INDEX

H	
Ha, Ju-Won138	3
Habl, Samar108	3
Hackman, Ann L69	
Haeri, Sophia	
Hales, Deborah J	
Halfon, Olivier	
Hall, James	
Halpern, John H	
Haltzman, Scott D	
Halverson, Jerry L	
Hamarman, Stephanie79	Э
Hamlin, Ed	
Hammerness, Paul G148	
Han, Doug Hyun151	
Han, Sang Ick	
Haney, Margaret	
Haq, Fasiha	
Harbin, Henry	
Hare, Todd	
Harpel, Joanne76, 116	
Harris, Toi	2
Harvey, Philip D	
Harvey, Renee112	
Hasin, Deborah S98, 121	
Hasler, Gregor	
Hassan, Farah S	
Hatti, Shivkumar S	
Heckel, Sally	
Heim, Christine	
Heinssen, Robert K96	
Hellerstein, David J	3
Helmer, Amanda108	
Henderson, Melinda S	
Hendren, Robert L	
Hendriksen, Mariëlle	
Herbert, Sarah E	
Herbst, Luis G	
Herman, Barry K	
Hernández-Ribas, Rosa153, 154	4
Herring, Matthew P	Э
Heru, Alison M104	4
Hien, Denise	
Hilderbrand, Richard	
Hilty, Donald M	
Hinton, Devon	
Hira-Brar, Shabneet	
Hirshkowitz, Max	
Hlastala, Stefanie A	
Hobday, Gabrielle79	Э
Hoffman, Perry D89, 110	С
Hoffman, William F	
Hoffpauir, Sarah	
Hoge, Steven K	
Høglend, Per	
Hollander, Eric	
Holtzheimer, Paul	
Hong, Chang Hyung157	
Hong, Elliot	
Hong, Minha158	
Hong, Yang146	3
Hong, Youjin139	Э

Honore, Russel	1	115
Hoogenboom, Wouter S		
Hoop, Jinger G12	20, 1	125
Horey, Jonathan T		
Horowitz, Mardi		
Hoschl, Cyril		
Houchins, Rachel A	1	138
Houston, Michael		
Howe, Edmund G		
Hristov, Svetoslav		
Hsiung, Robert C		
Huang, David		
Huang, Rex W		
Huang, Tiao-Lai14		
Huang, Yueqin		
Huang, Zhen		
Huguelet, Philippe		
Hunt, Justin B.		
Hunter, Jon J Huremovic, Damir		
Hurley, Robin		
Hurwitz, Thomas D		
Husain, Arshad6		
Husni, Mariwan93, 14		
Hussain, Arshad		
Hutchens, Steven E.		
Hutton, Todd M		
Hwang, Soonjo		
Hyun, Aerin		
1		
larovici, Doris M	. 67,	76
lbrahim, Fayaz A		.69
Inczedy-Farkas, Gabriella		
Insel, Thomas		.96
losifescu, Dan V12	21, 1	154
lsenberg, Keith		
Ishiyama, Takeo		
Islam, Sadaf		
Ismail, Mostafa K	1	125
J		
Jadresic, Enrique		
Jaffe, Eli		
Jain, Rakesh14		
Janardhanan, Thulasiram Jang, Sae-Heon		
Janicak, Philip G7		
Javed, Qaiser Q		
Javier, Pena		
Jeevarakshagan, Shamala		
Jennings, Gillian142, 146, 14		
	La 1	0-
_		161
Jensen, Signe	1	
Jensen, Signe Jeong-Ho, Seok	1 1	154
Jensen, Signe Jeong-Ho, Seok Jermendy, Agnes	1 1	54   45
Jensen, Signe Jeong-Ho, Seok Jermendy, Agnes Jeste, Dilip V.	1 1 1 88,	154 145 98
Jensen, Signe Jeong-Ho, Seok Jermendy, Agnes Jeste, Dilip V. Jibson, Michael D.	1 1 1 88,	154 145 98 .70
Jensen, Signe Jeong-Ho, Seok Jermendy, Agnes Jeste, Dilip V. Jibson, Michael D. Jimenez-Trevino, Luis	1 1 1 88, 1	154 145 98 . 70
Jensen, Signe Jeong-Ho, Seok Jermendy, Agnes Jeste, Dilip V. Jibson, Michael D.	1 1 1 88, 1	154 98 . 70 163
Jensen, Signe Jeong-Ho, Seok Jermendy, Agnes Jeste, Dilip V. Jibson, Michael D. Jimenez-Trevino, Luis Jimerson, David C.	1 1 1 1 1 1	154 98 . 70 163 154
Jensen, Signe Jeong-Ho, Seok Jermendy, Agnes Jeste, Dilip V. Jibson, Michael D. Jimenez-Trevino, Luis Jimerson, David C. Jing, Yonghua Joep, Schoemaker Johnson, Paula	1 1 88, 1 1 1	154 98 . 70 . 63 . 61 . 80
Jensen, Signe Jeong-Ho, Seok Jermendy, Agnes Jeste, Dilip V. Jibson, Michael D. Jimenez-Trevino, Luis Jimerson, David C. Jing, Yonghua Joep, Schoemaker Johnson, Paula	1 1 88, 1 1 1	154 98 .70 163 109 154 161

Jones, Ashley B	144	Kingdon, David G.	90, 110, 12 <sup>-</sup>
Jones, Cheryl W.		8 .	7
Jones, Hendree			148
Jørgensen, Anders			153
Jorgenson, Linda M.			82, 90, 104, 112, 12 <sup>-1</sup>
Joseph, Robert C.	77, 92		7 <sup>-</sup>
Jun, Tae-Youn	145, 161	Knoll, James	89
Jung, Han-Yong	139, 157, 158	Ko, Young-Hoon	148, 15 <sup>-</sup>
Jung, Seung-Ho	141	Koenig, Barbara A	106
Jung, Wooyul	139, 157, 158	Koenigsberg, Harold W	87, 87
Juthani, Nalini V.	67, 110	Kogan, Jane N	143, 147
		Kogan, Richard	9 <sup>-</sup>
		Koh, Steve	68
K		Kohn, Robert	7
		Kohrt, Brandon A	65
Kahn, René S.	96. 141	Kolling, Pieternel	148
Kahn, Tara A.		Kontis, Dimitrios	140, 159
Kalali, Amir H.		Koo, Bon-Hoon	142, 144, 156
Kalivas, Peter W.		Kool, Simone S	70, 86
Kalkay, Asli Funda		Kopelowicz, Alex	83
Kalman, Thomas P		Koslow, Stephen	107
Kane, Cecelia		Kosten, Thomas	98, 118
Kane, John M.		Koszycki, Diana	64
Kang, Suk-Hoon		Kozma, Chris M	159, 16 <sup>-</sup>
Kanner, Andres M		Krain, Lewis	122
Kapczinski, Flavio		Krakowski, Menaheim I	111
Kaplan, Allan S.		Kramer, Milton	67, 76, 79, 157
Kaplan, Stuart L.		Kramer, Peter D	107
Karasu, Sylvia R.		Krasnik, Catherine E	7
Karayal, Onur N.		Kratochvil, Christopher J	66
Karlsson, Hasse			162
Karnik, Niranjan S			96
Katon, Wayne		Krishna, Sowmya	147
Katz, Curren E.		Krupitsky, Evgeny	16 <sup>-</sup>
Katz, Maor			104, 141, 153, 163, 164
Katz-Bearnot, Sherry P.		Kukoyi, Oladipo	67
Katzman, Martin	66, 79	Kumar, Anand	99
Katzman, Martin			99
	65, 95	Kumar, Vinod	
Kaufmann, Walter E.	65, 95 72	Kumar, Vinod Kung, Simon	16 <sup>-</sup>
Kaufmann, Walter E. Kautz, Mary A.	65, 95 72 97, 113, 114	Kumar, Vinod Kung, Simon Kunik, Mark E	16 <sup>2</sup> 146, 154
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald	65, 95 72 97, 113, 114 64	Kumar, Vinod Kung, Simon Kunik, Mark E. Kupfer, David J.	16· 146, 154 68
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald Kaye, Walter		Kumar, Vinod Kung, Simon Kunik, Mark E. Kupfer, David J.	16° 146, 154 65 84, 91, 107, 124, 125
Kaufmann, Walter E.  Kautz, Mary A.  Kay, Jerald		Kumar, Vinod Kung, Simon Kunik, Mark E. Kupfer, David J.	16° 146, 154 65 84, 91, 107, 124, 125
Kaufmann, Walter E.  Kautz, Mary A.  Kay, Jerald		Kumar, Vinod Kung, Simon Kunik, Mark E. Kupfer, David J.	16° 146, 154 65 84, 91, 107, 124, 125
Kaufmann, Walter E.  Kautz, Mary A.  Kay, Jerald  Kaye, Walter  Keitner, Gabor I.  Kellner, Charles H.  Kelly, Meredith A.		Kumar, Vinod Kung, Simon Kunik, Mark E. Kupfer, David J.	16° 146, 154 65 84, 91, 107, 124, 125
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, VinodKung, SimonKunik, Mark EKupfer, David JKyomen, Helen H	16° 146, 154 65 84, 91, 107, 124, 125
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald Kaye, Walter Keitner, Gabor I. Kellner, Charles H. Kelly, Meredith A. Kennedy, Robert S. Kennedy, Sidney H. Kent, Laura K. Kern Sliwa, Jennifer Kernberg, Otto F. Kerner, Melissa		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald Kaye, Walter Keitner, Gabor I. Kellner, Charles H. Kelly, Meredith A. Kennedy, Robert S. Kennedy, Sidney H. Kent, Laura K. Kern Sliwa, Jennifer Kernberg, Otto F. Kerner, Melissa Kesebir, Sermin		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald Kaye, Walter Keitner, Gabor I. Kellner, Charles H. Kelly, Meredith A. Kennedy, Robert S. Kennedy, Sidney H. Kent, Laura K. Kern Sliwa, Jennifer Kernberg, Otto F. Kerner, Melissa Kesebir, Sermin Kessler, David Kessler, Ronald C. Ketter, Terence A. Khail, Afaf H. Khan, Arif Khan, Rizwan Kilpatrick, Michael Kim, Eun Jin		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald Kaye, Walter Keitner, Gabor I. Kellner, Charles H. Kelly, Meredith A. Kennedy, Robert S. Kennedy, Sidney H. Kent, Laura K. Kern Sliwa, Jennifer Kernberg, Otto F. Kerner, Melissa Kesebir, Sermin Kessler, David Kessler, Ronald C. Ketter, Terence A. Khali, Afaf H. Khan, Arif Khan, Rizwan Kilpatrick, Michael Kim, Eun Jin Kim, Hwang Lyong		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald Kaye, Walter Keitner, Gabor I. Kellner, Charles H. Kelly, Meredith A. Kennedy, Robert S. Kennedy, Sidney H. Kent, Laura K. Kern Sliwa, Jennifer Kernberg, Otto F. Kerner, Melissa Kesebir, Sermin Kessler, David Kessler, Ronald C. Ketter, Terence A. Khail, Afaf H. Khan, Arif Khan, Rizwan Kilpatrick, Michael Kim, Eun Jin Kim, Hwang Lyong Kim, Jin-Woo		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald Kaye, Walter Keitner, Gabor I. Kellner, Charles H. Kelly, Meredith A. Kennedy, Robert S. Kennedy, Sidney H. Kent, Laura K. Kern Sliwa, Jennifer Kernberg, Otto F. Kerner, Melissa Kesebir, Sermin Kessler, David Kessler, Ronald C. Ketter, Terence A. Khalil, Afaf H. Khan, Arif Khan, Rizwan Kilpatrick, Michael Kim, Eun Jin Kim, Hwang Lyong Kim, Jin-Woo Kim, Jun Won		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald Kaye, Walter Keitner, Gabor I. Kellner, Charles H. Kelly, Meredith A. Kennedy, Robert S. Kennedy, Sidney H. Kent, Laura K. Kern Sliwa, Jennifer Kernberg, Otto F. Kerner, Melissa Kesebir, Sermin Kessler, David Kessler, Ronald C. Ketter, Terence A. Khalil, Afaf H. Khan, Arif Khan, Rizwan Kilpatrick, Michael Kim, Eun Jin Kim, Hwang Lyong Kim, Jun Won Kim, Scott		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	
Kaufmann, Walter E. Kautz, Mary A. Kay, Jerald		Kumar, Vinod	

_eisteat, Samuei	142	Maffei, Cesare	124
_eli, Ubaldo	106	Mago, Rajnish	109, 139, 140
_entz, Vanessa		Maj, Mario	70
_eón-Andrade, Carlos	119, 125	Maki, Pirjo H	118
_ester, Natalie A		Maldonado, Jose R	62, 86
_eszcz, Molyn	108	Malmquist, Carl P	
_eung, Joey Shuk Yan		Manalai, Partam	153
_evander, Eric	62	Manber, Rachel	
_evenson, Hanna		Mandel, Francine	
_evenson, James L		Manepalli, Jothika	
_evin, Frances R		Mangurian, Christina V	
_evine, Ruth E		Mankoski, Raymond	
_evine, Stephen B		Mannelli, Paolo	
_evinson, Douglas F		Manohar, Velandy	
_evkovitz, Yechiel		Mantovani, Antonio	
_evounis, Petros		Manzardo, Ann	
_evy, Kenneth N		Mao, Alice R.	
_evy, Norman B		Marcu, Jahan	
_ewis, Janet L		Marder, Stephen R.	
_ewis, Jerry L		Marella, Srimannaravana	
_ewis-Fernández, Roberto		Margarita, Alegria	
_ewy, Alfred J		Margery Bertoglia, Solange	
_ewy, Colleen S		Marissen, Marlies	164
_icinio, Julio	77, 84, 98, 99, 105, 119	Markov, Dimitri D	68, 80
_ieberman, Jeffrey A	89, 96, 104	Markowitz, John C	64, 81
_im, Russell F	63, 86, 113, 124	Marks, Saul I	72
_in, Chin-Chuen	146	Marsh, Laura	104
_in, Jin-Jia		Martin, Glenn A	83
_indberg, Marc A		Martin, Peter S	
_indeman, Jeffrey B		Maruyama, Nancy C	
_ineberry, Timothy		Matharu, Yogi	
_ink, Patrick E		Matorin, Anu A	
_inks, Paul S		Matthews, Annette M.	
_ippolis, L. Charolette		Mayers-Elder, Chanda	
_ipsitt, Donald R		McCann, David J	
_isanby, Sarah H		McCarron, Robert O	
_itman, Robert E		McCarthy, Kevin S.	
_iu, Timothy C			
		McCarthy, Malia	
_iu, Xianchen		McCollough, Monique	
_iu, Zhifen		McCormick, Laurie	
_ivesley, John		McCormick, Richard A	
_obo, Antonio		McDonald, William M	
_oboPrabhu, Sheila M		McDougle, Christopher J	
_ock, James		McElroy, Susan	
_ocklear, Julie		McFarlane, William R	
_oebel, Anthony		McGee, Michael D	72, 78
_omax, James W	108, 111	McGlashan, Thomas H	115
_ongstreth, James		McGorry, Patrick	96
_ord, Catherine	64	McGraw, Deven C	83
_ow, Yinghui Yh	141	McInnis, Melvin G	93
_owe, Matthew	142	McIntyre, Kathryn	67
_owenkopf, Eugene	95	McIntyre, Roger S	83, 99, 152, 177
_u, Francis	86	McLay, Robert	79, 138, 144, 164
_ukas, Scott E		McLean, Alexandra	
_una, Beatriz		McLellan, A. Thomas	
_uo, John		McMahon, Francis	
_usskin, Shari I		McNicholas, Laura	
_utv, Suzanne		McNulty, Karen	
_ynch, Minda R		McQuistion, Hunter	
_ysaker, Paul H		Meesala, Anil	
	95	Mehl-Madrona, Lewis	
		Meier, Linda	
N/I			
IVI		Melonas, Jacqueline M	
Maha D May		Meltzer, Herbert Y.	
Vabe, P. Alex		Mendez, Mario F.	
Mack, Avram H		Mendonca, James D	
Mackey, Sean C		Mensah, Jason O.	
Madaan, Vishal63		Menvielle, Edgardo J	
Maddox, Jill	79	Menza, Matthew A	86, 155

Mercader, Carolina	143. 144	Nemat, Ali	80
Merkel, Richard L		Nemeroff, Charles B	
Meyer, Donald J		Newcomer, John W	
Meyer, Fremonta		Newton, Thomas	
Meyer, Jonathan M	160	Ng, Anthony T	76
Meyer-Lindenberg, Andreas	70	Nicol, Ginger E	83, 142, 147, 156
Meyers, Diana	96	Nicolò, Giuseppe	78, 95, 124
Mian, Ayesha	82	Nielsen, Jimmi	160
Michels, Robert	79	Nierenberg, Andrew A	
Miciano, Armando S	157	Ninan, Philip T	104, 152
Miettunen, Jouko		Nino, Johanna	
Mihai, Adriana A	71	Nivoli, Alessandra	139
Milev, Roumen V		Noel, Richard L	
Miller, Earl K	72	Nonacs, Ruta M	
Miller, Gary E		Nordon, Clementine	
Miller, Gregory		Norris, Donna M	
Min, Jungwon		Noteboom, Annemieke A	
Mintz, David L.		Notman, Malkah T	
Mirza, Bushra F.		Nunes, Edward V.	
Mischoulon, David		Nunes, Sandra Odebrecht Vargas	
Misra, Sahana		Nurenberg, Jeffry R	
Misri, Shaila		Nyberg, Svante	
Mitchell, James E.		Nyhus, Nadine J	69
Mittal, Sukriti			
Moamai, Javad			
Moen, Richelle		$\cup$	
Moffic, Evan			
Mohandas, E		O'Brien, Charles P	
Montaner, Julio		Ochsner, Kevin N.	, -
Montgomery, Stuart		Odlaug, Brian L	
Montoya, Ivan D.		Oepen, Godehard	
Moran, Scott		O'Gorman, Cedric	
Morse, Gary		Oh, Hyun Young	
Mosier, Jessica		Okusaga, Olaoluwa O	
Moutier, Christine		Oldham, John M	
Mrazek, David A.		Olin, Jason T Olsen, John L	
Mucic, Davor		Ong, Jason	
Mukherjee, Dahlia		Oquendo, Maria	
Muniz, Rafael		O'Reardon, John	
Munoz, Kristine		Osinski, Alphonse	
Muñoz, Rodrigo A		Oslin, David	
Musalek, Michael		Osofsky, Howard J.	
Musgnung, Jeff		Osofsky, Joy D.	
Mushatt, David		Ospina, Jorge	
Musher, Jeremy S		Ostacher, Michael J	
Muskin, Philip R.		Ostrow, David G.	
Mustafa, Husain	68, 107	O'Sullivan, Michael	
Myers, Michael F		Owen, Randall	
Myers, Wade	72, 110	Ozerdem, Aysegul	
Ν		Р	
Na. Haeran	138	Pain, Clare	90
Nace, David K		Palmer, Brian A.	
Nadelson, Carol C.		Pandina, Gahan	
Naeem, Farooq		Pang, Peng	
Nahas, Ziad H.		Pappadopulos, Elizabeth	
Nanda, Aarti		Pardes, Herbert	
Narasimhan, Meera		Parikh, Sagar	
Nardi, Antonio E		Paris, Joel F.	
Narrow, William E		Park, Han Kyul	
Nascimento, Antonio		Passik, Steven	
Nasr, Mohamed		Patel, Amita R	
Naylor, Magdalena R		Patel, Jayendra	
Nejad, Shamim H		Patel, Meeta	
Nelson, Randy J	65	Patil, Uday	
Neltner, Matthew	114	Patkar, Ashwin A	

-ato, Michele I		Rasic, Daniel		111
Paulsen, Jane S	91, 98	Rasmussen, Andrew		65
Payne, Kate	92	Rasyidi, Ernest		123
Pechnick, Robert N	121	Rathod, Shanaya	110,	121
Pedersen, Charlotte	50	Ravitz, Paula	90,	108
Peeters, Frenk	64	Ravven, Simha E	119,	143
Pelaez, Clara	157			
Pelletier, Elise	153	Rawlings, Joseph		71
Peluso, Erica		Reardon. Claudia L	67	. 80
Penninx, Brenda				
Penska, Keith				
Perahia, David				
Perkins, Matthew				
Perlick, Deborah A				
Perroud, Nader				
Perry, Dana		_	63, 91, 95, 98, 114, 123, 124,	
Peselow, Eric D				
Peteet, John R			66,	
Peterson, Bradley S				
Petitjean, Francois C	72	Reider, Eve E		122
Petrini, Mark J	62	Reifler, Burton V		110
Petry, Nancy M	98	Reiss, Allen		50
Pflanz, Steven E	63	Rej, Soham		145
Phillips, Katharine A		Remedi, Carolina		125
Pinals, Debra				
Plakun, Eric M			79, 104, 112,	
Pleak, Richard R				
Plovnick, Robert			91, 96	
Pogge, David L.			92,	
Pollack, David A.				
Pollack, Mark H.				
Poncelet, Jean Luc				
Pontius, Edward				
Pope, Harrison			67,	
Pope, Kayla				
Pope, Laura E	147	Richards, Lawrence K		63
Potash, Mordecai	125	Richardson, Jarrett W	106,	116
Powsner, Seth	76	Richeimer, Steven		80
Prabhakar, Deepak	100	Richter, Peggy		113
Preskorn, Sheldon H	93	Riefer, Melody J		64
Preston, Kenzie L	82	Ries, Richard K		112
Preven, David W	108. 109			
Prieto, Rita				
Primm, Annelle B		9		
Prince, Jefferson B			63, 89,	
Prudent, Vasthie			100,	
Prudic, Joan			120,	
Puchalski, Christina				
uu iaiski, ui ii islii lä			01	
			81	
			150,	
Q			62, 89,	
Qiao, Meihua	155	Roca, Robert P	93,	111
Quintanilla, Beatriz	158	Rogers, Hollister		76
		Rohde, Paul		98
		Roman Mazuecos, Eva		142
R		Román, Ma		143
			145,	
Rachal, Funmilayo	118			
Ragins, Mark				
Ramanathan, Anita S				
Ramirez, Luis R.				
Randhawa, Jyoti				
Rao, Nyapati R			104 152	
Rapaport, Mark H		•	104, 153,	
Rappaport, Lance M				
Rappaport, Nancy				
Rasenick, Mark M		•	86,	
Rasgon, Natalie L	66, 77, 83, 152, 154	Rostain, Anthony L	78	, 94

Rothbaum, Barbara	122	Shannahoff-Khalsa, David	108. 118
Rothschild, Anthony J	94, 104, 144	Shapiro, Edward Robert	
Roy-Byrne, Peter	65, 66	Sharfstein, Joshua	51
	118	Sharfstein, Steven S	
Rubin, Jonathan	148, 155, 157	Shea, Shawn C	79
Rue, David S	68	Sheehan, David V.	
Rueda-Jaimes, German E.	147	Sheline, Yvette	69, 97
	a119	Shim, Ruth S.	
	89	Shin, Chul-Jin	
	80, 82, 88	Shinfuku, Naotaka	
	162	Shinozaki, Gen	
Rundell, James R	92	Shiroma, Paulo	
	113	Shoyinka, Sosunmolu O	
	78	Shrivastava, Amresh	
	125	Shyu, Irene	
		Sibrava, Nicholas J	
	81, 158	Siefert, Caleb J.	
•	95	Siggins, Lorraine D.	
T ty or int, 7 to o ivi.		Sikirica, Mirko	
		Silberman, Edward K	
S		Silk, Kenneth R.	
$\mathcal{I}$		Silva, Hernán	
Sood Emms	120	Silva, Paula	
	120	Silverman, Morton	
· ·		Simon, Robert I.	
	98	Simpson, George	
	105	Singh, Jaskaran	
	78	Sinha, Rajita	
	95	Sivrioglu, Yusuf	
	70	Sklar, Pamela	
		Skodol, Andrew E	
	151, 154	Sledge, William H.	
		Slotema, Christina C.	
		Smith, David W.	
	65	Smith, Delaney	
		Smith, Dwight	
	142, 146, 164	Smith, Eric G.	
		Smith, Gwenn	
	79	Smith, Mary Kay	
	93	Smith, Tyler C.	
		Snyder, Solomon H	
	66, 69, 80, 84, 95, 100, 105, 163	Soares, Claudio N.	
	86	Sohal, Vikaas	
	69	Sohi, Manmohandeep	
	73	Soloff, Paul H.	
	94, 108 93	Soltys, Stephen M.	
		Song, Young-Heon	
		Sood, Aradhana	
	147	Sorel, Eliot	
	62	Sorensen, Roger G	
	90	Sorrentino, Erica	
	98	Sorrentino, Renee M.	
	64	Spear, Linda Patia	
	71, 77, 109	Speier, Anthony	
	112	Spera, Allan	
	64	Sperber, Jacob E	
		Spiegel, David	
	82	Spila, Bozena	
		Spinelli, Margaret	
	89, 110	Spitznas, Cecelia M	
•	80, 105, 113	Springgate, Benjamin	
		Spurgeon, Joyce A	
		Spyker, Daniel A	
• • • • • • • • • • • • • • • • • • • •		Staal, Steven S	
	108, 118	Stahl, Stephen	
	107	Stankowski, Joy	
	107	Stanley, Barbara H	
		Starr, Harriette L.	
	147	Stein, Bradley D	
oriamai, Amin	144	oton 1, bradiey D	145, 147

# PRESENTER INDEX

Stein. Murrav B	65	Tjoa, Christopher W	1 <i>O</i>
	88	Tohen, Mauricio	
	144	Townsend, Mark H.	
	78	Tracy, Martin G.	
Stewart, Donna E	89	Trestman, Robert L	
Stewart, Jonathan T	63	Trimble, Michael	8
Stigler, Kimberly A	79, 156	Trivedi, Madhukar H	66, 89, 153, 15
Stoddard, Frederick J	69, 70	Trivedi, Reena	6
Stoddard, Joel	69	Truong, Kiet T.V	6
Stotland, Nada L	89, 106, 114	Trzepacz, Paula	
Strain, James J	120	Tseng, Kuan-Chiao	15
Strakowski, Stephen M	70, 91	Tsuang, John W	8
	113	Tsuang, Ming T	12
•	146	Tucker, Phebe M	69, 10
	89	Turell, Jeffrey M	
Sudak, Donna M	67, 73, 79	Turkington, Douglas	
	160	Turner, Norris	
	77	Tzuang, Dan	
	105	0.	
	111		
	144	$\cup$	
	139, 140	<u> </u>	
	107, 114	Uemura, Vivian	
1.1	112	Ursano, Robert J	
	111		
	152		
	79	$\vee$	
	107-108	V	
	96	Vaidya, Swapna	6
	64	Vaillant, George E.	
	81, 152	Vaks, Yakir K.	
	162	Van, Henricus	
	109, 116, 118, 123	Van Ameringen, Michael	
	96, 152, 160	Van Boeijen, Christine A.	
	70	Van Den Oord, Edwin, J.C.G.	
	155	Van Wattum, Pieter Joost	
•	146, 161	Van Wel, Bas E.B.	
,, g		Vanderpool, Donna	
		Vannucci, Elizabeth	
<b>一</b>		Varughese, Sajan	
'		Vaswani, Meera	
Tackett lennifer	77	Vaswani, Sanjay	
	151	Vavrusova, Livia	
	83, 100, 110	Vela, Ricardo M.	
	72	Velásquez, Elvia	
	78	Vemuri, Mytilee	
	107	Venter, Jacob	
· ·	82	Verdela, Helena	
	96	Verduin, Marcia L	
0	79, 115	Vermani, Monica	
	108	Viguera, Adele	
	70, 104	Vilhauer, Jennice	
	124	Vince, Bradley	
	146, 161	Vinson, Sarah	
	125	Vogel-Scibilia, Suzanne E.	
0 . 0	51	Volkow, Nora D72, 90, 98, 99, 104, 105,	
	67	Volman, Susan	
		Volpp, Serena Y.	
	65, 81, 90, 99, 119, 151, 152, 153		
	140, 159		
	71	W	
	92	VV	
	150, 154	Wahlbeck, Kristian	10
	89	Wahlstrom, Carl M	
	64, 69, 113	Walaszek, Art	
· ·		Walkup, John T.	
•	141, 144 65	Walsh, B. Timothy	
		Wang, Junling	
ıııı ıaı, Jane G	76, 112	Wang, Po W	9

# PRESENTER INDEX

Warner, Christopher H
Waseem, Atif
Washington, Harriet A
Wass, Caroline
Watanabe, Norio
Weber, Natalya S
Webster, Cecil R122, 142
Weerasekera, Priyanthy
Weiden, Peter77, 159, 161
Weinberger, Daniel R
Weine, Stevan83
Weiner, Elyse D68
Weiner, Richard107
Weingeroff, Jolie, 140
Weinstein, Aviv
Weinstein, Faye M80
Weinstein, Henry C80
Weisler, Richard155
Weiss, Mitchell G71
Weiss, Roger D82, 98
Wells, Kenneth B
Wells, Trevor
West, Joyce C63, 64, 95, 123
Westermeyer, Joseph71
Wetherington, Cora Lee
Wexler, Micaela P
Whalen, Gerald
Wheelis, Joan
Widzowski, Daniel
Wigal, Sharon
Wilens, Timothy E
Wilk, Joshua63
Williams, Deidre E
Wills, Celia E64
Winhusen, Theresa
Winstead, Daniel K
Winstead, Nathaniel S
Wise, Inge63
Wise, Michael Jan63, 122
Wisner, Katherine L
Witte, Michael M
Wolf, Robert
Wong, Felicia K
Wonseok, Choi
Woodbury-Farina, Michael A93
Woods, Scott W
Woolley, Stephen B
Wrenn, Glenda
Wright, Jesse H73, 79, 90, 108
Wulsin, Lawson R91
Wynn, Pe S
X
Xu, Yong
Y
Yager, Joel63, 109
Yang, Chunxia
Yang, Hyunjoo
Yang, Jun
Vanaga Zinasi
Yaseen, Zimri
Yatham, Lakshmi N

Yeomans, Frank E. .....79, 124

Yeung, Albert	77, 116, 140, 144
Yildirim, Yilmaz	83, 142
Yohanan, Monique	81, 91
Yoon, Jin-Sang	146, 148, 158
Youcha, Sharon	156, 157
Young, Melinda L	80
Yudofskv. Stuart C	115. 118



Zachar, Peter	107
Zanarini, Mary C.	66, 92, 97, 120, 140
Zarate, Carlos	119
Zarif, Nashwa	125
Zeanah, Charles	88
Zhang, Jing	89
Zhao, Bing	139, 140
Ziedonis, Douglas M	64
Ziegler, Penelope	86
Zimbrean, Paula	67
Zimmerman, Mark	83, 116, 123, 152
Zonana, Howard V	122
Zorick, Todd	86, 138
Zucker, Kenneth J	98
Zun, Leslie	123, 147
Zurowski, Mateusz	94



**GEODON®** (ziprasidone HCI) Capsules

GEODON® (ziprasidone mesylate) injection for intramuscular use

BRIEF SUMMARY: See package insert for full prescribing information.

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS—Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. GEODON (ziprasidone) is not approved for the treatment of patients with Dementia-Related Psychosis (see WARNINGS).

### **INDICATIONS**

GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute agitation in schizophrenic patients.

### DOSAGE AND ADMINISTRATION

Schizophrenia GEODON Capsules should be administered at an initial daily dose of 20 mg twice daily with food. In some patients, daily dosage may subsequently be adjusted on the basis of individual clinical status up to 80 mg twice daily. Dosage adjustments, if indicated, should generally occur at intervals of not less than 2 days, as steady-state is achieved within 1 to 3 days. In order to ensure use of the lowest effective dose, patients should ordinarily be observed for improvement for several weeks before upward dosage adjustment. Efficacy in schizophrenia was demonstrated in a dose range of 20 mg to 100 mg twice daily in short-term, placebo-controlled clinical trials. There were trends toward dose response within the range of 20 mg to 80 mg twice daily, but results were not consistent. An increase to a dose greater than 80 mg twice daily is not generally recommended. The safety of doses above 100 mg twice daily has not been systematically evaluated in clinical trials. Maintenance Treatment-While there is no body of evidence available to answer the question of how long a patient treated with ziprasidone should remain on it, a maintenance study in patients who had been symptomatically stable and then randomized to continue ziprasidone or switch to placebo demonstrated a delay in time to relapse for patients receiving GEODON. No additional benefit was demonstrated for doses above 20 mg twice daily. Patients should be periodically reassessed to determine the need for maintenance treatment. Bipolar I Disorder Acute Treatment of Manic or Mixed Episodes— Dose Selection: Oral ziprasidone should be administered at an initial daily dose of 40 mg twice daily with food. The dose may then be increased to 60 mg or 80 mg twice daily on the second day of treatment and subsequently adjusted on the basis of tolerance and efficacy within the range 40 mg to 80 mg twice daily. In the flexible-dose clinical trials, the mean daily dose administered was approximately 120 mg. Maintenance Treatment (as an adjunct to lithium or valproate)—Continue treatment at the same dose on which the patient was initially stabilized, within the range of 40 mg to 80 mg twice daily with food. Patients should be periodically reassessed to determine the need for maintenance treatment. Acute Treatment of Agitation in Schizophrenia Intramuscular Dosing—The recommended dose is 10 mg to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day. Intramuscular administration of ziprasidone for more than three consecutive days has not been studied. If long-term therapy is indicated, oral ziprasidone hydrochloride capsules should replace the intramuscular administration as soon

as possible. Since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended. Ziprasidone intramuscular is intended for intramuscular use only and should not be administered intravenously. Intramuscular Preparation for Administration GEODON for Injection (ziprasidone mesylate) should only be administered by intramuscular injection and should not be administered intravenously. Single-dose vials require reconstitution prior to administration. Add 1.2 mL of Sterile Water for Injection to the vial and shake vigorously until all the drug is dissolved. Each mL of reconstituted solution contains 20 mg ziprasidone. To administer a 10 mg dose, draw up 0.5 mL of the reconstituted solution. To administer a 20 mg dose, draw up 1.0 mL of the reconstituted solution. Any unused portion should be discarded. Since no preservative or bacteriostatic agent is present in this product, aseptic technique must be used in preparation of the final solution. This medicinal product must not be mixed with other medicinal products or solvents other than Sterile Water for Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Dosing in Special Populations Oral: Dosage adjustments are generally not required on the basis of age, gender, race, or renal or hepatic impairment. GEODON is not approved for use in children or adolescents. Intramuscular: Ziprasidone intramuscular has not been systematically evaluated in elderly patients or in patients with hepatic or renal impairment. As the cyclodextrin excipient is cleared by renal filtration, ziprasidone intramuscular should be administered with caution to patients with impaired renal function. Dosing adjustments are not required on the basis of gender or race.

### CONTRAINDICATIONS

QT Prolongation Because of ziprasidone's dose-related prolongation of the QT interval and the known association of fatal arrhythmias with QT prolongation by some other drugs, ziprasidone is contraindicated in patients with a known history of QT prolongation (including congenital long QT syndrome), with recent acute myocardial infarction, or with uncompensated heart failure (see WARNINGS). Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. An additive effect of ziprasidone and other drugs that prolong the QT interval cannot be excluded. Therefore, ziprasidone should not be given with dofetilide, sotalol, quinidine, other Class la and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus. Ziprasidone is also contraindicated with other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects and have this effect described in the full prescribing information as a contraindication or a boxed or bolded warning [see WARNINGS]. Ziprasidone is contraindicated in individuals with a known hypersensitivity to the product.

### WARNINGS

**Increased Mortality in Elderly Patients with Dementia-Related Psychosis:** Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. GEODON is not approved for the treatment of dementia-related psychosis (see BOXED WARNING).

QT Prolongation and Risk of Sudden Death Ziprasidone use should be avoided in combination with other drugs that are known to prolong the QTc interval. Additionally, clinicians should be alert to the identification of other drugs that have been consistently observed to prolong the  $\ensuremath{\text{QT}_{\text{C}}}$  interval. Such drugs should not be prescribed with ziprasidone. Ziprasidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias (see CONTRAINDICATIONS).

QT Prolongation in Clinical Trials A study directly comparing the QT/QTc prolonging effect of oral ziprasidone with several other drugs effective in the treatment of schizophrenia was conducted in patient volunteers. The mean increase in QTc from baseline for ziprasidone ranged from approximately 9 to 14 msec greater than for four of the comparator drugs (risperidone, olanzapine, quetiapine, and haloperidol), but was approximately 14 msec less than the prolongation observed for thioridazine. In this study, the effect of ziprasidone on QTc length was not augmented by the presence of a metabolic inhibitor (ketoconazole

200 mg twice daily). In placebo-controlled trials, oral ziprasidone increased the QTc interval compared to placebo by approximately 10 msec at the highest recommended daily dose of 160 mg. In clinical trials the electrocardiograms of 2/2988 (0.06%) patients who received GEODON and 1/440 (0.23%) patients who received placebo revealed QTc intervals exceeding the potentially clinically relevant threshold of 500 msec. In the ziprasidone-treated patients, neither case suggested a role of ziprasidone. QT Prolongation and Torsade De Pointes Some drugs that prolong the QT/QTc interval have been associated with the occurrence of torsade de pointes and with sudden unexplained death. The relationship of QT prolongation to torsade de pointes is clearest for larger increases (20 msec and greater) but it is possible that smaller QT/QTc prolongations may also increase risk, or increase it in susceptible individuals. Although torsade de pointes has not been observed in association with the use of ziprasidone in premarketing studies and experience is too limited to rule out an increased risk, there have been rare post-marketing reports (in the presence of multiple confounding factors) (see ADVERSE REACTIONS). A study evaluating the QT/QTc prolonging effect of intramuscular ziprasidone, with intramuscular haloperidol as a control, was conducted in patient volunteers. In the trial, ECGs were obtained at the time of maximum plasma concentration following two injections of ziprasidone (20 mg then 30 mg) or haloperidol (7.5 mg then 10 mg) given four hours apart. Note that a 30 mg dose of intramuscular ziprasidone is 50% higher than the recommended therapeutic dose. The mean change in QTc from baseline was calculated for each drug, using a sample-based correction that removes the effect of heart rate on the QT interval. The mean increase in QTc from baseline for ziprasidone was 4.6 msec following the first injection and 12.8 msec following the second injection. The mean increase in QTc from baseline for haloperidol was 6.0 msec following the first injection and 14.7 msec following the second injection. In this study, no patients had a QTc interval exceeding 500 msec. As with other antipsychotic drugs and placebo, sudden unexplained deaths have been reported in patients taking ziprasidone at recommended doses. The premarketing experience for ziprasidone did not reveal an excess risk of mortality for ziprasidone compared to other antipsychotic drugs or placebo, but the extent of exposure was limited, especially for the drugs used as active controls and placebo. Nevertheless, ziprasidone's larger prolongation of QTc length compared to several other antipsychotic drugs raises the possibility that the risk of sudden death may be greater for ziprasidone than for other available drugs for treating schizophrenia. This possibility needs to be considered in deciding among alternative drug products. Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval. Electrolyte Disturbances May Increase The Risk of QT **Prolongation** It is recommended that patients being considered for ziprasidone treatment who are at risk for significant electrolyte disturbances, hypokalemia in particular, have baseline serum potassium and magnesium measurements. Hypokalemia (and/or hypomagnesemia) may increase the risk of QT prolongation and arrhythmia. Hypokalemia may result from diuretic therapy, diarrhea, and other causes. Patients with low serum potassium and/or magnesium should be repleted with those electrolytes before proceeding with treatment. It is essential to periodically monitor serum electrolytes in patients for whom diuretic therapy is introduced during ziprasidone treatment. Persistently prolonged QTc intervals may also increase the risk of further prolongation and arrhythmia, but it is not clear that routine screening ECG measures are effective in detecting such patients. Rather, ziprasidone should be avoided in patients with histories of significant cardiovascular illness, e.g., QT prolongation, recent acute myocardial infarction, uncompensated heart failure, or cardiac arrhythmia. Ziprasidone should be discontinued in patients who are found to have persistent QTc measurements >500 msec. Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs. The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. Tardive Dyskinesia A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients undergoing treatment with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. If signs and symptoms of tardive dyskinesia appear in a patient on ziprasidone, drug discontinuation should be considered. Hyperglycemia and **Diabetes Mellitus** Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical anti-psychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia.

### **PRECAUTIONS**

Leukopenia, Neutropenia, and Agranulocytosis In clinical trial and postmarketing experience, events of leukopenia/neutropenia and agranulocytosis (including fatal cases) have been reported temporally related to antipsychotic agents. Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug induced leukopenia/neutropenia. Patients with a pre-existing low WBC or a history of drug induced leukopenia/ neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue GEODON at the first sign of decline in WBC in the absence of other causative factors. Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm3) should discontinue GEODON and have their WBC followed until recovery. Rash In premarketing trials with ziprasidone, about 5% of patients developed rash and/or urticaria, with discontinuation of treatment in about one-sixth of these cases. The occurrence of rash was related to dose of ziprasidone, although the finding might also be explained by the longer exposure time in the higher dose patients. Several patients with rash had signs and symptoms of associated systemic illness, e.g., elevated WBCs. Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. Upon appearance of rash for which an alternative etiology cannot be identified, ziprasidone should be discontinued. **Orthostatic Hypotension** Ziprasidone may induce orthostatic hypotension associated with dizziness, tachycardia, and, in some patients, syncope, especially during the initial dose-titration period, probably reflecting its  $\alpha$ ,-adrenergic antagonist properties. Syncope was reported in 0.6% of the patients treated with ziprasidone. Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). Seizures In clinical trials, seizures occurred in 0.4% of patients treated with ziprasidone. There were confounding factors that may have contributed to the occurrence of seizures in many of these cases. As with other antipsychotic drugs, ziprasidone should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. **Dysphagia** Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia, and ziprasidone and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia (see BOXED WARNING and Increased Mortality in Elderly Patients with Dementia-Related Psychosis in WARNINGS). Hyperprolactinemia As with other drugs that antagonize dopamine D2 receptors, ziprasidone elevates prolactin levels in humans. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic

administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time. Potential for Cognitive and Motor Impairment Somnolence was a commonly reported adverse reaction in patients treated with ziprasidone. In the 4- and 6-week placebo-controlled trials, somnolence was reported in 14% of patients on ziprasidone compared to 7% of placebo patients. Somnolence led to discontinuation in 0.3% of patients in short-term clinical trials. Since ziprasidone has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until they are reasonably certain that ziprasidone therapy does not affect them adversely. Priapism One case of priapism was reported in the premarketing database. Body Temperature **Regulation** Although not reported with ziprasidone in premarketing trials, disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Suicide The possibility of a suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. Prescriptions for ziprasidone should be written for the smallest quantity of capsules consistent with good patient management in order to reduce overdose risk. Patients With Concomitant Illnesses Clinical experience with ziprasidone in patients with certain concomitant systemic illnesses is limited. Ziprasidone has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies. Because of the risk of QTc prolongation and orthostatic hypotension with ziprasidone, caution should be observed in cardiac patients (see QT Prolongation and Risk of Sudden Death in WARNINGS and Orthostatic Hypotension in **PRECAUTIONS**). **Information for Patients** To assure safe and effective use of GEODON, the information and instructions provided in the patient information should be discussed with patients. Laboratory Tests Patients being considered for ziprasidone treatment who are at risk of significant electrolyte disturbances should have baseline serum potassium and magnesium measurements. Low serum potassium and magnesium should be replaced before proceeding with treatment. Patients who are started on diuretics during Ziprasidone therapy need periodic monitoring of serum potassium and magnesium. Discontinue ziprasidone in patients who are found to have persistent QTc measurements >500 msec (see WARNINGS).

### **DRUG INTERACTIONS**

(1) Ziprasidone should not be used with any drug that prolongs the QT interval. (2) Given the primary CNS effects of ziprasidone, caution should be used when it is taken in combination with other centrally acting drugs. (3) Because of its potential for inducing hypotension, ziprasidone may enhance the effects of certain antihypertensive agents. (4) Ziprasidone may antagonize the effects of levodopa and dopamine agonists. Effect of Other Drugs on Ziprasidone Carbamazepine, 200 mg bid for 21 days, resulted in a decrease of approximately 35% in the AUC of ziprasidone. Ketoconazole, a potent inhibitor of CYP3A4, 400 mg ad for 5 days. increased the AUC and Cmax of ziprasidone by about 35-40%. Cimetidine, 800 mg qd for 2 days, did not affect ziprasidone pharmacokinetics. Co-administration of 30 mL of Maalox® did not affect ziprasidone pharmacokinetics. Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam. Effect of Ziprasidone on Other Drugs In vitro studies revealed little potential for ziprasidone to interfere with the metabolism of drugs cleared primarily by CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and little potential for drug interactions with ziprasidone due to displacement. Ziprasidone 40 mg bid administered concomitantly with lithium 450 mg bid for 7 days did not affect the steady-state level or renal clearance of lithium. In vivo studies have revealed no effect of ziprasidone on the pharmacokinetics of estrogen or progesterone components. Ziprasidone 20 mg bid did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg). Consistent with in vitro results, a study in normal healthy volunteers showed that ziprasidone did not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio.

### NONCLINICAL TOXICOLOGY

Carcinogenesis, Mutagenesis, Impairment of Fertility Lifetime carcinogenicity studies were conducted with ziprasidone in Long Evans rats and CD-1 mice. In male mice, there was no increase in incidence of tumors relative to controls. In female mice, there were dose-related increases in the incidences of pituitary gland adenoma and carcinoma, and mammary gland adenocarcinoma at all doses tested. Increases in serum prolactin were observed in a 1-month dietary study in female, but not male, mice. Ziprasidone had no effect on serum prolactin in rats in a 5-week dietary study at the doses that were used in the carcinogenicity study. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown (see Hyperprolactinemia in PRECAUTIONS). Mutagenesis: There was a reproducible mutagenic response in the Ames assay in one strain of S. typhimurium in the absence of metabolic activation. Positive results were obtained in both the in vitro mammalian cell gene mutation assay and the in vitro chromosomal aberration assay in human lymphocytes. Impairment of Fertility: Ziprasidone increase time to copulation in Sprague-Dawley rats in two fertility and early embryonic development studies at doses of 10 to 160 mg/kg/ day (0.5 to 8 times the MRHD of 200 mg/day on a mg/m2 basis). Fertility rate was reduced at 160 mg/kg/day (8 times the MRHD on a mg/m2 basis). There was no effect on fertility at 40 mg/kg/day (2 times the MRHD on a mg/m2 basis). The fertility of female rats was reduced.

### **USE IN SPECIFIC POPULATIONS**

**Pregnancy** Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Ziprasidone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Labor and Delivery The effect of ziprasidone on labor and delivery in humans is unknown. Nursing Mothers It is not known whether ziprasidone or its metabolites are excreted in human milk. It is recommended that women receiving ziprasidone should not breastfeed. **Pediatric Use** The safety and effectiveness of ziprasidone in pediatric patients have not been established. **Geriatric Use** Of the total number of subjects in clinical studies of ziprasidone, 2.4 percent were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Nevertheless, the presence of multiple factors that might increase the pharmacodynamic response to ziprasidone, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, slower titration, and careful monitoring during the initial dosing period for some elderly patients.

### **ADVERSE REACTIONS**

Adverse Findings Observed in Short-term, Placebo-Controlled Trials The following findings are based on the short-term placebo-controlled premarketing trials for schizophrenia (a pool of two 6-week, and two 4-week fixed-dose trials) and bipolar mania (a pool of two 3-week flexible-dose trials) in which GEODON was administered in doses ranging from 10 to 200 mg/day. Adverse Events **Associated With Discontinuation** *Schizophrenia:* Approximately 4.1% (29/702) of ziprasidone-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse reaction, compared with about 2.2% (6/273) on placebo. The most common reaction associated with dropout was rash, including 7 dropouts for rash among ziprasidone patients (1%) compared to no placebo patients (see **PRECAUTIONS**). Bipolar Mania: Approximately 6.5% (18/279) of ziprasidone-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse reaction, compared with about 3.7% (5/136) on placebo. The most common reactions associated with dropout in the ziprasidone-treated patients were akathisia, anxiety, depression, dizziness, dystonia, rash and vomiting, with 2 dropouts for each of these reactions among ziprasidone patients (1%) compared to one placebo patient each for dystonia and rash (1%) and no placebo patients for the remaining adverse events. Adverse Events at an Incidence of ≥5% and at Least Twice the Rate of Placebo The most commonly observed adverse events associated with GEODON in schizophrenia trials were somnolence (14%) and respiratory tract infection (8%). The most commonly observed adverse events associated with the use of GEODON in bipolar mania trials were somnolence (31%), extrapyramidal symptoms (31%), dizziness (16%), akathisia (10%), abnormal vision (6%), asthenia (6%), and vomiting (5%). The following list enumerates the treatment-emergent adverse events that occurred during acute therapy, including only those events that

occurred in 2% of GEODON patients and at a greater incidence than in placebo. Schizophrenia: Body as a Whole-asthenia, accidental injury, chest pain. Cardiovascular—tachycardia. Digestive—nausea, constipation, dyspepsia, diarrhea, dry mouth, anorexia. Nervous—extrapyramidal symptoms, somnolence, akathisia, dizziness. Respiratory-respiratory tract infection, rhinitis, cough increased. Skin and Appendages-rash, fungal dermatitis. Special Sensesabnormal vision. Bipolar Mania: Body as a Whole—headache, asthenia, accidental injury. Cardiovascular-hypertension. Digestive-nausea, diarrhea, dry mouth, vomiting, increased salivation, tongue edema, dysphagia. Musculoskeletalmyalgia. Nervous-somnolence, extrapyramidal symptoms, dizziness, akathisia, anxiety, hypesthesia, speech disorder. Respiratory—pharyngitis, dyspnea. Skin and Appendages—fungal dermatitis. Special Senses—abnormal vision. Dose **Dependency** An analysis for dose response in the schizophrenia 4-study pool revealed an apparent relation of adverse reaction to dose for the following reactions: asthenia, postural hypotension, anorexia, dry mouth, increased salivation, arthralgia, anxiety, dizziness, dystonia, hypertonia, somnolence, tremor, rhinitis, rash, and abnormal vision. Extrapyramidal Symptoms (EPS) The incidence of reported EPS for ziprasidone patients in the short-term, placebocontrolled schizophrenia trials was 14% vs. 8% for placebo. Objectively collected data from those trials on the Simpson-Angus Rating Scale (for EPS) and the Barnes Akathisia Scale (for akathisia) did not generally show a difference between ziprasidone and placebo. **Dystonia** Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. Elevated risk of acute dystonia is observed in males and younger age groups. Vital Sign Changes Ziprasidone is associated with orthostatic hypotension (see PRECAUTIONS). Weight Gain In short-term schizophrenia trials, the proportions of patients meeting a weight gain criterion of ≥7% of body weight were compared, revealing a statistically significantly greater incidence of weight gain for ziprasidone (10%) compared to placebo (4%). A median weight gain of 0.5 kg was observed in ziprasidone patients compared to no median weight change in placebo patients. Weight gain was reported as an adverse event in 0.4% of both ziprasidone and placebo patients. During long-term therapy with ziprasidone, a categorization of patients at baseline on the basis of body mass index (BMI) revealed the greatest mean weight gain and highest incidence of clinically significant weight gain (>7% of body weight) in patients with low BMI (<23) compared to normal (23-27) or overweight patients (>27). There was a mean weight gain of 1.4 kg for those patients with a "low" baseline BMI, no mean change for patients with a "normal" BMI, and a 1.3 kg mean weight loss for patients who entered the program with a "high" BMI. **ECG Changes** Ziprasidone is associated with an increase in the QT<sub>c</sub> interval (see WARNINGS). In the schizophrenia trials, ziprasidone was associated with a mean increase in heart rate of 1.4 beats per minute compared to a 0.2 beats per minute decrease among placebo patients. Other Adverse Events Observed During the Premarketing Evaluation of Ziprasidone in Schizophrenia Frequent adverse events are those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare adverse events are those occurring in fewer than 1/1000 patients. Body as a Whole—Frequent: abdominal pain, flu syndrome, fever, accidental fall, face edema, chills, photosensitivity reaction, flank pain, hypothermia, motor vehicle accident. Cardiovascular System—Frequent: tachycardia, hypertension, postural hypotension. Infrequent: bradycardia, angina pectoris, atrial fibrillation. Rare: first degree AV block, bundle branch block, phlebitis, pulmonary embolus, cardiomegaly, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, myocarditis, thrombophlebitis. Digestive System-Frequent: anorexia, vomiting. Infrequent rectal hemorrhage, dysphagia, tongue edema. Rare: gum hemorrhage, jaundice, fecal impaction, gamma glutamyl trans-peptidase increased, hematemesis, cholestatic jaundice, hepatitis, hepatomegaly, leukoplakia of mouth, fatty liver deposit, melena. Endocrine—Rare: hypothyroidism, hyperthyroidism, thyroiditis. Hemic and Lymphatic System-Infrequent: anemia, ecchymosis, leukocytosis, leukopenia, eosinophilia, lymphadenopathy. Rare: thrombocytopenia, hypochromic anemia, lymphocytosis, monocytosis, basophilia, lymphedema, polycythemia, thrombocythemia. Metabolic and Nutritional Disorders-Infrequent: thirst, transaminase increased, peripheral edema, hyperglycemia, creatine phosphokinase increased, alkaline phosphatase increased, hypercholesteremia, dehydration, lactic dehydrogenase increased, albuminuria, hypokalemia. Rare: BUN increased, creatinine increased, hyperlipemia, hypocholesteremia, hyperkalemia, hypochloremia, hypoglycemia, hyponatremia, hypoproteinemia, glucose tolerance decreased, gout, hyperchloremia, hyperuricemia, hypocalcemia, hypoglycemic reaction, hypomagnesemia, ketosis, respiratory alkalosis. Musculoskeletal System—Frequent: myalgia. Infrequent: tenosynovitis. Rare: myopathy. Nervous System—Frequent: agitation, extrapyramidal syndrome, tremor, dystonia, hypertonia, dyskinesia, hostility, twitching, paresthesia, confusion, vertigo, hypokinesia, hyperkinesia, abnormal gait, oculogyric crisis, hypesthesia, ataxia, amnesia, cogwheel rigidity, delirium, hypotonia, akinesia, dysarthria, withdrawal syndrome, buccoglossal syndrome, choreoathetosis, diplopia, incoordination, neuropathy. Infrequent: paralysis. Rare: myoclonus, nystagmus, torticollis, circumoral paresthesia, opisthotonos, reflexes increased, trismus. Respiratory System—Frequent: dyspnea Infrequent pneumonia, epistaxis. Rare: hemoptysis, laryngismus. Skin and Appendages-Infrequent: maculopapular rash, urticaria, alopecia, eczema, exfoliative dermatitis, contact dermatitis, vesiculobullous rash. Special Senses—Frequent: fungal dermatitis. Infrequent: conjunctivitis, dry eyes, tinnitus, blepharitis, cataract, photophobia. Rare: eye hemorrhage, visual field defect, keratitis, keratoconjunctivitis. *Urogenital System*—Infrequent: impotence, abnormal ejaculation, amenorrhea, hematuria, menorrhagia, female lactation, polyuria, urinary retention, metrorrhagia, male sexual dysfunction, anorgasmia, glycosuria. Rare: gynecomastia, vaginal hemorrhage, nocturia, oliguria, female sexual dysfunction, uterine hemorrhage. Adverse Findings Observed in Trials of Intramuscular Ziprasidone In these studies, the most commonly observed adverse reactions associated with the use of intramuscular ziprasidone (≥5%) and observed at a rate on intramuscular ziprasidone (in the higher dose groups) at least twice that of the lowest intramuscular ziprasidone group were headache (13%), nausea (12%), and somnolence (20%). Adverse Events at an Incidence of ≥1% in Short-Term Fixed-Dose Intramuscular Trials The following list enumerates the treatment-emergent adverse events that occurred in ≥1% of patients during acute therapy with intramuscular ziprasidone: Body as a Whole headache, injection site pain, asthenia, abdominal pain, flu syndrome, back pain. Cardiovascular—postural hypotension, hypertension, bradycardia, vasodilation. Digestive—nausea, rectal hemorrhage, diarrhea, vomiting, dyspepsia, anorexia, constipation, tooth disorder, dry mouth. Nervous—dizziness, anxiety, insomnia, somnolence, akathisia, agitation, extrapyramidal syndrome, hypertonia, cogwheel rigidity, paresthesia, personality disorder, psychosis, speech disorder. Respiratory— Skin and Appendages—furunculosis, sweating. Urogenital dysmenorrhea, priapism. Other Events Observed During Post-marketing Use Adverse reaction reports not listed above that have been received since market introduction include rare occurrences of the following—Cardiac Disorders: Tachycardia, torsade de pointes (in the presence of multiple confounding factors), (see **WARNINGS**); Digestive System Disorders: Swollen Tongue; Reproductive System and Breast Disorders: Galactorrhea, priapism; Nervous System Disorders: Facial Droop, neuroleptic malignant syndrome, serotonin syndrome (alone or in combination with serotonergic medicinal products), tardive dyskinesia; *Psychiatric* Disorders: Insomnia, mania/hypomania; Skin and subcutaneous Tissue Disorders: Allergic reaction (such as allergic dermatitis, angioedema, orofacial edema, urticaria), rash; Urogenital System Disorders: Enuresis, urinary incontinence; Vascular Disorders: Postural hypotension, syncope.

### DRUG ABUSE AND DEPENDENCE

Controlled Substance Class Ziprasidone is not a controlled substance.

### **OVERDOSAGE**

In premarketing trials in over 5400 patients, accidental or intentional overdosage of oral ziprasidone was documented in 10 patients. All patients survived without sequelae. In the patient taking the largest confirmed amount (3240 mg), the only symptoms reported were minimal sedation, slurring of speech, and transitory hypertension (200/95).



# **BIPOLAR I MAINTENANCE TREATMENT**

# PROVEN SUPERIOR TO LITHIUM OR VALPROATE ALONE IN PREVENTING RELAPSE

GEODON® (ziprasidone HCI) Capsules

GEODON is indicated for acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder and for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate. For full symptoms and diagnostic criteria, see the DSM-IV-TR® (2000).

### **IMPORTANT SAFETY INFORMATION**

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. GEODON is not approved for the treatment of patients with dementia-related psychosis.

GEODON is contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with certain other QT-prolonging drugs. GEODON has a greater capacity to prolong the QT interval than several antipsychotics. In some drugs, QT prolongation has been associated with torsade de pointes, a potentially fatal arrhythmia. In many cases this would lead to the conclusion that other drugs should be tried first. Hypokalemia may increase the risk of QT prolongation and arrhythmia.

As with all antipsychotic medications, a rare and potentially fatal condition known as neuroleptic malignant syndrome (NMS) has been reported with GEODON. NMS can cause hyperpyrexia, muscle rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac dysrhythmia, and altered mental status. If signs and symptoms appear, immediate discontinuation, treatment, and monitoring are recommended.

Prescribing should be consistent with the need to minimize tardive dyskinesia (TD), a potentially irreversible dose- and duration-dependent syndrome. If signs and symptoms appear, discontinuation should be considered since TD may remit partially or completely.

Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia.

Precautions include the risk of rash, orthostatic hypotension, and seizures.

The most common adverse events associated with GEODON in bipolar mania were somnolence, extrapyramidal symptoms, dizziness, akathisia, and abnormal vision.

The most common adverse events (≥5%) associated with GEODON in the bipolar maintenance study were tremor and insomnia.

Please see brief summary of prescribing information on adjacent page. For more information, please visit www.pfizerpro.com/GEODON